%PDF-1.6%‚„œ”
1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R>>>>endobj2 0 obj<</Length 12391/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.0-c000 79.cca54b0, 2022/11/26-09:29:55        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2023-02-07T14:24:40-05:00</xmp:CreateDate>
         <xmp:MetadataDate>2023-02-07T14:24:41-05:00</xmp:MetadataDate>
         <xmp:ModifyDate>2023-02-07T14:24:41-05:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 18.1 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:9b7eb655-e7fa-b745-9fd9-fed38828bba3</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:72764818-cad5-43f1-84b8-ee3fa1a8b760</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:416fb827-e348-4ddb-892d-dba471b43a8b</stRef:instanceID>
            <stRef:documentID>xmp.did:4bcd62d9-3e53-493a-a33d-d24571dfb7a9</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 18.1 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2023-02-07T14:24:40-05:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1157997266</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Geneva</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1157997266</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Geneva</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>13.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2360395111</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>PostScript</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2360395111</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>29583</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeue-Medium</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>001.002</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2027153225</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2027153225</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4226815537</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4226815537</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1672649462</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType Collection</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1672649462</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Helvetica</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>13.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1593802331</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Verdana</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1593802331</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Microsoft</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Verdana-Bold</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.02</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2888882455</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2888882455</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.045</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj3 0 obj<</Count 15/Kids[14 0 R 15 0 R]/Type/Pages>>endobj14 0 obj<</Count 5/Kids[5 0 R 6 0 R 7 0 R 8 0 R 9 0 R]/Parent 3 0 R/Type/Pages>>endobj15 0 obj<</Count 10/Kids[10 0 R 11 0 R 12 0 R 13 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R]/Parent 3 0 R/Type/Pages>>endobj10 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 22 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3964>>/PageWidthList<</0 612.0>>>>>>>>endobj11 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 30 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R/T1_3 31 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3983>>/PageWidthList<</0 612.0>>>>>>>>endobj12 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 32 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</T1_0 31 0 R/T1_1 27 0 R/T1_2 28 0 R/T1_3 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 21922>>/PageWidthList<</0 612.0>>>>>>>>endobj13 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 33 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ColorSpace<</CS0 34 0 R>>/ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 35 0 R/T1_3 36 0 R/T1_4 37 0 R/T1_5 28 0 R/T1_6 31 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 38 0 R>>/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 22024>>/PageWidthList<</0 612.0>>>>>>>>endobj16 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 39 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R/GS3 40 0 R>>/Font<</T1_0 27 0 R/T1_1 28 0 R/T1_2 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340031005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 24437>>/PageWidthList<</0 612.0>>>>>>>>endobj17 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 41 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340031005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 24562>>/PageWidthList<</0 612.0>>>>>>>>endobj18 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 42 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340031005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25033>>/PageWidthList<</0 612.0>>>>>>>>endobj19 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 43 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</C2_0 44 0 R/C2_1 45 0 R/TT0 46 0 R/TT1 47 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 48 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340031005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[15575.0 0.0 3.0 -270.0 -360.0 270.0 -349.4 1.0 0.0 0.0 1.0 -195.0 -285.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 22778>>/PageWidthList<</0 612.0>>>>>>>>endobj20 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 49 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</C2_0 44 0 R/C2_1 45 0 R/TT0 46 0 R/TT1 47 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 48 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340031005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[15575.0 0.0 3.0 -270.0 -360.0 270.0 -349.4 1.0 0.0 0.0 1.0 -195.0 -285.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 23742>>/PageWidthList<</0 612.0>>>>>>>>endobj21 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 50 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R>>/Font<</C2_0 44 0 R/TT0 47 0 R/TT1 46 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 51 0 R>>/XObject<</Fm0 48 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340031005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[15575.0 0.0 3.0 -270.0 -360.0 270.0 -349.4 1.0 0.0 0.0 1.0 -195.0 -285.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25233>>/PageWidthList<</0 612.0>>>>>>>>endobj50 0 obj<</Length 27136>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 413.6983 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 315.2383 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 241.1383 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/C2_0 1 Tf
-0.013 Tc 0.013 Tw 10 0 0 10 46 715.6797 Tm
[<0037004B00480003>-14 <00500052005600570003>-14 <0046005200500050005200510003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <004900480046005700560003>-14 <005200490003>-14 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <004C00510003>-13.9 <004400470058004F005700560003>-14 <0044005100470003>-14 <0046004B004C004F00470055004800510003>-13.9 <0055004800460048004C0059004C0051004A0003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <0044004F0052005100480003>-13.9 <004C00510046004F005800470048001D>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.614 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(tiredness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.259 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.259 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(skin rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(muscle pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.259 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
-1.8 -1.586 Td
[<0037004B00480003>-14 <00500052005600570003>-14 <0046005200500050005200510003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <004900480046005700560003>-14 <005200490003>-14 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <004C00510003>-13.9 <0046004B004C004F00470055004800510003>-13.9 <0055004800460048004C0059004C0051004A0003>-13.9 <003600330035>17.6 <003C00260028002F>36.8 <0003>-14 <005A004C0057004B0003>-14 <0046004B0048005000520057004B0048005500440053005C0003>-14 <004C00510046004F005800470048001D>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.614 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056005A0048004F004F004C0051004A000F0003>-13.9 <00530044004C00510003>-14 <0044005100470003>-13.9 <00550048004700510048005600560003>-14 <005200490003>-13.9 <0057004B00480003>-14 <004F004C0051004C0051004A0003>-13.9 <005200490003>-14 <005C005200580055>]TJ
/TT0 1 Tf
0 Tc 0 Tw 20.023 0 Td
( )Tj
/C2_0 1 Tf
-0.013 Tc 0.013 Tw -20.023 -1.175 Td
[<0050005200580057004B000F0003>-13.9 <0057004B0055005200440057000F0003>-14 <005600570052005000440046004B0003>-14 <0044005100470003>-13.9 <00450052005A0048004F0003>-14 <000B00500058004600520056004C0057004C0056000C>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004F0052005A0003>-13.9 <005A004B004C005700480003>-13.9 <0045004F0052005200470003>-14 <00460048004F004F0003>-14 <0046005200580051005700560003>-13.9 <005A004C0057004B0003>-13.9 <00490048005900480055>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
<00490048005900480055>Tj
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(vomiting)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(muscle pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(stomach-area \(abdominal\) pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.337 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.841 14.544 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(tiredness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(constipation)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(abnormal heart rate)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(high blood pressure \(hypertension\))Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.013 Tw 1.8 0 Td
(swelling)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
<004C00510049004800460057004C005200510056>Tj
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(low blood pressure)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(decreased appetite)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(allergic reactions)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(nose bleed)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<005100580050004500510048005600560003>-14 <005200550003>-14 <0057004C0051004A004F004C0051004A0003>-13.9 <005200490003>-14 <005C0052005800550003>-13.9 <004B00440051004700560003>-13.9 <0044005100470003>-14 <0049004800480057>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.212 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004900480048004F004C0051004A0003>-14 <004600520051004900580056004800470003>-13.9 <005200550003>-13.9 <0047004C005600520055004C00480051005700480047>]TJ
-27.85 -2 Td
[<003600330035>17.6 <003C00260028002F>36.8 <0003>-7 <00500044005C0003>-7 <004600440058005600480003>-7 <0049004800550057004C004F004C0057005C0003>-7 <0053005500520045004F0048005000560003>-7.1 <004C00510003>-7 <00500044004F004800560003>-7 <0044005100470003>-7 <0049004800500044004F0048005600110003>11.1 <0037>110.7 <0044004F004E0003>-7 <005700520003>-7 <005C0052005800550003>-7 <004B00480044004F0057004B00460044005500480003>-7 <0053005500520059004C0047004800550003>-7 <004C00490003>-7 <0057004B004C00560003>-6.9 <004C00560003>-7 <00440003>-7 <00460052005100460048005500510003>-7 <0049005200550003>-7 <005C005200580011>]TJ
-0.014 Tc 0.014 Tw 0 -1.734 Td
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
-0.013 Tc 0.013 Tw 0 -1.05 Td
[<0053005200560056004C0045004F00480003>-14 <0056004C004700480003>-14 <00480049>18.1 <004900480046005700560003>-13.9 <005200490003>-14 <003600330035>17.7 <003C00260028002F0011>]TJ
0 -1.41 Td
[<00260044004F004F0003>-14 <005C0052005800550003>-13.9 <0047005200460057005200550003>-13.9 <0049005200550003>-13.9 <005000480047004C00460044004F0003>-13.9 <004400470059004C004600480003>-13.9 <004400450052005800570003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <0049004800460057005600110003>4.1 <003C>91.6 <005200580003>-14 <00500044005C0003>-13.9 <0055004800530052005500570003>-13.9 <0056004C004700480003>-13.9 <00480049>18 <004900480046005700560003>-14 <005700520003>-13.9 <002900270024>55 <0003>-14 <004400570003>-13.9 <00140010001B001300130010002900270024001000140013001B001B0011>]TJ
/TT1 1 Tf
0.014 Tw 0 -2.4 Td
[(How should I store SPR)36.7 (YCEL?)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.662 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003600570052005500480003>-13.9 <003600330035>17.7 <003C00260028002F>36.8 <0003>-14 <004400570003>-14 <00550052005200500003>-13.9 <005700480050005300480055004400570058005500480003>-13.9 <004500480057005A0048004800510003>-14 <0019001B008300290003>-13.9 <005700520003>-13.9 <001A001A008300290003>-13.9 <000B00150013008300260003>-13.9 <005700520003>-13.9 <0015001800830026000C0011>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.374 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<00240056004E0003>-13.9 <005C0052005800550003>-14 <004B00480044004F0057004B00460044005500480003>-13.9 <0053005500520059004C0047004800550003>-13.9 <005200550003>-13.9 <0053004B00440055005000440046004C005600570003>-13.9 <004400450052005800570003>-14 <0057004B00480003>-14 <0055004C004A004B00570003>-13.9 <005A0044005C0003>-14 <005700520003>-13.9 <0057004B00550052005A0003>-14 <0044005A0044005C0003>-13.9 <0048005B0053004C0055004800470003>-14 <005200550003>-13.9 <0058005100580056004800470003>-14 <003600330035>17.7 <003C00260028002F0011>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.374 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003A>18 <0048004400550003>-13.9 <004F004400570048005B0003>-14 <005200550003>-13.9 <0051004C00570055004C004F00480003>-14 <004A004F00520059004800560003>-14 <005A004B004800510003>-14 <004B004400510047004F004C0051004A0003>-13.9 <005700440045004F0048005700560003>-13.9 <0057004B004400570003>-13.9 <004B0044005900480003>-13.9 <004400460046004C00470048005100570044004F004F005C0003>-13.9 <00450048004800510003>-14 <0046005500580056004B004800470003>-14 <005200550003>-13.9 <004500550052004E004800510011>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.374 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0029004800500044004F004800560003>-14 <005A004B00520003>-14 <0044005500480003>-14 <005300550048004A00510044005100570003>-14 <0056004B00520058004F00470003>-13.9 <0051005200570003>-14 <004B004400510047004F00480003>-14 <0046005500580056004B004800470003>-14 <005200550003>-14 <004500550052004E004800510003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <005700440045004F0048005700560011>]TJ
/TT1 1 Tf
0.014 Tw -1.8 -1.662 Td
[(Keep SPR)36.7 (YCEL)18 ( and all medicines out of the reach of children.)]TJ
0 -2.4 Td
[(General information about the safe and effective use of SPR)36.7 (YCEL.)]TJ
/C2_0 1 Tf
-0.002 Tc 0.002 Tw 0 -1.86 Td
[<003000480047004C0046004C0051004800560003>-65.8 <0044005500480003>-65.7 <00560052005000480057>0.5 <004C0050004800560003>-65.7 <005300550048005600460055004C0045004800470003>-65.7 <0049>0.5 <005200550003>-65.7 <005300580055005300520056004800560003>-65.7 <00520057>0.5 <004B004800550003>-65.7 <0057004B004400510003>-65.7 <0057>0.5 <004B0052005600480003>-65.7 <004F004C00560057>0.5 <004800470003>-65.7 <004C00510003>-65.8 <00440003>-65.8 <003300440057>0.5 <004C004800510057>0.5 <0003>-65.7 <002C00510049>0.5 <00520055005000440057>0.5 <004C005200510003>-65.7 <004F0048004400C000480057>0.5 <0011>0.5 <0003>-65.8 <002700520003>-65.7 <005100520057>0.5 <0003>-65.7 <005800560048>-2.2 <0003>]TJ
0 -1.05 Td
[<003600330035>17.9 <003C00260028002F>37 <0003>-67.5 <0049005200550003>-67.4 <00440003>-67.5 <0046005200510047004C0057004C005200510003>-67.4 <0049005200550003>-67.4 <005A004B004C0046004B0003>-67.5 <004C00570003>-67.5 <004C00560003>-67.5 <0051005200570003>-67.5 <005300550048005600460055004C00450048004700110003>-67.4 <002700520003>-67.5 <0051005200570003>-67.5 <004A004C005900480003>-67.5 <003600330035>17.9 <003C00260028002F>37 <0003>-67.5 <005700520003>-67.4 <00520057004B004800550003>-67.5 <0053004800520053004F00480003>-67.5 <00480059004800510003>-67.5 <004C00490003>-67.5 <0057004B0048005C0003>-67.5 <004B0044005900480003>-67.5 <0057004B0048>-2.2 <0003>]TJ
-0.011 Tc 0.011 Tw 0 -1.05 Td
[<00560044005000480003>-27.5 <0056005C0050005300570052005000560003>-27.6 <005C005200580003>-27.6 <004B00440059004800110003>-27.6 <002C00570003>-27.5 <00500044005C0003>-27.6 <004B0044005500500003>-27.5 <0057004B0048005000110003>-9.6 <003C>91.9 <005200580003>-27.6 <0046004400510003>-27.6 <00440056004E0003>-27.5 <005C0052005800550003>-27.6 <004B00480044004F0057004B00460044005500480003>-27.5 <0053005500520059004C0047004800550003>-27.6 <005200550003>-27.6 <0053004B00440055005000440046004C005600570003>-27.5 <0049005200550003>-27.6 <004C0051004900520055005000440057004C005200510003>-27.6 <00440045005200580057>-10.9 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.05 Td
[<003600330035>17.6 <003C00260028002F>36.8 <0003>-14 <0057004B004400570003>-14 <004C00560003>-14 <005A0055004C00570057004800510003>-13.9 <0049005200550003>-14 <004B00480044004F0057004B0003>-14 <0053005500520049004800560056004C005200510044004F00560011>]TJ
/TT1 1 Tf
0.014 Tw 0 -2.4 Td
[(What are the ingredients in SPR)36.7 (YCEL?)]TJ
0 -1.734 Td
(Active ingredient:)Tj
/C2_0 1 Tf
0.013 Tw [<0BD8>-0.7 <0003>-13.9 <00470044005600440057004C0051004C0045>]TJ
/TT1 1 Tf
-0.01 Tc 0.027 Tw 0 -1.734 Td
[(I)0.7 (n)0.7 (act)0.5 (i)0.7 (ve i)0.7 (n)0.7 (g)0.7 (red)0.6 (i)0.8 (en)0.7 (t)0.6 (s:)]TJ
/C2_0 1 Tf
0.01 Tw 9.531 0 Td
[<0BD80003>-27.1 <004F00440046>0.6 <0057>0.7 <00520056>0.5 <00480003>-27.1 <0050>0.5 <005200510052004B005C>0.5 <00470055>0.5 <00440057>0.7 <0048000F>0.7 <0003>-27.1 <0050>0.5 <004C0046>0.5 <0055>0.6 <00520046>0.5 <0055>0.5 <005C>0.6 <0056>0.5 <0057>0.7 <0044004F004F004C005100480003>-27.1 <0046>0.5 <0048004F004F0058004F00520056>0.5 <0048000F>0.7 <0003>-27.1 <0046>0.6 <0055>0.5 <00520056>0.5 <0046>0.6 <00440055>0.6 <0050>0.5 <0048004F004F00520056>0.6 <00480003>-27 <0056>0.5 <00520047004C00580050>0.6 <000F>0.7 <0003>-27.1 <004B005C>0.5 <00470055>0.5 <0052005B>0.5 <005C>0.6 <00530055>0.5 <00520053005C>0.5 <004F0003>-27.1 <0046>0.5 <0048004F004F0058004F00520056>0.5 <0048000F>-9.8 <0003>]TJ
-0.013 Tc 0.013 Tw -9.531 -1.05 Td
[<0044005100470003>-14 <00500044004A005100480056004C005800500003>-14 <0056005700480044005500440057004800110003>4.1 <0037004B00480003>-13.9 <005700440045004F004800570003>-14 <0046005200440057004C0051004A0003>-14 <0046005200510056004C0056005700560003>-13.9 <005200490003>-14 <004B005C00530055005200500048004F004F005200560048000F0003>-13.9 <0057004C005700440051004C005800500003>-13.9 <0047004C0052005B004C00470048000F0003>-13.9 <0044005100470003>-14 <00530052004F005C00480057004B005C004F0048005100480003>-13.9 <004A004F005C00460052004F0011>]TJ
9 0 0 9 46 164.3584 Tm
[<0027004C005600570055004C004500580057004800470003>-14 <0045005C001D0003>-14 <00250055004C005600570052004F00100030005C0048005500560003>-14 <003600540058004C004500450003>-13.9 <002600520050005300440051005C>74 <000F0003>-14 <00330055004C005100460048005700520051000F0003>-14 <0031002D0003>-13.9 <0013001B0018001700160003>-14 <003800360024>]TJ
0 -1.26 Td
[<0029005200550003>-13.9 <00500052005500480003>-14 <004C0051004900520055005000440057004C00520051000F0003>-14 <004A00520003>-14 <005700520003>-13.9 <005A005A005A>54.7 <0011005600530055005C00460048004F00110046005200500003>-14 <005200550003>-13.9 <00460044004F004F0003>-13.9 <00140010001B001300130010001600160015001000150013001800190011>]TJ
ET
4 M 
36.5 143.519 539 588.941 re
S
10 M 
q 1 0 0 1 36 98.5863 cm
0 0 m
540 0 l
S
Q
BT
9 0 0 9 36 127.4663 Tm
[<0037>-11.1 <004B>-4.6 <004C>-8.2 <00560003>-13.9 <0033>4.5 <00440057>-10.5 <004C>-9.7 <0048>-7.4 <0051>1.6 <00570003>-14 <002C>-6.3 <0051>-1.3 <0049>-5.4 <0052>-10.1 <0055>-21.2 <0050>-7.1 <00440057>-10.5 <004C>-11.2 <0052>-9.8 <00510003>-13.9 <004B>-5.8 <0044>-4.5 <00560003>-13.9 <0045>-9.3 <0048>-8.9 <0048>-7.4 <00510003>-14 <0044>-5.3 <0053>-8.3 <0053>-8.8 <0055>-8.8 <0052>7.3 <0059>7.9 <0048>-9.8 <00470003>-13.9 <0045>11.1 <005C0003>-13.9 <0057>-11.1 <004B>-7.3 <00480003>-13.9 <0038>13.9 <0011>-4.4 <0036>-5.5 <00110003>-14 <0029>11.8 <0052>-12.7 <0052>-12.2 <00470003>-13.9 <0044>-5.4 <0051>-7.7 <00470003>-14 <0027>-14.2 <0055>-22 <0058>-7.3 <004A0003>-14 <0024>-4 <0047>-3.4 <0050>-6 <004C>-5.5 <0051>-4.2 <004C>-8.2 <0056>-2.6 <0057>-11.4 <0055>-9.7 <00440057>-10.6 <004C>-11.2 <0052>-9.7 <0051>1.1 <0011>]TJ
-0.005 Tc 0.005 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -2.704 Td
<0003>Tj
EMC 
49.464 0 Td
[<0035>12 <0048>17.6 <0059>-0.7 <004C0056>0.7 <0048>-1.8 <0047>23 <001D>8 <0003>-6 <0029>21.7 <0048>0.6 <00450055>-14 <0058>2.6 <0044>2.1 <0055>-34.9 <005C>7.7 <0003>-5.9 <0015>-1 <00130015>]TJ
0 Tc 0 Tw 9.98 0 Td
<0016>Tj
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-59.444 -1.76 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.004 Tc 0.004 Tw 49.321 0 Td
[<001A>9.6 <0015>-4.1 <001C>-39.8 <0010>-27.2 <0038>2.8 <0036>-31.3 <0010>10.6 <00150016>-12.9 <0013>-20.7 <0013>-20.7 <0013>26.3 <0014>48.1 <0016>8.6 <0003>-4.9 <0003>-5 <0013>0.7 <0015>-22.7 <0012>-3.6 <00150016>]TJ
ET
0 0 0 0 k
/GS0 gs
225.859 66.272 160.283 23.728 re
f
/PlacedPDF /MC0 BDC 
q
225.859 66.272 160.283 23.728 re
W n
0 0 0 1 k
q 1 0 0 1 241.8554 69.086 cm
0 0 m
-0.143 -0.296 -0.448 -0.486 -0.776 -0.486 c
-0.907 -0.486 -1.033 -0.457 -1.152 -0.4 c
-3.857 0.912 -5.286 3.222 -5.286 6.283 c
-5.286 9.74 l
-5.286 10.216 -4.899 10.602 -4.424 10.602 c
-3.948 10.602 -3.562 10.216 -3.562 9.74 c
-3.562 6.283 l
-3.562 3.896 -2.498 2.169 -0.399 1.151 c
0.028 0.944 0.208 0.427 0 0 c
-2.551 8.012 m
-2.551 7.523 -2.155 7.128 -1.666 7.128 c
-1.178 7.128 -0.781 7.523 -0.781 8.012 c
-0.781 15.067 l
-0.781 15.556 -1.178 15.952 -1.666 15.952 c
-2.155 15.952 -2.551 15.556 -2.551 15.067 c
h
0.186 8.217 m
0.186 7.729 0.582 7.333 1.071 7.333 c
1.559 7.333 1.955 7.729 1.955 8.217 c
1.955 17.702 l
1.955 18.191 1.559 18.587 1.071 18.587 c
0.582 18.587 0.186 18.191 0.186 17.702 c
h
2.923 7.565 m
2.923 7.076 3.319 6.68 3.808 6.68 c
4.296 6.68 4.692 7.076 4.692 7.565 c
4.692 16.079 l
4.692 16.568 4.296 16.964 3.808 16.964 c
3.319 16.964 2.923 16.568 2.923 16.079 c
h
5.66 6.438 m
5.66 5.964 6.044 5.58 6.518 5.58 c
6.992 5.58 7.376 5.964 7.376 6.438 c
7.376 12.192 l
7.376 12.666 6.992 13.051 6.518 13.051 c
6.044 13.051 5.66 12.666 5.66 12.192 c
h
f
Q
q 1 0 0 1 375.4299 79.9704 cm
0 0 m
0 2.164 l
-0.458 2.164 l
-0.992 0.488 l
-1.008 0.488 l
-1.537 2.164 l
-2.016 2.164 l
-2.016 0 l
-1.744 0 l
-1.744 1.864 l
-1.728 1.864 l
-1.141 0 l
-0.881 0 l
-0.291 1.864 l
-0.275 1.864 l
-0.275 0 l
h
-2.859 0 m
-2.859 1.917 l
-2.278 1.917 l
-2.278 2.164 l
-3.715 2.164 l
-3.715 1.917 l
-3.141 1.917 l
-3.141 0 l
h
-117.038 -2.821 m
-117.036 -2.768 l
-115.923 -2.386 -115.233 -1.716 -115.233 -0.521 c
-115.233 -0.337 l
-115.233 1.035 -116.349 2.164 -118.624 2.164 c
-121.772 2.164 l
-121.772 -8.547 l
-118.396 -8.547 l
-116.184 -8.547 -114.666 -7.435 -114.666 -5.655 c
-114.666 -5.548 l
-114.666 -4.159 -115.484 -3.142 -117.038 -2.821 c
-120.395 0.955 m
-118.821 0.955 l
-117.321 0.955 -116.555 0.387 -116.555 -0.63 c
-116.555 -0.738 l
-116.555 -1.966 -117.617 -2.36 -119.012 -2.36 c
-120.395 -2.36 l
h
-116.077 -5.532 m
-116.077 -6.857 -117.121 -7.353 -118.644 -7.353 c
-120.395 -7.353 l
-120.395 -3.492 l
-118.619 -3.492 l
-117.12 -3.492 -116.077 -3.99 -116.077 -5.364 c
h
-110.165 -0.437 m
-109.767 -0.437 l
-109.767 -1.692 l
-110.088 -1.692 l
-111.374 -1.692 -112.216 -2.334 -112.216 -4.033 c
-112.216 -8.547 l
-113.5 -8.547 l
-113.5 -0.437 l
-112.216 -0.437 l
-112.216 -1.891 l
-112.154 -1.891 l
-111.925 -1.157 -111.328 -0.437 -110.165 -0.437 c
-108.624 -0.437 1.286 -8.11 re
-107.197 1.382 m
-107.197 0.756 -107.482 0.462 -107.981 0.462 c
-108.48 0.462 -108.765 0.756 -108.765 1.382 c
-108.765 2.009 -108.48 2.32 -107.981 2.32 c
-107.482 2.32 -107.197 2.009 -107.197 1.382 c
-100.208 -6.313 m
-100.208 -7.874 -101.372 -8.699 -103.07 -8.699 c
-104.783 -8.699 -105.916 -7.965 -106.008 -6.313 c
-104.722 -6.313 l
-104.677 -7.307 -103.942 -7.629 -103.07 -7.629 c
-102.198 -7.629 -101.494 -7.246 -101.494 -6.404 c
-101.494 -4.431 -105.916 -5.793 -105.916 -2.595 c
-105.916 -1.263 -104.937 -0.284 -103.147 -0.284 c
-101.509 -0.284 -100.423 -1.095 -100.3 -2.671 c
-101.586 -2.671 l
-101.662 -1.722 -102.32 -1.355 -103.147 -1.355 c
-104.08 -1.355 -104.661 -1.783 -104.661 -2.595 c
-104.661 -4.507 -100.208 -3.329 -100.208 -6.313 c
-97.243 -0.437 m
-95.499 -0.437 l
-95.499 -1.569 l
-97.243 -1.569 l
-97.243 -6.052 l
-97.243 -7.231 -96.937 -7.475 -96.157 -7.475 c
-95.942 -7.475 -95.698 -7.445 -95.499 -7.429 c
-95.499 -8.532 l
-95.743 -8.577 -96.065 -8.608 -96.294 -8.608 c
-97.886 -8.608 -98.528 -7.981 -98.528 -6.251 c
-98.528 -1.569 l
-99.89 -1.569 l
-99.89 -0.437 l
-98.528 -0.437 l
-98.528 2.164 l
-97.243 2.164 l
h
-91.702 -0.284 m
-93.707 -0.284 -94.777 -1.661 -94.777 -3.895 c
-94.777 -5.089 l
-94.777 -7.323 -93.707 -8.699 -91.702 -8.699 c
-89.698 -8.699 -88.627 -7.323 -88.627 -5.089 c
-88.627 -3.895 l
-88.627 -1.661 -89.698 -0.284 -91.702 -0.284 c
-89.927 -5.012 m
-89.927 -6.94 -90.6 -7.567 -91.702 -7.567 c
-92.804 -7.567 -93.476 -6.94 -93.476 -5.012 c
-93.476 -3.972 l
-93.476 -2.043 -92.804 -1.416 -91.702 -1.416 c
-90.6 -1.416 -89.927 -2.043 -89.927 -3.972 c
h
-87.268 2.164 1.286 -10.71 re
-73.585 2.164 m
-71.403 2.164 l
-71.403 -8.547 l
-72.765 -8.547 l
-72.765 0.68 l
-72.842 0.68 l
-75.581 -6.774 l
-77.249 -6.774 l
-79.957 0.68 l
-80.033 0.68 l
-80.033 -8.547 l
-81.38 -8.547 l
-81.38 2.164 l
-79.092 2.164 l
-76.392 -5.276 l
-76.315 -5.276 l
h
-65.153 -0.437 m
-63.853 -0.437 l
-67.448 -11.148 l
-68.779 -11.148 l
-67.876 -8.608 l
-70.509 -0.437 l
-69.146 -0.437 l
-67.203 -6.757 l
-67.142 -6.757 l
h
-60.399 -0.284 m
-62.404 -0.284 -63.475 -1.722 -63.475 -3.895 c
-63.475 -5.089 l
-63.475 -7.323 -62.404 -8.699 -60.399 -8.699 c
-58.793 -8.699 -57.844 -7.812 -57.523 -6.297 c
-58.839 -6.297 l
-59.068 -7.231 -59.588 -7.567 -60.399 -7.567 c
-61.501 -7.567 -62.174 -6.94 -62.174 -5.012 c
-62.174 -4.905 l
-57.477 -4.905 l
-57.477 -3.895 l
-57.477 -1.722 -58.395 -0.284 -60.399 -0.284 c
-60.399 -1.416 m
-59.358 -1.416 -58.794 -2.029 -58.779 -3.895 c
-62.172 -3.895 l
-62.154 -2.029 -61.486 -1.416 -60.399 -1.416 c
-52.711 -0.437 m
-52.314 -0.437 l
-52.314 -1.692 l
-52.635 -1.692 l
-53.92 -1.692 -54.762 -2.334 -54.762 -4.033 c
-54.762 -8.547 l
-56.047 -8.547 l
-56.047 -0.437 l
-54.762 -0.437 l
-54.762 -1.891 l
-54.7 -1.891 l
-54.471 -1.157 -53.874 -0.437 -52.711 -0.437 c
-45.826 -6.313 m
-45.826 -7.874 -46.989 -8.699 -48.688 -8.699 c
-50.401 -8.699 -51.533 -7.965 -51.626 -6.313 c
-50.34 -6.313 l
-50.294 -7.307 -49.559 -7.629 -48.688 -7.629 c
-47.816 -7.629 -47.112 -7.246 -47.112 -6.404 c
-47.112 -4.431 -51.533 -5.793 -51.533 -2.595 c
-51.533 -1.263 -50.554 -0.284 -48.764 -0.284 c
-47.127 -0.284 -46.04 -1.095 -45.918 -2.671 c
-47.203 -2.671 l
-47.279 -1.722 -47.937 -1.355 -48.764 -1.355 c
-49.697 -1.355 -50.279 -1.783 -50.279 -2.595 c
-50.279 -4.507 -45.826 -3.329 -45.826 -6.313 c
-35.611 -5.716 m
-35.611 -7.629 -36.927 -8.699 -38.947 -8.699 c
-40.844 -8.699 -42.405 -7.781 -42.603 -5.731 c
-41.181 -5.731 l
-41.012 -6.94 -40.155 -7.506 -38.962 -7.506 c
-37.6 -7.506 -36.988 -6.695 -36.988 -5.793 c
-36.988 -2.747 -42.435 -4.507 -42.435 -0.514 c
-42.435 1.2 -41.073 2.317 -39.176 2.317 c
-37.34 2.317 -35.81 1.414 -35.718 -0.697 c
-37.141 -0.697 l
-37.263 0.603 -38.089 1.124 -39.191 1.124 c
-40.492 1.124 -41.058 0.358 -41.058 -0.452 c
-41.058 -3.145 -35.611 -1.554 -35.611 -5.716 c
-29.803 -1.416 m
-29.866 -1.416 l
-30.213 -0.7 -30.874 -0.284 -31.716 -0.284 c
-33.721 -0.284 -34.639 -1.661 -34.639 -3.895 c
-34.639 -5.089 l
-34.639 -7.323 -33.721 -8.699 -31.716 -8.699 c
-30.874 -8.699 -30.213 -8.283 -29.866 -7.567 c
-29.803 -7.567 l
-29.803 -8.547 l
-29.803 -11.148 l
-28.518 -11.148 l
-28.518 -0.437 l
-29.803 -0.437 l
h
-31.563 -7.567 m
-32.665 -7.567 -33.338 -6.94 -33.338 -5.012 c
-33.338 -3.972 l
-33.338 -2.043 -32.665 -1.416 -31.563 -1.416 c
-30.462 -1.416 -29.788 -2.043 -29.788 -3.972 c
-29.788 -5.012 l
-29.788 -6.94 -30.462 -7.567 -31.563 -7.567 c
-22.615 -0.437 m
-21.33 -0.437 l
-21.33 -8.547 l
-22.615 -8.547 l
-22.615 -7.506 l
-22.676 -7.506 l
-22.982 -8.164 -23.64 -8.699 -24.665 -8.699 c
-26.18 -8.699 -27.114 -7.842 -27.114 -5.93 c
-27.114 -0.437 l
-25.813 -0.437 l
-25.813 -5.747 l
-25.813 -7.047 -25.277 -7.613 -24.313 -7.613 c
-23.38 -7.613 -22.615 -6.986 -22.615 -5.41 c
h
-19.679 -0.437 1.285 -8.11 re
-13.472 -0.284 m
-14.328 -0.284 -14.979 -0.7 -15.323 -1.416 c
-15.385 -1.416 l
-15.385 -0.437 l
-15.385 2.164 l
-16.67 2.164 l
-16.67 -8.547 l
-15.385 -8.547 l
-15.385 -7.567 l
-15.323 -7.567 l
-14.979 -8.283 -14.328 -8.699 -13.472 -8.699 c
-11.468 -8.699 -10.55 -7.323 -10.55 -5.089 c
-10.55 -3.895 l
-10.55 -1.661 -11.468 -0.284 -13.472 -0.284 c
-11.85 -5.012 m
-11.85 -6.94 -12.524 -7.567 -13.625 -7.567 c
-14.727 -7.567 -15.4 -6.94 -15.4 -5.012 c
-15.4 -3.972 l
-15.4 -2.043 -14.727 -1.416 -13.625 -1.416 c
-12.524 -1.416 -11.85 -2.043 -11.85 -3.972 c
h
-6.091 -0.284 m
-6.946 -0.284 -7.598 -0.7 -7.942 -1.416 c
-8.004 -1.416 l
-8.004 -0.437 l
-8.004 2.164 l
-9.288 2.164 l
-9.288 -8.547 l
-8.004 -8.547 l
-8.004 -7.567 l
-7.942 -7.567 l
-7.598 -8.283 -6.946 -8.699 -6.091 -8.699 c
-4.086 -8.699 -3.169 -7.323 -3.169 -5.089 c
-3.169 -3.895 l
-3.169 -1.661 -4.086 -0.284 -6.091 -0.284 c
-4.469 -5.012 m
-4.469 -6.94 -5.142 -7.567 -6.244 -7.567 c
-7.345 -7.567 -8.019 -6.94 -8.019 -5.012 c
-8.019 -3.972 l
-8.019 -2.043 -7.345 -1.416 -6.244 -1.416 c
-5.142 -1.416 -4.469 -2.043 -4.469 -3.972 c
h
-18.252 1.382 m
-18.252 0.756 -18.538 0.462 -19.037 0.462 c
-19.535 0.462 -19.821 0.756 -19.821 1.382 c
-19.821 2.009 -19.535 2.32 -19.037 2.32 c
-18.538 2.32 -18.252 2.009 -18.252 1.382 c
f
Q
EMC 
Q
endstreamendobj48 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 281/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 25 0 R>>/Font<</TT0 52 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 743.6487 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.025 Tc 0.025 Tw 0 Ts 100 Tz 0 Tr 12 0 0 12 36 747.2637 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 9 0 0 9 90.1324 750.4637 Tm
(\256)Tj
-0.025 Tc 12 0 0 12 96.5388 747.2637 Tm
( \(dasatinib\))Tj
ET
endstreamendobj52 0 obj<</BaseFont/IEWGNW+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 53 0 R/LastChar 174/Subtype/TrueType/ToUnicode 54 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 667 0 0 0 0 0 0 611 0 0 0 667 0 722 667 0 0 0 0 0 667 0 0 0 0 0 0 0 556 611 0 611 0 0 0 0 278 0 0 0 0 611 0 0 0 0 556 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj53 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 55 0 R/FontName/IEWGNW+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj54 0 obj<</Filter/FlateDecode/Length 312>>stream
Hâ\ëÀj√0E˜˙äY6ã‡G#;cn
^ÙA›~Ä#çSA-ŸY¯Ô;“Ñ*∞Á›{ëfí¶}j≠Y y˜ìÍpÅ¡XÌqûÆ^!úÒb¨»r–F-∑]¸´±w"!s∑Œé≠&QUê|–·º¯éz:„F$o^£7ˆ_M∑Å§ª:˜É#⁄R®k–8P–KÔ^˚!â∂m´È‹,Îñ<äœ’!‰qüÒe‘§qvΩBﬂ€ä*•UCıL´hıøÛlœ∂Û†æ{/™<à”î
Òûy¯¿| ﬁ=F¶B,ôe‡Üπ!ñú#CéÃôÛ¿Ïï¡+9SÜÃ"ãLÖòıE–;Ê]`÷Qb>óúYÜÃíıe–YC%<¸ˆ¬–ö‹˚´ÆﬁSk„8cOC7ç≈˚ƒ›‰Ä\·ø ][ó>endstreamendobj55 0 obj<</Filter/FlateDecode/Length 19497/Length1 46354>>stream
Hâåï	XWÄ´¶ª´ÅÅƒk¶{z	k\eŸËÇÒX˜0íËn‚DA≈3Q…]jBÒ‰P¡oAQQ#¢¢"á˜åûQ«h‚˙ôuò}|lˆ€/_ˆÕW’UÔU}Øﬂ?Ø™Sßœå7H¬Gézª¥3ì»Ë§®î,æ‚ Ü x~=+Un_÷¨«∆¶LNj˜ª≥!ar‚‹XCIM2Ä4¿g`\L‘§ö◊#ÇV≤†‡86—tû)ˇ∏§‘9˛wLÆ$&GG°¶d¿îSÃøë5'•}}S.SÚ‘®§òÂ•+é2ˇ ?9%yF™= Æ:ﬁKNô”_∆ﬁ∑8ÓäÍ‡$¨˙≥SÙlru´“8	*µ»´ÉoÇ ˚Iò3ò•:;ÚGè,˚ŸõÖÜ÷±øä˚√ Ìv;€◊(î;vûi`€Üﬁå≥∞ÇéIˆT©1ˇ=ÿ"«$:9ª®]›∫∏{xjºº}∫˙vÎﬁ£g/≠Níı?≈¯∆õΩﬁ
¸Uü∑˚˛∫_ˇ†ﬂˇˆùÚnË{aÉﬁ<dË∞ﬂˇ√ˇÙÁåˇ£Q£ˇÚ◊è?3v‹¯O#&DF¡ƒËI1±ì„¶ƒ'$&MMNô6}FÍÃY≥ÁÃù˜ŸÁÛ,L˚‚o_¶/Z¸˜åØ2≥ñ,]ˆuˆÚ+W≠ŒY≥6wlÿ∏is^~A·ñ≠€ää∑Ôÿ…Ì*ŸΩgÔæ˝*-;|§¸Ë±„'NûÇ”ïg™Œû;_}·‚•öÀµPWﬂpÂÍµÎpÛñ…|€“ºG(;h;™A∞ Ì*Y5FU¬˘q#πdn&∑ÄÀ‰ñp˘\˜äw„GÚã/·¨DxI˘POíh Eê]L“∆k¥ßµ’Zªn°nΩÓ›k…G“JC•“«“iúÙ©4_:(UJíIz.ΩîZewŸ Â>r_9H(á»°Ú9BNñ ´‰CzAÔ•˜’ÙF}˝˙—˙}∫~µæÿ†2ê¡›†1¯z$Co√[Ü·Ü(Cåü œ√OØÄ¢R\≈[È¶ÙR¸ï@%H	Qï4%]…Pñ(+ï|eó≤_)Wé)ï EÂ≤rSyh1Üﬂ7F£ç±∆cr`b‡Ï>æE=äÙ6ï-ÿbµ≤±Ì≥=∂Ÿõ'∂º◊Ú¢•π’ØµŸﬁÏ∏gÏÜÂ©@•WçUÌÊ¸πp.ïõ«•3jÀ∏BÆñ˚ëÔ¬áÛ¬r°V¯ûÄ‘åöéÙFëb∏µDm•∂U∫4]ûÓÖR7IñÜK·‘&HiR©T%]ìnK/§WÏ≤kµ F≠ü<†ìZ<£ñ-ÁµQÎ⁄AmÑ~î~£ñ›IÕìQÎn–uPã4Lj£&ˇµNjŸJû≤£ìZ5£vÉQÿI-∆œ®E¶2jæE≤mZ€;åZòm∞mò≠¡÷‹—⁄FMnMsP≥ﬂcı˘úI=ÎGÔ2ÈÌ(∏÷)Õ◊2+†Ωõkõ/˘ÏYˇü≤|ú>¿∫‡!´n´è’ÀÍiu∑∫Y]≠j´ã’Ÿ*Z…*X9´ 
Oˇ4-b≤öIz”Î;≈M≥ü∆3ªÏÈ ¶3õÊ4∆7Œm*∑^∫ÿ¥Ã∫∂±∏1«íc)∞dX∂9Ú}-”,ò◊◊fÈoÒ735áòòÉÕ˝Õ}ÕΩÕsO≥∑MœLV”#””]Gñ© t¬Ta*c÷”V””P”˚¶A&ì¡§7ÈÓÁ6o*µçıç’¨7àÎ≈ubn˚9È1Ö∫›r´s}" ›÷µX◊ÁXÁ«3bCò§	LØ≥hW&¡T nœv“1ÈÎ‘œiíSû≥¿•´c÷E”!√‡ÜKêÀGL≥>Ì2Î'≥m}ª}∆e√œÊ.vàKFáó˛K{˝$sºKDß=ˆˇàÈ¥b’!Í∏ˇ	‡†“a9√2»Çç∞∂Äd2§_¬J¯~Ä•∞2Ÿ˜Ù9lÇx/° v¡9®Çò—êì†b‡,úá∏ ·|±Pó°v√dxÀ·
‘Cƒ¡c∞¬WS í ¶B$√4HÅÈ0fB*ÃÇŸÊ¿<òü¡|¯  ¬ˆïˇû¿S8Ç9∏U»!èÿ†◊b.Æ√ı–≠H(¢ÿqnƒM∏Û0ù—’ËäXØ‡G‹Ç[qa1n«∏wa	Ó∆=∏˜·~< ˇÑ´òâYxa)ñ·at√.xÀ—=–5–w–ΩÒ(CÏäK8V‡	<âßÙ≈n∞ˆbwÏÅß±{b/‘¢œ`ºÜ¡]∏á ®Gû≈sx´Ò^ƒKXÉ~Ëè
Ò2÷b÷c^År|ﬂƒﬁ ˜·^•L ¢%¥îñ—◊îMÀi≠§U¥örh≠¸)ó÷¡6ZOh#m¢ÕîG˘T@Ö¥Ö∂“6*‚„˘*¶Ì¥Év“.*°›¥áˆ“>⁄OË ü»'—!*•2:LG®úé“1:NtÇN“)˙ÜNS%ù°*:KÁË<U”∫Hó®Ü.S-ﬂÃ∑≠º] ï¿	º $àÇì‡,∏j™£zj†´tçÆ”∫I∑»Df∫Mj§&∫CwÈ›ßÙêæ•G¨÷üêïû“wÙØ·uºÅ7Òö‘—CÙ5¢óË-˙à]E_±õÿ]Ï)ˆµ¢NîDY‘ãµó⁄[Ì£vˇ7Õı‹eë∆¸›gœÓÛºœ˛ 	5“HCQ¡ÇHÔÑ"¢¢¢áËYAgEïñP•yw" †¢‚ú®ßûb•#]JËê@®IHÄ‹z7˜«˛µ≥≥3œ|f˜˚ïÉrHJ‰∞ë£rLéÀ	9È.ª
WÈ™‹WÌj‹UwÕ]wµ— ™¢`[Ÿ÷6Ÿ¶ÿTõf”mÜÕƒdi(çÏ´vºù`'⁄Iˆ5˚∫ùlﬂ∞SÏõˆ-˚∂ùjßŸÈvÜùiãl±ùeg;ÉÉvN∞€ŒµÛÏ|ˇz-Øÿ"ªÿ.±Ô⁄øŸø€ÿ˜Ç=¡ﬁ`_p¿'¿˝v©}ﬂ.≥ÀÌ
˚Å]iWŸ’ˆC˚ë˝ÿÆ±üÿOÌgv≠4ñxi"M%AöI¢4ó“Rí§ï¥ñdIëTIãEä©S‰∫ì:”]‘Ö∫F∆P7ÍN=®'ı¢ﬁ‘á˙R?ÍOh “ LCh(›M√ËN˜“}t?çàÃñt…êL…íli#m%GN…i)ï29#πí'˘4ï¶—töA3©àäiÕ¶94óÊ—|zá–BZ’—HÉDUÆŒ©ÛÍuA]TóTÖ™TUÍä™Vô™F]U◊‘uïÂ≥U >hÇÜ ∞@¿™lpÖ:Pb ‚†‘Wm†4TmU4Ç∆M†)$@3HÑÊ>£ΩÌÛFí Uy–JÂCkHÜHÖ4Há»îi'˚‰Ÿ/g•\Œ…y˙	≤ ⁄@[»Å\»É|(Ävp‹H?”/º„‡%x^ÅWa<LÄâ0	^£_·uòLø—⁄Hõh3m°≠¥ç∂”Ô¥Év“.⁄M{h/Ì£?h?†ÉtàJË0°£tåé”	:Iß©î Ëù•r:GÁÈ]§Ktô*®í™Ë
U√0c0ñjË*∆a=∫F◊±>6¿Üÿàj9`≈Äç1û5GŸ∞ebÊêÖ6¡¶òÄÕ0õsîÎp]é¡ÿì∞«r◊„˙‹Är#nÃÒ‹Ñõr7„DnŒ-∏%'q´®·dN·TN„tŒ‡LŒ¬÷òÃŸ‹Ü€rÁrÁs∑„¯Fnœ7ÒÕòÇ©|w‡é|+ﬂ∆∑Û‹âÔ‰Œ|wërëªr∑®çRî£aT¢éªsÓ…Ω∏7˜·æ‹è˚Û »Ö<àÛçFÎDÎFc¯n∆˜pæóÔ„˚y?¿ÚC<íÊG¯/<äïK<ö„«˘Ø¸?…OÒ”¸?Àcx,?SaLá0ä†f¡lò#óa.ÃÉ˘,ÄÖ∞√~^*§R™‰
î…˚≤Tñ…rY!»JYÖ˘Rg°\è◊ıkz≤û¢ßÍÈ∫Xœ÷Ûı"ﬂñÍz•^≠?“kÙZ˝Ö˛Zß◊Î_ÙF8ß∑ÍzèﬁØKÙ1}Jü—Â˙<úáp.¡e®ÄJ®¬ˆxﬁ,´ÂC˘Hj‰™\ìÎRÎ∏’PW·\áZh•AkÅ2çòÜYxv¿[Òv∫v∆.ÿ{`ÄÉqòné˜·É¯é∆'|Nß‚¯≤œEpæéo‡õ¯6N√>#Õ¬98œ˜ Ö:„ª¯.«U¯1~Üü„:¸ø¡Ô}≥˘7„Vùç€qÓ√ÉxDÁ‚	,≈rºàïXÉµæ˜Xü·ÎöXSœ4“•&ﬁ4Û-®ÖOÙI¶µI1i&√dô6&G∑3y¶¿¥˜ÈVüˆ;ôŒöÃ]¶ãÈj∫ôÓ¶áÈizôﬁ¶èÈk˙ô˛fÄh
Õ 3ÿ1CÕ›fòﬂπG÷»ßˇüèµh˜ø˘ò·fÑiFôGe≠g\ËÍ∏8◊–5qâ.…•∏4ó·≤\é+pÌ]wªÎÏ∫π^Æü+tC›p7¬çt£‹h˜∏à6é∆´˝ÍÄ:®©uòk√ T!Ñ:åÑö–ÜrÜ∫0÷	ÎÜ1al÷Î´#Íh§"R©ä\âTGjdìlñ-≤U∂…v˘]v»NŸ%ªeúÑSpJe}∞&¯ﬁ4ÎUA∞6¯<¯^>>~êÉ	¡w¡d›«˜ŒæCıWS’4˘I“Éı=T‘Ö·ı∞VÇ‡≤:!J@›(Z"m‰Â‡+Òﬂ≠XâëX∑…mv[‹VxKˆÛÉ3¡øÉ•Aë∫-òÆÓPœ©ô™H´ÁÉ™q¬fåkûáÂY'_ WÚµ¸KæëoÂ;¯	~Ü_‡W¯6¿FÿõalÖm∞¿A8%pé¿Q8«·Ñ◊Ÿ—kàÖ8H7◊-tKù‰M>Ñ#ÒaÔ¥/ˆ√˛^È˝8r{b/ÏÌ≠˝ÄÎÒGÔmnƒMﬁÓ≥8«z≈O‚S¯¥N’i:]gxÕ/‚8|…Kû‚=OˆûﬂÚæ_—ô:À´û©≥u›VÁË\ùßÛuÅWz	/cÖ[Üg¨w„•∆˝yßwöhF{´èô«u©>ÌWôwyáóyßó~K∞◊õÓßz√ôÿ≈‰ò\o:Ÿ{Œˆäo1LGL«t›Nﬂ†/ÍK∏.H¯ÔZ$DRÇÑˇ]5@Q]W¯ú˚Ó.à(Î"†ˆ-OàeA£çäà∫¬.j©
¢f5›EËÄ±ëTc™MÇøÉÛ§ç&∆I™±©≠Ò/?µ5L«N&—Z´±∆öƒ1£ëkµF˜ı{ÈL|oŒΩÁﬁ{˛œ=á»∫xÔ©∂.⁄8˚_\EÔ“∑ı€ˆÏBe˝Tz:ÌÊ€îD∑PA¶	$È&jˆ∑QﬂæD=i*≠G⁄üz—4öÄ8ô=Tœ¨Ö÷E/–fk//≥v ˇ<™Ù[‡‡3…4ú&a˝4TÍW¥K¥~K±TGùi$M·^F≈rönÄái‚g¨[†⁄˛˜Â—Xk∂ÓP&’À5é3ù˛Ñä˛ ;≠ŸV5ı£42Ö«:m}NDgÒxÚpìOnT˘+ÈeN÷˛Ë%Ùé≥¥«{†4Å¶£˛öLtrw.vúq¥Xø≤.ììz– TMWx(O[dº5⁄:K3h} yÌ∑IŒê[3"c¨W≠˜)ëˆ¢∆ó;Ü8~sw©ı{Î-ä?É°ëI†SéûÊ0:î—7¢÷™•ÒT
 GPïÎ®µi‘œâÁ¥ì4“Œ∑O—ÔH¡"˚È Ñn˛âöˇ*˛T˛1ó#fæAuR!ék¥=⁄)…r;ÙmP:t¥ —ıN¥:Œúˇ0ÛûáûÂU>/î∏&n Xπ\~+Ô:2"Á#ﬂZì¨‘õRË'Ëzj°€?D„ˇØÙ1˙≠ÎÙÙ9\Ö>F!]Cuî&&ã±^lo"7¨’À°2_>.è…≥àá’1·ò»ù◊#/Fﬁåú∞ˆZ'‡;]q~B£K·[Ë=tc£˝î.ÿ˛ÉÛGr?*ÛyØC?t›«UHI—7Må>Pù'~=-ãﬁ¶[êÏpV|*æ74áñÜxw¢“µøi_JóÃêÂ`9Yñ°'Çw2¬6«N«˚éƒMÖ≥∆˘jÍ±GÔfﬁ˝,Bë™àäÏÜÔ∆¬ìCõ–mæ]@èy˘V¯7¨êÇﬁÈ!=Çπà'Ú£<ì+y◊!óΩÃ–ÈΩ	 Í…4·cE©ãJ‘ou®
ˆ‡›è\vZúÕ‡<I3ê;k¥2mÜˆdX†=ß≠Äf◊j;¥„⁄IÌ≤ˆï÷´%…~Ú)πXæ"∑ =Ú2»œÒn∆=Ÿ‰8·∏„∏„ŒgÁ ‰îmŒ1Œòa1≈ËN≈\è≠Aò	Œu∫Ô…à¡~báË)kπ}YR$˜¿•àäÎ4Fã¿.]m<xK…≤áΩ”Èï
˚ G®÷)4&íÁiüÁÂü≈(t±!Nñ[µ'
7ÌD6Z#ﬁ8üˆà<1]l‘à/Ò6∫ˇ%≠„«y>Ì‰fŒÂgy8◊“)—K+Âîgmí;Òn!p@Ke=F|xù£+ëM≤ã|˘©ë÷√¢o–Áºùn≥√∫ÜÏ¶!ÖëeÍ·Ô+…Œz≥gµà«ddêπŒ„¥áùD1√ù£Âbj°ˇ“«~xT>2ÈÂHµ‹$ø∞Ü[Ÿà0DmC‹U—8DÃ%x…AåÌ—LDzr…Du1ïQ=ã¨∑÷R÷Fkπµ»öGaÔmÙ!∑˘5DD#v‰—xüßOx5‚p‹ÉÂ¸æ'RAMtï{s:A<4;‚f⁄Å∫Íê„òs0¥ΩÇ6¿£/¿õ„ ¡l:AWÈ&«¬6…îEèÄﬂ†π"®§N°ƒÏ ‰Ò¸6IÊ„îe–ﬁFƒÛAƒFÚƒL:DgXp$ö˙±8ßz˛)Vø.Á›ò©@÷Œ§Ø!wWŒ@œãì÷#k5ÅßsÙ%¥mE˘ B^Òtúuì•
PF≈‹ ºC#êY}⁄QËª?ª(ü”¯èÿBÑv•æ4¬Ò äL≤rDµvwåÖ˘◊p{•“(~\$@éªî»ìihd
x8…öT¸˜(ØàJ´N{:2ó>¢Ì∞âW.åÒy«Nıé=*odÓàú·C˘—ê¡òùÂ…¸·Äá2“˚in˝˝˙ˆIMIÓù‘+±gèÓ›\	]ªƒwéÎ„tHM0e˘ç¬êÆ2BJf„«g€c#åâ}!•c™∞„•á¢ÀÙé+ΩX˘≥ˇ[Èm]Èm_….=èÚ≤≥tø°´c>Co‰≤í ‡_˚å†Æö£ƒ(º&
wÏvcÉÓÔ]Â”átø*\Xe˙C>◊–9Æ¿(®åÀŒ¢Ü∏Œ ;RIFM'çÊ( í¸πÇbªÄ)ïb¯¸*ŸŸ(-›ÆP≈%ø/’Ìfg).òmî+2ÚUÇ'∫Ñ
¢dî≥@≈D…Ë’∂4¥Zo»j2Î]TÚƒW·ô•ÖÉ6çn–ı©§≈{7ƒ·›u˜cS5”ﬂªZ∑á¶Yß´¶í¿˝X∑˝‚ÏÈÖ!≥§Î°ƒ¢R‘ƒ `@ÒJê‘mIl©ZÂ´4¸ˆLhéÆ:˘Fï9'”§òä¶,rÔJIÒÓ≥ŒSä_7ß∑ìj√æ>=…ú≤hw≤WOÓà…ŒjpukUlC◊Ñ6 æÀ˝@e;.
Eó€P—îvÕ≤Õë1°ÙŸ:8	ê)«˛©Ã!svñ·	2v©
X§Zu*ôÆ\{ﬁﬁØÈ.C7o<¿hæ÷q&‹6„Lw› ¥˝§›’Äø+èGef⁄.S õÇ«——Ò–Ï¨ÖçbòQ„“ÒıQ1tÊÇ˙›n€¿´ΩTéÅZRhÎTû∫ãºÉ<A%B6¶È&qöçYr”æ=d¿ì˜.'JT±ÌüWØ˛™\≈ΩÄÆl≈ïE%e›oÜ⁄t[4µ√®ü”ékÉTèÇÄñ*⁄ ë™E±p ôÌãÌA ^…t|úQßÆPú2:¡z°rÖ∆∑˛„‹ÓÔ›”{ﬂ¶F´≈ﬁ˝˚n[ó*◊”q<≤√∏wÒ¶~eÜ(öZföqpÖH@¶YhËÖf»7ZK ›eò˚ƒV±’¨ÒáÓ¥—⁄ø:U÷!DÁ¬YÂ7º™§¡À´JˇGuµ Gmú·›ïV:…'ùtÔáﬂI>˚‡ls∆gó£g¨bÍ`\Ã”s‘µfZ8&Êëh»064ôI“(CS<My¶Âaì‘&LöÈtJ…êLHÎñ@cú!.–‚ìª:{
=i˜óvn¥ﬂ~ˇˇ˚ÔcM ¡ãõzD’-≥õõã2˝Å…E∂iÃ>Ö†¡∞˝®Jw L‡Y⁄Ä¿ga∞Å®3∞ p§:ıoT∫ìÃ$§—d}&	™»≥4F∫“XH…a“A≤„è©¡1É˚ HíZ¨1—*¸!ê@ç.Flá(d· ‡$`∑úÖ*‡ $=@/Í<˜çu_êé—àÓGª˚‰kÃS√ô—aiTUIIâÃSP+@Âí£‚[eπúvèµûﬂ€≥rÈˆ¡ùÌïÂö—xﬁæAjHtÌ¨ÒÅ±Ï÷oå√˚⁄L$’âûER´{Q!ﬂé⁄˘=Ñ—√"ÀY$@nªdbd≈YLß,ﬂ‡}VçΩ£⁄D3ú˙0éYTyQenªÀ…"ÍªãÊÃÃm€ynœ°Ÿuø5{ﬂ∏˜yÁ-xNªb<rÔÉc‘∏o"˘¡¯uºÇ ÒÉÀzC∑”π”Ω¸ÇyóªD] ˘≈Öπà5"LqNqw‚NÆ[XÎÒ8<û)h*∆lÔ≈{∏‘€9∏
Œ'5¡B	¿kdáF†|∞Oˆ∆≥ñàÖèÈo1mu—ÎæoÉÛm–¶ªºq[?åË™Ωòßl#‚R0≤üÚ«raÆ´∞áÖ66èç±	çg˚[y£ƒı©t˝pÉî∫ì™%<dF£©ÙP‘¥ÊC™4R0ïJAÃ–Z»=n.(–TFñ‹e”+Ë*ò7€¯”W∆ß∆¯$åC·ßW˝6º¸«˜z6EÅÂ_ﬂÄœë#Àè·Æ˝+N‘¨ﬂ~”¯èqÛ´›&sªH¸5>M
ÎÁıJ¶YKò±Áa√«1¬ò£Ë0	tûÁ R‘Qh.r`é?(ƒ]†öí¢0fÖûÈ≥ñNÆ åËÏ≤íı£…—â‡6õúòñJ= x|∞WI`íâΩ˛¨9ÈHD£—fÚ'
KIer»ölªË™±ËZ&Hï·”˜å◊ÔÈª˝K˝|å§^•Ó_¿∂M¸	,4ˆìËyS:04√ƒToÇ2£éLE&y	F–5|Ï~Ì]´YfÓfl§€®á<‡Rèbÿé/cdó√Ç(ÇÄd“cw·q≤fêp9q”√∫;Oâ)- :Â)+íÌa,π”T/•ÔDI<&Cˆƒ¥¨ÄT:ãã∏õ‘g√2öÊCƒﬂÂÒÇ¬mº
≈Ö[è>æß°„¬˘_ﬂPΩbny>Ì}vºªµÏ \°ﬂ4ZJˇŒÇUO&&Ó∆g»z\ ÓÈO'lµ∂elGNáı(wHÏ—^?Êx∆¬ãõØkƒkë8Ÿ):mN©B¨∞=jÎ7KÚ9õ∏Mæ náØKa8∑ì≥⁄ƒEbß∏]|Q|YƒbP∞:¡j≥∫è;Ïêú∞≈Ÿ„DN'ÜL∫q.`˚·ΩíÄÑKÅ¬Ê3»\dh¶{ùÉZLCZ»ı0kjÈ ¨I©4ë≤—îIëéIÊRib°lO$∫K¢)qãÙîÄºgÛ(ù2	ùûÂìuª=éUÇ4Mñ∞™ÌFkˇ˘—SoûoŸ“—g¸ÍÚ˙≈+⁄íW?ÍHŒüõÍ:>=ˇ˝ß\…ù—ıäÒWXıJs(ÛK™!øiˆºÂVlf”ºÒ–∑â¡ãzÂÄ‹Øºyßà&b„"b„ÚF[qk‰	fìD‰ÎeÕ⁄Ã/ó®Õ⁄*kõΩ=¥:“^¥QÈRvá¨v≠¸Zﬂ#yq”Í≠>ºQm‘Œ´Á5:≠¶µmÍ6ÌıçâÚSÖ|5_Kq≠éØÊ®’Zá–™mûTw
?UÚáÑ√™É„9ÅQÕ«˚∑ ™/––≥‘´˚ÇÒµ^∏÷ªﬂãºßQ+åÍV"/ ≈N
ÃÖ$†ıZ0É:\@*¶ÁaŸª…ŸÎ≠˚È‚©úwd‹=∫√˜‘±Ö˛íº¬ÈÑÑ§:8"O8–W¸ó…òØ[‘tË3öÎMÔ5HwàçÆ7•/MEá&Ï˙Ëê›ìH•“Î£—¨\®ÑèÄ2ãqq“˛≠◊ëP	=ƒê∑ΩvÛÌ¢n≥'Ñ†=¡gõÕ˚R≠dLH^≥eeÊ¡Ø˘$É™7ÈÆô¸L°\-'<÷
’jçvê?¢Ú ’<ôäé∞€T€lòòWyº¢¢,HOH1À∏ú7ùç,SßÁ¡†˜s/T~/>p´•˚'#G†zX„c«ñ-€jßÕÄ'˛‹˘Ï88g‹4.√œr_ÿ±π1^∞ó|{ÈÊcÎ˛–v˚}!Ω≤\Mƒ√”⁄~tˆô≠üÆÅ§∆Ä„í√M$á-‡Ì@èø°œ )‰!M—òbirl√œAù¡ÏHêaM˘Ä4K1ñÜ¢8`ﬁóùj◊scäB‰ ƒøé<‰€Úº ≤ñ @˝»Û{¯ølÎ„V¨Ã÷Iü4‰ï2fàlﬂIsˇñÓôπgOò9ÁI»ƒÉ›∏$j!iH¨7˚@4%Ÿmëﬁ2UDC2©+»-#wÊ:\õ·B∏$Ûw¥öjÃúAs∆~óŸKfÆˇí.°gLái}Î∑‰b≈Ìüòõ[æ*}.sæﬂ≤Ç6_{AW¡œ|?˜Ùﬁıø∞2å‡r3>w!3≈’Ï€à∫–AÊUÊ∆z.˛âÑî¸È•rëêØGK‚˘∫!ùOâØÕÀG˘5ä˚1—ØT P$ÂÑÚoÖVî"Xt2jy⁄íêû+WÖÙÄD∫ˇR]Ó¡M\WﬁªªZi•’kµ“Jk˘±+YÀ©Z[Pº`À6‘&2£ÿ¥Äq2ví¶@qì$±†Põ)åCÀc^võŒ∏LiahÜ‰èîi
”!%eÍ¡3•@ºÓπ+ßèµ•ª˜ÓΩ;:Áû{~ﬂÒK™<AæxÜ6svk9÷xf¥ÿhaF9Ã–4¡VT±ƒŸò=[Ãsd1áÊ8ƒiü I≠*Rª õº]âJ∆ÂN›Q´ÿ)n)1êÏY2èœ√ŸÈõŒa°M‰{∑0HNCXÉòÃBÉOîë˘0Ø(D}ŸÈ|gíœMù+(TWÖ◊á…\"õÉ∞ÅîÙÎb_á~'MJâ2é}Ü	)F¸ßjSpÄD÷'Ø Üjk–Üπƒµ+M¥P•˙õÀL=y$w‰WÌ?~˜¬Ú∂Õ-´–”µw¬©5çÀ3Ióç¸ÀWfwü”'ﬁ|my0∞45çtº’,-	ÆÃ,‘ØÒ’˛Ë¢ÖÌ’ëTx∏|D√†°ÀA‚–$¡œ=‘™lÈT¡◊
Hæùi∑∂˚⁄˝Ÿ‡3SC/¥/Ù‘dË{ã'S0hﬁœZ9@!¡&åõÃﬁèÕÊ$¨¢lëzãPë+NR π∏∆°^¢gÆ¬˙ºø˚≠òû]Ù◊ØÉ^Á’z˛∞R˜¢5¨—lôç÷çæç˛û†)ó%r	L‡:®ız G‰S∏l
l?ØÎ≥ìkOjº∫lkÓ’›vö~1;3®ﬂ÷ˇ•œË◊◊fíeG[{á~ˆ!Ã$´¿ˆuÛ∂Ô’û‡≥L÷öÂÛÔÛ≤loQπÄRπ^5–L5rÕﬁ∆¿~ñìmÿrÕa3;ú`V1Ó∞G∂÷È$§=ÿ~Ÿ(\≥»0ìiﬂ˝º’ù`ãÁïÏµ˜0=÷>o1ìÀ réÄT>Y-BıÚøÊ“ÎÙGKNvú”ÈÁ«∑£¿,_—∏m›¿éÓıªÆÕ¢((äI◊„ﬁü-ÓËësáá¡ﬁ˜ È{q]ı›IÇÖYÔ∂÷klKˆ≥cÏ{ïΩÀöäŸ.ˆevLcÜ¢ãÎ4‚*qVÊ`øc¶≠§9Çh|™Y9¨“K}ﬁÃƒ|˘eÑÅüÆ˘|¬ªà‡Û
Ë∑QÄ>ãh˝Ò£f:ÚË:∏†ƒ,‰&1¨˘Õ—”aŸd°'h§ZTW£•—˘7óâ¡>/tõvÜ≥Ÿ¿Ì$ä¯≠$¨ûÄú/ë¸¯W˘î∞∫◊?‚'{˝3~ÚÆ˘≠∂òö¬3ú∞dÑC3ê)‚¸ØÖÑúvºù˚∆Äaê¡EˇŸ1Yv´FŸ¿x⁄Ö»,"ΩtVø^ô^ˆbå3ΩÒqÓ@k1Yt|C]€éqΩòé<›∞i«˜0€TBÏπ¿“2Úº6≈∏ôê%*∫≈–>~ü~t®å5M…ˇ“>È¯ù¸yË°˝æ¬ƒÌ´ÌÏC∂˜˘Qeí3/	i·∆H∑≤>≤ãﬂ%ÏT^≥©HÜi≤5€[ùMÚR ìp4í‚jd¨√5a3c5πYŸoèrä¢ÑÃaE+Å€"lıæˇNŸÄwGŸÔPŸiÂt»ﬁèˆào˙˜ó++gDŸß…!’ßã’b∫·Cæ§En+›SJñj˛BµT¬…X!í⁄ Qe9™(GÂEr•πíH6*='[üØ¸¨F´±,î~Åƒñ	ÏÛ«ê&çÃ;ÔqLÔx”ƒ<L‘01»á"J≠‹$ØBYq=ÍÔ#+IZí2Ê±sdLÍ~jäŸ⁄$$5yÃı≥9¯«≤˘Â'◊WÄ—ÁÚ©XHKæU4„˛ÕS≈·|? }≠ nûµ£Z•IŸgT~£|¢0≤¬ŸiZ¬vú	®DS›)Òâzh«N±÷≈F_)U⁄+îÇ*ÅÚºGw°~4É(π˙£çôÃDH[A–®ìû°IlÇOÉW˚í¢Ô5x©®’§T+´®ï∆·ﬁÎã£≈’í—ÓîPõ4'ëÛ∆ h\∑∏{/aÓÊù1OlyeÍÉ+ó3‡0<wIcm|Ω3_‡áøüµß9ÅK„€q3‡ùì∂4Å#X	;Os U*ËYÿ†9–∏ˇÉ9√‰ÌJ$Òœ}Î€©R¡ªL?æˆá◊?ø˛IL‡Ó\≥π≤$AøŒÆπw˜è≥®"Ò‘ÍX∞¢ƒ+∏[∑Ô˝£∑ﬂ®Zº¥ÿ*Ú76∑Ï|˜⁄ú¢‚π/»wLáà Ò-^Bî†ê5Ó\‡hvdùÊÄóS>/!Ú†EûêübÕV3Á«Óv‚à8&R]–LL z‹ãpZ?Ex≥ë◊9[a≠ à
‘	23¥òüäà¸joΩ0,ú®.°_ÿ+\f!∏Ñ°R†ÖÄ¥e‰K¢hK}£el· p´07Uó]¥‚1‘TPtπÓn~,yP}¡‘[@
Ó§.Ãr»rÜOEÏ4»ÓPM≤¶‘Mnõ≤EÉ—fˇ7øø|[⁄∆æÚ
íË»M}’ˆD∞‡zYre¶j]π˘Ò}7 ÌÉπ?ô˛a˙î¿xUG4@U±5]4äéôè±£NSöØı’JTk≤U%ΩeØEF©Q”∂Ï'ü%,/E∂&†Rõ
w´ìT∑ß€ªI¢j}j∑H’Úi)]D≈’4YÎ†*’Uµ ù©M•Íñ6dî^…∫TU]]˜2‘ú˙,∂≈ÿÎˆ·:ªª£b-’xƒZ_’[’_µ∑äÆö #ö58–ßX 4‘¡”≥Úûí·≤ûú∏@„”ì®ô»´È,p3Œ“˜s¯™ü>\ı¿ Œ”˘áÓt.`]b|⁄2fÉ≠p[ôªYóEπ¸’G‰r®öÊΩIáî0Y£ÚaQ°IØ¿”…Í0_£íaE≠˘=_È˙D1Öÿ˛o≠˜‰?/†gÆ\÷á.^‘á._Aœ¸ˆ'˙üGä¬#áQË»®˛ôn>˙E©µ_}aSi,ƒ&ª~ﬂòÈ»$ˆdb—'ﬂj0}zAﬂ{	/ΩåûΩx	ı^¯—øπ/ˇ Ø™*Äü˜˚*¨[(?Y]‹u	AXDê2Å]~h`Ñ4@‰éå8ò#Çõ¸˘ ö≤X¢‘PÆ—ÑÄ´ñÆ9Aö∏R9BÍÓ≤Øœπﬂ˜vûo¡Ãz3ü9˜˜=˜ﬁsÔ9o}√õ66ºπy≥ıççõ¨ÓÎÎúv–sJÒòŸ≠[u∫¸‹—õÔü7∏·Î•∂ΩªtÓu°z~hÏá^y—	≠˚ù»¥œà~õéÙÎ†rè;cimm˝……¥°m–Ùo&Ér§∂∂ˆûúÏ8âÔº^~Td˜âÿ";ú2√-ì`H–A∆z{eúıπï∫i0»È _w∑J	ÌÔ"_Ü\f˜	O“æ6AO∏∫¡-0:b$§œ>ÿ¬t#è»‘†JÆa.Åï=XÓï 
Íˆ˚»D-gÆEå—ÖÙ#îØÛ∑»“´®´mç‘˛•ÚmÍÛI/ÛJ√0(óÄ2!}íÚ∂ÃøTuFvc˛2∑,<F˙R∆˛ıÛë%»QëæÌL˙àˆ1k’5>®iˆgÂK`,Ñ[ÿÌ_Høã…óì>ΩZ œÖVÆHg⁄Ù≥Øëßë=òP¥n1ÎfçkB£”©)Q˝í†ìÆÎ(T¡+	›“îä2πŒÈiŒO◊|Ùµ´‰Zˆ•A◊ÂΩ~§`wo∞Æ]‡πì‰äåÑ[–sÄ∑]Vë/Ç~Ü2±‹µ2›9Œló{¸ï≤ër±ØÄˇHW˚}…ıªJoˆo„èÜ€sè±áI™C¯>Úb˜m…e¨€`*sÔã˜I˜Ü¸PŒumÎı>∞Ø˜√ˆ`‹©˙1ÅÓ9Á˛ëU⁄$m1œ
s^l`ÌŸsïªËˇ#∆≤Ã<Ÿs»J†~*{˙sxûWbåùEò±∂àco	?D~r°
ñ®Ω¡m–G€0K⁄∑4ˆäÕ®m™}®mx{ç≠éT›≥k0waatgÓ†ˇ-–∫˚[Â÷àÓ¥’˝ô®6´˜%[mKm&ñ∆¶ßªA◊©6ïêÀΩJπYu0Ûb[±‘{«∏≥T:måN´ùjY¨6´ˆK›µ5Ωèz'"9<±÷¸Ëé‰”ˇ"cÎÿb,„Ωhî/Àj∆,ıó`ß52Ã=(√úeò7πîı˝ö2÷„VÛÜ]&7e*%è≥ºâæè§‰*%®∂¶2◊Cn{Q-ÎÃæV€ù›jÀÛ*¬£ûX˚º
{éI7ëi¨ lùJ%Yw¶ÂgÉ˝∫W!ìIøÁUá!ÎY™w"®±
°c,)ÓÖK3óY´2”¨Aâ‰¯"«a∫[,W{≈“€≠în)fü∫R^‚_oﬁ›≈åø◊™ërŒÎÅ†çtqéÚ62ó˝:˛t|‰ç	;˙îÕ•m)ñ±Ω¶•⁄åæªHŸû{∑v¡¡àø¡aÏq(\ØæAﬂg„x£°<kØ·±F˚‹'kë?âÌ3eßó¶Ï3H€eZ™o—˜›¯Ó)zî«Î◊˜Qﬂ8}#ıùSﬂ∑OÀDˇº6ÔpïåãÓuBcÏéﬁë]Œé8wÙ]ˇ’pW0 ‹ÂÏw˘èÑè”¬¸Ì·Z÷ù◊ËS+≥oôﬁßÿóÍ>©_å˝®◊M&GÔŸj”ñ˘ç-5ÔÄ¯≥∏Se"„æ®~UÔ°≥ñ{«~2ﬁ}ÓÚC˜∞,F˜÷Œ/≤ÂÓH¶o¢;ì4ÂºÈZé≥ÿ‘èp?îônÈ'êk‰|?êô˛Ô¥OXe édÎ¥Ã'cwÓÉ≤Ÿ€&cÙ¨tvØpøû=w>7sØ¨>,´›Z÷\…˜π∆ÿìˆ}6¨’ı}ÂBœa}⁄¥£˝Xiˆ¢“Ï—
c√ÏÖéÈøf‚!_Ì˝TfgZ ÍÃ%ºO'$7‡-1smì—ôb≥ÔÆÒ◊p?j∞±Y‡}5¸ƒÿˇ÷0tjπC5‹/≈¢Æç¥˜jdwiÅŸü¨\®˜«©ë6j#¨oîâ'j∞Ò«‰NøB˘ïÿ]5æ†ös´a-”‰õ§ó∏am3ÜË‹îﬂl‚ıS≈·+z_ÇJi3?mTˇ1ØÛ6˙.ìº%35Ú®ﬂQ
qè4^Wd1˘π0e1e9YiubåŸZnﬂ./†Ö-Zz‹'π{kd†Û3iÈN&~xOÓ≥dæ3ª;Üœpd∂Ê›|ÈÓìúèçˇôÔµîﬁ¶][¸¯ª2‹KˇJô‰>#ìúêt;XÅ=“œ€!„ºÔgçgú˚*˙¥ê·˛B“·VmgÊ¯8l´∏≥§»ÙK`tçQù7%t^¡™~å=®æ§ì˙™ÆçzF:ûJ?≥Nó~¶Õ_e ˚Ù&tÕ ÜõÌr©ÄˆA‚Jôc≠w≤ØCRMÊ›9÷Æ;G÷#{ ﬂÉjXª·ün/ô«ÿœ#ü’ˇ≈˛-oí˙«‡7V\óDÁ9Uy˜ùpg2ÔI≈ŒÁMœˇtùiø^ÆtÔÊ.w*ŒLi©¯≠$/»Hû}òÚR˙•Ú^wyÿùN€‚4ß”g¡Wòÿ«‚‰„Û@∂˝ºôêUrøz®˛"˙ùúÔ\¯ÅŸˇrπ±°wâ…Épèµ[∆[á¬Zﬁs_…Ê%◊ÏÁz9?>' òÚ‘˘a+WÈûßÀI˜S‚|˙\õÀ3Óî$±ƒER¨∏o—“y¸A±‚´çÂ7Õ7Œ{:F…ïÏ”w∫nö˜s§@±gê_E˝;râ“ò%yä∂Uÿ€.
{ΩS±K'≈A›”æøíÿ◊1∫ØN•ˆ5˝Õ˘ƒvû>˙ä˚{ﬁ£ø3èí‹¥LﬁŸÙΩMó≈o…©⁄§ÓF·È∆¸Çª≥ˆ¬æ‘y∞sK∞U»b∫Wâ7û&V}îÃR.rrÅH›Û"ıxá¡ıOQVB∫ÚhGŸ$ﬁ®ÓÈ‘ΩU∞¡˝ö‹≈ïÌ…Œˆ=˘x4^◊lÌWK¥SwU∂›|XC˙%¿ Íˆ ó#O–˛i˙çE‘ﬂáºí¸p¿ÍˇHæ?‡˜ÎØÜ£ÄûıÑ1ıÙ_359≈ËˇVûÊˇ„ÛJtú
ﬂ51'˙¶ˇ!>∑åœ≥ô˛◊àœø9ˇK4ë—>ÛÌWˇ>ü˘èKŒÛìà„/˜¡$1e`‚hbYsk¸IoWõx“21e$ŸO’„\çù5~EÆ5ˇy/£Oô|ΩJç^±Iº≠væ‹m#x˜dm˛Ñ>ˇÊÌiç=AlπXëÏ7>Kx ﬂ’ö7˜9kwxYEææ¨EÏ”‚∑µ…€‘ß}©˘3ıëg·Soäòí".üëÆ/àË¨§}Òô“úÔ>k_~ùÙ”_4˚˘ò˝•H	ä—ª∏i\öéöÀ7Áûi>w$Ú€îœ®7˘t\Á”4©oj{Ÿx&ó˚ì∫wg
˜ÙZwz¯ó¯æ∆:§Ôq„}ãÚ˛\π«“zB∫Ûé‰¡¢Ëø´i|`xè˙∑LΩeûí"ÚøÑ_eﬂúpl÷˜Öã¨Ìƒ“Èì”0è|‡Vô∂c"∆6gœiª’¯‹ƒáÏô—}1gq\
†/\ €‡éˇ≤^6¿UW?y˜æ{ìÄ|(h %êÇéX@'E, ∂êJÂc`Iê‚@µ-úé¥h≠µD˘— C√Gh•)	
„iËZ@+VG™•@Ö‘X≠ö‡‘y€ﬂŸª7y>xaúÚf˛sv˜ÌÓ9{ÓŸs˛€ˆ≠yC¢{üGÂ’wÆ˜OÛ	{}íçfìºÛÊÈ{è~W˙]…≈Ö¡v)JÓñu¥#Ûë˘‰˜*p+9ª"π◊¥œ⁄9∑_πH&ëÁg'=πÀo4ı‰Ù€í<5Ê…J≠ù dÌ÷.•]àÏ~(´Ÿg+ÎWh®É-Råñ"∆÷:æ√‹o„€o&éIyæ/ˇ898òÉÍU0–÷ò.å]ÍÁjî`∫?LÆ√˘ÔÀ`ÜwäΩ7⁄µ'F…6Ô¥lÛ∑J%˚ÌÃﬂ"´Úˆ ™\ŒìW)µ·§÷ü'èÁèêﬁo5Ù´µ^≈uﬂß‚6‹mKÿGn÷s≥˜ 'À„3grkﬂ0ÚÍp≥1]oº.∑ﬂîq˛ΩRCø˙|‹Ü}ÆÉ¡I–î©Ok≥◊«ºI˘©´Ò∑∑’¸Jœ>◊–d}ªAÜ¯≠æ’∂VS≥ìùŸß≥µ›˙8”ñX~iÕ∆Öbnn¥q”(5∆Ë=‹XπÂ£e"ﬂk2(H.ñôî%∂ò=ms‡LG˛≥À‘NÖ∆óãπ«õπ£ì⁄ˆﬂê«˘F:‹OúnRﬂ˙'dπµ±º@)√WMÌ‡nµ¡4˘uËR‡/µ«aù?≈∆g/õÖ˛ß2ŒﬂlcÊbŒügm≠ÍªπƒË0á˘‰3ÓT,≠ØN‡˜e2ŸûNÂ’∑¯«€ øjîÒ‹‹ØJy∏îx}ÜÿYàﬁ±“7®'• ∏~∏åsﬂ»⁄Ö≤$Ò±î(rVò„	ü6Ü(<ëfNÓëúwÂÔeôãøj¿¿*Œ”¢–yvnΩÃr∏JëÿíSÃˇª@‹æ$j€±óZ6•ÅyÊ8ù¯ ›≈Ïü¿ÆG6y›à’∞Ê6Ù¡¸*æ˙,J3¡ZïWgÇqïóg¬ç˜Œ„*«dÇÒ1Á∞#€ºlvdø"å_qÏ»∂oˇL0ﬁø˚&dÇÒ	ü√él~ê	∆t`«§L0>)”Ú”3‡èºQ£ıìZ}r;rÚ.4mﬁΩf∂ÎÔsÛÓhá˛L_áØÉYÃ°õ˜¡z0•™ÀÙå÷ƒzÃù¥õëﬂàtÈ⁄‘ÆH∑Ö”ô⁄‰l}¸6≠Ø∂£;u<“gucG™!‚1f≠õ?“È}*≤;uÚ˚—|˝_œh◊=’√ı3‰ÒV=€‘v®Ì©m¥üà8SjßÛÂ∆Ho+ÔD”vˇ/iœ≤èw‚c‰√Z´s"*5◊⁄ú[%=“jïÂ¥¶˘.¿ˇzÈ¿·ÿ#_yÉÊp˚û$Ô€˜‰õ∏Ç≈ Í»Ùè±«/à√.‰ÕEr•Í?ÜØ∞∑÷]Âﬁ2Eaπ∆n[´Gk=»%”ÉÿtRz≥ax@ñ3…ß—[∂Sx˝€·?î  îπdy¯ˇ{2ñzUè«o€‡AcíÉ§S,;çêÈyøg|\™∑LP}·µRÅœÆãu∑˘°^ﬂπˆª´ˇ∑Ä≠"gæ&Zõ±ŸYhk±r'ı…~YÇ=É¥~‚∑Ó~é\\∆Ω:#WÜyã≤$/!k¬YÃS]?W^◊Ê˚¡ﬁ	Èº.ÉíHOÎÎ'e^pø~.Ì$ıay8R.K÷sÆZYÎÔcØZÈóÏ)Ω,w8h˜édº«¯Ã	YGLÙŒ‰51èj„7ØpÅ6Ó<*µv¶ùﬂ 4æa˝û‹.”¸;Â+˛)«3dlSxPjÉÉ6fZ˛uÉÃÔ•∂nï±¡)Mñ¬”«KinoÈ>)ΩîüÖ≥âMÂk‘Ë†üNÆÓ∏)Â˚ÏGﬁ∂π˚]ÈÓ‹õ†ﬁÂé≤h‹ﬁM∆Z◊∫Ò9‡>P˝ØˇôüDÌ÷£˝Ì˜EÛ[5Wq◊r∏Q©Z¡›ù˝T€i~^m9˝Ÿ“ÒzYÂxk«2Éfìzá˘Œi|8‚ìgÀI»ëqü˚˘zÂrÊ@Ã£3%sk-∑≥“úpÚàì/k¨)◊Àîiº˙ú2mÁ±Óû≈2‚’ã≥»È1ø>ül„ﬂYd_?ü¨4FÛT,√G$TKó«:∑K«À€ﬂOôr%<Ì®„± ﬂ«·˜G∏sì:Ç∆ù"h1ÕAK∫$GÔœ‘Ës (b^ëH¯¥iünó˙VÏ¡£¨{î˙“◊4ÁˆMó“CÅÕèE0;¿pºûªΩ”ÏÂ†ß⁄4√’”$µ£⁄æO ŒÖ†ΩµË©@Y<‹èΩd≠wŒ.aäu∑Ÿ3∂h-Ï–[»}=±ÊzNYŸ¢à˝˚1ˆg{◊~ØÿÊXø€˜ˇ˝éÏπº#dˇ.¶Eq°Œ›ëÌ…ΩÊ5pD€‹•√Ó]Ç4-äõWXªõ8#ßE–˚Ã‹fá¸˙¯ªÊ(á¿./ç-èP†«=ôq–‚‡˙zAìy+oéË=vöì
ÂRÁÚO¯]Û1x$\ç<¿ö9ˆç§‹Î0w5_Ûª¬Âæ‚ºW®_‰⁄˝¥÷Án#∂Ö¸ÛºÃ˛,Á3S]ﬁ»>Bæ∏8xV ΩîLÍx€v&'˝’4)–µ»aøCuƒ˝Ãã‡OëüÌ¯Ø”·ë"ÌËCã©u|[yÏº©w£Òvª‚‹Î√ÑyÎ
gªïÔ›’Úó5ÿ∂F
·<Àï/ÿ—U∆˘dú≤ãÚÂˆ.Ãó°¬2áb¸RÓØÑ76 Tã˜òWgN+îŸÔ‘(SÇ2≈ê_m^$Ozˇ Õ¨}ŒY!K¯ÔbÂ>∫áÚAÂE^#~$ßxy„¬úΩ_"+"¯Ú>)…ôG=J{(b¸ã»ª¡=¥Ø@ﬁfÄz7˛#)Iˆ`Ø$mE1ÛvD“"!ÒjØ:OºƒºE24—ÃÿM ås–9øÉ„ÈcÏºíƒ{Ëò(˘^°kóÚﬂ!ê—˝|–Ï˛ãÁåiüì¸@∆Ê◊¿©.KMCr¥i»yOä¸rÈ∆7Ω%S˙zŒÒ(n´ô6–ˇ(Ò©Rx∞A±€4xÎÅì…}2<πRJÇKea≤óL‡-0:ËJæYÆ$ˇÜKWDo¢îæÌÓÁõ3|∑EﬁAÏx€bªì¡_dHﬁ"ﬁΩ∞,LóX&Í 2ß¬÷N!∂$GŸ[]ƒ»íÔòˇË]ãyn¯-y$|.˘ÑÃpπHπñ÷íÓZ◊i◊ÿIî1ÏDı1c"éoÙ>L%7Ë˝≠rw∏ _*ø“ÿr\PÁ◊{ó èë◊%j√()rko„¿˝Œá„ŸwC≤Åƒ j †}ΩÇvÉ"Ìˇ“˜7pøÓ!∑\C˚ö≥˚|œ…ü˘∂aâ|M·eû¢\Üzª··Â¨9~˛~–MÆV$Ê“Ø9Gøãse†][y˛~‚∏+º2|\vv˝7(⁄Œ}ûæ∑^˙+‚xkãÈlÁo4œ+á÷<ˆ—∂9^Ùh+àe√áà•bÊ=ê¯à;{ò˙pZ˙F9ú|ÿH‹mü⁄¯[Ì?øúúüfŒ\≠ Å5∑¬]g+/ıÃÕs -ÑˇÈZx>9v≤}ó› ˇcølc£8Œ8˛Ïå}áÏ;6Æ‹&óò_GIÖwC —∏S»áƒvÒª8wßÛH∞”*ÿ*8ÙE}QÍMJäèΩæ`ı%°U⁄*Â‘¶
©TÂ>Pµ™⁄íVU? %Óû› H™(R´±ı€ÁŸ›˘ÕŒŒÃÕÓ~ö◊Z¨©hÀ9ı.™æ”x*g|jùQkêÒ&ïRÎå¯ˆ”ÿøŸ]óT.v‡◊∞yÁ◊∫ÎîZÉdúªÏÆYºf™µM˝±^I<Ñ˝?y`Å¸±€ÒGä‡∑p–E=sﬁSœ&^;Ö[Ø¯+ÆÉ\}ªÔˆ3¥@˝QŒ~ø˜%Ô˝ÚùwÃsÔﬁø˜Bî˘Ÿ’º˚ººà1hß:<o¬xßyÌ™QÔÚWæª˙ÈVıÃˆ-„Ô^w0ñıWﬁÛ’3O='’8©Ò⁄G≥∞¶‘_Û] )°∆∂Ùi2’≥˝ÙSÍU±√Öü”™ˇ¿k•AÚ5∞∆yÛŒ«Ô5Í˚N};|w˙ï´æ˝ﬁ˘ñ´ÒÊ÷b‹€◊‹[:AÎΩÁ˝‘˝∂«3
’nw≈•æ‡üò%C‚¥û⁄ÔÕ´ˇN…3.>t„åûÎSˆ–Ê&‹ÁÃóä-◊·ÚµT^ºñ™F¢Ÿü˙ˇ°˙.çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çÊC¡ ™XNßO“Úë† 5”&"ﬂeÒ"ïbü®íN`+I˝}é∑*˜”iÏ‰˛-7zπ§Ÿ∆^^ÇºœÀ}»Ω‹OQ“()Suóº‹†ÒÄó™É^.q¸K^^Ç<ÁÂ>‰Ø{9⁄#¶È92)Ba¸ﬂÅ¨ùz(Ü∏éizîí|d%ˆR»’∂«{πƒRú±©ˇ&mƒ±m”‘œ{1ƒJÔ¿∂%m‰ΩpUŸ^.”“\_7 <Çò¢Ì8ñ†áˇã∂®Z„\£Îm¬^/ˆ‘’M∫YÔπWé„h3◊`r›=‹Vì∂bo g”‹ZUzÈsf$æ√lÔâôÎÒD˙—dÃ\ôH%©Æto"æ‘¥˚˙ÃçΩ€z“˝Ê∆X,µ#÷ΩtÌ™Õk÷o^bßzª˙öÓIÙuØkˇ`á87{˚Õ.3ùÍÍé=“ï⁄n&~œÀõΩq3çsõ‚ΩÈX∑y∫+ÉÔnN§ÃŒ§Ã≠âÅx:’Î_˙˜ZZEõi≠«v…UÉﬂD˜†Æ>îYáÎ+o:ºèˇÉ9f©ˇŸIÈ-/4˝qzçÆÛw≤}»Æêœ”8¿Ö≠	2@í%üœ˘+"÷)ƒ™9ùö%ëâÈ<íªñÒÒ¶ØDÜŒ»„‘AÀp¯∏≥I>û≥Óçp\v∑õoÁËÃpO˚ÁDBv¥f (‡e¿0¶Ä:NoÄi Â≥Ú∞≥:Ñé¢¢Ä=G≈ fa{Lâ÷≈Ω•Kﬁë¥ÍHÆl¶∫¸∂ÍÂXlÉ`åÉÛ†îÿéÅi ë∆π√$‰ay»	ÜÇvπ¸6!øI√†jˇz.»}Ûç\`vƒ≤ÉÚ´Ç≤rÂÅ@µOA{ääﬂÁ4›Œ]x_Æº2D˘4z¡%3ÿºoU~$7ªFUˇE'0ãΩ›N∏≈Mr¡⁄HΩy2dL∆ÈV
…=à∑"ŒG¸¨Ï¶
nßï#C∏^ä∑…j∫ßmYÉﬂyHﬁ+Î®ûã8ïÓuú≈ç‹ÒJYÀE≤ÇZgHø	ôì“‚Œﬂõ+ªIµoØ¨éúïOJ?ÕA©!îö
úïÂŸræìˆ\YEd‘û)€qõÌËñ⁄h†ó„\Q‹AEˆ,πJŒ£ú€.ÁS5‚jπÄ„w‰!Zç¯tÆa^(?)øÃ÷AU).ø¬ùZ+rïëº]&W‡lVÓ« ÏÁãèÊÓåê› SÙÒ ≤AûÙ√»Ü1j√©aå‘05åŸGrŒÏCôfπãír'çÇ1‰jZU;Ë–	N.éL»è…ZtLp]i‡h]Æ¨Rµ¨÷©öÕ≈js3+#mge?Êy?Í¥d:7∑6íòîç|+ü»’÷+!È`∫ûïs›°ÅX£Ü‰¨úáéP3_.p™CY;Ñ}5ëCdàüãÇÍ$ÒkÒ5‹‚<ˆU¸Ö_Ò‚/›8ù˜G!~•b—û'~è :ƒÔhôì‚%,˛!Ò[qJµBº.&®Òˆª'ó!ûvn~9tJú !†Ìﬂr*j‘Õäóú%Õ^Z‰%sÎΩ§™&b//äh™xq!‚"O∑ N!÷"ÊEö^F¸ÅXNw#~ﬂãÁƒ5≈≈èƒÈNƒúS©öêu¸*å;>N8‰ÓEõCgƒ	qúÍPÙ{NCé>õkX
L¢>Cig~® .áå-∆?P(CT§*qÿiUïå:gÃ–Ñ£Vm´µ»j≤é…¢pS¯ò4ôMf´yÃ¥Éb?ê1ÅﬂØ¡∂ïLÅŸ,0*ˆ9%≠Y˚-‹ì∫/ACÿf8Îƒ6…aºrˆMŒ⁄ƒì¥‘±Ç!^ÿF≈.∞<Á#i0 vb5I¬H¬H¬H≤ëÑëÑëÑëd#…W  ËÑ—	£F'ù0:at¬ËdCµ∑F'QQQQ6¢0¢0¢0¢lDaDaDŸ∞`X0,Ü√b√Ça¡∞ÿ√√√≥ÜÜÜf###ÃÜ	√Ña¬0Ÿ0aò0L&&Ü…FFFFêç å å å Aü†å"å"å"å"EEEE6ä0ä0äbÁIY∞• • •¿JJJJÅïîîÇwÎiÓÅi≥Ç!†‹<‹<‹<‹<ªyû^@πYYYY6≤0≤0≤0≤ldadadŸ»¿»¿»¿»∞ëÅëÅëÅëa#√w („∆'Âçx¬ÿ2œZ1d‹∆qê˛Ãq]‡¯8ù‰¯„∏õæ¿qµr‹IQ«4ÖfN®5`◊`	ÿ :@åÅq0¸úùoÄi±‹∫•$‡ﬂ‡Ûè˚ß¸•„˛¢_||cæqﬂîØt‹WÙ	”Æºébi°ºƒˆ¿C€6Œ⁄DÆ€Çuv9˛[Dã5Î/Ê•F„|£1’hå7ªL¨1˛Ez’ƒ¥qD·ôµ√. à∫°t÷l◊ÿ:T‚ "ºvÏTÕ0âvÛ#Rr*íÌDΩ–4RQB™T©™T—BM´é◊
]'Æ	ıXıJo=pk™ˆ‘+}o÷™˙÷±ﬂ|≥Ô}ÔΩÒõÒÓNX‹ÈTíí`‚‘±:”l$ï0¶·Œ¥±˚Í5Ê%.2ü÷∂L¿W êmê' )êqê$à¬Ñn¯é5‘Y1@‚ *¶ ˝˝Çÿ€£X5)J∑´?EI;Ê1ŒÅﬂœ∏ ‡{∆˚ ?x∆"À¥”]b‡[}+˜{èÄ˘ª æıÿÄèΩp◊3Œ‹ˆåüY&JoF◊π‡w#ŒzÏ&–f<6`zFŸ#êHÎ0u»†ﬁz+»§yl
`»cì»VàÅO€HRLÔb®
˙≥Fù0µ:ÿÏ3ˆ
‹á¬¬ˆ¯Uı√ øË>ΩiEX=˘ê3ÃÀDêœáJ9‚3∂≠Ø±/!’wŸÏ<€H˙
®◊aﬁk"Ö«û®æÙ‘:√≥¨î<`Evç-∞YvWΩ«Ó∞:Nì∏‘ëûÓ≤Î=¯∫«ﬁ’}1≈´ÏCf1ÉM™u¨/πƒM%ÎX2dÍ;¢˚∏«o§|⁄cç»…õÚm9+O…ö<$ø) }JØ“≠t)ùJDQî6%¨H
Q˙¸√ﬂ,ì¿∂ÌkÎFhc„n	{Ë†'U$rç3![≤YjÛó˜àΩ®ÚøöO#3∑¯)-KyØMÏπ,ød⁄æ|8ÀS¶ÕÂÎ∑ù
•.hπÙâO…ú„”CT≠ﬁ+`$´Î5BÈÎ´ÎÆKb˝”±tÔtœ‰’\ãnæ—õ«-vr8»?∑ˇf–Â„88tm˛qAΩ„‘§”R4ü´I]ÆS/KßÛ≥®/Á\†ÏÊ.†hJñ®HÉ˚Ii∞F/Ó¿ã# /%	¡KD¢Ç¶»´Ï´˘\EUG'd_pˆurÇ;|sïDB∞4ï:»¢é¶äâã@å%…Ö¬{ùƒ®H∆Gè)zÉ2qDôπBÙò√Nﬂπ&ßÔpÃˇŸñ≤&≠éïWˆÚKZ~^À/ÅÃÛOﬁèÒ«ã™ZY)£AÂ°ƒ¸‚Ω˚àKº¨-Â¯äñS+c{-Ã{h”r≤óüs*{÷RŒ≥∆Ú⁄BŒ≠¶/;ôÂZ; Â\nÏ2s0W:”¬úAsse0Ws•≠¥»ïÄ˚˛∫SQH÷Ωr'¿™‘Å=<?w≥˝›À”∏°kSÒÿ ¿Û0°;§√tyßñÂQ4%3…ö‡Ü¶.Pünòb+SÒÅÁtßaÍuèñ%Õ“$Ÿ|b∆ÊÒ¬-∑
∑ZØYõ0«H˛Aæp]üìLRlŸJ≠Zπ\.bW6ãÑÿ|§`Ûã30YÜTÛ9tÁõ∫PHË*ÌÌyˇ%Mò-a:ô‘Ñ
Z8u…“V€ñ,·Q°T=;8˛¡èˇŒq“#otLú"Uát<øî™£¬q—;á’∏"ÍZ=IlÍõ…Õ‘ñæï‹JµÅvwîl•ﬁËvàîÃb≥0,πPlòÊ˚⁄{cP$ﬁ¬Åi∫fëäz˝∑ÿ¥YÙ£¬Qã"|©π Åæÿ+d/7› 'a,ß Hpu‘7∏˙GÄ ‰dßªendstreamendobj25 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj51 0 obj<</Metadata 56 0 R>>endobj56 0 obj<</Length 5172/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.0-c000 79.cca54b0, 2022/11/26-09:29:55        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">bms_logo_cmyk_blk</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmp:CreatorTool>Adobe Illustrator 24.0 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2020-02-04T11:00:37-05:00</xmp:CreateDate>
         <xmp:ModifyDate>2020-02-04T11:00:39-05:00</xmp:ModifyDate>
         <xmp:MetadataDate>2020-02-04T11:00:39-05:00</xmp:MetadataDate>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:OriginalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.did:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:6a99bcf6-4cf4-bd41-81f5-4016ae20b87a</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:db5659f3-6411-f742-bf8f-b16bfaa386c3</stRef:instanceID>
            <stRef:documentID>xmp.did:4edd90c1-b301-4d0d-b22f-f129dd224159</stRef:documentID>
            <stRef:originalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:b521286a-9a99-48db-800b-c0dd2945b62d</stEvt:instanceID>
                  <stEvt:when>2020-01-02T15:36:11-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</stEvt:instanceID>
                  <stEvt:when>2020-01-30T11:01:24-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Web</illustrator:StartupProfile>
         <illustrator:Type>Document</illustrator:Type>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>415.562183</stDim:w>
            <stDim:h>104.989900</stDim:h>
            <stDim:unit>Points</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 15.00</pdf:Producer>
         <pdfx:CreatorVersion>21.0.2</pdfx:CreatorVersion>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj44 0 obj<</BaseFont/IEWGNW+ArialMT/DescendantFonts 57 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 58 0 R/Type/Font>>endobj47 0 obj<</BaseFont/IEWGNW+ArialMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 59 0 R/LastChar 148/Subtype/TrueType/ToUnicode 60 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 584 0 333 278 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 667 0 722 0 667 0 0 722 0 0 0 556 833 0 0 667 0 722 667 0 0 0 0 0 667 0 0 0 0 0 0 0 556 556 500 556 556 0 556 556 222 0 500 222 833 556 556 556 0 333 500 278 556 500 722 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222 333 333]>>endobj46 0 obj<</BaseFont/IEWGNW+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 61 0 R/LastChar 174/Subtype/TrueType/ToUnicode 62 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 0 0 0 556 0 0 0 0 0 0 0 333 0 0 0 0 611 0 722 722 722 0 667 611 778 722 278 0 722 611 833 722 778 667 0 722 667 611 0 0 944 0 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 0 389 556 333 611 556 778 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj61 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 63 0 R/FontName/IEWGNW+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj62 0 obj<</Filter/FlateDecode/Length 458>>stream
Hâ\ì›j„0ÖÔ˝∫l/äÛ#Õ¥`i“B.ˆáÕÓ8∂íŸ(ŒEﬁ~Á¯Ñ.¨!—g$çæcFÂf∑›•ntÂœ‹7˚8∫có⁄/˝57—‚©K≈|·⁄ÆÔo”sÆá¢¥Õ˚€eåÁ]:ˆEUπÚóM^∆|sÎ∂?ƒ«¢¸ë€òªtr6˚GWÓØ√œ1çnÊV+◊∆£˙VﬂÎstÂ¥Ìi◊⁄|7ﬁûlœøøoCtãÈ}Nô¶o„e®õòÎtäE5≥gÂ™w{VELÌÛ·æÌpl>Í\T,ûÕl0~&?É_»/‡yﬁí∑‡7ÚõÒr1±∆kÚ¸N6ô œ'∂¡òÎ=÷˚%y	‰ ≤Äï¨`zzxzzzx˙WÚ+òŒŒûŒŒûŒŒûnnÅﬂ!‡;∫∏∫∏Oˆ`˙¯:83
2
ÎÍÎÍÎÍÛ
Ú
Û
Ú
ÎÍÛ
Ú
œíÈ,Ê‰Ê‰Ê‰Ê‰Ê‰UÊU‰Uz*<ïû
O•ß¬SÈ©Tz*<ïû
O•õ¬mÕsm@ﬁªÌh∑∆}ızsÕŸ⁄|∫ZS£≥ªønﬂ–Œv·W¸` …;ÂQendstreamendobj63 0 obj<</Filter/FlateDecode/Length 27104/Length1 56440>>stream
Hâåï	XWÄ´¶ª´aÄ»)*Œtœ@èë∞Í*ÀFó<◊=å$∫õxAëCPÒLT≤Aó ¿PÔ5"*xpxœ8‡u\M\?≥Ó ì7¿«fø˝Úeﬂ|UØ^Ω™Ôı˚ß´:eÊÏhpÅT‡ lÙòæ˝°}òòDD%F&gÚœ0¿Ìì®9)r˚∂˚* q|LÚ‘ƒˆuw#ƒOMòc™…⁄ çŒèçéúr”˝ÕhÄ	oXPP,s¥«OÏÀî_lb ºéıÄ¿´	IQëú[^!@N/∂æô9/π}ˇ¨ç)yzdbtNÈäc U ?59iVäÕn T/µÔ'œåÓàØ.bœ[wUup÷ÿ-|⁄gÆbTÓÇ I‰Uˆ¡7ÅøÌÃ RÌ˘cGïÅ˝lÕBCÎá8@¡°Ä6{ﬁ î€Oûi`€Åûå≥∞Ç'õU*{Ã∂…Òâéj'gó∑∫∏∫π{xzuıÓ÷ΩáOOçVíuz_?≈–ÎÌﬁ˛Ô¸™Oﬂ~øÓ? 7Aø}w‡†ﬂøÚ~Ë‡!CáÒ˚ë¯„ü˛<ÍÉ—a~4fÏ_˛˙Ò'„∆Oò¯i¯§àHò5%:fjÏ¥∏¯ÑƒÈI…3fŒJô=gÓº˘>˚|·¢≈©_¸ÌÀ¥%Kˇû˛UFf÷≤Â_gÁ¨XπjuÓöµÎ÷Cﬁ∆MõÛ
∑l›VT\≤}«Nn◊Ó={˜Ì?p–·“≤#GÀè?QqÚ‘i8Sy∂Í‹˘’5/]æRuıWØ]ø∑nMwÃç¿ªÜ∞ã≤´äã–¶íU„Tª9_n4óƒÕÊq\W¿]Ê^Û.¸h~©‡!úû
Øà#/Ú!âQ8ŸƒDMú&^sFS≠±ik7hø◊æëº$ç4\%},çì&HüJ•CR•‘ •“+©UÓ"ÎeÉ‹GÓ' É‰`9D&áÀIÚbyï|X'Ë<tﬁ:ΩŒ†Î£˚@7VÆK”≠÷ïËUz“w—ªÎΩÙ=Ùíæ∑˛˝H}§>⁄WÂÎÍ´S@Q)Œä´‚©tSz*~JÄ®+	J™í¶§+Y J•@Ÿ•P ï„J•rQπ¢‹RÇ°Ü!ÜCî!∆oH
Hò€«ª∏G±Œ™≤YÉ≠!÷¡÷a÷˝÷'V[Û‰ñ˜[^∂4∑˙∂6€ömmÔ;‰´@•SçWÌ·¸∏0.Ö[¿•1jÀπ-\-˜ˇ∆ß9B≠91jZ“Q(Eàa`‘4ïöV-hSµ˘⁄óH›$Y)ÖuPõ$•J•Rït]∫#Ωî^≥ó›ùQÛg‘˙À;©≈1jŸr~µÆ‘FÈ∆Ë&0jŸù‘‹µÓzmµ˝î6jÚœPÎ§ñ≠‰+;:©U3j7µAù‘¢qåZD@
£Ê],[—™±æÀ®ÖZáZGX¨ÕÕ·-!m‘‰÷T;5€}Vü/ò‘≥~ÙìﬁˆÇkùf◊|-≥¸€K∞π∂πF(`s˝ Úy¿˛≈( ÀbÄG¨∫-^ãõ•ã≈≈‚lq≤®-é—B¡¬YTxjˇè†i	ì’L“öﬁ‹-iö˚,éŸeœ2ù—¥†1Æq~SπÂ“˝Ä¶Âñµç%çπÊ\s°9¿\dœoÙ6œ0Ob´~ÊPÛ ≥üiÑi∏)ÿ4–d`ÍgÍm“õ|Lû&4>7Zåèçç˜ÏY∆*„IcÖ±åYgç€å{ç√çCåÉç~FΩQg‘>X◊t¢©‘|,∆;∆]®`%ò'n◊ãÎ⁄ÔIO(ƒÂ∂KùÛS∏®∂Æ≈∫>«:8?ë∆$UHgzÖpÑE;3	¢BÒH{∂ÉñI?á˛SÚÕ ÍÆvØ⁄ΩCF¿/u†˙#¶YüVœ˘â∑≠o∑{‘y?õª‘.ÍÙéU⁄/ùıìÃâÍN{¸ˇ‹i≈8;≈˛O [ ñp·êè`),áLÿ€a+∏BC˙%¨ÑÔ‡{Xk ë}O_¿&ÿˇÑó

aúá*ÿì!
≤a
TC4úÉpj‡"\Ço!Í‡
‘¬ò
œ!ÆB=4@,<|q0‚!`:‰CÃÄdò	≥`6§¿òèa,Ä˘,Ñœ°
`1,b_˘/‡)<É£òãkPÖÚ(Äöq-Æ√ı∏Z†	Et Ê·F‹Ñõ1–’ËÑŒXà[‡5¸Ä[qa1ñ‡v‹Å;qÓ∆=∏˜·~<Ä·_p30·a,≈2<Ç.¯≈rÏÇÆËÜÓ–w—=ÒG/ÏäYx+$û¬”¯zc7ÿ˚∞;ˆ¿3Xâ>ÿ5®≈≥Xo‡ﬂpÓ£Ñ2ÍPèÁ<^¿j¨¡ãx	/£/˙°ÇºÇµXáıÿÄW°{·€ÿ˝·<ƒkîAôîEÀh9}MŸîC+h%≠¢’îKkh≠‡GÎh=— £ç¥â6S>P!m°≠¥çä®òè„„©Ñ∂”⁄Iªh7Ì°Ω¥èˆ”:Há¯>ëS)ï—:JÂtåé”	™†ìtäN”7tÜ*È,U—9:O®öjË"]¢ÀtÖj˘fæÖoÂm(®N‡A AGA-8Q’S]£ÎtÉn“-∫MF2—2S#5—]∫G˜È=§GÙ-=fµ˛î,Ùå˛AœÒ:ﬁ¿õxo£—…]t›Dw—CÙΩƒÆ¢∑ÿMÏ.˙à=Eç®%Qu¢ﬁ…√ÈGöÎ;HÀ"	¯;=_œtø=ª‰º¿¬Ê¿&Çä
àHéKF@EOë3"Tô	
®‰,(ﬁùàX'Í)ß®HëúDY`ÅM,ª7ﬁ’˝1MMMU◊Øfûßñ‘ñ9!'Âîúñ3rVŒ…or^~w%Æ‘ïπÎÆ‹›pÓ¶ªÂ*]U4à™(ÿÊ∂ÖM∞â6…&€õj”0AÍH]˚™ùh'Ÿ…vä}Õænß⁄iv∫}√æiﬂ≤3ÏL;ÀŒ∂sÏ\;œŒ∑ÇÉ¡	ª0¯≈.≤ãÌˇz-ıØÿ;ˆ]ª‹ægˇfˇnˇaﬂøGÇ„>≥+Ïv•]eW€Ìª÷Æ≥Ÿıˆcª¡~b7⁄Mv≥‘ì˙“@J#i,q“DöJ3âóÊ“B$Qí$9272è:Fûß{®›KùÈæ»8ÍB]©uß‘ìzQoÍC}©ıß|@i¶!4îÜ—p∫üF–HY )í*ií.í)-%K˛êR ÂídKé‰“öI≥h6Õ°π4èÊ”ZHãh1-°∑i)-£ÂQçD1àSÖÍä∫™é™k™H´RU¶Æ´ruC•©
uS›Rï*›g´ |–@0`ÅÄ!T ‡ 
’ b°:‘ÄöPKeBm®£Z™,®ı†>4ÄÜ–C4ÒÌ-ü7‚U∂ ÅÊ*Z@$B$C
§Bö‰I+9"GÂò\ñBπ"WÈ{Há»ÑñêŸêπê≠†5¥°h;</¿ãºØ¿´0&¡dòØ—è:L•¥ìv—n⁄C{iÌßÙ˝LÈ˝BáÈW:BGÈßtíN—i:CgÈ˝FÁÈw∫@të.—e*§+tïÆQS	ïR]ßr∫”`:∆bu™†õXk“-™ƒZXÎ`]™‚Ä÷√˙¨9¬»Ü-3á,Ï∞6ƒFÿ„∞	Gπ«p,6≈fèÕπ:◊‡ö\ãksÆÀı∏>7‡Ü‹às7·¶‹å„πy‘p'r's
ßrßcL‡Œ‰ñú≈Ÿú√πú«≠∏5∑·∂|ﬂéâòƒwp;æìÔ‚ªπ=w‡é|w‚{π≥\ì"æèªDmî¢£u‹ïªqwÓ¡=π˜Ê>‹ó˚qŒÁ<êÒ‡h4Z-çÂ!<îáÒpæüGH≈É¸èÊá˘˛? èI1è·«y,ˇïü‡'˘)~öü·gy?«„aÃÑY0Ê¿\òÛa,îXãa	ºKaºÔ¬rû •R&◊•. ≤BV *Y- Yãπr.C°û®'Î◊ÙT=]œ–≥Ù<Ω@/—Ô¯∞BØ÷kÙ:Ω^o–õıg˙KΩUo”€ı.∏¢˜Èüıa}Lü“ÁÙ˙í.‘W·*\É"(Ü(Ö2∏émÒ6º]÷…G≤^*‰¶‹íJ©rî√®Äõp*°JZi–ZG‡¢FL∆tº€·]ÿﬁüÓàù∞3v¡nÿ˚·@™õ‡|¡1¯>É„u>è/˚\4	ß‡Î8ﬂ¿∑p&Œˆi>.ƒ≈æW.”i¯.æáÔ„*\ã„&¸∑‡Á¯~„õÕ‹É˚t¿CxO‡ùçÁ± ±À∞´|Ô±>√«òÍ¶¶©´L}”ÿ∑†¶>—«õ&—$õTìn2MñnerLûiÎ“]>Ìw4ù4ô{MgsüÈb∫ön¶ªÈazö^¶∑Èc˙ö~¶ø…7Ã@3»6CÃPø3L6»∆ˇœGáZ¥˚ﬂ|Ãp3 å6èö«d≥g\Ë™πÆék‡‚\ºKt….’•ª,óÁ⁄∫vÆΩÎ‰∫∏ÆèÀwÉ›p7 çvè∫1n¨è÷ã÷W«‘quBùTß‘iÆ
ÉPÖÍ0bhBR»aJË¬hX-å	c√Íaç∞fXKùQg#•ë≤»ıHy‰F§BvÀŸ+˚døêü‰g9(á‰9ø√p
d[∞!¯ﬁ0€T^∞9¯4¯Fù6õÇoÂª`R∞5ò™{˘ﬁŸœw®æjÜö)ﬂÎz†§Î˛:?¨´$J‘yQ™çhâ¿◊ëóÉ/ƒ∑b%V™ª›nè€Îˆ¡õÚk∞$∏¸;XÃUw≥T5^ÕQs’<5!¯ßzQÿå3œô	ù|&[‰s˘Bæî…WÚµlÖÔ·ÿ?¬ÿ	ª`7ÏÅΩ∞ˆ√8'‡$úÇ”pŒ¬9¯Œ{ùwzç˝1Ë&∫©n¶„Ω…áp4>Ïùˆ∆>ÿ◊+â£/∑;ˆ¿ûﬁ⁄∑∏øÛﬁv‚.‹ÌÌ>ã„9Ø¯I|
ü÷I:YßËTØ˘|_Úíß{œSΩÁ7ΩÔWtöN˜™ÁËù©[Í,ù≠stÆŒÛJã±KΩÿãx	/{ß±^jç?ÔÙN„Ãoıq3VË~]Ù.;xô˜xÈ'ÒûˆzSº·$o8;õ,ìÌM'xœ^Ò¶ùπS0E∑“≠uë.∆-A£ˇÆï¡¯Æ‡®™3¸ˇÁû›Ñ`yÊÙn.â4õÄ°B∞$ªÅ4¬”› v7$ù©ƒÇX®ûÁíVPd¥ µ¥»À«	P	 Ï–qJ)Hë¢2"Hf®îBˆˆªõìŒ»Ω˚¯œ˘œ9ˇ˚?ˇﬂW¶S_"Î‚˝o§⁄∫h„ÏqΩKøñoÎ≥ïı?PÈÈ¥õÔP›FôM≈$Èjˆ∑QﬂæDΩh*≠G:Ä˙–4*Fúƒ™Á÷BÎ
ç§h≥µóó[;ÄU˙mpôdF∞~*ı+⁄%
Zø•X™£Œ4Ç&s
£b9M7¡√ã¥éÒ3÷mPÌˇ{ÅÚiç±[w)ÉÍÂ«ôNBEÄù÷l´ö˙S*ô¬cù∂>ßt
¢≥x<y∏Ié#7™¸UÙ2'iÙ˙ã«ãYZ°„=P*¶È®ˇü&ù≈á‹ÉKg◊≠_Yó…I=i x™¶+ú√„≈oç≤Œ“⁄G@^˚mí3‰V«å»hÎUÎ}ÍM{Q„øÀáCøπ∑Ã˙Ωı≈ÉülhdËî£ß9åÂ_Ùç®µjiMÂ#® u‘⁄˘4jâ%bâvíA⁄Y‡ˆ)˙)Xd?†É–Õ?QÛ_B≈ü¬?ÊrƒÃ7®N*ƒqmÉ∂G;%YnáæJÉé ∫ﬁâˆA«ŸÅÛÊRû√Û–≥º ÁÖ◊ƒ-+W»oÂ=Gz‰|‰[kÇuì)ô~ÇÆß∫˝C4˛ˇJ£ﬂ∫AˇAœëÀUËc≤—5TG©b¢®Î≈Ò&r√ZÌ∞ÃëÚqyLûE<¨é	«DÓæy1Úf‰Ñµ◊:ﬂÈäÛ”©]ØÿBÔ°˚Ëßt¡ˆú?ÇÀ¯1PôœœÒ:ÙCG–}\Öî}S≈·’y‚–”ÚËm∫¿Œg≈ß‚kqSsh©àÄ'q'*≠Q˚õˆ•t…t9HfÀâ≤=¡ºcë∂9v:ﬁw\G‹T8kú_°¶^{Ù^∆Ωœ"©ä®»n¯n,<i14±	›Ê€–≈ÙòG°ëO`Ö√
…Ëùﬂ√πàKx<? 3πíósrŸÀºùﬁ[ê 2†ûL1FLaQâ˙≠U¡º˚ëÀNã3¢ú'hrG∂V¨ïi3¥' √mâ∂ö]´Ì–ék'µÀ⁄WZ3¨ñ ˚Àß‰b˘ä‹*˜»» ?«ª˜dì„Ñ„Æ„ÆS8ìù}ùÉëS∂9/ƒ8cÜ∆î¢O8s#∂]`8◊©›#íÉ˝≈—K÷r3&˙±§nê‹;LAT‹†—ZvÈj„¡[oë${⁄;ù^©∞†>BµN°1ë<Oª¯ú8/ˇ,F¢ãqí‹™=·¯P∏i'≤—ÒÆ8¿¥G‰ãÈb£F|â∑—%¯˚/i?ŒÛi'7s?À√∏ñNâ>⁄^I˘÷f!πÛu¥LV–cÙ¿áá”9∫Ÿ$ª»gêüi=,˙}Œ€È;¨k»n≤QY¶˛æäÏ¨7qVãxLBôÎ<N{ÿI3Ã9J.¶ÎÙ_∫‚ÿè*@&Ω©ñõ‰÷0+Ü(£màª*ãàπ/9à±=öâHèC.Ç®.•2™†gëı÷Z ⁄h≠∞YÛË#ÏΩÉ>‰øÜàhƒé|˙ ÔÛÙ	ØFé}∞úﬂ˜D*®âÆr"ßÒƒC≥c!n¶®´9é9≥°Ìï¥}ﬁ	f”	∫J∑8∂I¢Lz¸ÊÇ˜ ÕAÌ r2’ f"è¥J2ß,áˆ6"û"6Æ#OÃ§CtÜ'@¢Ÿ†ãsJ†ÁübıÎ∞‡
ﬁçô
dÌ˙rwÂ\± Ùº8i=≤Vx:G_B€VîØL‰O«Y∑ËQ™ Ö°T ∞¿;4ô’ßÖæ∞ã
8ïˇà}!DhWÍG√_∞†Ã»+WTkq«Xò∑W
ç‰'¡E7»qèzÛD âL'YìäˇÂ‚Qi’iOGÊ“G¥6Ò Ö1>Ôò©ﬁ—£FÊè»û;,Áë…~x†¨LO∆>îû6¿HuÎ?ËﬂØoJrRbBüﬁΩzˆËÓÍ÷µK|Á∏N±1Ná‘S¶ﬂ(
È*=§d∫1n\ñ=6¬ò∑õ)SE◊(=]¶w\È≈ ü˝ﬂJoÀJo€JvÈ˘îüï©˚]Ûz#óM
 ˛µœÍ™9
èè¬k¢p¿n76Ë˛ƒ*üÆ8§˚U—¬*”Ú·∏ÜŒqÖFae\V&5ƒuÿêJ0j8aGë‡œk€L©d√ÁWIÜœÊ@ii˛pÖ*ù˚R‹Ó`V¶‚¬ŸFπ"£@uÛDóPaîår™ò(Ω⁄ñÜVÎôMf}£ã Cû¯
£"<3†¥p–¶—›∫>ï∞¯b‚wCﬁ£0P◊õ¢ô˛ƒj›öfùÆö&⁄c›ˆo0à3∞W§ÖÃ"êÆáK¶Ë†&VäWÅ§nKbK’"_•·∑gBst’…(0™Ã9!ò&ŸT4yë{Wr≤wüuûí˝∫95`∏’Ë#ˆımËEÊ‰EªìºzRGLVfÉ´{ãb∫vk‚ª¥*€pQ(∫‹ÜJ&∑iñméåb8Ñ“gÎ‡$`@¶\˚ß2óÃŸπXÜ'»ÿ•*`ëj’©0d∫ÚÏy{ør§π›ºI £˘Z«ôpÎå3Õuìl–ˆì6W˛>¨<ïëaªHL!l
GE«9Yô≈P£∆•„Í£RË6Ãıª›∂ÅW7z©µtR†e¨Sy .ÚˆïŸò¶˚òﬁ”lÃ“˚ò∂Ì!ûºáp9QoõﬁˆÈÊÍ””_ïß∏œ–ï-¯í)F…§≤ÄÓ7C≠∫-ô⁄a‘Çœm√µB™ga@K≠êH—¢X8ÂÃ∂≈ˆ Ød>Œ®SW(Nù`ΩHπB„Z~Éqn˜˜Óiåâm∑©—∫nÔä˛}∑≠ïKïÁÈ8—a‹ÅªxSø2]îL-3Õ∏∏"$ ”,2Ù"3dÜ≠•ÂÜÓ2Ã}b´ÿj÷¯C˜⁄hÌ_ù¢äÍÉ¢äÛ‡¨Ç
~n“ˇÿÆÿ¶Æ+|Ô}Ôæ€âüÌÿÒo¸úƒââ¡qÁ«‘≠	-å,¸ñüd}–B!¶ïTmŸ∫E*"°c*∆@j™ Äí–*âÄf£Ö©®U«‘ICS∆üp©ä°øÏ\áUÌ4€Ô^?˚Ωwœ˝ŒwæsŒÄÜ˚ñu¨QR˚û\5H0iy∫πΩ}"Ãﬁê¶E‘|ö`CáIZs  2âºÅëG®A∏3∏…Pù∫ë;™L§r©ÖJ6’ñK°4|W&a®âál![RÂ∆&5ä ïÉZm6ñêçÙ3§†'¥¬àıéH2F≤ÇÏ“Y\ädÑaD‰MÕ$ﬂ≥T˘8O¯a≤o»vx3[Qœ‰≤%É“i%•¿ZX«e§^q44÷‚,≤ª»˙?Ë_∑b˚ÿŒŒGÎÀå%77∑†Ü$◊ŒWåï_˝¡8zp≥§,—Úñ¸HsWíJS'È4ÌDèä≤§ ¯ÿfÇÁm:-›£-Ã˚¶fM&7˛Ccèqı	¬’πÏŒ"ëpè/õ;€øaÁá˚ﬂin=a,<wˇ›_·?‚Íø%˜Ø‹5≤∆fI∑1ÇcV¶ﬂó%≥`áqâÊ·&≥…ÙÆÀ≠(àTD=ñŒ≠Ó(¿Æ∑çÁ`Ì∂L6ámIdK&k‚éê≥Hƒ ÜÜ∆≤]ÿS’›—∏|>È√ûã€~≥E}—øv9[oÓ%œë~w≠äc™àFæ¬©\ú„ππT…Ø≈!¯ßl≠qΩMπÆ£ÍåKÄwÁê‘ﬂ„{⁄NÄı*◊ú§	ôH≈˜¨Âø≥6«l≠â◊¡˝{X_7}w≤:≈pZ[Ûæ˚ÔàÔˇ±˚≤˚≤Á≤WjÒµ¯[+<˘ΩÓc¸ø$xUΩÛ˘wãß≈+ïªÀ=Â^ŒU¡Ø‡˚‹á|á¸á«¸«íîÄ®	llÏ|ê√Scö´»ô≈b∞Mf•¶√_CvWì∑á∂XáÒ
≠,h©∂ãø[é8®|’ÂÇ
#o–zUyâxJ>˚(øµ∂lf°2—ïJµ1.‰¢]„QΩ+e≥'±≠.™ÉÇå†¿‘ÿ†-…l¥Ê'≠PIÚíí§íf[2öµ§Â…UöYˆy|ƒÁ¿¨Ä¡Gogk]≤Í,ÚAÜÛ√ò∫÷‘‘‘éªt]«∂PÉΩ±°±°>QQV*à·ÜÚ∫Z(éQ‡ë∑LV*˝wŒEgØo_µQ2nz∞t·o˜Áµ’Û\òﬁƒÚóÈïÀWØﬂÙsˇÕK∑ﬂ[7¥vNvq0]W˝ö
¶1Õ«5aAh‚MÚIé°´4N	=)}z<£L
R(ùIg¶˘¶Ÿ.2ècW¿Ê…{”˛'h¯Ω•bΩ¶U	J°#A≈ûòÌûÌ—ËrÁÔqQê]§yÇ	F,Ç:Jö¸÷a≤gP˘D„ãZ©˚M~D NHëCäKuó7d)
V<Í·ñád~Ç—û¨Œ∞àÖ¿Õe«ï‹u=jg—ÉÙh‰§>—?(Úy∂AÓN·•ÓkœoﬁÌ33ˆ]ˇó<w¢=öRok¥¸¢ˇì`Õ#Kª∑Ω™}õ;™ycAáaœoó∞v»Q@—ÑÁå qÍ™&7&BëqBé‘'8ª™-U¬0Ã@U|çò™-M®ë¶-õ–&≤û€@7Jù¶õúuÅÄôår&YÊECü#A;%»<ØR°àRA2iﬁ¿c&∂ÑŸHò¬Ñ„^∆g¥BA$îÁ1í,≈≈^àÄg4sûÅ„∏sxòîkrP∆qπG&Ú()G<\!´Sèyı∫ˇ∑gBÔ Í]Ó‹¬«◊œΩÈ Mß⁄2¿€jàÜh™ó∆¢ΩØûÔçπŸ$*©TÔ˘Û”d?-'‰Çä2~∑û2/k=UπrqS∆†ƒõFß@jr@‡õö≤}:VB!ﬁ8‰‡8˙°qÆ'˜¡+∆ÚNV]∫Ä€å!::˘:Qs◊Xf€»Ø‰ı3—U-˝RﬁX¯r’u~ÇÁÂêS"3Caó=Ë\‰$qÁI'q:ã J√vá§Ö1"æ -Bè@Ñ÷HÂI∂0¡êÕ	‡ﬂ.––ò[{:∂%÷€ÎèIj,#±¢R©é∏É8Ü…Øáf’,õãÂÀ6EÔöàvÅxÎô|Ódá-Y≠wÂ≈¬9’3H:ôXxŸ‘3‡`˙–a@î	¬wXY´ì
∏ËHwÑjKc´ÀïœÅ’660>WVîÖûTîÌ#ﬁ;ﬁ€Ò¸öªı∑∑.0˛e‡»GÔV˝xeÎÇôWéa{¥yôˆ %:xÍ¿öŒ— 3øzˆlWÅD¯∆ªT^9oÓrôÊFåóeãæ∞˘©*¶ÁœL›†´!´z—⁄¬ÚŒ¢ùÆ∑–oÖèÂœπœÕˇÊ‰∞±D
fÕpu”nyïDáX\Ï(.ûA™∏0#Ù ›/_‰˛l¶iº2”R·k–míºF€‹â¸læ@k•ªgÒR°VhO∂Æ±‚EVl’úÓËwD+µœ2q÷ªÖ+–]îî7Ó«~geøà≠bPåãî9ªÜ|ø|Ëó.¶:à,”Ò,H¯xîÕÏãŒ‰3ô•_¶"õÇBj±´òV0ô∞)Æ∫⁄>çÉÕ∆ßwåø}xN‡Ç£œ÷_zo˝˝_>Èﬂzå¯~Úı-¸Ó¿?√{ﬂZ}Íâ∂ﬂ6æ5nﬂŸ«ê€J¯50‘åvkèJî•∞`Rß'A\©ÃÒa(⁄Lrÿå†…mÂ»|2c≥W-àh\/´ò•3 
ÿf˘>€Ú€JµeSŸ‘ˇ!ñíXd£? G!NÛ9€zxÏÂ”ì∑»µú ’——ˇ∞]-∞QgxwfvÁ±∑{ÎÛŸ˜∞Øqå-å¡gÿË6Ö8Pî`a #©ãA≠6¡V ßUåIÄÖVPµµAAXy®I√√åaöäT*®DR—Z"´™´®JÅ ∑Ó?{gUŒæô›’hÔˇˇ˘Ê˚øÔ∂w‚ñ◊v¢ÔÅË∑@Ù\iw”ΩÆïSá’∞”ÏåLc;bL…¶¿!˛¥æŒ“Í≈£∆@∆√ÒãoãøYÜ/É…‡ø-æ<ö©C´3o»ÿﬁπùŸ%+ª
0y
0È¿πoxt¬¢	ÀË∂!∞ïm	lçl)‚zD/
EBEïyï— xÂ∂¿xÜ,ÂO≠‰g‰ß—„G≠£ˆüÃèÏKˆ€¬≈∫#1ËñƒgCÀQ %µ∞∏ZÁ!	√–¢≈˘jæƒ`æƒ‡‰¬Í MÎƒûÖ«°e®ƒq0§<±f"ö´ËjPîàÅÖƒbiÁæá∞(ì∑ømÛY4ãIÄ‰hû‰‘∂™zü|X™µ•yÄÀâè†⁄àÄ…!≥¿2g’‚4Ílˆˆ˘¬€ˇﬁ–ÒüˇUÕSgLÒ>+y∑ÎÉÎ#'õOÃCE∑2Oo?£Æπx]]˝Ï¬Îœ˙ÒÀ7ˇ„›ıÓ.LBûíA'˚¯|À-ÁDqQNB∞ä±¢kl%e–©1G?OU8]Øª]≥—l1Ò:≥ÀD™}ÊêILdd7{Hj/ÆÎ&«ˆõÕ9_·7‰û˚x≈>^qñÂÙxáƒ˝øﬂ®ïhæZÈ]Œú‘3ß—cw–ÊÃ&»i¿„êV^œA2ï“$øîï˚≥õGRäÊjçZó6¨i%Zã∂N˚R#]	¬
C¯
¯ßÉ ∞Çá$K…§.¿Qû'”«7≥=óJ⁄7	mÌ≠åoáZ©ﬁiÄ8vCm?îµUwπq¶´°êFò Ös¡ô–8„Ç®«‹*™á)’±lÌZªZπ¿És–)trL1Fß’áµ&7D}¢@˜+?N?¸¶Ó1	πhñ˛Óó=uáûô≠¿öx¥äºlüı/òº`v=;ãÂXüÌÊG∏cò)ÿóè≥
ËÍ≤≠+ÛV∏±IzﬂIzı>rê∫Eˇ!75P!c√˝≥ñ§∏,¯#pQÆœ/‚mx7ﬁÕ˜à˝xü√‚æÄÔ	<W|£vP jU[ÛJ˙ÿH»HÎc#n~–Hì≥Ü@8M#îÜH.ÙcŸŸädgX·œ∞»üsÎ[˘i%+.‘¨WõÂNÅÑö∑ê¥L˝EÊ2j6{?∫Œ¨GØg˛xo3:¯_Ôqÿ…Ω¿ÉÔhÔ+ö2◊ç7Râ}MaDãÉ#|∞ˆ˙Ù„Rú'Úd&ø{·˜Üµ˜Ô.º%y»LèJ(Íûƒ&`◊TºÀÂ≈sR¬ôSóÚ´ôõ›∑ãß¬St¿–5˛/ZGà|TLl^" –‚i`|◊íÁx´ÿà:»€|ø8¬≈M~GÓ#;˘>Ò?'.°À‰S~E‹@#‰:ˇß07ÚÒ*⁄A^Â;ƒNDWœ°V≤ÜØ–KÑŒGã»|æH,gÀ˘
A£böïBsHä◊â¥E1
ùsQÄ‚$¬iŒÒî@°◊î&u+êÙ)bçÃLr≥¥ YÃµ*RÜ‡—Æ-/ÜUÖ ˇÖIÏ¶Î%b≥Ÿ¨Ç⁄ˇdT>(´s´·W¬8Ob∆ò Cà$Fpâ‡58@
¿°‚îïX™5†ö˝†¢» 8[Iœ4gâ!“¥4•%©K71ïù⁄ªp på @è∫!`*.,Rí%R.¬kL…qˆWm£UUv˝øÌ˙xÃŒ¥e⁄Í„Q2<∞?oÉ‡mˇ‰e€ä9ßéÛõ Òll¯ê·H)‹Ï|F©R‡D l ©YƒÊÌRO®B•ÍIo‘ªÍ]Û˛Ç8äGÓ4êWÓv /`™òßLˆmı/Æ≈±Œb8¬Hx™´»s%V¶-gw2dÑìî1Ã¢òCΩ†Vò»åâÃò$ıÛ‡$˚«\£—h1:£À@}∆êÅ≤ΩûÒ‹K˝3o55•xÚ°~ Ë`†#å∑∏ÛôTÍ`‡§Ÿ≥_õ*ìá
eq$˚√∞ÀÃ…bdËó®Ò-FïOGÛ¸U]GçZ÷e‘˙âÕçOM±&4\àìÿ≈§oŸ“«≥œ±~ügü1Ï‡i,ÖÎÿbˆKºèı·Ï >Õå¨uõQõBÓﬂ∫ªÊ¥d
9r†·Zx“„Ú“©)¥u√Ó``à“(¬:U–:4É>Ö\˙}¥åÚ0*¢O¢«È˙.˝3∫ÇF–˙52*P%˝.Ì†›Ù=§Àn“^5˛Q∆°∞RÒë 9DÕÎU¥BÕ˜.e ™Ò≈;¯‰Ω˘
––JPF7@ï"ÂM˜{=ZÎÙZÑ©‘bA≠àvç!∫1Ø£`ŸŒ∂∂Y[C€√››ëÓË∂xÄÜ 	ÒÇP<èƒi~µ…c’V™"l·duçÎ‘$‹DKb]¢+—ó–ùƒó	î∞+˙5®î¿ÆÀ=ﬂ—_‹˘·}Ò„˚#y°§G”£íõ€¿›§¿ªHuìïﬂäñ‚ÃùïÛíø_≥Ω_ùØnı:ΩSﬁqØSù˛≈°C◊Æ;6å>Ó]w∏jé˜º∑«€ÎΩ "|Ì◊ﬁÿÿÿΩ€we§ˆæß@÷a£[Æk«√«£¯	M]£}™°P^πiYJë-’kPaêûT7Y(=Ñ[Xí®…Âß%Ï‡É,_¸∞ÌÀ∫æod,åR¬µ˘åÜ"g€  bRÀπ∂_´S≠%ù˚Wı<’zÓÃõ6Ã˚¡Ç⁄>m∞∞ÙÍÅ◊~îWêπD>Z¶Æz¨q≠)‡á•V≠£(• m˜ïŸ¡Ö¡Â¥’hÏÁøµ˙ éZóπ–ô."¨PÃ¥¨Ü e6œ[·`ÿûiÕ>\oΩd_FÔàmHtÛÓÿ∂ÑŒ√<¥ö¨ı÷ÎW÷[ñf9f löÅ`†¿åñÁ€aµ%‹F·∞‚î rA·
4˙?™À∏âÎ
√˜ÓSª⁄ïıñV≤@⁄ï_»ÿ∆^€ÿp±çm‹Äkïä0ìÿ`2[Jg(ê∂84I	M&≈)¥$)ml 6è‹íÃt¬0	iCj Ü:d2$ı‹ï Wè{ˆﬁ]I´sŒ˝œwNEH∂Ä|,⁄À‰NqÁ8ÜÎÔ”pX´–(-‚ôÍ5u*óòπ01ôxÄ% S@6`Ï®C˜ë8ô ≠4˝…{Ω>WÑ.£4Õ·xËUÌE™˜∆G[FOØ⁄¥v(˝áÎñ≠ÏÆˇÏ£µımã£áØ±«⁄ﬁjﬂ«˘≥∑HÅÁàGRtk¥ÛªM+$ñT„¶ÃUÊÿ;•¯úÒ»àc8t¥¯L)Ì¨⁄Yè?÷≈vØÁ~*Ø/˛D∫†Iqqπmπ◊÷H›Œ’ëû‚’•B€B/F$ßF*ˆ¥È:±Fó–€’vÌ¥zZcíjR€™n’.´ó5.&Œê£jT´ìu≠Ylñ™¥µró∂Q˛ô∫]˛µ∫_|M~]u. ú iä®»^ïW5Qf∞Ø√o(aΩ◊è{˝{¸îˇ’ÖÇ†B¥0AúÈ¶—bLd©1÷+∞Åó‚Uxﬁã‚SÿÇøbå@ùù¡ÃÃÇˇf∆á}ÜÀß˚ö˘¢¬@ŸÙ¢ΩˆÉv ﬁåo:≤TfûœÂ|Û£ùáê1;ﬁB¢◊jø6∂¬ÕÀd"6ñµÎbcPÌ≤“eù
˛ÜÊiÃ≤ˆ?ÉÆ:‹fÔ:…ÏúëÁ¨ì√Œ:—|Áëµ/õkrùË'oW]lÍ#ûCœqé\≠VÉÂjÉ∂_|CQ"û€äÆØ7+,EÊ≥ZØyÿRÒú«ÌÛ2ff1Z5·p`Oˇow>≤D˘jUˇÊõo`7ˆÒÈª6m⁄⁄X^:¸‡'œf–€ÈÎÈ¯b˛Œß7∂ÎçAgŸ‹éçÔ˚G˜7ÔÀ…«´’:Ω†º˚«'ü˘˘ÁObLÚ´4iˆ0è÷ZπP¡T∞KÖ>aã∞C‡9ÃRMÒ»"¯|f3©∑x¶!r|W†Õd¡‘A€ñR}‘j≈Pä%ı◊\T⁄;Qï˙ÿ_©zu-ÀiRΩâüP8™#¿àKÈÊπt+3zÁŒ∑Û‡ÆxÑ¯gÉ‚å·å—1.l≠≤2à√V#0Gﬂ2ñûbïj®Ú◊!“EÈ˛ëK≤>ÓÈL∞êì»#î†ÅØI∑Öª‚mâ=Àæ'ûï>EÖ^êÆ£+ÇpÄ˘3{@‹'gÜÿ„‚È]F(cT∂\Kªôÿ›‚Ô$K6‚á-ÿ&sD±më,»p !∑<0îÂÀ√ChÛ	2≥r4¬< •`%œC¢4E'xx‘ ∞··L≈@9ú©4~D#)åhä
c‰Ü äÀVZE∑’*
œá-Ç€b´$Â–~ÑñÖâfE+/X8œ≥§ÖÂ4!§‚[å9å+1Ãù¥û4 	Û√T
C∞°√P‰ï9µ(-©D¿üJîT¬ﬂ
aΩ˙Ä(Ìπßy˜rò#r–lôJöˇo≤ƒdÇf2GdH&"8‚ tEHsÑª“¬Â±∫Å/„ÈÅÙôÙÁÈã ˙Ê=ƒ †Œ≈ﬂ#úIAmÍÑ≤†wFìyÀòg≠>%bÜfXögXÜf≥«a
ª¡ÊJò„IYƒÑ
Q°)‡Nƒä‹ıwµaÂ¿’ ≤à«)|7G˘é £ÜπÔM¸†¥t	ƒYv`I≈>‰ù5ê˝9›#r÷9L◊8rnô⁄ÛB≠¨áæ˜üƒ-(vø;tPﬁ‘5º«Ò˜ÒÚ‘™ánOù†ﬁ˚[Íe¯Â∆ÃóL3i®'ç5|¿íœÜºÅ¶‡‚¸∆ÇœÏóBç“†¸†∞[Y]∏≠yÂÖ¿˛¿Hl‡›†ƒq≤«À)ﬁ"ÆƒW6P€®˝‹Ó'Ω≠bßB— YéR9jƒ Ù®°√†ÑÙﬁËΩ(mëTØ∞ÂÈèÑ0
ŸCCwCL(Tä´ê´Ñæ(¥<b‰;ÊGå†@èSÎè0º$ã•d«¿9”¬i”¬•pÖa∏≠”fZJÑb9>]⁄#Q–Ád†’1l^]
¥ÈX_zÒõ
Hé™í»c>|…á€|è˘z}¥O©Í˘Néı÷AMHN$ZÌâ[±Ïl,ÑMR∂‡æY)ÃzÀnÊ¡ÚN∆'Ó„~ ?“óEüàRâX<üÄ “6{V í	"ÈE ‡h∑◊!öŒqöjÍzmMm 1·.èÑñj™qW&v˛É√Õt∞ }›jÁÈ≈Ø&^=Ÿ±˚˘wñ,Ìm^ÜW÷\è÷v.\≤® n•æ(˚˝Æ¯ˆ7”√œ˛jI~≠bih|˙áœ5ÁÑÛ€ÕMüwV˙ãÍÁvT÷Fª¿Â˝êªLﬁÃGØå gÊé1ÀZW¸^êrvpbá∑√œøÕs’Ã\yÆ´:∏àiñõ]ãÇª¯óQ≤¡¶G¬ ÀªI,\Vk}K†oûf/°Ë¬ºa\bH∏m!94?ÎÔd}ÀD™˛j+phñBÅÆÁM&pbAßaÌÊ∫≈no∑ø'üM@àrÄÎú ‹‡∞"èjﬂÊÓ« SÉ£Ètjd≈!√©7nL¸‚ó´ª∂±«R_ÔJ_KﬂMù˛tE|Äö±Ø≠oœÅ£|Ö‘µÂﬂÁ√NP–e£Ω3/Óå{◊‰ı8{ºõ¸ïó®ó§3ˆ3˛èÌ¸„‹∏e‹5Óπ√πfªf{öúMﬁ\Íë¯9ŒZo≠üﬁ¿n»Îg∑ÂmW^wæÊqı
63CÉ:±Gún›V%ìeön⁄<á.√¡gNáp)2‡:TµÚÙà6ß¬>ìUAÂ29ê#m6l˘à[	tf]ŸBÄ&—2õúà—L&∆ cSì±ÿ,GÄOMb»fUM-Kíé¥.êäÃ¨Ù€„m=õ6?π¥€É›±…çßo`ÔƒËÍøïè.€˘óì+zÀﬂ≈Öˇ£ªÍÉ£(œ¯æ˚˝qª∑˜±{ªGr…ô‰6ó#·.‘@‡6$F>ZÇ©â	NÅ§ê`U™2ÇCR+!J∞Z¥•â‘ÅÈ¥3˝C™É”±•8-mpZ¶≈@%∑ÈÛÓ]†é”dˆﬁ›ΩΩ}ﬂ˜y~œÔ˘˝ç8Tq˚îeª‹ºdW˚≥lVÃ˙ÛhŸ–∏-=ëæ9ìJ{fjis’‰Y†5ô˚!Ë¬E¬®±âSºê
1W‰¬HÒzâ.åù(o?ZwáΩcyƒ∏=0Ô≈\uXëªŸn±€üG€ûçFkWÁ˘øP°W8w~Ÿv π„¸zËydÊ¸…¶gWl€≤˙/<ñE®Lô?&’Òûü}uÕõoú:tˆ€ ˚µ +A¢˝dÑP°Nö•∫˝BøºG}ã9,ûNÀ√aû¢y‰Cl≥∏8Úñ|í=>'û˜|$˛¡sõª%ÀEﬁ"ÕÜ–l≈óˆjg¥˜5Js—…∏£Çë¸°÷∆ﬂ¢t*§b¯±>iNI£îü¿œó¶›Òæx~LTÁG£»m/–)¯YÇPaŸ~?Ñ˘8-˘Órâ#¢(©ÂAîåtD÷FFËà7 €≤7/∞aGºÉÍ&6æ ÜÌ†aW3ÜÒ¬P∞Åπ⁄’≤ôú+ñ˝∞x¬è˘Tç«°…GoZ∑˚æ◊·EÖpÏ∏ Œq/¢∑πgØ`mwßWlàíÇ'UÙä¡r@¨k"íE
w¬^`Ñ!^
Çcú†¢Æå‰Usà¸3>=Í¸„Ön¸Ú≥9õz~≈‹6ãZﬂ∫ºæ°áì˝áNÏæXH8Áú˜6Ïòáæ˝Ï¶∆∆'1oP ø•√ˆÙ4™¢K’R_ñÓ3û>cêöÓ#É~›ßºÑ™°íAÅ˜J®CöêH	'Bdëœ´£	È¯2¢¬{o¿´Ÿ@PR~1ﬂ¬S|•öÙu¯Hﬂ0¢mY	ƒ»`1®ü’IcB§u3¥~ÑÏ&Ú9J›<ﬁB⁄ºBP&ÿö¬ëÅè∫È^¯+Ù°@ u”CúÀ
ZJ+z-3Íˆ?µ˛…X„úŸµ|‡å–±ñ≠[ññˇF≠[≤“¯)jæ[˚Œ∫”UI¥»~‚ô‚ãIøGÓ©Ÿ*˜’–•®å,£¶°ô¢l‘H6Rèy≥¡lEkºRı-ÔmﬂÌÄñú“gU¶¶Çy‘V6MΩ·…Öƒù–≥%è,UydK—CZµÏ{cî„
8·VÄt≈ÁÇ‰∏‰…èïU˘(´»è5È|!⁄∑Òw0òpJº±\“8√d´‚R,l`“L3ﬁUÉjÄÇÜmëHïG˝Ê¥ªÏs≥¿?Í55we≤YÂnÆÀÀ–…˛O∏ãs'Ç‰∏EX∑XË‚ÎµBãÎuyÀ€ÏÆX_ïËN≤∏ÀÖ=4Ÿ˜kÅ¬
 ’F}AÖ,+°ﬁ„≤Ô°æ∏≤uÕW*Ú∆≥mx°3øÌC‹úû”ªú˝e|sÁÍù€∫Vnn∂–"QΩ¶ÏÒGNÏ∫à$˛≈+„˝Í›o÷èÏT»ÕoøzËµ7_Ö`˝º^x]'ÜÏÑï†:úHu.öÎ˚3˙8Fg …G}]>!2Ù˘TêD^‘bäD1®â:AHbåÏ“ÚÙQMHÄ0CJÙ˚ ”/ÉŸc‹0»Î2à`L◊\⁄Çg5tCCö ‰ﬂª.Qˇµ\=0úçÆÚ|ƒ5ài»ïWºÎ°`Å!5Är⁄mw,>E?ﬂˆﬁäÅ≈≈ŒhÈíŸÕkRŒ(»Çøú◊≥mWn7Ys∏≠∂i˚÷‹?a”ÄÌó°è¿)˛ÚôBÄïe|b∆Z≤O8&ú.◊¶DË6	ÉpÉ°Xé g ]Ã&.ü¿/€A±À—"…Aœt±-O”&_ÿ◊Ω}d‹Ú§Ô(/◊%x—pºåLgôÙID;„w–±;CÜ∂CÜ:`ÖÒÔÇö∏t\ˆe\#π¡¨NsîJXKX≈œàÁÖﬂâã‚R™ì"eŒöŸØÛO≥ÃI·2}çß?côE‹"~ªÅ˛}Ä`˙Ÿ~ÆüKh?õ†L[≈UÒIy!ΩêAì
¢¿ãå(P,-14ª$$âÁDJ%zò¸éfí|]	á∏ï2)≈PÅJ`¡¶'Û\Ab„}õÍXØÖ=ëœ$¸cwÉ_?YM‘ƒ˘!!ö&&M_/±5VÅyó√˘∂#ÕGmŒ+ËÁ˜Œgõ¡‚ç°ßùÔÁGó∂;G`Í{Ÿ\:B0£8Œ%”¬ê}Ã1Ê,sÅπŒ0%L'≥âÑlâIF≈1ô5¬§øîµBûR˘1Ô~ﬁsm$v∞¢Öfçq¯u;Ã]»£±∫'M•˘¥ë.k"‰4ö <•T2æTËå˜≈∆ﬂ`s?ıú`Oxé≈/ƒ?â+D<oÅ/Œƒ/«Ÿ∏.Jg‡∫œ˝í·¢4.∆mcH‰¢n˜†9’Á≥¶≈,†ÁUc~ü›V€ÈCkH√d≥ÌOâ¡ΩµE®≥¡Ωw*b1+Æ!Ç∞\"dhœÄu[®e7¿QGπï∂Ïô≥”IÎ}Î≤Ey≠´œ¢´‘öfMX¥eV˛µ~“DÂ)1ëÁ ˙1Ë˜–í∆z€Ò0Y∫™[æôkÿﬂbnÑxÆK‡∂ÑÅ®Ü˝Q»uI!›-eÎn)ﬂ´Íçà⁄qv’ûiÕØ/ÍıJ®Ìbk…¨Æ˚ù—HfFCWµ3J«vøΩÏëGñu,o⁄óÀíØ›_?o«á$õ¥Mmﬁ≤?79€çŸr¶mÉÑm|O”≤•6ÒMﬁOUÜu©Õ«)2Îë$ê™$äÈÑKmöÄó¸?j•òG¡Òïeœ]ÜÛ†–Âæ»pn§æDr˘¬òTπ—/Pö$ ::Îåñ/©õˇ›≥„√ˆ˛≈%d‰» Z∂9%tl‡ù∆Æ-œa^{Ùk?ÏT∑≥◊ûwçÚ∑∑4˙yï!˝&c
dVm¥ÍYc/πè›«Ôı…?2.zFôQˆ™¨˛/ﬂ’≈uÖÔùπ3≥Û⁄«ÏÏŒÓ¨±wgÌı⁄kcÉwm÷∏xHç1«Ê·ßrm•4∑¢∏Q’êaih£"≈™*≈Ö™1ÿ-víõ†“îVçö ~¥VÂÙÅÇb*ÍÄÔˆ‹Y;•©⁄’ÃΩsvösÓ7ﬂ˘>◊uÊ◊¸Æ_(‹A◊Û¸ÎsP(¥D:Ù¨`ˆGDòà;Ü˛√ûL^A¥/u?qØw7hˆΩ!ÇiÎ√Ω˛¥i°ÄØ4QˆPü€r|·‹]úŒΩ˘ﬁKπé„Ë©˝˚áá˜Ô?≈X/`˛xÓ⁄˚wso…è~{tt‰‹Ë(Õ˜DÓÛ‰4‰Îr÷^æ ﬂÊg¥4õU≥˛t§Ö›†n∑DDDÍqó|Àº ‚ÇÔÁa?îeØ«Ω‰g}n∑'·ı:FE˛∏£Ì∏”Èù˝/OÎÙ&⁄Ô©ß}»ßÄÉï§9/öZjU˛ùı	Ã◊˝‡sSò…}8µ˝d',q≈›;û;˙ƒûc∞¥];s»-‰Ês7[ª˛∆Nç_|e¸’Ôú@!ƒ68πè⁄…”›x+∑õ;»±5⁄v˜g›4"â•DaN*yÖiV:FôdŸÇ ¯f^J"—+÷äD"öœhÁ5¶O{F{M{K#ö%0Î‰œ0áÒfpÿ◊<Öã
"t‡!8œ˜Ü;
2*ËŒÆ,îb µè[€«2õﬂ~IZπ
Ís0˝ë Â}xÑ"˙ì˚Z˙{[ˇâ’[jH‚ÙæñÃ?ñØΩêª9÷ûΩêc%Û∫=Õ˚¯∏´‹Ò3⁄˝t˘p•(Ë≠:£˝Dùr_ãΩøØŒ[|Ö⁄≠ÓRáÂ”⁄´÷î"¨ç€•-â=÷Œƒê6§µæV*6$÷Ò≠ÚFµ””{ƒ¨“ÚDÉíâe¨L<S*Ác!µ\±,+.îZv’ïA˝ÀÅ/U¨<8Ry60\9aMƒ’√¯§ÒBËÂ ÔUéUÒF,h«‚È†]Tí.	‚?Ç‰Øs≈∫ Nñ1evhY∫Ã¨¢Ï` ÎvU·⁄*\SÖ´äcµ^Ï≠√1¥»ÃŒó˙í®B_JN“íl
u‡Œ"É§h<|Z©ù·1Êq'¨˙XklÓ1v‚Ω∆<ñ∞¡3f1Iø™0I≥è`“öîªLl∂˙∞Q˘∫¥˜D¶êïøNwl≤0[ì˘ôÒ‚Rœåóî‚∞Èƒvˆ©∏ﬁjµŒ®ﬂ≤ÆZÔX|ÃRTBL¥®ÈQU˜„Fu3^4ÄNlï•Èl/Éﬁáp-∂q&˝¯0û√,¬^à˙1qÆÙ·JåÌDpô#M!h√£ÉuÜœ5lx®ag“ÜùZCY\èQbÙOƒË6m`oèâªÃº…,&?ê∫◊[Ëe≥)ﬁK-v7ÍIi1
'{
éj ~ΩΩé≠-Õøiã≤÷ÏI¬ uxÔGjV—ï,=º¨d°B∑/…Y«∫b∏¯–_tDZ]9ÄºÌ~\¡ÆtpA–
uâZlj˚üx≤°Ll»}ˇ”_ΩıÓ≠wíπ|}€ü™ç%œ{∂ﬂ{ˇÊÆImÈN’D∫Ø}Õß^>˛”O¨XÛHI0^(⁄Ω±˝ËKøÉØ®$ˇWÊõ‹+–~cWDX7©¬”ËﬁËÓÒ· 
±¡ 24øéç—qàIPB¥‹dåc€”¥¡`Q/0•Ãq‡JùnEk§.±XÇöÿdàMZw†Y?Øø¶≥˝˙a˝˙[˙úŒ!›´GıZùËaspdIL¥è5 O¨ûòBz~zUO¡·ﬁÎmÚﬁs.–+0.\:2¬W∑Ëp{1ÿY›©©AãñÄí˙‚ô∫LôèyzZ./*ﬂ⁄ÒïMOgeÒŸg±I3πmœ•ä"∑*Î6Ø[1å;ÛˆwsœC}æ,≥ï$@ú≥ç«|{|ß8V‰√|”‰kg⁄}a«˘¯àDR@◊%ë˜Îâ@ QÇtïƒy¯ÊˇèJ]…ûsa◊ˇ6@ÖÛ1u–ÀNöêN⁄ııÙê}¥Òg{˜]ÿÑ√%[ö€æPâ√Áªw|Ê¬)f$öŸµ∫Û‡,ûKy †Éá<e±\“¨It‡È‡¢åﬂè√Ïòô®Ÿò>K0œ .ó§»‡ÿç5ES≤Pµ|MV‡€û≥ÉÀ¢i	q≤é¬r™î”®QBbÅí&$¨*Œ≥d—HåDÃ#	577¡2¶®,ÃFlMFë%QdÃ√±òUÈ°¢dZVK‘Z’Vâj¶Wjñ:¡ÑL2µ∂Lò¨LöI'a…èôZhámèíA8
¬‚∞r∞¶‡JÖ:ÓÙBßÍ?∫nWÀüùÿ—ßTújYØ‡|⁄)hXÙ;Ö_«¸F}C}É»ï‹6\˛ÀFÉw{Öc9®ﬁ¬ü~∏.X]Õj*ÇX5Uòr{TVB<#	úAA¶ò¯8S–≈b…ß(ZäMÒq9Àf˘6∂ç?√û·E7Õt∞j=îP&Ñ#¢,%ÇL‰t1,%éí§ú´ìRπ≤5pkƒV¥ûYœµ	ƒChê‚≈AÈê2Ñéë!ÓòxLRn¢õ‰wCº)›Pn£€dñõoK≥ ÙÄÃs˜ÖyÒÅ4ØTsì˘∑m1“ò&	ƒ…¸-'íh§,ùC4‚)á)<¶Ø¿,€0,.±Éb¶Á¡ƒ9˛4 ≤M#ô A"]tÍ	(£R>tV~‚uôp—…|«8/â0o≤W≤Hâ¬]¨ÇLñìdAtÒ.A‡8B(>	ÄÇ§w≥õq(\kEÏFQ®˘ìHÜ›F,vODqXΩ:ÖÕÇV1√fha¡/Ñ
 @ÖÂo^Ù(ﬁ&ÁÖ`Û9#Ú9o	∏@Úv8:¢Ã?!€j2æYÕB¬˜Åˆe[°ˇÃÌ≥Ö	¢ôÀ2çfñöÄ”E®.¢¯Ú”«X˜‰∆∞Ô⁄Ïπtrsø2kc&È˛œ[Ã≈Ön@ô;∑ôlî˘qzBKr¯_úW{PTÁ?˜ΩÇ¿ÚX^ÉJ@`-ØÂ±√*íÿ8‚+†`0÷5–NT&Œê—fb≈Q*h0ä®—hQp|∑£í∂õ¶VàR3”í:÷§©÷V%vl}ñ»ﬁ˛Œ∑ªŒÜ˙Oª3ø=ﬂ˝ûÁú˚;Á|7íÎnÏ0á%:$ÃaüŒZ4˙d~£Ω¯,UCÇCu´Lë∫)´8ﬂ»Ö∏túñé"Ù¬B2BÌîhÀ¥-¥)w‚¢*ß:X∫"F:lp≤ÍT\±qé5
_”\√dÒ$K2?EHNr%‰9)ìo…QøÒeıÙÈÉq¯Á^OO_±r∫ı˛_Ò}Pï·u=¢/\|
◊°÷Bvπ◊·U”éYQ&†(úP≠t÷ºã(ø{\±J¯Uà¨ô7]°!·Eë÷»8¸EƒÅ”wO‚ÅÂ	<{˜™∫€Uíì““8qÊáJÈû«R≤gCqJÒ‹53gï∆MŒ]¥ ÆïˇıD>SµhbR¯’ê⁄
§LÛëyUªß]¶0ET,≈∏Íú#€•C∆°aÌaö3"/:/^ôë3√!€∆ÆKmW⁄µÉ¡Cé¶ënYïZó≥⁄°,±¡—ñ£,ç\j[Ø‰EW:ñ∆(yŒxÁHeå√)ÁÖ*ôét%kÇ≥$/?ø`rqI“r„àµÅ§¨ÏÏÇ5âR‚ëÿK\ïCˆÿ•£ˆKˆ?€˚¥lÓ	* Zûµ6´)KÕ:-ß∫Ç÷‚ñ_R\Ä—ü?∑9qO¢úàëüE5èõ≤‡åÙ≤76¶>¨*‰ Û∞äõwPbëπì„√;ÓÃ¿ødç…A¢úv,o%LîÍTÛ´0⁄˚[AUUR∂aãíU|◊…πéà—1I™lãäPs≤GG‰:‰—R8n˛¯ûç“çËËòËòò‰4‹}í√√E)„ﬂd˘¡9©˙“OKw∑ßÂ¬%©˙∑ª=_∂(ç˛`Øîºø›ÛÖ«8p3aˆ¸âµÀRÏ…√r^úRRYí^ºπƒû6µ±Xª|Œ”‘√K/H5›=“Ús€v{.Ô€Îπ∫ø4zÔ>…æ˚è2^6rﬁpÕ[˙‹wÜœ›ˇÓ∫œ	Èw—˘…Iπ1ú”â4yÛº∏Ñ[ØÖ>∞ƒYà˚Æé`˘â∫|À¿¿ìA+Yl"ˇKb`º‡)•b+ºmıÓ…’}]≤”á:≠\†Âj-E /#®B;Oï“ﬂÈUå’ ≈ JPSÊøÖÁZ»≠≤”ƒ¸r`êLRÅ˘¿\Ê ì∞¶Ë¿ØÒ>B^ßj£ó&‚,∂ﬂﬁ” ©cÔÎNZƒ˝8kˆHF{˙wÈ‘åˆvåW\!y}9ΩåÒqho’ M”h$}Ñˆ ˙£q˛÷2Á◊™µÊ¥«bÔÔb|=d‰+>}cE˚:Ø∂≤ç∏ˇ‘£øòlÊ√?º>ÎF·πÌ`Ë5r8™%aN°<ëéAé«˘≈>ªIÿ;û⁄˝ÖNœFÎËƒv›zÅœtä∆o°ñ¶(9‚˝±Õ!¿Ûr/MÜ_<lóv√|ƒ Ô.√Æ.@SSñÖÃËY§ù¢ÌxŒ
jIR€ËMÂ>ﬁ¡)z[ﬂF{—OrêR‰Ø)^O°|¯oˆüºé=?|XÃ:ò_CéRo‡ÊQKÅjú›„˜˚œSÒ^ÁaÓé¯ı]‡¯`;∞íı√˘Ïsº˜GRπÁÊ~Ös¶1pÊ(ÿÓ}ØÙ÷Ø¿^í8«˚º¿x5|z¯1Î‡á‡ôbØR‰Ûd$ÙÕÃ7`!‡‰98?ÛÉ_¡Ê&ÛÉπ°ù\ù√∫{m±∞—3?ƒ˙˘@`◊”´>ÿ1ó˝≥à9ÀÒ‚ﬂõπ≈úÒK¡È¡˚n∂ì9 ﬂ”‹4ãuÁÇ[~…qá}ÎX*6°S´“GMÃYÊõ_≤_òkè>93¿÷qæáı#◊¡EøÙ˚‚©ºD≠ÿ≥\oO˚©TΩB• E*’Í ∑¿æ3ËÉ=jrX:Õ∞∏iﬁÂ¨›1Dng}R5Œ⁄¨v¬}¥K¯µONR˚$MÎ4oi$ıhùrΩhˇó
…Ìc…˚_˚ˇ»ükù¥Ì€Züi¬û-Føî	$˙%˙O kÅ±ñtiª•F:mîëU'∫º©∫hÇÊ¢|’ME™ç\S
˙ÀÙóDﬁm¬˛Á•~jƒ˚˙±a£dÂr#Œí?G} x»È<˙ÁÜr…/˝|*ô3úw!5»8ƒ›Y†∏‚√_Äk‡„T‡%ÆúüE}@éΩ|5Ô<ÂgµA˛ƒœœ!<;Ñü∆P^ï\[8øã⁄Ç8Öç~˚9?ré„…yékü˛P∞æπ„è"˜R•/Æ« ô@ˆ¯»óG∫põøèΩ©ˇﬁÏ2äÃ.ÂS≥Kﬂa˛‘®1ªıSfÏÛ¥¶∫Ωπå„…_KŸO\˝uTK•%æ|÷*Ê‚|QGÀE ΩÒWMã∞ÔEÆ´áJ‚˛ƒ~Ô®ÈÍ5jÇÓa Qoø:áJ9'™´–F?r:è+Mb|∂zèV©c–>πì¬uÉVÈøÊ5fØËªÓ„>≠íﬁÔ2‘¥_;NÛ¯]±rÆ˘)ø{ƒ|ºe-Ì2æF≠Í lv√∆ÛBÓ|‚µ'Õ∂œxûb4ˆÒÄ◊hª(—Áèm¬n·£¡a¯Ç˜‘ˇ ÓÑx´∂áV[Ç®’íÜ¸ÙÄ‚‰q÷qökq	ø´¢^ˇÒ—éïQÉe˛[ˇ∞i*à°~ƒC¬òç‚¥~⁄âXj˛Ò ç?J?Ÿò#∞ÔqüË«–JΩì6ÈnÆµ†Ô≠∂‘P⁄Õjß˘Êñ`‚≥—?K‹O∏NπÃœ8^7≈.úè9¨É∏ˇ·\ÂÙ›J»%ì,˝Ù°ŒﬂT$Ò•q$êÂÖx^‘õº}VØƒWÂVZÕ˝ÚÎ‘-d"S‚XP!ˆv“$•ùÇ‘%∏?‹¶w‰ZØîÇwwP3ZÕœÍ8≤+whöÚX‘üıZÂãy—®„7i¶ZÅınZ¨û†≈äâv,–>bùvö*µÔ„ûµ ˚¯ ÁaÕ0ö©oD;√<ÃÛƒèÕhÜZGŸb] ÑÆ~∞Œ˚tnÅU?X_¥ıe]üÍÈ”ÒY˙	;y_¨s˛Dì‡ß´@äWzf…ç‘	| _¡=‹Mı“6Û,¸˙‚L|VÎ•`&†™ı¥r<‰m†h>˛°Ê“:Ï˝1‰I˛.`»øDÓÇƒ¯‡¿ó˛±@9œÍÑ˙∑ˇp_Ó1Vwˇ›{œ=gw•ÇtY ´†ªŸ"VPäÆ–¯÷uY›j!µ]åÅ`K≠1µ°*W!à‚RK#]bµmD%•`¥£`—[Í.§ >¶üﬂúôª◊≥{w≈«?Ω…'ø3sÁÒ;sf~øÔòM˘ÂlÖú°§ÀâÈÂü˛œ∂_-cÉà√cÃ&%3OJîX…»Ù^ÍkËó(gG»=¡l⁄VI¶'ü∫Éﬂòºuúîˇé˛{`O¯ºïgá®Â|ç“¸¸E¸˚<}oÜ´Ì˙? ß⁄=Ùö<2/§ûëÈ©wÃ‚y®ƒe)≥ÎπZéÛﬂâ˙Ö∂>Ò˝ÿ+„tÕìı<ü©¯rÚªˆTf‹∫|¸>D2I	ﬁ¶=$À‰ÉIJ®{¨ºs97o!™e,Î4%®∆óΩùÀa≠§ÁP^…ˇ˚Â[JÆ\-#m´∞∂√÷zìíﬁ+CïLˇUŸˆïºuΩL◊5≥Y˚⁄˛ˆ˚¯}û¸>Ùï`ÒË=4sµî%m˛ôMû€dùè%]µIúç1Ö∆¸Ç≥ÛlÖø|•Û∞œS¬^Ö>Ç¶˚z£≠˙{Óò€Âë∂Ö"-œâ¥Œ ëÉ[7P7çÁì±A)uuX≤QÀ;<œ·ø]∞»NWˆß<9Ó€∂÷çwR‹_˚AÌ¥åã˚∑,ÄU<ÔvYÀÿÂÿ√¥o§_-–:;ñÚÄ˝–˙
Ââ@ﬁoˇ¸lE∆¥é¶ˇjòßz§ã{Ëók‹?>´≈«Y#´9Ò7yá¯Ã÷œlÚÆ·øO÷ﬂ%:Y∑hæóîºªO∑wo˘ûü8¡¡`ëiCSFVG£e≠ÊV˝Ë¨’€ª≠ûLYMÈ,Î©~ÙRÌ¨˙{øΩÁΩå?◊ÀÖ¯Uc˝Úy$/∂¶ÀÂ*8¡A‹ìJ⁄ºä?ˇ!ˆÙ&øF[.Q$˛Mè1€…]Ωâπœ¶û1á±;($ó˚úÊckß€9ß}•Â£Õëü#ß^‰®K‡Îg:íˇèv|SIÊ‚£•ß‹˝πsyÅùüßøhŸÁyOÒD©P¢I¯=©≥.MÍÄû =È‹£-'uG^y£“Õˇ∂ú‘%æú§”ˇù˜^¨g 8oûƒπ;Z8ßÁ≥Õ˛ºzíÁ8wﬁ\9ºYŒÖ…ﬁ¶ñƒëëPÔÓ]√x&ö5øµJE—©†¸<«SÁ>Sü˙Z˙ør⁄o•;l€Àµ=ÌÁ‰æU}nı!kf}_¬∑8$£a·∫‹∑Ê…‹€2d^ΩÁfﬁ3áÎp!-X»rœõ´˜= Ω)˜&7 †ÏfY≈Ûl	∂Ñ¯^?&fOÀn5m·„∂Õ¸Wº)SâÛ3≥ôÏ3ÎâÈWfKπjÃïª5wBDﬂ{ÈªàÁÿﬁ—AY¡8ËßÊÄ®î<ÿ,”¬≥eu∑kÜü“ˆ'¨Ì”Ô  ‚¸`˛+uvT8ãy»W·Hõcé•ÓÑ@xØ}2jÉqr
ú¡ﬂÅÀ3G{çÌ{{˙,iÃ¥Hc∞AjÔ©íu≤ºx´,/‚}äk§!˙Ü4seY…xY…˝m%Â•öØ|^eÌ€˝3⁄m]4P.”˜fÏ·ŒV˚wNjÎﬂ8‚ÍfM˛ºæ_Q%kS≈˚oïïîóˆ§mÁtá`r>ÕÕôÅfGlÂ◊.«_ùÀ˘5r>„å·π‹ÆÌj95iÁ[as59;€ãqzYﬂÌ'}Òs±.mÖ¥ê◊&0ŸÓõ}2_˜Â±–◊’U[]p∂\»˜∫J≥§4X,UÈufKÆöI˜Q∞”ÓŸ≈Íß¢˚ÀÌπeÈá9£oH_}v…2æ—≠é_±O◊Í⁄§ﬁ˙¯<œ>6R≈ZÌÔÄ≥ï√Ïa.ÖıR´ÇãÌ˛ÏÔˆÊÄ‡c9/xÿÓô„yˇbÎÎR–µõ√Á∏ûx∆ôÚ÷Æ’÷}±\dﬂMïyÑ}À˙dV£Øˆ…Âæm—˜§:Zƒ~}åΩ3üyß»‡p%í“4Ù·bﬁ{2}ÁÀ¬ÙGR°§Ó4{”œ8¢dD*î9±GRÔÀôÌ2áıZ	?áÂºO≥¢Ìl€ı2√qäí^ó ˇOÉ˛z¸lÎ^r4;÷ÊA;Û.¥§ˇ≈‹C?ç_ˇé} ÙaØ&†œïéƒ˝∫‡R÷Í”T&°Ø⁄—I®W{RW_ñÑzµÁ$°˛ú.¸(‘ÆêÖÍONB˝…_ÇÖ∆ñÑ˙a›¯wAÍ/8
?
≠Û$‘Ô∆è©I®üöÙÉ¯Ù<Àı	Õü‰Í∞±gag√£<sÔ53]yõkwM˙3ÉÁ¬⁄êèÕáp?\‹ÅŒe˙≈}¸<ÊZûõ∞ﬂèÁ“æÌO«s[‹úÌkùØÑ?Âï’wÊnﬂœgÁ∆èˆM±é1˜πˆ‹º≈~∑üà˝Y‹^ˇ◊w¥˝Í¿p¸qºMﬂÌí‘˜ˆFûk¶ˆß‹ZÆâÁm„ûh˙√(˜ˇ¬é∏ €∏'.!Œ”\]îQ´±÷∆‹:Èõó´¨∆‡˘çw!ﬁg ¿«%™4Ü€˚$qﬂﬁ'_Cü†,√…#ª(øÀ∞è%nﬁ"#té‡#Ù
ckﬁUÕëŸ%+Vkl∂π˙lÕ%gIm8üI„àvJ}8ùxﬂeèâÆ°|5∫„óRF2Øhµ‘GØÛF¶êØ*}Ωø€Ü∑ì-ócº=fº‘ˇô˙[–RerÅŒù&”X≥”˝‹πuXØ˜\˚›u˝◊¡ë÷o√Ö÷g¸≈á`s±j']ìe!˛îk˛d›éRÚµDŒU´åàä—O ¬‚¥‹Õ†ùŒı[’uπµï9 ˝¬W•<˚Èg◊˙Aôæ…∫^áñvñ¸PMê≥ÎyØπ/ÿ∆X2$€O˙[Ì∞€é[?∆:ÙÃY≈û(KÍØ£r˙ÊeˆZ 7á{µö;Ûﬁﬂ⁄<Ωa◊=ªQ.ÆïÔGú>LXÔS¥[¬›vL∑˙k¢Lèn$∑nê)·©ÃV¢”œó ¢2=(˝UüE3Ÿõ™◊»—·ï]%úqS…˜y˚htÁª∆ùπ◊`ΩãUqΩ=õ‘µ›ÁÍg¡MPˇØˇôõ„Á∂ÉÒ¯ˆøõ‚ˆm´8k)NT˚AG|‚ŒÏ«˙ú∑Œ+¨¶ÔlùÆóÂN∑vo˙≥ê’3Ãw.Õ”√±ûÏlßb'¯2ÁÛ’’rfß◊—IK€´Ì¨5ú›„Ïv›k™ıí6OWwiÈ◊ÎŒô∑±Æ^P¿÷z}›ìÕÈÔ6ß◊{≤5∆húÚ6∫C"’†ﬁ∫8÷´√:]ﬁqJ⁄ª—io;´˙˝<÷˝Œ‹‘Ó–}ßÑÕ¶)lŒ∑ƒH»¸ï›· ⁄â5M—£VÔä›ﬁEøª»/ÉMS—‡|+}|^cûÑ-6|è√ÊL 4eRÃ≥‘4°’Û,πc©ΩüTuEÿ¿ºÃ3ç˘à‚—ã¯K–|◊hvâ⁄Èw•}«fÕÖ›≤ìyPE∑1œmÙ9¬<G¨mV¸∫˚uÙÎ¬ªΩoøó˜ŸœÔ∆˝¢ﬂë1Îª£w1Õ óıﬁ›˘û›j^Å=˙ÃYzÀ›K∞¶YI¯|ßı{?Ô—•1zûi€‰hf]ˇ◊ÂxûÜtoeÿ
Û8ò'πöÆ¨gQ	˜õ◊£ÛÕ=ôßÃ!EµTWÎ]e^aÓâV`w“gñΩ#©ˆzã≥Z¢Ò]q±ohÒÚ±ÄÁ!öÎãŸ€B¸yNf~ZÛôK\^Û?ˆÀ=8Í´ä„ÁwÔ>H$ŸÖêd)4è<˙#† Ü›h#Â6≈⁄©…[“›Ãf°¥≈íiQ!X
®p ª(∆“›-j¥‘±’
SE-£-S®G-Úá:mÕœÔπø_ -m©„Lgn2üﬂ9˜ﬁs{Áûãv˛b∞/KQŸKã|]x€ÑO˙ç˝G}≠syﬁeã˚ŸœÅgùyV˘˚#´®îÅ>˝°{áosõrË}√…ø2Æ>ﬂÎA$å∑.·∑5cΩ*~Ÿé±mßƒ<_ÁxA›j¨¢Mà)Û9˛‡xAùÖv™E\ÿËRÜyâz∂"n<G`◊eøÕpL§÷È-ç¶û≥ ˛U˘E¯I˘*∏Ñ∫AÃŸDÎQ6òcnÉ„Aéã‰9Ã#|ä‹ã7."gπ≤…¡#!◊êe§£æ˝0(E˛ê˜Ç’–À!ÔwÇCn˛dyá†-/t¶v?p§B8àì“D»/¿n’äK»ª‰Ç∂9ÜèÀÍïù%.†è€(Wñ∏˙tîùÅp{p…-Î≥©øb„˝+Õ ›Üò™ l∞ªΩª€∏@•û(±¶y +ŸÀÔ°∫qN´=ÏD˙¢xÜ‚å\Ö10=v∑|∏“˚3öÏ›JñØàÚ£ŸxD|‹√ü£
¯üJƒ“MŒõ®óﬂvÀ=Ìˆ;X∑uÚ4∆qVÒî+ª}ß®*gﬁΩà≤0tÍì¢@MÍÓ$Ï-28zÎr"2ÔÎˆ?˘¨ı≈π˛/“#˛=à%˜–ùÆ/‚XãÔíA|ØCüÃ{«;ÜÍ—nªﬁâÒm>·¯¸∆›3˜l†'xoπ± €íEÙe»OämòáœP©[˜V– tÁ≥hwß◊¬1w Ä>ïÅﬁÕÙ+ø.iœNúØ’-5–kÆNc=Áπºkm˝Öœ+∞c¢T+{áGQÁµkß}A™fD“€ﬁ'ùOc¸hå™{˚µ”‚5*cd#Ê∏ÒÍ4˙Øc.ˇÓk§Â„4äÈ€oó˜Ù˝˛sˆè9Üf?Í…∫}<'°3ÿÀ6 Œ`/ï¡Óaqgˆ˜∏ﬁ¶ê„√·œaﬂ ˇR˚ÔkN{àœoÑœC<õ6æ#8fﬂäÿu)«•≤€>¡~écE"˛„∫
ƒ˘±Û‘ª¨é(_üä±ú‡Xîﬂi Â*|Ïgÿ)˚Òw§”Hó9~âu±
ßaÙ˘(op¸˚ πu#Ô-«g)ü…æçœ!¸ïÉ/ ˝g¯ q»gúqà?ëÖ≥∞’ÅÔúﬁ]|7)ﬂ)úv≈ﬂ–t~ª®s{;ïÚÑ]‰ZÒí_ˆ≈ò'ﬁõæV\õÁ˚Ûﬁryk•·∏oj”¸„*‚X˛Úª´ùFÒùÌõ†ﬁ+ Ô`-K.«˘|ÁÒ=…ÎƒÎµÅ¡ßî\ı.êî‰µıÓ ìÔ.Ã”O¡Ø˚…≈ÍûÊy|C˘JÉÓR}¿«π˚Œß‚~ﬂÒ€·{ˆã˝ﬁ~}oπ"woU‡∑=Ü{pΩ˜ÕuÔ˚chª◊Â	Ü«Ìx\j˝/¯vIG?∞EXÛnp„~8kÆ∆{∑ÉÔ<nä€àræÍê;ú%XµÊ=‰ÄM‡ —†wà
ê_àk•%á°ìàÜ=F4|¸F$F∂|8!¨Ö	ª2Dú7‡f˝¢¡MË≥åÌ0v>¿ºéo#™¸<QÓáÍY5câ& øv3—ƒ’Dì~A4Ÿròr¯„…‘›çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4Õu¡  õHóh*=J>§jj"ÚΩ%~B^§âÚÈ˚¯J‚øª’óu?u#eêÛ7—ÌÍí
å;\›Ω’’}–◊∫∫üÓ2∂¬“‰põ∆õÆnPπ∏√’ÂãµÆ.ëˇà´{†g]›˝eW«xÑM…$ãj?	ZîñSr%)“tµ©úÈH•†Û∑˘qeQÖíµ‚ﬂ§F‰-C˝4µ´T2ÎU¯∂¿2=é∫lW6Õ ≠⁄kÅÕ=ê)ZÅº$-˝∆¬≠&TãNΩ&§‚HqÔ&-Ñ÷¨RNœ	‰V´L’ˆr5Vìñ µ•i5Z∂Æ:hZ55ìÃËÚò9'ôH¶Ôkãô”ì©∂d™9O&™ÃHk´Ÿ_∂<›n6∆⁄c©U±ñ™Üôãnôªh\$on≠¨O∂∂Ãâ~¥,•õÒv≥ŸLßö[b˜4ßVò…•ÿΩOòiî5%‚ÈXãπ0›úé°r¢•:ô2ì(IôKí+ÈT<÷^ı\ÓöIãËöãÔ∏~ã_Iıh´6s–?◊[Ü	oUãˇ—Í\O´èÌ¶t›Ÿ7—oÈ}˛ûävDÚ‰!z¿G·kÇ›@RX ˙Û¨”êÉá(ô)g±{†Lô†Ú+øiuì]¥ò& ª+”ƒŸ]ŸK…	üvdıÕJf8≈˛!V(2’™Å†Ä´ÕèÇ]‡G¿áu—´¿Rê{3≥Bha?
DÜ»˝la|OHå~?~À~z”ÕÒ`T˚≤9π˚}™Vâ‹áZ|É†<	N/%Ò›l °ÌEŸ^rØ‹ì	ÜÇë\πì÷!øM√†Zﬂñ™πŸûX·HP~ãÊAáÂÍÕnAµ-$`>;Sy≥ö¬ŸŸ‹|+˚çÙFd#∫‹çØ°“a¿ˆ≥E‹¸√ô¿ UÔÅLM≠£dÉ≈÷|Ã¬j2dL&hÖ‰Éê•êK GB~I∂Pûg8ZËoÃß…BÉ‚à,¬9…r8ï(≥ïô|ßüïôä±~ÒtY¨L2èj!H∆
ôGeXM˛˙lŒ'x|Î3¡BÎ∏¸äÙ”Xu¿jh(p\Êbes’/âfsÚ¨ÕëÅ2äü≈¥Ñ0F≥úP%2h(2HŒî#®e+‰H*Ñú%Kï¸Æ‹C≥ wdÀGÑzé o®Z[πQt_Ál≠∫l^æ’…ëu(=,7a6©Œ7gÀ?eQ§\VPò„µ–÷™Mﬂ	≠´÷âïÍƒJubPùÿ}$7†dl™Â˝‘&Ô•Õ`tﬁVÖLË•åÆ∞é»a≤<ä©4ê;<õìœ#+Œ.Pf≈ŸÅ˘÷¥„≤˚ºmÜe:;¥ÿJïc’Oü-.·
ml◊„r®≥4®XƒKr\é¿Dƒåî•ô¬–·Hiﬁ»!2ƒ‚Oí¯ï8ÕÀ-N"ÕÚÁÆ|—ïøt§›#N9áBºƒÚldÑxç-†]–Ñ8*ûÖÛâ3‚iÖxY°iêøC˙?§óOl«≈gÜ4w%[•äjEùïË%-≤¥(U
m»0óô†·A¥ÂÀÿAißíSêå–¸ëdjv(P®ô %å∫âÜÀX°lR™»•0oUOÂ¡∑:pEoÖ˙fH….™K–ïﬁº·Ã˜õovv∏À˝|˛S¯=g‰[^gısˇÿÈê'À∂ù–xª¬ÕvÂŸ°v•o`2n≤?±Ø…s‚ØcØŸÖo¬·[¨HæÖﬂe”d˛E€ˇÃ6‰g_≤5r^s∫ÂÑ£I[u<“>wHÎSfúo∞œŸr°ü9˛£hΩ]Û„=˜1eøgEgò˜≈;Ÿ'‘¶ˇDPôÏH'}ÏS'*Yq6æŒVÿä5µL+lU\3éT\ÜiÑç®Q1‚^v7ê[ﬂ_ˆ! (1vdA+Ï∫„éä¯øqNÚºYFYVµ º™îﬁ˝ﬁÔU-∆ÆëYàaåEh	ZÜÆ‡€
{zz˙@µ°¥ÄªIDDD^yyyyE‰Uˆ$âàààú"r r r räêÛÕÅ»)""""£ààààå"2 2 2ä∞@X ,ñ",Ñ•Ñ¬RDDDDDED@D@DaÄ0@ E CÑ°///Ø"º º º ºä™ÎSÇ$————TDDDDSMMM∂Pu5‚ﬂ i i i(§§§§°êêêF˚‘ãj1∂Õ"¥-Cí›ªvÏñb∑‘ˆ*Aí B(BÄ °BÄä(É(É(É(+¢¢¢¢¨à≤⁄∏%H?|S˛‡K√ÆP[«≥ñ-”1ÂK‰ëÚE≤£¸RU˛>©(è\U˛.â*_ ~ÂOyëpù:<⁄¿-`˙9Ù6tZÖ6!M’@ávŸ¥5ÍÓ—fµ[⁄™∂©Z’öÎÒÃznyV=õûC´û¶áÒ!÷•Ó£∏µêèTπÑÚ1Ñá ò™≈ÿÚN·>;çø)6eı~g<“A∫§´A˙Qê∆;ÿK‘≠Ótâ2Lú⁄÷ˇæE˝Å3∏3›\{Ù,w¸œÛ:›hŸòÇ?Ç™P∫
E°I(ôWmAƒ€÷h{»( ç@ÜLA±ØW∑÷Y≠‘æÈ"2O‡8∏˚N ´;ÅYÿóN‡2èw–5êøäË]\π;Uá?D˜g-˚£√Ô√n;|
ˆ∫8ª‡˛¬„]Ù¬›=ﬂˆ9ú∑Ùsag>9øå"ëâﬁ1jìáp≥MkeÚ9|6ÍS2Z'y·©áÑ’ÙA“]5LËÒ:µ›‘:Ãø„øÊèÄˇãÌÒ7£ÓÜ=0ÎÙU´ìoÑá‡8w‚ù2œáj€ÖÙªºb^Ác,jÆÒﬂÚ¸f∏Æ£˘Ê}]•p¯U£ŒÓXœe·≈C^‡/ÛK¸›Dª√/Ú9Mí•6ª≥∆3g8”·/ôu5≈˘/π≈¸î±!◊óúlço» ì≠Ï?¡˙Õ∫‹„ØDÎ¥◊
jﬂk+⁄-°Õh>mT˚±6¨ıÎ}∫WÔ÷èËù∫Æ{t∑Œt¢˜◊wõVà`€ˆ{º“<nY∫U›Àdâ%aTg‰e"ûq•Yz.A”bÎíælàÕ˘Í¥ÛÏk‚ê/AE_ö§œ'ƒ…P∫ÆÌû—PZhôvï“õY¥
ˆ´:%ÁÌ:›ïM◊ÜDﬂË$◊n≠JtÌF6Kﬁâ∆˙ŒÙûz1y@ëkó°'«‡”’aÒõÙú-˛0úì≤≤;úMã+s∆E{ùı∞ÆTrùuKÀ⁄ÎÓ<ÎIùìÌÓ|2ã∞á*ªπa$ azÇ2˜ìÑ√5j≈˘Å#nD‚:ªà_≈˘;ªTúõ ∏ÍéëJVC≈òÑÏ®òì<É6Yı˚Uîœ†∂å¢∂œPSqéê0W!øÎ‘@ú™db¸IàŸôﬁôVπ\ÙIo≈ÙﬂãÈ?éò–ˇyÃ'B¥6QZ‹NÕ˚R9_j âﬂysP,_6åÍbIv¬Âœ]~„MÈóÊE…7üãæ§Qùÿ>†{[vO¯íU≤ù:oW∑≠˘§3aM§|óíŸZÏ¥ˇØ\◊˜sŸßÏ¥ÃñπbÒ∫„≤;&s≈eÆ∏Ã≥b*WÍ-πÔ3vU'âÏ[^cá;±ásC#ŸƒÄ7FnËıôë¡≈°{nBoì√°¨8‚Kà.HvÖ„·∏Ï¬˜Lvu£πß›5∏832tèﬁnwy—‹ÎKêΩ•%2(-¶œ¶≈»‹k∂‹*¬∫t5+»Cuí‘[I¸„sQ	OGí¬ÅGÒ†£T*dQ
Iã‡\Z<3—4§ %≥h;±◊Êr©∂jGG™æªÖŒ&Aã2ù¨Öh+hu‚≠KceOYcÚU°X;:<˘ˆWxÇ/AxècŒ¯ÑzãX®çöÚ˝•Xün9^W•;GG&ë°*›lπ’Fe≈\	ØDÀf9\éz–∫VA#Ø»G©3^qëb®∞∑®≥XlLKÊ˚ƒynX%.ÀJ(î®ZØˇ]l∫∑Ë˚[hèZP√˜.H´Ω–W¢ïΩ¥áï⁄êÍ,)®5HÎ”~Ò‰¿ßˇ0 6Âendstreamendobj59 0 obj<</Ascent 1006/CapHeight 716/Descent -325/Flags 32/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 64 0 R/FontName/IEWGNW+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj60 0 obj<</Filter/FlateDecode/Length 425>>stream
Hâ\ì¡nÍ0E˜˛
/€EïíôFäêZh%Ø≠J˚!1ºH'2a¡ﬂ?_ﬂ™ï	|Çg∆'ì![o7[?Ã6{c∑s≥=æÓ<^BÁÏﬁoÖÌán˛∫Kﬂ›©ùLìw◊ÛÏN[M”ÿÏ=nûÁpµ7˝∏w∑&{ΩÉ?⁄õœıÓ÷fªÀ4˝s'Ágõ€’ ˆÓ˝ißóˆ‰lñ“Ó∂}‹ÊÎ]Ã˘â¯∏NŒÈ~AônÏ›yj;Zt¶…„µ≤ÕsºV∆˘˛◊~Y0mË˛∂¡4ÇÛ<.ëÔ…˜‡ö\É…è‡y~"?E^>$éãi E‚∏D^íó‡ä\ÅyVâ≥ 5yf˝ı+∫Up´
rfÕ
5+zVû+8W/à∆‚•$ó`˙|D…
¶õ¿MX_R}ˆA–°≥¿YË,pˆD–y&«—(üEÒ,J7Öõ“M·¶tS∏)›n*d”S·©tS∏)˚ØËç˙Eæ¿Ôıíœ∫$o“`|M F$N≤˝ûøÓBΩ4ÓiÊ0mÉwﬂˇàiúlÃ¬«¸` yÂ–endstreamendobj64 0 obj<</Filter/FlateDecode/Length 26081/Length1 55908>>stream
Hâåï	TTW@´˙ˇ_à¨Çb˜ˇ›;ë0ÜQÜâ!∏é3#âNó à "*Æq!t®¡wT¿}Eçàää,Ó›6∏Fm«c∆i†Û8LÊÃ……ºs™^’{U˝Œª˝´^Í¥±‡i¿AƒÔÙÜˆabìùí≈ó5`(Ä€g13SÂˆm˜U 42.ebRªÔÛ@húò8'n^ìÓÄˆ@ˇ—Ò±—n^xX ~*àÖƒ≥Öˆ¯®8¶¸„ìRgw¯ô ¡◊ìc¢πZ ¨éd˛≠§ËŸ)Ì˚ï!L…S¢ìb•!AΩòˇ	 îí<=’ 9 UãÌ˚)”b;‚´
 ú Ä„20p÷}ÿ-|€gÆ‚TÓÇ âxï}`;≥≤TG{˛»aeŸ÷,‘µ~Ñ}ƒ0<h≥Ÿÿπ°‘~L´ €Ùd¸òÖ›ôt,≤Y•≤«¸˜`õ/êË‡®vrvy£ã´õªáßWWoün›}{h¥í¨”˚˘+Ü7ﬂÍv‡ozΩÙ€ﬁ}ÇÚ˚w˚ˆ˚CË{aÔá˜0p–‡!˙ß?óaè¯Ë„#ˇ˙…ßüç=fÏÁë„¢¢a|ÃÑÿ∏âÒì&'&MINô:mzÍåô≥fœô˚≈º˘¶}˘∑Ø“-˛{∆◊ôYKñ.˚&{˘äï´VÁ¨Yªn=l‹¥yKn^˛÷m€
ãvÏ‹≈Ìﬁ≥wﬂ˛>r¥¯ÿÒí“'ÀNù>gÀœUúøp±Ú“Â+UW´°¶∂Ó⁄ı7·ˆ£ÈÆπx◊0v—`vUÇa⁄T≤jîjÁ«Áíπ‹.ì[¬ÂqU‹+ﬁÖŒ/<ÑÛ¬3·%q‰Eæ$Q?ä$õò§I–L÷ú’Tjl⁄Ö⁄⁄¥Ø%/I#ñÜIüJ£§1“Á“|È∞T.’IF©Iz)µ ]dΩlê{…Ar∞‹Oï√‰Ar§ú,/îW…GtÇŒCÁ≠”Î∫^∫u#uë∫t›j]ë^•'}ΩªﬁKﬂ]/È{Íﬂ÷’GÎc˝T~Æ~:ï‚¨∏*ûäè“CÒWï`%TIT“ît%CY¢¨TÚî› A•D9°î+óï´ mÂ±!‘n`à2ƒ‚ì…ÅâÅ≥zyv/‘YU÷k®5Ã⁄ﬂ:»z¿˙‘jkﬂÚ~ÀãñÊVø÷f[≥˝;c_XÆ
T:’h’^Œüã‡Rππ\:£∂å€ Us?Úo|Ü∞\®æ' 'FMK:
ß(1BåZ¢¶\”™mö6W˚B…Gí•°RDµqRötT™ênHw•“+dwF-ÄQÎ-˜Ì§ñ¿®eÀπm‘∫vP¶°√®ewRsc‘∫Èµ‘¢Ù⁄®…ø@-¢ìZ∂í´ÏÏ§V…®›b‘˙uRã5$0jQÅ©åöw°lE´∆˙.£nhb≠≥67G∂ÑµQì[”Ï‘lX}61©e˝Ë=&=Ì◊:…Æ˘jf¥ó`suÛ%!èÕµˇ)ÀF÷cö¯¶a ñÖ èYu[º,7Kãã≈Ÿ‚dQ[-¢Ö,ÇÖ≥®,Ã˛A√"&´ô§7ºæW‘0Îy≥ãü˜e:≥a>@}B˝úÜÀïÅÀ,kÎãÍsÃ9Ê|sÄπ¿û_Ômûj«º s∏πèŸﬂ4ƒ4ÿjÍk
1ı1ôzöÙ&_ìß	ççFãÒâÒëÒæ=ÀXa<e,33Îúqªqüq∞qÄ±ø—ﬂ®7Íå⁄áÎN65ó∆y«πe¨7äƒı‚∫ˆ{“S
sπ„R„¸L .¶≠k±Æœ±.œèeƒ1I2ò^!c—ŒLB(_<÷ûÌ†e‰–€aÇCÆ£@›’æ™vÔê!+C¨˛òi÷ß’3∂⁄÷∑€W‘1w±]‘^˙Øùı≥Ã±Í»N{Ùˇ⁄i≈9Ö:≈ˇO [!qëÏıyãad¡&ÿ€¿2“Ø`%|?¿RXàÏ=mÇÕ∞˛	/‡%‰√n∏ ∞∆Cd√®ÑX8°
.¡e∏ﬂA‘¿U®ÜΩ0a9\ÉZ®Éxx
¯`LÜ$HÑ)ê…0R`Láê
3a<ÅŸ0Ê¿0ÊA1‰¡BX¿^˘/·<á„òÉkPÖÚ(Äöq-Æ√ı∏Z†	Et nƒM∏∑`.Ê°#™—	ù1∑¬+¯∑·v,¿B,¬∏w·n‹É{qÓ«x¡ø‡:fb∆#xãÒ∫‡xK∞∫¢∫C‹CÙƒR<Å^ÿó‡I,√Sxœ‡∑Ëç>∞ˆc7Ïég±}±jPãÁ∞^√ø·><@	e‘°œ„ºàïx	/„¨B?ÙGx´±k±ØA	æâoaOÄáØS&e—ZJÀË ¶Â¥ÇV“*ZM9¥Ü÷
˛¥é÷Cm†ç¥â6” •< ß≠¥ç∂SÚ	¸d*¢¥ìv—n⁄C{iÌßtê—a>ëO¢#tîäÈß*•tí Ëù¶3Ù-ù•r:Gtû.–E™§KtôÆP]•jæôo·[yõ 
*ÅxAH¡QPNTCµTG◊È›§[tõÓêëLtóÃTOtèÓ”zHèË1}GOX≠?#=ßP#ﬁ¿õxo„4:πãÆ¢õË.zàû¢óÿUÙ}ƒn¢ØÿC‘àZQeQ'Íù<ú<¢πæÉ¥,í0Äø”ÛıL˜€Û±Kf	,lﬁÖ]XÇD$ÁúTÙ9#°
%ã‰íº;Q∞N‘SNëísŒvÅˆÊÍÍ˛òø¶¶¶™ÎW3œ#≈%FN )9-g‰¨úìÛrA. %wﬂÂ∫<˜¿=tè\æ{Ïû∏ßÆ DUl%[Ÿ&⁄$õlSl™M≥Èò(%§§˝»é¥£Ïh;∆éµ„Ïx˚±ù`?±Ì$;ŸN±SÌ4;›Œ∞3Ì,;;8ú¥sÇCvÆùgÁ˚◊kÅ≈Ÿ≈vâ˝Ã˛Õ˛›˛√~éGÉ¡¡‡∏]jø∞_⁄evπ˝ Æ∞+Ì*˚µ]mø±kÏ∑v≠]g◊K)âì“RF J9âóÚRA*JÇTí í(Ií,)ëëô‘02å^†F‘òöP”» jFÕ©µ§V‘ö⁄P[jGÌ©u§N‘ô∫PWÍF›©ı§^Ù"ı¶>‘72[R%M“%C2•äTï,π,W‰™\ìÎí-’§:M¶)4ï¶—töA3iÕ¶94óÊ—|˙î–BZ’—HÉxuS›R∑’1uG›U˜TÆ S‘CıH•´|ıX=QOUÜœV¯†	"Ä`¿C®2A¿A
AƒBa(E°ò™≈°Ñ™™≤†$îÇ8(e†,îÉx(Ô3⁄$ü7T∂™ïTu®âê…ê©êÈí#5‰®ì„rCn -πM[ 2°
TÖ,»ÜjPr†‘ÑZÙ;mÖa>á`|¡H£aå•?`åßm¥ùv–N⁄EªiÌ•}Ù'Ìßtê—a:BGÈßtíN—i:CgÈùßtë.—∫J◊Ë:›†õtãn”∫K˜Ë>ÂR=†áÙ>Ü	ãÖ)üc,JOË)√‚XKR¨∞∆±Ê#∂LÃ≤∞√“XÀb9å«ÚÂB√±X+bV‚¬\Ñãr1.Œ%∏$ó‚8.Õe∏,ó„x.œ∏"'p•®·DN‚dN·TN„tŒ¿ ò»ô\Ö´rgs5ÆŒ9\Ékr-ÆÕœ≥òÑ…\áÎr=Æœœq~ûÚ‹àsπ#wπ)7ã⁄(E9F%Í∏9∑‡ñ‹ä[snÀÌ∏=w‡é‹â;sÓ ›¢—h°hL4ñªsÓ…Ω¯EÓÕ}∏/øƒ/Û+‹è_Â◊¯/‹ü_ó{<Äﬂ‡Å¸W~ìﬂ‚∑˘~óﬂ„A<òá¿dòSaLá0f¡lò#˜a.ÃÉ˘),ÄÖ∞√*πí'‰!\ì/d©|)Àdπ|%+d%VóGpnÍëz¥´«Î	z≤û™gÍŸzæ^‰;¿RΩ\Ø–´ÙjΩFØ◊ﬂÎüÙFΩIo’;‡ñﬁ£˜Î√˙∏>≠œÎÀ˙∫æ©o√m∏w·‹á\»ÉXü¡geï|-´%_Ày*.ÄáÚ·1<ÅßP†≠4h≠#pM#¶`÷¡∫X¯”±6¡fÿ€`ÏÇ=tyÏç/„k8 ﬂƒwqàN∆a8¬Á¢Q8«·«¯	N¬)8Õg§Y8Á˘^πPß„b¸?«e∏ø¡u¯n¿g¸’7õm∏˜ËL‹áÒ(ûƒ≥:/‚Uºâw1Û±¿˜Î3|å)läöí˙™â3Â|™‡}Ç©líLäI3¶ä…“5L5ìcj˚ÜTﬂß˝Ü¶ë&”ÿ41MM3”‹¥0-M+”⁄¥1mM;”ﬁt0M'”Ÿt1]M7”›Ù;=eç¨˝ˇ|t®EªˇÕ«Ù2}M?”ﬂº.Î8„BW»q%\iÔ\íKqi.√eπW€’u\#◊ÃµrÌ\'◊Õır}]?◊ﬂpÂD¥T4NW'‘IuJùVg∏ BB®√Hà°	mH!áa(°£a°0&åáE¬¢a1uVùã‰FÚ""#è"˘≤Sv…nŸ#{eü¸)˚ÂÄîCr.¡e∏WeS∞&¯>1õTN∞>¯.¯Uù÷ÎÇﬂds0*ÿå◊m|ÔÏ‡;T{5YMë-∫≥Ó¢ªÍn∫£Ó>$Ó´ã¢T-—Å_"#Ç≈∑b%V
ªùnó€Ìˆ¿D9ÃÆˇñ3‘s¡Tıº¢¶´j¶¸S6ÉÃ`36À˜≤A~êÂ'˘ó¸,ø»Fÿø√V¯∂¡vÿ;aÏÜ=∞ˆ¡	8	ß‡4úÅ≥pŒ√∏Ëu÷Û;b'Ï¨ÀÎ
∫¢N&_¡~¯™w⁄€a{Ø¥ˆ≈óº‹ñÿ
[{kø·&‹ÏΩm«∏”€}·`Ø¯-|ﬂ—…:EßÍ4Ø˘}éx…ºÁÒﬁÛDÔ˚CùÆ3ºÍÈ:SW—UuñŒ÷’tuù„ïﬁ√˚òÎ≈^√Îx√;çıRã¸˜NÔ4ﬁVﬂ0ıU}≈ØkﬁÂÛ^Ê^˙)<çgºﬁTo8ŸN«&&Àd{”âﬁs¶W\«‘5ı0Su]Sﬂ’˜pCÁWÈˇ0^ı—QW¸Œ«€KñèêèEyÀ3©d≥"°îbX≤Ÿ‰Kw” ª!)	∂T$*àê¯–rê
•⁄îñæ§Å*m§Í±GC(ÿVl jAèH˙µÿ◊ﬂ€ÑòÙèûÓÏ{ÔŒ‹;3wÓ‹πÛª >JóYîFd^ƒs…˙∆ÕKﬂ˙ÚœÄƒ;˚¢˝Ù÷L˝;:Œz…¬èG‡oS*”†‡‘B6™FÀ&*GQ–æÉ•õ4	¯X‡ÈÜÏ=¿…Gi,K3?fﬁ N£◊J¢	4ãioeÛÃïTCÁ‰zöFÛÄøõÿZ3dn3∑õ/¬+éà∑Õ4ú2ÄÏóP∑˘ÖÚæ˘7Ú¢«≥úsl˚∞C‰√,k!˘c`ˆ›bëdÊRÛ+h‡rÔ&I•‘Õ∫∏£◊”Eñ∆öÖ£Ï5ÛHç£E»v”Ne≥π[©1KÕnã9Va‘]‘ép69F∞D•◊|—Ï•t °πXOù`]"vc]l&,¶¿Ji:8ÀÈ∑»?N;øŒó+âJ.‚‚£Ê{4Ü&S¥›áûg_‚&«].ﬁíA≥àíaóX÷¶7ÅÂ3Ä)∞ªÅñÛÁ≈îÄ'£‘!SŸDœaÙ≥@-áÅHzƒ^y@^≥›;o&cG≤ËG»ù^GÜêDˇ {Hı#ÓÁãqø\;‰+Úî=äUﬂã|g+@ˆ1äÂ±2ˆ÷¿öYNﬂ.‡˛ìÏü≈+˘}∏iƒ
qL°T»Âzx¯f€•X(ˆFÏè±/Õ\s#ï¡÷A˚gëïu¿OzÄ%œ–9∫¿‰9…(VnQ≈÷†<éòÒ≥x¶”ÅYN≤ÏS‡±´Ïpoπ,ÃÑ¢Ò¯#∏#˜‡\['˚s˛oë*&‡LM",ñC´Ò !Ò°Ãê=@˘π(;ïpgPé+Ω∂D˚ì	îÓıΩ7≤oúçQ¨5∂3÷Î0?§Ïa¨0û
†}eˆ{'<ÓótôYv õ≤y∞Ãb∂å≠`´`…ßê’Ω◊˝ Ú¨nd W†sü•Û¿jE| ΩºûØ¿=øùw?ÛØÑw¬ë"≤≈l±H‘ãáƒj±S‚]‹≈ƒ?≈uS:‰x9AfIèú-ÀïÚyyQ^Tj}>±9lﬂ∑mD˛Û˚∑ÏÖˆÖˆ2˚" ¸√ˆ˜"VÑFú˛5˙±Û¿qà∂Ò)2±Ò¸y1’âROÂ˚Y+åu€îU∂|õOΩ2∂~ãø 0Cî≤VAÀ¯‰æ—lc‰´¯»ﬂ”e˘÷v#Ø≤%≤«˘["µ3‚”1Áõ‚NÈÔ–‚≥Àü“_•ôÁeæO,ÑìÖJà‹b+ÿctàà◊∂¿èÁ≥W*Y.˚ó0I˘¢i‚#ZO˜Ò˜q?<B≠ÙCV'ó“6ö¬öÈ"ΩåS1Qπ0Ö˝Å7JùèfƒÂ+X›td¨BCO±Eb∑Ì
?C+©G:Ë¨¯9¥Ô·E©ÏU YN¿c¥ëVòÎhµíßÿR\€wS¶<èË÷,r•ﬂ'Uj”„tEò%J—íœôø®BÑÿçÚ‚ÑÑ5‚åﬂÉ(vÇ:lïºìñ*…QáHæ+ßjÛe⁄e.•˚ÕÌ‰E<h1õ1‚~˙Ñû¶˝lCl5—≠89gŸ<%»{î†ÈÂ:?√+¯Œ°˚kg≤4˙Â *Ö oHó°
öin1ˇÔæv’“∑Èc¨ÚÃ0Gt—îÿ|ﬁfE÷{é Ã}ÊxÊ†Û{¥Ä^£óÏ
EÌÏ±¡NaΩk®ûóõâ˙X#Ï4¨‡ÉµV"˛lÚ˘´*g˘fﬁU0#zﬁ¥©ﬂúí;˘ŒIwxs<ŸoˇFVÊm⁄∑:˛÷[∆π2“”R«¶å=j§sDrR‚p«∞ªMëÇ3 	h¡àjdEô•Õô„µÍZ—ACESp®å°F‚bÍPI$ø˚_íæ>IﬂÄ$s™T‡ÕQöjtkj'´.ÅﬁZ¨ÖU„rú.ç”œƒÈ$–n7:®Å¥Üb’`5`n–ëb◊6‹·◊¸ıoµ9ÜÉ H’ö⁄Xj!ã<5êﬂ∆)!	JZq¿H◊ä-ëà÷ÀBÅbó€ˆÊÃøD´5H+2Fx‚"‰èOcÿ¸Ü=>ç⁄h≠Ü6´m9]˙ñN'’F<âuZ]¥&dàhÿöc§Û©è~úˆuÉèÚáZs]B§5™VU◊[T„'e°¡\∑ıá1˙ÚÃ`DbÍ-0bIÖäŸ¯Üp»`0•j≠ƒZUﬂ˙ÍµÄ’Y¶√¥"≠A_¡÷dËïØv∑gd¯éòÁ)#†Íï!ÕmÃti·hÒ∏∂1§óØ˛U∫OM ÒÊ¥9Gˆ∂-yD?ëò4ò®‡≈©∏∏EïîXñYis·Ü∫DÖ&!k ≥^ıy§/…É~aÜ^Fv§—ÊèËŒ|´›Ío(ôNM’Ø<@ª¸˘–ñhã-”yï,“ÚìWˇ&mx<Fv∂Â"v?ˆ:∆ÎSΩ9wrMkr™¯¿|¥∂çÜÛ'¡¸n∑µ¡õ;}Tãä±∂,‘WW©÷’NæIû∞¡#ßÎ&'• ‚¨Ω…Ë—‡…ƒ4RåÑ¨ÅˇÁÿ—ÅÜ|Éç˝Ï˙>~IÖVRVRz§ﬂ∂%ïCj}¸º^?eåˆáÑã˜S‹%‚\8eÕÄ∞U	%2[‹©Î:Ì	 xSÉÜ32ßÔv∏›ˇgßN≥◊Íˇ|›≠_M#ﬂ3¥>cH}àzâ∫Ä¬∏*K*´u›1ÑWÎõpnˇOï!∑Í7®
'3ˇN≥+œz¬.√ì˘-¯__Suà†´ü„gyß7'à@ßÎAMÍ=⁄iÆ≠’Tß¶·«˘qΩ)πÈ8ùÊ—Õ.#∏%[5∞|
NEmk-kÛ±÷äÍ–'ë⁄ZjÁå˚#EaÀê‹_º{Ò#ˆgqx´≤ù»=“=2/Ü+Ô∫*∫Æ˚∫F™Ï¬µDÕ±2QNììÓÚ˝áÒjÅm‚º„ﬂ„^æó?_‚8ƒ9'Ü&¡I¿√(◊≠bm33 ñîÆ !Z‘é(A{T†!“—V•Tçxhº F∂Ç √0'§Zñ°mUïï±ïn’6ÿñ2*Õ¥É(KIÏÏˇù√`õ¥ÌÏ˚ﬂˇÓÏÔ˚ø~ˇá:«è≥dÖ±4éùEáLÆN@>d>Å(É)å“ÅÔºå≤17;ñac‘îhJ‘’bWë@˝¢∆E1IÜO√¯ÍkøH∂lˇ∆ú•ïQÕ=6Ä«±yÛÉÏƒ•∂]=ﬁ ïÁÏŸÉ£WìjF|*√»Úq	‘C√5Ö—'Làác§òÒîﬂÔ1#)√òø:~U%-~≥‹$Ê	kZ∆(ˇ&gA%
‘œ©ÇOlT:F≤€q4Z±tŒ7∑¥'ﬂÕ=ÜØ·?ÙıÏjø<ë˝‡fÓVN)7Cï˝åp&õ≈N9ÍëO⁄! íØC‘OE‹—m$!%˙„Ì¡Ër6Í&GôI$PÕh"õ≠´ùà4D±@§( 8◊Ö_˛~9◊ï¡{z˘µ7◊˚<à”‰i≤	¸6ﬂ)È$ùî$qí\âHHÏÑîù/ÒF\v’$3uµ®îjà=HÊ‚Ùπs‹ß˝@∫añ¢h∂$	§íƒZr∂B≥,Ü˜áÖ#{=˚∏`X"÷+ÍÜf¶Ñw¬‹…#g±c"ídëM`IÄïjP"‹sGoïQ∑Vi ∞XÒ8|Îj`A
g,J€Üá'è√‚&C$∂¡¸*#?uõ~&IO›JM3„‡Mâ3£NõÆK->ùS—£5¨ñ=•lÙ≠cœ”›ÏmÒß“ ˚Ñiäÿc◊
∂Q;≈nÎ∑ç€¶O–C0)¥.¢ ËÜ©H≤¨Ø¿|¿ÄmøÆìdÀz!º"îÚgE¸µΩ˛Âã¢ñ®î&ùé)˙G‡éÙca¨9ñn£2]π∆ò´›-`!ç±£≠–Â´:›≠cùﬂ3ø¸ÆL∂ €d"øÍøÚ~ﬁZ%p¬7ï∞Lõ°L”HÇAƒd∫≈¢—Áÿ≈ÓÇﬁ’3j Ôf/ö/vã˘+ÑrÛ)ÌKÕß¬ ˛î‡ßä‹ì.ö_Gﬁ‹Â4Zâc∏íFhAÑVÕëdJbø$´~ˇFˆ¿ëﬂ‚øÌ[V13&ˆﬂYÜrëv‹”˜µó^‡Ù‰‘_ƒ-Ä 2Ù´sÎ…”eßßn§4Mj˚›p÷rŒFçı–µl⁄Q∂Ìﬂ†ﬂ5˙h ¯ôq	çî›.òVY†¨åŒì™Ûf⁄Âü7Z/j-Ÿ(>Sˆ¨ıÇµüÓ3˜œÏ≈«Ho‡=≥ zÒ+d!"‡g™„∞Á†≥†:Œ¸•aùñÜ´Ú?ä™låq®º∏ V∞¢siîí˙5ˆ¢n2≥Ç;ôÂ·›î	CH»]∑ÅUf\,	ï≥HCΩ5+∂P(ñ´™*+$RThÕà-lRCKs?˘0ì{ˇ¿õ¯sCø√Ûó¸(6ÙÍ˜ˇºf”ıùØˇâê∫è'~å;.à[N_{g¡·=Gsør!˜—Ænπ£0;‹Ä◊–kNë$ÜEñ¬>™/¨!EÊZï1´^˛2}‘VmÉ®!CŸòc Ê	L<Ê%8è·	ò;)/fÛåÁÜOï√π˙í’y≈Ω√M$≥	Oˇ—ë(§ΩlÇüVº&¡≤êÛ	(fM§—…˜Ë±ˇdÆÈDŒ8…u88≠t¯M2@‹PAQΩ@√>ı∞zI%™Hà¶(¢bÀ≤îû∫È…
Ã-G„¬JåK
˜◊ú ˜åÑπ¿íªÕ¿—Úzr®∞ËSÿ—<çïÈ®˚˚]Ω«ù”z€∂ç∆:£”ñ¥£nãFÔö!õ`n˛ñkÓÄ∏[ì‡F¿—œƒpV=6DÓe%±?˚=“~g9õMÇå=‡…y`mrtL@)6á:9Ó¯eBˇoóç›}⁄e“í5<ﬂ'Íu7Ô+Ó!Ó£û!rêy˚$l±!…í02rö¢ﬂáî©±º}”x…Ûfä3"0N5Átãø˝:ı!Lüf"≈GTM‚ÚjåÀ®ÅåÁ˘Ø4¬]OMk2~Wì…º&5 „∞G œ≤KóVq<ıPE•ß%.îS.€ûø=J=*xTÙ®¬#§ísƒC,ï∏Uày/”´ïÔÖ¨úsU"÷m’™˜{D‘)¬&@ILq≈˘j„-rÅ¥"l’Í»€IwÕÔ-ã0◊e¥‚E"Øåõ◊∆;êGKù≠à¯ïBR™[Ùù˙œ¡î˙#˙#~:WòmÃ7W—’¬„Îf∑°hDT‚F£˘E“Lí%i|÷T˜í}¥GÓQzÈqY≤àﬂ4kER(äD—£VTÄUÙï˛ïÿÅ“¢(>U¸ò&„~Zgm≥à’OzëÅÎŒà64bué™˚T€—∑jXÎ%M¨¡íÜÇ‰É∆Õˆw2Ã“§ıá∂∏N‹&R1Mzœ80J†Óå∫â ƒôWsÄ˝ÛfƒÖ
f`˜}BPóx%Í~Œ+DpÅF„^¡yÈSÉW†®_ÒÍMÛ)ﬁU√;û1∆Oõ*
ç>ø˝ı˘H‹úâi`≈ÕÖã<ˆ‹x∫ û7yT,‘Âb∑≠¬œ(n\Ñ# O\â{Ò,º∫vFI^ã≈π÷7s´ƒ˛â[Ø<º‚ ùº≥Lxg¢A∏6aC˜r0õ§(àŒ8Û7û)$Õ¨πp5[](hz|ÄäÉ<#≈™RTﬂ
õéŒQßîä≤Cæ°†Ò?>ù£ÙÈıüππ‰~†{H_Œ∫º¥î‰]”tfˆríã\–|aq
âD¿76‘CßZ9HÊÓI~eO€Õ‹€πÁÒ≥›/‘Ì»}[Ï7≠Á7]»e≥'(~qÎöoºá;˘˚$X!à*§±4[ç3€ÀüT6ïCı∞ÂQŸ£≥˛¡xµ7qù—Ω˚íV˚î¨∑Ví%≠VíÖC2F`‚-`ﬁ`7‘!+ò¿6`∆4fí∆LÇy5Öæ»4$(iZh:ò!8.•öa“4	”vh¬4JúB[ò0©√Mlıﬁ+)0”?µºªüvØtÔ’wæsŒŸSL Ñr¿ó€H·⁄)õ7Ø∑OÖc+zÔèeî“U.]·ÛN˘ı‚s8^)]—sc>¢“uAÂRæ]›®n·ûê˙Âùñ›ÚÛ‚1yDæ!]ó»ïVŸnµ VY‡l>2‰uZXõU∆ÕqNó◊p!˝†›Â"BaúO∑[ñ%s@ó^dëW)iR1UXå¬XñX¥c6W©m÷4Jªˇﬂ≥ˇ´C•G¶ˇ‚>˝-
pIz<£n‘z†í*Â:	ü5f´!Â ËKvIììty(˝…˚ˇÂ`˘≥!geeö’6U	»„öí
^O÷ˆdmê5´ÑÌ¬√Q*©$™§:ß”agM∞◊qUD®…$ÑSCa+:BÓ=ˇ˛ˆwˇ¥8ﬁ∂®0ˆV[œ≤Th·ﬂ¿ëùó<t¢Ü9”ÚNˇãó˝QmIlYjü˝ÓTﬁ4ﬁG•˙Áv"Ø–^∏Nˇ:≈“aƒVS´È^j+MGcıTVùEÕ7-Ú7gksbK©Â¶vˇ≤¯û
)Ç,?˙Ωµr-z9àïÉNEqp1àñΩ¿¡wå9(äã∫FjT,:EŒDfGõ´©|(“›¿wãÎ•µˆ5Ó~~ª∏]~JÈ”z£É‘^~è∏W~NŸ©=˝ÅxP>Ëî¥,“m>›ÀÈ	†D¬k£Îjub,.1’Ô€„#}Qßò
ƒ¢  8ƒ≈^%ê‚'Ö}gZ˜<Jó@BS}´¯Ú©®&â<R˝üŸƒ“…Ç®Ü˜†mÙ•ºÇ›~»C∑úD
{a¨Ë
®≠†l F¿êQëBS¢©·äp:ë âë¬?_ó$≤-Åñ&¢œ%ºupO@áz?≤ïAn˚∫%≤}’ÇßvıäR;
Q˚î%à¡Óje<óEß1¥#c‘£ .á*ëÀﬂC1»Â+d∫à∂òÆ≈tΩ>3eJ¢≤‰∫vóìvaê≤–ìÎÌoà+ﬂyj”Ò•≠Ì”'6|≥k›w>ˇ——ªÉÃ˘W«ÜédßÇÿ>¯ÂKøü¯˜O¿_îûÁñÕÏù›º.‚Zïl8∫f”ÔÔzá¥Ô{;V¥§”Î„”OoÎªÿªı©,d≈9ê–=lÊ¶QÙtn§p˝îÕïÅ‹›ê`@{‡âB'Òò;Ñ}`Láá'õN'ÃUñjâÓùl'ˇ1K34E±f«≤KqÇê´¥vtZÀQöNtó™$Åù$+,†H#§«‡,é"°I#§€‡ÓA√2 -ˆ8mà<˚LÍ¡r?IíË a/3ï¡c™J<u≠‰6I˜∞(ΩÍÄúîºStøc9ò≤‚ÂÔHt†÷èa◊lŸ]∞›4Cbp√â¢]®ÕT‡i·êj∫äL≥¿	Ùô¬A∆ Ó0Q¶f(éÉdÜ€∂ìD>ÀøF@»
˚O,Êi`%ßèøwÑZõg>
‘k„oê©≈sû|≤˜ 8Ò’©Ò"ÌZP∏A´ÙDúh S∆$N‰™<¢∑*!VUAÉÂhM´ö_ïsU›bWUGÕ^q0ÒÇÛê˜òËàó[‘jQ±:ºÍ9ˆ¸&~ﬁs1˛G«GqÛl'†ä∞¢bµŸp…‚¬≠G
—Ü¢†+ËNN™ dÈÏ§˘ÙºIôó'◊öªí€Ñ]¬Ñª‚›§µ!#Z©÷2Æ∫ê›Ω2±)A&‘j©I⁄/Ω,$ÊeÈÑÙôDIJêÑJÂLB;Ömì$+À,©îkÑ<>Ï˛±]UM‰≈
”≥‘©üX•¨"Xú‰hHC≈[¢Œõ≈vK£Qﬁ·˚Q∏yå·_5x4ùÜ'“êüG_¨çê+)f∫¢WÍ5˙	ù…"Ä8RÍÂa‘¢{Üàdj≤Á≤‰·,»∫–⁄æÅæ—uá´µ7Ÿã,dõXíï∞‹b(≤n¨≥Zãç+aÕUpX;ıû CBI*ê0ª‹*Îg≤q<˘ÈßàhFìM∑∆G≠H5K„ÛE:Õb*Eƒ,ìá"EÇÈ•øÍ31D0¶ÿ$Êß√aw∫":≈ö$h±úêï‡ ™ÒÒ_wü8;∑w^˝˙+Î@∫y˜”˝˛!wœ•=ªè∑*ú+|Vu=v~S{›∆ÆŒüÍ˛g⁄Ê¸rÁíKÏíË’¢ñû‘åÂyw~ﬂBc’Ç…O‹˛rÁå©‡£∏™ƒWœÎX—2„€—É—A‘Ω~0`å kL=”Ã0M¡° Ü’¥:S›<dßU4:Ωãúãº9sN|XŒ9ıvõ7àùrè≥«{.¯°p≈u≈s≠‚¶Î¶Áˇ’`!Ë©d™Âj{”$Ã"πïYÀ\ÒAˇGáD≥$·SY∞8Tâwkóx†ﬂ¡t–¿- ∆(Ô.µÉw ÆÔ6∆∂<0∏ä¡ÉÓ’(ü¸V`M|ççPöäí‰9 uÈ0∑M†PPª&0haï·G*@Aü6Ä°PìÜÜá:—‘¿çÊv4Ê6‹Ôµ0*∂4.V∆·(I˜nb•ÇˇVÑó"YÂ∑˘Pƒö∂B˝Å&[!"·Â'ç}6Ñ
H˝¸ı-';ë7&>ˇÌŸıd¶Ì˚€^˚Yﬂ∂◊ò3„_ÏoŸˇnÔƒgó_ﬂl€w·ΩKo_Ä™“Z∏A›Ç|Âèú$±u»HOÀ@ÊÅA¥õ	ä†m*or´4$á…åvo¬ª7	h˜&ÌﬁÑ~·œoıı|Æµ5>c.'Ä†:´bñki≈RWGEáÎyàzA|Ey≈+òEè•õÏ¢∫ô>a≥8 æ*úÊÜ-ß¡	€’OHJ
Øî7…OÀî ≈˝5ZT\÷‚0qï∏MpÑ,ÛƒΩ5™pÈöd∆¸ˆ¡˝i|2U `‡8;ÛpNº8'ÛUáv—Ç¶&ií– ì2az˝/◊U≈qÖwvgwoˆºæ›ÛﬁÆÌ;˚Ó0kw%Äœ£SXB1jl˛Éi.5
mÉ- Ñƒ¡)$êîDV•TâT£PDiå±R†QπD•ä §Ö®%·'äQ!)`•‘!€}oŒ7≤o˛vwvÁ}Ô{Ô{Í‘pÍ‘H	®‰»üi©[\V«ãE2úù—x£Âv‚F?;ê›¨y»»Ù¬?WÄ[#qê€Çô
¢t∏Ø9)}∏‰÷˚Üænπ˛Í{üFm[±Î‡æÎﬁ /;øÎ!%D{óà/⁄^ˇ£ìˇ¯O?≈Sò]Fö¿»•ﬁ>M§∫´ßÙÔÍrïUy\\¢-≤GûWÀkÿ*´)íçûìœ\,∫Zp’∫Â|Ytï3œéF≈H◊∫b‰Æ:YØO∂gäUzù8WØµæy\[¶?≠_U˛eê€˘	I˘~# åÙ´¶ îî¸ÖïDpÕÄkgMbòûŸd∂ô@MÙâAÕ 2«‰I©j*ËA&',¨~∑Ç≈Õ|¥8Ãorñö®ËAtÃç¡Ò'‘ı≤:¨RÑ®Aï‘RÓr<N´•9W‰∞Ò¥§ÚÏ£ï¶åaZ¶y˛ç¡±§K®)z≥4˛¨94´¬X¡8péXx&ÕXsj€˘MÎŒmo˙≈CGcÔn⁄¸ÎœoŸ˚ Øvﬂ}gë^[8[Ã®Ég˛Ú«”ŒúBÃÍ äñœBÄŸbœâ
ëh™åúaK˝k§ıÚ3lçﬂ¬,»èoéJ"ÿVˇ)X˝≈tjpf—‘»Ï‡¸‚ŸëÖ¡'äEV\º2≤EŸÍ˚¡&›qÿMˆ[≤#Åv£√ÉÜ#ö*¢«éF≥,∞Ïn ;ﬁ, ˆ8ûYóãj±¿WÎòˇ—§:ﬁœ*&•:u¢Gavƒ-OaÔÕ∆4%Qª“Øz„'•FëäçA*¬ë ,¬1≤9^Ä‘ÿòòIÃÏ≠7@Ö˜s%>#!hıD/'W&=ÿú&òC.í·)î4∑åRÃ*ß	¶•∆mƒãƒÀyïû<ûºyÏ˙–-b}zû‰ì{◊¥ÆóWÌº .Ãõ±Ï’~Cñ9Ôtì(˚<2aË“–7FÏ–Òµ‰ÕWÊ¨›Ë=2¥P˙–+&ëgº&ø_∂í~◊zÃ?◊RXIQI“_n%Àj¸’÷£˛Zkô∫‹ø÷?†˝7î?π,YÒpŸ√èU¥';íjuºz‚¨d≠ø6>w‚í¯íâ?TW≈WMlJ∂%/T\ãﬂ,ªUa:∂:*Óû)Py‘3b¬Û⁄Ñ¨pV â%∂z”‰H$†Õ…”ÏP•[©πÖÖgb8û”‰¥94È˘¡ÊINAáS–πOAáS–±˘5@7GAºK¡yéÇ&∞G gcÄ∏¬∏Ë¯Åû¿Â¿pÄF≥î9∫ÅbD70wDpß ÁaÄÛ0PîHnå#ıc®x˚ÜÒ-6ˆˆßË^ƒ∫˚4¢€‘ql''v* a1«Iß™“‰Wy¡b>u»?mŒ∆÷]Ö˘dsÁ'}?˘Ëı∑Ó_ÛI«æx{Îﬁ€∫Â¿Ú‚ÖÓ¥’+¶w˛å§/æE»Ó∑⁄Ó≠ª”≥Â∑“§è≤'Œú<}k≠ùÇ ]Ékëï«<=uJl.]Z%ÕïéÎî/ÕtäRéœÃ3-I&B "´ñ_ÀsôWYùf$ÀàÕ„°Ì!lo-ÑÄ°6—påÎVå˜1^°!ôÖê0Ü~|/”PP‡ı–∂¨ﬁFÚ9©ÍTß›gãÏª”∂©-Z.8Ω·˙‡<B<Áä@aq†{§ ¸à	‰√W_ÀØqÌ"à\…ã\’áÊ-IÑ#®Å“M£¸£f¯206ùì.X°Mù2Á9/_…W›|%/Lt_ LÑI$^ÄÏ$QôS4∂2ÀL£2wvøò›¸~]˜¶ı^OÉ|˘ÍÁô}ø¸Å∏wÁÛãﬂh¸=pr ó@°®¬_Ω'Y5û†Åµ≥÷…≤Ï2Îc™¿¢lkc{FñÆ∞a¶EËïäTº/Aë™)™+tÌ†ù4KØP%K˚®(–=3Js∫N\JÔ€çrªQﬂJ-¥ÕUJ|0ƒc'EihCZÔ˚∂ıZ¿zXÕŒ∫¡√˛–Â[öUï!	¨≤´ªªõ~Ÿ”s7DÀÔ^@øÑ3Kw‡Ã~q•Vr˘NY¶¨`R@ˇè‹ØH,øRA›ãüßçÿË@¬‚“¿óJœjbPâƒS>ÃGÇ)Ü¬˙†Ã‚|¡€+
•2U¶≥yTvïÔhÀµg•M⁄ÈsE›Øê2•\u}5 6Ko–i£≤\md≠Ù9˘mvZ˘˝XÈUÆ´_+ﬂ¯BAMì%âää¢2ÊÉ	Û˘\U±TUë(ueÕíeM`®èÄ˘eEıÅg
=Jì)Øx«˘pèq≈∆À2µ∏ííﬂDÙª@f	‡! É7ï˚∏¡ÎO.◊éò‰ûŒ%û¿Â¢Pîßü˜‘òHÖÅi>ËÑêé˙[‹µ¯ÿ“¶S≥Sûú†≠∆)Ë˘0P_⁄óñx{X·zZØc$ vH"+‘Õ¯|s#‡<ÁâÂû∆í%5ÃWRí¿.uï‘@wÆ+∆ª√Ò˛	ç†F@ìâ<qLPÜ≥]Ò 1€ecw©À®QrüÂÒÓ∞?˜p¢hÜz¡ãî¯,ﬁfYiﬁ¿S˝]Ö¯øás∑ìLcÆ"ÖQ3Á%©$§å®‡â‰‡ı°u‰ƒ•°Ω€‰„˜>$ùCõWã—≠CﬂGø‹ÕtŒ≈œ?ê9e‘”g§xü™ ıS¶Ê˙q.Ô=¬j@é {‰À2mÄ¶Oñ¢ÚπMñ)D-MîrÅw‚-TYï⁄#ê,HqlTªÛ ™ïåâj9¨9;RS•&Üy¢ÓsT®ßˇœQ$i"ë£)œF-πe¥Ãˆn˘¯@ÌHÆP Aîë?t†nÔ;:2 ˝√õÔ◊S.Ì•ΩÏ3ÁjL>/˜«D«+cÖ·ì§≤“à¬‘©•¨∏»–Œ∫§›ÌpE◊qäÛ›vìòî´ËBÆ†1k¯πä∂ê&2⁄¡Éö"◊“y\K+¿Må˜£äzDYíåóWË∂áIòoæø]òoÛõûâ€Öy6ˇèÓjÅmÍ:√˜\_˚>müÎkﬂá'∆vÏ`áWdÑF #ËX	6 F⁄%$]îQô†YWF)—N€ #ÇçN"ÑÄ†Z4è™ô∫n´&”26eBB€⁄$;ˇ±∂»π˛ÔÕ}ÂˇŒˇ=h
¿,Q
(pc≤ˇ%Ωq Óß3lu§3r[∆¿¸ŸË¸üô?Öb¢ÁïÊÀ¡<,“^*99(\πëåñ_@€ŒNj*ˆyÚ$.-°ÏXscÎ¸ª›$ë544ä•CL∆à∂ HäWãy5Ä<N_AêÚví‡ÎõIç?lr≤D[±@≠:—æıpŸwØˇÏ‘ŸHfN◊è_⁄∞∏ßûãj^ª˛•Oüã≥?ÌX[®oÏ0;∞m€?~gÏ≥Ç∑∏K÷ãév¶5ªÕ°±?«_l”Ó€j(∑Å,ò◊1zõwÃ	ì	^óW˜oÅ∫Sr∫W‘§~¬§ﬁB¶ÆB¶ÆB~‰*d:ròû¶ÆB¶ÆÇÏˇ;®L]ÖÆÉ“°Lçãå»Gn6aË¸‡0Ã˚&€e1˚Õ!ì3mlµOß≥˘pPUsì˜øçÖÙî±Pãåóüƒ°¥Ái£“l‡áŸÓ«òí)|@Õ∆G…œ(ac©—«nCw®¢$Hºds‡Iú‰ñ<yê=`+…¢(ÉÔ0ûÄ∏˜ÿk∑÷}KÉâç6ü‰báO7v-©⁄9∂ô}„’Œπné˝
Ú‹|íÁ‚E'c°çÁ}&¸'ôD:dn…ÕPYÙ^≤î&«a•cïä£MjpΩß^Ø5Ò"œ"Ω—Ãÿ3‚rúıdıÂfßΩS‹Ä;=ù˙Û;»':ÏŒ’∂Ì/J´ï[´ΩUÍP$£Ñ„UBﬁhÄz¸ ]<∏yÍÒyì¶-ú?zê∆.(®gÄp†P Aãñ◊LÁ√c>D¬€å€Ñ#‡¯ÛÔHÌä2äÀ‚I«Y°¯ñP|i¨ÀO-ÂFßß…-ÅXfÜbı1r$‰ef≥EXíê%T€MTdK\a_!Æ∑Ø9–&8E√u4∆GÕ?Sl˛Á˜ΩyÂOHﬂ~Ô≠€„£zﬂ8ªßwÄ’P|ﬂ÷Ò?è}tÔ{®9oﬁ∏˘€+7ÆìÍo„&=L)Züﬁß‡)¯9ºs©Pà-MV"¡*_Up^∞+¥?$‘ıÅÖ∆¬¿*aµí12Åva£“Ü;ççÅ°–'ﬁ[Ê-ˇ'•#ﬁë“;°âê·í8È´ÂÍÒ◊∏Ö∏ˇUæ«≤Í≤È%%¿ÚzâKf\VtXBXJKÎ§]¢Ü(úƒ∑›MÀ §dÊ˜ˇS0tˇ§XRgJ∞÷"–li“™ŸjO9√Ñé†~tqe(Öñí`:GŸQ6Fîç]!HÅ["f¿éûJ R‡∆Ñ"	Æ»*k™3Q≤?EƒxÏ¡»„8óÌ&(aaô,'”≠HU˜yYnq’VÑ^o_˝Åo}∏˝µ€€[ﬁû™ûÿ∫ÌÉì[6üo≥_˙¡≤e{'ﬁ=>˛≈[ãÎ«æ∞ı}t˘∆ß7Æˇ∏t≈´Cïπñû=MCòCÆÜ˚*∑Ç{ô€¬9DU—©©¢ì±	H¶Õg$±bøÄÑpHCVˇVz‰*˛ïVã(ÕAó¸⁄ïãKé";ŸÏi∫¸L\¡ŸõFH†;$QEö≈‡kΩÆùó°WõP∂†>}·	%Ì96ß-µzÕúyÛfØÒñr±£›ÍO∆õRÎ6ç˝∫êö¯ªÌÈ¬tõëﬁŒÖΩ·zq°8?∫2‹ﬁ!ÓwGOhT˛∆ÊøiL_T˘{√`øŒ≤∏
IfF»à)#gîå≥]h€•vπ]iw∆„Óx,èNûmëV…b*∂D∂DwEJ?QTÆ<4ΩO˙Ör<ﬁWq6v%¶W<O∏PD
E¥PT‰rH˛("Ö"Z(Çƒ¡¶=•≥ZÑxπ"q˛PÃ«…SÉ˛Ï©tÿ™ÑÊóY)k©µ÷:m}l9‹VôımÎ∂≈ïYo[¨uâ`„#Î‚É™^8£4b1&ëaƒ"pî^ΩQÿ]jBS3¡é ,ÒÒºudqÓnZÄπí©rô˘£VZ3k™‡Úi0§ñô€¬\Y:¨+WZ!∏ ¢≈“©\`W—πÙ\…¨·J¿S‡äà‹Üp)˛q.J¯È£&≈5Î™Ü™ÿT’Æ*∂
#Ñ¢åôsVt…Ör]&$º i^"u”Qw”◊sá‡47ËqûÈv¡›4P∫√∑ öúM>€Ω$?Ù£‰ìØMÕTå·PwrIë˚%ÆNJçv{fMÀyhBÙã,vÚ!kﬁ»Èt:>•4b˜V∆TÏ¡∂9¬ŒPÄ+¯ ≤O!õR/Ÿù‰äòpƒ©ì• ™àãí#…ò2EOBÀm Î$…ûû¶à†PvSwV´”sTè≈ß≤µ53ÎrTDfå™æ◊ .¿(es≤K∏ﬂ‹æc[m˘¡´Ô-ù˚ïƒ;+v^jQ˚ïÕm;⁄u}Z`˜ØØlª∫Û„œ–s%7µŒ.bñW=ﬂ”‹ÙzEYr¡ˆWÃÂôÂuëí†&E´ÁÓ»¥ºˇç_¬úF'>gˆ˜É˘„EF"k0´Ÿπ§ÿe!)N	ŸãI∑DD¬&ªqò	#ßß\Aº–(6Æ„ª¯]¸~ûcàF·˚˘!~òw ¿U|NhÒ˘ püs˛˘¿Ás^-ß˛†2§r‰M@Œø≤Ìåâfûy˘©8Dà~î81<Ú†§öî@Úju5æ)ô,7†±Z5R[≠÷&ã®^h=ã˝ã÷wTÓﬁ}ˆ‹9-YQzÙ}<ßı˚ÕΩàÔˇ·ﬁ±ÉK*˝4I.ª√≈»”ó^d¸§7"…àlH”k‹∂’oMRCQA”§È2!sï¥â©÷ÀMå´ü∫bÉ˙a√0h¿ÅîæçGNÿ†Nÿ zßNÿ†—∆ 'ÏÑ~Lh»@F≥ü&O0¡˛˚~∂ÀƒﬂÔüs~•\|$"bƒê8,ﬁ9± ‚#·ÈìE	û*¬˝©^à‘ã,ÕâÕ÷·ì◊Ë≥vó(Ù=’êS:D~ªún'Î‡á`àÂÂî „‘ Ü7ëË!LÆùTK°âp™U≤‡a fBmKÌ¯tÕÒ•Xî’Wó-€7˚øTWkl◊æ˜ŒŒÃù;Ôá◊ªﬁØ∂◊¬nΩ∆l‚‘”êÜáE±ãX¿-Q"¡ƒA°¿*%1–¥®¸)QZQUm©™1~ii)ïíV.®•§E"Aä”X4n"’°¢Óz{ÓxM®gÁŒ}ÃåÁûÛùÔ|gÉ+w∂5æHN‰æÛÖÎ⁄è!ŸÈ[‡pë0ﬁa¯n?!À;6•"EåJXbHT®àâ∏ê√O¨ÛoèY∑« <€ÒOMå4äU⁄Y∆˘]∑≥
4 L7 W\º¬î˘îÜ&T8JeUE°Å—≠‡`zI•†1µZîV™Y5≤ïh[è◊ì›†l≈[…v∫]y	Ì≈{…>˙í≤óı‚^ÚöpT>Bè)?D'ïÔ±ü£≥_¢πüΩÉ~«n°ø∞è—lM±≈∞CQñF’¨âµ°Ä)b‡D3"@%”/Ö{W`?|Îàã±¿‰nd(‰Pn>
'nïpñà¢¶Ç€Ín˚`8«¸1’µ¥ÑÆLML¶¥Jaû¢0$¬ƒ√>ÑÅd°î,…LÎ4¨U“ î√
QFqb(ãDÑ^†§HÄ+’ª‚hö,ãÁ;Ûùe±…ÒN.5∏⁄hiÊtŸ°€+.Ò{_æ⁄ª$∆/9 æ⁄˚·Ú
uÊ*pÉ-]⁄‰6`¸ãôÆ_çWï«¸è/Ã<©Œø≤≠ªc9‡ tHâ#Ä'2oêFkQY
ïTT≥75=L±Å {vJõ]¯ı†aÖêZyœ¬1≥å4PCX2¡∫&ÒÄ“lL",b3>∞ÁàŒÜ¨36f›≥n¯c}‹¿<„”ÜD†áEjYmo≤økv*Ùﬂh·NHÅëπéÕiG)Ø»X…y5úÆ?F f"í¶∏RBâ;bE$UQÍX»<9IÍ<®ï™‰E‘72®Q~Ñ>j<!¨êymUóõ+Ï’Œ&Û)gá¸,›ÊÏìˆÀªÈÈ¢9Ï|&M+i’N£¥^c§ÕßŒ[ÜöúΩÙ5zR¯ævü!g‘üiChX∫hºπ)˝MôàLò9S“î§*Ò/÷¬÷
[#lÕ∞uä∞M0√å8»¶2≠íÕ*ÉÜ,ËX´“G7É&ŒR:†oQXËÿs%¶⁄’Ã∑;"O±Õvó›c≥ôÕ"ÄEÓéY«|nÍŒP÷÷˘S„ckú≥Ÿ~â¿DK∆®™iÃ≤m‡˜÷9†YV[ôi§~kÀ4%€é„ã≤'ä≤~Æ“O◊
UÆœ®è#ÒA§ Çe'BM[3ÙÛ‡qJeôáécöÜÅòwœ“Ò˝˝∞.Ë£¯t¿Rmw≥Cå∞QÚµ@i≥q∑}»&6©ñà∑à/@p	\ßá=˜ﬁ÷P≈◊Luv∆@◊¿èYgÏÔ"À*∞u\å:;l{◊<pˇTˆ÷UŸ∞ö˘…˚¸l=WﬁæaPOi)ÚV·h⁄;»(\Dıf å‚e≈ø\ÎπL;D-\ÔóÎq8Q—ﬁzÆa›∆pˆNøúöùu`v~8/)Ô∂∫~^ÆÁo<èñëã≥ˇÈ¡À<W>gÓ∞T$Ö¯–^æ9|€ça'ã√	ﬁÔfaGππ2ëS	◊äPÜÑÚâ[ IeÅP#‡÷ôKœ∂DŒ^8’¯ÿpﬂÃ‡•≥µÔ¡º9nˇû<ü?˘á1≤u˙È˙Ô5`öäôu¬?Åi øãyhÛLAíq”ëT…3•Z ïπØÛÀnó≈∆ ‚øÑXH	â3âMûêv&≥ioΩŸ«Ñ@Lb¶“ıã7≤¶8Q=Ê‘®5ZçæT[™7oÿj⁄Iª+£9'ÁÊJ∂;€›Ì%˚§=˙>{ø∑ø‰U˝ò˝∫Û∫{‘;…Œ®oYóÏãﬁ]ˆë˜ôû∑Ó{Ö‰¸πPå∫j21ü0_13˛‡ÛgDßGêLS≥  +ƒ=◊≠ròS†W©JÊ:é¶©JZIRóºú$…Q“2dÇ-oîtjã8‰Œeá8£¯ÒaW¢Ø$_
≠§¥z≠M÷jçhp«@ù	∂!-ÉâTÄåóﬂ• $ËN∆¨©Ò∏5ﬁπk≤,fMÜ=„¢ê#üg˙2 Xp–A∞Äss3DÄ§ È“
H-L‡áq‰ﬁn ≤ ¶¨˘a®$kWñp,˘9ÆÖ‰'¿ê[√ıK?>OO@C†qyè.n^YjWãÍÃŒ+∑˝ rˇÉ¡ôÆ//¨ÔYüôŸv÷J/LÏ0ÁE“˘7æ˘≠û=d«Ù€}èÁ⁄yKÉæπ∏2p_†;£‰J¸Eß4ÒÒ«@Å˛(]	VCßñ§ï:+ã≥l~í<IW)m÷f‹A:ËFe≠’Öü!œ–Áîx7=†|øJè*˜ÒIƒi5Æ•æí•?•ÔbŸÇl7bïdÑ$ò¡(í»#
#î±*LÄ⁄Œì»”¢[dOÎHÁÚB	ô⁄7≈Ê ù(]"õB2,F˘¢\©ˇ»¿»å-∆a„SC4¯s˘í±±É˜!‹Ü∫Q	(∆ßQ‹¥vWÙ\ç˘˛Wß rõ◊XìVûw∆}kä;7œºfÎCêˇ⁄úœã2¬2Æ˙‡√0 √Tﬁ™≈’î‡9ÎQnK]·V‰¶oƒªr∏3Ù=-ºwﬁ‰F(^&FYÖFèÒƒ{æ4JjÕŒ≤hvN¶‰±¥†¢±¢ÀK*J“‰'/nòiûÕˇ¶{ﬂs¯'*ùÿõˇ˙ÂM»®]¯Ÿ(˛©º6üä˜≈…'Ú'.y_~ﬂ%◊‰k.π,_vIü‹ÁíSÚ)óóèª‰†|–%”t⁄#]¥À#ÈFèhTÛàÁR™	Ê}C∏Où`≠YGÕ:≈kÉ:∑[>$óˇ«}µWuîÒo˜ÏyPΩI!0º #Ñg $@Ωê¥•@(ê&¡@§h+)ñê¢mK B!Via(L2 ò0X™-£6LmcÍÙÖÜVA•3"∂"h	·¯˚ˆús{9PQf¸«;Ûõo˜;˚Ì~Ô›kÿ"269⁄)1!äÀ(∑k˜—ùñ	{¨ïÇ¢ÜÒú2µ[Ÿ.}øî¿Ò¯ß’~	¢ﬁàrJèÎƒÉ√ *º˚îíZ¯ˇ--++e˛Oîàî~Y£Q]-ÀÓ7…á˙û;tÃhCºå‘/>ÿYùô>©Î‹¢œG‘d„¥úa∂hOÕù°=u÷9õ,Ö#íÂq˚xDæoøëMvSDÓ≥˜EdΩ]ëÏπ ^ëKÏ%π–Yò,Ûù|ﬂSù:î‹aﬂ$$¬eù‡,·4⁄Ã»p†§®ù:G‡Ø¥ƒÆŸ]âÀ§4¢ó•Q!ƒ"Ì≠§ã%Q¸3ÖèÿU'ìÙI >jˇ$†W;+Êß≤2¯MîD≤2SímÀNÀŒì7.:‘{»‹°ŸY∆G¡@˝˙“¨Ù…∑Õœˇ|ƒ›„1„¥Ø}ıDÓ¿_€'lπﬂ~√ñÁÒºSÁ»rgï#úÖx»;¬Å|É{iÉEGòL1Î¥y©	€ûä%ÉoUª{œ
¬Œqè7a˘ı¥eÒDóœ]>LyÛ;G/8=‚_˝â¥¡LﬂPKæ{io˚#I‰$`⁄ÎY∞'\ôAw'—•ΩóûNÚˆâ˚%fY>Kéãaü¸êæ™ )òb˜§oöÖ4G¨°bŸ@ÀFO U{h)÷6`~'ËAñ≈˙‡è@(∫˚ºÈ¿@>œ±ˆ5ñ≈KxMÀ©ÿÈMèõÖn;Œ€d6”√¿våÎ’	⁄mç£≈òÔÄ‹ÎähØÅÃ&´Å6Éˇæ?ﬁv–9ò◊a<r˛∏É]C©L¸tÏ≥Œ∑7Õ8DŸ™‹˝∂|{N™p∆L–I¿4¨âÄﬁ¨ÕT-ö›z|•JúøÜ˘¿DüÊaü’¯ûπ˛òWb‹zX†ùÅæ¿ πá–Èß†#`ëg7–Lè≤Õ1õ†øØ”µtúú˘3†üÁûÌß[ï!L12©¥ËÃíÔ–bıe◊ãÊ)2»;ˆ”ÄÒjÕ¿\@œ|Û m·90]£‹mW/Q≠qû∆‚€”÷&ÿ± ˛	\§ÚØ4Ã@+ê_±ˇJ`;ˆ¸≥ŒátŒö©NÈ™÷„¨ø~bﬂ`æqùç≥.s=@>òå∏T è±>8˚ú„.
Øå√⁄ìX3è~WÿŒ9…2,èΩ¯yXˇ9•z¨©Å_èÉ* Öu†ÛÃæΩÖ}RË	Nı@)p0Ñ≥	Á:_ë3úõ:?êf3|›tŒz6l◊ÒÙj¶ŒﬂãœÈkÌ°R}yOÆŒYË≤?ÿõkäs&†:øKuﬁ vrN≈(jOù°…¨ÉÆA‰V@πÓ†3◊√&Y@’†[ê«ïú≥¨_@Ÿ/úk⁄'®	üF„lÕ–5jıÛsΩ2†Å/bÙQ⁄Å=Ô∑DO©•<ıÂﬂ£’Yöh§”p3<ÿÉµ˚‰öÌ4Q&by/Ê/ÜËfÜ›*ôM∞≥˛l•miôjï∑´VaöçÓiìDãŸ(ü—„kh¢…˚∆îˇÌøÂﬂ‰≥=≥—˝ãŸÍ∫∞g◊Ñ}Fd }
˛èÄ
`∞3DlvJ≈´v%YDÁÅ«U.›aÊ“’Ñ¯§†œ£¿/0?¶◊çZ´Z›ﬂä
™ê≠Teß–rzŒíG®í¡˚É.âÀ£´r.úKÚ5LπÁ˚9’‘B˝ΩÎ„§èã¿‰—4‰d*ﬂ‹üı˝ÄTy˘Í^äÂgÌ]‰g(OKC˘ôŒÀ0’w˙{Pß–cm`?˜GÓq‹#πœqü	÷áiú¸≥≤yÃ}¯*ˆÎ˙vS°„ü¸⁄GFºã\◊ö‰Ó≤∏ªç[››÷(å?LwÏ~2vßŒqØ¯˜izpóz|Í‹£f&-ˆ˚Ÿ›oŒ—˙-‘˙u∞ˆ“
≥qG‘˙÷˙5BÔRu?|æÖ÷√éTcÍ|`˚D«Ç®ﬂ|'·gæãj®“8ä˜ÀfR}_‰Pto—<‹©LôgQΩuÜF©Ù⁄&Z¿±b;XéΩ≥åùÙâV©~à5)t÷’j‰“.ù,[ä|a?D6rv÷~uZ&ónı˝±C˚BÀ„-¬9Ãæ¿ûV
Õ÷Ôâ3Ù}≥ÄäPCuv’·°.vcèùê+`] ◊]ﬂ◊i.Í´Ω©=át˛ªmF#Ïy}0*‡£FÍfV¿á•⁄ˆâ Î±k∏~å»9bmDÊ˜ƒFzV°{¨R™Ø∆DüƒπÎ¿˚6Í7µªÚΩ˝æM8{-¯,õ√o~#pΩÿπ±*Ù;Ä¥¸N¡˘∆i™3¶R5Ú¯Ng#¸∞öÜ!•˘—ÿÈAœüÒ±ﬁÉÊ%yTÙ5íË[Ãóôt't$r˘}M≠§Ø©BeåDÌv°aÍ‘Íg¥’ËLÛ’€¥UΩJÎyÆ"4»ÿ˚‡m…¸˜h&ÛÂaÃ7S±äBæöæÆÊSπ±π˜∫E=åXCŒ¸Ú§?‰œa_‚Ö®≠*å?s˜:}∆∑à°ÚhòñãÉ÷5@Hg9VMEL°/èØ“∫∆Ùtºé~⁄NﬁrºFm•(¸t‡—+≥d5µÚwt∑1ùûª›ÉÎ§Ú‚Á*K,Ü´,˙	∞„°†?ˆzsº›≤Ë(∞{}ôˇ0‰]îÕºÌ¿f‡W¡∑x9◊„«√Ï·ºj˛
Ó@úw2¬Î·Álúó≠∆ª»≈©k%€ﬂ†d#¸^êÕÕ®ßW®øAÓ?n§”ø~q~Ãç∑1àËmˇé≈—>L˝ª·¶uªY æ+ÄÌﬂO)≈À!Í$é∏«@≈J2ñ!Ãáa	¸ƒ	¸Á5??‰
±œ√¸<◊ÕÂÀ4?AƒÚaM`®¨¬sßÖ&0¨7ÒÌÕkÁj◊PLÉç-¨r0Ì⁄πu/•1dË⁄ùePs@l˛z¿kµ|"MfpÌ2‰¸_bﬂ≥ËFú_≥ŸØ∆Ô{ü .·¯@ø\ı.M:4tj@„k6\∑a^–KÆ∑&T_¥ÁˇP;oÕ¿[ˇÎ≥!WÅ$¿:ÜwHﬁë≠xüÃ•J¢vÙíÀ#Ä†›˙!x∏ΩØ§âwÔ–mDm0^
~´W™TÎø+S¡˚±/Î¯˚Â{Úmø$∫tÿÎ…∑5 ã0˛;Ä˚ºÌ˜ˇbΩ‹É´*Ó8˛À=Øƒ I:I
ÜéhS3c+’Vå°ò(ïK
Âa}åµ»U$<[Kë"TäZ:¯Dg®èä¯@˚áUßé:*8HFåπßüﬂû=77'$·Œ|Ê{wœÓŸ=˚˙}}
]C˘è®∑}:zﬁ<ÖÙM$ÈC§g¡˛ØDK–@Ù§˛jE˝Hõ{Ë)◊„ﬂ?æÆ‚Y¶“œ
t:/yá¯⁄œg'öºkƒÛﬂôzˆ.—V£q‡ŒÙæoGÓ›ß£;N¨Ãg&∑6l∆Sû¶>ZΩ¨˙g„≠ö˚õÒ±¥+R+˝)Pˇ™ﬁY˝+™Ôo=”üZ˙uïÈóçπgkﬁÁ≤∫√∑≠Œ§Ã±TˇpgO!Î˚w£˚“ßC]D¯
±´êX∑õs˜˙2ÈﬁËë8¶≈gkõ3∂ìòv™”'#øAL≠≤LI–^~ÃπñKîd,>Q:ã›ﬂ8ñ∑£s„Ù…¶„8SS©RÇ°·.%ÈK€¯ÄN“ù˘‹M'}«	ßæ$N'iÛ<πˆb?S.ÂY˚ÓD—ªÖ˚pã˜è˚ê‹«Ÿ˝f”å—≈πp∞1tÁ˛?Ïƒ®.ÚnÕˇJ™Ú∑KÈáÅ∏ô˘MÎ3Ù/y+DRG√f“∑ëÓÓæl N∞§;[œ…u´˛‹¯C∆ÃúÉ+µˇ2ŒÉûòœµﬁ!i˚ÕQWÔπÓ§àª∞S=GÆÉÌ§Ir˚=8∑á _˘øÌÇv·|ıúÂcº=a≥?◊î…≥˜F¡9?«}çwæ>Àô>€ÕHapö4;o'ÜV|5uì.AKÉ>r?Ôyå˙À4¯ü«4v–nù¨áôîΩ‹˝TÓv∫ 0ﬁ”◊}_ä≠ˆö‰jçW˛@ÍÛ»˚:¿Ë˚r∂;YÜ¡ºÔ|ç5ŒV÷»~ÍR≈Ú§3Zût∑…ıºoGóFY_∞G÷Áß•&æ¨ˆeµ≥Nn'o]{YÁWJÉæ#é´„ˇò©º†∑â˘≥Ió[≠éø9È	Lˇ&À(‚Ú¶‹v„z˘5ƒ“O˘~⁄÷ævÊmàÒK!Õw∏Ë—d{:F©∆•He∫çÒ7ec~ùL¶üËòö±ù,cù[π˜iL◊ˆ7£ˇë+›E`«8Ÿó∏-∆•π=/{˛èá:œë"]Wf-E‘zÕ|]¢sÊucÍ¸áèÎ¯n¶|J ‹√¿“~*¨Ø2X¢§÷≥GÁ∞WXÉÓ*<S£,¥P6‹lÍÕ2ıÜ˘„‡˙UO;ç·-»-Ñ∏µ≤‘¿xÈ¸•ä√«—ÎS/“÷)4„w}ZŒ<_Ö)gıªK›‰Î˙ºò¯-ÈæÊ€≠ö±JΩBÓu˙çx*g†œÚùÛ‘_1n∂l®‘CYØ]•∆€)}ùkÒ/ˇ‰¨Î≈‹çd^ÂvÁ=9√=W¶:=$≠‰’Ñ˚Ú°8u%ı˘o¢wínêI©◊ÂJ∆kÃÇ•|wì·º∞_~mô¶§Ûæ√Û∑a¢˝ﬂ;˙Oﬁyƒø£Q6Á@π=hJ›M€’íN=FËÌ8›Ÿ	®sçeÄmg∏;û=÷öãíPWuPÚUøõƒÊó'!_µ:	˘’«ÈG{Â⁄ÎG{˘˝íêﬂÔÙ£Ω˜ûôÑ¸3;Ëﬂ•I»øÙ˙—ﬁ8˜MB~ﬂ˙1:	˘£ì˝‡|‚õyéªÈ6ÙÔ¢£PV_ÊY˛søÎm˙[ÓO∞ÓÅœ°⁄¬ôN°L˙?ÿc[»ÏE{â˘≈ÌÑ´‡˚Pµ•u3ODmlõôùQ˝ÊÌ∂ø9ÈÃ∑‡@‘ûi[œﬁ]Ëô∞÷ñ_l€›ı=≥™•º>◊o4ıv¥:3ûW†„Z»<>É˛ﬁÇ=º˝Ü˝ÊGı]-ÁÇ|ÈÆïÂzj¨ELÃæEFô3˜ïV± x‚ÃsﬁÖú}ÁKïﬂrØT´o–3‹õf /Û“ƒ&¡ü‡å_xW<˜_RÊÌó)ÓÊ<Ç/ŒyKÓÂÁ˙n=∑’s8K‰2£1åsSc·•úπ]2˛•;eä›ÈÔ=≤õ;€boÇt’Û<Hz%ﬂ≤Qnˆnëπ˘≥e∑ˇ	}}MÍâW˛‚›&#‚ª≠?[
º”VªÊ…‘Ç^‰7w»∞Ç|›´2Ü1˚Q‹vv)&_Áßóa‰2Ã˝Wï0 Ùô˛‚√\∑?Üg2Ò˙åI⁄Ùg¥∆O˜Aqù"ﬁab˜%2 (¿{í≈•≤¡? w¯¥U©æ.;ˆÉùFÈ¸RŒˆ§üWÀU‚õ?`úØê.±r∂Ô¶J‡M
õn›È∆/ˆt∑J©ÒƒÆ¨∆Ôhî5ﬁYŒöòÙ5±è z
œÃqm‹Fˆ{PçüŸÔ∑ö„7Ã∏ì?“-ëJØÑµÉÔh£∂OAâl°Ï≤ÿœªed‡†õ•ﬁ_$„ºÀó"<#=É·R™˛,åØõ≠1⁄;Ü'˝X˚Ÿ˝˛–Ω4‹ÓÒ…∂E˚Q˜óÊõΩI^ÛZõˇ+ò3¢Á˙,ú˝o>Ωﬂ<õïofÜÀ∂î˙QÀ;Ê“'◊ß?yÎ÷öııf˝‘t™	ˇŸûÍfçe˝pÏ'€Í*tzú∆ÁΩ√Ωã∫}¿è}tR)ªèrk§∆™>`ı>]kÍıíöı’Ìh{˛5««F˚,÷»Wﬂë–+≠ˆã˝ugöıﬂ≠4m˙Ù¨_ÔLÎ§¿¯N´¡
ŒC<h¨6ø0G˝6˜ß\5s"éı±ÍﬂG™øv7‡E;@◊ù‚ﬂ∆hMù‚‹)◊üH¢≥Zc}~ª¯†‰W$	?SËÛÔ"¬?[Y6)Nûà‚ﬁô$¸Ã†w∑„‡ﬂKªêVD∞7¬¯ˇ`$`Á˜4Ík,Ï\Ü∂,ã	C%˜x„q·€›”≥}é€∑Ô=Ÿy<Ÿy9Uﬂ›QﬂsaOÓáX}Â∏˝f~üEË˘DŸ"ãœ∏>[·À*ÖΩRŒæ=‚Lc=Anù6Î`wS≈¶u/*>Œ.(çˆw§è"d‚Ò∆'ò≠ø†4N^ì\mΩ◊~æ£õûÔä=˚˙åëçÊ,®ì
=[àª∫œªOI}kœéc›îÈﬁ NzîÔ·›(5©√˚ºπú	üÑœ{ÛÒ@[-{-"Ô˛˝±Á!Ú8˙`.‹mœP¥Ì› Xø≠>ˆ˙àÃáQ~Kø‚≥◊˘ÇÔhí2ıÓP)3˛eÜ4@ôsàÁ¯æa±sµ\®1√˘!ﬁ
ˇ°~¡Ïë"˜m4¢„2∆Ÿí≥ø+e°[À8Åz"3Oœ¥¸s¶~π=h[ŒLŒÒˇJEÍÂxFΩ≈˙Ô!ô´æ»·F·]Œ∫KŸ±·øù5ËÀ0á˛÷…å‘B9À©ó™‘´¯ùÚØÉk˘_ä¬DX7…Ÿ&øâuÚ%Â¡qIøÑzíÜ™‘1ÀÚ}ûW-È‘#í∆ßy_TÓ5S'¬ótﬁ”¶≠¥SÕ˚(ó‚¶‰‡(ú˚ﬂÁ˘‘€ç·}yá¢wôgqôÇñ2ﬁ«R”•^j¸"XÓÚ.wÂîÛ›I“É9ÌÁ0◊˚Ï˝A}‘+¿hÖÎIøê⁄)SÁ†å4¨w9˝¡™∑]fx?ë≥ºf¸¡[¨Éwˇœ~π«Fq‹q¸7≥Á≥1≤ÔÏ∆6–ÛÌ⁄ò3ÿƒgŒ<Õ√w&åJBBõ:V|¿Å„CÁö˛•Rï≈îV4M⁄ò"Zïò¥é»a#ïRh
àï!$≠⁄¶UÍ™BMH◊ÔÃÆyÑóµU+Õ≠>ø«ºvnfˆ734+ÎÙRVçw/∆>∂óƒZö	ƒ›nï´+sÎÆÖü…g?E_n¿˝çxÉÊc	ﬂkﬁ†Ÿrπ÷41qzÎµOd∏whŒ∑&œπŸ–3¯év,≤œZ˜°nÆ¯ˆ`7À=ˆ«Tjü„ƒÍ*F+#æáƒÜ\‘Y‚|√K∞û~$÷ñsD’Ã^~J‹k3”¯òL?_L~ßÓóÌ{iÊi]∞Ì˛ ˜òzªîŸ!∏¡Ô¸ª}◊öÍöf√û}´è˘9‹4∑ÓÌ4G‡j@9¡J™“^uÌπæóÔn¶JØ¿;∆‹∆ﬂå{›F‹E]ˇΩ}˛ç»ıVy´èˇ4OpÌﬂÀœ√⁄√ÎÌ⁄öæ”ˇÔ à3ÚÉÿW“ÓW2g‡øæç¯∫[‡¢LyùÛ⁄≥⁄H|€I‹Aõ®¬é·àç]‰G¸Úª∂bÌ·‹o∑G_@lj±q˛äÿ#ú˝Ôõh˜ü‚\™çB¸±gEß}qOZ Íãs>‚^ìà}Yìiπàµ"¶ =gQqOCºi±Ö•:~≈éAÏåÑD,“
;—«F©•Õ´úò“H#x˛Àwl4OÊ®åI˘vÃ“Ì•D<√˛k«´Rmåø¯i;Ò(3Ã%g
·[8d#ˆú´{‰ﬁÙâ'e,Dú∂∏ª8˜'è¯/"˜:/9gÀﬁOÈÅa}Øs°Sß◊©sk˘ï‘‚:éu≤s'ˆ‰7iB÷#4Ú⁄Ωã®Nå÷‰}eÚ≈‰˙9_ÏybüîÛÑ9Zé3—_à}˙^‡:C-bn≥¬T(ˆ.å”p˙›j#˜i1éƒπ,˚Óó‰;„–~÷È%ßü‚~2ÎÙπkwø·ª‹]Éh¶Îe⁄≠≠∆Y®ñ8˚˝°Ó∑ªbùŸó™>Ø`U-vH9†M^ˇŸqgp
ë‡Ñ$qœπvÉõ¡^ó˚ÒuF^µ…_KTpﬂÌ)Ïø;E[âJP4ˆÅ1ßà|€l¸&ëQÅÈe3v?Q≈^¢¿y˚.O;—ƒÒ6˜◊‡8xñh“'XJ/M9@ToÿÃ˙—ú«ˇ	æE>`Y©P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°¯ÖÂM°ø”,˙!e'/Èa"◊W)e¡' ßüAj$~k•v6ı√cdˇ¶∞
«÷(ü=Íÿ.ÿ´€{Écg”cÏîdÆ¢Mv—±˘¯B«ÊîœW9∂ÜÙ§cª`osl7ÏΩéç˛_“2(Dµx¶¬ZFk(
Ωà‚‘	íÙ≠ó)s·%`ŸÜÙò,QÉúu‡1h)“V£~í∫§Öé¢ÙF»vîå¿é°Æ(ìe⁄@R∂◊é2OB'h“‚¥ÍsÙE¥⁄)[¥Î-áÉ'ﬁnP¨6ÈŸoÓDjP∂`»∂◊»æÙº»M ﬁä“5{åPmÌTcŸö®±(ﬁO>µ>jÃç'÷«m…Xº≥∆àttKc´◊$ªå•—Æhbc¥Ω¶iﬁä˘≠®é$bmãñ›Õì àumF2—÷}≤-±ŒàØ∫„˚åXßëDﬁÚŒX2⁄n¥$€íQTÓl∆F9	„â¯ÜŒd"Ì™˘/ŒoÕ£4üÇ¨æa∂·≠¢Ùjåkáú„ªï¸ºyˇ∑´Àâî©§tõﬂAZ¶çÔå“O“&–E¿µ	Vu©~P´‘J≠ôz8•çÌ+,
y"˜k"BPJ2ˆÅ4pQ´ÊG∫r30¡>ê'ÅÅ»/s=‡¢»—J5üeËﬁH•6uG#“x¥†ëÕ†tÉ‡ñÂDJli7ô÷J¨ÌuË{âıúT}k;B“m≥›Ø<&›æè⁄z—[?–d´∑ãMöl'◊4⁄∫r¢≠«ÖL°sÛBá#≈Z1˛d1:æíÒ_êá1“ißVD˚◊‹NJX+Ï´Ñz“öãò∆5Üâ‘3á5fÂÑ"π<√á®êt˛W˛°ù√?ÏÀ/ıDÚ˜iHçøèÁ=˛mÊ≈òC6Äê'¿pÛãxﬁ≈sÅ_ áÇ†¥ÇêC õøÈÂÁ≈~ •∞ ÁÁ!Ω¸m¸≠∑!=¸¨s¸∫ˆk⁄å–AiTCÁ%_tå¬‚Päü≤.O¿ä
`¶±¢¥röCuZπ5níû“FY≥bzäˇÆœ®÷wFj˘i⁄∞”AzÅÉ«¡z‡Üu÷Y2¡6∞ÏXeê^`c‡-pñjA,9¸§Ö◊§¯	+–®Gä˘q˛&ï`ƒçÕJË∑¯©≈ﬂê˙(¥˙?b˘uäåD>°é⁄D~ˇy_E°ûâ4∆NáÇ–ZA7pÛ4/∑⁄ıB42@«r%-˙@Íü–Æ
Ø’√ÅπXÄÜÅ˙Ÿ∞ zåû v|ÆÅÁ∑√"ç≠∞Ñ|},!a	h_Kà¿ VXBöó¡ÇHÒó_Ø®‘ß5ØcFƒ√7aî6aî6aî6ëão]vâæΩdUUaƒ^WO®“Õ~fbÊRfÓbfîôO3s3g1Û´Ã¨f¶èô~fÜô9¿¶c(L~Ì&wFx3è1ÛUfv13¿ÃqÃ¨`¶¡¶ÖSºÃj™ìjûT}Ò—AœûÉË„·e—2¨˘2ƒÑ4‰	êë^Öårªhø–Â}U∂_SäGATƒ4“ª¿Ö	ƒ2D#Éh¿Ÿ Z¡a02¿ç“ÂËx∑î» h ≠`3nŸù!¿)ÓtqüÏX–Èt≥¯ ûr<eº,\Íıy´Ω¥nÛ¯Y≥?„Á”®∏π∞ ß ≈Ú|î˜ÒGy4"2Ç?œª©±Õ—›÷ÂR=≈^∞z§à}è¸.¨:6ÉlÙtÍí˛ÚÂ=ß≤^ËêÂ{’<V`¢ﬁœÚE≠˙eﬂÔı|)ÛOæ˝∑F ≈,˝RzËß}œÍGÉ©§
§Tø!ãÙM◊_=&ãnA∆ø/üﬂ¶a(é€ÌX“ç±nL£¢Yì)+Ã/°AÅ¢.t	E‰@YäKÖ∫UïÜ∏ •Â∆¥À$&$¸àì√§©Œ˚+ˆ'0\À{N⁄ÅVÌÁºÔ«~∂„$Ó«/˙öm˝ïV“ükRhÖ¬SÆ¨q}ÈLMø˝Ÿ⁄än˘–Á∂æ†=’oá‘5l≥≠_Å!∞∞z{NìAÕåÏQÆKW≠ ≈S(◊ï´ eV—ï%≠L©ìjR=°WGTUVá‘òJ‘©noﬂbn›‘pÕñC≤ûåaâj|ÈQ5FÓq2Ó∆‹Jë∫‚[ì∏+Ü¯Y1ªt‰aM3ãTL∫ƒ≠≈Êvïﬁí»1W(Â'^@È;^{›•§Íui]i1πËÌJ'6ﬁ¶—û›xÀ9IMø\H-L&nﬁµè(Q…SÍè˙å¯‡V<ÒyÜã´XÈÕpWºØuoá˛†ﬂ{á†·ﬁNº@8KËèlŒ›.},9b–‡`«HNÖ3rƒP3!˜1‰≤–∏94¿%$+πl"!π!ä\‡œ9v07'ôSÒ%„ü2~gˆ≤¿d≥íô^'{íŸõ^GF$¢iÄd4â–”DìàFOK‰Ò!r9B6»¶åßáå2c˚}flˆø©UdånÂy≥Ó¥Lßa:-»ÒÊÂjJ¨ØF–‰("~¶±“\Eª‹‹lŸ¢i⁄FêØ!◊QŒõv@ÍN’ÍVÀ˛í∑ÚéπlÛ≠Ry>˜G¨ÕA¨˘Úùï±≥yåU !ÁP.a¨∆ a¨íUí±à‹„e/PIë/÷CªÅ˝⁄HœÚ‚tÚEAnﬁ¸lj-ΩßïOdîqq‹,ä1»(]ºsÒJL°t‹„ëîZÀœ¶wÈßHJÇ{¬,÷Ó¯írûŸ·œáÆv<,ôˇØö#¨e€o‚äÛW,<¨yÅ¢Ä∑ÅS∑˙æ—Qß€˚:/ÅÛ:„Òàæ€ËK$"Ô˚ﬂâÏ">Î±Ø[‘ P¯s¬„"„Vc*®÷`Æıö∑g)¸<¯&ËSF˝~—∞#·5¡9˜sª’¢µhG6l	M¸˛í.¨Xõ±_ °úÇendstreamendobj57 0 obj[65 0 R]endobj58 0 obj<</Filter/FlateDecode/Length 539>>stream
Hâ\îÕé⁄0E˜y
/g£$∂?$Ñ°H,˙£“>@HçTB¬Ç∑ØÒAåT§ÈL»‹s/ƒyµ€Ï˙nR˘èÒ“Ï√§é]ﬂé·zπçMPápÍ˙¨‘™ÌöÈIÈwsÆá,è7ÔÔ◊)úw˝Òí-*ˇ/^ßÒÆﬁVÌÂﬁ≥¸˚ÿÜ±ÎOÍÌwµW˘˛6√9Ùì*‘r©⁄påˇËk=|´œAÂÈ∂è]Øw”˝#ﬁÛ˘é_˜!(ù∏D¶π¥·:‘MÎ˛≤E_Kµÿ∆◊2}˚ﬂu7Á∂√±˘SèÈÌ&æΩ(t±L¥ÜfPÕ°-T%*hï–HC[àCBi°HC2êá,4ÉöCZA¢É°CICár≠i\,.ãã∆≈‚¢q±∏h\,.ãã∆≈‚¢I∑§k“Ì3ù=-{ˆ¥Ïiÿ”≤ßaAaAÉµ`m∞¨÷Çµ¡Z∞6X÷O¡”‡)xZ	ñGÇ%¡ë`Ip$X	ñ]ªXÚyñœ»ÒY“›3ùï+≈	≠!6sl&lÊÿLÿÃ±ôt|Ö=
˝<˝Ñ~û~B?O?°üßü–œ”OËÁÈ'ÙÛÙ˙y˙	˝|ÍW˙i©h4√lùÃ πÂ÷Îg[˜⁄¶*>ˇí6XoN∫(VÈq>◊è?ûOÍu™4∑qåJ:ƒ“IÚ8C∫>ºŒπ·2®x◊„'˚'¿ —É*˜endstreamendobj65 0 obj<</BaseFont/IEWGNW+ArialMT/CIDSystemInfo 66 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 67 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 15[278 333]17 18 278 19 28 556 29[278]36 37 667 38 39 722 40[667 611 778]44[278 500]47[556 833 722]51[667 778 722 667 611 722]58[944]60[667]68 69 556 70[500]71 72 556 73[278]74 75 556 76 77 222 78[500 222 833]81 84 556 85[333 500 278 556 500 722]91 92 500 131[400]191 192 500 380[604]404[604]3032[83]]>>endobj66 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj67 0 obj<</Ascent 1006/CIDSet 68 0 R/CapHeight 716/Descent -325/Flags 4/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 69 0 R/FontName/IEWGNW+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj68 0 obj<</Filter/FlateDecode/Length 41>>stream
Hâö ˘ˇˇ€˚+¯ˇˇˇ¡ `¿ÿ¿ÄpÄ—(†h 0 —	Nendstreamendobj69 0 obj<</Filter/FlateDecode/Length 28957/Length1 60728>>stream
Hâ\UxMW˛◊ﬁ˚‹y	Eí≠s…TI’+!π°%»C%∆„^…ïDE‚’∆£TïË≠W}jHU«®äöÍâ	J´/c>ç(¶ËLΩ™C˚ô˘>5S‹3Î&jò≥æsˆ⁄kØ˜Z{ùŸ3ÁxÇ!—kT^œd¥>¯u=7[o›Rg¿ñ?•≤§ºuoØ¥Î%”ÊN	Õ˚h+6.ızäOπ¸0´3=Y ÑV˛Y„¯”≠¥|v’Ω˝B‡âS”*ä<ZÏÜ˝@m.Ôœî{™*[œøâÁè>›SÓÌí’´ÔüTØ ôﬁ{ÁÁ!B Â¥Ç¥-ÖΩåi]Âóò"⁄i"ƒ¶D‡QoBUã∂	»ÁggËHán›—N˙s(≈ûFª”Añe±ù8ÌÉÄu(m?¢˘uh€≠‚XW¯ΩX˝e÷’¿y`?0√ΩóÉ¡{TÜ˜>°fñz˚Pè#àD&6a÷°6åc +»e–òæé¢≠zÙƒÆ√42ÔX,ƒ~t¢(Î{,¬Ryí•ñ"]1£QÅï4¬öÉÒ8Øñ†/F`:*ÈE´¿Ze≠µﬁ∆6ÏìG¨ª\Yä≠Î⁄ÎÔHbâ◊±Áimõ=úÅ±\˘}ÚMÃDçú†»*±~fúxû}P»F#	¨›ã+EdkŸjô÷gÃ’PäÏß>4T8µÒV∂’àNl£äµnƒnÏeh¿A|M°Z≥ı∂’åh$‚)éß«ËêÙﬂ]Ïƒ”8K›—üO*!˛å„d–«¢B’íµtmûu
–cÿ€Ì,˘∫%2,íáUñ5·úó◊Ÿ∆Á∏HÍI£Ë—]TàÕr&ÇÿboÜbîqæ7∞ˆsî@{E®hí[’Nu€ˆ®ˇÇŒâ√xSG™”,zâæ¢oEÜò$ﬁó‰:µCù∞{8Íâ(«JÏƒ-jO˝(á~C•¥Ä™È5⁄HçtúÆä¡"_<+n»R9CTCÚ‘,µD[¶ΩjªÍ/Êˇ“ÀJ∂ñ!á˚a1{ˇ:6sd˚–Ñ≥Áqâ4
°pùú4ÜÊ3,§ïÙ{™•TœVé”%˙û˛E7È∂ ÉMƒßË `àô‚y±NlM«≈è‚?2Rvï	≤èLïÖ≤ÇΩ™ñkˆ»ã °öî≈yN÷÷koiµ⁄NÌ≠Ÿj)A_‹Ÿz7˛Ó9?¸À˝Î˝ª˝ı÷Et‰:8]ê ﬁ{¶rΩ◊s«Ωèì πsP<•—ŒÃ$öJ3®ä3˘2’–∂ﬂw—Œ“i∫¡>áâŒ->˜}ƒ1äa¢äbçX+Í≈W‚gió!≤≠Ï(„ÂP9AzÂl9WÆó¶¸B~#/…ü‰K´.™´äS	j®ö§Ê®ÕÍä∫¢ç◊éjﬂŸÇmÂ∂e∂€?ÌO⁄”Ï£Ì9ˆ	ˆ’ˆΩˆSAnÓŒO±¬]êã•KÓ¡*ë¢¢≈1qå˚yäe∂‡Nµ¥\º@ı¢õVe(“H4´8ŒıaÒñ¯IîŸ4úÚ0UÙn’fÎ†ﬁÂ%U}äkÍ «vå5WŸBi°∏a≈nÇËœ6?óΩTÇ<äØÂy≤´-¯õ
¶H∫&∂À—‹UöV ß‹Ñ]rΩÄ=¬ﬂZ¡}<íﬁÂπêO…ÙoiAäë‹E}Â∑XÇg≈\„{ºø•bUÇUH°∏Çw¯Vt◊¶€‚mÈ/¢L˘ƒ#T°vpt˝©I≠^¶	≤∆vCú≈4©`úì`Ôõƒ.ô≠öµ\*ÂñaÜµsµuÇJ ÈƒÚ†]á2Y9y]ƒSe<œ¥Ω|ª˜Û,≥ô≈ù3Ç˚bOàÜ<'wPﬂÒ±<≈é°ﬁñ/P¢ÖOû«G˝πgΩÉçV	¶[këƒÛ†⁄Z¿kÒV£ññ˙Á£èÒÕ9G#¥,—§eYI¬'Œä<±˛·˙r∂c)
?0Ï‚Mœzü:ç<≤VXÂÓ~ú'ÏFL∆”∏ÃQ^g√‰!§¯Gä:+KVrºÁëcm∑∫P0J≠i≈ˇ mv{◊ÿ§Ô|xEÆ5[z˝eúá’úÖtŒ÷û?Ø§gå…ú>(Ì◊©ÙÔ◊∑œ)…Ω{ıÏëîòﬂ˝Ò_≈≈v3∫:ı.è=⁄9∆Ÿ©cáG⁄∑ãh‹&»n”îÑDóëÂ÷Õ8∑©‚åa√í{√√œ∑©3)ÎaSw∑∞Ès¶3Áîˇ„LoÂLøœIz*Rìuó°õçôÜﬁ@„r
_ôiÍÊµ<ª_”Çá1Ót≤ÄÓä*Õ‘MrÎ.3ÎπRüÀù…ÍÍBÇ3åopR"ÍÇCaÃå4*Î(2çZÈP'∆Nô#”eFôLÎÚõ£s
\ô1NgaR¢IE∆d∆≥mB2ZÃò∂”ﬁbF/DÉWı∫ƒCæòÏN-6ä=„LÈ)ÿhó¿v3Õ»yó£˛∑eÂÌ3
™<çë>WTôÿ˙|’∫˘ªúÇOùÅoa!Î`YõÂˆe±Èúƒ·y:[KLZ &ı@$Å®Z„ÛÆ ≈=U7€CåRﬂT7ó∆·3ë;◊π€·Hﬂg]Ä√•˚Úß9(∆(ÙdvÆÎ _Ó‹?FßÎ—ü$%÷E¥kMl]x€{HhÿÉà˜˛Y÷¬¿ÜÁﬁœ,<2û‚Ü0ı"ù=)08¶~Åè∑|E˝òçüBb)≥ò+Rf∂…p˚"ËySãç0tﬂMp◊~|ò‚πG±≈F‹D Ù…˝V„Û_p3!¡åè¥à˝øåWp«ﬁ›{Y“ù¥'…≤^ëœ®»0ÿ¯">ò&'ÏƒrQ0è§ßÆSà	è$ÿ¥°è»ê)ùñÇlÏ"?í∏î	3n⁄:√LÈ°†¶C=L¡Rˇ=Ÿ¶n;ùût{ª˚ÔÌˇÔˇ}ˇø∑UÄ)ÿ¯®—û3}⁄¶$	7R‡>¥|ª*:∑‹_P¿ ﬁù‘—jh$∂/´œ∂5¥⁄◊âÙ¢p4Aôd`Lí[«$€«$„Ø7Å…]C“»M‰Ñ∆ˇ6ÍrTØõõ¿Æˇ!~>+_º<∏xYCΩVoıÌ‚⁄	≠¨º|\6ZK8™Í9≠gHÅî+∆≥FΩú‡'√_4HΩ6)Â +ç¨-J–∆«≤e‘\PæîÃ‹aoèáØçöôòûÿû7°=¡<9ŒÅ¡∞U.Æmà«Õd@µ¨¬«G¿xT[_†U%PDÊd¯'3ÂÏé˙:∏¨ä ˛eªFõ˙FÎQ∏;ßO[â._‘≈„´íôÌ´É∆{»Yr6æ±∫qå8…LÔn_b—û(¯jûAA–¬é n_÷°„ˆÂı=NÌµıùì™∆ÖQÊHRU[ˇØË!ùé6>o8î 	°µ@ùÜ-ÔÅ∆<–ti¸ lK®5Ωå4
Cà¢˘∫π–ÜµK9î&qÒitÿöO]ï[üCÂ4é„N®ÔÌqáÈpld8EáS®2Rô5«pà®%e•e≈¢ø\äÒÔ¸∂¶°«Ê¬˘¡0ßóı„{ÿz˚Ú»˝ﬂE„˚˙>JÁßµ	˙ü◊Â)d
%&3≈»nbòsû]Ë0˜ú¯–E)©É Ω.õÕ®\ÎR£Ú•n3õIùÕöo%÷ˆQ√p˝õùé RK
C+v¡NG…»Oö_∏eGCÕgp.ªäˇ‹ﬂ≥/ﬁá˚#óoßˇñŒ+?H_¡Ø√ÈƒåûÏ6ÉS)&ÒR=Ñπ!ÿå#»L8h ±\ö˚|πmÄÔê# ¿À—`…›ÿ›k4°T…Jö¢#)¨⁄+fÕ,ûSúÎ•¬““≤_.}vvE)78ÿº;T„Yı–ª '…zÚ-¿qöÓŸH6r§◊Ä  "^a#øÁ?IØ≈ËTTìö55√"Á‰. Sq≤ªõag]‹÷sh≤Ó&ÃÿH÷ƒSà?Ú#ºaÂp,~JeçÍdÔ¬©ìT >ZﬁÉ∏ÃïNgIfÆËö≥b?á	wò;≈n¬Nƒ„êôªâ»M¿Ì8(ÁOoÅô#Ùnäf1hfÑc[È9ÜE8úãã1>æ7]Ôæ¸Ã@P]ÊØº* ¡uÑQ\7{º‡(Jû)ôπi`œ*∫áÅoRëÃzêKñ°îY*‡°Ñı∞˘:ƒˇúÈ.Ã$≤ôn ãå m›c±àlJ zïeV≤æÒ)ŒŸ%jÍZvÕÚ1lë.∏Ìp€2Wı’ºÿF⁄-Ì∂V¡$Y‹§⁄±$˜	OïØ÷±"wÖÁi_ì‘dY„x)∑…”Ë€Læ+n≤l±µâ§}ÙÇ˚2π$^≤¸…Ê7∑≈§Kfö02Q1ÌÕW[d›
Ω|Ë¥7p~wñÙ¿˜Xs85j&é5£*gÜ;uP{iÒlóÀ‰Éì
CÍ*û]™“Ppí$÷5Ÿ‘˘Ú¬ıCG?ﬂ¸Éû„≠≠«èø÷˙Dåaœ?±Út:s9ùNˇÊ‰Å3¯ΩÙ˛ØÓ¿9t˝Ìw1Æ| ﬁÏÃËîÆq∫¢ñ4Ò€»€‰`Ç«&$
Ñ3	X&¯¢Ÿ∞ﬁÃ÷Ñ0À…ÃU#∫°rKW@˝†VP≤Óapçab‡„ï]±ïcûò)`M–"x,Ω8ÇﬂDŸ–hÉ_¬Ÿëöƒ º
¨V0ˇ†X∏ ®ä¢4¢∞ò‹ÔZ0Tªˇ/E/ÛØ>⁄öˇ·◊/Ædkã ó%X[ üÂíI•ä€·ÎF%U5*∑u•P8Ö £h0i¿oI@fñí§Oóâ9/OÀß*!Z>dÉ¢œY9àäRÃ“JVûõÕ»K∆ v;1Í&õJ∆Ù\’-v©8Yõª¶f°b±ê∫<ñ/˛7måœL”f(”KÁ	Ûƒ>·±O:üs¡/=.GÂZkìº÷∫≈æ≈ÒñΩﬂ~›{›w«+b9„ >Íßè– ?Œ‹Aê?û&@À0”QºË˜:˝~oéﬂŸ"«ÎÁî MícßüR±öƒÓn∂d∏√Üâln…o3Æ„>≤ià‚r]Vª+…J≤Ål#<È%_C˘¯Ìé,Ÿ!ØáYzÅ‰2©LçƒÆ©vÜ,m÷a+§öl¶EcPéb8ˆÌhtrnA®/-ùS‘7í0ƒ§cÿ¿Dâóîëº…?}˜´_|uÁ!‹„∏˜˚°·«~~ˆ˝Åì'D÷ºvÓ˙M?:w|ˆ«['Î?Ë?÷æj0ÂôÃﬁL	„Ë(pè[g˛w˚fTÀ–¿SÉf≈&€fÛ‘‹ÄüLıSï†"ª=∞˝iîë_ìBE6<Tƒ≤œ`˚!{Ee%l")¿/ı)˝‘^AœÖg≥õ·7EP\Jµ≤K·´’g’M>Ói◊KtΩs≠Î; fÁ.%Ó|À˜3≈,hú¡ã¨Xy	É^Ã`—a}pTùä<ßKñsyw/9Ü<dù^V
`¶boY©m–àÊfL÷∂K-!#7Ö0
—ãÔûaí–ﬁÈÓ$.ÔÙ·^\…Änyò≠¶%Ò;∆ñÅ"ÀYw√±lﬁπ∆»	˚$√3'Ñ* —äõ£é2ÀYpRŸxuC¢ƒJúz¶+ˇù¶mßﬁﬂZºƒi∑¥$w≠qè≥´‡÷áØ\lzaÌŒΩÈõó~ù¡Øª∂%v∂u˛Ñº≤uÕŒ7ﬁ–∫œ≥sÌ C3} ˝˜`¥r z!ø)8§ó⁄ÎÂuÚªÚq˘Ç,,·ñ(?Ê9;p…"'	f'!Ç˝"«;9éÁDdÖó∏æ“]-¿M\WÙΩ›’Æ>+ÌÆd},€Îµ˛…€Ä®63J¿n$¢—8$S≈∆–¥
Û1¡LJ»gÄ)·”8aå16°ih”z“ÜÜ§Ìî°ÖV7Cl—{ü$c:≠F´}⁄∑ªÔsœ9˜\Ó}bãv¿¥AÄ[»Gv°ó[r⁄b±õ9πïˆ¥⁄ìââ5æ` ﬁKßòN…ÃUJÛ™§ÖC89úïÑS9É„9|üÅ∆ç|Ü;ÂÍ•ÌlßˇÍ«ÑpÂ•ZΩ©2T´á™µnr$“VÄ2ä¢¿vÉOÔ#N»˘ÓHŒe”Q·Û'Dx!'ß_Ö`¿=fÜl:"Ú∆⁄àlD‰¸l8Oà0µçÇÌ¨¢ZÖ7§ÒÂˆé¥roæz·Bw¢ä÷Ê{Üø}8qHΩg§Äáπ?œÚ6hÏÇ$s˙Öı9qA4€e◊Ωﬁl7JÖC=€È¢D
@æ`éÄ5ÀP”ê%à# —H?0âQÏf⁄´∞ﬂŸ¡ü‰lœŸÎ9‚˘µ|E˛<ÀjÛ\%AﬁVn)wú„Å™«Óu{<πîó'√•8Å"¶'b∫Ä—t)¶ó¶&uZË%§®öi‡Ù¥zu•∫A›•
*ê$¿H†$†∏@ö$Å√}ñVÖÓPMÌrù˙_d…}î,ÈCG	açipÄ,‹h≥ñÖ-E¬Ñèim∑ımÄ+û<o|!ﬁ	ú@¡¸_z_[æ©ª≥˝©ˆ¢cØpWGN◊¥Ó>O≠´w˛fÑnT∑ÔË?¥ø´f∫èª˚N‚Gœ$Ü>π∏ªÎ/Ë⁄Ê@‰º†y9§Ñ÷§T/W°π¥ûÚ4´H7ù‘ÈÑTïe…◊3úvùíÒ*&1Ê‡T›Øb˝LÛ¸Ã¡˘Svk‡ÚÄ˙a:í±∏⁄√HNhÃ§3$”;#sÜ±–=œh‰Kã≠À‹ãç’÷5Ÿ/[∑d_±^ˆiíÅ[\ò‰Ñ8?ƒ[y¨C¬éB#d‰aáÜ≥¨ur0œ,z©	¢gKœ¸ÏT”MNçoQY °FQÅ•∞ä;ß—ë®•våúN#¶o∫øﬁø“ø¡/¯}ÿÁ˜·p˛^n‹…p“§„£AL)S:Xc*bHTª(ï†ZAk&J(nnLP°|¢©SPÍh∆òêÚ_üîŒj\¯¸Á∏«œ6tèºá÷ø&nºπÌù◊F¶‘º2w’œΩ∏ˆ∏PÁZV>ß¸±/˛¸¸≥âˇq{¸ßt6]Gè}pÙW√◊b«£ΩoÌ{Ô=ÿÄE†w>À‚$M¶´ﬂI¯rV¡ZÜ,,Á®`ìù-<œ·ñ‘∞ÕsA≈⁄b˚'©Åÿ◊s¸t8≠§¿<f∫R(ûıPsıú¡¯\u›VòΩ#Z$ô™¨X¡àÑ•–d∑{ "˛T{">{≤“«o∫∑M∏ﬂŸæ'·N|›˚y'ΩM/æÅun 0Ë'!RŒë$ªeí•ó°FÇ„ÊóïπÛt—R§ªù∫MF∞a–√™à∞Çı%¬PI'l∞N%¿ßãO>}?
_~úW∆€ΩÏç^_Ô√j·—RW<≠HN≥âàÈâà…â‹`ïâí÷‘¯x√f>^ƒaÒI/ì3/[È√ı•É±Ëƒ‘“2hJïè˚f˘f‹îoï[lÂt=YO◊	´≠ÕéUÚÁZˇ≤ù∂[¨/9ZÂ-Œù˛ﬂk<Ó|`JW∂ƒìaLƒ”£ È£2—DÜi(£cv∫Âúç⁄zπS∑(¶‹Q(QTÖSzÈÓûIÅñ<Â°øk\ãw¥§Òö^Œ€Òç—íf∏?òîºxjm1∂8LZ)∆0ùã≠j&Õ—(-(®™LŸπ¥ p≈ì1Ü-c©Có5-øyÓ¸Ì∆m;CWØ&Üv?∑•qÈÀ€ñ4lù6´£Ó•£ùõ6·≥ä˜-;ŸıK~V\⁄øıÏBÈ˘]–yK[7◊?ﬂ÷:¸`NGÕ€7?öÆeì:®‚ª©x;r!å◊ ±Äb&`Í¿ß#–XH5VÈh≠4Ï(“WÆ´∆≈ª\§ñRf#ù*T3M>öh‹ï˛plëIlc ⁄?UÙ⁄á£ïƒòI<Ãùf	KûCÒˇı—±˛k®âc2+ßüÙô°Ô˘û
-·ó˚VBkÉÎıˆ‡}øÔXl∂Ô¶1dxæÂ{À◊È„ß/πBÃª! S œç"Ω∆UèI6á§ójìí‹çì»=C#ƒä¨=öV;JQßªQ¶µQ,i¶∆i·ãc›&B)>6w¶eóƒöi,ö îèqUïÖ®∂p& &∑¶rò()Éåóa©©”∑nQ›˙⁄…tÚ˚+zÜ©taW¸≈µwΩÛ˜ª√´‹ul›˙É¥N]˚√'7|⁄$4RÎß◊©∫?Ò∑ƒóâø'Næ{éØ|Ωßˇçvê\¿Lî?[ÑP4âLa!¢d„ƒjÅØ¶¢`Á™¡◊ŒÄΩ8h=∏V¨@˝ÑjÄ≈Å—¡SU·Â·Ë‡£√G˜`ÑK¸´D\¥°á∫ï≈/ªSçØ9T∂(%&0ˆ;Q-W¨Kmœ™[˘ı∑ñ‚yıéÍ∞Z¢tW´.uúPÔ…˜ú˜\6AúÇãwÿmAÄÍ¬*Jím´(Kî∆Tcƒê‰Ë‚xØyÒor<e”-´.Úb/◊d⁄àUæerî„ŒPŒa∫eÉ|_‚ø[+|,\¯Å
ΩîöéZ˘ºt]Ê;d*„Uë>ñ∏“Fâì^UÆ¸)π[ôp¿7 ;ÃTÅÈ’¡¯Ù’jæmñ≤pºS[YÄùŸ¶Ç;nS˚˚]˝˝mñ‰–2˚Ñ£nˆ	˝;üÓﬁ*ùÅ¬ó<¯
A•´–o·'D+hàœ„=y|A°(Ò\≈'‹”◊~1Ú˙¡´ÙÓk3Û≥+,gÓœ§g3∏Ötoﬂ;w`6€ô˜DJcé ”Gà…á8_fÜÑñÑZl≠6Ò¡5ñ&[ãc≥e≥C,ÙŸ¯@aâÓÀ±Ÿ<nΩ§§∏òdÁË∞oπ∫Æk†@î1ÖâPWòH{—çîE‹y—äoY¨≈ƒÅ8o|ÅúçO»vºOF\xÒ.9Xö£Ah`?IäY™Å˜B„~7r≤!b„éi«˜íX¯õœ$M~bê˘Á≤?s‚É…Ka 4\≈®YeJd‚HØ÷‡&Æ+|Ô›]ÈJ´ïvı≤,[Ú
€≤AP¸¬F±);uB∆âÀ§∆L q√´¥i0)⁄“ÚH°Ñ0¿–&ò	0«6t 73¥%Lô<h¶IS¶ít
…$°±ΩÓπw%„Ü?t*[wèV∂tœ9ﬂ˘Ó˜iIÊ-™(QÆ≈F˘<7…«±≤™JFÊÒ|0eUlvYºãƒ€/¨Zºd„÷«⁄Œm1_¿S÷OûQ7Ìπ}Ê{∏u^ºvŒèÓ‹bvH}MΩãÊΩR^t∫mIgK©0K.Æü˛‘ÿÅv◊‰e”f=]
Éâ(≠ëﬁÇÆºur!Y!ÿ<øèå˘,“Qô≤-G´#mhCd⁄#Ω*º¨Ù
] yÂ∫˘<¢πΩ-∆Ÿäµqπzﬁ7ïFˇcÅ∆Ï'§eëgº?ÛÓ^tÔ…m«ø!Ì⁄;nÚ£∞ÍW√"LÊ«ãìú¸''U¬bé/Ír¢¢Cç{f†∏,ŒÀäÎS€Õé.úÀ5W"Uœ¨i≈©ÒbBR+††	ºgŸƒ¸1P8oAyôòeè3ö#øóùÿ’?≈¸›µÊü_:äk˚ﬂ«„´œî˜øp¯s[Ø?ˇÎøR˙…¿9¸›7Ø·Ôt^π0·¿éÉÊ'€OôˇÙ4„µ}¿=s —®›5c¢ûák©ÖNMçzÖ-;pû¡µï√…ÂÒ;zúí¬yıæ°˜Ezw2–ã~zÈ8ur•%µOïBéù⁄®DE*⁄≤C·±…Nòß`˝A_P∞ÂY1Ïu√¢π1tj1UL$∆¡c=N1Ñf≥Ç ÿ	‡≥0VVi‘|l˛˜´s÷6≠^ı∑_‹hv‚‰ˆóK™ˇ’ìwòoH}Å»Ã«Õ?Ω~»4/(Î®,}Ë„WÆ1.
Yf¯Í(£ùF¿&E)µ€ë ≤B:QQ;CGDıVÿfËN]!Œ∞":˛èquU7[ J≠ûl™˛÷’ƒWÁ¥¥≤ƒ“œÉb¡‡>!1¯é∞AÍÎ0ß1ï6E éƒçêÉ˝‹H∂⁄ÒHê¬^ùË2!a˘>ˆm»|„ÆÙö˜lﬂY=w‘ˆGÌˇ™e;ÿÈˇ’Ω∑ºFé5∞}?–1¥ˆ–
≥ﬂ≥_à}F8«ü -ExıaØPPÄbﬁ,Rà¢ÑßŒˆÄ±-+Í@;0éËÇ yµÄG≤$~˙Ùeô@ﬁ~˙Ê∞ˇ'+€äpQ$Æ;±ìKAgv|aÛ»(◊´©€È|`ÛÃ:éå˛öÒ%<ô°@?(ÊÁ‰Üs≥sõ+Æ‚yqZ(∆ÛCJ$ÜÇ_˛ÿÔ”ÌjåT√π2 €Ø¡uƒb®@ÄqS
:ØF≠IdÎ(Ö'jˇ≈¡,˚◊–áÕB…+ÅTi¬L“∫’ºt‡]s◊	‹ﬁ~åwƒè∆Ô~jcˇ˜cì7a≤}Ìß_'Sè‡°++Wı‚yÔ^∆´∫ñÙ¸≤dy[˝∑7<≤yˇÎÊù∂UXÉ~ú(≠	Ëçì5DÇ“üò<•Ç_À+¨ÎÑÎZ<÷∫ÊZ◊H‘∫Ü¬¸
ÍW≠–•m“Q	∫2e+:Äé!q"2P˙˙I^nnCˇsô√/îÜÂø2∞ºôÅÂmCµ4áÂAÒr”(⁄©ù;˚xôT”äï5C©L!k èÑÂ⁄ô~&
 «™·Ö\6‘Edâm5˘ûm≥≤Y≥98“∫d¥6d1Íq8‚N'çÀL÷≥ùÒÄmH∂ÊÇ÷q≈ÓAÜ*9•˚∞Ó3|æüË√qvíe»‡üôiz?=MuﬁÓL&7‘‘
+#¶õ |7∞}î≤§30$‚g‚9^}‘æ|·Ù•≈˝MÁû;wµˇ®v’Z·≥¡Ïû?.˝Ä1”;„ O	µ.LD!*!™3YG;ÓõænﬂC˘∂{(ˇz ‚-´ÿ±¿Æ~Ú&¸Û¯ä›Ÿ<∞ï\µÃR/¢–MN2‘≠h|B°Õ n≈,ryŸ€í«%8&‘!ªußl„]P”-¯≤õ∑@ÖÕ]ÔJgr'ì…†ï	≥k˘`8{VΩtÈ¨¢'ë‡'uÂX6“»≥sdŸ¯*U‰´ƒW
ºb‰≥àpbÑ°gå‚æ´Íù|µgD?eÀcQ\¬.›È≠Er	ª·X°pæ∞ƒŸßÒÄ»)“àºP´FCI3∞-S~˛±≥\nMÚÖíO≠©±íIYŸÁîDé±ıì*Æq=Ô˙=î“5›5›#åïÒÓŸB≥∏F˘Å{ìBe"—§RÈ~Ñ‘	⁄ZØ|√Ì‹M^vŸw—v·ê›Ê%∑ªD"~I"‘•(%Öê∫fyfal•ßÏv´¨O-ﬁ6/Òˆëv§‡“„íN{p©·t9ú∫·Z'cπítcﬁ!=`> ¢gπä’“¯ö.µHmêi?°U√ldÉ«∏ï™	Œ∏øÄ8<Ú‚j
‹îAı¬\«¶gπÈÄL—]sÒ[‰ ^wô{ã∫c.xØﬁÎE ùN∑ì›Ra/ﬂÓé%›„cI•¬™§ª¨äá''¿›	I´‰M‡N–äÛπ Ã™¨¬1-_√˘X€çpsI0{ûè•Sf„Qs∂‘7Ÿˆo5º$~9Mº00Iº2¿Üq/(∫<vä„g;Ω2#Eß/PACÆ ¯8¶Üc,¢`Ôt;£Gâ]®C$ƒaß¢†€lRÜ9%WN©í5I ›å0ásJó±.7»-ÚrπMñd
ä ±/S‡ÀÓOàiipØtVè¢ÂDäú@j\)0E¿!ˆ3ˇ'ÚY„◊ãÑ·+Øπ¥
™√n*-a#Ù†ã”íê˛ŸÓiIjîYaY“>&;…‰{w6ÑeV»ÓÊÛ–êÛìv∑û>ˆ˙V∑¬àF ∞Ng ›ø5:–¬r4Ω€{^ }ÁMhÿzq4´m†-≠Ω≈!ËîÇBË∏1~ë∂ÃOÍ‘:≥⁄ÏeW¶eÖ,ÌÂçSÓˆ®öÊë¥°a=å·7R˛WIvØ¢ÃM…i∏"ey¿Q∆•8ì\HG¡ÜêXLÉxDCì±;Íü‹—t”¸Éπ?sz_jfÈÛ'Rü€ª®ªıî94tD¿[÷Õ˝q@aUò=¸È¶Ù6
†b¸Ñ±s~|údá™ˇaºj`õ8œ}w˜ùÔŒgﬂèÌÛ˘'é€Á$V‡b©∑-	
~
!bçB°îˇ- &™2~ªu+¥TBŸ¶và–(ù¥ñ1Q÷™ì∂“ñ∂k7ƒOYáTïiÖ8{ø≥/eö&Ì¢˚æ◊wÁ¯ªÔ}ﬁÁ}⁄e+â:ÚW˙ì\-ÆfÕf‹úaŒ¡sÇfw%{Ãx'≥d‚Á®ü2?£N2W©´˙MÍf¶é‚,Uãõ1[¿œGÃ´&õ÷kÕ=ov—∂ ∂‰ls1ﬂ£vñFóV,ÆÏéwW≠¡´kÕùÊ·ËaÛC„#3‰6P *ıl$[ıé’…≥Üﬂ®≈30K3z5„™6S\ÇÒÖ1M>P8ã…Õßb.!l˙í	ü£B|Ná‡sõ∑!µiôVöd≈7ã«kw◊“µ	*Õmÿ‚¿&qw®∆qé%ÎX∏ﬂY—∂¥dYcÛîöSÆ(W
eGIm&¸≤isd†ô·—Öƒ¡’FµÅwI©
ïõ:›Ã∞ˇÿúÒ¯‡Ô/ÛÎ”®Ì õ®˝‰˙±[/≠;ŸÁG◊ä◊Q‰£’ΩÀ˙é≤˘ùÀ^CΩ\C+G^/˛¸ÉÛ≈O’é°¸Y$˛∏¯^.æùiAŒO Gù‰Tzh%4∑iç—•ï´¯uï¨†ÿùœ]ˆò"íälôáÏ	$'p;Å6<~}H7¿¸˘PU¶A%ü+2JyñÀ3‹®¬,›áÁïÚLÓ[§Ω≥¢≥‚›Ω—u—Õ¬wº˝ÚÒÚQœÀÚ∞¸©˜∂¨@∑é´≤_UeUñ-B'¬∫»i™‚ë∞!z0ä	ÜH“ÇA*Qe◊∞8Ú1”{å# †‡úÚÑ‡ØVyé#oÃ‚©ç©›)&Ue¸øuÕ˝O>M6øÙ_V´lSB7@ç› ıùÖ{-˘z¿ x'eÒ.Â)˘Ï£UVÃñ»[r^Vf®⁄B{hì›Òº¿û·P^~’‡ÙZ—ºRÂá≥Œ	¬$}n™Æ¸úKÍA_íôDÖ$m:!|íLú†˜_zk«˛‹Y›5g|Ùb◊˙Ó∫ƒÏø°{éÃ=:XúåGÊΩ—Ï›ätjÓ∂‚&4Â˚õ‹Æ±mLnzˇÃ’{âÜÌøÕ~˛p2∞2+òÏf+À¶3”ò|ÙLákNE[ek™=≥êY‚Í≠ËÆﬁÁÛ&â˝#˚ùrÇ¥òNêqÇ§ùä“√• Ì¶dàÛh'Qµ«L—)&ìnîí≠È∂˙•Ò≈…ÆÙSÓ'=kΩ´¸}Fø{ágáºKŸñ⁄íﬁÀÏwÔÛÏó){RﬂK?Î9"	ƒ J≥.aj3,ò5`®ö∞∆NùbR}P\û∫˛»æIÎû∫X&ç“X«ÑXleâcuB,¶3∂)ÕGJñîLDd`˝›“_ƒ™Kßº7ND+bﬁ≈±Õ°t™
Æq8©[vœ@Ôπ´SuƒˆX∂JPPÕGÀ—FÙCƒÅ	:m˘Í»OíüÜœL™’„ı“]5diÚΩöTx'djD~ê[örç`Y∂´|©Ö–îÀl@:oÿéXæÕÜ£6ﬁU¿Ω› √(y#Ä±J‰ÑKà⁄ÙäÅ}”ctÆÑ∂åô òÊ¥Ü∆∆†òê¯É:¥AJ¯“Ï}≈ÛÕ7vm¯Â¬˘ΩÕ≈ß¨y‚ª_¸d_{Òà|ÍÂ”'ÚMËZœÓ{ø\º˜zOY®˚Î[Z€ûHøïù>ÿ∑·ıïkﬁz⁄{‡”ÀÊÂrk´õœoﬂˆ«-[Ô§N=0¨Ë¢ˆYL«`√)ÿwÃ
√Ùñ!€v!Ù
Gt=Éàœ#õà®s€Ù¿óπ·«v]wH‚°C
≈í ˇëø¬£∂‘’ç¬-B•v?erBMLK*Ì+V∞˚ãÏ9uÍÀ{dµ'∆o„*X≠ü∫fâ¶‹√ˆWxV'0–A6∞Õ|;;ãﬂ.ˇ*ª$äVáÈWœqÇﬂ§}IOËKZ!¶	Fm{TàÎ(Æœ◊ÈÂ˙F}∑ŒË3."—ë≥¢Má¢Cá¢ÉqÇE∂lâJt(N–°Xy˘fw;ïBaìΩù6ÄlÖì•
(ß˙i÷Óí Â¸∫@QŸÂWºÛvÒÀçgû⁄ıÓ<ÚÃ_ä#œfﬁ√≥ø=ˇÌã»Oˆ(DQÆÌ§œ°-≥Ü2’Õ4ÚT£ö◊çj¶⁄°Õ4z®nµGÎ6îÁ˘Áe∫\ﬁ9ÖCŸ@nêZq´4;∞/íñV‚ï“⁄¿VºU⁄êqÄ∏@çá¥”<È0èëÉ ûTr>±b^ãsÒ<aWèWñ%øO”z–0@÷¥a àìY“T2[K Â)L”†Á˝QÊ˘X¿Ü&	B,†A®©í,«’Ø(™&Hº¿≤™@éaIò1YûßaMÜ¶©*≈áÉ¡∞Ú5-†‚îc Nã¬h¡Öx!
£gJM™uéÅ5á∆åπm}≠∑&˙ìcÕHoÇ˜Sùl@Á£FÌ?'»ÍÄWπt	ÜñKNÙË ŒMÁ¶Çs;´â`©dÁ“p±÷∂s‘¯kMK ÊœWÜ$[–	⁄\H†úœ6k9üì/Üƒï°ã;/í
7â(¯˜?ÕKFÎn˝Æ∏˛’‚õW–_º∏yÏËsü•òè«¬≈‹;pé˘òÉ¬¡xﬂÃÉÄTR;†GBO^‡Ö€,èﬂ“Ç†ˇo[^ÿ¢kåπıæ’[Éf≤5|≠XÔeW£’‹j˜«ãYÜ·xó¿q«¢u$ƒE∑_›√	iU:π ƒi‰áríõC@E»=Lá,AÜbÚ”Ü%H¬„ñ∏[§≈atﬁÚ∏›RúbüG?C”4π" Ç¸ér±‹6=IeJ∫^&)⁄∏‡Ò^L,áÙgÔó<ﬁh(º4›"L‘qãZJ˚¿§lñEÇIzÌh¿âT`ò}:	äBÇŒÒí ±#„£‡GQ6Û#[±(N<ﬁô#K&:BBE9T &RÈÊS]Ì¡Mg¸ˆN“I:›ÈN:=N>˚,[∂dI‡óåm∆‡„aÛ∞Êa	"¬ÀÑáL†0eSÖÑ)n;‰hjR-î÷J∑ı0”$åôòâ&±[“bÃdÄŸ›oeKw´õÔÌ˛æﬂ„K}v˘k&/AÍ◊©Ù:¶a®v˚ˆMm®„ŸŸ‘œ°ô9|œ†&R!™ú£G-º%¨æpWÚ„\Â„√3¬q>nÊ◊ÑEÔ{
π˚NÆƒ@P© (8Iã«ïì°Û B]JwËoÆ;!ÛT7 áî@ƒb·ƒ»À@+õ`§y4o$éU*£3”£Ãã"+Õk"[l?∂˝’ˆîë c2àÖÅòßƒ/{_/ÿP@®ÖBµp@hÜcª–!å`Ä∞f¿LÄÖ]¢hjl†úÇ…n«WAe<ÈìÁΩeUe)ò‰#ÊR¥ñ®W∞T\Jô»y˛ h˝Hî∫ü÷˙Äp«ø{ÒÊ…‡9<∏>ÜGd°¿®k.“ØÈBPßÚ≈¸Ï¸¢¸é|c%têpƒ∫uûä·ôŒgÂ∆ä*;+È#ï®“Ô6	˛£'œõS∏bÍ6—ö©⁄DõøI)öº$w€‡e‡ä”∑@2∏ãõä+F-2O‚ÄqÄÄ¥—ˇ‹@™Rëæ>çﬁHu™WÇ=2?ôéWï$ZA	í‘ëƒ7*ôÅÇƒçrÚWB‡`Éií?‹.óÏˆ‰Ê3&V†ÒõûƒTΩÒIs«Âiõ¶ó≠ÌYÖJkˆÓÿñy⁄ª˛˙æΩ'Eã'Á≤ÍY÷µaq…∫5´ïüπ´©ˆ∑ªgÌú%º/êg]?f¬¢§7˘nùætÊÿ≠øﬂ=°›	©b®°pz‚µŸ~Ä+zÆhÎéHe¢V˝02⁄Ïcô±∆h¨÷Nk¥¶Â®•Ídu£÷¶ô∆;´‹UæzwΩ/néÛØÿ„Ó%æfÛõ¸j˚z˜z_ßˆ•≠«”£|ÌºÔπØ|ìyW÷îlc°ΩP.2V€ucΩΩ—∏“ÿì˘ÿ0(⁄Dó`0—TÜä•”ÍRŒ∏Œ!ë”π◊ 4–‚Hçr^2€Èí"Ì ‹%≈OÙB¿ì{I•)> @BP)ìG”ùÁ‘#Ë4zà™F≥É &A—‚¡3= ëRA$¶ î
"•Çg¸˜TôÍÜ•ë÷E2,Åî¨iÂˇ6†*Z™ƒ~Ç#Íãá$x‡èıí´dïÙÁ‚‰ÅÛhÌ©‹ú É„(.ËçrLhÃØœµúY÷ë‘áæ˚„Âµt¨Èß[N}∏yÀ)„•‘„≥|∫ih`Ë÷˚ËΩ+MÔ^˚Ï˙’kÿUáÔ1˝XØ|Ë’34…1aáŸ9§Sç‘Fä°ïcΩ™ÅCÇã5√ÓY≤{÷ªgEÿ=K*¸⁄ç´Èº›/ÅoqQÜ>ÕbCö:≈9≈3œ9œìp&<áÈ√Ã!˛òxÃg3Ûäµô^√47€6Ú≠¸q€«ñÛ÷èm6∑mèÌör^∑o∞Ô∞3vÑ%FﬂVD¡K%kµQG®ª‘C BŸÌı‚U¸Í¡LÙ)'Ô/¿E4Ï:8UË ù†3ù`‚#òÃP]Ånil5K≥Lb≠0â%Ú gƒ∫Fr1F%M˛xK›º‹:ídÅ˛ñGë˛≤wLv©≤På˜‚È.0nãê∏MI1¥œ;	@é©:ì9˚û°ˇ¥|ªÔw∑µe«´{O{ª˘'h∑ÁB7 D÷SàﬁŸÒA∆⁄7ˇÚ≈≠?ˇ<¶cˆf§ÑŸ§≥“>èèÒSycô\¶.§Á[Á Û‘UÙ∆ñÂrBÌ‘no:Ô(}Œ>y¿Ûo•è0œ≠i–µŒ‹e«“~¨{<]∆◊—5|≠<C]h]¿Ø‚˚Lˇt¢GÇà\å¿âvÃHéï(LIÜÛñ"*O≤Áâ‚u	âí.%§V	Sj"MP…ÃëàiU%TêD+ë¿'.	p‚¯˜¬R	‚˘d@GzÀ∏¬v≥_±√¨ öÕ2l)9¢”lV∫	lƒñX‚>¨ík|âiÒdCÍe“Uâê)zIºáÔû%„òfe†≈Xå”ÄaŒ!˘œòä];nnnæ±+Ò^·ŸTˆ©Õ[>¸Õ∑~∞Áó˚ø?⁄éòwÊL¢Ö¡Z⁄Ò˘ß∫⁄Ûy`VáU4ÛÃÖ1õß{4Ju·L7∆-M‹
f≠qÉegvÅím„Å>Fô*\Éé/çÉÚü°ÿ1^)V'9|ì‘9é≈ \u©cùo©∫’¥’ıÑ~‚)7≤ÛO£:%∆≠⁄€ƒ#"-äÜ’ RóËìP±£j÷âŸÄœ]ƒÏ8ËƒÏÒË<v]“:ÒÄ,ÕÉˇ√ëÚ0ﬂ«NÛà˜i¯◊Ÿº¸‹ıI`≥“‹•bÄ’·ÿ(RŸ/!•§“S	FnÇFÍeMåGRΩ≥ƒ$N…Á-X
;d/!Wº*ï¨"˝¿Ö‚ƒBQ≤eîb"UZBI2Î'›ÚÁeñ\ä>¯‰€°$ﬂæâÙÏûı£›À˜ßzË9∂ä˚∂ü@<Gœ!ãΩÖÜ˛>ÙTÃÓ∏¥‹3eıq¨"Na´Ò Éx=K∂ ªR®)∫≤Q9l˚Ç7˚¯ZÈT
úG»ß≈2Õ<c≥´V‰¢#≤”¿ò(kªå‰aßn‰(Ü˛ñ%8ƒ‚ä‹ıà™≈⁄(§Ë@EÁ1MF¬ràÂ âÀﬂ•˚ZJÜÛ§“ç˛A/êv‘´\Fó(?ıY©—L=JíÆq’/ˆ˜«”—:ÖÈÄ{®‚¢)€tYîL÷d∆	I¥82(…dœ@	Ô‹â"ò'-•RnYiY¨|¶	ñ5P5W©+W˙®Ω›È€µ•~qFE…‹©››Ã°˝…µ±⁄Öé˜≠µâe˚ü≠ƒåò<4á˘fDFÙ«Â(ó'◊s5≤…í©dFπ|9ö[…çìgrµÚˆn57h}Ï∆ÊFÉs'ÎÉm—#Qvú\Au¥ñ´ı◊Ã˜œ/X√.˜//HD[£=¡{˛πA…„6π.“gŒÖT'KúDÃ¶äàè¥˛èÌÍÅë¢∫√ÔÕº73ofˇÃ˛õôª=ºÃ—∏¥v·<∫È≠—+Z Å√)[‘ÄmQáä®=ã—rks%5H”ñ√jl¨«±!@MΩDkì∆hj”Jå‘j-Õ•5WDÓÆøﬂoñs•=éyoﬁŒºΩ˜æ˜}øÔcÏ€™UÀññ§›◊—≥Ω\1,⁄aÛπÎW¸[˝ÌæX[Æ›∏êdÕ'YÛÁdÕ'YÛ=˙–àdü2>í5M¡◊–˚˜&y»:ZÁøí<ö<ôúMä÷dor:bL≤±Mv‡l…ú)I⁄ñ$mK6ﬁ€éÚVËoê∑èœ∏)‹ÙÈ©2êÁ4ÚÁ4∂edÃ %ﬂ˜¸»@. ÷hëŒ˘Kä©,ô–LÉÿ›Òí≥¯ {á|Îÿâ…ªè?ıÚÉ˚6ú˝ıﬂwÔ˙ŒÛ/>∏Ì˘5Õ◊Üã◊ﬂ‹=ˆ$/ø˝Áﬂf˚˘çgèn˚Ö~ÈÒâWﬁxııWphò1˝®ZY~€aÊ¡¡œAV≈ÿBˆ:KÙ>˝H\––2ø©‰[©X*´KŒí-“Ã:v,Tï‚““¨‚ä{Tcº
¬†æ@◊,B†0X§p„y;’åœ) õ∏ë*ãê(,0~Ø≤ë.¯˘A‹[’Ô!˝“““ò7ÈiõΩQoÃõıÑßeC‚k≈Öøa÷√⁄‡‰úb©V´á⁄süXŸJøöâ:CœE~êiDKç,gn˘Í∫π®£È°åë¢¡!“0®`9≤Éòzâù	#aÜ	#ñÁqx…ÄòÖGêöäëKÙº\™3E0π‘pÌ·â≠ø\QªÔŒ’Oï¡˛kgıπüLØ”ˆ?t˝Ü¶ú|ÄÇè¿ıôÏ˜ïo®•∏ÇUjDç™15°N™Ie2’™6´ÌjO}ËîöUv´èe
MWÜ˛0gÜ4Ñmò°dbècbBú∆Ñòm‚‹	yeÌF1∑oÇˆMÿ¯≠ÇîM\P6Å&˜L âl‹C—o]º{[`˜P∆zœPâ¿ˇx‰∑2Kä9vÂÒZ≠&>:zÙ”úË˙Ù-êıŸggÆÂÀhÕiˆf•O»P~YÂ)}KJSM»„qG”≥1ëíéâ+t≥%ïE˜}`e<¥Ìá∑:ΩŒ*GwpE›∏"«•dBA¡°LÈ\B…$Üãr, $ƒmß)ì}±}y#´â≈ê ˝nﬂÜ´ﬁdΩ+1¿™“=sÎKã√ÆUéNÑÂ&ª,◊Œsï0Û,:ºäkÁ›DiÿÅ¨	ﬂQõ˘V«“÷Ó•µ‚ªÆ?˛…Cª◊Ïk?}mÂz‰+ú˝,Ïã£›V…ë∑2n2nVz2˛o9eË*ÜËò±pyˆÖé∫–*PqÒ≈ı˚m-m¥e⁄KÑ≥È%Ö!⁄¥§Åv®<#ÜR›j9@a|—^cﬂØﬂgø•øgò˚ﬁitô°’c\Æz„´‚b¿Xc®!ÒÄ‹≠^7˛ ˛dú6>4ˇc|bÂ“∂-u]hÜa*e¡ç≤¨–4≤¶iËBÑ“ŒJi€p`Ö≈·XJ√¥Ä±Ãáx≤¢§@ldáÖwÌmî\≤-Õ#`Äúêi!dE∆{Ÿ*`œ "‚>!ŒqF'ô•I(N0ä&¨)∑}˘çX‘Pá¡˙L™ ÁDy˛¡q.ß¸ûa˘•Çr_É6($†cÏVYßÎ~É≤[|Ö‚≠Í1]SA<U-ÄÛÂ⁄5[-ú◊£¨yÛ  ÿ;„Ûz†˘„x5˚€{ËO Á˛ó
∆afÃNå∑˜ à„6Ôåª=F‘–]åö˝NÙra æXIø-∏ïı‡€≤Ÿ2]‡≠©Ò _˛«˛|Ù8Øêu√ﬁ È/rﬁ…M`(·√ôç¸ïwfˆ~W9ˇ2õŸ:Ω^k}pÊ<óè¬•õ¯˙ﬁAI%—Fu_^¢∂¥$j/[µ!µï MR∂ =Ú§´‡2)ıVπYnó≥RÄö€ö	<ŒDBüg≥áÒ	àôZ£⁄ü˝LÌÁ5®}Ñu‰«¨∫ã$:≥d ÿúv±~ÒyÌBÒ*"˘¢*Ω%∆ùy¥&èú˚jΩÜ]‡ô:˘o≥8–ß∑’;¿†?WV:ÒR(Nã”Í]ˇØmÚM9’¶˘V[ß
ÚmJ◊;/i1rh)Lnt67πˆ±êèÑ£°Çé%¬ëO	Jl•5¨¶%∂,.2Öåˆq°)çr…ÿ¬$eñssÈ≠ûbxµ¬ë<œ”t˘πÈÚ4‹ˇ≥í¬ÈÚT%Û6NóG.QqŒ«pb∏?OÁq>èi≈Œêc¿ΩQ¶µ2‰üN¸õ˜?¸#≈e^Ωüø‡ë?Æd©GP$"JŒÒm.V`**êH‹Üë3≈π:›O⁄ºÖ°yÜ“C$∫ríÈHñcŸLW6ñ Ût<w°P◊£‡õ[J!/Qπ&›X∏˜.ﬁ∑qÎÆ÷á˜≥tÆ˝ Ê’÷¨ˇ˙#ÀD◊”˝În_s‰•É”¥üﬁµnŸ”œMÔ“∆∑m[˝„NˇÂÇÁzŒã«á*©Ìy˜ê˚û˛∑Ã§>ï1JnÃ.∆=ú
f—feY/ûã^‹é'bâ˘˘¨Ä<óCnÀ!∑ÂÃπ-áH‡t–∏√‰∂r[pˇI®CnÀA7FrËê°s8¸:˝íÆùW0hõÉ—`,òD†k≈úG‹ú™•RÛ˛ø·≤/2\©√%ÍLú®§/6p˝æ;U¸S`·«d¬>7
?g@ç—áAûsaûëR∂eõ∂n∏])#ëÁI;]˘“G–n√"î—è˘üÉx¯Ÿ˚ﬁæuÔj◊Æ]zÁ’˜¸\tÌz©oÛ ≈C”˜h;Óﬁt≈Œ7¶_á¬Æö˝@, „¨âﬂy0‡J2¿D"Y)yˆöËÉ¥i7≈ñW[7÷7ço[V…]ñ^Ê-	˙‹È^_∞VÆU◊π’t’ª.ÿ$7©ıÓ¶Ù&o}p?œ)C∆o—oê7ÿ∑ƒÓ“7»ˆ]1€of
$#;?OŸ'O«¿ƒîCŸ«p‘tÎ£ì5‹Íêg¿‚@*†Bf~X∫Ã‰ÃtÕ6S7ùç¿Òk.È,]˝ƒ|K`ÏMùcÑo·õ |#÷í˛0èÆ¿î([‘\ÍFq≠~Üú;X®NU´XB2Í=R9vÀñ∫^^Ønó∑+Åµ	…∏› ÀQ(bç°Ë™Áû¯Õ	Ó=Ù—ì'gŒﬁ1~‡{√„⁄…Æ⁄ÿ¶Æ3|ŒÒµÔ=«◊ÒıG|}Ìÿql«6vHh‚ê%|¯Ú—ÜBIDYY		C•∞%–ïÑîUXÈ†4—JùJQ≠e*)a•ìP—TîFd∫ñ	¡‘µtŸ™ä,…Œ{≥îJˆπÔµÔπ˜‹˜9ÔÛ>è'{7å˛}d‡õ_‚0v|zÒ”øúª¯	_–Œ—v©å#ËFa¸îŸ´jìµ⁄M EéGHidíUWáfá÷EˆFîΩ!8_ü\™,S[ı÷`á≤Fm◊û—◊œD.{Ø˚Ø.ááºC·õë±à/&e¥Lq≠‘†="Õ◊Z¥ÿø	çjvWë≈WR,Ô+)≤£"#>»∞∆L∂Çı0)" å8πnªe⁄HÊ?ø[tˇX
e2ÿk1H6Î∆ûR„.GËWA¯ >éø≈R)Œ·fl¡–Ác¡∆X∞1;´pK≈ÿâKÖ1¬*‹òS$«•çu~úi“ bm‰Œ–ˇmn['G1'4±‡Z‘çuz
§Í+ˆ0¥Ióez;è4Ï˚˘Æ¡éÁnliŸSÈ:∫a”ªowØÔm∑û~y—¢›cØΩ˜Î«FÓYéúΩxı‚'Ö*ú7⁄nπ…1‘P	ûjˆ⁄IÜ§˝”»≤YµÂäs∆co¯`ÿöıdÉπ\œ‹‡bœ‚‡Jœ ‡äpO¯äÌ™˚ñÌkı∂_õD¢j¶∏û‘™èíG‘“NæPˇÊˇ“˜µq+¯_‚ƒí√(±ÀE6oâƒÅ”ãjPπ¶:±Ê4ù+ú=N)l⁄y:√=ßò–	å+ä—iÉ¥;}‚?—H!ıN‰®BT†∏<'ÿ£€ˇHæ$ﬂê«d©îã‹f^åqQ…ò(GEm˚Ú¬W‘≥
wóe't…∂ŒÖ√#ô	8MÁ(Mˇ!0®ªD%π≤ é^À5ﬂT,ÈOú˝˜≥óü?◊yh§Ïÿ¶ıGﬂ€‹·—v¢Lk¬ïX>8˙¬—ﬁªs,ø¯Û«W>˚:‹ãöÛ∫`N´Ú`M¬1)+ÕëK´•n…F]
U®√„¢dQ∞]îb4µW¡J4‚¡uÂÖü©=ÿ&hΩˇòÆ	ç∆&àË{äBÏadõ Úõ‹çgøoOyg“⁄ÓtÒ‰@jÍ˘G9§]ÿY¥Ì,$™∑4Å.C^dﬁ(^<4≥=∑l˘ÃŸ≥ß-˜Ü•ƒ[ùÛﬁN6ÊVtç\Å,‰∆æ≤ÙÒ,L±ËÊ)Íç6–˘tn|ItUt+Ì•;‚G=ÔV¸…‚†z¿ØOYPÒôní'—™1Û∑*≠¥ïµ⁄[’VGá“A;XáΩCÌpÙ'˙ìŒd"ûåOöoaKÌO'ûNu«∫„=Ò˝Ïu_Í@≈o¶aøS'è§N$Œ%|©ÇçÇX!àÇTﬁé_A¨ƒAà˚
”ÆoQíÂ*ìëD±dØNëwÃ®Q…/5rF≥ÒS„=„ías•∆≥∆C*5ˆƒ8Õ±)Ê˚‚Ñ9™^∏\√&&‰Fkò`–˘^_ÿã\Yå+[CkC$TR,K∞òƒÉ[`L ,ïT⁄K87Lè?[”´†Ï~Ñj1|∞GåÃ4"0À∆—â.}ä,{_éß˘‘ì%ıÉiúÜß¿å4î'‹&]®S‹˛LJƒ£ íÈÏäÍ3’$W›SM™5åq˘ÛzWlπH>Àú⁄!Ä@`∞àH‹)ÿ)ñÁåå3ƒ]3"x£HÉ*H!z£`kçá†ìrÊE>N≈√¸´ÒCWìêHSgf·M<Ãµ0\îÓt◊WÂù'mq‡õù¯û◊ÛÍ…LN«¨ﬁäÑKskÕbã:"ADSr['Û!ÏÂßeE± ä∆™2âq*Iô-#Q©ùï—∏*À‡@3ÈÃˆÌ€—:¬m]ùmû:_ûjíâd%©ÕN≠À7^cBãyuÆÕÙ0…7˚DÓ}ÁK[∂n™-ﬂ˛ıÊY?Jø∫x€È◊qu}˚÷üØ*∏„£K⁄œoªÙûQ≤¶k’‹1yı£€õ7ßJ3Û∂¸ÃˇxÎ„u±íêá≈kfmmmyÛ'«†N„cﬂë¥ıu§£œ?DåÔ¡X"KŸY<Ë10¬™ÉaÚi4„dºu[ÏN-ä¢ÿ·.WÒò¨<L^!Øì{‰Ω≤Ñ∏r:(óœ»É≤MÜf\%ÁõµæÎŒíÛ~l<¨ûW–yMΩüG∂qiñWïÚIÚ„©}´0©º˝s}¨√ÁxÔ™©—.ÄmÕd u»_¢÷„¸^«ô,ÊÚBÍâxl˙Sk+vÏ8qÚ§'ì
øı¶6s’!≤r7ñ◊éæ≤{dˇ¬ä ‰ËŒe7•zÛá(¿sCãı,âx|Y'¨∂∆ÌÕf<8Æx|*ˆ¯ÏúÃ]<M®∆WÓ◊¡NÑW—ÖK—›ê ]ÿN»Ä.Ë[øÔOt·Ot†w·Ota8u'»«òéœËXo
 F≈`Mﬂ»∫¿¡¿Ò¿X@
®ÂÙ~„†—§7©DçÉﬁoT<ô2x*Ö˚ã~AÖ7°ûMõû˜≥Õãk¯á&Ñw»{nzæsà"
HZë√È 6Y±)VÖI"á‚
"∞!ÈÙvﬁ˘‹≤ZMíÉS„‚
b*ƒñ‹÷´À7kˆ~ªÎãıNÎ£ﬁ3ÕµÎ…æëØ<‘∏hÒû]§˛ﬁ5éá»ÚGá·€}ÑÃ˘Òì¶nUSlÿ∆êï*VL¨qÿ~÷™ÃıÌ˙ ﬂ–Ì`©¡j≠E]ı¯›·™ß‹ffg∫¸à«è¸äœM.À¢ÑÓ§—Ú,ÚÒÅü]3üOUfQÑNuJ—´GµljdK≤TyíÆ∆´Iª“N7°çx#Ÿ¨l¢ŸNºì¸ ÚíºKyô˛ΩF_e«–!v} ˜±ËªÜÆ≤¢/Ÿ=táU◊a~‰c)î`u¨ôåZM∑/kÂ[%€gÔN˘˚¿´#ê»¶`dHp(‰~r≤"~%V´jÁ∞U]œ‹Ô@f É™r9e–¨c≤¢îSÊ•î!!\òx1Êa\≤(
!ÿ&3jAÿZ•b5™ò¶I{(°ßp¨Wl◊}ofv˛3oÊÕ¨=˚ã◊.∆K±+€òWL˘,
	îfì¨ö -!|Br¯(¥NCı#%¶Qõ§jU~∂1&
®E%5–ñïñä™NBi\µíCïÔˆæ∑ká§R•JıÏºy3≥;û9sÓ9ÁˆÖë›!≥PK!Æ3nˇÜ±i$+å‚¡»pÅEñ6Ê¥3πú•€ôûÌ~Í|˜ÙÄmÚ@≤YËàÓmzQ!_ãõΩ™Ím^3∆?/Æ}∏æ&»æw∫¯∏4ylÔöç+∑	œ 9Ä2BëS¿*• Ï8ç(K¶\}dnTr•«∏⁄kZ‹boADÖôõ6À'Œı⁄?÷ fn»˜uWƒ»Ñ4ÑehX¶Ã
 t± Èí´≥w\Ë\pù°!Á⁄ês5;ƒÿ« féS±V	®@Oï¶Ë¬˜˜Wt”¸˝înr	î∆'.ì≠¶∂≈I¶ò\ˇ#<U3©EíMÕìZåF$$…Üfÿ*uê'˙JRM)Ë`Îï©j÷nA≠ ,u∂=_\$á Rµ√òGπKË#‰A∫N˘ö∫Ünów([’”Ú ÈßÔÀwµå·fP∆j∞3§Å6˙3Q˝Ü˙mµG|…<Ñáçüò}®_¥/J◊‰ﬂk∑§[‰]:*®%ô›±…Gáè6	iÖ∂	›&EÆ™®ı
©∑Yg+¢ÖÕzk†t-lc*e˚¶Ú^Õ¬æ'ÎÜ;Yœ∫+•ıG›ınó˚¨´ª∫\dØ£¸b>Ü∫¿cmcv>lﬂfKŸ˝·ì}1¡R"öÆ´–£ËéÎÇæwúå 
ôeq∏Z'v˙óÆ¢¶ó“lDÒ#≈Ü˜\oŸæeŸ*¥;Y]ı·Á(2Q)H¿
ïT‚ö∂≈oèÇé´™¢∞“°Ñÿ6“˝;éÖ≥û∞v[¢5ÄÖzzôé7ÍªtAæjÀ\º—›Â
.€3ú~,Úó≈u®ﬂÒÓ¨Êë(∂t¥P ◊¿áY!xg¢≤ú èé+UÁÚ±{ÈΩ˜…∞≤€vŒ+∂”ŒV6gk«±öıZi3-ºV∫	ôˆ&≤KWzQIS‡(ûY˘ÀwkYßñÆWö0?Pª¢„XÛÛ£7è+ÈÚQ
GÔ„G·B˝·⁄†VWN(MÏä'–La∞¸ü&.>Òªj˛;∑tÛ§ûñ“àù Ÿ¿ÛÂWª⁄Osh¨P‡«Ω<Qæbfõôî∞¨≠ Æ'^5ïœà"Ó(û<2Gj>r˙ï÷œ˜-ˆû92Â-òóá›7Ñ««zﬁVﬂΩ.tı}tîÜÄ˝î∆¡¨¯Pî`CñMdIx"'çYNJ∑ö˚°ò‘≈r2ÛüÂ±‹√‰EÈEuø˝Cr.rN>ßºI4VÂ‚¢ßE≠∏”äg{Ü⁄Hø,ÂïºÒê˝Ó—{åS¬Äy—x√˛ïs]¸ùˆkÎŒ€:/.√D‘%Å¡BfÍf≥ëë`!]†Fò@Üÿ&ÆñeQQ5À≤ëDà|¸‹¬ÑXé°B∞—ttôDw.†ö‡‘#ÕGHÎÇÖ≠zSÙMS‘5M:”D˙2äÈbkßYßìØ ⁄ŒPg8 ÀÂ›≤(ÛB;-ÓÍññã›.ﬁ®FÀf^·ºÌåéºS¯üôW*l-<ÂúGÏˆ	ÈV9KÀ#lu€’ˆ
)zÌ ï3ﬁF*g÷UÁDXŸ˛â⁄ú√4^èÊp]mNìπq«…6°,xßπöYOÃÄ&ò‡Ω≈˝>8=9≠˛‰[≈Ô·}7Æœ*˛U»‡‚ãöÊ6ﬂ-öcóí|± œU[|@¸;p$éˇU·HJ˜âhà…°≤!{!%i#4”Æƒ≥ÒÒ`(sÿÜgÑ€F‚$Ib¬bC2óÒWë£∫Z!ºêt¶©≈aÉbj¥ 
hÉ—`6X3ÃV´Ωﬂ524„›_ïßy/]K◊zk£€Âm÷vwáø#˙-ÎY˜9˙ú˜øG?lºÊúq˝€˙ª˛˚÷òÛÅ_Jﬁ7Œ®*œH&$2üÏ%"âM‹>ø?xÖ
è⁄1–JH1ﬂÛÍ©Ó√1AÎ›7›£‘4ô] %ù§–ò<õí¬ú>XÑ˛Ä∞24Ê–ê
_°g©@‹~ÇÎ–ÇÑŒNq¥¬¥Ÿd.3≈Âf…L¯∆…FÿszÈ.F ol¥ã@"òéŒËpÃ.lâŒü°Ä5„åRÅI∞≤vÖR›ú?†z6®M jsô•[»(›¬˜jç_˙S[NØkÀŸPe}—ú[ÕUÿJË„5∞å€∆ñè#X‰‡]˛ÏiÌ˜Wªì#Fq√/ndÎj≤È-Æˇ¬§¶ÆU-≈5GúÃ§ƒ:íí2c˚ü‹”µMXw˜‚—π˘‡0h∑xX¯i‰∑»Ä>nˆiDÑÁ˚êÜµß£¬Û'DLa”G¿ü6ai®¯≥‡G€yâçåF ¿√¯π&ØÖµ†–qB*oÛÀÌ)kFw‹ºı¿¡-õnË\∏†≥s¡¬NÈı-lŸr¿÷ÖùùaE"¸o$>	wE1î¬…≥U™a≈t5∂3@VR≈ûêìî∫Æ$âr<™CﬁO$‚a*à≈í…TπÒÉ`ïrXbJïsÑ®î…Z"ÿøN1†9y%u6UJâ©xÕwıc‡êJΩ3ÆÔGCë$∞‹ÔÇ8PÊ©&ÔÒ&≤Êì]Nd≠¶aLúí˘©Pgóc˜u-ÁVZÈmñ:£eﬂÑ≥¶√Ö/:w ›?æîüp⁄πÜ:„_6çT¡õ!€&≤b+NAÊI`»z{ˆ4≥f¥ï°]≠0Ä£Q÷ñ‚÷Ê®›œ©W_}Êù+ì≠”
Û/]¬´z{{≈ó˜≠˘Ò·Ím…7Ï˚ËÎ“ﬂ._æï&C»8Ó[ ∏„T8ï°.ÍjT#œá®W0g/!VUÖÙa,ÆìAÿ¢`ÚÄC0»ßq»É≥A)Éx‚»}Hˇ'‘„ˇuX>< g6P)€ πç˝Ô∞◊˛'‰+?xd√Ö¨“N†s_Ó¡]UGﬂ˚¸˝PëàJDﬁb¢±Qy("òÑFDF≠±§RÎPçºÑ¥ññá®,4°ÇD3∂Ä•ÿAßñƒ∂“á"3’¥∂u¿é¡‰ˆ≥Áwo¯qÉF–˛”;ÛùÔ›sœcœû›={óª=ùi+¸ Z9,“≥á0gÓÖ=|?3
ö>ˆ=sÕkjz~wS”ºCsn{ff›⁄µµ3üqÊöKõeÔ.˝›‹¶Ìò∂∂Æn-DHûú;6≥]rﬂ…πNùAˇq“ûÀS≤gˇ‡ÂU´¶∑v<Ÿ%iæTÈ;@˘WÓ˝è6loº+CíÁ!∂°øé â·M‰∫iÿﬁPFl^ë∂C˝∞…Œk∆˚-ôÊñJ&õË*ﬂˆ
eäµTäÌ*ôØp∫JæªMÊ“∑
˘∏F«“ø ¸Ö +lª‹&´Lﬂu,s‹ØÛ.ï‚d7ô„ç¨∑∆€/wÇºW∫Gd´ü'≥ë73nè+rÖˆaÃøJ÷—˛ﬂÔ†m<yÔSóæ∑ITHge‡”ﬁüyVÑ˚ÌÎÏì\∑4xáΩ|ù9«Å%¨1∆”ß#|-XjÌóe÷˛†íÔ∞î≥˛Rm#C√<ã˘>ÇqΩêÀyœBn∫É~ˆ6…≥;…K`ˆ_î⁄7ÿ/wÎûõ˜Ñ˛°N-ë“q|:XÛ†ßùÖ€§ÈGycù!RóÄ.‡f˚†Ãvo{=ÊGÅﬂ©ù˛Ævg…d='{;eΩ ‡FÉ“†—}B6:«‰Jæ=‰Øa≥∞7Œl,ÉÌøÀ@ø∑,ƒøF2ˇ"∞Å9ˇf¸añ‹¬˙É‡!ÓQ„CK¿J÷˙gd'µÚ"Œuk}™Ò¿¯…‡zŒ•‹´˙∞˛`µπûªUÿîGﬂ˜Ë3UA˚ÖÏ]}R«ËxÊÍ˙aÂIñJ˙T`◊ø¬.»T"?¡∑Wôß3AW0ï†\∆É~¨-¨Î≈g‘7ç‡ﬁ~làn∆gS{ÿ`Œ33õ¬πtùÓ˛6)	—]Á‘xQüEóg£π5¶‘g"6˛]b¸˛C›ß˙T3{nΩ\Ø:òƒ∑"÷∏Cgçá5vÅ,É◊„«ÂÍ≥™_ƒjı5cb"‰ai{Õ61;"=C_/è8≤E3ﬂ-õôsÜ?ìú≤Q∆∏ﬂí1Œe¶˚/ÈÙóA^6mÏáæ;Ïzôî‹+C8ÀõêãÒ:E¢÷∫«€À>´±g≠<âMøÈ÷⁄=‹ZÀÛ™É˜=±x’ˆÛﬁÇ„∞ˆ¶æ)+“øùi˚Ÿ¿ÆÛ™…ô’¡^m∞üUâz+\1Ì?e`@ÚRk]≤ƒz!Q æ»10«Õó´º|π¬›À˘díÁâ⁄ºwdèS¡]V¸¡*ì2ªVñ$2Âv{9çµÏ:)WË¸˝i~täœ≈})‚»_„¨9?Ù©n∞O¸Ω‚ΩÉ„¯—x|≤≥ﬁöüÕ˝@éKR˛44˚Áy^˘gÃOKb˛y^‹/„lÓÚ{ßË±<⁄øÊGÕqö#5œiûâ˙«9m¸#v~¨y¯†áq›#ƒ8t|7å}Ú0Á]˛Ë`ãø3ÿÍt∂˙9ºˇx¡ˆ˝`Ûù:%h
Ô”˛—]öjós£{‘"≥√|∂Ÿ‰õè‰«Ê-4˙µÒ∑ÀBÔÁN4˙nc{¢wâ;õØóïÏ£≥≥îx§LUõò≥πHÔΩù’ÿYÔ¢
)wﬁ¶^–±C§Ωπ/FH∫0m‹© ⁄ÊI•_/9nπvØÃ“≥“}®>zˆ…§m2ì<Q+óª?•O¶úCøç∆˘≤≈¯Öé-°†¬â;$ÅœN†èŒ∑…å…ó°=6[òÒ‘"Í√jÊÙ3eí©'ÍÂ)Ø@äà°Mâ2Ÿ‰sô≤ï9ûf\ÅÍ¬∏,s_Øñ[âØe‰¶e‰1˛_úp™ŸœÉ‰u‡îa£jπ»+√Ü%fÔ#›Té]™Ò„TIı5yXÎâ’Úà{©åÚK§Ç∂
è<…∫+h{ò¯Õ&vó3æ[ò∑Öµó”ÆcGh-£5Ç∆K"_:˙e¶£É÷)¨Ôº/õúq≤?æ&π;,ñÅ∏¥çßJSSû™º ƒ L[Fä≠ÓNÜ|W€Ì!Ú&+ú+Ë˙¢ªHæ·Jés9±€^∫ø%V?ë«ùv2›}Mw_êï*ª•ü≥É˝Ô§∂‘ˆ7d¢∂€o"Øìbw„ó…}Ót)uû≈˜…9Óùú5„ºÔ„'ΩˇÛÜ∞éH±SHl-·˝ì`õˆ3kÏäÓh∆•¡Ë!¶≥=û]ç„L—WﬂO—]õıåt<ç~fü:/„¥è˚∏√NáAÔ7›lWH5ÿhˇQÆsnîÔX[ÉÏ::Ü1È≤;‘öπCe7Xƒ˚e/¡ˆîLÌ6Tﬁãô{¸ú˛(Ïk%Wô∂`¯MÙ-∫ŒÈ⁄”·u	jNëwq◊ ÎXP£à˜«Œπ¨óÎ^‘(≈q
°tJÃìNN_⁄/f\Lˆ∫Oª§ó#¡Z”ÈÛ¿ìùf«¸Ù=FÁ_p8ç/QÔÜ≥÷Ìl¡˘.∑˚~(ô)íÛ≠∫‡0\h’IÜÛ >ê"wåÏùÌ?2Ì±Û√WDmoèÀÒsmM∂üìÈÈà¸†ŸV…pÖ;Ç˛ .'»pÖˇ
ﬂ^i)ª[ZA±p÷´N¯`ﬂñ≤ìÙUÿΩ–5K«s†Y~É¥ØﬂVÆWhÏ*Ïù¸ØÅÊÔCeî"ÕÆπjWg}Í{t>—πƒœ˝Ú›◊e,‹ŒÉ'√„"NèŸx‹∆€¢\r∫>±ÿ»˛¨9ˇü@ÏºˆÉWˇ◊kYÇØÇ‡¶AYK}r´îã4íK>~B∫~ã6nÔ¶˛†-ÔÌiª~R‰ƒqﬁÁ“^õB`ª]dcXWv¶Ì˘pl2úorj¸â_ã4€S„OTÅ{xˇ7‡>?Ò'xºé˛0Óa¯Â‘˜∆È»Û¿K»ı»˜Ç)º?
g¬óÅé†„◊(¥iÒ˙ïÛÈˇ?æ(S≥‹Åû›‡x~¸‚stû≠p¸_#:ˇ÷ÿˇ%Zr ¸3ΩK›∑#˝ﬂÁÛ˛q"Ê<õ“·ç‘îÁi≠µ¨÷œ¶~Ÿ¸øô:ñuE:Eå>m¥~’⁄YÎWXÁ_Í{FüÙöaÙ
ÔçÙ‹jì t	πÑ>üÿ}É◊…=ÌÔ„¸mV ü
Sﬁ‡Ój«]∑áº{>à‹>›iQnmëc[π”æj˘LÔ»≥∏SsBLè·≥⁄#\b¨"~ü)Zªªœ˙.ˇå;:˝û˛≤rtœGh3\râ¸†FØK[‘≠»≠’πg*«Îé3ñcuI$«—‚{‹˜¢z&K≤öãª3Ö˛[∏ªN÷˛ëÒ8né∑P∆F£“AËﬁ°ï‰Íˇ†+‡é
V—∂ ˘©‰$&9»ª ˜f”?‡Y˙~ ™±?ëøáú·4}ßÑò’ö?«˝VÎsSb3ìU˝e0¯¯/ÎÂ[ey∆ÒÁ|◊∂»*¥]⁄F[:`6"ê†Cq`≈Ç°]•(2Z:òÇàshD-ó∫q	xaXpc—©†	€º£A∑Ñ©ôQ£¢A∂`µˆ|˚=Ô˜~ßßß-Õ¢'˘Â9Ô˚Ω˜ÀÛ¸ﬂ¡gXîÏµæ!È˚á®´Ô\oVÙôwr4`øvå\ì.$]à/.·∑'»¯;∂ [ÄoÄ|yΩˇ|‘,7eÍ¯VÎ-ì…¯˘≈ﬁ!⁄|/züæ»KKaxí¥;WC+˘æë∫´Ió`K√”‰⁄yÇ˙Î4«âÉ3âá˘;Ë∑I∂¬UîùÓóª‹2ëv™º˜§ÿ⁄ë~áÃ”xå†1èº`á˚ûåÚfÀDO{„4÷∏ª8#á©K¸qäÂ)wö<ÂÌñ%¥∑ß†]∂Ê?/[Ûö•6oÖl⁄e£ªEVí∑%¸µl	™•U€H‚™∆ƒ‰?b*ûjb˛"“Â÷÷$sŒ’f|≥e*q˘æÏ~ìzyµƒ“„Ãüæu¨˝ib¸ZhfˆÛ‹˛tçúˆËÂÿ „ØÀƒ¸&ôÕ8«Îööµù-ÓMº˚4¶kˇ;∞ˇí9ﬁÌ`◊8w,I_¨Kg_Z(—&¸ü	ìuü"EzÆÃYäô·1˚uëÓô?ê;\®˚Ì’ı1\OyG ºc¿“q*úØ2X£8[π£ãπ+úAoö©]VY(Ì0ıÆ6ı&ç0ûqµ–O{Ù~r[—˚ﬁYk`Ωtˇú‚h/vâÛ}çïB≥~KS˚¸SÙêH9Î®Û.ıÜìØÁÛ`ˇ·W§´Ã‹≠5k5ÅzÖºÎtéh*wÑﬂÚ‹sU_±n∂l¯∏‘Ü8Ø§÷D™‹k–/≈◊ù¬ﬁ’±ØÖ≤“}W*º ïÓ iVRµ—¡‘Q,J]q>"ˇÏz“≠2ÀyMÊ∞^7√’∞ñyw†Ä˚ÚÀ|≈iO}èÔo¡eˆˇ©ÒÚ∆ cÜ§çvŸëÂ¢w°√πãæk§ŸyÇ>∂1˙qOÊ˛Â@ù+,√m?ìºô‹±Ó\êu’ûô˘jøüãÕ/œÖ|µ5πê_”À8˙*◊◊8˙ ö˘CøÖqÙ’Óê\»rÇÒM…Ö¸)ˇ«8˙ZÁ™\»Ø:¡8¶ÂB˛¥‹q‡üx«¶ü„m∫˚∫ç˜G∞S±úæÙ3¸Á}µÿÙÎ∂‹Ôa‹üBçüÕ•L+ˆ?∞∫Høà=EÃ/È'⁄ ßCS‹ó÷M?˜m∞}¶âÎw>l«õïN>à˚3}´Ô›áõm˘’∂ﬂ=Òÿ”∫ Îwù£©∑ßã»ÖÛΩ€ÿE˙/1—”ÿ?¬õ<º`ˇWÿı–9?Æmu˘˘ €,mÍ5VáÌ"&fﬂ Sçœ}•[¨2É8≥”¯ªﬂ7NF—!˜JçÍı·˛|S~ùﬂLlÙ	Z¡ËÖwƒ˜ûï2ˇ∞ÃıÀD˜1tÒ$¸-}xøìÀµmı€™9‹5r1‘k√oj,úÇœm-x‘Ëóì)SÏ}»xÔñ˝ºŸV˚ó  ıÁ·“øe.€ÂzˇYû∑Hˆ3÷C“Bº™Ê XˇVôúºmÉEíÔüÑ.∞v@JÆÃ?Ö¸v‚Ó21ø]˜™‘≥fg'}g÷!îbÚuœPziV.Õﬁ]SÕò/:ÃÛ™—ch&Ø¬ö4õÒL”¯È=$û{≥àåÿ}ëÛ—^g Í¸RŸ|Œ<˙™V]óY˚ënª&£¸VÍœ`è™—ÕÔ≥ŒóHAbÒÌ˚√+%ÙgEh∑Ìﬁ£{ª§‘hbW∆&m¥À&ˇfi„Lå»’5âé h
ﬂÏÒå§èÃ|∞?3Û∑6Koòu'øŒ+ëjøÑ≥ÉÓËaÌò¬ŸIŸuâû˜K]ËbwHKpª4˙≥.E“>-É√IR™˙,çÆ[§1⁄ˇ-⁄(C9˚ÿ˚˛K–ª4…ﬁÒe‰øª„˚®˜KÛÕ›$Øs≥Õˇ9‹„Ô˙-ZˇÔ<∑oæ›óÔ‰Fm,õ£z‘Úvåyáúñ≠Sççµuwõ—ıÊ¸‘ˆksÙg_VÔ0g§(£á=Ÿ”n¿.H“Ëº∑π£wR˜4ùk)ªçrSlç6T˚†µ˜ÎYS≠ók3∫∫€ó~Õ“±Ò=Kl¨´oÀ±s¨öËÎ˛lFw≥Qd”ﬂ…Ëı˛lì‰›imx˛öXõ_òeÉÔßlkˆD\´cUø◊©æˆ∂°EOÄû;%∏ï3–ù&≈]/WÙF@$Q¬´ªcu~üø°‰UÊ}¢0Ê[b¢{,G-˜)nJDÒ÷Á}b–∑[/˜“/‰ùæcÙˇ	`$‰Á66–XxBPJxÃ≤.!äîd›ìuL÷Öπ}¿ºd∆úÙo€˝¶˚¯M˜Â€ö˜â∆ûwÚ0$6Pz7˚c¯$F˝eã,Î˙$ÏÇñ
w•ú{˚ô;üÛŸuzúÉ;xõ*6≠wQ	Pvai|x#}#óı∂>·¸¯¸Ö√‚uÚ;dû’^áô«@ıÔäı}U˘ı≤›¯Ç&©TﬂB‹’{>“˚õ¥t◊|Q#Á¶LÔq“ß¸ ô‘:/E˜˚ÀÒ	G/¯+–@_´,/Z∂≈⁄/˙ˆ≥Œce/ˆ°lx€V(ZÜ˛ñ¬ÉVo´é]ì˛0ŒÔW‚{›/òGáî©n&Hô—/• ‹£|G/0á’Ó<9_cÜ{⁄
˝°z¡‹ë"Ô-lÃ@÷•ﬁ›ôuø´eï7Éu’Dfüû#h˘ÁL˝rÎák_ÓU¯ÒK•sîr|£ﬁjm√Tñ´.ryQ¯”9îmà˛·n¬N∂|ãoì,tV…nãåv^EÔîê-\√ˇRl!\[‡:eÚ;8'_Q\èÙÀX_öa¥Û••-Føßj§ŸyLö—ƒÕ¥ó;dÍƒ“ú˙ªÈ´Ÿ≠°= 9ºî\Ö[bˇ|øçz˚Q ¥ó:∑eæ%eÚª ¯ˇï⁄Ç©ä`M¥œ??⁄ó:"„ºY2à=cÿÎÉˆ˝†:Í`µ¢≠§8è»\≈="uÜÕ—>wXÎ?,˝Û‰ø}&Á‡Á.˜¯„exPO€-zñŒ}€µxK£Ø9wçŒ°Ë`j'c…"∏TJÚüïIÏ°p?$±Œ.¿¶fòx$úiI©z€+2ﬁÆΩkFÁÜe%˜∏b_k≠bÍË›„ˇtcîScßo®4´È}hƒ7Pß¡ﬁ·Œ”v=[VR5⁄Ì¸Sﬂµ—ŸNy¥œ©ó
[˜Ú¯]›wAÌn·séí˙4⁄®d•˜)ﬂv⁄ªEŒÚ∆¿y¸?Øgö˝mÈ∂∑¡ùÚ#≈O9eñúÓn÷∫Ò^˜ó¶À0≈©¢èÚ^“+x◊]«€PÎVÙüvï!ä9o√z¶ô”ÖJfﬁ˝•r∂ 9oô3›◊¸óF™ëkâ+˚ÉˆËÈ«a=˛ı≈ì(‚€^´◊÷∏∏€ÀxÉ^$U±«7.ï
¸WÖ◊∆ŸC˜«ÌIæ©F}#~˛kç6˛µ“náÍR∑ˇØæ≠h€◊w“d≠Ø:ø˜?ˆÀ∂©„é„øªÁÿ&mb'ÉÜ„˜”ƒi Å¶ƒPYö?ÿ ƒê@Gâu⁄‡UÎ¶MùÍ§nÎ¥UU%∆:<ß A
S6Z+®&—ñ¶]µ≠›⁄TUµéiZˆΩ{èéu*’*≠Z’Û”Á˜˚››ÔÓ›ª;ˇÓn≠à}ã©]ƒZSÂûÅ≥®∏ß!ﬁtãÿ¬œPˇªÉÿ%	âX§Â v‘£èıRKõóŸ1•ûfÒ*|Àw,4œÃì≤≠ò•⁄KãxÜ˝◊äW⁄Á≠¯≈/Z1à_ÖœuﬁoPˇÖìbœ˘«π7˝Õäì2"N[‹]Ï˚ìG¸/¢u^≤œñG?†«ØÎè:⁄ué⁄u˛”3µ:û√:9åπ{Ú3Tö—A∑ºÔ"™„üÒ{y_i@π8É¸Îú/ˆ<±O y¬µ„LÙ'bº8.Q´ò€åÂäΩ„t\ºAwZ»}Zå„p.Àƒæ˚˘ƒ8¥?ÎÙ]ªü‚~2ÎÙ°˜Ô~◊Ôr◊ÔDw8£'¥ù8URÉΩﬂüº·~˚Ñ@¨3+‚RŸ¡è∞™÷ﬂ¿≥ôlÄÿ»O ¢ÔEo¡IÍ+D≥6eé›:@î}xá(Á¯,¯ÕŒ˚pÊú" Ô öãï7Ô
˛6ÿªÊ∑˘^≥(¿;˝Iq∫®õ®8€¢d6—BqKï#éóü#∫˝mã 
ãEoŒ‚'âñ>HTSC¥ÏœN|s-∆m≈[DÙ)äo®GüV/%∫ˇÉÜmDÎn#j|É®	∑ëÊUXèV|o;æg√”Dœm©%Íºó®+˝ˇÀ∂ü-∂c}∆ääœ˚ˇ«å)
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P| 9≠P(äOFîµÑﬁ°Z˙!πàìóB¥Å»—„(†§â≤È'êâﬂ.)ÖÌ¢H1≤~KX±mkîÕ6Ÿ∂ˆN€v¬ﬁc€.⁄¬æOÊò%⁄dS∂Õ»«◊Ÿ6ßlæ√∂5‰'l€˚êm;aˇÿ∂—˛,!É¬Tâg)¨6Í°t≈©$Ë~ê9+ëÑ-dÚ{•GJ¢‘á«†‰ÌD˝…T:ÔΩê›å¬ÓE]·€+}∫@B∂◊ü˚†i7Ú‚¥„cÙE¥⁄/[¥Íµ#’ãîxªA≠∞∫d zs?rC≤C∂›#˚j–v§ˆ†4!{+º+é·  •F[OÃhä˜«˜ƒåïÒ¡Å¯`W¢7ﬁ_aD˚˙åñﬁù=â!£%6‹ÎÆXªz„öª7£ÉΩ]}Mm7KIeÙ]Fb∞´;v_◊‡n#æ„CﬂgÙˆ	îµ˜˜&b›Fk¢+CÂ˛ÓP|–à£d–ÿﬂ”üÏçU|ÇÛªñV”FZCwCoòÌ&ºUxÔƒ∏ˆ…9æôÁ«-˚‘ÆÆ„‘¶›6ò´_8©ï“‡Zi*X†◊j©;ÙHZ[0ö;'ÏâﬁÆ¯«á§4 „‡ò Í‘¸»˜B &8&¿‡D†ÒÀRƒ¡ò%ZÅÊK∫7∫Põá∫ÛI<Z>MÉ†ëÕ†É‡î~"'Ä	∂,âh˘©á´–˜¸‘CRçÓÍÀdóï¸“ô›∏…“M˜Xz’ZÀmπÂ∂h±ï]QoÈÖÂñŒ-	õBgfÖOEÛ¥<|d:> …¯/»√ÈtXõCI¿5ßù—rGã·ë	ÕAL„√DÈ3ß4ñ  	G3˘ü¶\“˘[¸M´Ñø9öùâÆ„Ø“104˛*ûW¯+tÄOâ1á¨#`ú”¿…ßºåÁ*øJ˛Ö@Ë#`L	“À_Ò^Ja◊Œ_ÑÙÚY/@z¯XW¯tÌ7©Íe·„“ÜlC/±ç¸˘∂ëõNÛÁS◊J±¢òi¨®q≠àVPïVî*Y§ßµπ©⁄^=Õ7jı√—J~ëí ;§`=∏ '¨À∞.ì	Å√ 	∞  Ω¿‡g¡9pô*A¨n~!Ö◊§˘˘T†^èÊÒÁ¯3îèˇ56#°œÒ”RˇäˇRÍ3–~Ë≥¸t ØSÙîÍx°Ω–!îgüèÁÍ3—>Å±”!C†4ÉN0ú|Ç•∫ı\42Ng›œΩ.ıìÙ∏õ"ªÙH`%†!D`˘ù∞ Fåë è˘>íB>Kà¿ÉﬂÜ%D‡À¿"–∑ñÅÓ]∞ÑlÓÑ%D†πDö?ˆ≥‚ÖzuÛnfD=|FiFiFi9¯>Ò–5áË€Ree±G#¡“2›<¡ÃìÃlaÊ„Ãå1s?3`f-3∑23»L3˝Ãå0sú’`(Ly˙ﬂíÀ"sôyñôO1sàôfñ0≥òô´é§yajmïT´•çä?Ùù+}<º#Zà5_àò0yÃ»TNFëÂ<œ/t—hYùïÆXéG¯$*Nb&Èe‡¿MbM¢ëI4‡Å¨ù‡ò3¿	Ô"t|XJd‘ÅNp LßÏŒ4‡∑ªxLv,dw∫Y§¯$û"<Öº0R‡ıyÉﬁmÿ«<~÷ÏüÒÛj À√Ò*7«ùìfYcÔe˝ıΩ,öù≈Úa*¿D≤ıpÍZÅûfﬂK∆ıËˆ]Ú;∞Íÿ2
∞ËíÈ%‰sΩßÆ£–·îo™yRÅr˝Àµ∆Ùkæ◊Ù◊}iÛèæq˝∑F⁄¡R˙%‰”/˙æ•ü	•›»9H3®Üt=Ó´—ü:+]@¡£)}øPc˙W}kÙ›>Y≥
∂!ÒË-ÅÕz⁄[Â€¶GÜ–Êò^Á€™◊Z^KDù1Ω]Zf:[Íì/]‡ó∂WßYO§‹ıà´√’ÏZÍ
ª ]Ö.›U‡öÔöÌŒu{›ŸÓ[›ôn∑€Èv∏πõ‹≥”3Së aÍf;ΩB9B:§ÌÂBä≥zÃÕi%?ß5Ú∆÷z÷ò<µù∑…ø¥.H≥Ã{6'3‘≥dn#5∂’'kÇçi◊LK≤:ÿòt≠ˇb«O;∏	πI˛Õ4£∂é4õY_üü¸'„Â”öFÜÒ∑êXks0K¸√ j)“B§Ÿ¢FwÎ¡ã≠vd“[a5«‡%)9zË'=Õ÷K¥óû˝˘5_ }ﬂŸUj°É3Ô¯<øô◊g›u∑jO	•±ãÀ∆góú5~VRKª≈ÿÎ∑ÊÜ¶¥l]‘{˝î¯Ro⁄‚[äãWÿπKÒ∫¯‹‘{JoÈ/Àú“nOï"Ωµﬁ£ÆMŒÎ◊ÙXrD£‡‡ƒ,$∑7f‰à∂ùˆπØ>óÉÒ¿e1 ìú‰r·∞‰P‰<7kô^6+ô=ç∏íq˜¥?ôyò\N2ÒôKf!#äI&I'%B˜IR"I∫/ë„5Ú2@∆+d,3)tÕ$}&z≥d¢7¿∞ˇ-˝
ctbûcıu´£[}®ÒÈÏT£MÛzM(O;'ΩSå›æ‡zﬂ=›‘<√Ÿ`;h∫È«jŸûSÓõﬂç≤aÈ]ìOjç|·^ÆÒ*Wæ±a≤Nñ«\µ¬ªÄvs0Ws’ 5ôã»3ﬁ∞ΩmR·U«èìP‰!ú◊N"√+ÒùèEyxçåzûò¡” â0.ÈÖä÷¡—¡ZpM°ı‰'Å•ûôƒå^÷»1ΩBÿ`Ëâj}0˝ó§¡7‹oô˚Øû% ]”RœõuQz◊∂Ω≠-P;∏$q∏‘"Î˙Óß/æ ÒEEYÅ®ΩA-¿øøˇa´xåB?&¥ú¶ÁÉ+"]oÖ‡ß†’Üµ:m{œRx{p9,–•å∫À9ÇèÕÒﬂ\Û≤ÜA/ÿãA˝ë0ƒ]n…™‡f±’é˚-¿ Ï®Ãendstreamendobj23 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj49 0 obj<</Length 25103>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
-0.013 Tc 0.014 Tw 10 0 0 10 46 715.6797 Tm
[(What are the possible side effects of SPR)36.7 (YCEL?)]TJ
0 -1.757 Td
[(SPR)36.7 (YCEL)18 ( may cause serious side effects, including:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.469 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.006 Tc 0.047 Tw 1.8 0 Td
(Low blood cell counts.)Tj
/C2_0 1 Tf
0.006 Tw [<0BD80003>-46.9 <002F0052005A0003>-46.8 <0045004F0052005200470003>-46.9 <00460048004F004F0003>-46.9 <0046005200580051005700560003>-46.9 <0044005500480003>-46.9 <0046005200500050005200510003>-46.9 <005A004C0057004B0003>-46.9 <003600330035>18 <003C00260028002F>37.1 <0003>-46.9 <0044005100470003>-46.8 <0046004400510003>-46.8 <004500480003>-46.9 <005600480059004800550048000F0003>-46.9 <004C00510046004F00580047004C0051004A0003>-46.9 <004F0052005A0003>-46.9 <005500480047>-6.2 <0003>]TJ
0 -1.073 Td
[<0045004F0052005200470003>-48.1 <00460048004F004F0003>-48 <0046005200580051005700560003>-48.1 <000B0044005100480050004C0044000C000F0003>-48.1 <004F0052005A0003>-48.1 <005A004B004C005700480003>-48.1 <0045004F0052005200470003>-48.1 <00460048004F004F0003>-48.1 <0046005200580051005700560003>-48.1 <000B005100480058005700550052005300480051004C0044000C000F0003>-48.1 <0044005100470003>-48.1 <004F0052005A0003>-48.1 <0053004F004400570048004F004800570003>-48.1 <0046005200580051005700560003>-48.1 <000B0057004B005500520050004500520046005C00570052005300480051004C0044000C0011>-5.8 <0003>]TJ
/TT1 1 Tf
0 Tc 0.076 Tw 0 -1.073 Td
[(Y)92.1 (our healt)0.5 (hcare provider will do blood t)0.5 (est)0.5 (s t)0.5 (o check your blood cell counts regularly during your t)0.5 (reat)0.5 (ment with )]TJ
/C2_0 1 Tf
-0.012 Tc 0.012 Tw 0 -1.073 Td
[<003600330035>17.6 <003C00260028002F00110003>-27.9 <00260044004F004F0003>-27.9 <005C0052005800550003>-27.9 <004B00480044004F0057004B00460044005500480003>-27.9 <0053005500520059004C0047004800550003>-27.9 <0055004C004A004B00570003>-27.9 <0044005A0044005C0003>-27.9 <004C00490003>-27.9 <005C005200580003>-27.9 <004B0044005900480003>-27.9 <00440003>-27.9 <004900480059004800550003>-27.9 <005200550003>-27.9 <00440051005C0003>-27.9 <0056004C004A005100560003>-27.8 <005200490003>-27.9 <004400510003>-27.9 <004C00510049004800460057004C005200510003>-27.8 <004700580055004C0051004A0003>-27.9 <005700550048004400570050004800510057>-11.8 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.073 Td
[(with SPR)17.7 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.009 Tc 0.031 Tw 1.8 0 Td
[(Bl)0.5 (eed)0.5 (i)0.6 (n)0.5 (g)0.5 ( )0.7 (p)0.5 (ro)0.5 (b)0.6 (l)0.5 (ems.)]TJ
/C2_0 1 Tf
0.009 Tw 9.141 0 Td
[<0BD80003>-30.4 <0025004F004800480047004C0051004A0003>-30.4 <0053005500520045004F0048005000560003>-30.4 <0044005500480003>-30.3 <0046005200500050005200510003>-30.3 <005A004C0057>0.5 <004B0003>-30.3 <003600330035>18.3 <003C00260028002F0011>0.5 <0003>-30.4 <00360052005000480057>0.6 <004C0050004800560003>-30.3 <0057>0.5 <004B0048005600480003>-30.3 <0045004F004800480047004C0051004A0003>-30.4 <0053005500520045004F0048005000560003>-30.4 <0046004400510003>-30.3 <00450048>-9.2 <0003>]TJ
-0.013 Tc 0.013 Tw -9.141 -1.073 Td
[<005600480055004C0052005800560003>-13.9 <0044005100470003>-13.9 <004F0048004400470003>-14 <005700520003>-13.9 <0047004800440057004B00110003>-14 <00260044004F004F0003>-14 <005C0052005800550003>-13.9 <004B00480044004F0057004B00460044005500480003>-13.9 <0053005500520059004C0047004800550003>-13.9 <0055004C004A004B00570003>-13.9 <0044005A0044005C0003>-13.9 <004C00490003>-14 <005C005200580003>-13.9 <004B004400590048001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.235 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<005800510058005600580044004F0003>-13.9 <0045004F004800480047004C0051004A0003>-13.9 <005200550003>-13.9 <004500550058004C0056004C0051004A0003>-13.9 <005200490003>-13.9 <005C0052005800550003>-14 <0056004E004C0051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(bright red or dark tar-like stools)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0047004800460055004800440056004800470003>-14 <0044004F0048005500570051004800560056000F0003>-14 <004B00480044004700440046004B0048000F0003>-13.9 <005200550003>-14 <0046004B00440051004A00480003>-13.9 <004C00510003>-13.9 <00560053004800480046004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.415 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/C2_1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[<003C>74.4 <005200580055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.378 0 Td
<004500520047005C>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.563 0 Td
<00500044005C>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.194 0 Td
<004B0052004F0047>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.284 0 Td
<005700520052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.747 0 Td
<005000580046004B>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.841 0 Td
<00C00058004C0047>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.284 0 Td
<000B00C00058004C0047>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.599 0 Td
<005500480057004800510057004C00520051000C00110BD8>Tj
/C2_0 1 Tf
[<0BD80003>13.3 <0029004F0058004C00470003>13.2 <005500480057004800510057004C005200510003>13.3 <004C00560003>13.2 <0046005200500050005200510003>13.2 <005A004C0057004B0003>13.3 <003600330035>18 <003C00260028002F>37.1 <0003>13.3 <0044005100470003>13.3 <0046004400510003>13.3 <00560052005000480057004C005000480056>-18 <0003>]TJ
/TT1 1 Tf
0 Tc 0 Tw 31.31 0 Td
( )Tj
/C2_0 1 Tf
-0.013 Tc 0.013 Tw -50.2 -1.073 Td
[<004500480003>-17.1 <00560048005900480055004800110003>-17.2 <002C00510003>-17.2 <0056004800590048005500480003>-17.2 <00460044005600480056000F0003>-17.2 <00C00058004C00470003>-17.2 <00500044005C0003>-17.2 <00450058004C004F00470003>-17.2 <005800530003>-17.2 <004C00510003>-17.1 <0057004B00480003>-17.2 <004F004C0051004C0051004A0003>-17.2 <005200490003>-17.2 <005C0052005800550003>-17.2 <004F00580051004A0056000F0003>-17.1 <0057004B00480003>-17.2 <0056004400460003>-17.2 <0044005500520058005100470003>-17.2 <005C0052005800550003>-17.1 <004B0048004400550057000F0003>-17.2 <005200550003>-17.2 <005C0052005800550003>-17.1 <005600570052005000440046004B>-13.2 <0003>]TJ
0 -1.073 Td
[<004600440059004C0057005C>74 <00110003>-14 <00260044004F004F0003>-14 <005C0052005800550003>-13.9 <004B00480044004F0057004B00460044005500480003>-14 <0053005500520059004C0047004800550003>-13.9 <0055004C004A004B00570003>-14 <0044005A0044005C0003>-14 <004C00490003>-14 <005C005200580003>-14 <004A004800570003>-13.9 <00440051005C0003>-14 <005200490003>-13.9 <0057004B0048005600480003>-14 <0056005C0050005300570052005000560003>-14 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-14 <005A004C0057004B0003>-13.9 <003600330035>17.7 <003C00260028002F001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.235 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(swelling all over your body)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(weight gain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B000F0003>-13.9 <00480056005300480046004C0044004F004F005C0003>-13.9 <004C00490003>-13.9 <0057004B004C00560003>-13.9 <004B0044005300530048005100560003>-13.9 <005A004C0057004B0003>-14 <004F0052005A0003>-14 <004F004800590048004F00560003>-14 <005200490003>-14 <0053004B005C0056004C00460044004F0003>-13.9 <004400460057004C0059004C0057005C0003>-14 <005200550003>-13.9 <004400570003>-14 <0055004800560057>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(dry cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.253 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(chest pain when taking a deep breath)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.415 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.013 Tc 0.012 Tw 1.8 0 Td
(Heart and blood vessel \(cardiovascular\) problems.)Tj
/C2_0 1 Tf
0.013 Tw [<0BD8>-0.7 <0003>-12.2 <003600330035>17.7 <003C00260028002F>36.8 <0003>-12.3 <00500044005C0003>-12.3 <004600440058005600480003>-12.3 <004B00480044005500570003>-12.2 <0053005500520045004F004800500056000F0003>-12.3 <004C00510046004F00580047004C0051004A0003>-12.3 <004400510003>-12.3 <0044004500510052005500500044004F>-13.2 <0003>]TJ
-0.001 Tc 0.001 Tw 0 -1.073 Td
[<004B00480044005500570003>-72.7 <0055004400570048000F0003>-72.7 <00440003>-72.7 <004B00480044005500570003>-72.8 <00440057005700440046004E000F0003>-72.7 <005200550003>-72.8 <005600500044004F004F0003>-72.8 <0056005700550052004E004800560003>-72.7 <0057004B004400570003>-72.7 <004F0044005600570003>-72.7 <00520051004F005C0003>-72.7 <00440003>-72.7 <00490048005A0003>-72.7 <0050004C005100580057004800560003>-72.7 <005200550003>-72.7 <00440003>-72.7 <00490048005A0003>-72.7 <004B0052005800550056000F0003>-72.7 <00460044004F004F004800470003>-72.7 <00570055004400510056004C0048005100570003>-72.7 <004C00560046004B00480050004C0046>-1 <0003>]TJ
-0.011 Tc 0.011 Tw 0 -1.073 Td
[<00440057005700440046004E00560003>-27.4 <000B0037002C00240056000C00110003>-9.4 <0037002C002400560003>-27.5 <0044005500480003>-27.5 <005200490057004800510003>-27.5 <00440003>-27.4 <005A004400550051004C0051004A0003>-27.5 <0056004C004A00510003>-27.5 <0057004B004400570003>-27.5 <005C005200580003>-27.5 <0044005500480003>-27.5 <004400570003>-27.4 <0055004C0056004E0003>-27.4 <0049005200550003>-27.5 <00440003>-27.5 <00500052005500480003>-27.4 <005600480055004C0052005800560003>-27.4 <0056005700550052004E004800110003>-9.4 <003C>91.9 <0052005800550003>-27.4 <004B00480044004F0057004B00460044005500480003>-27.5 <0053005500520059004C004700480055>-11 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<005A004C004F004F0003>-13.9 <005000520051004C0057005200550003>-14 <0057004B00480003>-13.9 <005300520057004400560056004C005800500003>-14 <0044005100470003>-14 <00500044004A005100480056004C005800500003>-13.9 <004F004800590048004F00560003>-14 <004C00510003>-14 <005C0052005800550003>-13.9 <0045004F0052005200470003>-14 <0044005100470003>-13.9 <005C0052005800550003>-14 <004B00480044005500570003>-13.9 <00490058005100460057004C005200510011>]TJ
-0.367 -1.451 Td
[<002A004800570003>-13.9 <005000480047004C00460044004F0003>-13.9 <004B0048004F00530003>-14 <0055004C004A004B00570003>-14 <0044005A0044005C0003>-14 <004C00490003>-14 <005C005200580003>-14 <0047004800590048004F005200530003>-13.9 <00440051005C0003>-13.9 <005200490003>-14 <0057004B00480003>-13.9 <00490052004F004F0052005A004C0051004A0003>-13.9 <0056005C0050005300570052005000560003>-14 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-13.9 <005A004C0057004B0003>-14 <003600330035>17.7 <003C00260028002F001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.958 -1.469 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(chest pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004900480048004F004C0051004A0003>-14 <004F004C004E00480003>-13.9 <005C0052005800550003>-14 <004B00480044005500570003>-14 <004C00560003>-13.9 <0045004800440057004C0051004A0003>-13.9 <0057005200520003>-14 <00490044005600570003>-13.9 <005200550003>-14 <005C005200580003>-14 <004900480048004F0003>-13.9 <0044004500510052005500500044004F0003>-13.9 <004B00480044005500570003>-13.9 <00450048004400570056>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0059004C0056004C005200510003>-13.9 <0046004B00440051004A004800560003>-14 <0057004B004400570003>-14 <00500044005C0003>-14 <004F0044005600570003>-13.9 <0049005200550003>-13.9 <00440003>-14 <0056004B0052005500570003>-14 <0057004C00500048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.433 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(slurred speech)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.415 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.009 Tc 0.035 Tw 1.8 0 Td
[(Pulmonary )37.6 (Arterial )0.5 (Hypertension )0.5 (\(P)73.9 (AH\).)]TJ
/C2_0 1 Tf
0.009 Tw [<0BD8>-0.8 <0003>-34.6 <003600330035>17.6 <003C00260028002F>36.7 <0003>-34.6 <00500044005C0003>-34.6 <004600440058005600480003>-34.6 <004B004C004A004B0003>-34.6 <0045004F0052005200470003>-34.5 <005300550048005600560058005500480003>-34.6 <004C00510003>-34.5 <0057004B00480003>-34.6 <00590048005600560048004F00560003>-34.5 <005200490003>-34.5 <005C0052005800550003>-34.6 <004F00580051004A00560011>-8.9 <0003>]TJ
/TT1 1 Tf
-0.003 Tc 0.065 Tw 0 -1.073 Td
[(P)73.8 (AH)-0.6 ( may h)-0.6 (ap)-0.6 (p)-0.6 (en)-0.6 ( a)-0.6 (t a)-0.6 (ny time d)-0.6 (urin)-0.6 (g you)-0.6 (r trea)-0.6 (tme)-0.6 (nt w)-0.6 (ith SPR)17.5 (YC)-0.6 (EL)-0.6 (. )18.1 (Y)91.4 (o)-0.6 (ur he)-0.6 (a)-0.6 (lthca)-0.6 (re pro)-0.6 (vi)-0.6 (de)-0.6 (r sho)-0.6 (u)-0.6 (ld)-0.6 ( ch)-0.6 (eck you)-0.6 (r)-3 ( )]TJ
/C2_0 1 Tf
-0.005 Tc 0.005 Tw 0 -1.073 Td
[<004B00480044005500570003>-54.5 <0044005100470003>-54.5 <004F00580051004A00560003>-54.5 <0045004800490052005500480003>-54.5 <0044005100470003>-54.5 <004700580055004C0051004A0003>-54.5 <0057005500480044005700500048005100570003>-54.5 <005A004C0057004B0003>-54.5 <003600330035>17.6 <003C00260028002F00110003>-54.5 <00260044004F004F0003>-54.5 <005C0052005800550003>-54.5 <004B00480044004F0057004B00460044005500480003>-54.5 <0053005500520059004C0047004800550003>-54.5 <0055004C004A004B00570003>-54.5 <0044005A0044005C0003>-54.5 <004C00490003>-54.5 <005C005200580003>-54.5 <004B004400590048>-5.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B000F0003>-13.9 <0057004C0055004800470051004800560056000F0003>-14 <005200550003>-13.9 <0056005A0048004F004F004C0051004A0003>-14 <0044004F004F0003>-14 <00520059004800550003>-13.9 <005C0052005800550003>-14 <004500520047005C0003>-13.9 <000B00C00058004C00470003>-14 <005500480057004800510057004C00520051000C0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.011 Tc 0.028 Tw 1.8 0 Td
(Severe skin reactions.)Tj
/C2_0 1 Tf
0.011 Tw [<0BD80003>-27.6 <003600330035>17.9 <003C00260028002F>37 <0003>-27.7 <00500044005C0003>-27.6 <004600440058005600480003>-27.6 <0056004E004C00510003>-27.7 <00550048004400460057004C0052005100560003>-27.6 <0057004B004400570003>-27.7 <0046004400510003>-27.7 <00560052005000480057004C0050004800560003>-27.7 <004500480003>-27.7 <00560048005900480055004800110003>-27.6 <002A004800570003>-27.6 <005000480047004C00460044004F0003>-27.6 <004B0048004F00530003>-27.7 <0055004C004A004B0057>-10.9 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<0044005A0044005C0003>-13.9 <004C00490003>-14 <005C005200580003>-13.9 <004A004800570003>-14 <00440003>-14 <0056004E004C00510003>-13.9 <00550048004400460057004C005200510003>-14 <005A004C0057004B0003>-13.9 <00490048005900480055>55 <000F0003>-13.9 <00560052005500480003>-14 <0050005200580057004B0003>-13.9 <005200550003>-14 <0057004B0055005200440057000F0003>-13.9 <005200550003>-14 <0045004F004C0056005700480055004C0051004A0003>-14 <005200550003>-14 <005300480048004F004C0051004A0003>-13.9 <005200490003>-13.9 <005C0052005800550003>-14 <0056004E004C00510003>-13.9 <005200550003>-14 <004C00510003>-14 <0057004B00480003>-13.9 <0050005200580057004B0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.003 Tc 0.062 Tw 1.8 0 Td
[(T)74.5 (umor L)37.4 (ysis Syndrome \(TLS\).)]TJ
/C2_0 1 Tf
0.003 Tw [<0BD80003>-43.7 <0037002F00360003>-61.8 <004C00560003>-61.8 <0046004400580056004800470003>-61.8 <0045005C0003>-61.9 <00440003>-61.8 <00490044005600570003>-61.8 <0045005500480044004E00470052005A00510003>-61.8 <005200490003>-61.8 <0046004400510046004800550003>-61.9 <00460048004F004F005600110003>-43.8 <0037002F00360003>-61.8 <0046004400510003>-61.8 <004600440058005600480003>-61.8 <005C005200580003>-61.8 <005700520003>-61.8 <004B004400590048>-3.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<004E>0.5 <004C004700510048005C>0.5 <0003>0.7 <0049>0.7 <0044004C004F00580055>0.5 <00480003>0.7 <0044005100470003>0.7 <0057>0.7 <004B00480003>0.7 <00510048004800470003>0.7 <0049>0.6 <00520055>0.5 <0003>0.7 <0047004C0044004F005C>0.6 <0056>0.5 <004C0056>0.6 <0003>0.6 <0057>0.7 <0055>0.5 <004800440057>0.7 <0050>0.5 <004800510057>0.7 <000F>0.7 <0003>0.7 <0044005100470003>0.7 <004400510003>0.7 <00440045005100520055>0.5 <0050>0.5 <0044004F0003>0.7 <004B004800440055>0.5 <0057>0.7 <0045004800440057>0.7 <0011>0.7 <0003>18.7 <003C>92.4 <005200580055>0.5 <0003>0.7 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>0.7 <00530055>0.5 <00520059>0.5 <004C004700480055>0.5 <0003>0.7 <0050>0.5 <0044005C>0.5 <0003>0.7 <004700520003>0.6 <0045004F005200520047>-13.2 <0003>]TJ
-0.007 Tc 0.007 Tw 0 -1.073 Td
[<005700480056005700560003>-44.2 <005700520003>-44.1 <0046004B00480046004E0003>-44.2 <005C005200580003>-44.1 <0049005200550003>-26.1 <0037002F003600110003>-44.2 <00260044004F004F0003>-44.1 <005C0052005800550003>-44.1 <004B00480044004F0057004B00460044005500480003>-44.1 <0053005500520059004C0047004800550003>-44.1 <005200550003>-44.2 <004A004800570003>-44.1 <0048005000480055004A004800510046005C0003>-44.1 <005000480047004C00460044004F0003>-44.2 <004B0048004F00530003>-44.2 <0055004C004A004B00570003>-44.2 <0044005A0044005C0003>-44.1 <004C00490003>-44.2 <005C005200580003>-44.1 <0047004800590048004F00520053>-7.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<00440051005C0003>-13.9 <005200490003>-14 <0057004B0048005600480003>-13.9 <0056005C0050005300570052005000560003>-13.9 <004700580055004C0051004A0003>-14 <0057005500480044005700500048005100570003>-13.9 <005A004C0057004B0003>-13.9 <003600330035>17.6 <003C00260028002F001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.565 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(nausea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 3.6 0 Td
[<0056004B00520055005700510048005600560003>-14 <005200490003>-14 <00450055004800440057004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(vomiting)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 3.6 0 Td
(muscle cramps)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(weakness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(seizures)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(swelling)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-4.809 -1.321 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
0.018 Tc 0.167 Tw 1.8 0 Td
[(Slowing )0.6 (of )0.5 (growth )0.6 (and )0.5 (development )0.5 (in )0.5 (children.)]TJ
/C2_0 1 Tf
-0.018 Tw [<0BD80003>-166.5 <00280049>18.4 <004900480046005700560003>-166.4 <005200510003>-166.5 <00450052005100480003>-166.5 <004A00550052005A0057004B0003>-166.5 <0044005100470003>-166.4 <0047004800590048004F0052005300500048005100570003>-166.5 <004C00510003>-166.5 <0046004B004C004F0047005500480051>17.9 <0003>]TJ
/TT1 1 Tf
0 Tc 0 Tw 50.2 0 Td
( )Tj
-0.002 Tc 0.068 Tw -50.2 -1.073 Td
[(have )0.6 (happened )0.5 (with )0.6 (SPR)17.9 (YCEL)37 ( )0.5 (and )0.6 (can )0.6 (sometimes )0.6 (be )0.6 (severe. )18.5 (Y)91.9 (our )0.6 (healthcare )0.6 (provider )0.5 (will )0.5 (monitor )0.6 (your )0.5 (child\222)17.9 (s)-2 ( )]TJ
/C2_0 1 Tf
-0.008 Tc 0.008 Tw 0 -1.073 Td
[<00450052005100480003>-36.1 <004A00550052005A0057>0.5 <004B0003>-36 <0044005100470003>-36 <0047004800590048004F005200530050004800510057>0.5 <0003>-36 <004700580055004C0051004A0003>-36 <00570055004800440057>0.5 <0050004800510057>0.5 <0003>-36 <005A004C0057004B0003>-36 <003600330035>18.1 <003C00260028002F00110003>-36 <002A004800570003>-36 <005000480047004C00460044004F0003>-36.1 <004B0048004F00530003>-36 <0055004C004A004B00570003>-36 <0044005A0044005C0003>-36 <004C00490003>-36 <005C0052005800550003>-36 <0046004B004C004F00470003>-36 <0047004800590048004F005200530056>-8 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.073 Td
(bone pain.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.397 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT0 1 Tf
-0.006 Tc 0.047 Tw 1.8 0 Td
(Liver problems.)Tj
/C2_0 1 Tf
0.006 Tw [<0BD80003>-47 <003600330035>18 <003C00260028002F>37.1 <0003>-47 <0046004400510003>-47 <004600440058005600480003>-47 <004F004C0059004800550003>-47 <0053005500520045004F00480050005600110003>-47 <0033004800520053004F00480003>-46.9 <005A004B00520003>-46.9 <004B0044005900480003>-47 <004B004400470003>-47 <004F004C0059004800550003>-47 <0053005500520045004F0048005000560003>-47 <004C00510003>-46.9 <0057004B00480003>-47 <00530044005600570003>-46.9 <00500044005C0003>-46.9 <004500480003>-47 <00440057>-5.9 <0003>]TJ
-0.003 Tc 0.003 Tw 0 -1.073 Td
[<0055004C0056004E0003>-63.5 <0049005200550003>-63.4 <004A004800570057004C0051004A0003>-63.4 <004F004C0059004800550003>-63.4 <0053005500520045004F0048005000560003>-63.4 <005A004C0057004B0003>-63.4 <003600330035>17.7 <003C00260028002F00110003>-45.4 <003C>91.7 <0052005800550003>-63.5 <004B00480044004F0057004B00460044005500480003>-63.5 <0053005500520059004C0047004800550003>-63.4 <005A004C004F004F0003>-63.4 <005000520051004C0057005200550003>-63.4 <005C0052005800550003>-63.4 <004F004C0059004800550003>-63.5 <00490058005100460057004C005200510003>-63.5 <004400560003>-63.4 <005100480048004700480047>-3.2 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.073 Td
[<004700580055004C0051004A0003>-26.1 <0057004B00480003>-26.1 <0057005500480044005700500048005100570003>-26.1 <005A004C0057004B0003>-26.1 <003600330035>17.6 <003C00260028002F00110003>-26.1 <00260044004F004F0003>-26 <005C0052005800550003>-26.1 <004B00480044004F0057004B00460044005500480003>-26.1 <0053005500520059004C0047004800550003>-26.1 <005200550003>-26.1 <004A004800570003>-26.1 <005000480047004C00460044004F0003>-26.1 <004B0048004F00530003>-26.1 <0055004C004A004B00570003>-26.1 <0044005A0044005C0003>-26 <004C00490003>-26.1 <005C005200580003>-26.1 <0047004800590048004F005200530003>-26.1 <00440051005C>-13 <0003>]TJ
0 -1.073 Td
[<0056005C0050005300570052005000560003>-14 <005200490003>-14 <004F004C0059004800550003>-13.9 <0053005500520045004F004800500056000F0003>-14 <004C00510046004F00580047004C0051004A001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.565 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 3.6 0 Td
(stomach-area \(abdominal\) pain)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(bleeding)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 3.6 0 Td
[<005C0048004F004F0052005A004C0051004A0003>-13.9 <005200490003>-13.9 <005C0052005800550003>-14 <0056004E004C00510003>-13.9 <005200550003>-13.9 <005A004B004C005700480003>-14 <00530044005500570003>-14 <005200490003>-13.9 <005C0052005800550003>-14 <0048005C00480056>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.013 Tw 3.6 0 Td
(bruising)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.059 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 3.6 0 Td
[<004F0052005600560003>-13.9 <005200490003>-13.9 <00440053005300480057004C00570048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.041 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 3.6 0 Td
(dark \223tea-colored\224 urine)Tj
ET
0 0 0 1 K
4 M 
36.5 36.5 539 695.96 re
S
endstreamendobj45 0 obj<</BaseFont/IEWGNW+Arial-BoldMT/DescendantFonts 70 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 71 0 R/Type/Font>>endobj70 0 obj[72 0 R]endobj71 0 obj<</Filter/FlateDecode/Length 427>>stream
Hâ\ì€j„0ÜÔ˝∫l/äO:¥â”@.ˆ¿¶˚ é≠dçlÁ"o_YüIa∂˘,ÕÃˇ£¥ﬁo˜ÆüD˙€Ì¡N‚‘ªŒ€ÎpÛ≠G{Ó]í¢Î€i°¯n/Õò§!¯pøNˆ≤wß!Y≠D˙'l^'OÎn8⁄Á$˝Â;Î{wOÎ√≥H∑q¸¥Î&ëâ™ù=ÖD?öÒgs±"ça/˚.Ï˜”˝%ƒ|ü¯∏èVësƒ¥CgØc”Zﬂ∏≥MVYXïXÌ¬™Î∫ˇˆeAÿÒ‘˛k|<^Ü„·ÛVE⁄D*^°ZˆvP)œ°wh©\G*t$YBí–+§†7HCTêT(3h°SeêÇ
àzäz%ııJ<(<3È"ã&ã$ã&ã$ã&ãDµFµDµFµ\C¢ÉöJ™Î•˙;¥Åp´q´p´q´ËÆ¶ª¡f§D'ùPx0xPx0xPx0xPx0xPx0xPx0xP®6®ﬁ,:ı√Gù}ˇâÍ7€9wëeÎ8tÀtÕ„nâxÃv{Û>åuºJqûÁIÓù}‹∂qEàöü‰KÄ ¯€·kendstreamendobj72 0 obj<</BaseFont/IEWGNW+Arial-BoldMT/CIDSystemInfo 73 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 74 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 15[278]17[278]29[333]38 39 722 40[667 611]47[611 833]51[667]53[722 667 611]60[667]68[556 611 556 611 556 333]74 75 611 76[278]78[556 278 889]81 83 611 85[389 556 333 611 556 778]92[556]191 192 611 3032[83]]>>endobj73 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj74 0 obj<</Ascent 1010/CIDSet 75 0 R/CapHeight 716/Descent -376/Flags 4/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 76 0 R/FontName/IEWGNW+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj75 0 obj<</Filter/FlateDecode/Length 33>>stream
Hâö È¿¬|p:ˇÔÔ/Ä±Åa–4  QT;endstreamendobj76 0 obj<</Filter/FlateDecode/Length 20572/Length1 48376>>stream
Hâ|UxMW˛◊ﬁ˚‹õ"BûÃI.©…â7A$7¡(BTì†sØ$$ûA§òV*òÃ\:‘T©ñ÷õŒ	RœË|:≠"jR£mF´JÂ˚c® =≥Óçô—˘æÈﬁﬂ9gØΩ◊^Î_œS2oA¸Ò$zå…ÍûÑñqîG^iâﬁBR$`ÕùZ<mVÌS
h3¶Õ\4ı¸ﬁs@´ø›j
ú˘Aﬂèí70SüBﬁh·OÆ„WÁ¬Y%”wÅ^gŒ…sä‹Sç¿‹?3›0Àπ∞∏Â|˚õ¸“g;gT\sÑÈÄöV<Ø‡Ò˘û†ÌyHyQÖÌu≠'£åh˘ zLA>ö∑*·™±f-¶ÒU_œ˝Ò£“t4i‹c©ßu0ÌOô¶…zb¥√ÌP¸çÙ>;©b¿>0ø˛˜„.2øˆúyæ‚&ÎÓÿÚ<˚±°Æ§„ =DP%bÓ≥ßˇÄfºä`å«z
Bgt¿3Aäy‚∞ä6ö•Ê¬l5Qππõœ_¡x¿æPÑæÕ¸œ† 7‰5‰òØ√√ÅG‡ƒ%û˜√Z¨√qz¡|¿ZÉQŒÚí1CÕìÊ#ƒbïZ≠5¯˛ï8B3œ,B'D√%‚ÃKÊóàAﬁ∆^∆Gµj8¢0+Ö…xı*ﬁÅõƒdô¶qdÿÆ	òçÁ·¬nú¶  ‘¥€ÊØÃÎ∞†∫2¶"‹†ﬁ4JlSÊ`Û2&‚=|»ˆzf≠ö®vh›CÃ7Ã˜—á»èé“I-I˚]ÛRsã˘.O"{d4ÎôÇe8âèw‹efÜ#ã5ü¢é§S{¸íKƒy›ÿ⁄…åvﬁÑ¡9å#8∆æ˘+qçÇ)Ç~AS®íÓà ë/Í‰FY-/*Rªÿﬂ6taï`‚Œ¢é4ñﬂÉ2i:Õ°ﬂ”‘(qK‹W>jô˙A5k1ÓF˜ÊhÛBéß±eÏ€∑q ’8áOqwÒO
§~TH[»†F∫%|E¥#ä≈z±MÏì£e•<©z´T5CùUóµ_k+≠N´˚—v˜Z˜>wΩy»¨Á‹iÕÚcê¡] Y±'pÅ•Üœq’ì?, Â“s¨e>˝Ü÷—>:Eıtì≠ÑwFãÅ¬ŒZÁàyÏßr±V¨cÌu<?ó≈Á‚;qOj2ZˆësÂi»˘â¸F™’M%™1*Wôô$mòñ•Ì‘ˆhÔk∑-…ñ|K±Â[kπuπœôÊÿÊ/‹p∫˜Œ]Œ§≈ÏâÕÿ y_Õ18Õ=«àÒéB8E—Såª?e–HEœ“$*†r™†5Ùm§≠Ù.[¿6+cèCEñpä±\TàóE5œ√‚#qI4à&F"m2N& 2WNî≥ŸÜπD.gœV ›≤N^ê◊Â∑≤â£¢:©j±⁄†v®jUØ=≠Õ‚πU;°’jı⁄#ÌëEX¬-ëñÓñÈñùñ´Vãµè5”˙[ÎEÎ]übä§XFÆ„â!¬∏;â›"XïQot$Ö6ly«!ã´‚.ÜH7«•µÁú±µa™ùÁ¶%E|øÑé†7ùBôEH‚>‘à˝tE4™?âA¯î¶v»Ÿ⁄iÖ=‹çVã£‚•¢Z$ã	bì]£ù∏∆˘æÎhÕ«j¢Ù"ı•2\d-G≤πU(Ú•tå KU>û√OÍè+∏·ﬁ¨Z©∏?’`=Gt/æ§]xHöyãªõ‰n‰‰.≥äÛ}<]o2◊Y◊cwêôñ:TìÖˇ }-É’b‹∆˜∏°ÊåJÂNz›]§6´ØÃæfWWvr›bWÃ5ŒícL{®I\È~‹Kí∏™3ëã|º»]Ø“4ÃMÊ2së9Û›áOÈ-ÆàæëåyæÇœh%◊·∞ü∂Ûˇw>jqìB©%q=4i•⁄jm∑V≠◊ŒZŸ€À±ë3˙*g≥[êáz‹ƒ}Ú·ÿÑ!Ωo?∆ûçô"GCÖ£òk∂+˜Ò‘«ñÃg)ÂÏΩM\œ«∏6nsüòÑ„h A!lQÎ˜a9#ŸœødÓÌ¡etÄwÚπk«‚;∂ª5ı%¨/Ö%≠ÁÆUÀòÆ‡ˆ∂È≈œ}¡NX÷}<ã|÷–ôT≈8à˛‹YÌÚ˚ª3"ï¢ÈæÁ‡
mçéËØ}EÒÓ—f?Q$èÒ?∆‰˝∑¯ÔÅA4óQ¥a;ö—û∆†∑{c∏@RtﬁãbÉ(0+‰ÛÓô¯ª8&)™‘jO:>e»‡A…ÙÔ◊∑wØûIâ=∫wKàèã˝y◊ßb∫t∂EGÈ?Î‘12"<,4§C˚‡vAm€¥n‡ÔÁÎcµhJ
B|∫-√°1C≈ÿÜO–6'o8üÿp:oe¸ò«–^6˝«ú)Ã9ı8SZ8S˛√IÅz2í‚ıtõnúµ€Ù õÕÎóÌ∂›hÚÆGy◊´ΩÎVºéä‚zzh°]7»°ß•ÖÆtáù≈U˘˚•Ÿ“
¸‚QÂÁœK^!∂‚*
LﬁÖIP%‡”äA·6{∫f≥{≤K∫3ﬂ»õùnèàä Ià7(-œ6≈Ä-’hÁeAöWçaI3¨^5zë«¨‘´‚k]´j1≈êoÀwN 6§3«££mÎµ!ãø˝/…¬É“≤+û<çêÆÙ–"›C∫\∫Q;6˚…”(œ;'áe]—%√· `’´ÿâ#≥t÷&V‰d¥ÇUÍK<VµÿW`K˜Ï8¶ÎÜØ-’VËöÓ‡–Ñªå[µ?<<Â=≥·È∫k|∂- aÀq⁄#´Ç·˙ﬂ’€‘uÜœ9˜yÓµùk;±ùGõk\;!&ƒIÚ¿‡+»
¬#°sÅåNF}h+l†ÜiTÂ1H¡XUõIÀöUÎ64uRU‘n⁄∫F+a@#<ÒÕ˛„Ñ,ë∫]˚û◊œ9ﬂˇˇﬂy¸À^Ì/4Ù¬©í }ö}Ã∞}∂ºÒÇ≈:π–=!Àïrü≥RlŸÑe1C‰[ÑHÈÎt@“·ùX“›ÄíÎ‡3x:1ÙJ≠è|'EõªíZkg˝SÇ_ÛÈ…˚‡À‹ö⁄≤fºEÙk˜+2ûLP‰OÀ©`0UQ¡("5ÉO„‹\ΩÆr∆÷4ôÂ€¨ÈêÅ˘–R∞ÌöŒ¶*0ø◊Àº7m†µPImoÎ´ÎhmÒydT;S§ãIüJ
V0…ˆßíâÓ]>`Úá*H…ÅâûÊr.ËiJa◊ˇwè…cÌæX€Í}A≤k‹∂±ÂSjcÚÜ	Ÿx)ÂlÓ‡ä…xâs9)êÚ€≥Já%≈˚·/ÊHΩ>≈)sXoIi]«“N≈Î˝ü}“í<©SzÙ.ÎïÀ˛€me™)8µ>{J}
:Kíº|ÄƒñØN&ï)≤ÿÄí…üﬁíÏJÆIèn_Î”5_Ú9MN'7/ËzÍ–ÙË¿ﬁ‚TÀæNP¢7Y	ö◊Á√ª€˙ºª}u«%"ó›À;ŒLöªÊuvV"¬¸!¿éi	Õª@∞)Ji5úH‡M)obT(ãÇI∏˜q Q∏ùzê'®=àd#ãµ·Hk6Ç¢P÷F ©yÌ^ª'˛àŒézÇt~Ó
Ë%≥çÙü"µ∂Úº”ë)FTC˘2û—ÜëÜBÔYéÍ|à'|öÍ∑üzâÕœdá3ZE£ZDÉπp˚§NsŒ™Ø%§ ﬂ·vëÓﬂ9±nÂŒ¡=Á‘˘Ã∂Î¯ﬂ7‡IÜ.õüò´nü4œ›¿ê4#ádë·)#e F≤Q9=cì®¨!¯;4Ü	b¬1L‰{¬QC„ÿ‘Ã–d≤◊¶ÇqŒÂÍ¬Ñ´u9
Ú%¬-hüﬂT≤aœáOœãΩc∂ùˇÕ£/{o„_‡™œÕg}r«6ü0$ΩÊ%|
≥ÎaÙ"ïUQë“¯Y£X<ÜTEŸÇ“sy®"ŒX¥–≤q´'fè∑^À¬‹≠ô·,∂7"{ccu»È-»E©l÷¨zﬂ>\X—ª∫~≈B≤^yÌ'õıÔó¨]¡Ê{íw`>=gê§ê¿§Ò˘âÒ≥lÙÍP-¯Û-âô◊¡
Z!¸O∏`2∂Ã4äπ,äºBœqÑà¨!ÅÁ‰èôÛ£E‰äf¢0íF¬^acA¨he˘»Ω±ë1Z3z]x<RÑ>3øA˜‰ÔqG?ˇ@ØrW’˚ı”rKπuz˛tWØ–Kﬂd…)π›N∑{:©‡¸ÇT.”+‹G™≈K‡n¥LCxn*•G˚Ìûp.W¨ê„’Ü€S…À6√Ê€b/Ê·%y8œ(ÑÛ“∏‹òÊ®T∏º;∂ïË U*¡%e'$ú'ïJ!âÉ%≤Øø¯ıˆ1[%Z3ãµ¯É8x|í∆◊Ç,gÖxu≈q<«Ç»˚td◊êWwª‹B ‡õ&⁄5WmÕ,>äKÁôﬂ2ˇnÓ∆Ø·0∂ûY_c˛≠Ë‘÷üˇÈè'∂û%≈œﬂΩÅ
°€˜¡„/§Z∂Ïºi>6oﬁ:ƒ|r Va ∏\ä∂µÂBπÚ-w7ﬂm*‹çÓÖÆNWèKhtœ*ﬁU|D8§
•v?FƒÈÁiraŸ9	KÃ0T3≠Áv/÷Ω!/Ò⁄:“µêF¥4Ÿ€ØWèkÀV|´O<Çﬁπ•Õ≠|O¿÷∏]π ≤üœãÌµ5ısI]8(¯êg~›ı£tWe˝Ü÷kOf?≈Â_¸†~·ãë»w€Á^Jö◊ˇ|q«âu±äR˛√ë:õcÂGgœ˛jÉ√∆8rüª†©äˆsdÅódøË(pH8¥(«˚akS®_Epåqd°ÇT¨È÷ê’∞rVûÍò(Y&kîs`§u82ô–…ﬁXO¿	p		£ÉÁüi`Ô=_îÀ˙úç¡`∞>‚-…≠ìÔ¯{êèé‹ CYù´ôÔ=4˝a@ø–S¥≈àzQK∫í?êøî˘*yøLdç©@T\QÊ2ˆhR§´!ï®SÒ+ﬂÑ?Œ‡3˛õÊ2ŸŸd}ˆ√vÍQˆMfŸ∑€)·]8ÊEK%‡<·aU!ôä`/õ<≠X}iÚ¥&õ∞ïåÌÅlªºçÀ…êÓìEŸÿ0ÅXz[à«PU. TéÁ0f4hISX—õfáizt®<7NñÃÑVHD*+_—[
œSEqí^£•äèÃ‡uZ[vﬂM7)/ìW¯ìÙ¨rë(Ëc≈uúﬂOè+øßWîœ…_¯œË_ïÎ‰k˛_Ù¶b}ôæ¢Ï ˚¯tü≤üHj7Ÿƒo§= VÚ*/Õ'1~>ç)´‰U¥Cë<Jï-Lö¯0ù≠DmG,ºH©R@äx7ï˙D“ºº√(C)T∞HRçh≥‘¿A™¡±∂T∂ÜUñ‰¥¥©÷∞lÿ ¬*K†Èò°±Ç*spNb")H+ÇÌ7#<q\ï—ÆfXCqzt∂Q	≥ËºLi«ÁsO‡t®·	√YxB,äB©$ó⁄∞-ç≠˝,Ä»€ˇ|<¥4‹ÌÀ√BçdH€d,_ﬁ^∏¨Í™Ö§IÉ·ÄªÄ">B5•la√X´{a3NdÇA-r[ãjŸD6)ÚhŸ`¥k	 œN¡h–Ófw˝wªfzXÏZƒRŒvXEÚËPü™74t≤Ìûƒ¶(
&m0fW8´Ìo‚˜ (ï˚f∆¸¬¸ ¸á00‚·æ~‹¬ˇ¯…ÎÏ"≤ù‡pÍ?dWp”Ê÷'Î«í%Ÿñm…≤≠`[ŒIHîC uÑ@ IÅ4göï%!ÈÌípP»ÓR~÷&∞µ+t¨åçélk°ÖmÖt@íAYÀ÷ﬁÌ ±⁄±GóñKÈır]z´ùΩ≤3ËnˆYØÙI∂•Á{ﬁÁy>;,3∑Ÿ9‚ÒZñë®ùºB‚¢3õÃÔ0{…éY•ˇS9iñZ¨∂®›ÍïTˆØÛ;øBwOÁföÍæ÷¡MÉêKi”•4M¡A…ÀAË@Á~åÆ!·¡«è=r`UÁ[~˘ cK÷//$G•–Øw8=…´ƒX™•ë6Ú,¸19yû«ÉÖ∞)cWÃ^càÓ¥ur«ò£¬†vZxèa)+≈ Vâ-™Öj;mu0N∑‡∂ªÂBπ}ô}ã–Î¯k€∆lSSw3ªï~ïb$7√ŸÖ’¬·	aø+ÅÇ<ÁÊyŒŒyxY v9‹®≈=Ë∆›n,2·‡<òt÷»≈xèÛıÁR'®Û‘%ä†∫5‘ä5\yæéZxÓÜ˚®ôÓêòòLò∞•iq_éêSå≈
£	°œÒF:∫à±¥Cˆ$L@K“x“í$ªBñB\”úŒ˚®jœ·]wﬁ›1v°•ØÛ’‘œØlZ≥æ≠Ú⁄ªùïıÀ#øªIé÷øΩÎ≈´Åy˝«S¢≈«„°‰!À™HÛ7j◊q§©Cµ”üC¬(@óåÖ#Œaıtﬁ≈bÑbÑ«m%[Û6S€¯ÕyÔsW4.ŒÆ÷Ü„⁄FÆMlu‰µlU˚’ÁBú®ôZï5K7´—™¯Ù∆p£v!|A#z¬=⁄ŒNÌF¯ÜFEŸŸ|$—bºÆ’±u|Uxâ÷…∑jΩ¸w√{¯Ôáè∞G˘ó¬.Üex*Li
´Ròk,O π…k(AΩÀã∫ºáΩ∏wo≈¸–øú/6Àè¸s‹l92∫∆‘ãëÅ`M∏B:?è¨ËS¬≈"ÊÃfºwße$.YóÎË‹_·¨‹A«	pı:t◊ôô@eŒÂŒ◊≠n>âÛ‚+ÕŸ[Â¯jtìjz¢ìâËx¶näéCüg˙7mèa¿√Ø.<.Õ‘πbaÄ
Ω5$öGóª„ÉbåMÏÊÿ'Ü¿¡cΩÊ«5£~3Ø¯å»zÊ≥Û˘≤p‡X√/	WkGÿó√,ñàˇ7vdKféJ”ƒ|óÈÂÂ•A"≤h „ñ%"Õ,3Å’¢†Ô¿3˚Æ–G>mÿ~˜e‰F2ùzœ’◊∑≥¶®`:ÒŒñß¶±◊S∑SW–Å}ª{ıøX∏†©˜∑›h˚¸mægCY8¶gµ}Á‹ˇ˚£ô¸* MÅ¶¡ﬂµ"¶ò(&ònf≥ó°)D‚ŸÑß1+#À>b;â»a4«`):àä±Ìf¡°”"4‡›¯|/N‡ä5˘ÎôYil>â√¨§˝=Y	õ•≠U„3öTô6^œ2”›—ı‘J‚È‘*bljÍﬂã04ùeiÜª≤boé`ƒÙk∆"[ŸyÇ¥–IX»Ã~GnGÈë Eõ¢Ü⁄BYiYpC`$kEM†ûÌÜç¢Hå«¨ÏÔq~õ¬ÂS4mb‡$ÚtO⁄^e÷o»¨«88F¶¿Ωg√Ò≈∏©bÃT9ÊúÒ+àTozîÆr¿Íx√|L,öˆ”&p)y≠CqÙ Zõ¸Ô∞4&œ‚U_˝&y˛πf˙¢êXÑiX	Í16“>kÄT%_≠y†&˚ö„∫ì)W™ïár⁄îˆú˛úgï˘é¯F¸Ù˝…œQÔë(E •Ú=qe+ﬁè°NQ)Óu˝}ÆFJÊ:¯à-‘#F86ä™wEæä‡ëj’Ï»b¡Æ/T¶:‘Íó*°™®3`‘\g·ÿ⁄êp.~lº>=4åo>E–œòÁ“Nß+\Q WÜ€ñ57«öœ‰ÒÒY‹aûã6IÁ|ı:“[ÄÉ?,FïÊáñ—u’ÀÀ]≤EVJ;òY™lÇéÓôHòq1ö9OBÇsèù¿–”}ûVÎh¶˘ÜäT‘ü»å`ëÈÛg¸™æ&ÚÌûà∆ò@ã‡»±'a6$¨AKM)∑∏%9dv$Ei·tWVîW@ó¬ ôÆÈqC€¬Pyjùé^~ÁÏpù≈üù∫ms–ñÂ/$^8◊Ù≥gﬂ\—–U∑≠/ø©hÆZ±¥‘a√?,¸È˛¯û3©·ßû\®P¨’’Cªø˘t] ;h\∫ uY,ÒÊV.h*…©à¥‰¿Ü˝È¥¿û¡ƒÈ)cÆ-V·_Ê«≈&™âmíöºÒ¿øh™åX¿/pï˘óu|ùk©?}êa9‚0ÊÉI"i∑9.õÕé±r»ÍÎŒBYé|‹í«|ÉC›ÿSO’≈º{*WN$+?^)"ì!&‡mÊáX.i6lmT€&µy;d"é%¢f~ËDX%`π(WFÿ ≤§ÏK•í#ÎN¢^”õ¯ﬁÌ≠˝‰hÚ≥˝©õ©/Sü•˛∂.~ü˝b}˜·„ßÒº©Jk·ŸC'(ÿ£±Ÿa9hÔ;§>oØr ?¿]t\Ù^u\Òﬁ¢nYoπny¶(◊<◊<O≠X+U{„\Gœ+§
Øe+π’>@ˆ€˜(/âG•Ò¥ƒiÜ˙u≥û›∫P õ#JñûÆvßŒè"c3—i√∏3‡:¨t/ttìÄSAôFÊ(
aEºπ√áÍ!√˙¸t»≠¯ö3PÆ4Ì(±r":9?öLåcìì—(‘å ¶iΩœ∞™ºÇ4Iáí@EbnÍé∞°æ£o˚£m‰éN˛˘VÍí&∆>¬ˇY≤zÕæcÁ≠Î*zmÂ ≤gˆQÊq`˜≠ﬁÏ5Êàq*Œ∆≈[~‘òbòÓ¨Y¯|ãŒÕ˜ËJ≠•ä´ıT)∆ù¶ãÕdƒZ∞√T∞ræ¿Á ì)v;Ê{∆‰N»™®Õï˜û∞Á?tWpÂﬂoﬂè€ª›Ω€ΩΩ<.9ì‹Êr‡ÓBM	‹ÜƒE!Ä¶M$&8í> `Q™2ƒB— #D	Vã∂t†A Å:0}A«ŒHup:∂ß•NÕ@[Trõ˛øΩ»8MfÔøèo˜˚æˇ„˜˚˝G≥„b;Œñú6Ç\ë;ŸN±SÀf€⁄âTÂ6®%ßA@>UË%ŒÕ⁄ü∑wn:øxÖ2Z¢˛…%õ{ñ˝Ÿæáõë¡ãB?$ï±Æü‹ø‚ı◊éÔﬂ˚≠Ö˝Zê+¢ ˝hàP†N§Í=BØºSyÉ9 ûN Éy<@≥…˚ÿq~¯˘{,Ôåx÷ÛÅ¯GœÓ∫,¯
tB∑Ωj ßü“ﬂ’)›ÕÜp⁄µﬁ XÚ˚6S≠—€Ó%Ω¶ÜµÃ±P~
%5è),NπˆÆX÷∆'g≠Y‡Z€p⁄.%Xvõ¶Åõè–ífbwóJA	=õDâp[xex_ò˚"º-˚R‡∆±«[qR]É‚)cLª<ê6Ì∞~ ÇMå’ÆIg\©£¡"`ÑÜÉ¥Tc;01`÷U/Ó<–™Ò¢Çÿ>"à3›À⁄Hö	#h´;Ω◊/yÒ§^<Ω◊gÓG°Òà«ApÅÇNb&\hÅpäÉ‹¡9NPW˘≥ö'H~ÜÃir˛˘L'
º?Ç46cSO/ô’bQkõ◊‘ ¥0—ªˇËéêqÁåÛˆ∫≠≥—∑û‹PW˜∆
‡†ñb–û:çFt±R¨6”›&√”ßLR7T2†™◊Ô#Ø
xüÑ⁄§qâîp D©>ç»¿óaæ{>Õ˙¢êLÛÛ˘Fû‚ÀïÑ⁄¶íÍ ¢mŸÎèíÅ6¢ﬂ8mêŒ	¡ì2B¡µCd'ëç@Í®û±VêA°KÑ	eÇ8“S=’9Ú']85»π®†'ıÄ◊≥ØzœöµèEÎfŒ®zÔ=g∏èé6nÍYT˙k•z¡‹c«©9nÌ;ËvWA$–<˚—'
ü-$5è‹UπIÓÆ§ãt@‘î$ìîçÍ»:Ía_s†π¨)÷°˙¶ÔÜz√ØMóì∆ÙÚ‰$ê˛∆‹Ú˙IW=ô†∏8[Ú»RÖG∂ºFPü,{@úö•∏é∫‡&∫Wuì‰à‰…⁄Úälîîeme*[ÇûÔÉß»ga„'cáK:gÜÿäòÕ31Ë°P^ﬁˆJT	4hãD≤4¢Ö¶‹Bük9¸QFîÃ•	≤ \[ùï‚¸O∏ãs'Ä‡∏Èã∞n√ù\5>∞^ÀQ‹*∑|ùÅŒ≤Â±eÒŒãY.»¡	ﬁØÀ%p∞*-YRB¡∏çeﬂEµ|ay”ä/ï˘Âıß?X˜(Bß~”ç∏ô]'∑;ˇ˛Îÿ∆ˆÂ€6w,›ÿ`›£á#Fe…#{›~I(Ôg/ç›˜ãﬂ®⁄Ê%7æ˘Ú˛W^Ôúı(ıf¿uÉ∞„>TÑ™q ïYhñ˙Ù_$på¡îí_S;T!“P5? ë;µê‚QË¢AíÂª∏4uH@„¿Õ„Æ“‘Ã~ìÏ2Øö‰ôD jË.l¡ÿ~]’ë
¶≥éá.™ÊÅL úçÊÆ\¸}úü]y≈ª:ÿ Ñ0©C*ß\∫cÒ)˙ÈÊ∑óÙÕ/tÜãÃhXëtÜA¸}ﬂÏÆÕ€3;» -Uı[6e>ÅMCnøÖxN)ËUû"XYZ”∂–(ê›¬a·¥pN∏"0EBª∞AËá≈rt¿b6qé¯ﬁlMƒ2,Gã$úÈÊb§4Eá¯‹ænÔ#Ìñ'≈(xGYë∏:Ó«ãÜ„ErÜQà>ÜhgÏÊWËËÕ!B[ Bm∞Bâ¯œAç_8"´i
œ±.49≈Q
Âg-a{H<%ûﬁ?≈ET;E ú)4∞_Âgôc¬EzÑ£?eôy‹<~ªé~ûﬁK˜1Ωl/◊ÀãE¥∆∆È8S¡Vp|BûKœeD–§Ç("#
KKÕ¬.	I‚9ëEâ$ømÁ1	æ∫àC‹Rôî¢®õ@E∞‡ê'˝TNb„}áî—U&TÓqàl$·w7∏£·k&™â?; DRDº∑P}5(j¨≥]ßnA!4µ8/°gú?8ündNåç¢«ùÔeA∂8aÍ€—\4D0‡£é%”»ê›ÃaÊ4séπ¬0EL;≥ÅÈálâIFE15"D!jπ8%≥1bN|÷ s≠'v7†¢Ö¶1xªÊÚË¨·IQ)>e¶JÍ…{˘{Õ˙O1ïà-⁄c›±}±◊ÿ‹è=GŸ£û√±s±èb^"ñà5¬ÉS±ã16fÁ§“p›Ì>d∏ÕÂb⁄πàÀ4ß®™ï_PµDH=ü’Tª•™]E+!ë…€óó-,Ä{+P{*Ä{oïE£V\aπ"DHckOÉu[0‘≤k·®Å£‘JYˆóg§÷ª÷EãÚYEV∑EV±5≈∑h+T˛∑öâ&*âÒ,V÷åﬂ%çÆj≈f¢t∑|”#∏ø≈ÿ˛\«¥Ñ‚˛àé˚£†€%∑î≠[•|ª™◊#jÎÈe;ß4º∫xÕ´ÂP€Ö÷ÇÈw;√·Ù¥⁄é…Œ0›ÒÊÉ=Ù`€‚˙›ôf≤Ìïªkfo›Èêd√ﬁñI={2c≥Ì f±œ69–ﬂ¬wÙ ç ZJ=_Ô˚XaX⁄TŒ+≥I©J¢®A∏–F†q¯»ˇÉ6Qäzºÿø≤ÏπÖptXÓNÑs=ıêÀ∆Ñ ç‹iÆì ËËfg∏tAıúÔƒ(ò≠Ô∑ˆŒ/"√óﬁ”ÿ3‡——æ∑Í:zû¬∏∂Ùk/ÏTÜngó=˚2ÊØ˚ØÎÙÚ2Cj!&$êÕJìø…h6wëªŸ›¸.œ†pû¸Ûg·ºgòf/À ˛Ú˜ÏØ¯ﬂzò5¸∂áßT7• vQÄÊ’\^{~W>ôÔçw¥'Ÿ&/+⁄'ÿOËTñÅfÔ4iÑ©µ˙Slã––‡ïFÀ>«süÀÙ˝•úﬂ}ÚÇs˝9T¸?æ´56é´
ﬂ;sgfÁµèŸŸù›Y«ﬁùµ◊kØo‚];ÎòÏ§8é«µÛ0çãå≠4JhZÉBLÖHZ™8mJ'i‘6VÖTì ‚ƒÜÿ<$S"®m$í`!óGDTìàzósgÌ¡jÊ‹9Û⁄9Áû˚ùÔ;}Ë–ËË°CßÎEÃøP∏˛˛Öü?Wm||ÏïÒqÔ…¬Á…à◊˙‰úΩzùø√œh6ßÊ¸ôHªE›‚oã‹èàT„ÆËñE·~ƒÎÁA=îeØ«Ω¢g}5n∑'·ı:BE˛∏¢Ì∫”
Èùˇ/MÎÙ&⁄Ô©¶}@ß Éô§1/ãZ*U˛ıIÃ7~ˇs3ò)|8≥˚T7Lq•˝{û=˛ÿÅ0µ={ø/,7€{ó˛ ŒL^|uÚç◊œCAé ƒ6;±è€…3›x'∑ü;Ã±⁄n˜g›OiD=JÖ¬úRä
ìW∫Fôféÿ5Ç ıÕ2ºîD¢WLãOâD4èjÁ5f@;™]“ﬁ÷àÊE	Ã:Ò3Ã1<ÜˆÂgpYâÑ=PŒã˝·ÆÖL@uÁ÷ñR1Ñ:'åùùŸÌèÓæ,≠]yà95˝!Â}xåVÙ'∂ˆ=≤˘Îw4êƒôÉmŸ¨ﬁx°ƒòÜzˆBåµÃõˆ,Ô„„Æj√gƒœjgı3’£µ¢†∑Îåˆcu∆}=ˆ^¸û∫hÒ5jØ∫OïœhoX3ä∞1nW∂%X{#⁄à~‹˙Z•ÿúÿƒ∑À[’nO{Ï!K∞*´ÕJ6ñµ≤Òl•¿KúOåÖ‘j≈≤¨∏PiŸu_TÜı/æTs∏ˆD‡π⁄sÅ—⁄)k*Æ√ßåC/◊~∑v¢é7bA;œÌ≤äLEˇ(£+÷Su™ä©≤C´2UfEP∑ßßÎpCÆ+è•Ωÿ€àchôùn)ı%QÖæîû¶)ˇ–Í–ùeIQp¯*µR;ÀcÃ„ NXM±ˆÿ.‹gÏ≈èãX¬CÃò≈$˝™¬$ÕÇI{RÓ1±ŸÓ@3¿FÈÎ ﬁ?ôAVÒ- ∏c”•—ö.ŒMñWRn≤¢≤‰áM«∑#ppP≈MVªuV˝∂uÕz◊‚cñ¢b¢eNè)ªü4ÍÛxY :æUï°£Ω
z¬il„LÒ1ºÄYÑΩ‡b‚‹È¬ù€]à‡≤@B–ÜWﬁkÿR√Œ6g;µLUxØ«®0å'bÙö6†∑«ƒ=f—dñÉJ›Ì/ı≤˘uÔ¶ñª’§4•ã}%E5ø˛~G÷Viã≤ñ˜$¡@˛ˆC5ßËJé^Qrê°€óÂú#]1<xËØ
:§?≠Æä¥Ì~\IÆtPA–
u–â46µCè=—\•∂æ˜ÈØﬁzÔ÷ª…¬?}ªüLGÀ¯g}ªÔæs	7§vÙ&À¢›◊π·S/øìóNÆŸPE0^(€øµÛ¯∑~;´®¢¯Êõ‹´–~m◊DH7©∆”‚ﬁÍÓÛ· 
±¡ 24øéç—qàIPB4›då;√¨¡ QØ0ÖÃI‡
ùnE§*q PÇäÿdàMZo Øü◊/ÈÏ†~LˇÜ˛∂æ†sH˜ÍQ=≠=lè≠êâŒâf¿âıÄ3H/ŒÆÎ+)‹ª˝≠ﬁªé¬xƒÖ[ÁÅF¯ón?9´;95h“êR_<€ò≠Ú1Oœ ’e’[C{æ≤ÌÈú,>Û6IbÆ∞ÎŸTY‰Vm„ˆMkFÒoÊﬁ˘N·y»œ◊evíÉWl„ﬂﬂié˘0ﬂ ¥˙:ôNﬂü¡Q>>"ë–uI‰˝z"@ ›Aá%q÷¸ˇa	¢Î#z‡¬.Ï˙ﬂ®‘b>∆˙cYﬁ	3‘¿	ª©â≤∑¸ÙÒÉ∂·p≈é|«jq¯|Ôûœ\8ÕåBs˚÷wû«≥ ) Nx–£ßå#vÄKöÅû5 0~7	£#f¢fKÊ¡<+ª\í"Ébc4÷M…BıÚuYÅµΩ`WE3‚dÖÂ*T+gPã<Çƒ$MIXUúw…¢ë!âòG Á[aSîÊ"∂&#â»í(2Ê·XÃ©ÙâPY2#´jZµU¢ÜÈïÚR7àêi&mÀÑ……$O∫	K~ƒ§Å†≥=J·(@ã√ 5®≠0-ÆT®ÎN?t™˛√õˆµ˝…Ò~J…©ñ√	Œ“NA√¢Î~1ÛMÕMÕ~ Wªpı/ZﬁÌ˝é {K¸¡¶`}=S^ ©z`‰Ta™Ì5êY	Òå$pbôr‚„LAÀ%ü¢h)6≈«Âõ„;ÿ˛,{ñ›4“·∫ÕêBôéà≤Dî2Iê”≈∞Pî8JíjÆ^LJ’ ‘Ãm€—ff3◊!lè†arÑá•# :AF∏‚	iDπâní‹Ò¶tCπçnìyn^º-Õ+˜—}≤»›≈˚“¢RœMﬂ±≈HKÜ$¿à”≈[é'QOYπÜ®«S∑–ÚòΩ
£lÉYûb∆LØÉàsÙi dõz2 .@ât“©&†àJÒ–ô˘©7e¬Eßã]ìº$¬∏Õ^À"%
O±
b0QXNí—≈ªÅ„°ı°HP(HjpÁ›åä¬µQƒnÖú?Ådÿmƒb˜Tá’k3ÿ,q3‹µdÜññÃR®T®4˝˘eç‚mu>6ücëœ˘J®To√° ä¸S≤≠Ê ‚{W‘|`_∂zf`ü-‡Õ]ë©7∑“ú.By≠/?›påeq_a˚Æ_≈ûÀo·@·b·ÔWß†∆:òi∫ˇÎsq©™Ã]ÿNv@ï˘qfJKrÿO˚nHÒd\A’ì®·©·Çpé°”P´d)Qe7Ôeêü'~Ü¿ˇÒıÈò∆ó`Èy‘wEÈ¿`Ä]Ä%ÓtÂDÜé∂VVû	@íIéµC·ÃQñ¬ì^-@Q]g¯ø˜û{Ô.DX‰πÄÄRQÒÃ*kHç—Òä±îÿâ6£»Ëhfƒ4ìF•Òmjõ6ßçèiÿvS3£¶aö1%ÕXõ¶Xëÿ⁄KÄ€Ô?w/≥Æ∂∆dgæ˝œ˚¸Á;ˇ„‹~∑*k™¢rm∞R@˛‘	„2(ü_…qo£zŒ¨>/˛Ÿ˚$Î995´gy∫ˇéÔÉä<õzx_å¸2î‘õQSn^1ÛUí¬$$Öc¬C-÷ux˘ı£öGy ørôÇuÎä?jPLa¨'÷ãø¡IÖ∞ÈÎ«Qayu{≠rõn3JÀ6bŒâQJNˇM%≥K—¢KÊ{_µƒÍ£‘˜™ØWTMsqPm9Ÿîé∏9K˘!ô“®€ø¢ª”•FäëóQòQÌ™v◊∫÷∫Øg∏GâIb>5ÖK(Ò	1j‹‡Ñò®ÿhÚD≈*‰Q„íá§%¶¶$G'*˛D%±¬õDCRçh∑RÈ˛ß€rknN2˜E#5¸5:R©åT"—+CââFf·æ°9FZJJl\Ñ7-+)/•0ev “ë2¡=÷5“√ÈwPTlñWI	ﬁÙuvÇ±ÛiØŸ4È≥
ﬂ@j©Òı’»G˚ç¸±ãﬁ®®Òi∫á{}¡4ãæ`∆‚µ2pèèã‘;4&S¡#Ω±`ﬂöuµYES&è?æˇ„F-^Ò‚iBKû{vﬁ7ﬁÙÃô˘óﬁ◊¥Gï'—ﬂ˚≈ë≈ÒSΩÖ€Û˛á;]J§Hy©Ö©º¶ﬁïWyÔ,&'&2ã…`1±0qv‚R<Ô»b =≤¯%yª#g∑Ò’˚öﬁ“3ç˘›o◊uı˘2≠?∂2⁄w√Âu…û√ó|CXû´vˆÙÙˆy»/≥î"g Êî˛b*ÚPOOœSû∞uâç7ÇMjAMtR˚=≠µ4òf°r˝-R>¶«–∑(“ÜP™8B•øıZ»]jÅ’áÒe¿a`,0»ÇòL≈ús@÷®‰u§ºDÀÕ6öåΩÿ|xA/£›Ë€kP∑cØmX#Â}h?h4—î–_Œc•‰˘e4˝π(Ô“À,À¨'mÑr⁄∞ˇN÷2˚◊äZÎ £∞ˆ£ËﬂY
9?®oí,_‚9Ú¨|∆-\?uhﬂÃ∂ã¡œœ«ºt‘ÎQéÑ^n»˚Ä(A4c|Ídzr4ˆ/
ûõ‰πqéÅ3A©”ùQ ˙Ö:Òπ:Å6‡ù›¬QjÈam¨º?>Û ‡Aµç/˝|.˝≤ı9v˜>Œ’
Ë¢öÓwë’=ı‘Ä˙¿'QKäh§ïZ7Ó‡=eÏ°£ùT≥˙W?°dc8M±˛‡q¨yZ⁄C5Î`}ô..„}TKKÅÂÿ˚ú√sÉ˙t‹ÎBåÌe ØœOÄÉ`5Îá˝Ûòs‹˚ÁJYˇ+˚!ˆô…¿ûÈ8ª}Ø¥Ûk∞ñ"˜±Ô¡ñ ˙óÉ”_ øﬁ`H;BÆ’Dö⁄d}
$m¿∂7`)P¿c∞∆GH{ÖÕ∞m≤}∞mËg§≠Œc›Ì3H_ÿÙô'11‡FGË± Fb,ÛS≈6À˛‚¨Õ∂≈6„Hi”+§›üÂs≤MÖ»Ù Õa‰æ∞-G≤ﬂa›ı,µx©”~≠ù∂≥Õ≤Ω9íya[cdü íê≥Ê}$Û”§≠√Èp1 ˇ@˚±fô±v⁄E≈‚koS±ær'Œ˜:⁄p—éñC≥] ∆]Œ∆‹}a≤Åa∂+À±◊Û¢\¥”A…kª:L¥+∫ﬁluÍ§ú”õ’:YæMÜC	ÿ},°}˜⁄˛U†æß7”2îØÍÌñÖÛÏdü0ªî| √ëh?<årÂ(Æ I≥î<Q7∞R¯iíÓßâ"@Ö"û¸‡i8⁄KçGd‹›éıœ(]Tè˚zŒåßL≠±{©Ô!? º>‰¨;∫≈Ê¬m…ëéΩÜK∂éªê:§~◊¥Ç¯–{ú<¬πÅ„≥Ãà—@ΩmØ÷µ˚<Gçê?tÏ3ÃNGÖŸßnó·ís«wô[‡ß–£ﬁ9?«Géq#9ŒqÓs∆áÀê˘ª;˛$„p-
˙u6ê‰açS¡8“äoén¯Ë„]´’,¥Zµ∑¨Vcüı3sÖu÷8a5‚‹Ÿ95`«2ˆ''ó2Oúù<™g—≤`<€/«bôGÀd c=¸o9Ua›∑9Ø≤jç;âıû/”˜DmáÓ—⁄/Ìv1èä9&äµ(£1ù˚#µÌ≤Æ¯î÷älî_Ü<@1ÜIkçﬂÒ´M∂]≤˚∏M_D{awyb˝T?J˘Æ¯ÍxÎ-æ{¯|≤Îi:hl∏Éˆãú9Ä3ûëÚÄ¥'û{‹Í·ÛôR¢Æ·|<‡9˙A Ú±GrêÌñ6.xM„èÚΩA˙˚ˇ#⁄‡ä†˝ÆàO7(ŸD,ë{•.ø‰]»|˝/¯Gl¨î6Îq÷§˝±,≠>‘ˇb(Ëã'ØﬁE‡Kõ%?∂‹ ˛£uQ<€Œ7_æ'∫`„/—j£ô∂ÿ];rA;Ó≠gYA†ºC4[_`Ï∑∞Òﬁhü#ﬂ'úß¸÷;Ï/fÄíL?ˆ«÷Aæˇ∞Øv˙Ó¢Õà%S]]ÙÉø¸H·Gcö˝4ïœSÆoÍÄm6dõ«ñ P¨±Å€’«È,¥Pâ,Ö}Aºﬂ;@SµüSÑXÜ˜√UzFÕ£MZ1ÏÓrÜF∏.ri§vçfj7e˛Ÿ§G–D9.y¸
ïàrÃPµ8F’öÖr∞ˆày˙IZ§Ô¨%X'uÊ∏©ƒÿärûuÑ«…=nZ	±û∆»y!ê∫:`ùáËºß˙>ÏÅıE9T_÷u@œ†éw“Oûì◊≈<9Êœ4<]Ü€≤éZOÕ¿ãÍº√TßÏ±Z¿Î¥0L≠ã:e3PQGá GC^⁄ÅF‡1û~ÄµﬂÄ<Œﬂı7à]êË	¯5Å”
ﬁÁNÌ°Y-°u}0‘\ƒÙ‹[˚‰¯C4N¨CŒ∑Z⁄Zä`Qîm∫([Ì@{ÊÖ’ıë¥W¨ƒÿπ§›Mßˇ¸ÚCxÙáû—π»Ñ/Åã!2É%¸k4ÁÁØ£ﬂWÓw#]…ˇãÙMiCW&7≠” )Z¢|hı ûªN…íœC„‹⁄7Àˆ∞˚É≠L`Œ√€Qˆ1úz¯Ωﬁ≠éuüÖcÃ1‰gà0Ø#¯€XÓÌıÅ}ˇÊ”84MÃá.∑◊Â1‘U®7†ˇ#¡®œßlèeÄ€L∏na®4î°ÕEﬂ\9~
#Ñ◊ÖÃ´ˆ_ÓÀ?∏™‚ä„ÁΩ{ﬂΩI§F)hHJ EF-àì*V®Vâÿ,êS-å∂¢‡8:ÿ¢µNÌPƒÄ†Âá°G§¸–0Vjk;¢“Rp†PT¨ãu∞•&0UíºÌÁÏ›õ<oÚÒ«?}3ü9ª˚ÓÓûªw˜úÔn“æ∂ø˝>Ò>O~˙äøôxÙöπJJì6˜Ã&œm≤-é%]=ì8gÊÛˇ	ŒŒã∞˛ÙÖŒ√>O	{é4›_–h’G∏cnóy"msDZûiùB"∑Æß≠öÚÏPB€4,Ÿ®ÂM 7Ûﬂÿ˚erõ”ï˝®èâ˙∂≠r„ùı◊~GP;-#¢˛-≥a9Âù¿.kyª{òÁËWãE¥Œ¬ûE˝€¿~h›E˝| Ô∑éÑ˜ ?[ë1≠√Èøf™È‚˙˘⁄<˜èOjÒq:|◊jN¸Mﬁ!>±çøg6y◊àøO6æKt≤n–|/*9wünÔ8±Â{~‰8˝{Mö2¥:-k5∑ÍGg≠ﬁﬁkıd jJgYOı£ójg’ØÿáÏ=Ô%¸πE.√ØÎWúGrbkz®\'8à{R…3ªÒÁ?ƒûbÚÎa¥ÂE¢ﬂ‰≥ù‹ULÃ}6ı{sªÉzrYaú”‚ÿ⁄)∆vŒi_h˝hs‰ß»©ó;¶%à€ß:íˇwú§$sÒ—“SÓ˛‘π<OéŒÕ”üµÁ˘ò¬Û•B	/¿Ô:Î“§Ë©ﬁìŒ=⁄zRw‰‘7(›¸oÎI]◊ìt˙øÛﬁãÙL)Á-&qÓéŒÈhˇ&Ûj|^cíÁ∏˝ºπzpß\cbõZ-ßGNÉ:wÔ:ô29–‹Æ˘≠†U*
÷Kıß`csLmî˚L]Í◊hÈˇj»…ﬁM=ÙwÿgØp‘ˆ¥üì˚Vıπ’á¨ôı}ﬂ‚êáQ–6¿çÌﬂö;$soı»ºzœıﬁ1áÎp>-òœrœõ°˜=Í≈‘ãâ≈e¡)œlíÂîgcã∞Eƒ˜ip51ª:≥≈¥O⁄gÆ‚ø*ˇ5GúüöÒ‰&ø—¨#¶_ì)·™1C–‹	!}ó“˜^ eÿ‚†,fúıÙüØ9 ,!6Kup°î”vüÊa¯>œ~èµ˝N˙-)'Œ‡øgá”ôá|úfsÃ±¥ù‡Ô’(#°÷!ß√π¸˜5∏“;¬ÿ+mﬂ˚“ÁIÉ◊"˛z©aºßã÷»¢¬-≤®Ä˜)¨ë˙+RÔœêãF ÓoK®/‘|ÁU÷>ó—nk¬˛rÖæ7cv∂*~Á§&∞˛ç ÆûkVÊŒ˜+®dm&˛[d	ıÖ=i∆9Ü¡!ÿüúOs≥◊ﬂÏà¨¸‘Â¯Î⁄s~çåeú3)µkªBŒO≥Û-∂πöúùÈ≈8Ω¨Ôvçìæƒs±.m˘¥P¨M`å›7ç2K˜ı≥†èk´≤∫‡BπåÔu9îdfKâ?W&§◊òÕÌœ†ôt˘;Ìûù´~*∫ø‹û{0Ωö3˙™Ù—≤øG‰›Ì¯	˚tïÆ≠@Í¨èk·yˆ±ë	¨’˛8[Ìò˝˛ZÊRX/ı«±‹o˜g?∑7À¸Âµ›3ΩyˇBÎÎB–µªô=:¬qÒå3[ªVX˜πrπ}G4ï∑ñ}À˙x+–Wçre¸l¡7•*ºó˝˙{gÛ^,Ç%pHJÇ≥—ásyÔ1Ùù%s“HÖíöoﬁN˚îqDÒD*|î9±GRÔ UﬁvπôıZ?ÑEºO≥¢œŸg◊…«ÈJzMjˇ?q˘ÀQŸ∂ΩËhv¨ ÅÁÃ[–í˛sb¸4~˝;Ú…;éΩöÄ>◊8<Ëè˚”¸I¨’«©LB_µ√ì–Æˆî$ÆΩ4	ÌjG'°}t~‰{.ü˘⁄á$°}»Á‡GæqONB˚…›¯wi⁄/=
?Ú≠Û‡$¥Ó∆èqIhóÙÉ¯Ù<Àı)Õü‰Í€∞∞ÁaoÇ«)sÔ5S]}´{Ó˙Ùg8.Ç)<C>6Ô√C0æùÀÙç˙ƒÛò(7aøÕ•}≥œDs[‹úŸUŒ◊ﬂ¿osÍÍ;sgﬂéÊ≥s„Gˆwëé1À‹Û£‹ºèE~gOƒ˛ z^ˇ◊w¥˝Î¿p¸qºMﬂmbÍ{∂ÅÚ/#Õî}⁄≠Â hﬁ6Óâ¶sˇœÈà≤ï{‚‚·LÕ’iµkmÃù&}rrï’îÆÒ.¿ˇ“?@√1FëÍç·ˆ>I‹∑˜…ó—'hÀ`Ú»Ío1∆√Ï√câõw…©:áˇzÖ±5Ô™Êˆ»x≈jçM6W_®˘†Ë<©F‚”!)e¸≤pß‘ìâß—]ˆòzÍ◊°;~$5A(3VH]¯
ˇ{r1˘™2nèÔ∂¡›∆dÜ 1±=f§‘˛Åˆª–R•r©Œû-’¨Ÿ9Ò‹ÌÎ∞NÔπˆªÎ˙ØÅı"≠_ÖÀ¨œ¯ã=[fs±j']ìm2Üj˛d›é˜SÚ•‡DŒU´ú¢/6 ú¬¥,ßúŒı’uÌk?Ã; }É›24Û3Èk◊˙Qôº∆∫ﬁàñvñ¸Péí3ÎxØzYÊoe¨zòÈ+˝¨vÿk«él<∆ÙÃYŒû(MÍöXGµÎõóÿhÅˆ9‹˚®’‹ôÛ˛÷ÊËªÓô2…øAæÓq˙0acü¬ΩRÏµ{`≤’_ÁÀ‰vrÎzπ8ÿ,ïôJt˙X©,(ïÅ·£“OıY8ïΩ©zçîaôÂ¬7ï|ümÿ[°¡ùÔwÊ^Üu.vLà⁄ÌŸ§≠môküw¿¥Ë˝œ‹ï€F„€ˇÓàûo”X≈YKq¢≤më;≥j9gù[MﬂŸ:]/ãúnÌﬁ&Ùg>´gòÔ\í£á#=ŸŸé√éäÎúœ›™ÂÃŒXG'-œ÷[mg≠9‡Ï>g∑Î^S≠ó¥9∫∫KõOøvËXwŒbÈÍŸylm¨Ø{≤Ì˙;èm◊Î=Ÿc4N≈6ú'°j–ÿ∫8÷´√:]ﬁqJ⁄–io8´˙˝÷}gn\wËæSÇf”4ÁZb$x&GwAPŒsÂ"·„¶)|º√Í]±;Ç˚Èw?˘eÄi*êk•èÇœ"ÃFÿo¿˚$lÚR¶…K1œB”ÑVœ±‰éÖˆ~2°+ÇzÊ≠gûjÊ#äá€ó(†˘Æ;–ÏfÈwç}«fÕÖ›≤ìyP˜0œ=Ù9¬<G¨mV‚uè◊1^ﬁÌ]˚Ωbü„˘›∏üı;2f]w‰ˇ.¶Y˘ºﬁª;ﬂ3[Ã.ÿßeŒ“ÎÓ^Ç5ÕJ¬Á˘÷Ô˝º#Ñì"Ù<Ûlì£ôu˝¸Mcî„yx˛©{Àc(Ã„`û‰>hv∏∫ûE%ÿo^	«ö}zºßÕ!EµTWÎ^kv±˜Öã±;È3›ﬁëT{ΩŒY-“¯Æ∏ÿ7®p˘ãX@y†Ê˙Çˆ∂ûì©◊|f¢ã¡+GàΩÉ'• À §`-w€^ƒ§øö˝
s›ÂÿÊXi?ÛGx!Zg€˛´\º3§\°<í˘ò≈‘;Ω≠:vFDˆ›®Ω√Ø8ˆ˙(aÓ∫¬ª]Õ˜.∂˙e)æ-ï24OùÍõ#äÂ¶ÃGS´˙CıÇ=∑»YË¬	éA¨Kïˇ ∫±Q&Zﬁ„πµ¶EQMdøS£åÀxˇM æ⁄∏HúÙ˛MÙ}ÕY-s¯Ø∑jCı†Í"Øëu$¶x+π„¢úΩG∞’æáΩC*R3–®oPnÄr⁄O¬ﬁ
∑QÇΩÆÑuÆ˝«RëÈ√X   û€YK:‚ÏópTW«ø='ªK"IK»k/Öd¬#è^†im{C°E‰!lJ;N•ë,∞%›Õ$∂:ñå≠J¬î¶®TJxKΩ´m^¥Å¢É’
£¢-„É°t¥ù—"”QßZ÷ˇwÓçELÎt::svÁwøÔúÛùsœ=èÔ|GúrêﬁÅ|ÒÏ¶Y‚ÚnY`Å€ ∆„≤:egä◊éOPñ,tıπ(;F!·ˆ2¿%∑l»¶ÓÔi~÷6ƒTy†=›Áµ“}û◊®$#BÃi6¿L^Ê˚–3nÖ›ö^v }Q<K1Fn@ò¡tü‹\È=I7y∑íÈ“Ωi!Óñ/ÁùTˇSÅX∫ﬁπ]Êª›⁄å÷Ù?0oÀ3Ë«9≈SÆÏÛù¶ ÃáqÔEîÖÆ”ê› “SØŒN¬⁄"Go›NDÊ}5˝WﬁkCqÆˇzƒø±‰.˙îÎã8÷‚≥düÎ–o‚µ„ùJuh	ßO∫ŒâÒ”ºñ√7˛çπ{8ñ—N{ymπ± €îA˙dçÿÜq¯ï∏uo¿ÉÓ~ÌÓö# f‡–oa†˜1√ ?êt∆ÏØ˚·[™°W_ù∆|.q˘óπıõf2~;&B≥‰ ‚Íú9ÌP#öëﬁˆo“94’?ä¶™∫wåúÁi#óaåó]ù∆˚kô+ﬂ=BZnß…Ã–zª≤¶Øı˝Ø§èqÕ~‘_Ãz˙¯ÅÑŒ`-ßQvkiÏ±gçÛ·Ôr|8¸·+Xw¿ﬂ‘˙˚ä”‚ÛR¯<ƒ”∞iÊ3Çc`ˆ≠à]Ws\*˚“'ÿœq¨®‚Aƒ\WÅ8>vâ∫ó’“'ïØÖOE_Np, ˜4ÂÉ≤>ˆ3ÏÉ<)˚Òg§ìHOr¸Îbv√ËKQæ¿ÒSÏÉ‰J‘Yâº∑ü•|&˚6ﬁáW2>çÙÎ.A‚$êœ:˝ {a´ü9óª¯lRæS8Ìä?·=–˘Ó¢ˆÌT¬{v÷HÒí_≈ò'ﬁù).ÑÕèÜÛÓrys°ú7’àiﬁFøÇÀ_πwµ“d>≥}3’}E˘Ãe·ï8üœ<>'yûxæ⁄i|J·U˜I	û[ÔdŸÖq˙!¯≈0π“Aù”<éøWæ“Cw´w¿«πÎŒß‚æﬂÒ›·;Èá›˝ÜÓrAwmï„€«9∏…€Kã›Û~ m_vŸÀpøèKMÔÉø`ï¥„¢É®|üly#q≥r/"ﬂ5@‰?ÍÈw»¸≤C÷ÎDŸ◊ŸÁÆ&Áóˇô¿¢1∞À+"7ö(òO4‰øI4<ÓPà˛·[äœï¸Ñ(Ñ16z&m'öÇ¸2ueËKy-—¥Ω3Æ”¸ØPÅ≥ΩÚÄF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—∏Ùh4çÊC¬Cî=õ.—-Ù(˘HPÄ™®û»˜ñ8N^§ârËûí¯wØz≤Óß>§<‰¸f{¶∏∫§<œ]ÆûΩ…’}–7∫∫üÓˆlÖ•'#ì€Ùº·Í*wπ∫†±—’%ÚqıË)W˜AŸ’—ë¶'… ì™ÒøZÑ÷Rr%(íÙ 5´úπHµ@ÁgÚc ¢%5·o–2‰≠A˝$µ™T2
Îx6¬“ÇC]∂ç)õêTÌ5¬Ê>»Záº≠˛/˙¬≠∆UãNΩz§bHÒ€Z≠A•ú7«ë[•Z0T€kU_ZÖ‘zî&UoŸ∫ÚI√¨Ææ¡à¨çãÒDÚÅÊ®17—“úhiH∆ÒJ√jj2ñ≈÷¨M∂À¢≠—ñ—∆ ÛV‹∂x≈t´%÷–TQóhj\yoYJ7b≠FÉëlihåﬁ◊–≤ŒH¨æÊÎçX‹H¢¨>KFçÂ…Üdï„çUâ#ÅícUb}<Ÿã∂V~à”ΩÄÊ—
∫ç„9}ÿ‰WP⁄jÇÕ"ºüÎ≠¡Ä7©…ou>H´ˇ€E˘T§Õ ñÈ0Ä¬” ;Å§∞<òÚgõ·»±„î¥É”ÕﬁÙ îèŒT˘_3€d7≠§ô»Ó∂Î9ª;æ’TrÊÕé¨∫^I{îSÏgÜ¨T´Çr]m	xtÅÁÄÍ¶ﬂÅ4êÚÄ‹mœ°Ö}h(◊'˜¡sÖÒ<“@¢˜˚-˚Ë7'Ω⁄ì ÕØﬂ£j =®ïãg ¥Å√‡Rœ.ê⁄nîÌ&!wÀ]v ∞≤‰⁄Ñ¸&Âz<BÎ€R56ﬂHÂÊôa+ øNKÅ†#rÅfCµ«H¿|°]qΩ¬Ö©¨3 ˚ÕËÙftd3^πOèJá€oNÂπ˘áÏ‹1™ﬁÁÌÍYéí
‰õK1
˜ìGFeú&SH>Yπ
≤Ú3≤ë≤U?√©‹ÄŸÜ˜ÕÅ˘9û¶¢ÿíAÏ„êºUP°2[oÁ8ÔYoóO3Ò≈seæ2…ïŸ4rîÙ€f»Ëóa5¯õRô·˛m≤„Õ£ÚK“O„`’´	°‹£23õ•æ$í Ã6;≠—2Çœå`XBË££W≈m4dçëÛdQ∂N”x»˘≤D…oÀ]4ÚâTYQh∞_~U’⁄ ç‚ıµŒ“™MeÁòÉV¶¨EÈπ∞EΩº3Uv£IVô,ßj 0∆°mTãæZf≠3’ÅôÍ@ß:∞˙H∂£§6UÚs‘,?Kù†:/´Ò6¥W)S Õ^9QÊc`˝JrRô9‹≥|{lû2ÀOçŒ1Áï≠XÁ≠h3,ì©	˘f¢_NSü2#ï_»öm,◊£rÇ35®‰)9*ã0<0≈≤ƒ:bÖêÊÖ"èxAúÊA?gx∫≈)§Y˛ÿï/∫ÚßéLä”Œ¶?cyŒ*Ø¢±ï‚7‘Mà~Ò<ú{Hú=‹Ò≤Ë•9ê/!›Ÿ9≤œût2‘#zRË˚∑ÏÏ ¨xﬁû^Â*°RWôPË*cÉ¶U*éãcTÑ&~9Úò§Î üÉÃáI:	˘}1õnÜ¸û+Oà^‚‚Ò4›ô≤s∏Gl?ã√∂è≈!õú‘“™–Ä8$∫© ¶ﬂµÀ
ê{ U6%î€èˆ<büH⁄≈°±VñÿÂπ”Û&åv“K,i¨ÿm◊p#ùˆÄÍù¢3ú_.WÑ˜ÀÍ“ÍäÍ˝“(5*åcøaƒ8ê.Å˝+6„YCÜ¿Ía–)⁄Ìåö#÷€¯&˛.AmxÓT⁄=x6+ç˛Iz˘Ö∂q‰q|f≠h◊NÀÆÒπı˘fmu•X[%≤±´ÜÑh•J-≠¨ƒiY5)ß$“ß
$’ÙüÌé§ÜÉÉ„‡¢{1°π√£uÂ÷%”«=∫O’Cﬁöê<ı’˝ŒO≤ì£~)∑Œwæ£ôﬂg~£ô…Æe`ø˜)’⁄6icZÇñ°k¯A∂¢}}
}}N-e®-‡nRQQQ$¢¢¢¢HDë≤W E@@@à(Ä(Ä(Ä(°Ê[ Q """"GDDDDéàààÑ¬!¬·Äp@8D8 1111"b b b bDƒ@ƒ@ƒà0Aò L&&Ñ	¬$¬aÇ0âÄÄÄ    "@˚SÅ————"¢¢¢¢EDDDK[®u5ìﬂiii““““$§	§	§Ÿ˘ÍeZ«fZÇñ!≈nÅ›ªvãÿ-:^H±Ñ!AH"$	BÇêDHÑ$¢
¢
¢
¢JDDDDïà*‹
§àﬂ(˜÷h◊∏k‡Y´-Û	Ú%ˆà|ëÌêŒj‰ü±UÚOŸuÚOXú|ÅÖ»1yô	É{"ﬁó¬-`˙3Ù!tZÉÓC:’@?Aª⁄å3ÓÎ”gı;˙ö~_?¥¶∑t≠œ?Îø„_Ûﬂ˜ZÛ∑¸öô—zÈ>ä[˚Ç %îO <DP&®ñ–¶ëw˜Ÿ¸Mk”NˇcÛIÑ?à˚æ·_Dx≤[{ì˚ËNg≤∏Üâs◊9:#v†x(|w¶€Îè˛ º–´¢¡7€6·ÿGPZÖÆCqh
äB$®-Çx◊Ôπ	Ö°1»T)ÿ–^˙gCÎÂ´ıÔ{Y∑ >Ó[/É5º,Ïk/|Y$ª˘:´_E¸+Ï‹=¯ö'¢˚øm˚è'æÖ›ıƒ4Ï}/|v¡ˇ íΩ¸&|
=ﬂÒ9|oÂÁ<Ò.¬Œzbf{·êäé ëÖﬁ	Ó≤áp´CΩ‹ŒÙƒ)ÿ∏'N™hÉÖ’∆s?ã“ÙA ªÍò–ìÓ˙∏sX<èÄˇåÖ≈Ò¯—l¯`¨◊Èõ—!8)ºdèä«Û°÷q©¸+±j›ˇƒX‹Zˇ«≈Ìh√@Û-Ã˚&•ƒu≥°›s^À"& —á¢$ﬁóƒ9ÒæÖvO\õjö,œ]Ìﬁ∫»a¿∑-,Oºi5häoàèÖ#¬‚§π©÷óΩ÷7›T+¿¶⁄Ÿ_¡˙F¨Ü:„ÔƒºﬂâËOı˝Çû“OÈA}\ˇì>™F¿8j1z√>C3ò1ÿÿm96√±Ùî˘}™ÙQ=†©J¶qCco3˘BWVÀŒ•xVn]aŸÀ¶¸e.ÿ‡=gﬂìáÇ).≤,{>%_≥≥}˜úå€Y©Á.∏5ŒoÁ—*µø48;Ô6¯Æj∫1"^G'ªqkdÉq˛‚ç[˘<˙(1ú8”ÚçÙE°S⁄œÆ·Á´£ÚÔŸ9W~9öóS™≤;öœ ksÊEwCÎ”z3ÈÌ®≤ºª·+j}ôs™›WLÁˆê¬pöè"åÖï!ÃH1SÖ·~íRaÿ£v\8‚∆î!ÆßóÖ(.‘”Kq>Æ‚j;f&]3Mä±€°òã=É6]Ö(*hrWEq7h“ƒ&h !¬Òªéúí…œB¨N»Ã~»ÂÍ‚œbD;fÿ^Ã‡1ƒÿˇÁ5ü≤y}≤≤∏ùôf
¡Ã<Tê˝ËÍ∞\ælöµ≈äÍ0eW®p˘ UÂóÊe%8üñã¡¥Yõ‹>†{[uO”5∂ù9Ô÷∂ù˘¥7ÈLfÇó“˘z‚¥õ¸ü\7˜sπßÏ¥ÃUπ…∫ì™;°r%UÆ§ ïpî+ÛÅ:˜9∑f∞T˛ıãmØká{pÜ#c˘‘P†xFËçSc√ã#ﬂ¯øÀ€yy$òíΩêÍä&£I’Öˇg™Î(ö˚:]√ãß∆Fæ·w;]4˜Sloiô
  ô≥Y96˜û´éät.ºg%uQ˜0À|ê∆?|.ì˜|$+xï∫*ïJIªƒXVFÊ≤Ú’≥òâÆ#U!ùG€ÒΩ∂Æ.j´uwgª[Ë¥1	^VÈTÕÊ6V–È¡[óÆU˝U]SØ
Â˙K£S~á'¯Ñ˜8m¡;1IoıqKΩøîÎ'f⁄é◊UÂﬁKcS»PèUnµ›Èè¢≤b≠DW‚U´≠∆˝h]_E£XUèRÔƒj+€•ΩÖ@µú«bcZ*ﬂøΩ?éR‚™™ÿvﬁ.qZØﬂ.6ﬂ[Ù˝Ö-uF-—ÂΩi∑ó:É`'⁄Ÿ+{X•QgÖ†ˆ ÌO˚≈≥ü~` ÙZendstreamendobj43 0 obj<</Length 21676>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 670.1523 cm
0 0 m
537.86 0 l
S
Q
q 1 0 0 1 37 524.7407 cm
0 0 m
537.86 0 l
S
Q
q 1 0 0 1 37 206.35 cm
0 0 m
537.86 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.013 Tc 0.014 Tw 10 0 0 10 250.0721 715.6797 Tm
[(P)74 (A)73.8 (TIENT INFORMA)73.9 (TION)]TJ
0.013 Tw 0.495 -1.501 Td
[(SPR)36.7 (YCEL)]TJ
0 Tc 0 Tw 7.5 0 0 7.5 300.9913 703.1706 Tm
(\256)Tj
-0.013 Tc 0.014 Tw 10 0 0 10 306.4216 700.6706 Tm
( \(Spry-sell\))Tj
0 Tc 0 Tw 5.041 0 Td
( )Tj
-0.013 Tc 0.013 Tw -7.554 -1.051 Td
(\(dasatinib\))Tj
0 Tc 0 Tw 4.928 0 Td
( )Tj
-0.013 Tc 0.013 Tw -4.037 -1.051 Td
(tablets)Tj
0.014 Tw -24.42 -2.401 Td
[(What is SPR)36.7 (YCEL?)]TJ
/TT1 1 Tf
0 -1.519 Td
[(SPR)17.6 (YCEL)36.8 ( is a prescription medicine used to treat:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.447 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.003 Tc 0.06 Tw 1.8 0 Td
[(adult)0.6 (s wit)0.6 (h newly)0.5 ( diagnosed Philadelphia c)0.5 (hromos)0.5 (om)0.5 (e-posit)0.6 (ive \(P)0.5 (h)]TJ
0 Tc 0 Tw 29.936 0.1 Td
(+)Tj
-0.003 Tc 0.06 Tw 0.581 -0.1 Td
[(\) c)0.5 (hr)0.5 (onic)0.5 ( myeloid leukemia \(CML\) in chronic)-3 ( )]TJ
-0.013 Tc 0.013 Tw -30.517 -1.051 Td
(phase.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(adults with Ph)Tj
0 Tc 0 Tw 6.074 0.1 Td
(+)Tj
/C2_0 1 Tf
-0.013 Tc 0.013 Tw 0.571 -0.1 Td
[<0003>-13.9 <00260030002F>36.8 <0003>-14 <005A004B00520003>-14 <005100520003>-14 <004F00520051004A004800550003>-13.9 <004500480051004800BF00570003>-13.9 <0049005500520050000F0003>-13.9 <005200550003>-14 <0047004C00470003>-14 <0051005200570003>-13.9 <00570052004F00480055004400570048000F0003>-13.9 <00520057004B004800550003>-14 <005700550048004400570050004800510057000F0003>-13.9 <004C00510046004F00580047004C0051004A0003>-13.9 <004C005000440057004C0051004C00450011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-7.854 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
0.004 Tc 0.095 Tw 1.8 0 Td
[(adult)0.7 (s)0.5 ( )0.5 (wit)0.7 (h P)0.5 (h)]TJ
0 Tc 0 Tw 6.465 0.1 Td
(+)Tj
0.004 Tc 0.095 Tw 0.587 -0.1 Td
[( )0.5 (ac)0.5 (ut)0.6 (e )0.5 (ly)0.5 (m)0.5 (phoblas)0.6 (t)0.6 (ic)0.5 ( leuk)0.5 (em)0.5 (ia )0.5 (\()0.5 (P)0.5 (h)]TJ
0 Tc 0 Tw 15.67 0.1 Td
(+)Tj
/C2_0 1 Tf
0.004 Tc -0.004 Tw 0.587 -0.1 Td
[<0003>-39.4 <0024>0.5 <002F002F000C>0.5 <0003>-94.6 <005A004B00520003>-94.6 <005100520003>-94.5 <004F00520051004A00480055>0.6 <0003>-94.6 <004500480051004800BF>0.5 <0057>0.7 <0003>-94.5 <0049>0.6 <0055>0.5 <00520050>0.5 <000F>0.7 <0003>-94.6 <00520055>0.5 <0003>-94.6 <0047004C00470003>-94.6 <005100520057>0.7 <0003>-94.5 <0057>0.7 <0052004F00480055>0.5 <00440057>0.7 <0048000F>0.7 <0003>-94.6 <00520057>0.7 <004B00480055>4 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.013 Tw -23.31 -1.051 Td
(treatment.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0046004B004C004F00470055004800510003>-14 <00140003>-13.9 <005C0048004400550003>-14 <005200490003>-13.9 <0044004A00480003>-14 <0044005100470003>-14 <0052004F0047004800550003>-14 <005A004C0057004B0003>-13.9 <0033004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw 17.222 0.1 Td
(+)Tj
-0.013 Tc 0.014 Tw 0.571 -0.1 Td
[( CML)36.7 ( in chronic phase.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-19.002 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0046004B004C004F00470055004800510003>-14 <00140003>-13.9 <005C0048004400550003>-14 <005200490003>-13.9 <0044004A00480003>-14 <0044005100470003>-14 <0052004F0047004800550003>-14 <005A004C0057004B0003>-13.9 <00510048005A004F005C0003>-13.9 <0047004C0044004A005100520056004800470003>-14 <0033004B>]TJ
/TT1 1 Tf
0 Tc 0 Tw 24.773 0.1 Td
(+)Tj
-0.013 Tc 0.014 Tw 0.571 -0.1 Td
[( )55.2 (ALL)36.7 ( in combination with chemotherapy)74 (.)]TJ
/C2_0 1 Tf
0.013 Tw -27.144 -1.573 Td
[<002C00570003>-14 <004C00560003>-13.9 <0051005200570003>-14 <004E00510052005A00510003>-14 <004C00490003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <004C00560003>-14 <00560044004900480003>-14 <0044005100470003>-13.9 <00480049>18 <0049004800460057004C005900480003>-13.9 <004C00510003>-13.9 <0046004B004C004F00470055004800510003>-13.9 <005800510047004800550003>-14 <00140003>-13.9 <005C0048004400550003>-14 <005200490003>-13.9 <0044004A00480011>]TJ
/TT0 1 Tf
0.014 Tw 0 -2.851 Td
[(Before taking SPR)36.7 (YCEL, tell your healthcare provider about all of your medical conditions\, including if you:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.447 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(have problems with your immune system)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<004B0044005900480003>-13.9 <004B00480044005500570003>-14 <0053005500520045004F004800500056000F0003>-13.9 <004C00510046004F00580047004C0051004A0003>-13.9 <00440003>-13.9 <0046005200510047004C0057004C005200510003>-13.9 <00460044004F004F004800470003>-13.9 <004600520051004A00480051004C00570044004F0003>-14 <004F00520051004A0003>-13.9 <00340037>18 <0003>-13.9 <0056005C005100470055005200500048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(have low potassium or low magnesium levels in your blood)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(have liver problems)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
(are lactose \(milk sugar\) intolerant)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
[(are pregnant or plan to become pregnant. SPR)17.7 (YCEL)36.7 ( can harm your unborn baby)74 (.)-12.8 ( )]TJ
/C2_1 1 Tf
0.013 Tw -1.8 -1.537 Td
[<0003>-1535 <0029004800500044004F00480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.992 0 Td
<005A004B0052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.24 0 Td
<004600440051>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.964 0 Td
<004500480046005200500048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.982 0 Td
[<005300550048004A0051004400510057001D>-13 <0BD8>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-11.786 -1.465 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
/TT1 1 Tf
-0.013 Tc 0.014 Tw 1.8 0 Td
[(Y)91.6 (ou should not become pregnant during treatment with SPR)17.6 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.221 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.579 0 Td
<017C>Tj
-0.009 Tc 0.009 Tw 1.8 0 Td
[<003C>92.1 <005200580003>-90.7 <0056004B00520058004F00470003>-90.7 <0058005600480003>-90.6 <00480049>18.6 <0049>0.5 <004800460057004C005900480003>-90.7 <0045004C00550057>0.5 <004B0003>-90.7 <0046005200510057>0.5 <00550052004F0003>-90.6 <000B0046005200510057>0.5 <005500440046004800530057>0.5 <004C00520051000C0003>-90.7 <004700580055004C0051004A0003>-90.7 <00570055004800440057>0.5 <0050004800510057>0.5 <0003>-90.7 <0044005100470003>-90.7 <0049>0.5 <005200550003>-90.7 <001600130003>-90.7 <00470044005C00560003>-90.7 <00440049>0.5 <0057>0.5 <004800550003>-90.7 <005C0052005800550003>-90.7 <004F0044005600570003>-90.7 <00470052005600480003>-90.7 <00520049>-8.8 <0003>]TJ
/TT1 1 Tf
-0.025 Tc 0.025 Tw 0 -1.051 Td
[(SPR)17.7 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.016 Tc 0.016 Tw 1.8 0 Td
[<0037>111.5 <0044004F004E>0.5 <0003>5.5 <0057>0.7 <00520003>5.5 <005C>0.5 <005200580055>0.5 <0003>5.5 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>5.4 <00530055>0.5 <00520059>0.5 <004C004700480055>0.5 <0003>5.5 <0055>0.5 <004C004A004B0057>0.7 <0003>5.4 <0044005A0044005C>0.5 <0003>5.5 <004C0049>0.7 <0003>5.5 <005C>0.5 <005200580003>5.5 <004500480046>0.5 <00520050>0.5 <00480003>5.5 <00530055>0.5 <0048004A0051004400510057>0.7 <0003>5.5 <00520055>0.5 <0003>5.5 <0057>0.7 <004B004C0051004E>0.5 <0003>5.4 <005C>0.5 <005200580003>5.4 <0050>0.5 <0044005C>0.5 <0003>5.5 <004500480003>5.5 <00530055>0.5 <0048004A0051004400510057>0.7 <0003>5.5 <004700580055>0.5 <004C0051004A0003>5.4 <0057>0.7 <0055>0.5 <004800440057>0.7 <0050>0.5 <004800510057>-15.8 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.051 Td
[(with SPR)17.7 (YCEL.)]TJ
/C2_1 1 Tf
0.013 Tw -3.6 -1.555 Td
[<0003>-1535 <00300044004F00480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.794 0 Td
<005A004C0057004B>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.227 0 Td
<0049004800500044004F0048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.371 0 Td
<00530044005500570051004800550056>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.178 0 Td
<005A004B0052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.24 0 Td
<004600440051>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.964 0 Td
<004500480046005200500048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.982 0 Td
[<005300550048004A0051004400510057001D>-13 <0BD8>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-20.385 -1.465 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.571 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003C>91.6 <005200580003>-113.7 <0056004B00520058004F00470003>-113.7 <0058005600480003>-113.8 <00480049>18 <0049004800460057004C005900480003>-113.7 <0045004C00550057004B0003>-113.8 <004600520051005700550052004F0003>-113.7 <000B0046005200510057005500440046004800530057004C00520051000C0003>-113.8 <004700580055004C0051004A0003>-113.7 <0057005500480044005700500048005100570003>-113.7 <0044005100470003>-113.7 <0049005200550003>-113.8 <001600130003>-113.7 <00470044005C00560003>-113.7 <004400490057004800550003>-113.8 <005C0052005800550003>-113.8 <004F0044005600570003>-113.8 <00470052005600480003>-113.8 <00520049>-12.9 <0003>]TJ
/TT1 1 Tf
-0.033 Tc 0.033 Tw 0 -1.051 Td
[(SPR)17.6 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003C>91.6 <0052005800550003>-2.1 <0049004800500044004F00480003>-2.1 <00530044005500570051004800550003>-2 <0056004B00520058004F00470003>-2.1 <00460044004F004F0003>-2.1 <004B004800550003>-2 <004B00480044004F0057004B00460044005500480003>-2.1 <0053005500520059004C0047004800550003>-2.1 <004C00490003>-2 <0056004B00480003>-2.1 <00450048004600520050004800560003>-2.1 <005300550048004A00510044005100570003>-2 <005200550003>-2.1 <0057004B004C0051004E00560003>-2.1 <0056004B00480003>-2.1 <004C00560003>-2.1 <005300550048004A00510044005100570003>-2.1 <004700580055004C0051004A>-13.2 <0003>]TJ
/TT1 1 Tf
0.014 Tw 0 -1.051 Td
[(your treatment with SPR)17.7 (YCEL.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.393 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.004 Tc 0.004 Tw 1.8 0 Td
[<00440055>0.5 <00480003>-54.5 <00450055>0.5 <004800440056>0.6 <0057>0.7 <0049>0.7 <004800480047004C0051004A0003>-54.5 <00520055>0.5 <0003>-54.5 <0053004F004400510003>-54.4 <0057>0.7 <00520003>-54.5 <00450055>0.5 <004800440056>0.5 <0057>0.7 <0049>0.7 <0048004800470011>0.7 <0003>-54.4 <002C>0.7 <0057>0.7 <0003>-54.5 <004C0056>0.6 <0003>-54.5 <005100520057>0.7 <0003>-54.5 <004E>0.5 <00510052005A00510003>-54.5 <004C0049>0.7 <0003>-54.5 <0036>0.5 <0033>0.6 <0035>18.4 <003C>0.5 <00260028>0.5 <002F>37.5 <0003>-54.5 <005300440056>0.5 <0056>0.6 <00480056>0.6 <0003>-54.5 <004C00510057>0.7 <00520003>-54.5 <005C>0.6 <005200580055>0.5 <0003>-54.4 <00450055>0.5 <004800440056>0.5 <0057>0.7 <0003>-54.5 <0050>0.6 <004C004F004E>0.5 <0011>0.7 <0003>-36.4 <003C>92.3 <005200580003>-54.5 <0056>0.5 <004B00520058004F00470003>-54.5 <005100520057>-3.8 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.051 Td
[<00450055004800440056005700490048004800470003>-14 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-14 <0044005100470003>-14 <0049005200550003>-14 <00150003>-14 <005A00480048004E00560003>-13.9 <004400490057004800550003>-13.9 <005C0052005800550003>-13.9 <004F0044005600570003>-14 <00470052005600480003>-14 <005200490003>-13.9 <003600330035>17.7 <003C00260028002F0011>]TJ
/C2_1 1 Tf
-0.016 Tc 0.016 Tw -1.8 -1.663 Td
[<0037>74.7 <0048004F>0.5 <004F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.583 0 Td
<0003>Tj
EMC 
0.257 0 Td
[<005C0052>0.5 <0058>0.6 <0055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.359 0 Td
[<004B>0.5 <00480044004F>0.5 <0057004B>0.5 <0046004400550048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.096 0 Td
[<0053>0.5 <00550052>0.5 <0059004C>0.5 <0047>0.5 <00480055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.127 0 Td
[<00440045>0.6 <0052>0.5 <0058>0.5 <0057>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.897 0 Td
[<0044004F>0.6 <004F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.063 0 Td
<0003>Tj
EMC 
0.257 0 Td
[<0057004B>0.5 <0048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.708 0 Td
[<005000480047>0.5 <004C>0.6 <0046004C>0.5 <0051>0.6 <00480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.001 0 Td
[<005C0052>0.5 <0058>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.729 0 Td
<0003>Tj
EMC 
0.257 0 Td
[<00570044004E0048000F>0.5 <0BD8>]TJ
/C2_0 1 Tf
[<0003>4.6 <004C00510046004F00580047004C0051004A0003>4.7 <005300550048005600460055004C00530057>0.5 <004C005200510003>4.6 <0044005100470003>4.6 <005200590048005500100057>0.5 <004B0048001000460052005800510057>0.6 <004800550003>4.6 <005000480047004C0046004C005100480056000F>-15.9 <0003>]TJ
-0.012 Tc 0.012 Tw -26.335 -1.051 Td
[<0059004C005700440050004C00510056000F0003>-28 <00440051005700440046004C0047>-0.6 <0056000F0003>-27.9 <0044005100470003>-28 <004B0048005500450044004F0003>-28 <0056005800530053004F0048005000480051005700560011>]TJ
/Span<</ActualText<FEFF00A0>>> BDC 
<0003>Tj
EMC 
/TT0 1 Tf
0.028 Tw 19.359 0 Td
[(If you take an anta)-0.6 (cid medic)-0.6 (ine, take it 2 hours before or 2 hours after)-12.1 ( )]TJ
-0.013 Tc 0.014 Tw -19.359 -1.051 Td
[(your dose of SPR)36.7 (YCEL.)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
11.028 0 Td
( )Tj
EMC 
-11.028 -2.401 Td
[(How should I take SPR)36.7 (YCEL?)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.447 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0037>110.8 <0044004E00480003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <0048005B004400460057004F005C0003>-13.9 <004400560003>-14 <005C0052005800550003>-13.9 <004B00480044004F0057004B00460044005500480003>-13.9 <0053005500520059004C0047004800550003>-13.9 <00570048004F004F00560003>-13.9 <005C005200580003>-13.9 <005700520003>-13.9 <00570044004E00480003>-14 <004C00570011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
0.009 Tc -0.009 Tw 1.8 0 Td
[<003C>91.8 <0052005800550003>-122.5 <004B00480044004F0057004B00460044005500480003>-122.5 <0053005500520059004C0047004800550003>-122.5 <00500044005C0003>-122.4 <0046004B00440051004A00480003>-122.4 <005C0052005800550003>-122.5 <00470052005600480003>-122.5 <005200490003>-122.5 <003600330035>17.9 <003C00260028002F>37 <0003>-122.5 <005200550003>-122.5 <00570048005000530052005500440055004C004F005C0003>-122.5 <00560057005200530003>-122.5 <0057005500480044005700500048005100570003>-122.5 <005A004C0057004B0003>-122.5 <003600330035>17.9 <003C00260028002F0011>]TJ
/Span<</ActualText<FEFF00A0>>> BDC 
50.186 0 Td
<0003>Tj
EMC 
T*
<0003>Tj
/C2_1 1 Tf
-0.013 Tc 0.013 Tw -50.186 -1.051 Td
<00270052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.586 0 Td
<005100520057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.795 0 Td
<0046004B00440051004A0048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.703 0 Td
<005C005200580055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.395 0 Td
<0047005200560048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.562 0 Td
<00520055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.253 0 Td
<0056005700520053>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.339 0 Td
<00570044004E004C0051004A>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.147 0 Td
[<003600330035>36.7 <003C00260028002F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
4.579 0 Td
<0003>Tj
EMC 
0.279 0 Td
<005A004C0057004B005200580057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.744 0 Td
<00BF005500560057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.117 0 Td
<00570044004F004E004C0051004A>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.412 0 Td
<00570052>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.197 0 Td
<005C005200580055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.395 0 Td
<004B00480044004F0057004B0046004400550048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
5.154 0 Td
[<0053005500520059004C004700480055>54.8 <0011>]TJ
/C2_0 1 Tf
0 Tc 0 Tw 4.121 0 Td
<0BD8>Tj
/TT1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-46.987 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0037>110.8 <0044004E00480003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <00140003>-13.9 <0057004C005000480003>-13.9 <00440003>-14 <00470044005C>74 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0037>110.8 <0044004E00480003>-13.9 <003600330035>17.7 <003C00260028002F>36.7 <0003>-13.9 <005A004C0057004B0003>-14 <005200550003>-13.9 <005A004C0057004B0052005800570003>-14 <0049005200520047000F0003>-14 <0048004C0057004B004800550003>-13.9 <004C00510003>-13.9 <0057004B00480003>-14 <0050005200550051004C0051004A0003>-14 <005200550003>-13.9 <004C00510003>-13.9 <0057004B00480003>-14 <0048005900480051004C0051004A0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<0036005A0044004F004F0052005A0003>-14 <003600330035>17.7 <003C00260028002F>36.8 <0003>-14 <005700440045004F0048005700560003>-13.9 <005A004B0052004F004800110003>-13.9 <002700520003>-14 <0051005200570003>-13.9 <0046005500580056004B000F0003>-13.9 <0046005800570003>-13.9 <005200550003>-14 <0046004B0048005A0003>-14 <0057004B00480003>-13.9 <005700440045004F0048005700560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.591 -1.393 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<017C>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<002C00490003>-14 <005C0052005800550003>-13.9 <0046004B004C004F00470003>-13.9 <0046004400510051005200570003>-13.9 <0056005A0044004F004F0052005A0003>-14 <005700440045004F0048005700560003>-14 <005A004B0052004F0048000F0003>-14 <00570044004F004E0003>-14 <005A004C0057004B0003>-13.9 <005C0052005800550003>-14 <004B00480044004F0057004B00460044005500480003>-14 <0053005500520059004C004700480055>54.9 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.009 -1.393 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.013 Tc 0.013 Tw 1.8 0 Td
[<003C>91.6 <005200580003>-13.9 <0056004B00520058004F00470003>-14 <0051005200570003>-13.9 <00470055004C0051004E0003>-14 <004A0055004400530048004900550058004C00570003>-13.9 <004D0058004C004600480003>-13.9 <004700580055004C0051004A0003>-13.9 <0057005500480044005700500048005100570003>-14 <005A004C0057004B0003>-13.9 <003600330035>17.6 <003C00260028002F0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.209 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.591 0 Td
<0194>Tj
-0.001 Tc 0.001 Tw 1.8 0 Td
[<002C00490003>-75.2 <005C0052>-0.6 <0058>-0.6 <0003>-75.2 <0050004C>-0.6 <005600560003>-75.1 <0044>-0.6 <0003>-75.2 <0047>-0.6 <0052>-0.6 <00560048>-0.6 <0003>-75.2 <0052>-0.6 <00490003>-75.2 <003600330035>17.4 <003C0026>-0.6 <0028002F>-0.6 <000F0003>-75.2 <00570044>-0.6 <004E0048>-0.6 <0003>-75.2 <005C0052>-0.6 <0058>-0.6 <00550003>-75.2 <0051>-0.6 <0048>-0.6 <005B00570003>-75.2 <00560046004B>-0.6 <0048>-0.6 <0047>-0.6 <0058>-0.6 <004F>-0.6 <00480047>-0.6 <0003>-75.2 <0047>-0.6 <0052>-0.6 <00560048>-0.6 <0003>-75.2 <004400570003>-75.2 <005C0052>-0.6 <0058>-0.6 <00550003>-75.2 <00550048>-0.6 <004A>-0.6 <0058>-0.6 <004F>-0.6 <0044>-0.6 <00550003>-75.2 <0057004C>-0.6 <00500048>-0.6 <00110003>-75.2 <0027>-0.6 <0052>-0.6 <0003>-75.2 <0051>-0.6 <005200570003>-75.2 <00570044>-0.6 <004E00480003>-75.2 <0057005A>-0.6 <0052>-0.6 <0003>-75.1 <0047>-0.6 <0052>-0.6 <0056004800560003>-75.1 <0044>-0.6 <0057>-0.9 <0003>]TJ
/TT1 1 Tf
-0.013 Tc 0.014 Tw 0 -1.051 Td
(the same time.)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.375 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.02 Tc 0.02 Tw 1.8 0 Td
[<002C>0.7 <0049>0.7 <0003>0.6 <005C>0.6 <005200580003>0.6 <0057>0.7 <0044004E>0.5 <00480003>0.6 <0057>0.7 <005200520003>0.6 <0050>0.5 <00580046>0.5 <004B0003>0.6 <0036>0.6 <0033>0.5 <0035>18.4 <003C>0.5 <00260028>0.5 <002F000F>0.7 <0003>0.7 <0046>0.5 <0044004F004F0003>0.7 <005C>0.6 <005200580055>0.5 <0003>0.7 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>0.6 <00530055>0.5 <00520059>0.5 <004C004700480055>0.5 <0003>0.7 <00520055>0.5 <0003>0.7 <004A00520003>0.7 <0057>0.7 <00520003>0.7 <0057>0.7 <004B00480003>0.7 <0051004800440055>0.5 <00480056>0.5 <0057>0.7 <0003>0.7 <004B00520056>0.5 <0053004C0057>0.7 <0044004F0003>0.7 <00480050>0.6 <00480055>0.5 <004A004800510046>0.5 <005C>0.5 <0003>0.7 <0055>0.5 <005200520050>0.5 <0003>0.7 <0055>0.5 <004C004A004B0057>0.7 <0003>0.7 <0044005A0044005C>74.7 <0011>]TJ
ET
4 M 
36.5 36.5 538.86 695.96 re
S
endstreamendobj42 0 obj<</Length 20769>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 683.1981 cm
0 0 m
42.736 0 l
S
Q
q 1 0 0 1 36 423.7547 cm
0 0 m
24.176 0 l
S
Q
q 1 0 0 1 36 391.6547 cm
0 0 m
69.527 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 36 727.7881 Tm
(15)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(REFERENCES)Tj
/T1_1 1 Tf
0.857 Tw -2.375 -1.653 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
[(http://www)37 (.osha.gov/SL)94.1 (TC/hazardousdrugs/index.html)]TJ
/T1_0 1 Tf
0.01 Tw -1.663 -2.035 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
-3.375 -1.72 Td
(How Supplied)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.355 Td
[(SPR)18 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 62.3997 675.4881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 67.1396 673.6881 Tm
[( \(dasa)-10 (tinib\) tablets are a)-10 (vailable as described in )37 (T)74 (able)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(21.)Tj
ET
0 0 0 0 k
/GS0 gs
36 663.608 252 -9.312 re
36 654.296 48.6 -19.472 re
84.6 654.296 33.84 -19.472 re
118.44 654.296 132.84 -19.472 re
251.28 654.296 36.72 -19.472 re
36 634.824 48.6 -28.912 re
84.6 634.824 33.84 -28.912 re
118.44 634.824 132.84 -28.912 re
251.28 634.824 36.72 -28.912 re
36 605.912 48.6 -28.912 re
84.6 605.912 33.84 -28.912 re
118.44 605.912 132.84 -28.912 re
251.28 605.912 36.72 -28.912 re
36 577 48.6 -28.912 re
84.6 577 33.84 -28.912 re
118.44 577 132.84 -28.912 re
251.28 577 36.72 -28.912 re
36 548.089 48.6 -36.912 re
84.6 548.089 33.84 -36.912 re
118.44 548.089 132.84 -36.912 re
251.28 548.089 36.72 -36.912 re
36 511.177 48.6 -30.6 re
84.6 511.177 33.84 -30.6 re
118.44 511.177 132.84 -30.6 re
251.28 511.177 36.72 -30.6 re
36 480.577 48.6 -36.912 re
84.6 480.577 33.84 -36.912 re
118.44 480.577 132.84 -36.912 re
251.28 480.577 36.72 -36.912 re
f
/GS2 gs
q 1 0 0 1 84.6 606.1624 cm
0 0 m
0 28.162 l
S
Q
q 1 0 0 1 118.44 606.1624 cm
0 0 m
0 28.162 l
S
Q
q 1 0 0 1 251.28 606.1624 cm
0 0 m
0 28.162 l
S
Q
q 1 0 0 1 36 605.9124 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 605.9124 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 577.2504 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 118.44 605.9124 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 577.2504 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 251.28 605.9124 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 577.2504 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 36 577.0004 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 577.0004 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 548.3385 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 118.44 577.0004 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 548.3385 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 251.28 577.0004 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 548.3385 cm
0 0 m
0 28.412 l
S
Q
q 1 0 0 1 36 548.0885 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 548.0885 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 511.4266 cm
0 0 m
0 36.412 l
S
Q
q 1 0 0 1 118.44 548.0885 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 511.4266 cm
0 0 m
0 36.412 l
S
Q
q 1 0 0 1 251.28 548.0885 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 511.4266 cm
0 0 m
0 36.412 l
S
Q
q 1 0 0 1 36 511.1766 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 511.1766 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 480.8266 cm
0 0 m
0 30.1 l
S
Q
q 1 0 0 1 118.44 511.1766 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 480.8266 cm
0 0 m
0 30.1 l
S
Q
q 1 0 0 1 251.28 511.1766 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 480.8266 cm
0 0 m
0 30.1 l
S
Q
q 1 0 0 1 36 480.5766 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 480.5766 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 84.6 444.1647 cm
0 0 m
0 36.162 l
S
Q
q 1 0 0 1 118.44 480.5766 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 118.44 444.1647 cm
0 0 m
0 36.162 l
S
Q
q 1 0 0 1 251.28 480.5766 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 251.28 444.1647 cm
0 0 m
0 36.162 l
S
Q
1 w 
q 1 0 0 1 36 443.6647 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 443.6647 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 118.44 443.6647 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 251.28 443.6647 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 36 654.2962 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 654.2962 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 118.44 654.2962 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 251.28 654.2962 cm
0 0 m
36.72 0 l
S
Q
q 1 0 0 1 36 634.8243 cm
0 0 m
48.6 0 l
S
Q
q 1 0 0 1 84.6 634.8243 cm
0 0 m
33.84 0 l
S
Q
q 1 0 0 1 118.44 634.8243 cm
0 0 m
132.84 0 l
S
Q
q 1 0 0 1 251.28 634.8243 cm
0 0 m
36.72 0 l
S
Q
0.5 w 
q 1 0 0 1 84.6 635.3243 cm
0 0 m
0 18.472 l
S
Q
q 1 0 0 1 118.44 635.3243 cm
0 0 m
0 18.472 l
S
Q
q 1 0 0 1 251.28 635.3243 cm
0 0 m
0 18.472 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.024 Tw 8 0 0 8 36 657.8962 Tm
(Table 21:)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
(SPRYCEL Trade Presentations)Tj
-0.02 Tc 7.2 0 0 8 42.5461 641.7043 Tm
(NDC Number)Tj
0.02 Tw 6.557 0 Td
(Strength)Tj
11.042 0 Td
(Description)Tj
12.567 0.5 Td
(Tablets)Tj
0 Tc 0 Tw 7.2 0 0 8 279.7872 645.7043 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 256.4056 637.7043 Tm
(per Bottle)Tj
/T1_1 1 Tf
-0.005 Tc 0.005 Tw -29.979 -2.524 Td
(0003-0527-11)Tj
0.024 Tw 7.272 0 Td
(20)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.543 1 Td
[(white to off-white,)37 ( biconvex,)37 ( round,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 233.6063 625.5123 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 129.4105 617.5123 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( debossed on)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 244.2262 617.5123 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 137.6507 609.5123 Tm
[(one side and )37 (\223527\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(60)Tj
-31.357 -3.614 Td
(0003-0528-11)Tj
0.024 Tw 7.272 0 Td
(50)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.854 1 Td
[(white to off-white,)37 ( biconvex,)37 ( oval,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 231.3707 596.6005 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 129.4105 588.6005 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( debossed on)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 244.2262 588.6005 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 137.6507 580.6005 Tm
[(one side and )37 (\223528\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(60)Tj
-31.357 -3.614 Td
(0003-0524-11)Tj
0.024 Tw 7.272 0 Td
(70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.543 1 Td
[(white to off-white,)37 ( biconvex,)37 ( round,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 233.6063 567.6885 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 129.4105 559.6885 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( debossed on)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 244.2262 559.6885 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 137.6507 551.6885 Tm
[(one side and )37 (\223524\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(60)Tj
-31.357 -4.114 Td
(0003-0855-22)Tj
0.024 Tw 7.272 0 Td
(80)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.234 1.5 Td
[(white to off-white,)37 ( biconvex,)37 ( triangle,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 235.831 538.7766 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 141.1319 530.7766 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 232.5048 530.7766 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 130.9655 522.7766 Tm
[(\22380\224)37 ( \(BMS over 80\) debossed on one side)-9.9 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 242.6711 522.7766 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 149.5556 514.7766 Tm
[(and )37 (\223855\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 16.218 1.5 Td
(30)Tj
-31.357 -4.219 Td
(0003-0852-22)Tj
0.024 Tw 7.035 0 Td
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 7.091 1 Td
[(white to off-white,)37 ( biconvex,)37 ( oval,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 231.3707 501.0206 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 123.4202 493.0206 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS 100\224)37 ( debossed on)-9.9 ( )]TJ
1.976 -1 Td
[(one side and )37 (\223852\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 17.872 1 Td
(30)Tj
-31.357 -4.219 Td
(0003-0857-22)Tj
0.024 Tw 7.035 0 Td
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg)Tj
-0.01 Tc 6.781 1.5 Td
[(white to off-white,)37 ( biconvex,)37 ( round,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 233.6063 471.2647 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 141.1318 463.2647 Tm
[(film-coa)-10 (ted tablet with )37 (\223BMS\224)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 232.5048 463.2647 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 127.5816 455.2647 Tm
[(\223140\224)37 ( \(BMS over 140\) debossed on one side)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 246.0551 455.2647 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 149.5556 447.2647 Tm
[(and )37 (\223857\224)37 ( on the other side)]TJ
-0.005 Tc 0.005 Tw 16.218 1.5 Td
(30)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 35.9999 425.0847 Tm
(Storage)Tj
/T1_1 1 Tf
-0.001 Tw 0 -1.292 Td
[(SPR)18 (YCEL tablets should be stored a)-10 (t 20\260C to 25\260C \(68\260F to 77\260F\); excursions permitted)-10 ( )]TJ
0 Tw 0 -1 Td
(between 15\260C and 30\260C \(59\260F and 86\260F\) )Tj
0 Tc ([)Tj
15.302 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
[(ee USP Controlled Room )37 (T)74 (empera)-10 (ture])]TJ
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -15.699 -1.72 Td
(Handling and Disposal)Tj
/T1_1 1 Tf
-0.036 Tw 0 -1.292 Td
[(SPR)18 (YCEL is an antineoplastic product.)37 ( F)20 (ollo)-9.9 (w special handling and disposal procedures.)]TJ
0 Tc 0 Tw 6 0 0 6 285.12 385.4447 Tm
(1)Tj
-0.01 Tc 8 0 0 8 35.9999 371.2247 Tm
[(P)18 (ersonnel who are pregnant should a)-10 (void exposure to crushed or broken tablets.)]TJ
0.199 Tw 0 -1.427 Td
[(SPR)18 (YCEL tablets consist of a core tablet,)37 ( surrounded by a \037lm coa)-10 (ting to prevent)-10 ( )]TJ
0.035 Tw 0 -1 Td
[(exposure of healthcare professionals to the active substance.)37 ( )36.9 (The use of la)-10 (tex or nitrile)-10 ( )]TJ
0.031 Tw 0 -1 Td
[(gloves for a)-9.9 (ppropria)-10 (te disposal when handling tablets tha)-10 (t are inadvertently crushed or)-10 ( )]TJ
0 Tw 0 -1 Td
[(broken is recommended,)37 ( to minimize the risk of dermal exposure.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -2.485 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)54 (A)55 (TIENT COUNSELING INFORMA)55 (TION)]TJ
/T1_1 1 Tf
-3.375 -1.653 Td
[(Advise the pa)-10 (tient to read the FDA-a)-10 (pproved pa)-10 (tient labeling \(P)18 (a)-10 (tient Informa)-10 (tion\).)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.72 Td
(Myelosuppression)Tj
/T1_1 1 Tf
0.03 Tw 0 -1.292 Td
[(Inform pa)-10 (tients of the )0.5 (possibility of developing lo)-9.9 (w blood cell counts.)37 ( )37.4 (Advise pa)-10 (tients to)-9.9 ( )]TJ
-0.009 Tw 0 -1 Td
[(immedia)-10 (tely report fever particularly in associa)-10 (tion with an)-10 (y suggestion of infection )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
[(W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.364 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -9.385 -1.495 Td
(Bleeding)Tj
/T1_1 1 Tf
0.161 Tw 0 -1.292 Td
[(Inform pa)-10 (tients of the possibility of serious bleeding and to report immedia)-10 (tely an)-10 (y)-10 ( )]TJ
0.047 Tw 0 -1 Td
[(signs or symptoms suggestive of hemorrha)-9.9 (ge \(unusual bleeding or easy bruising\) )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
[(W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.364 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.2\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -9.385 -1.653 Td
(Fluid Retention)Tj
/T1_1 1 Tf
0.138 Tw 0 -1.653 Td
[(P)18 (a)-10 (tients should be informed of the possibility of developing \035uid reten\tion \(s)-10 (welling,)27 ( )]TJ
-0.004 Tw 0 -1 Td
[(weight gain,)37.1 ( dr)-18 (y cough,)37 ( chest pain on respira)-10 (tion,)37 ( or shortness of brea)-10 (th\) and advised to)-10 ( )]TJ
-0.02 Tw 0 -1 Td
[(seek medical a)-10 (ttention promptly if those symptoms arise )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
20.707 0 Td
(s)Tj
-0.01 Tc -0.057 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.02 Tw 4.405 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
( )Tj
-0.01 Tc 0.01 Tw -25.509 -1 Td
(\(5.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.01 Tc 0 -1.495 Td
[(Cardio)-10 (v)16 (ascular T)74 (oxicity)]TJ
/T1_1 1 Tf
0.348 Tw 0 -1.292 Td
[(Inform pa)-10 (tients of the possibility of developing cardiovascular toxicity)55 (,)37.1 ( inc)20 (luding)-10 ( )]TJ
0.294 Tw 0 -1 Td
[(cardiac ischemic events,)37 ( cardiac-rela)-9.9 (ted \035uid retention,)37 ( conduction abnormalities,)27 ( )]TJ
0.043 Tw 0 -1 Td
[(and )37 (TIAs.)37 ( )36.9 (Advise pa)-10 (tients to seek immedia)-9.9 (te medical a)-10 (ttention if symptoms suggestive)-9.9 ( )]TJ
0.103 Tw 0 -1 Td
[(of cardiovascular toxicity occur)74 (,)37 ( such as chest pain,)37 ( shortness of brea)-9.9 (th,)37 ( palpita)-10 (tions,)27 ( )]TJ
0 Tw 0 -1 Td
[(transient vision problems,)37 ( or slurred speech )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
16.212 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.4\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 8.946 76.028 Td
[(Pulmonar)-18 (y Arterial Hypertension)]TJ
/T1_1 1 Tf
-0.04 Tw 0 -1.292 Td
[(Inform pa)-9.9 (tients of the possibility of developing pulmonar)-18 (y arterial hypertension \(d)-10 (yspnea,)27 ( )]TJ
-0.021 Tw 0 -1 Td
[(fa)-10 (tigue,)37 ( hypoxia,)37 ( and \035uid retention\) and advise them to seek medical a)-9.9 (ttention promptly)-10 ( )]TJ
0 Tw 0 -1 Td
(if those symptoms arise )Tj
/T1_2 1 Tf
0 Tc ([)Tj
9.074 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.5\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -19.917 -1.495 Td
[(T)74 (umor L)37.1 (ysis Syndrome)]TJ
/T1_1 1 Tf
0.134 Tw 0 -1.292 Td
[(Inform pa)-10 (tients to immedia)-10 (tely report and seek medical a)-10 (ttention for an)-10 (y symptoms)-10 ( )]TJ
0.032 Tw 0 -1 Td
[(such as nausea,)37 ( vomiting,)37 ( weakness,)37 ( edema,)37 ( shortness of brea)-9.9 (th,)37 ( musc)20 (le cramps,)37 ( and)-10 ( )]TJ
-0.045 Tw 0 -1 Td
[(seizures,)37 ( which may indica)-10 (te tumor lysis syndrome )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
18.522 0 Td
(s)Tj
-0.01 Tc -0.082 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.045 Tw 4.38 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.045 Tw 5.931 0 Td
( \(5.8\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.01 Tc -29.231 -1.495 Td
[(Growth and Development in P)24 (ediatric P)24 (atients)]TJ
/T1_1 1 Tf
-0.044 Tw 0 -1.293 Td
[(Inform pedia)-10 (tric pa)-10 (tients and their caregivers of the possibility of developing bone gro)-10 (wth)-10 ( )]TJ
0.072 Tw 0 -1 Td
[(abnormalities,)37 ( bone pain,)37 ( or g)-10 (ynecomastia and advise them to seek medical a)-10 (ttention)-10 ( )]TJ
0 Tw 0 -1 Td
(promptly if those symptoms arise )Tj
/T1_2 1 Tf
0 Tc ([)Tj
12.481 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -23.323 -1.495 Td
[(Embr)-17.9 (yo-F)20 (etal T)74 (oxicity)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.069 Tw 1.625 0 Td
(Advise pregnant women of the potential risk to a fetus )Tj
/T1_2 1 Tf
[([see )37.2 (W)18 (arnings and Precautions)-10 ( )]TJ
0 Tw 0 -1 Td
[(\(5.9\) and Use in Speci\037c P)18 (opula)-9.9 (tions \(8.1\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.291 Tw 1.625 0 Td
[(Advise females )0.5 (of )0.5 (reproductive )0.5 (potential )0.5 (and males )0.5 (with )0.5 (female partners )0.5 (of)-10 ( )]TJ
-0.039 Tw 0 -1 Td
[(reproductive potential to use effective contraception during trea)-10 (tment with SPR)18 (YCEL)-10 ( )]TJ
-0.079 Tw 0 -1 Td
[(and for 30 days after the last dose.)37 ( )37.3 (Advise females to contact their healthcare provider)-9.9 ( )]TJ
0.042 Tw 0 -1 Td
[(if they become pregnant,)37 ( or if pregnanc)20 (y is suspected,)37 ( while taking SPR)18 (YCEL )]TJ
/T1_2 1 Tf
0.01 Tw [([see)-10 ( )]TJ
0 Tw 0 -1 Td
[(W)18 (arnings and Precautions \(5.9\) and Use in Speci\037c P)18 (opula)-10 (tions \(8.1,)37 ( 8.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -1.625 -1.495 Td
(Lactation)Tj
/T1_1 1 Tf
0 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.24 Tw 1.625 0 Td
[(Advise women tha)-10 (t breastfeeding is not recommended during trea)-10 (tment with)-10 ( )]TJ
-0.028 Tw 0 -1 Td
[(SPR)18 (YCEL )0.5 (and )0.6 (for )0.6 (2 )0.5 (weeks )0.6 (after )0.6 (the )0.6 (\037nal )0.6 (dose )]TJ
/T1_2 1 Tf
16.269 0 Td
[([see )0.5 (Use )0.6 (in )0.6 (Speci\037c )0.6 (P)18 (opula)-10 (tions )0.5 (\(8.2\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.01 Tc -17.894 -1.495 Td
(Gastrointestinal Complaints)Tj
/T1_1 1 Tf
0.051 Tw 0 -1.292 Td
[(Inform pa)-10 (tients tha)-10 (t they may experience nausea,)37 ( vomiting,)37 ( or diarrhea with SPR)18 (YCEL.)27 ( )]TJ
0.275 Tw 0 -1 Td
[(Advise pa)-10 (tients to seek medical a)-10 (ttention if these symptoms are bothersome or)-9.9 ( )]TJ
0.01 Tw 0 -1 Td
(persistent.)Tj
0.022 Tw 0 -1.427 Td
[(Advise pa)-10 (tients using antacids to a)-9.9 (void taking SPR)18 (YCEL and antacids less than 2 hours)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(a)-10 (part )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 2.096 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee Drug Interaction)Tj
0 Tc (s)Tj
-0.01 Tc 7.259 0 Td
( \(7.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -10.001 -1.495 Td
[(P)24 (ain)]TJ
/T1_1 1 Tf
0.246 Tw 0 -1.292 Td
[(Inform pa)-9.9 (tients tha)-9.9 (t they may experience headache or musculoskeletal pain with)-9.9 ( )]TJ
0.026 Tw 0 -1 Td
[(SPR)18 (YCEL.)37 ( )36.6 (Advise pa)-10 (tients to seek medical a)-10 (ttention if these symptoms are bothersome)-9.9 ( )]TJ
0 Tw 0 -1 Td
(or persistent.)Tj
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
[(F)20 (atigue)]TJ
/T1_1 1 Tf
0.004 Tw 0 -1.292 Td
[(Inform )0.5 (pa)-9.9 (tients )0.6 (tha)-10 (t )0.6 (they )0.6 (may )0.6 (experience )0.5 (fa)-10 (tigue )0.5 (with )0.6 (SPR)18 (YCEL.)37 ( )37.6 (Advise )0.6 (pa)-10 (tients )0.5 (to )0.6 (seek)-9.9 ( )]TJ
0 Tw 0 -1 Td
[(medical a)-9.9 (ttention if this symptom is bothersome or persistent.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
(Rash)Tj
/T1_1 1 Tf
0.097 Tw 0 -1.292 Td
[(Inform pa)-9.9 (tients tha)-10 (t they may experience skin rash with SPR)18 (YCEL.)37 ( )36.6 (Advise pa)-10 (tients to)-9.9 ( )]TJ
0 Tw 0 -1 Td
[(seek medical a)-10 (ttention if this symptom is bothersome or persistent.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
(Lactose)Tj
/T1_1 1 Tf
0.399 Tw 0 -1.292 Td
[(Inform pa)-10 (tients tha)-9.9 (t SPR)18 (YCEL contains 135 mg of lactose monohydra)-10 (te in a)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1 Td
[(100-mg daily dose and 189 mg of lactose monohydra)-10 (te in a 140-mg daily dose.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.495 Td
(Hepatotoxicity)Tj
/T1_1 1 Tf
0.037 Tw 0 -1.292 Td
[(Advise pa)-9.9 (tients tha)-10 (t SPR)18 (YCEL can cause hepa)-10 (totoxicity and tha)-9.9 (t pa)-9.9 (tients with previous)-10 ( )]TJ
0.144 Tw 0 -1 Td
[(histor)-18 (y of liver diseases may be a)-9.9 (t risk.)37.1 ( )36.7 (Advise pa)-10 (tients to seek immedia)-9.9 (te medical)-10 ( )]TJ
0.056 Tw 0 -1 Td
[(a)-10 (ttention if an)-10 (y symptoms suggestive of hepa)-10 (totoxicity occur)74 (,)37 ( such as abdominal pain,)27 ( )]TJ
0.099 Tw 0 -1 Td
[(jaundice and sc)20 (leral icterus,)37 ( anorexia,)37 ( bleeding,)37 ( bruising,)37 ( and dark-colored urine )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
[(W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.364 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5.11\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc -9.385 -1.495 Td
[(Instructions for T)74 (aking SPR)18 (YCEL)]TJ
/T1_1 1 Tf
0.01 Tw 1.125 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
(Missed Dose)Tj
0.17 Tw -1.625 -1.427 Td
[(Advise pa)-10 (tients tha)-10 (t if they miss a dose of SPR)18 (YCEL,)37 ( they should take the next)-10 ( )]TJ
0.127 Tw 0 -1 Td
[(scheduled )0.5 (dose )0.5 (a)-9.9 (t )0.5 (its )0.6 (regular )0.5 (time.)37 ( )37.5 (The )0.6 (pa)-10 (tient )0.5 (should )0.5 (not )0.5 (take )0.5 (two )0.5 (doses )0.5 (a)-10 (t )0.6 (the)-10 ( )]TJ
0 Tw 0 -1 Td
(same time.)Tj
0.01 Tw 0 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Gra)-9.9 (pefruit Juice)]TJ
-0.046 Tw -1.625 -1.427 Td
[(Advise pa)-10 (tients not to drink gra)-10 (pefruit juice as it may increase the amount of SPR)18 (YCEL)-10 ( )]TJ
0 Tw 0 -1 Td
(in their blood and therefore increase their risk of adverse reactions.)Tj
-1.125 -2.823 Td
(Distributed by:)Tj
0 Tc 5.19 0 Td
( )Tj
-0.01 Tc -5.19 -1 Td
[(Bristol-Myers Squibb Compan)-9.9 (y)]TJ
0 Tc 11.179 0 Td
( )Tj
-0.01 Tc -11.179 -1 Td
[(Princeton,)37 ( NJ 08543 USA)]TJ
ET
endstreamendobj29 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 486/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 25 0 R>>/Font<</T1_0 77 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 747.0331 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 750.2881 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 72.6396 752.0881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 77.3795 750.2881 Tm
( \(dasatinib\))Tj
ET
q 1 0 0 1 324 747.0331 cm
0 0 m
252 0 l
S
Q
BT
0.01 Tw 8 0 0 8 493.5973 750.2881 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 530.2369 752.0881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 534.9768 750.2881 Tm
( \(dasatinib\))Tj
ET
endstreamendobj77 0 obj<</BaseFont/JMGMBU+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 78 0 R/LastChar 174/Subtype/Type1/ToUnicode 79 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 741 0 648 0 0 0 0 0 0 593 0 0 0 667 0 722 649 0 0 0 0 0 667 0 0 0 0 0 0 0 574 611 0 611 0 0 0 0 258 0 0 0 0 593 0 0 0 0 537 352 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj78 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/C/E/L/P/R/S/Y/a/b/d/i/n/s/t/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 80 0 R/FontName/JMGMBU+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj79 0 obj<</Filter/FlateDecode/Length 312>>stream
Hâ\ëÀj√0E˜˙äY6ã‡G#;cn
^ÙA›~Ä#çSA-ŸY¯Ô;“Ñ*∞Á›{ëfí¶}j≠Y y˜ìÍpÅ¡XÌqûÆ^!úÒb¨»r–F-∑]¸´±w"!s∑Œé≠&QUê|–·º¯éz:„F$o^£7ˆ_M∑Å§ª:˜É#⁄R®k–8P–KÔ^˚!â∂m´È‹,Îñ<äœ’!‰qüÒe‘§qvΩBﬂ€ä*•UCıL´hıøÛlœ∂Û†æ{/™<à”î
Òûy¯¿| ﬁ=F¶B,ôe‡Üπ!ñú#CéÃôÛ¿Ïï¡+9SÜÃ"ãLÖòıE–;Ê]`÷Qb>óúYÜÃíıe–YC%<¸ˆ¬–ö‹˚´ÆﬁSk„8cOC7ç≈˚ƒ›‰Ä\·ø ][ó>endstreamendobj80 0 obj<</Filter/FlateDecode/Length 1660/Subtype/Type1C>>stream
HâÑTPT◊~è›ΩHû Ú(ÓÍ€ÁJ¥éÏ.(Ç(®ÄÜD1˚ê%∞œÏ.ˇ®MõZà	íäÒß$ƒ6
q¥©ï®¯K⁄8:5M£àåÌTJcRRÀyxv:ΩK5ùt⁄Èª3˜ûsﬂ9ﬂ9ﬂπ˜ñQ0,ÀŒ Zï±*•`¡
©¢ZÚ:KÏ9Rï¥2?œÎàJq¯åäÅU¬‘ Ã—ıÚ√çÚÏTe˚Ùgj]°LÄf3ÎMï∑‘πùõÀº¢5aÒb3ù,ìs¨Y¥Y,61Ÿ!Kb^ù«+UzƒLWâÏﬁ"ªÌ^…-&WTàìŒ—-y$wµÛˇ"Æt∫do›IÃ®,^Ò?@æ·%:=¢]Ù∫Ì©“Ó~AîKˇÌüJSâ¶Nõù49∑‰ù.—[&â—y—‚jö¢À+⁄]1ˇÔ‹“Rgâ4πYiØ)±o{óHnØùÆ2ÖqãÂUnß«·,Ò:eóÁ1∏À^)˝ó,d∑Ë§*(ºÀ#IˇA2&=/ﬂØƒâ©î°À1¡L$3óâb¨L,«$2)L*ì∆d1πL>S¿ftÙàòf”Ã\d√ÿel!{ê˝GÄpP¶*W]Rç®Á©õ’ø“b‰Œ>Âã>ñŒë}™ùj•ibµØâ¿´ÿœcÏ—¿A/‡W|mZ)öî!	©NîÛº_Bø∆˘8\X˝…ˆ<òT∞rBÊcQ∑	sqæ-}hªç3&…ÈÿÙs¨ü¬l·±ﬂòﬂOçY¸ Ù‰¬|=X
¡ñ ≥&ü‚ìÔ¢mzå)Ck2ä˜E=D(µ¡û ´jbï‚‚!°#Ó°’Ä/b8&`]·EHÖ©@ }øÕ$j{AÊŒ^!0¶_†ÀÏõø-x˙u#∑{'DP[¢(Ï5
{-\˘9D¯x∫˘%p¯%D)OP˝(·û°¶ `Õc´]ÅU—J∏∑:´°ùbîÁˇ`¶Tháö√5–@ ¶É”çxùÄ98Ú˚+KVCä9¬›§›†Üçè0z&£P°¨dùÚÂ?6ÓY€ú~®(êÍÚ{-√MΩ;>©∫ûÙì¿]⁄¡Ów/ÎÅI¸#Ü	>˛QÄÂ‰„ïÈ©ReöóÆµ8•∏–.0cò·0òu∫ë.xâ«ßõ·ªOÅÕ ÎææﬂÅE◊≥æ√®¿å˜ùmË›ﬂŸw˝7U[0H¿YWp>Ú(§·\‘èˇ]»„€íÙ)Ò˘Çn$>˘¯®—_ïâ¢⁄(hÛS˘)ÅÉ J¶⁄ké·8¶¡4˚}+4\⁄÷—ƒœ FCª¡E`“ı*!∞ÅØ¯Q,™6w\8ˇﬁß⁄ÖS{˙Z∫:1Á©ıÿõ}'øü≥&Ò’∏m∆ÿÌ±2Ègﬂ|ˆ˛Â´N˜
∫⁄ñ˙›ı≠ÅI∂uÓ8}ZojaN{+qJ	Œ¯Å¿ïoèÅ·q»Æ	ΩH#øD#ü’5^—ùΩ∫KªˆËeÔ√◊†Çµ∞UCëŸŸûue∆fË@Q¶˙6Kó∆«ó~~˜¯‡Ò•qﬂFıÛŸÒ/Te	Öù(Bv4ìs/‰Œ1†9â“h‘ù≈97ê>Ä´˝]ózÑ]§÷Òã‰Ñ®ÿ“;ü›Èæ5rÔ»íxÅÛÖwV+˚jæÇ ∂üæû˛p0)˚h4F!OqÉ¿D/*µâø?‘ìå6˙kI˘ò†ã<Ë˘Â¿’∑ÌãÏ•˙Ô¥&›¡π´‰5õÖ&¢¯ZN‹:JœÅ˝µ»¶1ﬁÅ•<ŒzÇä ƒ ¡|
f˛%Ò»‚C∆ƒCK⁄ŒÈOû~≠˚‹…∆¸›-Ëæ7Áj®B‚ƒÀm◊Ì:„X’áçœÎ◊7Á≠˚£WË˚Ô˝!ΩÈ◊FŸ{˛∞m"ŒüzÃBÛÁÿO"o‘‹˝Ÿ—ñ›]®¥Mç[_i4<∑}Ô#¥ˇmtéñK˝-8xÆ›b˜è¡å!∞;¶⁄y¨ÖLúõË»ÑyP5ò	sqôÙ¶÷c·¥õMßù¡
1†√©¥ì-CN√¥‚tòÀòÅ?Á…fhÓTC∂Ê£÷3GÙZ›c–FÜ≤¯è…â3/=SˆÚc2·ÍL¿Ú}‘N⁄«⁄}˚¥è6˜¬·∂Ø⁄|ﬁ4¶)„ØáÑÄÈçê'‡lÿDˇO ïùâpendstreamendobj26 0 obj<</BaseFont/IEWGNW+HelveticaNeueLTStd-BdCn/Encoding 81 0 R/FirstChar 30/FontDescriptor 82 0 R/LastChar 174/Subtype/Type1/ToUnicode 83 0 R/Type/Font/Widths[487 537 240 0 0 0 0 778 0 0 296 296 390 600 240 370 240 332 480 480 480 480 480 480 480 480 480 480 240 0 0 600 0 0 0 556 556 537 574 481 463 556 556 258 463 0 463 740 574 556 519 556 556 519 480 538 519 760 537 520 0 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 500 333 444 296 500 444 704 462 444 426 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj27 0 obj<</BaseFont/IEWGNW+HelveticaNeueLTStd-Cn/Encoding 84 0 R/FirstChar 25/FontDescriptor 85 0 R/LastChar 239/Subtype/Type1/ToUnicode 86 0 R/Type/Font/Widths[600 240 463 497 463 497 463 240 0 0 0 0 759 0 0 241 241 352 600 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 240 600 600 600 0 0 500 519 519 556 463 444 537 537 204 426 500 444 704 556 556 481 556 519 500 463 519 462 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 204 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 240 240 407 407 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 600 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 204]>>endobj28 0 obj<</BaseFont/IEWGNW+HelveticaNeueLTStd-CnO/Encoding 87 0 R/FirstChar 30/FontDescriptor 88 0 R/LastChar 150/Subtype/Type1/ToUnicode 89 0 R/Type/Font/Widths[618 463 240 0 0 0 0 759 0 0 241 241 0 0 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 0 600 0 0 0 0 500 519 519 556 463 444 537 537 204 0 0 444 704 556 556 481 556 519 500 463 519 0 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 0 0 204 722 463 444 463 0 296 407 259 463 406 648 406 406 389 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500]>>endobj87 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[30/greaterequal/f_i]/Type/Encoding>>endobj88 0 obj<</Ascent 932/CapHeight 714/CharSet(/greaterequal/f_i/space/percent/parenleft/parenright/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/less/A/B/C/D/E/F/G/H/I/L/M/N/O/P/Q/R/S/T/U/W/Y/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/l/m/n/o/p/r/s/t/u/v/w/x/y/z/en\dash)/Descent -272/Flags 96/FontBBox[-171 -272 1068 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 90 0 R/FontName/IEWGNW+HelveticaNeueLTStd-CnO/FontStretch/Condensed/FontWeight 400/ItalicAngle -12/StemV 84/Type/FontDescriptor/XHeight 536>>endobj89 0 obj<</Filter/FlateDecode/Length 543>>stream
Hâ\‘Õä€0‡ΩüBÀô≈‡]]M¿2I≤ËM˚ é≠§Ü∆6égë∑ØéNòBéè∞‰˚qëúoª√–/&ˇ>èÌ1,Ê‹›n„«‹s
ó~»  t}ª<FÈøΩ6Sñ«≈«˚m	◊√p≥∫6˘è¯∂ÃwÛ¥È∆SxŒÚosÊ~∏òß_€„≥…è”Ù'\√∞ò¬¨◊¶Á¯¢/ÕÙµπìße/á.>Ôó˚K\Ûo∆œ˚Lï∆%1ÌÿÖ€‘¥anÜK»Í"˛÷¶~èøuÜÓøÁ∫‚≤”π˝›ÃY]Ó„‰™R∑é˘=Ê¢Pç◊*é´"ç„-f«åy’+Û+Úä9Õﬂ2oëwÃ;‰=Ûô5‚-´-ﬂoÒ~[2ó»sÖlô-≤02=´ÃäÏô=2ùNKßÖ”nò7»4[òÖÅAhÑÅAhÑÅAhÑÅAhÑÅAXWR]ˆJ–+aØΩˆJ–+«^9Ù —È‡tt:8ùNGßÉ”—È‡t¥9ÿ=˜∆¸ÜLèÉGYKQKYKQKYKQKYKQKY+Ì'’«~Bf]E]eO=Q“~SˆD—•AìÅ=QÙD{=ÒÏâGO<m6OõáÕ”ÊaÛ¥yÿ<m6OõáÕ”ÊaÛ¥yÿ<˜å«ûYamUî6∞«I¬Qã_Ûyé€èyéG8}6“Ÿ≈©Ìá˘eô∆…ƒU∏≤ø ˚ÖÎendstreamendobj90 0 obj<</Filter/FlateDecode/Length 4709/Subtype/Type1C>>stream
HâlTiTWÆ¢©G±ÿh◊ñ§*†"1Ïä¥— ¡„B£†¥B∑v∑çlj‘q	—¡AâöàjN‚Ç£‚'≠éTT$ Œë—sŒ-|ùô©Ü,gŒÃèzuﬂ´ÔªÔ{_›wI¬Ÿâ IÚ≠¯Y…sÊ%Oås-¢Yó°ù'Æí4ÊÃ†X˝|¬OÚ%%ÁıN“[,é∆áﬂ\yEIÇß¥p‘wcºî™°Tƒb$9éœ6äZ≥hWØ—Êf•Èb´
å∫Ï≥¶Váæ+ÑáÜÜ1ôÜèEAS`2ãy&!^üa0Æ2eZf∞ìõ+LÇQ4âFãcÒuÇŒ$h≥Qõ)Êiç+Cñê†”Ã´D!VŒ,ì≤u&áÄLAßÃ9¢∞(X,,ê≥ÎÕÇVü)$˝¬ûüï•ÀáÛ¥Ç¨ÈøŸ¢—¨ïﬂ9çQX±∆®3eÍ2Ã:ÉﬁÙsrΩ6O¸?*FA'ü WNØ7â‚ØüÁ‰}2[ì‰òL2≈,Bˆé$DÆ≤âJ¬ó ¸h"»ïà"à©1ç ﬁ'àh‚wŒÑÜ&πï$f;è'à2åÃ#À»£‰E≤…)¬)›©^°VXùó8Ô¶&Ru‘}j °r‘„2—%’•‘≈NG–“:∫û˛ßÎB◊]Æˇv”πY›˙›C‹7∫ütorˇ—c∑«øF,q^È≠LV∂z
û3=óyﬁÈ22u‰≠QÆ£Ù£Œéz£ßZ´˙J’œ¯1j&áπ
K/I//ë0¡K⁄6∏¿æ¡N|ì≈ÔC9›¯
éâΩÃ≈éRábxÀs$5∞é;fJlP¬ïí´P{uπcPÅø∆ﬁøp_ò¯ì§d5ªØ∑ÏÁ[ˆÌΩ~ùªæQ£.‰’≈c√˛IÉY‘,ƒ¥&˝ j ˇZ"Cô‹ßYp?÷ıÍs˛UMYvÁ∞{nHÄÖX≥9‹9¶û„NrºÎUç)Ü¨ÇX69 J¨«S,oºÚ…gÕ
ËLe±'ˆäƒìt8bﬂá#Ô`ñ˛Jˇ-0∂"O@»mòN‡Cˇ Ö§«ä
ú¿Ç'x˝ ìN@DÑ@d<∞ÙRt˚Ô¬csp‰
íÄ'c;∏Ü“Ú,åW4yùC[L3÷ÂãÖ>ü,Î8Xs∑Í°Oı*)ÿﬁL@•b ∂≥∞Ìk¶64Ãmô€Ö8ê8æÃ2XòOÆìñ)÷ï∞V$ç,§‚ë≤¶ƒ*Ω∞í?ºÄS/I	ökê	ÔÁ·É”µêà5÷$·L∫Ç«”≤ı84úoX=q
¸Ä‡Ä0aø°œÅ+≥±?&8L<Œ+kj,RÌ-†e‚‡∞‚§Z&"LŸk©VÔ¶PÛë1` Ü∞-¥≤¶¥Y∫f#•¥NÖ¥¥ô≈7–Åßæ©?Ó/ºªÔﬁ∏q˙ªäœÄ¡Q7#è6mËÎÚ/Åí{X?o_4}Yz‹í9KºÉÊá∞7-	CgÑ:ÎÔ-p–™˙æ6th€ô«xŒ2Oœ£∂⁄‰®{„V'sSã4VÚh˚F*w≥	OÖD∆¥v {Ñg.ËÀ∏]EÔpiﬁÒˆﬁ˚4Û¯Òæı˝xáÖG¨ñ’4¸˘ÀÁ›‹›ä≈sK¯ô≈iãfpi»·D€$1ü¥JKR†tá›Åf„'éC3 ÿ¬iÏFŸ8Z∂‰DSOPïçzıI"5eX¸K+7ìMÌiª~≠Ï√≠‘æùó˛ µÔQO/‰cã3∞s ¥´˚tπ,>q˝VÃ√4&¥ÄºèxlQÎ€‹“îÇúl~˚h)ÿ1T-˜Ü7xjÉD´™•6u¶µ3íÙµtíe˙OîÌ_¨Ê∞6õqdèrW„Öê¬ÅwG?¯÷Úå>µÈùÿìõæhÒÍ|~;⁄sùb˙OóüÉô‡∆›:î∫`èkÒñëö™NwÙp=üÜ≈Ò1EÈa”±•£©j∏LÏÕ$íE”%;èPDÿÙÄπ˛Ò~…ÿ)[†˚–9◊#Ôyg†È˘•ÀUﬂ{€'ã?oÖb´ ÷˛«vò–&ˇ⁄˛fHfÉ◊Vc"8à∏tw5_”k¯v⁄ëGµgÍ´“L/†CIVÏÃaÁ®xåL|QÙÁÀı4”jH^`y◊Å∏,iÿøU/â+·„K2>˙êõ[x…Z…ﬂ©¸Íb£¨ãˆÏ≥˝ı∑[∏ñ	rE,OPsÍ¸€œˆÛC≤m‘™z“ûﬁ	õ⁄ôó≠*[∫bs1ˆ5⁄õ`Ü»:∆˚Bæe)ˆÛ√æzûyâ}gB¡ìkævÂãj~ZØë-Õﬁúäga7næπ˛ÊéÇlÈÀEY·A\–gÌ™¯Ug⁄€damª¬gÒC= .8⁄¿2DHcŸü:&Ï;éïvÖÖÏë=`b•Â∏®“j˜ÇdI…r‘Äã(Â7rÌ¶ÿ†ÔuiæjìT¡<⁄$˜î^H°`-⁄çS®.î1òJa7ƒt◊çóÀz?Ó£pRﬁ*µAç6ÿT“‹û•ΩÃk–C7€è]-¸ÏíÂ	¡ˆ@ccYXå ∞˜[wîØn3ﬁâ™ë/ÿΩÍ+çïç4”|Ì{Ád§ŸbŸ†ÁG“cäyÏdöº1ã/ÔRbìzm‰ÎN∏ﬂ#7πN≤dVV¿hPü‰ÂÁú)πŒ=≥ßÛ]Ñ√È-x<á?ä¡'ÚÚSÇ5∆´5*™Î
3é˜HL2ôrè…’Z0àÜòhààAD§"®(ÒA"ïAGN	
Xyàµ*‡ãî®%È¯öäà»´1Kõ˜e¨›g ∆ïÿµ˙c÷ösÔ9˚~{ÔÔ€{ü0
ŒÕ†Z!©ËçÚ%,DY˜ïp™œ√Æql{#Jb#>	fŒÃÅ:ô°áXt<¡ªRÇ‡{¿ï≈`π$*Ω	≤LkR‘…˘ :k˘7f±}AŒAñ ˘ÊE>9±îÛEø@TZt«sg:…5Ë¯_õMIFˇ:H1B•—ä;_¨ë{‰ME∆ò≈ñ=Á›ÇÂ;ò¯Q”Â3è ôDmºù` ÕÚ0Å≠#⁄Yå%bçC|8õ¿T/à[GÆœª[$ï	—=0Au¢ª™Ï{°ôÀ™ñJ†Zp!Ã·I®–I˛	H%3Ÿ\®Xfa|_(ÇÌfó¿…‚ÇŒÍM}jnK‚—Qô}<IÄˆ©˘[H’√$&∆˜Ì∂z™ò®≥xj1Gg!F◊s∂}CÖ4r…P¥èŸ·f;∞‚∆Ÿ$"V∞º˛F!ïƒ…ç|ç˘Ñ·váUù‹%FõÅº&7·…ﬁ˛&^˝	˚Ô·A¶êÔ	å‡…~}ﬂ7ªî≤g_§Êyﬁ$#oÇ)_á 3º+3!Ä”DdÜj≈‹±d∫Ø
≈/
≠™ÉzeÇTãøoéœ7p{ÅW][¨€ÀN1˝\ |ËﬂqhV{áÑ9asËoân≈RM}≠ø°¡X˛∏Ë{€g`~¯Ï©ú‚£R»W›Üı)Î^ Ï¯Œ±”÷.¨È(®ÍÌ5#ÏFEø˛mfè¯àæ◊xôT◊¶¸.I⁄ƒî)´v.Ã÷⁄ˆíç9€‰4 ’»¨ãÎœ˙e†®;újÕ3YbœJÊõão"wÎG“ZÊâ™~# AD]âÍ¯Ä_ó∫·z∑RÆìK5`Srôç¶lv ≥ôù$∞\¯º¥îÖZŒHÙ	ˆ§L≥ØΩ%O‚4\Û˘òNÅÕiÓ‘ÿ«û≤WN¬À˚kè]ßm˚Éx}D^™±„åìW(e«>µºÕ⁄
 õ<"å>QscÅÈ{3A—ﬁ•º´4ÿˇjﬁÜq∆tuÒˆ˜XﬁÖ¥”øKò8ô∫∆÷¸X4¯T˚ı`ÕÒrå∆‚	NO-u†mC¿Œ˙1#!ﬁL¬$·cµÃcI˝∑êÉ≈Ú-a,aqÊE..–‰gj;9B	z(”Ãceà≤ †\˛ÄW˜U¨√ÀÜJ/Ñ˘˙2ä*ô(´¯ÈEˆÑ	‹˙2ÑG¸?Ûzn[nÉv>‡zë§Ÿ∏Åπ=…¿Ì¯O™¥Iˇz¯6Ü¨Œu√¨€b,ìák“vÈ˘ÌwÈÖí®`ù¥-tÁ&üÏï’#ﬂã_î¯Æ•}BŸºáÙL›·/+Ã’ÁÉ≠«ÙGhaq˙üˆH9ı¬ß;RRut›Ó¬¢›R#‘
≤øcnîçò»TÎ$XÕ¢5bÕÇ-æ!Ë|]ÂπliÔÈ¸¬œÛN7eTñY™xîßa*ÿætù+ 
5?ÔÌ¶¶4w6"ZBK+\<ËÔ”¬êbI‘≤—¨P”ÇecêF¬?´Ø£†n∞«±whI>^U∆”¿˘QK¢p¢9…|[É-˝~<(
chÔ(ÂèÂó49z∆ªâ˚áÃâç¬˛‡ª‚®3ÿPeÄaw
$7‚øyÌåYt¬as5WÇE«ø.≠•ﬂd~§ìû≥∂î voƒ#U∂öh˜é±„‚8ˆ’.é‘#µK≤ZûØq#ãX2í‚ãm°áSfà∑™°Î%ÊÒQ	@§ué+0s◊bN,7Ä´AÅ_—µ)!nj“G2 ¿¢ì^Oﬁf)%J∏>[ìQ.¿∞Éπ0éèÿøÚiBÿ˛=}
OérõNﬂ,5^ΩêB8æ≠1 1*Z‡∂≤≈∫ç<î◊‡dÄ·u"9çBEf·æ£¥ä‰?2mÈ≤i•ÕæÇßñ	ËkÄ·FŸÆŒﬂhU’÷	⁄R±	n»1ö¡âçò‚L›ˆÇ¢£@é¯/X\ßôNƒ&≠Ü‚DÍ c˛îçˆbØ≥Òë8yØe¡‡Lø∫p®˙FBÎ)àÕ€ì¶‚Â$luAÕÙÅçJçæØ/Ìu‡ZŒ+Ç√s°ê'w+œ£Õ2L˚/ˇµöﬁÿ‚Ω<Yzªü‡Ñ~KVç9≈èŸtÒÏ»∞»ü¬õù\ñÔE=Ëîıhà\ÜoÚZ5m§∞Áß=\¬œvŒ„∆ãˇ<Å<©ﬁÈ´¥Â]*©¢WûC‚ßœpç•VÜ¨ñ.Ó\[2óÕ˝‰èk£x1ù®û}fr∑XÒx9ˆgW, ù‰˜äkê“©lGæ2˚µ{ô8Qpº4®!˚#[¡Ü9QÊËÕlΩ„Y§f

–Ú†Ñø™áwh˜ŒâÃ2F¬ﬂäâ†*ÊoÂ©8ñ¿ñNÒñY †*-Ôºg÷Úﬁ%V∫£ñw˜˛P$±˜po#g`+ÍxIVU‘ó$#ºÉG$p)_©@x¯éˇÚÒ37åAƒUœ∂î´Û ‚a#‹∫
nTû†á≤>›ï)â9˘≠Çx8=Yó∂âŒ[æt—*n·b^OV–@Œu@"÷ÅÖÚkö∆Ï<∞`Œ‘—eÒƒ8)ñ)7‘«’«5jµ≥xÉ⁄M›w|˝è§›]4£‡Cﬁ9èmP*Íı+ûW‰W4';ß—≤iC∆!zqoÑWWUäQûdPÙ‹U¬BπL3(ûOÌæè:Ëﬂä””˛,Â^vm›ö∫ëÜmœ;ô%ÒÒÎû#)g÷\db¨Lòoπ πômx$z}Jgd_:û)q
∏ëi˝j¡wsÏKk˛Rc£QßXAÍ{ﬂ‚‘∂µl-FÉìuÅl‰∂üô˙g¢∑…3ÕW
˝wˇï]ŸØ∑¿*Ô?Cc√≠Ôiˇ\ÅÕ∑òÔ“boAµû˜/`tı¸Òﬂ[Å¶Äk= øì≠(ß¡ˆ€Ãô‰ kΩ0`√„@Ÿ˜©Âåt3œ¯æZÙw“Ô’ ›ﬂ3N˛Œ ≤LøØ˛˛}*®
îˇ¸=‰ñ∞ﬂ.gJï3vˇòƒ¸›™A¥0Ü5Ø∫¥$E∫¨∫ß∑^û]3gvÆë˛∞˛ÏU`ÛgÂè ˝æ`Ô‘@º„
Ï
»\f\ˆ#î˘ª‹è—Ô’løÔ¸QUäAÂŸÔ&∂Ô7~»Õ∫»˙˚:∞·ÚΩÁ2„Å”ô|Ô˝—Rß&∆3˜3˛ò≥ü˘ª”è´¢˛Ïﬂﬂ˝vfÌ`ˇ¢¸Ÿ(}Oc=¿ﬁÛ˚´Ë˛?·Ï|‡“ÙÓkÔÀB∑‰ﬂ ±<˝.ˇ'K^Ùø@*|jg˛åõ˘;dÊwïôlﬂóNz4Èœ°…ÏUs~∆Õ˘ù5ù(Ú~“üó”9œr›Á>>q‚ƒÂ<<«˜˜Û˛H˘/
` 
r°Ïendstreamendobj84 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[25/minus/uni00A0/uni03BC/lessequal/f_l/greaterequal/f_i]/Type/Encoding>>endobj85 0 obj<</Ascent 932/CapHeight 714/CharSet(/minus/uni00A0/uni03BC/lessequal/f_l/greaterequal/f_i/space/percent/parenleft/parenright/asterisk/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U\/V/W/Y/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/quoteleft/quoteright/quotedblleft/quotedblright/bullet/endash/registered/degree/multiply/idieresis)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 91 0 R/FontName/IEWGNW+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 536>>endobj86 0 obj<</Filter/FlateDecode/Length 650>>stream
Hâ\‘Õj„0‡ΩüBÀvQlKWW5Ñ@˛
YÃìŒ§∂“1L„∏ãº˝ËËÑ&ê˙∏ír?]lïõ˝v?Ù≥)NóˆgsÍánä◊À«‘FÛﬂ˚°®≠È˙væﬂÂøÌ˘8eZ|∏]ÁxﬁßK±XòÚWºŒ”Õ<¨∫À[|, Sß~x7ø7áGS>∆Òo<«a6ïY.MOÈáæ«Ô«s4e^ˆ¥Ô“x?ﬂû“öØØ∑1õÔkb⁄KØ„±ç”qxè≈¢Jü•Yº§œ≤àC˜ﬂx#\ˆvjˇßbQ7i≤µµ]¶ºJπ™VÚŸ≠7»õ<GyõÁ®¶o€qÃ#ø|ç5ÈﬁV˘ﬁ‚˜¨g∆<˚Ã¸å‹0Á˘¨ü.)Øô◊»f‘≥¨ü.)Ôòw»¨ù.≈¬±ÆC]W3◊»ñ{uéŸ!3ˆÁËtp:eV‰¿êÈw;˙¸é~ø£ﬂ¡ÔËw;˙¸é~ø–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùß–)p
ùíùÏ≥†œû}ˆË≥ßﬂ√ÔÈ˜{˙=¸û~øßﬂ√ÔÈ˜{˙=¸ûf≥ß”√ÈiÛ∞)Î*Í*Î*Í*Î*Í*ÎÊÁWY7?Ø™˜Áôuuï}SÙMi»œ≥≤oäæ)=
è≤o˘}–˚˚ëmÏõ¢oz7–∑¿æÙ-–‡Ù¯˝˛@Ä?–‡Ù¯˝˛@Ä?–‡Ù¯‘µUç9çe∆ú∆1c/ç0c/çœŸ¬÷(ˇ€ä{\aèkÓkç}mÈŸ¬≥„ﬁw<êÓ'é¶tÇöœsØ˝ò¶t‰Âc6üu8Â˙!~ûƒ„e4iæ≈? Ë.L¥endstreamendobj91 0 obj<</Filter/FlateDecode/Length 5144/Subtype/Type1C>>stream
HâlT}TWCòIöq£&S@êV EbHQó¢+h[1íAÇò`†à¥¯UqYËÍ™’„⁄Z=VˆH[D[–•ËÍµf©RFz∞Z≈s_ˆcÇ∂û=ÎsﬂªÔﬁﬂoÓ«ªè@ﬁ^à à…©Û2Áßgæë¬s6cé>ù+‚“ñËlÜà$ì«A…øFº˘ ?«·ºgû≈ë|º?o{qR`ÉI$A˛(MDaËu"ÅH+2U*≠ ≥®ﬂJ*‡¨Vn]ëæ 7ª`µÖ”€8À’òd.,µWÁŸÿhçF5ççQ©bX≠¡ºäcu•V∑÷ ¶örÃñB≥EÄ"YmA;∞≤Œ Yä=áø≈Œ≠¨ûµYÙn≠ﬁ≤Ü5Á≤iFìŸVZ»±IK§ Zm¥z0∞FkÀ„ÿw"uëÏ"Å›dcı&ª‰7Ù¬‹\c7r∏V_ 
1˝/:á≥ÿÙ¬jh,l~ë≈h5slF≥…˙+πIøñ{Efk2(ËMVé{iûøvUJdT≤nâGôŒ∏\$Tó@àBH2†YÕF(!≠2#dC®°/:B†ZÑ:±çDŸûÆºç“—Ñ	5±Ü8@¥7â_à{ç˜ Û⁄·uK¥\Ù±®À{æ˜áﬁn≤Ä‹J÷ëW…GM•Q{â≈ÒÒIÄ$\≤LR)˘Lr}‘òQŸ£ˆéˆ…ˆ9Ô„Ùe|µæ˝÷˜ﬂü˝d~˚˝ÜFkFÔ›/-›*=#ÌÚß˝Á˘g˘˜ø7&fÃÔ«‹´ªql„ÿ«≤â2Ωlè¨[ˆ:û^LØ£è—∑∆m˜«qm„é{ƒƒ1sòπ ˚§™ôl&“,™ÚÊ+áπ+)®¡Ìéá?ë0@aüe¿£∏wä›‘äë=ƒcAß¯V∆≥√M*Ö˝ÂÁ†ˆ‹˚!;Ì {$›
Ûx)£´lÎÌ≠ikk´—i4ï:ùró{ÛóÜs…y›◊ˇ/’ˇ˚–≠Óp®g¿˜S◊√áπ∞/ˆ˝(*,Ï”(U“}|8æ˚jõîzJt∫Dù¸”h•r6ï‰≠Wº'Ó?¥„J∑¸VîX*D=≥¯Y@	Ò]üØ`¶·Ä,<´Â8¶«ﬁ√å‚•Ö‡’±rà™Ö7aÇ‚%®>Q+NcÓC@Lµb2!6≈ªT'˛á‡X9é2·≥∞¬ü,ÅzA°ºãaO-“ò—úÎ¯≈1•π>·ê_µ≥´H](ñ>9XÖv>∑ã‡Û ;
D*.ƒÖ©PHI´ûßÍC`{q*EÁ`;ï=∏Ú%¬ı4äíb”Œ‚·ı%ƒFhm,gÏl^O¶R“≤r;ÀNw¬Nl)g@∑:ºUXáuÿÄUxˆú:%¶‡™–$ò¬∑‚`å0⁄
¡Æêñ,Êk/,Ñπ20ı—W/Ûµº·ÆÌ£Ë˙·¨Öb˙Í∂0MEÃ«iYUˇ7—ËÑ5Nø†á¡ﬂSªõéûl®{x+«+ßæ$ø∏h·ëú¢Saπ¬Iù®àÓ/S”Á‰ÆÃXÆXºúú=_çÂ<;í
|eﬂZáÏ≤gºÛ[¯¬ô‚§ª* ˙ôSîÛDfˆK_ó©§õ*f≠ÈÍP™7Q{,»ÄIwÄyê’ÚÊ~EµònDùæπtM˛£qO≈„3‚h·˜≠ª˙Æ^∫@Aw£π˘Ô$*Íl ì1$8xNËwÉp¡Í˘ÀL5æÅS®ÑùÃlÿÖ˙ ·Ü„Mûõ)âq–ë=ƒ	'ÿú¢vËc∫∑ënh˝˚ÌZÕú§2ÏQ>PØPSG∞f√‘vA Ñ'ıΩˆÓ{•y&≈ˆÍ£†'°∫_}ûÛMdÿe_;¡‰Lr“C4œk˘Øô∫ròå5Xø€p,€áCñÇÇ¿+C0&º}˚œYπt]πr{UøÊÇèÇÊ/‘≠X§ﬁ≈t∏sOpøw Z´µF´ï4Ø∂ﬁÈTé¥◊›CÁßäéÛnÆS…—a˙‡Ï ˆ˙êï<†ˆ¬îs
à∆ßm˝-í∫ß>œ˚î6ÿeıŒT'§Ç~\ôLd#ñÄ‘ç ∏üs>ˆ®ÇºV{Ït∑®d;ˆ∆ﬁ…©òJ8ˆ˛5ìÇ~kŒY4MNB6Øc˛Qª<%’¥ÏwÃÕˆÀGˇ⁄°§c±{ÛS›•ﬁﬁ∫¥∏∏¸4ç&ˇ“Oäëøg8‡¶ßJIû:	UlìøOËwÉb!¥\∏Úû"·¿˘Ax2ûpQ˛=ﬂù=≤OY≠£Vo¡Û∞P§¡Ö˘ß€ï¬åt1â•1Ç{DÈÌÆÆ√∑ùJz–y8&Q)å4ΩxíBœ¸πkºG∆•·ïÉMœ›ûÏ-&ö¯QXæóëv±;2y·Ûl='“'‡cÖ˝Ö_ó‡gw◊P¯ê˜ÛÕKéÕÇ	 »NXR≈|"Œt)˝D∏∏Yx®™D∂ôﬂK_ﬂ‡¢ŒB	P-8ãtQx…
˚PÙ@[(SM›≈HºÑí™r¿A;T8dÌN∞∏í]¬Ω
Öfà∫~âO^ì©ƒ~î:âÅ•Ñ˜ûá)N√eıA•0Y|«grPF7F*∞ôr&1?S˝ı+µÿkÊ¶\e®@^Ó‡Ô;dg\∞€5√E?¢¯0·Uõ^π!åùà•e :¶Ÿ/,R%˝ËÓë‰Y’JÏ∂Ù^:/À^≠úÚÂÈÆ®(Æ+Ï∫;3ƒ‘e®¨ùëj@ÖäÏäH¥Aƒµ""" î*±˛Û+àÕ≤Ÿí‡O–ÇÄ6H£àöÒ'$J]c≥b\Åéa§ÿDÉ5Íù=ŒÈùÖò‡9=gœô}˚ˆﬁ˘Ó}ﬂwÔ}$Rˆ>LΩ
Æ†€+h[L6˘∫Mu]ÇÉΩjpxph¥Œ˜\¨d˛BÄtÒ«™ë∞Ç»Åƒ–⁄tìˆŸaõ]’å≤ıêi'`î€I9íÁ§Ωü¢µqò–Óü˛#A˜˝≥;l—ÕPhÉ∫°¯V∂Åmîw»•‹È¢›FV=`i-âÄEX©Ï_\j=,òi6w≤Uf»Ê0fÿˇwà—Oœ6v[0ßX–ûE Ï`…B `ƒÚ∫ª^ ±#Xí%x FÚ@¬æ`©Ãt$g·u$“⁄6«Ñ,Uïo†°F1D>Mz;.dÒ∂˙f˛ä~13˝‚Î2¯ûËñWXÙìÿC∑?ÇXÚÄzHìùr¨áÀ‘$öò»˜îæG˜q&ª√uËÔ≤÷NŒ;\ÒWXç^4=™Iˆó‘-Ec¶a⁄ÄÜí·–PÊ¬#i2æøç2‚Cn£pâß
£&g ∑`,≤£-ìÿ$B≥ÎÂ[fr˙oQ0Z	å-ÎøodHæ|ü"4⁄9i¶¬c®A6w¨ÁûSß©ì 	µÉòü1$A”Äˆ/ƒ+jv|ºêyAõáoBUÿîåoÌuÊ¢	T4åæ€c`	4E
d¡ ﬂªO«á˙«¶¸A¯Õ8‰?≠‰ØÑY©€ÅgèΩÜ^>ÿÂ≥•GéÛ—Wπ¸‹å¬Õ/(b‰‘›33bCÀÚXJ{ë}eÉ˜ùbÕV$ıD˜ºL≥≤Â≥¬I%¬Dm^[≤ÏPﬁòßtfÈŒä=w
A˚´=≠k/Gñ∏†hü¸´¢∫ÀÓ‘\¨»<ŸÆDÒÑÓjH	'ºø)N¢µ≈É™=.ÕÍÖ)¨óΩ…ﬁñcÂè84F~I∆Íàa#Ò4ÏMrz‡%íÏ5;6!úgÔn˜7B M¸ßC»#› ¡<{íÚX·ııßıÌ<{[¨é√ öé4qµ´ 
áïcWÊ€˚cB!b¿UrVÖπóêÖí˙¨ÂàØuN%„˛y~ÕÀEÅ˝EåÔ∆ÿﬂ≠k|¢,Ì:”£ÖΩnF9ç›s<@C√|¨y8Æêq˝Öi„dÆµêi¢˙ëj{ÀÿxòÏÒåf◊>ñoQf˙!RÌæhél+%™˛N4˜ë;)o⁄«˘ù®pÅl_7(gQPÀëZ	jàñÁ·ãà7È&c°õöåÚ, ≠é´ nW€q Ö´è£‰ëïD¸lÔ±]î)â0<(Ò1 n +ü¬ƒ,•”¿LπçK9J◊Ô´¯§åo`¶o+åòÌ‘Àh„vX£[‡?ô0“ÍV#Õ!LdœÉõ<ä{ü9l˙¶˜Ûè7$$õreÛÑZG±Û2ﬂäõ„Âw!™Ô“ïöã’<ñ§Ãy≈ı¶∫ ™‚˜>Zòw˜Ï6ÊÎ6õ*´∏¬|nzHÙƒ=.ñhy¯êl‚ÿÜ•Àíñ.…Æ˚¨·`eu_w§Ω‰x≠ã6])ãÚÃ»rkaÖƒ6"ó+π üˆÿ+Çâ;—fÜæñ”#y6o©‰:h∂—jfR4§6Î¿ı2xÇhrÇÚjl¸ÜŸÇvÈïRfÖo3AmUùê`â®ñy˘%ÓÔ[Ä¡⁄ºô†T6MEcØs¿‹ÂıtÙˆŸa>EHàø˙—ïT.é„á°√!kÖàË^At‡^—eÔ)˜O¥yÅSB≥∫¿ùá:y	ß'ªåÙÖÏ¯öDÒÀ¡ìÜÑ^$∞ÕııîJûgËp¶ﬁ¥BêUuZÇe»w∏ÕU0'ˆ√©˝‹(~#∏ì0y0á‡aÄ}N¬ò/pjæ>dÇ	\ª÷QÄ£Y∫hõ™CTwxàrzØ5†ç>]~∆∂àûπv’Laa®¡Œh”ë:x[ì'7G€0®7DÃ{6À[8gD#s¶O’ÔU∑3HÅ˝¢öπöΩadŒÂ'’GÎ»ÿ’8!Ω:w?I¿{©⁄R.ò√È¥‚dé≈)k7ÓÙ4Ò:ú©V#⁄õ!»)_yãíIûs§®nBî4mo˝ÿÚıüÁø…˜”¢Ï ¥ôû>qÒ˙î~ï&%◊f˝˜;UãàΩAîkıtóF¸ŒπE⁄3´p◊≠Ed-0AÆÂÙ˝MtÇ)5Æ ﬂ¸^œfá1¨•®¥‘X™˚˜ÈO%¡Q¢—˚âŒvçnaπÇFe–ÕÅíïvµòò(£™H¡@ﬂa)«éˆº]‚p$Îï≤†ƒ§‰±MÑ9 «},€ÿÊLl=zÊ∆èÅ—Ã∞Â`úﬁK◊$mÂ[s”éFÍ‚b6.œå4€Ÿ¬ÊJÒÎLk˘øπÚv⁄Òhw[±C^…s≠™	“$uï¯’OÄ)gú2Ò[û»§)´â'Ò„±ø¨Á¶ÁˆÅ∏î˜›Ì)Û%.ƒ%«w	»ÑﬂŸ‰C PóùN]Çˆêt_Ê(¬g£0ü˛¿œ¬¡[Ñ3Ω‚∞e√Eß‡ulGÅâ@6:)55_	ÏÅU	ÏÁ~’	]Ëw|é˜käéxÖ¨ª(«n≈/:íB∂”`dÍÈ«&äüSƒÑãñö à§%Iò¥4qG÷1•í∞≠ò3Ë•Ô}YwÆzˇªE{y∂¥ãa[ãwΩmŒ’EΩµ2~´™¶/f”úYs˚´¯{fäsEgˇ¢‰W∏∂¢BA¶Í¶Ñ&˙ııÏk{ÔZÜ5/Ãkv‰ŒM¡9ªÜ:\j&:X–w≥	®ßÜ#™∞a™∂y›j)©n-OãPÙYhì'Zù‚Dé¢˚i:ºÚè›üTõ7ò¢w
å9∫î¸≤Û¬ˇ(/ˇê&¬0és\wWf"⁄â§›T≤\ö∫`ÆUòêÆ—¿$˝CƒA`EÑÿâ~	≠fòÜ»"àå2QBëmô¡@ª®Ü§≠ê	¢aS)Ìy«{Aœ›\Y∑˜«ÒÚ}πΩœÛyøeFŒÖ|‹W§˙ú<=$G;ﬂ<o>x¨zè„uüD¯%^∞:” ›;‘5pW≠Àß≠X`Œ•ÍOh'I∑º§Y2IØ∆∂-JÚh)“»ñ„Ìn ñb≠=º±ñíB¨MbÌ≥bA' â∏R≈⁄N^Â∑„´,>_Î±èP3hŸƒ¥âÖm–É•=∏+˝Nè™^"z ⁄QQOmÖC™¥ÅÀ·ß‹"ª.àçU‹ÒãgÎè§446_?Ø+Æπ\W{SÓ £wtêGﬁ‡¢m⁄ﬁ”#{O√K}™üÅŒiˆ19"B#OØ(\)˝Ùí MD‚ﬁ“˜¯ˇ.Ò√Ù+d‚«ø0ëñVfe4˚'q∞–ºä8¸äo<∞„¬˙!,Í¶P(ÖLΩﬁd“K®∏∏ïC:Á•ˇ·¯®ar•È∏lí;eÉåG˝e=dH4[É¡··`–:l4Z≠Fi0…Îv{ΩÓöääıq{•8xyŒ|êÏõı1e0»ÄU~£Ã¬êD,Ôxà•NÊi<ÿ8πÕÛhlC∞¢/[¢ªxôñãê<%<y⁄Tf9Ï∞È®R/R;“B∞cÇ÷‚®ê⁄1pû⁄%Ù##"5„uE{1‘÷åëJut/Ü⁄öuËUODçÍ	1ÍOªI3F XRﬂ-∫˚i)hQ”Ø^tqTb∑C)’¢{P¬E9 1	g∆ùŒÒƒôe$.öC‚¯Çôáõµ6.Ze~Oûè+&œè™	ë^åÂÂÇÎé£3EÀ"”j5ﬂÚ0œ<,)ˇ&˙:≈∫äyÿ«˘%É÷rï…§œEè¢Øå‘l¡#¸	Å	»CÕÇ.+uëÚV]ë"÷KFEõ s¥òC√2G˜q6Å§C-ÁÆ”o(ïıKÍ”Ï)iﬂÍÀ2;œπ¬’.ZÓÇM.Ó∑M∂)/n
goá´o”∫é’83ﬂ¶|ÓX#«L¨ıµ∂∂v≈∆˙Óµ¥ƒÆÉ¶ı§I¸)¿ •›^ endstreamendobj81 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[30/greaterequal/f_i]/Type/Encoding>>endobj82 0 obj<</Ascent 961/CapHeight 714/CharSet(/greaterequal/f_i/space/percent/parenleft/parenright/asterisk/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/equal/A/B/C/D/E/F/G/H/I/J/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/\registered)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 92 0 R/FontName/IEWGNW+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 140/Type/FontDescriptor/XHeight 538>>endobj83 0 obj<</Filter/FlateDecode/Length 563>>stream
Hâ\‘Õé¢@‡=OQÀÓE•n›€ù[Ìƒ≈¸dúy Ñ“!Å .|˚©√1=…ò(á ﬁ/'EÂõ˝vﬂµìÀøè}}àì;µ]3∆kÎËéÒ‹vŸ≤pM[Oè≥˘∑æTCñßá˜Î/˚Ó‘geÈÚÈ‚uÔÓi›Ù«¯úÂﬂ∆&émwvOø6ágón√'^b7πÖ[≠\OÈèæT√◊Í]>?ˆ≤o“ıv∫ø§g˛›ÒÛ>DWÃÁKbÍæâ◊°™„XuÁòïãÙYπÚ#}VYÏöˇÆ[‡c«S˝ª≥rπK7ÖÜU )/™È˚ñŒã≈|û)f‹Wº2ø"ø1œ˜Øô◊»ÔÃÔ»ÊÚñyãºcﬁ!sv:d•Á\èπ~…ºD.òdœÏëÖYêÈÙpzeVdc6d˙=¸û~øßﬂ√ÔÈÙp
É– 0É– 0É– 0É– 0É– 0{Ù&Ù»ÏaoÇﬁÑΩ	zÏ-†∑@sÄ9–`4òÕÊ@sÄ9–`4òÕÊ@sÄY9K1K9K1K9K1K9K1K9k^s™è5áÃYäY YäY YÛöTˆ£ËGπ∆kLŸï¢+eWäÆî])∫“«˙FW∆Æ]˝ø—o˝ø—o˝ø—o˝ø—o˝ø—oØiKº®è7Øl⁄Y‹Á~Pﬂ∆1mÛˆ3Ôx˚€.~ÓPC?∏ÙæŸ_ f:Kendstreamendobj92 0 obj<</Filter/FlateDecode/Length 4738/Subtype/Type1C>>stream
HâtTPSWŒ#… >Cè’†/O≈u$õòe\dQA@YQë›ÇIÄãR€hä∏:´ã’E¸ajÌ*˛-äJµZ¨ã’±;€©”Ç‚h’Ù<<Ïtobˇˆo2πÔ|Á~ÁªÁF°
P0cHI\<w˛bc≤TT.πÌ6Î|©LJ[îÂŒ7Õ ü]‚7ë«0ròJBxåA˜ãs/≤’≤0BûzktxΩŒÔH1\°e&0—ÖN…Íñú“ö2kQ¡oÏ≥•kùˆ¬ïnÒÁ”¶Y~&F[,—bBæcÖ$f≠uπ•bóòRbs8KN
À7ã	EE¢‡ùíKrñ˚øÁ&⁄]¢Ut;≠˘R±’πZtàiˆá{m©$Œ¶^ÃThw˘‰ãˆ—ΩR≥ÕYfqı^‚≠%˘‚¢Ô—võ‰?,∂Æ)ßG€$ß€Jgu„Wï9ÌÆ|ªÕmwî∏æs^b-ñ˛áS¥”ä®˚ó$˝ynÒädÛ‰§¨EæÕ1_*PPÌÖÇ(A:Ö†PåRòÜ+fçRT05å"Õßm∫bæ‚>3Ü…f63«ònf @P‡	¯LπDπS˘ç ≠jVOV7™œ´?#RM∫5ZMú∆¶π¨y¯´¿eÅÅùA∫†Ù†∂‡®‡Ω¡¡/ÜE+÷<¨;di»âê¡·Ÿ√[Ü…≥fØ∞ﬂåàë6‚ùµS¥€µèB'ÖÓΩ≠„tq:èÓ}épìπK‹WaÈ[<ÌÚ@;C«»v•G%◊.™%∞ﬂÁq&lWCA/‡€m”ë<ˇf"›˘<Ô[°o«≤NUTˆX}√Ó
]≥˜s/hÈ¿ù™Êz™ÂH·o÷∑∂∂÷€Êƒ÷ÿl∂ö÷ª¬ÿ˘ÉÈ†Ì¡N‡Å_”âZ‘ÆIG^†∏°XË˚ˇﬁ˙ˇv»Ω[ΩmË,ü»QÉµÍh¬‚r¸e˘ã
¶F*a·`?	-V4°®GÒö°Eí0QÔqzàk˛S0
? ÅP‰`ûÍS4∂ èqzå+B>ç˜,'¿¢D+ò&ÅE`E˘tÃß0Û=%òÈ}¶A∂’¨-~|◊≤€œnèÔ:ˇËŸ«»⁄‘¶aüÓ-á,–2∞¥JÿN„ÕÚ iºYÙGOÎ”AÈtÄÖGÀ˘uöÇ ¬ïoâöØˇp‡∂W·9®Ñ`ÊQûÇ'<√÷¸FÇÖöN€V>XY¡‘¬ ⁄*TË^ç*¬VVıÀ-˝ÃàD*a™¬CÍÆãW;ﬂZÅI¬L¶æíïñæÓ8$	Ÿ¬c˝93ƒC·HÅ%Pü”áÒXXç©ò#∞ï{ÀÂ⁄~ TìTüØª·É9c5qUôÖ¶àı&KSé≠ÙÄJﬁÏªPÄ(j$/èçd[Û˛c'é~“=≤˜÷°+_ÍÅMºâ„–òîÄ?JA–‹~s€’øGú>P≤`VıÍ¥ÖÜÃlı∏®ú)®”À…˛(`Cˇ⁄r®Ì◊5ÇÄa4Óqt÷A$w∑l|≠#Æ«¿Å˚+‰Éê˜W~hi0‘i∏ì]ªé_¸áB„/aÍ— ¿H“µ„Lg[Siä¿›Õ,ÀŒrMÑ˚¯π€êôñæqqbZ’È{õæàa"(ªÇi àæ‘˚Ï‰Q$4æ&u¡≠C°<l≈âî—ƒÎ†ö+g„$ÇÜ2‘îıcpÅ*˜1(@•Û)b¶|œ qÉ©¸êöpΩkÜx5Ñ;€∫µÈ¿Òàk{Va–‰5À3”_˚®ÕÄ¬ÔHÏ!˙Ï…êz˙kò™ 8Z‡zÁ[◊î6ë]54ºTßŸÊ~]}f’Ö£˜<Ád9[>¿√òMÊì"p}Mæ\L8Ä—∞‘¿=áËõ_¿T‡r˚QóûÎ*p6!œvˆÙú|f˜Íl˛?‡6Ω$pœ/6I∆Øe$89π˙rÔfø4rÕÙ&9YŸD¢y}NÉ\êÅÖeF≤rØÉÇ`Z h¸4i˙‰¯i“ß®û/üpÄ{⁄ π¸ÙC8ä&›íC0™˜æÌ∆å∑˙~=çØù”É!ˆ"-Z>69S{*ÑMÓÈåu∂ƒh=7@s˚ˇ·æ√mm˚VÕKq¨≤Záˇ&pO7‡u˛˙Óék◊vgœMÆ\îöZ˘^ó‡'bˆBÛK"%bÚÎ5–”x]◊˜€Ø"`}=,ÑÂê‡ÑhÙ…Ö—s,8π6Ë:€ˆøªﬂPg'„7ƒ«‹¿≤ ∑/PìjË‰?Ÿ~ÂF◊é”ﬂåe“¬¨≤£_…ÇÙ]ŸÜ˚JGêTﬂÆÿß˜@€O•lì∑(€‡/oÌ–ÇTﬂÆÿÀ4ç›†ıTË<ÚÓéGQ‰0’∞êF:EÃÃSc·˙>G-_G>¬n5ÕTˆ≤«´CÜW◊˛≤–˙â‚‰ˆp®!4bﬂ ’Éú+±;|ı"ﬂl¸ÀÂ;z3ı¯Å»±¸yrÛ∞snrai¨aô®Í§∞´mÆòò\gíÅv≥÷*Ø‹Ï’°ﬁÁPÔU≥è{"◊»≈¸≥W¿à+∞®ÕXå≈ÕhÜ"ÅÎÉÃ£0
Ãå$hñJßÉ"»€}Îñ¿=π∂7oºÅΩ„Ò õΩÃ%Í4ç6íK·PA ´ÉvÒﬂCA!å¡\V˚Ÿ}@ ‡è1Ùq~]ë6—0è∞Î<T´EÙK(çYŸN€˜?Ûd„˙·u:øN?n˜5T;’ˆÍèm√ÈçWl34ûjXÂùSo{·UØÓ$5Haíók£’\'oÊa¬º^å∆¥Ò]≠QQYXÑÓÜ¨ô%”ôù1=1‚˙à¯B4DÇD=
»SÃ`Q¡»Kˆ4é1» ÉÒ1 †8ÄB‚–‡#Çƒ$∞J≤&õ¨`ÿ∏Ò6[„9{´5Ÿ≥ª?ÊLWWﬂ™Ôﬁ˙æ{oÖêﬂíÌdg5Q√|ÅoÍh>⁄V•3±|˙¬AIEcÔ˚r|”‹–µqﬁòﬁÎ≠.Åoæ|tA∏N>‰.,e¥∆π„÷√X∫¿átÅ˚–
‚N àîa–$´DZëJ√„QntÚÒ
t∆0842’°©5öŒX—q¨˜Û2◊EDd~“-XàzGúNMÄI‡qÛ*L§˝hÖÒí˙‰m•07Ù|Ø‘g_v»:ww∏jâ–ãH`©√ƒoÎ`h•·•∆dÎ 5bàc›myåë}U c»zV—câ%÷¢≠˝–>«ƒÅü-áo4R€Fñ¯JÜFâ‰@â¥±T√êjò3∞·8fœxàOÇ◊…Üa>!—‹ ƒ¸’›ªÊ∑1πÖ|Ωº_B®†∞`,k!~PÂå'°¨ÈaaÃ_:`¸£»GƒCGvÀ¸igoYWœ˜çâ¶‰A≥≈‚–H;°_ƒÎ•”[Usˇ»4uÓ˝<Ø˘|—0 √Ey¶BÅ˜9d*‹up∑3Øø;ù¡…“R’«IœºıD€•Èç‚y˜ì \z®‚v≤üWØ_87&ﬁ_»wõá
?jey©áΩ|,.ƒ§€E^ KÃO2ß˛<˜∞IÊµπ_a‚ÊñﬂtF-?Ï-™π~ãÌ;W©ñ≥
ã]©‹H#Ü÷ä	|üRT	Q_ü≥˛Kº◊	øOl%#∞9ûe ∂?£©/™˚\‡{ZKcË@8¬¬KØ∑bQ„Âáâˇ7üÖ√Ë˜˛á˚ÎO¶,“ÆJ|^ZCáP¬…µ¢Â%s˙ m•ûO[∏„[O™¡:;mÎÜi_GYõÕa”‰ÉÂ√œ¬"A ∆ds~È·§_¸«=gJ∞|iüc>Å˜„,a)Ø¨√cm«ò÷C:∆(‡–N ≥ÈÁ ΩCõyl:‹`&{G*ƒ*~«V»‡ ‹®ô¿Úß|––»ŒBCŒí>ˆÅ‚¥}À=í≈”cÒ'èò∆˛≤ˇA≤bâ?<Ü90»ê©¨'…òôŒ*JÌÜÑ `óÿÊ3§
}Æ‚`âÑœûÏk§∑öÂå"√–$JÇx∑_i5·03`€√ßÛ"º)π®
πzãµæ±xcÙ:CFÙV·Më·õ&%GG{hﬁ©ö˝”çZs€	Sè∏k”.± ›{CeNÈ9|¬lË$ﬁ„ºVWa&$l_÷™ÇﬁKYªvsU›YÀÒ∂B—Æ“Ç√fgEæap =x4^© F,îØÇ¿oF∑-*p9–~•˝@ q!.ôÅÅôÌ‡"Å‡å;öK&.≤¢Fl—s·[–É>‚[¬Dƒä+tFi„∞3u~‡PÜ´é≈‹ -Ñ{	Oxœ%$ôlËƒ$ü›Ü±ñ…bL‘íÃV,Æ˚€;/Ïâ~Ô‰SxÛÜ·µ_y/ PÜá•à¬√ú#—»6$ƒñDhñ7÷æôË/x”RSrÆGÒÅœ70∫ˇóÛTïÃ^#»LêH4òí5{Q˘zpkÔÇvƒï]òï•]ñ~ıöÆÅ˚∆©Ñ;wËRÎ•}Q≥ÛÈe•‘ˇ„ÉúTe7ÇÌÎvA
∫”ˇF[i>P[P∞3∑ %ˆWéÔ3mL…€®ù˙¡]¿¸…]ú"ü,˛ÛtpoÑÔÔM°ŸI /bfá¨®á.©Z≈Wπ∂d}Ò-ôêF∆%âl}Fûi(;m’ô¸ÿ–‘U!:=cO¡ü≤• À\¨¡ÿÚßß‹à@ùÕºv^§Ω_O I-÷µ˝ÕWZãñì=”/]∫ı∆WsÙ òF‹ÅBÇc#˙ Cl{YyS]±&ÿ8Ùi7∏¨iÊR˝¢í#d–G√Í‘Ô0úG£Û‘Òj|}√	≠ü£ÛƒÔÅÙØgÏSe'-œ⁄æ”¥]xçÀ=r$˜ê\´ö‘I∑à¿=≥ÀóÜe©v;{ë`*◊|8íÃ¿$*…€ÿB«2üu$ä1JœS@TêO–PZ∞
0Sˇh|©{J˚oÙæYˆÚ{’Zq¶∂p„
¡6äéπ_ç%-˜œïó<E&ãÇëm›UπXªteÍÚXl◊˘ﬁV¢ÊÏÒ{≤>ÜèÔ˘Ò„?ï#ôûÄkÒ=◊®5Ωœ)˙¨h1q[ëÍ$∞q<Ã…`ZÀœ(Õ¿®ü…úô6û,÷—,7rœÌŒ∂‚Pd´fSh»ª›Üëxådä^ÉË	™ùÅˇ'm1Dª≤ºZº0,lﬂk◊vÿ12û‚∏${˘ÀÂO>]˛&≈˚TêœDäã;…'Ä\Ï6rÁ‚◊îÑK”ÆÀ’%ÂÿK)à7–‘9#ÒßhÙX˛&ts∑Zéù5ÊÊö1Æ\^÷∂º,mpL\D"ç˝©[U∏=e)∏íQ{•˝üˇ°¸Tiú{√ª»Á?µ”˚¡ôÂx4ﬁV&™–`)”‘T©˛ÙPRò Æv ®çº@^	Òù6ØVﬂùÑ5o ñ9˛aiF¨fe¢∏Jø±≤I(ÊPÏ=•ró•û‘ç
Eì+àÜ8Y#NXÛÛ+Ñü∏‹m[s∑jWo+™◊¡Ãÿ[ú=πI¡©Oâí_”ÊECÜÿ¿‰}Ù¶íA‚h([∆û◊w˘‹—ãÂ4{ÖÀöpÿ-˘;BLVŸπíä¡Œt∂jf∞†ï™Âz´Ò~B¥¢§Oº\|<‰œ/W7¸ÑèÌêîXø∞)ò Ç3µ¿:∏_Y?ú$ÿÚ`1‡j±ˆ}?ñB!C•zº‰]_&fºOV0‡Œﬁø;ƒè>®¿K†ô~°∑À_Ü‹H¸Tm,åÆ,ÉÄ≥:pìrÈ‚ÛmŒ∏”í≥º‚DÙ„ΩiâÀ¥ôôy¶Lù¬o'8A89ïéG›$¸õÃ2I √0Í›ˇó˝π‘5H\ë944àykÕm-÷Ad–÷8.w«ÅcA`KKE–b¥• äîcÅŸr|'ﬂ}ÜC ÔÚøm/ˇÛJòeêÖ¶Ï˙J†sÃbì¶¿cŒÖÉ˙W˝Ÿ\“s Ít@
—ÿ_THñYìÚ'õá¥\1oØ´—ˆ˙]L%>;+ ª∫9›ÿ‹œoÕ¨2¨Ì)®ÉÜË$˛ú^Í$ QWAö¢˙A@ÇDÅqRﬂ§~W#G«çÄ'j°ÔCIqh„í|∆Ò”rä{”∞#øÇ?´4¸ÿ2Ôo™U¬ê@î˙ÒﬂCü*ûˇl+ƒ∞â÷=ˇGôQ¶5Dôú›Àÿ∏f√úÕ‡¬|3˝JëñzôÓZ#îtMøcç∫aP«ÍñeÜU¢KnCåDÚìﬁâÚ+¿ Æ$)êendstreamendobj24 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj41 0 obj<</Length 32346>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.038 Tw 8 0 0 8 36 727.7881 Tm
[(Based on da)-10 (ta 7)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.199 0 Td
[(years after the last pa)-9.9 (tient was enrolled in the trial,)37 ( 44% were kno)-10 (wn)-10 ( )]TJ
0 Tw -6.199 -1.012 Td
[(to be alive,)37 ( 31% were kno)-9.9 (wn to ha)-10 (ve died,)37 ( and 25% had an unkno)-10 (wn sur)-17.9 (vival sta)-10 (tus.)]TJ
-0.005 Tw 0 -1.462 Td
[(By )0.5 (7)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.83 0 Td
[(years,)37 ( transforma)-10 (tion to )0.5 (either accelera)-10 (ted or blast phase occurred )0.5 (in nine pa)-9.9 (tients)-10 ( )]TJ
0 Tw -1.83 -1.012 Td
[(on trea)-10 (tment in the 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once-daily trea)-10 (tment group.)]TJ
/T1_1 1 Tf
0 -1.687 Td
[(Adv)16 (anced Phase CML and Ph)]TJ
0 Tc 11.248 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( ALL)Tj
/T1_2 1 Tf
0.01 Tw -11.838 -1.575 Td
(Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.447 Tw 1.377 0 Td
[(e-Optimiza)-10 (tion T)74 (rial:)]TJ
/T1_0 1 Tf
0.484 Tw /Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.785 0 Td
[( One randomized open-label trial \(NCT00123487\) was)-10 ( )]TJ
0.185 Tw -9.162 -1.012 Td
[(conducted in pa)-9.9 (tients with advanced phase CML \(accelera)-10 (ted phase CML,)37.1 ( myeloid)-10 ( )]TJ
0.068 Tw 0 -1.012 Td
[(blast phase CML,)37 ( or lymphoid blast phase CML\) to evalua)-10 (te the ef\037cac)20 (y and safety of)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.126 Tw -31.5 -1.012 Td
[(SPR)18 (YCEL administered once daily compared with SPR)17.9 (YCEL administered twice daily)55 (.)27 ( )]TJ
0.081 Tw 0 -1.012 Td
[(The primar)-17.9 (y ef\037cac)20 (y endpoint was MaHR.)-3 ( )37.4 (A total of 6)40 (1)80 (1 pa)-10 (tients were randomized to)-9.9 ( )]TJ
0.131 Tw 0 -1.012 Td
[(either the SPR)18.1 (YCEL 1)60 (40)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
9.149 0 Td
(mg once-daily or 70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
7.888 0 Td
[(mg twice-daily group.)37 ( Median dura)-9.9 (tion)-10 ( )]TJ
0.125 Tw -17.037 -1.012 Td
[(of trea)-9.9 (tment was a)-10 (pproxima)-10 (tely 6)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
12.871 0 Td
[(months for both trea)-9.9 (tment groups.)37 ( )36.8 (The once-daily)-10 ( )]TJ
0.478 Tw -12.871 -1.012 Td
[(schedule demonstra)-10 (ted comparable ef\037cac)20 (y \(non-inferiority\) to the twice-daily)-10 ( )]TJ
0.105 Tw 0 -1.012 Td
[(schedule on the primar)-18 (y ef\037cac)20 (y endpoint; ho)-10 (wever)73.9 (,)37.1 ( the 140-mg once-daily regimen)-10 ( )]TJ
0 Tw 0 -1.012 Td
[(demonstra)-9.9 (ted improved safety and tolerability)55 (.)]TJ
0 -1.552 Td
[(Response ra)-9.9 (tes for pa)-10 (tients in the 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once-daily group are presented in )37 (T)74 (able)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(19.)Tj
ET
0 0 0 0 k
/GS0 gs
36 579.401 252 -17.348 re
36 562.053 47.88 -13.5 re
83.88 562.053 204.12 -13.5 re
36 548.553 47.88 -19.777 re
83.88 548.553 54 -19.777 re
137.88 548.553 54 -19.777 re
191.88 548.553 54 -19.777 re
245.88 548.553 42.12 -19.777 re
36 528.775 47.88 -19.472 re
83.88 528.775 54 -19.472 re
137.88 528.775 54 -19.472 re
191.88 528.775 54 -19.472 re
245.88 528.775 42.12 -19.472 re
36 509.303 47.88 -19.472 re
83.88 509.303 54 -19.472 re
137.88 509.303 54 -19.472 re
191.88 509.303 54 -19.472 re
245.88 509.303 42.12 -19.472 re
36 489.831 47.88 -19.472 re
83.88 489.831 54 -19.472 re
137.88 489.831 54 -19.472 re
191.88 489.831 54 -19.472 re
245.88 489.831 42.12 -19.472 re
36 470.359 47.88 -19.472 re
83.88 470.359 54 -19.472 re
137.88 470.359 54 -19.472 re
191.88 470.359 54 -19.472 re
245.88 470.359 42.12 -19.472 re
36 450.888 47.88 -19.472 re
83.88 450.888 54 -19.472 re
137.88 450.888 54 -19.472 re
191.88 450.888 54 -19.472 re
245.88 450.888 42.12 -19.472 re
36 431.416 252 -88.872 re
f
0 0 0 1 K
/GS2 gs
q 1 0 0 1 36 562.0526 cm
0 0 m
47.88 0 l
S
Q
0.5 w 
q 1 0 0 1 137.88 548.5526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 548.5526 cm
0 0 m
54 0 l
S
Q
1 w 
q 1 0 0 1 83.88 562.0526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 137.88 562.0526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 562.0526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 245.88 562.0526 cm
0 0 m
42.12 0 l
S
Q
0.505 w 
q 1 0 0 1 137.88 528.7751 cm
0 0 m
54 0 l
S
Q
1.01 w 
q 1 0 0 1 137.88 431.4156 cm
0 0 m
54 0 l
S
Q
0.5 w 
q 1 0 0 1 36 470.3594 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 137.88 470.3594 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 470.3594 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 83.88 548.5526 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 83.88 470.3594 cm
0 0 m
54 0 l
S
Q
0.505 w 
q 1 0 0 1 83.88 528.7751 cm
0 0 m
54 0 l
S
Q
1.01 w 
q 1 0 0 1 83.88 431.4156 cm
0 0 m
54 0 l
S
Q
0.5 w 
q 1 0 0 1 245.88 509.3033 cm
0 0 m
0 19.219 l
S
Q
q 1 0 0 1 245.88 489.8313 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 245.88 470.6094 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 245.88 470.3594 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 450.8875 cm
0 0 m
0 19.222 l
S
Q
q 1 0 0 1 245.88 431.9206 cm
0 0 m
0 18.967 l
S
Q
1.01 w 
q 1 0 0 1 245.88 431.4156 cm
0 0 m
42.12 0 l
S
Q
0.5 w 
q 1 0 0 1 245.88 548.5526 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 245.88 529.0276 cm
0 0 m
0 19.275 l
S
Q
0.505 w 
q 1 0 0 1 245.88 528.7751 cm
0 0 m
42.12 0 l
S
Q
1.01 w 
q 1 0 0 1 36 431.4156 cm
0 0 m
47.88 0 l
S
Q
0.505 w 
q 1 0 0 1 36 342.5437 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 83.88 342.5437 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 137.88 342.5437 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 191.88 342.5437 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 245.88 342.5437 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 36 528.7751 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 191.88 528.7751 cm
0 0 m
54 0 l
S
Q
1.01 w 
q 1 0 0 1 191.88 431.4156 cm
0 0 m
54 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.542 Tw 8 0 0 8 36 573.6886 Tm
[(Table )518 (19:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(Efficacy of SPRYCEL in Imatinib-Resistant or -Intolerant)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Advanced Phase CML and Ph)Tj
0 Tc 0 Tw 11.36 0.125 Td
(+)Tj
-0.01 Tc 0.024 Tw 0.59 -0.125 Td
( ALL \(2-Year Results\))Tj
-0.02 Tc 7.2 0 0 8 160.2689 551.4326 Tm
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw -9.32 -1.347 Td
(Accelerated)Tj
0 Tc 0 Tw 7.2 0 0 8 125.7154 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 98.597 532.6552 Tm
(\(n=158\))Tj
0.024 Tw 6.432 1 Td
(Myeloid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 181.9724 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 154.253 532.6552 Tm
(\(n=75\))Tj
0.024 Tw 5.823 1 Td
(Lymphoid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 238.7012 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 208.253 532.6552 Tm
(\(n=33\))Tj
0.024 Tw 6.546 1 Td
(Ph+ ALL)Tj
0 Tc 0 Tw 7.2 0 0 8 278.7469 540.6552 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 257.878 532.6552 Tm
(\(n=40\))Tj
-0.01 Tc 0.01 Tw -30.816 -1.559 Td
(MaHR)Tj
0 Tc 0 Tw 5.4 0 0 6 52.5094 522.9832 Tm
(a)Tj
/T1_0 1 Tf
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 512.1832 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(66%)Tj
-0.581 -1 Td
(\(59\22674\))Tj
8.081 1 Td
(28%)Tj
-0.581 -1 Td
(\(18\22640\))Tj
8.081 1 Td
(42%)Tj
-0.581 -1 Td
(\(26\22661\))Tj
7.474 1 Td
(38%)Tj
-0.581 -1 Td
(\(23\22654\))Tj
-0.01 Tc 0.01 Tw -30.656 -1.434 Td
(CHR)Tj
0 Tc 0 Tw 5.4 0 0 6 47.1238 503.5113 Tm
(a)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 492.7113 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(47%)Tj
-0.581 -1 Td
(\(40\22656\))Tj
8.081 1 Td
(17%)Tj
-0.581 -1 Td
(\(10\22628\))Tj
8.081 1 Td
(21%)Tj
-0.344 -1 Td
(\(9\22639\))Tj
7.236 1 Td
(33%)Tj
-0.581 -1 Td
(\(19\22649\))Tj
-0.01 Tc 0.01 Tw -30.656 -1.434 Td
(NEL)Tj
0 Tc 0 Tw 5.4 0 0 6 46.3174 484.0394 Tm
(a)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 473.2394 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(19%)Tj
-0.581 -1 Td
(\(13\22626\))Tj
8.081 1 Td
(11%)Tj
-0.344 -1 Td
(\(5\22620\))Tj
7.844 1 Td
(21%)Tj
-0.344 -1 Td
(\(9\22639\))Tj
7.474 1 Td
(5%)Tj
-0.581 -1 Td
(\(1\22617\))Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -30.894 -1.434 Td
(MCyR)Tj
0 Tc 0 Tw 5.4 0 0 6 52.1061 464.5675 Tm
(b)Tj
/T1_0 1 Tf
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 453.7675 Tm
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(39%)Tj
-0.581 -1 Td
(\(31\22647\))Tj
8.081 1 Td
(28%)Tj
-0.581 -1 Td
(\(18\22640\))Tj
8.082 1 Td
(52%)Tj
-0.581 -1 Td
(\(34\22669\))Tj
7.474 1 Td
(70%)Tj
-0.581 -1 Td
(\(54\22683\))Tj
-0.01 Tc 0.01 Tw -30.656 -1.434 Td
(CCyR)Tj
0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1 Td
( )Tj
EMC 
1.262 0 Td
(\(95% CI\))Tj
-0.005 Tc 0.005 Tw 8.083 1 Td
(32%)Tj
-0.581 -1 Td
(\(25\22640\))Tj
8.081 1 Td
(17%)Tj
-0.581 -1 Td
(\(10\22628\))Tj
8.082 1 Td
(39%)Tj
-0.581 -1 Td
(\(23\22658\))Tj
7.474 1 Td
(50%)Tj
-0.581 -1 Td
(\(34\22666\))Tj
5.4 0 0 6 36 424.9037 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.177 Tw 7.2 0 0 8 39.6 422.1037 Tm
[(Hema)-9.9 (tologic response criteria \(all responses confirmed after 4 weeks\):)36.9 ( Major hema)-9.9 (tologic)-5 ( )]TJ
0 Tw 0 -1 Td
[(response:)37 ( \(MaHR\) = complete hema)-9.9 (tologic response \(CHR\) + no evidence of leukemia \(NEL\).)]TJ
0.412 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.5 -1.225 Td
( )Tj
EMC 
0.5 0 Td
[(CHR:)37 ( )37.5 (WBC )0.5 (\034 )0.5 (institutional )0.6 (ULN,)37 ( )37.4 (ANC )0.5 (\0361000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 179.0839 407.1037 Tm
(3)Tj
-0.005 Tc 0.412 Tw 7.2 0 0 8 181.6489 404.3037 Tm
[(,)37 ( )0.5 (pla)-10 (telets )0.5 (\036100,000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 252.6971 407.1037 Tm
(3)Tj
-0.005 Tc 0.412 Tw 7.2 0 0 8 255.2621 404.3037 Tm
[(,)37 ( )0.5 (no )0.5 (blasts)-5 ( )]TJ
0.5 Tw -29.953 -1 Td
[(or promyeloc)20 (ytes in peripheral blood,)37 ( bone marro)-10 (w blasts \0345%,)37 ( <5% myeloc)20 (ytes)-5 ( )]TJ
0.31 Tw 0 -1 Td
[(plus metamyeloc)20 (ytes in peripheral blood,)37 ( basophils in peripheral blood <20%,)37 ( and no)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 288 388.3037 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 39.6 380.3037 Tm
[(extramedullar)-18 (y involvement.)]TJ
0.008 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.5 -1.09 Td
( )Tj
EMC 
0.5 0 Td
[(NEL:)37 ( same criteria as for CHR but )36.6 (ANC \036500/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 167.9344 374.3837 Tm
(3)Tj
-0.005 Tc 0.008 Tw 7.2 0 0 8 170.4994 371.5837 Tm
( and <1000/mm)Tj
0 Tc 0 Tw 5.4 0 0 6 214.0129 374.3837 Tm
(3)Tj
-0.005 Tc 0.008 Tw 7.2 0 0 8 216.5779 371.5837 Tm
[(,)37 ( or pla)-10 (telets \03620,000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 285.4081 374.3837 Tm
(3)Tj
7.2 0 0 8 288 371.5837 Tm
( )Tj
-0.005 Tc -34.5 -1 Td
(and \034100,000/mm)Tj
0 Tc 5.4 0 0 6 89.092 366.3837 Tm
(3)Tj
7.2 0 0 8 91.657 363.5837 Tm
(.)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 36 357.6637 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 39.6 354.8637 Tm
(MCyR combines both complete \(0% Ph)Tj
0 Tc 14.21 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( meta)-9.9 (phases\) and partial \(>0%\22635%\) responses.)]TJ
-15.305 -1.09 Td
[(CI = confidence inter)-18 (val)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
10 0 Td
(ULN = upper limit of normal range.)Tj
0.055 Tw 8 0 0 8 36 324.4732 Tm
[(In the SPR)18 (YCEL 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
7.672 0 Td
[(mg once-daily group,)37 ( the median time to MaHR was 1)40 (.9)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
21.095 0 Td
[(months)-5 ( )]TJ
0.516 Tw -28.767 -1.012 Td
[(\(min-max:)37 ( 0.7-14.5\) for pa)-10 (tients with accelera)-9.9 (ted phase CML,)37 ( 1)60 (.9 months)-5 ( )]TJ
0.292 Tw 0 -1.012 Td
[(\(min-max:)37 ( 0.9-6.2\) for pa)-10 (tients with myeloid blast phase CML,)37 ( and 1)40 (.8)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
28.767 0 Td
[(months)-5 ( )]TJ
0 Tw -28.767 -1.012 Td
[(\(min-max:)37 ( 0.9-2.8\) for pa)-10 (tients with lymphoid blast phase CML.)]TJ
-0.01 Tc -0.023 Tw 0 -1.642 Td
[(In pa)-10 (tients with myeloid blast phase CML,)37 ( the median dura)-9.9 (tion of MaHR was 8.1)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
28.792 0 Td
[(months)-10 ( )]TJ
0.122 Tw -28.792 -1.012 Td
[(\(min-max:)37 ( 2.7-21.1\) and 9.0 \(min-max:)37 ( 1.8-23.1\) months for the 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
26.223 0 Td
[(mg once-daily)-10 ( )]TJ
0.124 Tw -26.223 -1.012 Td
(group and the 70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.787 0 Td
[(mg twice-daily group,)37 ( respectively)55 (.)37 ( In pa)-9.9 (tients with lymphoid blast)-10 ( )]TJ
0.168 Tw -6.787 -1.012 Td
[(phase CML,)37 ( the median dura)-9.9 (tion of MaHR was 4.7)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
19.679 0 Td
[(months \(min-max:)37 ( 3.0-9.0\) and)-10 ( )]TJ
0.003 Tw -19.679 -1.012 Td
[(7)40 (.9)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.36 0 Td
[(months )0.5 (\(min-max:)37 ( )0.6 (1.6-22.1\) )0.5 (for )0.6 (the )0.5 (140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
14.655 0 Td
[(mg )0.6 (once-daily )0.6 (group )0.6 (and )0.6 (the )0.6 (70 )0.5 (mg )0.5 (twice-)]TJ
0.148 Tw -16.015 -1.012 Td
[(daily group,)37 ( respectively)55 (.)37 ( In pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 16.61 0.125 Td
(+)Tj
-0.01 Tc 0.148 Tw 0.59 -0.125 Td
[( )36.9 (ALL who were trea)-10 (ted with SPR)18 (YCEL)-10 ( )]TJ
0.006 Tw -17.2 -1.012 Td
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.64 0 Td
[(mg once-daily)55 (,)37 ( the median dura)-10 (tion of MaHR was 4.6)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
19.437 0 Td
[(months \(min-max:)37 ( 1.4-10.2\).)27 ( )]TJ
-0.058 Tw -21.077 -1.012 Td
[(The medians of progression-free sur)-18 (vival for pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 21.509 0.125 Td
(+)Tj
-0.01 Tc -0.058 Tw 0.59 -0.125 Td
[( )37.1 (ALL trea)-9.9 (ted with SPR)18 (YCEL)-9.9 ( )]TJ
0.107 Tw -22.099 -1.012 Td
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
1.64 0 Td
(mg once-daily and 70)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
8.437 0 Td
(mg twice-daily were 4.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
9.313 0 Td
[(months \(min-max:)37 ( 0.4-11.1\) and)-10 ( )]TJ
0 Tw -19.39 -1.012 Td
(3.1)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(months \(min-max:)37 ( 0.3-20.8\),)37 ( respectively)55 (.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.8 Td
(14.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CML in P)24 (ediatric P)24 (atients)]TJ
/T1_0 1 Tf
0.113 Tw -3.375 -1.395 Td
[(The ef\037cac)20 (y of SPR)18 (YCEL in pedia)-10 (tric pa)-10 (tients was evalua)-10 (ted in two pedia)-10 (tric studies)-10 ( )]TJ
0.116 Tw 0 -1.012 Td
[(of 97 pa)-10 (tients with chronic phase CML.)37 ( )37.2 (Among 97 pa)-10 (tients with chronic phase CML)-10 ( )]TJ
0.228 Tw 0 -1.012 Td
[(trea)-10 (ted in two pedia)-10 (tric studies,)37 ( an open-label,)36.9 ( non-randomized dose-ranging trial)-10 ( )]TJ
0.089 Tw 0 -1.012 Td
[(\(NCT00306202\) )0.5 (and )0.5 (an )0.5 (open-label,)37 ( )0.5 (non-randomized,)37 ( )0.5 (single-arm )0.6 (trial )0.6 (\(NCT00777036\),)27 ( )]TJ
0.067 Tw 0 -1.012 Td
[(51 pa)-10 (tients \(exc)19.9 (lusively from the single-arm trial\) had newly dia)-10 (gnosed chronic phase)-10 ( )]TJ
0.055 Tw 0 -1.012 Td
[(CML and 46 pa)-9.9 (tients \(17 from the dose-ranging trial and 29 from the single-arm trial\\))-10 ( )]TJ
0.099 Tw 0 -1.012 Td
[(were resistant or intolerant to previous trea)-10 (tment with ima)-9.9 (tinib.)37 ( Ninety-one of the 97)-10 ( )]TJ
0.063 Tw 0 -1.012 Td
[(pedia)-9.9 (tric pa)-10 (tients were trea)-10 (ted with SPR)18 (YCEL tablets 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 220.0596 134.7177 Tm
(2)Tj
-0.01 Tc 0.063 Tw 8 0 0 8 222.8796 131.9177 Tm
[( once daily \(maximum)-9.9 ( )]TJ
-0.046 Tw -23.36 -1.012 Td
[(dose of 100 mg once daily for pa)-10 (tients with high BSA\).)37 ( P)18 (a)-10 (tients were trea)-10 (ted until disease)-10 ( )]TJ
0 Tw 0 -1.012 Td
[(progression or unacceptable toxicity)55 (.)]TJ
0.044 Tw 0 -1.44 Td
[(Baseline demogra)-9.9 (phic characteristics of the 46 ima)-10 (tinib resistant or intolerant pa)-9.9 (tients)-9.9 ( )]TJ
0.236 Tw 0 -1.012 Td
[(were:)37 ( median a)-10 (ge 13.5 )0.5 (years )0.5 (\(range )0.5 (2 to )0.5 (20 years\),)37 ( 78.3% )37.4 (White,)37 ( 15.2% )37.4 (Asian,)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.157 Tw -31.5 -1.012 Td
[(4.4% Black,)37 ( 2.2% other)74 (,)37 ( and 52% female.)37 ( Baseline characteristics of the 51 newly)-10 ( )]TJ
-0.032 Tw 0 -1.012 Td
[(dia)-9.9 (gnosed pa)-10 (tients were:)37 ( median a)-9.9 (ge 12.8 years \(range 1.9 to 17.8 years\),)37 ( 60.8% )36.7 (White,)27 ( )]TJ
0 Tw 0 -1.012 Td
[(31.4% )37 (Asian,)37 ( 5.9% Black,)37 ( 2% Other)74 (,)37 ( and 49% female.)]TJ
0.106 Tw 0 -1.44 Td
[(Median dura)-10 (tion of follo)-10 (w-up was 5.2 years \(range 0.5 to 9.3 years\) for the ima)-10 (tinib)-10 ( )]TJ
0.145 Tw 0 -1.012 Td
[(resistant or intolerant pa)-9.9 (tients and 4.5 years \(range 1.3 to 6.4 years\) for the newly)-10 ( )]TJ
0.25 Tw 0 -1.012 Td
[(dia)-9.9 (gnosed pa)-10 (tients,)37 ( respectively)55 (.)37 ( Ef\037cac)20 (y results for the two pedia)-9.9 (tric studies are)-9.9 ( )]TJ
0 Tw 0 -1.012 Td
[(summarized in )37 (T)74 (able 20.)]TJ
0.07 Tw 36 86.406 Td
[(T)74 (able 20 sho)-10 (ws increasing trend for response for CCyR,)37 ( MCyR,)37 ( and MMR across time)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -0.027 Tw -31.5 -1.043 Td
[(\(3 months to 24 months\).)37 ( )37.1 (The increasing trend in response for all three endpoints is seen)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(in both the newly dia)-10 (gnosed and ima)-10 (tinib resistant or intolerant pa)-9.9 (tients.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 700.133 252 -17.312 re
324 682.821 47.88 -12.912 re
371.88 682.821 54 -12.912 re
425.88 682.821 54 -12.912 re
479.88 682.821 54 -12.912 re
533.88 682.821 42.12 -12.912 re
324 669.91 47.88 -11.472 re
371.88 669.91 54 -11.472 re
425.88 669.91 54 -11.472 re
479.88 669.91 54 -11.472 re
533.88 669.91 42.12 -11.472 re
324 658.438 47.88 -11.472 re
371.88 658.438 54 -11.472 re
425.88 658.438 54 -11.472 re
479.88 658.438 54 -11.472 re
533.88 658.438 42.12 -11.472 re
324 646.966 47.88 -11.472 re
371.88 646.966 54 -11.472 re
425.88 646.966 54 -11.472 re
479.88 646.966 54 -11.472 re
533.88 646.966 42.12 -11.472 re
324 635.494 47.88 -11.472 re
371.88 635.494 54 -11.472 re
425.88 635.494 54 -11.472 re
479.88 635.494 54 -11.472 re
533.88 635.494 42.12 -11.472 re
324 624.022 47.88 -11.472 re
371.88 624.022 54 -11.472 re
425.88 624.022 54 -11.472 re
479.88 624.022 54 -11.472 re
533.88 624.022 42.12 -11.472 re
324 612.55 47.88 -11.472 re
371.88 612.55 54 -11.472 re
425.88 612.55 54 -11.472 re
479.88 612.55 54 -11.472 re
533.88 612.55 42.12 -11.472 re
324 601.078 47.88 -11.472 re
371.88 601.078 54 -11.472 re
425.88 601.078 54 -11.472 re
479.88 601.078 54 -11.472 re
533.88 601.078 42.12 -11.472 re
324 589.606 47.88 -11.472 re
371.88 589.606 54 -11.472 re
425.88 589.606 54 -11.472 re
479.88 589.606 54 -11.472 re
533.88 589.606 42.12 -11.472 re
324 578.134 47.88 -11.472 re
371.88 578.134 54 -11.472 re
425.88 578.134 54 -11.472 re
479.88 578.134 54 -11.472 re
533.88 578.134 42.12 -11.472 re
324 566.662 47.88 -11.472 re
371.88 566.662 54 -11.472 re
425.88 566.662 54 -11.472 re
479.88 566.662 54 -11.472 re
533.88 566.662 42.12 -11.472 re
324 555.19 47.88 -11.472 re
371.88 555.19 54 -11.472 re
425.88 555.19 54 -11.472 re
479.88 555.19 54 -11.472 re
533.88 555.19 42.12 -11.472 re
324 543.719 47.88 -11.472 re
371.88 543.719 54 -11.472 re
425.88 543.719 54 -11.472 re
479.88 543.719 54 -11.472 re
533.88 543.719 42.12 -11.472 re
324 532.247 47.88 -11.472 re
371.88 532.247 54 -11.472 re
425.88 532.247 54 -11.472 re
479.88 532.247 54 -11.472 re
533.88 532.247 42.12 -11.472 re
324 520.775 47.88 -11.472 re
371.88 520.775 54 -11.472 re
425.88 520.775 54 -11.472 re
479.88 520.775 54 -11.472 re
533.88 520.775 42.12 -11.472 re
324 509.303 47.88 -11.472 re
371.88 509.303 54 -11.472 re
425.88 509.303 54 -11.472 re
479.88 509.303 54 -11.472 re
533.88 509.303 42.12 -11.472 re
324 497.831 47.88 -11.472 re
371.88 497.831 54 -11.472 re
425.88 497.831 54 -11.472 re
479.88 497.831 54 -11.472 re
533.88 497.831 42.12 -11.472 re
324 486.359 47.88 -11.472 re
371.88 486.359 54 -11.472 re
425.88 486.359 54 -11.472 re
479.88 486.359 54 -11.472 re
533.88 486.359 42.12 -11.472 re
324 474.887 47.88 -11.472 re
371.88 474.887 54 -11.472 re
425.88 474.887 54 -11.472 re
479.88 474.887 54 -11.472 re
533.88 474.887 42.12 -11.472 re
324 463.415 252 -29.632 re
f
/GS2 gs
q 1 0 0 1 425.88 463.4151 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 371.88 463.4151 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 463.4151 cm
0 0 m
42.12 0 l
S
Q
q 1 0 0 1 479.88 463.4151 cm
0 0 m
54 0 l
S
Q
0.505 w 
q 1 0 0 1 324 669.9095 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 371.88 669.9095 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 425.88 669.9095 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 479.88 669.9095 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 669.9095 cm
0 0 m
42.12 0 l
S
Q
1 w 
q 1 0 0 1 324 682.8215 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 371.88 682.8215 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 425.88 682.8215 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 479.88 682.8215 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 682.8215 cm
0 0 m
42.12 0 l
S
Q
1.01 w 
q 1 0 0 1 324 463.4151 cm
0 0 m
47.88 0 l
S
Q
0.505 w 
q 1 0 0 1 324 433.7832 cm
0 0 m
47.88 0 l
S
Q
q 1 0 0 1 371.88 433.7832 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 425.88 433.7832 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 479.88 433.7832 cm
0 0 m
54 0 l
S
Q
q 1 0 0 1 533.88 433.7832 cm
0 0 m
42.12 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.528 Tw 8 0 0 8 324 694.4214 Tm
[(Table )504 (20:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(Efficacy of SPRYCEL in Pediatric Patients with CP-CML)-10 ( )]TJ
0.059 Tw 0 -1 Td
(Cumulative Response Over Time by Minimum Follow-Up Period)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 384.545 673.7895 Tm
(3 months)Tj
7.5 0 Td
(6 months)Tj
7.27 0 Td
(12 months)Tj
6.875 0 Td
(24 months)Tj
-0.01 Tc 0.01 Tw -30.054 -1.559 Td
(CCyR)Tj
0.024 Tw 0 -1.434 Td
(\(95% CI\))Tj
/T1_0 1 Tf
0 -1.434 Td
[(Newly dia)-10 (gnosed)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(43.1%)Tj
7.5 0 Td
(66.7%)Tj
7.5 0 Td
(96.1%)Tj
6.875 0 Td
(96.1%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=51\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 629.7018 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 626.9018 Tm
[(\(29.3,)37 ( 57.8\))]TJ
7.5 0 Td
[(\(52.1,)37 ( 79.2\))]TJ
7.5 0 Td
[(\(86.5,)37 ( 99.5\))]TJ
6.875 0 Td
[(\(86.5,)37 ( 99.5\))]TJ
-0.01 Tc -29.948 -1.434 Td
[(Prior ima)-9.9 (tinib)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(45.7%)Tj
7.5 0 Td
(71.7%)Tj
7.5 0 Td
(78.3%)Tj
6.875 0 Td
(82.6%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=46\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 606.758 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 603.958 Tm
[(\(30.9,)37 ( 61.0\))]TJ
7.5 0 Td
[(\(56.5,)37 ( 84.0\))]TJ
7.5 0 Td
[(\(63.6,)37 ( 89.1\))]TJ
6.875 0 Td
[(\(68.6,)37 ( 92.2\))]TJ
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -29.948 -1.434 Td
(MCyR)Tj
0.024 Tw 0 -1.434 Td
(\(95% CI\))Tj
/T1_0 1 Tf
0 -1.434 Td
[(Newly dia)-10 (gnosed)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(60.8%)Tj
7.5 0 Td
(90.2%)Tj
7.5 0 Td
(98.0%)Tj
6.875 0 Td
(98.0%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=51\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 560.8703 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 558.0703 Tm
[(\(46.1,)37 ( 74.2\))]TJ
7.5 0 Td
[(\(78.6,)37 ( 96.7\))]TJ
7.617 0 Td
[(\(89.6,)37 ( 100\))]TJ
6.875 0 Td
[(\(89.6,)37 ( 100\))]TJ
-0.01 Tc -30.066 -1.434 Td
[(Prior ima)-9.9 (tinib)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(60.9%)Tj
7.5 0 Td
(82.6%)Tj
7.5 0 Td
(89.1%)Tj
6.875 0 Td
(89.1%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=46\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 537.9265 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 382.1259 535.1265 Tm
[(\(45.4,)37 ( 74.9\))]TJ
7.5 0 Td
[(\(68.6,)37 ( 92.2\))]TJ
7.5 0 Td
[(\(76.4,)37 ( 96.4\))]TJ
6.875 0 Td
[(\(76.4,)37 ( 96.4\))]TJ
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -29.948 -1.434 Td
(MMR)Tj
0.024 Tw 0 -1.434 Td
(\(95% CI\))Tj
/T1_0 1 Tf
0 -1.434 Td
[(Newly dia)-10 (gnosed)]TJ
-0.005 Tc 0.005 Tw 9.228 0 Td
(7.8%)Tj
7.263 0 Td
(31.4%)Tj
7.5 0 Td
(56.9%)Tj
6.875 0 Td
(74.5%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=51\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 492.0388 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 383.8358 489.2388 Tm
[(\(2.2,)37 ( 18.9\))]TJ
7.262 0 Td
[(\(19.1,)37 ( 45.9\))]TJ
7.5 0 Td
[(\(42.2,)37 ( 70.7\))]TJ
6.875 0 Td
[(\(60.4,)37 ( 85.7\))]TJ
-0.01 Tc -29.948 -1.434 Td
[(Prior ima)-9.9 (tinib)]TJ
-0.005 Tc 0.005 Tw 8.991 0 Td
(15.2%)Tj
7.5 0 Td
(26.1%)Tj
7.5 0 Td
(39.1%)Tj
6.875 0 Td
(52.2%)Tj
-0.01 Tc 0.01 Tw -30.866 -1.434 Td
(\(N=46\))Tj
0 Tc 0 Tw 5.4 0 0 6 342.2734 469.095 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 383.8358 466.295 Tm
[(\(6.3,)37 ( 28.9\))]TJ
7.262 0 Td
[(\(14.3,)37 ( 41.1\))]TJ
7.5 0 Td
[(\(25.1,)37 ( 54.6\))]TJ
6.875 0 Td
[(\(36.9,)37 ( 67.1\))]TJ
0.005 Tw 5.4 0 0 6 324 456.9031 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 327.6 454.1031 Tm
[(P)18 (a)-10 (tients from pedia)-10 (tric stud)-10 (y of newly dia)-10 (gnosed CP-CML receiving oral tablet formula)-10 (tion)]TJ
0.005 Tw 5.4 0 0 6 324 448.1831 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.247 Tw 7.2 0 0 8 327.6 445.3831 Tm
[(P)18 (a)-10 (tients from pedia)-10 (tric studies of ima)-10 (tinib-resistant or -intolerant CP-CML receiving oral)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576 445.3831 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 327.6 437.3831 Tm
[(tablet formula)-10 (tion)]TJ
-0.01 Tc -0.011 Tw 8 0 0 8 324 415.6457 Tm
[(With a median follo)-9.9 (w-up of 4.5 years in newly dia)-9.9 (gnosed pa)-10 (tients,)37 ( the median dura)-10 (tions)-10 ( )]TJ
-0.054 Tw 0 -1.043 Td
[(of CCyR,)37 ( MCyR,)37 ( MMR could not be estima)-10 (ted as more than half of the responding pa)-9.9 (tients)-10 ( )]TJ
-0.006 Tw 0 -1.043 Td
[(had not progressed a)-10 (t the time of da)-10 (ta cut-off.)37 ( Range of dura)-10 (tion of response was \(2.5)]TJ
0 Tc 0 Tw 30.9 0.125 Td
(+)Tj
0.6 -0.125 Td
( )Tj
-0.01 Tc -0.023 Tw -31.5 -1.043 Td
(to 66.5)Tj
0 Tc 0 Tw 2.53 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
[( months for CCyR\),)37 ( \(1.4 to 66.5)]TJ
0 Tc 0 Tw 10.981 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
[( months for MCyR\),)37 ( and \(5.4)]TJ
0 Tc 0 Tw 9.976 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
( to 72.5)Tj
0 Tc 0 Tw 2.737 0.125 Td
(+)Tj
-0.01 Tc -0.023 Tw 0.59 -0.125 Td
[( months)-10 ( )]TJ
0.031 Tw -28.585 -1.043 Td
(for subjects who achieved MMR by month 24 and 0.03)Tj
0 Tc 0 Tw 20.02 0.125 Td
(+)Tj
-0.01 Tc 0.031 Tw 0.59 -0.125 Td
( to 72.5)Tj
0 Tc 0 Tw 2.846 0.125 Td
(+)Tj
-0.01 Tc 0.031 Tw 0.59 -0.125 Td
[( months for subjects)-10 ( )]TJ
0 Tw -24.046 -1.043 Td
[(who achieved MMR a)-9.9 (t an)-10 (y time\),)37 ( where )37 (\221)]TJ
0 Tc 14.683 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[(\222 indica)-10 (tes a censored obser)-18 (va)-9.9 (tion.)]TJ
0.074 Tw -15.273 -1.471 Td
[(With a median follo)-9.9 (w-up of 5.2 years in ima)-9.9 (tinib-resistant or - intolerant pa)-9.9 (tients,)37 ( the)-9.9 ( )]TJ
0.053 Tw 0 -1.043 Td
[(median )0.5 (dura)-10 (tions of CCyR,)37 ( MCyR,)37 ( and MMR could not )0.5 (be estima)-10 (ted as more )0.5 (than )0.5 (half)-9.9 ( )]TJ
-0.032 Tw 0 -1.043 Td
[(the responding pa)-10 (tients had not progressed a)-10 (t the time of da)-10 (ta cut-off.)37 ( Range of dura)-9.9 (tion)-10 ( )]TJ
0.028 Tw 0 -1.043 Td
(of response was \(2.4 to 86.9)Tj
0 Tc 0 Tw 10.454 0.125 Td
(+)Tj
-0.01 Tc 0.028 Tw 0.59 -0.125 Td
[( months for CCyR\),)37 ( \(2.4 to 86.9)]TJ
0 Tc 0 Tw 11.286 0.125 Td
(+)Tj
-0.01 Tc 0.028 Tw 0.59 -0.125 Td
[( months for MCyR\),)37 ( and)-10 ( )]TJ
0.01 Tw -22.919 -1.043 Td
(\(2.6)Tj
0 Tc 0 Tw 1.401 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( to 73.6)Tj
0 Tc 2.783 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( months for MMR\),)37 ( where )37 (\221)]TJ
0 Tc 9.576 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[(\222 indica)-10 (tes a censored obser)-18 (va)-9.9 (tion.)]TJ
0.279 Tw -15.53 -1.471 Td
[(The median time to response for MCyR was 2.9 months \(95% CI:)37 ( 2.8 months,)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.128 Tw -31.5 -1.043 Td
[(3.5 months\) in the pooled ima)-9.9 (tinib-resistant/intolerant CP-CML pa)-10 (tients.)37 ( )36.9 (The median)-10 ( )]TJ
0.1 Tw 0 -1.043 Td
[(time )0.5 (to )0.5 (response )0.6 (for )0.5 (CCyR )0.5 (was )0.5 (3.3 )0.5 (months )0.6 (\(95% )0.5 (CI:)37 ( )0.6 (2.8 )0.5 (months,)37 ( )0.5 (4.7 )0.5 (months\) )0.6 (in )0.5 (the)-10 ( )]TJ
0.213 Tw 0 -1.043 Td
[(pooled ima)-9.9 (tinib-resistant/intolerant CP-CML pa)-10 (tients.)37 ( )36.9 (The median time to response)-10 ( )]TJ
0.086 Tw 0 -1.043 Td
[(for MMR was 8.3 months \(95% CI:)37 ( 5.0 months,)37 ( 11.8 months\) in the pooled ima)-9.9 (tinib-)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(resistant/intolerant CP-CML pa)-10 (tients.)]TJ
0.279 Tw 0 -1.471 Td
[(The median time to response for MCyR was 3.0 months \(95% CI:)37 ( 2.8 months,)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -0.01 Tw -31.5 -1.043 Td
[(4.3 months\) in the newly dia)-10 (gnosed trea)-9.9 (tment-na\357ve CP-CML pa)-10 (tients.)37 ( )37.1 (The median time)-10 ( )]TJ
0.064 Tw 0 -1.043 Td
[(to response for CCyR was 5.5 months \(95% CI:)37 ( 3.0 months,)37 ( 5.7 months\) in the newly)-10 ( )]TJ
-0.038 Tw 0 -1.043 Td
[(dia)-10 (gnosed trea)-10 (tment-na\357ve CP-CML pa)-9.9 (tients.)37.1 ( )37.2 (The median time to response for MMR was)-10 ( )]TJ
0.003 Tw 0 -1.043 Td
[(8.9 months \(95% CI:)37 ( 6.2 months,)37.1 ( 11.7 months\) in the newly dia)-9.9 (gnosed trea)-9.9 (tment-na\357ve)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(CP-CML pa)-10 (tients.)]TJ
0.099 Tw 0 -1.471 Td
[(In the Phase II pedia)-9.9 (tric stud)-10 (y)55 (,)37 ( 1 newly dia)-10 (gnosed pa)-10 (tient and 2 ima)-9.9 (tinib-resistant or)-9.9 ( )]TJ
0 Tw 0 -1.043 Td
[(-intolerant pa)-10 (tients progressed to blast phase CML.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.741 Td
(14.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Ph)Tj
0 Tc 0 Tw 0.999 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( ALL in P)24 (ediatric P)24 (atients)]TJ
/T1_0 1 Tf
0.057 Tw -4.964 -1.426 Td
[(The ef\037cac)20 (y of SPR)18 (YCEL in combina)-10 (tion with chemothera)-9.9 (py was evalua)-10 (ted in a single)-10 ( )]TJ
0.149 Tw 0 -1.043 Td
[(cohort \(cohort 1\) of Stud)-10 (y CA180372 \(NCT01460160\),)37 ( a multicenter)74 (,)37 ( multiple-cohort)-10 ( )]TJ
0.16 Tw 0 -1.043 Td
[(stud)-10 (y of pedia)-10 (tric pa)-9.9 (tients with newly dia)-10 (gnosed B-cell precursor Ph)]TJ
0 Tc 0 Tw 25.972 0.125 Td
(+)Tj
-0.01 Tc 0.123 Tw 0.59 -0.125 Td
[( ALL.)37 ( The )-37.3 (78)-10 ( )]TJ
-0.003 Tw -26.562 -1.043 Td
[(pa)-10 (tients in cohort 1 received SPR)18 (YCEL a)-10 (t a daily dose of 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 512.9158 154.1236 Tm
(2)Tj
-0.01 Tc -0.003 Tw 8 0 0 8 515.7358 151.3236 Tm
[( for up to 24 months,)27 ( )]TJ
0.217 Tw -23.967 -1.043 Td
[(in combina)-9.9 (tion with chemothera)-10 (py)55 (.)37 ( )37 (The backbone chemothera)-10 (py regimen was the)-9.9 ( )]TJ
0 Tw 0 -1.043 Td
[(AIEOP-BFM )37 (ALL 2000 multi-a)-10 (gent chemothera)-9.9 (py protocol.)27 ( )]TJ
0.123 Tw 0 -1.471 Td
[(P)18 (a)-10 (tients had a median a)-10 (ge of 10.4 years \(range 2.6 to 17.9 years\) and inc)20 (luded 20)-10 ( )]TJ
0.114 Tw 0 -1.043 Td
[(pa)-10 (tients \(25%\) 2 to 6 years of a)-9.9 (ge,)37 ( 37 pa)-10 (tients \(46%\) 7 to 12 years of a)-9.9 (ge,)37 ( and 24)-10 ( )]TJ
0.078 Tw 0 -1.043 Td
[(pa)-10 (tients \(30%\) 13 to 17 years of a)-9.9 (ge.)37 ( Eighty-two percent of pa)-9.9 (tients were white,)37 ( and)-10 ( )]TJ
0.196 Tw 0 -1.043 Td
[(55% were male.)37 ( )37.3 (Thirty-two pa)-10 (tients \(41%\) had a white blood cell count \(WBC\) of)-10 ( )]TJ
0 Tw 0 -1.043 Td
[(\03650,000 mc)20 (l a)-9.9 (t dia)-9.9 (gnosis,)37 ( and 17 pa)-10 (tients \(22%\) had extramedullar)-17.9 (y disease.)27 ( )]TJ
0.117 Tw 0 -1.471 Td
[(Ef\037cac)20 (y was established on the basis of 3-year event-free sur)-17.9 (vival \(EFS\),)37 ( de\037ned as)-10 ( )]TJ
0.021 Tw 0 -1.043 Td
[(the time from the start of SPR)17.9 (YCEL to lack of complete response a)-9.9 (t the end of the third)-10 ( )]TJ
0.101 Tw 0 -1.043 Td
[(high risk block,)37 ( rela)-10 (pse,)37 ( secondar)-18 (y malignanc)20 (y)55 (,)37 ( or dea)-10 (th from an)-9.9 (y cause.)37 ( )37.1 (The 3-year)-10 ( )]TJ
0.001 Tw 0 -1.043 Td
[(EFS )0.5 (binar)-17.9 (y ra)-9.9 (te for pa)-10 (tients on )0.5 (Stud)-10 (y CA180372 was 64.1% \(95% CI:)37 ( )0.5 (52.4,)37 ( )0.5 (74.7\).)37 ( )37.4 (At the)-9.9 ( )]TJ
0.079 Tw 0 -1.043 Td
[(end of induction,)37 ( 75 pa)-9.9 (tients \(96%\) had a bone marro)-9.9 (w with <5% lymphoblasts,)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.043 Td
[(76 pa)-9.9 (tients \(97%\) achieved this by the end of consolida)-9.9 (tion.)]TJ
ET
endstreamendobj39 0 obj<</Length 27641>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.005 Tw 8 0 0 8 36 727.248 Tm
[(Dasa)-9.9 (tinib was c)20 (lastogenic when tested )]TJ
/T1_1 1 Tf
(in vitro)Tj
/T1_0 1 Tf
[( in Chinese hamster ovar)-17.9 (y cells,)37 ( with and)-10 ( )]TJ
0.098 Tw 0 -1.001 Td
[(without metabolic activa)-9.9 (tion.)37 ( Dasa)-10 (tinib was not muta)-10 (genic when tested in an )]TJ
/T1_1 1 Tf
(in vitro)Tj
/T1_0 1 Tf
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.015 Tc -0.042 Tw -31.5 -1.001 Td
(bacterial cell assay \(Ames test\) and was not genotoxic in an )Tj
/T1_1 1 Tf
(in vivo)Tj
/T1_0 1 Tf
[( ra)-10 (t micronuc)20 (leus stud)-10 (y)55 (.)]TJ
-0.01 Tc 0.172 Tw 0 -1.563 Td
[(Dasa)-9.9 (tinib did not affect ma)-10 (ting or fertility in male and female ra)-10 (ts a)-9.9 (t plasma drug)-10 ( )]TJ
0.034 Tw 0 -1.001 Td
[(exposure \(AUC\) similar to the human exposure a)-9.9 (t 100 mg daily)55.1 (.)37 ( In repea)-9.9 (t dose studies,)27 ( )]TJ
0.073 Tw 0 -1.001 Td
[(administra)-10 (tion of dasa)-9.9 (tinib resulted in reduced size and secretion of seminal vesic)20 (les,)27.1 ( )]TJ
0.192 Tw 0 -1.001 Td
[(and )0.5 (imma)-9.9 (ture )0.5 (prosta)-9.9 (te,)37 ( )0.5 (seminal )0.5 (vesic)20 (le,)37 ( and testis.)37 ( )37.4 (The administra)-9.9 (tion )0.5 (of )0.5 (dasa)-10 (tinib)-10 ( )]TJ
0.035 Tw 0 -1.001 Td
[(resulted in uterine in\035amma)-10 (tion and mineraliza)-9.9 (tion in monkeys,)37 ( and c)20 (ystic ovaries and)-10 ( )]TJ
0 Tw 0 -1.001 Td
(ovarian hypertrophy in rodents.)Tj
/T1_2 1 Tf
0.01 Tw 0 -2.171 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CLINIC)18 (AL STUDIES)]TJ
0.01 Tw -3.375 -1.653 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Newly Diagnosed Chronic Phase CML in Adults)Tj
/T1_0 1 Tf
0.103 Tw -3.375 -1.518 Td
[(DASISION )0.5 (\(Dasa)-10 (tinib vs Ima)-10 (tinib Stud)-10 (y in )37.4 (T)74 (rea)-9.9 (tment-Naive Chronic Myeloid Leukemia)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(P)18 (a)-10 (tients\) )0.5 (\(NCT00481247\) was )0.5 (an open-label,)37 ( multicenter)74 (,)37 ( interna)-10 (tional,)37 ( randomized trial)-10 ( )]TJ
0.101 Tw 0 -1.001 Td
[(conducted in adult pa)-10 (tients with newly dia)-9.9 (gnosed chronic phase CML.)37 ( )37 (A total of 519)-10 ( )]TJ
0.134 Tw 0 -1.001 Td
[(pa)-10 (tients were randomized to receive either SPR)18 (YCEL 100 mg once daily or ima)-10 (tinib)-10 ( )]TJ
0.032 Tw 0 -1.001 Td
[(400 )0.5 (mg once daily)55 (.)37 ( P)18 (a)-10 (tients with a )0.5 (histor)-17.9 (y of cardiac disease )0.5 (were )0.5 (inc)20 (luded )0.5 (in this )0.5 (trial)-9.9 ( )]TJ
0.022 Tw 0 -1.001 Td
[(except those who had a myocardial infarction within 6 months,)37 ( congestive heart failure)-10 ( )]TJ
0.145 Tw 0 -1.001 Td
[(within 3 months,)37 ( signi\037cant arrhythmias,)37 ( or QTc prolonga)-10 (tion.)37 ( )36.8 (The primar)-18 (y endpoint)-10 ( )]TJ
0.136 Tw 0 -1.001 Td
[(was the ra)-10 (te of con\037rmed complete c)20 (ytogenetic response \(CCyR\) within 12 months.)27 ( )]TJ
0.061 Tw 0 -1.001 Td
[(Con\037rmed CCyR was de\037ned as a CCyR noted on two consecutive occasi\ons \(a)-9.9 (t least)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(28 days a)-10 (part\).)]TJ
0.064 Tw 0 -1.563 Td
[(Median a)-9.9 (ge was 46 years in the SPR)18 (YCEL group and 49 years in the ima)-9.9 (tinib groups,)27 ( )]TJ
0.018 Tw 0 -1.001 Td
[(with 10% and 11% of pa)-9.9 (tients \03665 years of a)-10 (ge,)37 ( respectively)55 (.)37 ( )37.2 (There were slightly more)-10 ( )]TJ
0.18 Tw 0 -1.001 Td
[(male than female pa)-10 (tients in both groups \(59% vs 41%\).)37 ( F)18 (ifty-three percent of all)-9.9 ( )]TJ
0.075 Tw 0 -1.001 Td
[(pa)-10 (tients were Caucasian and 39% were )37 (Asian.)37 ( )37 (At baseline,)36.9 ( the distribution of Hasford)-10 ( )]TJ
0.07 Tw 0 -1.001 Td
[(scores was similar in the SPR)18 (YCEL and ima)-10 (tinib trea)-10 (tment groups \(lo)-10 (w risk:)37.1 ( 33% and)-9.9 ( )]TJ
0 -1.001 Td
[(34%; intermedia)-9.9 (te risk:)37 ( 48% and 47%; high risk:)37 ( 19% and 19%,)37 ( respectively\).)37 ( )36.7 (With a)-9.9 ( )]TJ
-0.001 Tw 0 -1.001 Td
[(minimum of 12 months follo)-9.9 (w-up,)37 ( 85% of pa)-10 (tients randomized to SPR)18 (YCEL and 81% of)-9.9 ( )]TJ
0 Tw 0 -1.001 Td
[(pa)-10 (tients randomized to ima)-10 (tinib were still on stud)-10 (y)55 (.)]TJ
0.024 Tw 0 -1.563 Td
[(With a minimum of 24 months follo)-10 (w-up,)37 ( 77% of pa)-10 (tients randomized to SPR)18 (YCEL and)-10 ( )]TJ
0.051 Tw 0 -1.001 Td
[(75% of pa)-9.9 (tients randomized to ima)-9.9 (tinib were still on stud)-10 (y and with a minimum of 60)-10 ( )]TJ
0.006 Tw 0 -1.001 Td
[(months follo)-10 (w-up,)37 ( 61% and 62% of pa)-9.9 (tients,)37 ( respectively)55 (,)37 ( were still on trea)-9.9 (tment a)-10 (t the)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(time of stud)-10 (y c)20 (losure.)]TJ
0 -1.563 Td
[(Ef\037cac)20 (y results are summarized in )37.1 (T)73.9 (able 16.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 415.199 252 -17.312 re
36 397.887 95.4 -19.472 re
131.4 397.887 78.3 -19.472 re
209.7 397.887 78.3 -19.472 re
36 378.415 95.4 -11.472 re
131.4 378.415 78.3 -11.472 re
209.7 378.415 78.3 -11.472 re
36 366.943 95.4 -11.472 re
131.4 366.943 78.3 -11.472 re
209.7 366.943 78.3 -11.472 re
36 355.471 95.4 -11.472 re
131.4 355.471 156.6 -11.472 re
36 343.999 95.4 -11.472 re
131.4 343.999 156.6 -11.472 re
36 332.527 95.4 -11.472 re
131.4 332.527 78.3 -11.472 re
209.7 332.527 78.3 -11.472 re
36 321.055 95.4 -11.472 re
131.4 321.055 156.6 -11.472 re
36 309.583 95.4 -11.472 re
131.4 309.583 78.3 -11.472 re
209.7 309.583 78.3 -11.472 re
36 298.111 252 -64.152 re
f
0 0 0 1 K
/GS2 gs
q 1 0 0 1 36 397.8868 cm
0 0 m
95.4 0 l
S
Q
0.5 w 
q 1 0 0 1 36 378.4149 cm
0 0 m
95.4 0 l
S
Q
1 w 
q 1 0 0 1 36 298.1115 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4 298.1115 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 298.1115 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 36 343.9991 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4 343.9991 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 343.9991 cm
0 0 m
78.3 0 l
S
Q
1 w 
q 1 0 0 1 131.4 397.8868 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 397.8868 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 131.4 378.4149 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 378.4149 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 36 233.9596 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4 233.9596 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7 233.9596 cm
0 0 m
78.3 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0.265 Tw 8 0 0 8 36 409.4868 Tm
[(Table )241 (16:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Efficacy Results in a Randomized Newly Diagnosed Chronic)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Phase CML Trial)Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 158.0402 389.2948 Tm
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 183.0598 389.2948 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 159.707 381.2948 Tm
(\(n=259\))Tj
10.815 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 260.1286 389.2948 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 238.007 381.2948 Tm
(\(n=260\))Tj
-0.01 Tc 0.024 Tw -28.057 -1.434 Td
(Confirmed CCyR)Tj
0 Tc 0 Tw 5.4 0 0 6 81.3951 372.6229 Tm
(a)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 358.351 Tm
( )Tj
EMC 
1.25 0 Td
(Within 12 months \(95% CI\))Tj
/T1_0 1 Tf
-0.005 Tc 13.955 0 Td
(76.8% \(71.2\22681.8\))Tj
11.125 0 Td
(66.2% \(60.1\22671.9\))Tj
/T1_2 1 Tf
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.33 -1.434 Td
( )Tj
EMC 
[(P-v)16.1 (alue)-10 ( )]TJ
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 22.882 0 Td
(0.007*)Tj
/T1_2 1 Tf
-0.01 Tc 0.024 Tw -22.882 -1.434 Td
(Major Molecular Response)Tj
0 Tc 0 Tw 5.4 0 0 6 110.533 338.2072 Tm
(b)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36 323.9353 Tm
( )Tj
EMC 
1.25 0 Td
(12 months \(95% CI\))Tj
/T1_0 1 Tf
-0.005 Tc 13.955 0 Td
(52.1% \(45.9\22658.3\))Tj
11.125 0 Td
(33.8% \(28.1\22639.9\))Tj
/T1_2 1 Tf
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-26.33 -1.434 Td
( )Tj
EMC 
[(P-v)16.1 (alue)]TJ
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 22.52 0 Td
(<0.0001)Tj
/T1_2 1 Tf
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-22.52 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(60 months \(95% CI\))Tj
/T1_0 1 Tf
-0.005 Tc 13.955 0 Td
(76.4% \(70.8\22681.5\))Tj
11.125 0 Td
(64.2% \(58.1\22670.1\))Tj
0.005 Tw 5.4 0 0 6 36 291.5995 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc -0.043 Tw 7.2 0 0 8 41 288.7995 Tm
[(Confirmed CCyR is defined as a CCyR noted on two consecutive occasions a\)-10 (t least 28)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
30.369 0 Td
[(days a)-9.9 (part.)]TJ
-0.005 Tc 0.005 Tw 5.4 0 0 6 36 281.7995 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.047 Tw 7.2 0 0 8 41 278.9995 Tm
[(Major molecular response \(a)-9.9 (t an)-10 (y time\) was defined as BCR-ABL ra)-10 (tios \0340.1% by RQ-PCR in)-5 ( )]TJ
0.043 Tw 0 -1 Td
[(peripheral blood samples standardized on the Interna)-10 (tional scale.)37 ( )36.5 (These are cumula)-10 (tive ra)-9.9 (tes)-5 ( )]TJ
0 Tw 0 -1 Td
[(representing minimum follo)-10 (w up for the time frame specified.)]TJ
0.004 Tw -0.694 -1.09 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.694 0 Td
[(Adjusted for Hasford score and indica)-10 (ted sta)-9.9 (tistical significance a)-10 (t a pre-defined nominal level)-5 ( )]TJ
0 Tw 0 -1 Td
(of significance.)Tj
-0.694 -1.09 Td
[(CI = confidence inter)-18 (val.)]TJ
-0.01 Tc 0.068 Tw 8 0 0 8 36 218.8646 Tm
[(The con\037rmed CCyR within 24,)37 ( 36,)37 ( and 60)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
15.948 0 Td
[(months for SPR)18 (YCEL versus ima)-9.9 (tinib arms)-9.9 ( )]TJ
-0.004 Tw -15.948 -1.001 Td
[(were 80% versus 74%,)37 ( 83% versus 77%,)37 ( and 83% versus 79%,)37 ( respectively)55 (.)37 ( )37.2 (The MMR)-9.9 ( )]TJ
-0.035 Tw 0 -1.001 Td
[(a)-10 (t 24 and 36)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.729 0 Td
[(months for SPR)18 (YCEL versus ima)-10 (tinib arms were 65% versus 50% and 69%)-10 ( )]TJ
0 Tw -4.729 -1.001 Td
[(versus 56%,)37 ( respectively)55 (.)]TJ
0.341 Tw 0 -1.496 Td
(After 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.449 0 Td
[(months follo)-10 (w-up,)37 ( median time to con\037rmed CCyR was 3.)120 (1)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
24.125 0 Td
[(months in)-10 ( )]TJ
0 Tc 0 Tw 3.926 0 Td
( )Tj
-0.01 Tc 0.072 Tw -31.5 -1.001 Td
[(21)40 (5 SPR)18 (YCEL responders and 5.8)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
12.645 0 Td
(months in 204)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.589 0 Td
[(ima)-9.9 (tinib responders.)37 ( Median time to)-9.9 ( )]TJ
0 Tc 0 Tw 13.265 0 Td
( )Tj
-0.01 Tc 0.208 Tw -31.5 -1.001 Td
(MMR after 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.595 0 Td
[(months follo)-10 (w-up was 9.3)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
10.282 0 Td
[(months in 198 SPR)18 (YCEL responders and)-10 ( )]TJ
0 Tw -15.877 -1.001 Td
[(1)20 (5.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(months in 167)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(ima)-10 (tinib responders.)]TJ
0.102 Tw 0 -1.451 Td
(At 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.241 0 Td
[(months,)37 ( 8 pa)-10 (tients \(3%\) on the dasa)-9.9 (tinib arm progressed to either accelera)-10 (ted)-10 ( )]TJ
0.09 Tw -2.241 -1.001 Td
[(phase or blast crisis )0.5 (while )0.5 (15 )0.5 (pa)-10 (tients \(6%\) )0.5 (on the ima)-10 (tinib )0.5 (arm progressed to either)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(accelera)-10 (ted phase or blast crisis.)]TJ
-0.028 Tw 0 -1.451 Td
[(The estima)-9.9 (ted 60-month sur)-18 (vival ra)-10 (tes for SPR)18 (YCEL- and ima)-10 (tinib-trea)-9.9 (ted pa)-10 (tients were)-9.9 ( )]TJ
0.051 Tw 0 -1.001 Td
[(90.9% \(CI:)37 ( 86.6%\22693.8%\) and 89.6% \(CI:)37 ( 85.2%\22692.8%\),)37 ( respectively)54.9 (.)37.1 ( Based on da)-9.9 (ta)-10 ( )]TJ
0.074 Tw 0 -1.001 Td
(5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
0.7 0 Td
[(years after the last pa)-10 (tient was enrolled in the trial,)37 ( 83% and 77% of pa)-10 (tients were)-10 ( )]TJ
-0.039 Tw -0.7 -1.001 Td
[(kno)-9.9 (wn to be alive in the dasa)-10 (tinib and ima)-10 (tinib trea)-10 (tment groups,)37 ( respectively)55 (,)37 ( 10% were)-9.9 ( )]TJ
0.033 Tw 0 -1.001 Td
[(kno)-9.9 (wn to ha)-9.9 (ve died in both trea)-10 (tment groups,)37 ( and 7% and 13% had unkno)-10 (wn sur)-18 (vival)-10 ( )]TJ
0 Tw 0 -1.001 Td
[(sta)-9.9 (tus in the dasa)-9.9 (tinib and ima)-10 (tinib trea)-10 (tment groups,)37 ( respectively)55.1 (.)]TJ
-0.011 Tc 0.049 Tw 0 -1.451 Td
(At 60)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.182 0 Td
[(months follo)-10 (w-up in the SPR)18 (YCEL arm,)37 ( the ra)-10 (te of MMR a)-10 (t an)-10 (y time in each risk)-11 ( )]TJ
0.108 Tw -2.182 -1.001 Td
[(group determined by Hasford score was 90% \(lo)-10 (w risk\),)37 ( 71% \(intermedia)-9.9 (te risk\) and)-11 ( )]TJ
0.099 Tw 0 -1.001 Td
[(67% \(high risk\).)37 ( In the ima)-10 (tinib arm,)37 ( the ra)-10 (te of MMR a)-10 (t an)-10 (y time in each risk group)-11.1 ( )]TJ
0.124 Tw 0 -1.001 Td
[(determined by Hasford score was 69% \(lo)-10 (w risk\),)37 ( 65% \(intermedia)-10 (te risk\),)37 ( and 54%)-11 ( )]TJ
0 Tw 0 -1.001 Td
(\(high risk\).)Tj
-0.01 Tc 0.18 Tw 36 86.406 Td
[(BCR-ABL sequencing was performed on blood samples from pa)-9.9 (tients in the newly)-10 ( )]TJ
-0.018 Tw 0 -1.002 Td
[(dia)-9.9 (gnosed trial who discontinued dasa)-9.9 (tinib or ima)-10 (tinib thera)-10 (py)55 (.)37 ( )37.2 (Among dasa)-10 (tinib-trea)-10 (ted)-10 ( )]TJ
0 Tw 0 -1.002 Td
[(pa)-10 (tients the muta)-9.9 (tions detected were )37 (T315I,)37 ( F317I/L,)37 ( and )37 (V299L.)]TJ
-0.038 Tw 0 -1.452 Td
[(Dasa)-9.9 (tinib does not a)-9.9 (ppear to be active a)-9.9 (gainst the )37.1 (T315I muta)-10 (tion,)37 ( based on )]TJ
/T1_1 1 Tf
(in vitro)Tj
/T1_0 1 Tf
[( da)-10 (ta.)]TJ
/T1_2 1 Tf
0.01 Tw 0 -1.789 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Imatinib-Resistant or -Intolerant CML or Ph)Tj
0 Tc 16.735 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( ALL in Adults)Tj
/T1_0 1 Tf
0.12 Tw -20.7 -1.497 Td
[(The ef\037cac)20 (y and safety of SPR)18 (YCEL were investiga)-10 (ted in adult pa)-10 (tients with CML or)-10 ( )]TJ
0.01 Tw 0 -1.002 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.174 Tw 0.59 -0.125 Td
[( )37.5 (ALL )0.5 (whose )0.5 (disease )0.5 (was )0.5 (resistant )0.5 (to )0.5 (or )0.5 (who )0.5 (were )0.5 (intolerant )0.5 (to )0.5 (ima)-9.9 (tinib:)37 ( )0.5 (1158)-9.9 ( )]TJ
0.125 Tw -1.514 -1.002 Td
[(pa)-10 (tients )0.5 (had chronic )0.5 (phase )0.5 (CML,)37 ( )0.6 (858 )0.5 (pa)-10 (tients )0.5 (had )0.5 (accelera)-9.9 (ted )0.5 (phase,)37 ( )0.5 (myeloid )0.5 (blast)-10 ( )]TJ
0.01 Tw 0 -1.002 Td
[(phase,)37 ( or lymphoid blast phase CML,)37 ( and 130 pa)-10 (tients had Ph)]TJ
0 Tc 0 Tw 22.387 0.125 Td
(+)Tj
-0.01 Tc 0.01 Tw 0.59 -0.125 Td
[( )37.1 (ALL.)37 ( In a c)20 (linical trial in)-10 ( )]TJ
0.012 Tw -22.977 -1.002 Td
[(chronic )0.5 (phase )0.5 (CML,)37 ( resistance )0.5 (to )0.5 (ima)-9.9 (tinib )0.5 (was de\037ned )0.5 (as )0.5 (failure )0.5 (to )0.5 (achieve )0.5 (a complete)-10 ( )]TJ
0.056 Tw 0 -1.002 Td
[(hema)-10 (tologic response \(CHR; after 3 months\),)37 ( major c)20 (ytogenetic response \(MCyR; after)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.159 Tw -31.5 -1.002 Td
[(6\032)-159.4 (months\),)37 ( or complete c)20 (ytogenetic response \(CCyR; after 12 months\); or loss of a)-10 ( )]TJ
0.185 Tw 0 -1.002 Td
(previous molecular response \(with concurrent \03610% increase in Ph)Tj
0 Tc 0 Tw 25.654 0.125 Td
(+)Tj
-0.01 Tc 0.185 Tw 0.59 -0.125 Td
[( meta)-10 (phases\),)27 ( )]TJ
0.151 Tw -26.244 -1.002 Td
[(c)20 (ytogenetic response,)37 ( or hema)-10 (tologic response.)37 ( Ima)-10 (tinib intolerance was de\037ned as)-10 ( )]TJ
0.082 Tw 0 -1.002 Td
[(inability to tolera)-10 (te 400 mg or more of ima)-10 (tinib per day or discontinua)-9.9 (tion of ima)-10 (tinib)-10 ( )]TJ
0 Tw 0 -1.002 Td
[(because of toxicity)55 (.)]TJ
0.004 Tw 0 -1.452 Td
[(Results described belo)-10 (w are based on a minimum of 2 years follo)-9.9 (w-up after the start of)-10 ( )]TJ
0.015 Tw 0 -1.002 Td
[(SPR)18 (YCEL thera)-10 (py )0.5 (in pa)-10 (tients with a )0.5 (median time from )0.5 (initial dia)-9.9 (gnosis )0.5 (of a)-9.9 (pproxima)-10 (tely)-9.9 ( )]TJ
0.047 Tw 0 -1.002 Td
[(5 years.)37 ( )36.8 (Across all studies,)37 ( 48% of pa)-10 (tients were women,)37 ( 81% were white,)37 ( 15% were)-10 ( )]TJ
0.088 Tw 0 -1.002 Td
[(black or )37.2 (Asian,)37 ( 25% were 65 years of a)-10 (ge or older)74 (,)37 ( and 5% were 75 years of a)-10 (ge or)-10 ( )]TJ
0.02 Tw 0 -1.002 Td
[(older)74 (.)37 ( Most pa)-10 (tients had long disease histories with extensive prior trea)-10 (tment,)37 ( inc)20 (luding)-10 ( )]TJ
0.076 Tw 0 -1.002 Td
[(ima)-9.9 (tinib,)37 ( c)19.9 (ytotoxic chemothera)-10 (py)55 (,)37 ( interferon,)37 ( and stem cell transplant.)37 ( Overall,)37.1 ( 80% of)-10 ( )]TJ
0.014 Tw 0 -1.002 Td
[(pa)-10 (tients had ima)-10 (tinib-resistant disease and 20% of pa)-10 (tients were intolerant to ima)-10 (tinib.)27 ( )]TJ
0.057 Tw 0 -1.002 Td
[(The maximum ima)-10 (tinib dose had been 400\226600 mg/day in about 60% of the pa)-10 (tients)-10 ( )]TJ
0 Tw 0 -1.002 Td
[(and >600 mg/day in 40% of the pa)-10 (tients.)]TJ
0.031 Tw 0 -1.452 Td
[(The primar)-18 (y ef\037cac)20 (y endpoint in chronic phase CML was MCyR,)37 ( de\037ned as elimina)-9.9 (tion)-10 ( )]TJ
0.042 Tw 0 -1.002 Td
[(\(CCyR\) or substantial diminution \(by )0.5 (a)-10 (t )0.5 (least )0.5 (65%,)37 ( )0.5 (partial c)20 (ytogenetic response\) )0.5 (of Ph)]TJ
0 Tc 0 Tw 30.9 0.125 Td
(+)Tj
0.6 -0.125 Td
( )Tj
-0.01 Tc 0.053 Tw -31.5 -1.002 Td
[(hema)-10 (topoietic cells.)37 ( )36.9 (The primar)-18 (y ef\037cac)20 (y endpoint in accelera)-10 (ted phase,)37 ( myeloid blast)-10 ( )]TJ
0.197 Tw 0 -1.002 Td
[(phase,)37 ( lymphoid blast phase CML,)37 ( and Ph)]TJ
0 Tc 0 Tw 16.209 0.125 Td
(+)Tj
-0.01 Tc 0.197 Tw 0.59 -0.125 Td
[( )36.7 (ALL was major hema)-10 (tologic response)-10 ( )]TJ
0 Tw -16.799 -1.002 Td
[(\(MaHR\),)37 ( de\037ned as either a CHR or no evidence of leukemia \(NEL\).)]TJ
/T1_2 1 Tf
0 -1.587 Td
(Chronic Phase CML)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.497 Td
(Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.014 Tw 1.377 0 Td
[(e-Optimiza)-9.9 (tion T)74 (rial:)]TJ
/T1_0 1 Tf
0.023 Tw /Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.325 0 Td
[( )37.3 (A randomized,)37 ( open-label trial \(NCT00123474\) was conducted)-10 ( )]TJ
-0.01 Tw -8.702 -1.002 Td
[(in adult pa)-10 (tients with chronic phase CML to evalua)-10 (te the ef\037cac)20 (y and safety of SPR)18 (YCEL)-9.9 ( )]TJ
-0.021 Tw 0 -1.002 Td
[(administered once daily compared with SPR)18 (YCEL administered twice daily)55 (.)37 ( P)18 (a)-10 (tients with)-10 ( )]TJ
-0.022 Tw 0 -1.002 Td
[(signi\037cant cardiac diseases,)37 ( inc)20 (luding myocardial infarction within 6 months,)37 ( congestive)-9.9 ( )]TJ
-0.044 Tw 0 -1.002 Td
[(heart failure within 3 months,)37.1 ( signi\037cant arrhythmias,)37 ( or QTc prolonga)-9.9 (tion were exc)20 (luded)-10 ( )]TJ
0.21 Tw 0 -1.002 Td
[(from the )0.5 (trial.)37 ( )37.5 (The )0.5 (primar)-18 (y )0.5 (ef\037cac)20 (y endpoint )0.5 (was )0.5 (MCyR )0.5 (in )0.5 (pa)-10 (tients )0.5 (with )0.5 (ima)-9.9 (tinib-)]TJ
-0.025 Tw 0 -1.002 Td
[(resistant CML.)37 ( )36.7 (A total of 670 pa)-10 (tients,)37 ( of whom 497 had ima)-10 (tinib-resistant disease,)37 ( were)-9.9 ( )]TJ
0.022 Tw 0 -1.002 Td
[(randomized to the SPR)18.1 (YCEL 100 mg once-daily)55 (,)37 ( 140 mg once-daily)55 (,)37 ( 50 mg twice-daily)55 (,)27 ( )]TJ
0 Tw 0 -1.002 Td
[(or 70 mg twice-daily group.)37.1 ( Median dura)-10 (tion of trea)-10 (tment was 22 months.)]TJ
-0.059 Tw 0 -1.452 Td
[(Ef\037cac)20 (y was achieved across all SPR)18 (YCEL trea)-9.9 (tment groups with the once-daily schedule)-10 ( )]TJ
0.072 Tw 0 -1.002 Td
[(demonstra)-10 (ting comparable ef\037cac)20 (y \(non-inferiority\) to the twice-daily schedule on the)-10 ( )]TJ
-0.017 Tw 0 -1.002 Td
[(primar)-18 (y ef\037cac)20 (y endpoint \(difference in MCyR 1.9%; 95% CI [\0316.8%\22610.6%]\); ho)-10 (wever)74 (,)27 ( )]TJ
0 Tw 0 -1.002 Td
[(the 100-mg once-daily regimen demonstra)-9.9 (ted improved safety and tolerability)55 (.)]TJ
0.015 Tw 0 -1.452 Td
[(Ef\037cac)20 (y results are presented in )36.7 (T)74 (ables 17 and 18 for adult pa)-10 (tients with chronic phase)-9.9 ( )]TJ
0 Tw 0 -1.002 Td
[(CML who received the recommended starting dose of 100 mg once daily)55.1 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 318.944 252 -17.312 re
324 301.632 138.96 -19.88 re
462.96 301.632 113.04 -19.88 re
324 281.752 138.96 -11.472 re
462.96 281.752 113.04 -11.472 re
324 270.28 138.96 -11.472 re
462.96 270.28 113.04 -11.472 re
324 258.808 138.96 -11.472 re
462.96 258.808 113.04 -11.472 re
324 247.336 138.96 -11.472 re
462.96 247.336 113.04 -11.472 re
324 235.865 138.96 -11.472 re
462.96 235.865 113.04 -11.472 re
324 224.393 252 -38.712 re
f
1 w 
/GS2 gs
q 1 0 0 1 323.9999 301.6322 cm
0 0 m
138.96 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 281.7522 cm
0 0 m
138.96 0 l
S
Q
1 w 
q 1 0 0 1 462.96 301.6322 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 462.96 281.7522 cm
0 0 m
113.04 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 224.3927 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 462.96 224.3927 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 323.9999 185.6808 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 462.96 185.6808 cm
0 0 m
113.04 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.02 Tc 0.087 Tw 8 0 0 8 323.9999 313.2322 Tm
[(T)-10 (a)-10 (b)-10 (l)-10 (e)-10 ( )53 (1)-10 (7)-10 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.538 0 Td
( )Tj
EMC 
3.087 0 Td
[(Efficacy of SPRYCEL in Adult Patients with Imatinib-Resistant or)-20 ( )]TJ
-0.025 Tc 0.024 Tw 0 -1 Td
[(-)-5 (Intolerant )0.5 (Chronic Phase )0.5 (CML )0.5 (\(minimum of )0.5 (24 months )0.5 (follow-up\))]TJ
-0.01 Tc 7.2 0 0 8 323.9999 293.0403 Tm
[(All P)24 (atients)]TJ
-0.02 Tc 23.585 0 Td
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0 Tc 0 Tw 7.2 0 0 8 545.1511 293.0403 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 508.6369 285.0403 Tm
(\(n=167\))Tj
-0.01 Tc 0.024 Tw -25.644 -1.485 Td
(Hematologic Response Rate % \(95% CI\))Tj
/T1_0 1 Tf
1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
(CHR)Tj
0 Tc 0 Tw 5.4 0 0 6 344.1238 264.4884 Tm
(a)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 502.0742 261.6884 Tm
(92% \(86\22695\))Tj
/T1_2 1 Tf
-0.01 Tc -24.733 -1.434 Td
(Cytogenetic Response Rate % \(95% CI\))Tj
/T1_0 1 Tf
1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
(MCyR)Tj
0 Tc 0 Tw 5.4 0 0 6 348.1775 241.5446 Tm
(b)Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 502.0743 238.7446 Tm
(63% \(56\22671\))Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.733 -1.434 Td
( )Tj
EMC 
(CCyR)Tj
-0.005 Tc 0.024 Tw 24.733 0 Td
(50% \(42\22658\))Tj
0.005 Tw 5.4 0 0 6 324.0001 217.8808 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tw 7.2 0 0 8 327.6001 215.0807 Tm
[(CHR \(response confirmed after 4 weeks\):)37 ( )36.7 (WBC \034 institutional ULN,)37 ( pla)-10 (telets <450,000/mm)]TJ
0 Tc 0 Tw 5.4 0 0 6 563.8937 217.8808 Tm
(3)Tj
-0.042 Tc 0.027 Tw 7.2 0 0 8 566.4587 215.0807 Tm
[(, n)-37 (o)-42 ( )]TJ
-0.005 Tc -0.043 Tw -33.175 -1 Td
[(blasts or promyeloc)20 (ytes in peripheral blood,)37 ( <5% myeloc)20 (ytes plus metamyeloc)20 (ytes in peripheral)-5 ( )]TJ
0 Tw 0 -1 Td
[(blood,)37 ( basophils in peripheral blood <20%,)37 ( and no extramedullar)-18 (y involvement.)]TJ
0.005 Tw 5.4 0 0 6 324.0001 192.0807 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 327.6001 189.2807 Tm
(MCyR combines both complete \(0% Ph)Tj
0 Tc 14.21 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( meta)-9.9 (phases\) and partial \(>0%\22635%\) responses.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 169.218 252 -25.312 re
324 143.906 101.52 -11.472 re
425.52 143.906 150.48 -11.472 re
324 132.434 101.52 -11.472 re
425.52 132.434 50.16 -11.472 re
475.68 132.434 50.16 -11.472 re
525.84 132.434 50.16 -11.472 re
324 120.962 101.52 -13.5 re
425.52 120.962 50.16 -13.5 re
475.68 120.962 50.16 -13.5 re
525.84 120.962 50.16 -13.5 re
324 107.462 101.52 -13.5 re
425.52 107.462 50.16 -13.5 re
475.68 107.462 50.16 -13.5 re
525.84 107.462 50.16 -13.5 re
324 93.962 101.52 -13.5 re
425.52 93.962 50.16 -13.5 re
475.68 93.962 50.16 -13.5 re
525.84 93.962 50.16 -13.5 re
324 80.462 101.52 -13.5 re
425.52 80.462 50.16 -13.5 re
475.68 80.462 50.16 -13.5 re
525.84 80.462 50.16 -13.5 re
324 66.962 252 -30.712 re
f
1 w 
/GS2 gs
q 1 0 0 1 425.5201 143.9057 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 143.9057 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 525.8401 143.9057 cm
0 0 m
50.16 0 l
S
Q
0.5 w 
q 1 0 0 1 425.5201 132.4338 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 132.4338 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 525.8401 132.4338 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 324.0001 120.9619 cm
0 0 m
101.52 0 l
S
Q
q 1 0 0 1 525.8401 120.9619 cm
0 0 m
50.16 0 l
S
Q
1 w 
q 1 0 0 1 525.8401 66.9619 cm
0 0 m
50.16 0 l
S
Q
0.5 w 
q 1 0 0 1 425.5201 120.9619 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 120.9619 cm
0 0 m
50.16 0 l
S
Q
0 0 0 0 K
/GS3 gs
q 1 0 0 1 525.8401 107.4619 cm
0 0 m
0 13.25 l
S
Q
q 1 0 0 1 525.8401 93.9619 cm
0 0 m
0 13.5 l
S
Q
q 1 0 0 1 525.8401 80.4619 cm
0 0 m
0 13.5 l
S
Q
q 1 0 0 1 525.8401 67.4619 cm
0 0 m
0 13 l
S
Q
0 0 0 1 K
1 w 
/GS2 gs
q 1 0 0 1 425.5201 66.9619 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 66.9619 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 324.0001 66.9619 cm
0 0 m
101.52 0 l
S
Q
0.5 w 
q 1 0 0 1 324.0001 36.2499 cm
0 0 m
101.52 0 l
S
Q
q 1 0 0 1 425.5201 36.2499 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 475.6801 36.2499 cm
0 0 m
50.16 0 l
S
Q
q 1 0 0 1 525.8401 36.2499 cm
0 0 m
50.16 0 l
S
Q
1 w 
q 1 0 0 1 324.0001 143.9057 cm
0 0 m
101.52 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.01 Tc 0.577 Tw 8 0 0 8 324.0001 163.5057 Tm
[(Table )553 (18:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Long-T)74 (erm MMR of SPR)18 (YCEL in the Dose Optimization)-10 ( )]TJ
0 Tc 0 Tw 24.875 0 Td
( )Tj
-0.01 Tc 0.441 Tw -24.875 -1 Td
[(T)74 (rial: Adult P)24 (atients with Imatinib-Resistant or -Intolerant)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Chronic Phase CML)Tj
0 Tc 0 Tw 6 0 0 6 437.4631 150.3057 Tm
(a)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 463.623 135.3138 Tm
(Minimum Follow-up Period)Tj
0 Tc 0 Tw -19.392 -1.434 Td
( )Tj
-0.02 Tc 0.024 Tw 16.151 0 Td
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years)Tj
6.967 0 Td
(5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years)Tj
6.967 0 Td
(7)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years)Tj
-0.01 Tc -30.084 -1.434 Td
(Major Molecular Response)Tj
0 Tc 0 Tw 5.4 0 0 6 398.5331 115.1699 Tm
(b)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 401.1791 112.3699 Tm
( % \(n/N\))Tj
/T1_0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-10.719 -1.687 Td
( )Tj
EMC 
1.25 0 Td
[(All P)18.1 (a)-10 (tients Randomized)-10 ( )]TJ
-0.005 Tc 13.789 0 Td
(34% \(57/167\))Tj
6.949 0 Td
(43% \(71/167\))Tj
7.234 0 Td
(44% \(73/167\))Tj
-0.01 Tc /Span<</ActualText<FEFF0009>>> BDC 
-29.223 -1.687 Td
( )Tj
EMC 
1.25 0 Td
[(Ima)-9.9 (tinib-Resistant P)18 (a)-10 (tients)]TJ
-0.005 Tc 13.789 0 Td
(33% \(41/124\))Tj
6.949 0 Td
(40% \(50/124\))Tj
7.234 0 Td
(41% \(51/124\))Tj
-0.01 Tc /Span<</ActualText<FEFF0009>>> BDC 
-29.223 -1.687 Td
( )Tj
EMC 
1.25 0 Td
[(Ima)-9.9 (tinib-Intolerant P)18 (a)-9.9 (tients)]TJ
-0.005 Tc 14.027 0 Td
(37% \(16/43\))Tj
6.949 0 Td
(49% \(21/43\))Tj
7.234 0 Td
(51% \(22/43\))Tj
0.005 Tw 5.4 0 0 6 324.0001 60.4499 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 329.0001 57.6499 Tm
(Results reported in recommended starting dose of 100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)55 (.)]TJ
0.005 Tw 5.4 0 0 6 324.0001 50.6499 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.04 Tw 7.2 0 0 8 329.0001 47.8499 Tm
[(Major molecular response criteria:)36.9 ( Defined as BCR-ABL/control transcripts \0340.1% by RQ-PCR)-5 ( )]TJ
0 Tw 0 -1 Td
(in peripheral blood samples.)Tj
ET
endstreamendobj40 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj33 0 obj<</Length 23153>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.005 Tc -0.042 Tw 8 0 0 8 36 727.2481 Tm
[(Acute overdose in animals was associa)-10 (ted with cardiotoxicity)55 (.)37 ( Evidence of cardiotoxicity)-5 ( )]TJ
-0.025 Tw 0 -1.019 Td
[(inc)20 (luded ventricular necrosis and valvular/ventricular/a)-10 (trial hemorrha)-9.9 (ge a)-9.9 (t single doses)-5 ( )]TJ
0.022 Tw 0 -1.019 Td
(\036100 mg/kg \(600 mg/m)Tj
0 Tc 0 Tw 6 0 0 6 106.8661 713.7367 Tm
(2)Tj
-0.005 Tc 0.022 Tw 8 0 0 8 109.716 710.9367 Tm
[(\) in rodents.)37 ( )37.2 (There was a tendenc)20 (y for increased systolic and)-5 ( )]TJ
0 Tw -9.215 -1.019 Td
[(diastolic blood pressure in monkeys a)-10 (t single doses \03610 mg/kg \(120 mg/m)]TJ
0 Tc 6 0 0 6 254.6435 705.5811 Tm
(2)Tj
-0.005 Tc 0.005 Tw 8 0 0 8 257.4935 702.7811 Tm
(\).)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -27.687 -1.919 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(DESCRIPTION)Tj
/T1_0 1 Tf
0.373 Tw -3.375 -1.312 Td
[(SPR)18 (YCEL \(dasa)-10 (tinib\) is a kinase inhibitor)74 (.)37 ( )36.6 (The chemical name for dasa)-9.9 (tinib is)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.012 Tc -0.012 Tw -31.5 -1.019 Td
[(N-\(2-chloro-6-methylphen)-10.3 (yl\)-2-[[6-[4-\(2-hydroxyethyl\)-1-piperazin)-10.3 (yl]-2-methyl-4-)]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.353 Tw -31.5 -1.019 Td
[(pyrimidin)-10 (yl]amino]-5-thiazolecarboxamide,)37 ( )0.5 (monohydra)-10 (te.)37 ( )37.5 (The )0.5 (molecular )0.5 (formula )0.5 (is)]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-31.5 -1.019 Td
(C)Tj
-0.01 Tc 0.01 Tw 6 0 0 6 40.072 650.9626 Tm
(22)Tj
0 Tc 0 Tw 8 0 0 8 45.7119 652.4626 Tm
(H)Tj
-0.01 Tc 0.01 Tw 6 0 0 6 49.9278 650.9626 Tm
(26)Tj
8 0 0 8 55.5678 652.4626 Tm
(ClN)Tj
0 Tc 0 Tw 6 0 0 6 65.5597 650.9626 Tm
(7)Tj
8 0 0 8 68.3797 652.4626 Tm
(O)Tj
6 0 0 6 72.7477 650.9626 Tm
(2)Tj
-0.01 Tc 0.549 Tw 8 0 0 8 75.5677 652.4626 Tm
(S \225 H)Tj
0 Tc 0 Tw 6 0 0 6 100.081 650.9626 Tm
(2)Tj
-0.01 Tc 0.549 Tw 8 0 0 8 102.9009 652.4626 Tm
[(O,)37 ( which corresponds to a formula )0.5 (weight )0.5 (of 506.02)-10 ( )]TJ
0 Tc 0 Tw 23.137 0 Td
( )Tj
-0.01 Tc 0.078 Tw -31.5 -1.019 Td
[(\(monohydra)-10 (te\).)37 ( )36.9 (The anhydrous free base has a molecular weight of 488.01.)37 ( Dasa)-10 (tinib)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(has the follo)-10 (wing chemical structure:)]TJ
ET
/PlacedGraphic /MC0 BDC 
EMC 
0 0 0 1 K
0.9 w 4 M 
/GS0 gs
q 1 0 0 1 133.0782 583.7868 cm
0 0 m
4.743 -3.23 l
B
Q
1 J 
q 1 0 0 1 86.9958 618.6249 cm
0 0 m
5.855 -2.813 l
0 0 m
-10.722 -5.323 l
-17.298 -1.386 m
-10.722 -5.323 l
S
Q
0 J 
q 1 0 0 1 170.5645 595.6603 cm
0 0 m
1.369 -6.007 l
S
Q
q 1 0 0 1 185.0131 595.6603 cm
0 0 m
-2.89 -9.581 l
B
Q
BT
/CS0 cs 1  scn
/T1_2 1 Tf
0 Tc 8.955 0 0 8.865 251.632 588.5729 Tm
(\267)Tj
0.302 0 Td
( )Tj
0.201 0 Td
( )Tj
/T1_3 1 Tf
0.302 0 Td
(H)Tj
6.8058 0 0 6.7374 265.0996 586.7404 Tm
(2)Tj
8.955 0 0 8.865 269.7958 588.5729 Tm
(O)Tj
8.0595 0 0 7.9785 124.7185 582.2588 Tm
(N)Tj
2.457 -0.063 Td
(N)Tj
-3.713 2.185 Td
(N)Tj
-2.54 1.487 Td
(N)Tj
ET
q
36 560.087 252 63.209 re
W n
BT
0.06 Tc -0.06 Tw 8.0595 0 0 7.9785 56.3185 616.4579 Tm
(HO)Tj
ET
Q
BT
8.0595 0 0 7.9785 155.0701 607.5546 Tm
(H)Tj
0.004 -1.027 Td
(N)Tj
1.59 -2.143 Td
(N)Tj
1.005 2.369 Td
(S)Tj
3.462 -1.579 Td
(N)Tj
0 -1.015 Td
(H)Tj
0.803 Tc -0.803 Tw -0.67 3.497 Td
(OC)Tj
0 Tc 0 Tw 2.345 0 Td
(l)Tj
-1.452 -5.108 Td
(H)Tj
6.6267 0 0 6.5601 211.9969 566.6881 Tm
(3)Tj
8.0595 0 0 7.9785 216.0973 567.6083 Tm
(C)Tj
-0.052 Tc 0.052 Tw -10.11 -0.533 Td
(CH)Tj
ET
q
36 560.087 252 63.209 re
W n
BT
0 Tc 0 Tw 6.6267 0 0 6.5601 146.2965 561.5368 Tm
(3)Tj
ET
Q
1 J 
q 1 0 0 1 113.6016 599.1022 cm
0 0 m
-6.508 -2.878 l
-16.442 2.535 l
-16.442 10.344 l
-12.404 16.337 m
-6.508 19.524 l
4.247 14.181 l
4.247 6.234 l
34.331 -10.765 m
34.331 -2.961 l
24.342 2.641 l
14.226 -3.064 l
7.434 0.039 l
84.615 0.1 m
73.844 -2.758 l
67.913 2.033 l
14.153 -10.765 m
14.153 -3.093 l
S
Q
0 J 
q 1 0 0 1 146.5489 594.6473 cm
0 0 m
0 -6.31 l
-17.274 0.177 m
-8.7 5.268 l
S
Q
0 0 0 1 k
q 1 0 0 1 147.9088 596.2365 cm
0 0 m
6.389 3.002 l
B
Q
1 J 
q 1 0 0 1 131.7981 582.1389 cm
0 0 m
5.762 -3.97 l
5.762 -11.142 l
S
Q
0 J 
q 1 0 0 1 143.5526 582.2548 cm
0 0 m
-5.992 -4.086 l
B
Q
1 J 
q 1 0 0 1 161.4979 599.2388 cm
0 0 m
6.716 -3.061 l
8.459 -10.422 l
6.716 -3.061 l
13.301 1.786 l
22.151 -14.808 m
25.955 -2.961 l
22.151 -14.808 l
h
13.722 -14.808 m
22.151 -14.808 l
42.062 -5.168 m
37.05 -0.385 l
S
Q
10 M 0 J 
q 1 0 0 1 199.54 607.2835 cm
0 0 m
-2.204 -8.228 l
S
Q
1 J 
q 1 0 0 1 221.3056 606.7649 cm
0 0 m
3.537 -6.057 l
-2.679 -15.96 l
-11.123 -15.895 l
3.748 -25.916 m
-2.679 -15.96 l
3.748 -25.916 l
h
-0.098 -32.237 m
3.748 -25.916 l
15.337 -25.864 l
20.597 -15.961 l
15.052 -6.058 l
3.537 -6.057 l
S
Q
0 J 
q 1 0 0 1 225.6247 582.6398 cm
0 0 m
-4.747 8.165 l
14.433 8.165 m
9.911 -0.053 l
S
Q
4 M 
q 1 0 0 1 236.2213 598.9172 cm
0 0 m
-10.823 0 l
S
Q
10 M 
q 1 0 0 1 201.1564 606.696 cm
0 0 m
-2.205 -8.228 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.05 Tw 8 0 0 8 36 542.9514 Tm
[(Dasa)-9.9 (tinib )0.6 (is )0.5 (a )0.6 (white )0.6 (to )0.6 (off-white )0.6 (po)-10 (wder)74 (.)37 ( )37.6 (The )0.6 (drug )0.5 (substance )0.6 (is )0.5 (insoluble )0.6 (in )0.5 (wa)-10 (ter )0.6 (and)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(slightly soluble in ethanol and methanol.)27.1 ( )]TJ
0.314 Tw 0 -1.312 Td
[(SPR)18 (YCEL tablets are white to off-white,)37 ( biconvex,)37 ( \037lm-coa)-9.9 (ted tablets containing)-10 ( )]TJ
0.012 Tw 0 -1.019 Td
[(dasa)-9.9 (tinib,)37 ( with the follo)-10 (wing inactive ingredients:)37 ( lactose monohydra)-10 (te,)37 ( microcr)-18 (ystalline)-10 ( )]TJ
0.164 Tw 0 -1.019 Td
[(cellulose,)37 ( croscarmellose sodium,)37.1 ( hydroxypropyl cellulose,)37 ( and ma)-10 (gnesium steara)-10 (te.)27 ( )]TJ
0 Tw 0 -1.019 Td
[(The tablet coa)-10 (ting consists of hypromellose,)37 ( titanium dioxide,)37 ( and polyethylene glycol.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -2.144 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(CLINIC)18 (AL PHARMACOLOGY)]TJ
0.01 Tw -3.375 -1.942 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Mechanism of Action)Tj
/T1_0 1 Tf
0.102 Tw -3.375 -1.402 Td
[(Dasa)-9.9 (tinib,)37 ( a)-10 (t nanomolar concentra)-9.9 (tions,)37 ( inhibits the follo)-9.9 (wing kinases:)37 ( BCR-ABL,)37 ( SRC)-10 ( )]TJ
0.101 Tw 0 -1.019 Td
[(family \(SRC,)37 ( LCK,)37 ( )36.7 (YES,)37 ( FYN\),)37 ( c-KIT)92 (,)37 ( EPHA2,)37 ( and PDGFR)]TJ
/T1_4 1 Tf
0 Tc 0 Tw (\037)Tj
/T1_0 1 Tf
-0.01 Tc 0.101 Tw 20.761 0 Td
[(.)37 ( Based on modeling studies,)27 ( )]TJ
0 Tw -20.761 -1.019 Td
[(dasa)-9.9 (tinib is predicted to bind to multiple conforma)-10 (tions of the )37 (ABL kinase.)]TJ
/T1_5 1 Tf
0.141 Tw 0 -1.312 Td
(In vitro)Tj
/T1_0 1 Tf
[(,)37 ( dasa)-9.9 (tinib was active in leukemic cell lines representing variants of ima)-10 (tinib)-10 ( )]TJ
0.594 Tw 0 -1.019 Td
[(mesyla)-10 (te-sensitive and )0.5 (resistant disease.)37 ( )0.5 (Dasa)-10 (tinib inhibited the gro)-9.9 (wth of)-10 ( )]TJ
0.201 Tw 0 -1.019 Td
[(chronic myeloid leukemia \(CML\) and acute lymphoblastic leukemia \(ALL\)\ cell lines)-10 ( )]TJ
0.007 Tw 0 -1.019 Td
[(overexpressing BCR-ABL.)37 ( Under the conditions of the assays,)37 ( dasa)-10 (tinib could overcome)-10 ( )]TJ
0.338 Tw 0 -1.019 Td
[(ima)-9.9 (tinib resistance resulting )0.5 (from BCR-ABL )0.5 (kinase )0.5 (domain muta)-9.9 (tions,)37 ( )0.5 (activa)-9.9 (tion)-10 ( )]TJ
0.239 Tw 0 -1.019 Td
[(of )0.5 (alterna)-10 (te signaling pa)-9.9 (thways involving the SRC family kinases \(L)92 (YN,)37 ( HCK\),)37 ( and)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.019 Td
(multi-drug resistance gene overexpression.)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.582 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacodynamics)Tj
0 Tw -3.375 -1.469 Td
[(Cardiac Electrophysiolog)-10 (y)]TJ
/T1_0 1 Tf
0.044 Tw 0 -1.312 Td
[(Of 2440 pa)-9.9 (tients trea)-10 (ted with SPR)18 (YCEL a)-10 (t all doses tested in c)20 (linical trials,)37 ( 16 pa)-10 (tients)-10 ( )]TJ
0.005 Tw 0 -1.019 Td
[(\(<1%\) had QTc )0.5 (prolonga)-9.9 (tion reported as an adverse reaction.)37 ( )37.4 (T)74 (wenty-two pa)-10 (tients \(1%\))-10 ( )]TJ
0.135 Tw 0 -1.019 Td
[(experienced a QTcF >500 ms.)37.1 ( In 865 pa)-10 (tients with leukemia trea)-10 (ted with SPR)18 (YCEL)-9.9 ( )]TJ
0.067 Tw 0 -1.019 Td
[(70 mg BID in \037ve Phase 2 studies,)37 ( the maximum mean changes in QTcF \(90% upper)-10 ( )]TJ
0 Tw 0 -1.019 Td
(bound CI\) from baseline ranged from 7 ms to 13.4 ms.)Tj
0.049 Tw 0 -1.447 Td
[(An analysis of the da)-9.9 (ta from \037ve Phase 2 studies in pa)-10 (tients \(70 mg BID\) and a Phase)-10 ( )]TJ
0.113 Tw 0 -1.019 Td
[(1 stud)-10 (y in healthy subjects \(100 mg single dose\) suggests tha)-10 (t there is a maximum)-10 ( )]TJ
0.123 Tw 0 -1.019 Td
[(increase of 3 to 6 milliseconds in F)20 (ridericia corrected QTc inter)-18 (val from baseline for)-10 ( )]TJ
-0.049 Tw 0 -1.019 Td
[(subjects receiving thera)-10 (peutic doses of dasa)-10 (tinib,)37 ( with associa)-10 (ted upper 95% con\037dence)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(inter)-18 (vals <10 msec.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.717 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
0.181 Tw -3.375 -1.402 Td
[(The pharmacokinetics of dasa)-10 (tinib exhibits dose proportional increases in )37.1 (AUC and)-10 ( )]TJ
0.144 Tw 0 -1.019 Td
[(linear elimina)-9.9 (tion characteristics over the dose range of 15 mg/day \(0.15 times the)-10 ( )]TJ
0.069 Tw 0 -1.019 Td
[(lo)-10 (west a)-10 (pproved recommended dose\) to 240 mg/day \(1.7 times the highest a)-9.9 (pproved)-10 ( )]TJ
0 Tw 0 -1.019 Td
(recommended dose\).)Tj
0.209 Tw 0 -1.447 Td
[(At 100 mg QD,)37 ( the maximum concentra)-10 (tion a)-10 (t stead)-10 (y sta)-10 (te \(C)]TJ
0.01 Tw 6 0 0 6 229.8712 206.9623 Tm
(max)Tj
0.209 Tw 8 0 0 8 239.123 207.4623 Tm
[(\) is 82.2 ng/mL)-9.9 ( )]TJ
0 Tc 0 Tw 6.11 0 Td
( )Tj
-0.01 Tc 0.433 Tw -31.5 -1.019 Td
[(\(CV% 69%\),)37 ( area under the plasma drug concentra)-9.9 (tion time cur)-18 (ve \(AUC\) is)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.142 Tw -31.5 -1.019 Td
[(397 ng/mL*hr \(CV% 55%\).)37 ( )36.7 (The c)20 (learance of dasa)-9.9 (tinib is found to be time-invariant.)27 ( )]TJ
0.037 Tw 0 -1.019 Td
[(When )0.5 (administered )0.5 (to )0.5 (adult )0.5 (healthy )0.6 (subjects )0.6 (as )0.6 (dispersed )0.5 (tablets )0.6 (in )0.5 (juice,)37 ( )0.5 (the )0.5 (adjusted)-10 ( )]TJ
0.211 Tw 0 -1.019 Td
[(geometric mean ra)-9.9 (tio was 0.97 \(90% CI:)37.1 ( 0.85,)37 ( 1.10\) for C)]TJ
0.01 Tw 6 0 0 6 218.1775 174.3396 Tm
(max)Tj
0.211 Tw 8 0 0 8 227.4292 174.8396 Tm
[( and 0.84 \(90% CI:)27 ( )]TJ
0 Tc 0 Tw 7.571 0 Td
( )Tj
-0.01 Tc -31.5 -1.019 Td
[(0.78,)37 ( 0.91\) for )37 (AUC as compared to intact tablets.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.604 Td
(Absorption)Tj
/T1_0 1 Tf
0.322 Tw 0 -1.312 Td
[(The maximum plasma concentra)-9.9 (tions \(C)]TJ
0.01 Tw 6 0 0 6 162.687 142.8525 Tm
(max)Tj
0.322 Tw 8 0 0 8 171.9387 143.3525 Tm
[(\) of dasa)-9.9 (tinib are obser)-18 (ved between)-10 ( )]TJ
0 Tw -16.992 -1.019 Td
(0.5 hours and 6 hours \(T)Tj
0.01 Tw 6 0 0 6 106.8787 134.6968 Tm
(max)Tj
0 Tw 8 0 0 8 116.1305 135.1968 Tm
[(\) follo)-10 (wing oral administra)-10 (tion.)]TJ
/T1_6 1 Tf
-10.016 -1.469 Td
(Food Effect)Tj
/T1_0 1 Tf
0.004 Tw 0 -1.312 Td
[(A high-fa)-10 (t meal increased the mean )37.2 (AUC of dasa)-10 (tinib follo)-9.9 (wing a single dose of 100 mg)-10 ( )]TJ
-0.024 Tw 0 -1.019 Td
[(by 14%.)37 ( )36.6 (The total calorie content of the high-fa)-10 (t meal was 985 kcal.)37 ( )36.7 (The calories derived)-10 ( )]TJ
0 Tw 0 -1.019 Td
[(from fa)-10 (t,)37 ( carbohydra)-10 (tes,)37 ( and protein were 52%,)37 ( 34%,)37 ( and 14% for the high-fa)-10 (t meal.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.604 Td
(Distribution)Tj
/T1_0 1 Tf
0 Tw 0 -1.312 Td
[(The a)-9.9 (pparent volume of distribution is 2505 L \(CV% 93%\).)]TJ
0.05 Tw 0 -1.312 Td
[(Binding of dasa)-10 (tinib to human plasma proteins )]TJ
/T1_5 1 Tf
(in vitro)Tj
/T1_0 1 Tf
[( was a)-9.9 (pproxima)-10 (tely 96% and of)-10 ( )]TJ
0.121 Tw 0 -1.019 Td
[(its active metabolite was 93%,)37 ( with no concentra)-10 (tion dependence over the range of)-10 ( )]TJ
0 Tw 0 -1.019 Td
(100 ng/mL to 500 ng/mL.)Tj
0 -1.312 Td
[(Dasa)-9.9 (tinib is a P-gp substra)-9.9 (te )]TJ
/T1_5 1 Tf
(in vitro)Tj
/T1_0 1 Tf
0 Tc (.)Tj
ET
0.5 w 
q 1 0 0 1 324 331.5566 cm
0 0 m
79.262 0 l
S
Q
q 1 0 0 1 324 252.7828 cm
0 0 m
84.263 0 l
S
Q
q 1 0 0 1 324 130.4679 cm
0 0 m
36.063 0 l
S
Q
BT
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 324 727.248 Tm
(Elimination)Tj
/T1_0 1 Tf
0.045 Tw 0 -1.296 Td
[(The mean terminal half-life of dasa)-10 (tinib is 3 hours to 5 hours.)37 ( )37.3 (The mean a)-9.9 (pparent oral)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(c)20 (learance is 363.8 L/hr \(CV% 81.3%\).)]TJ
/T1_6 1 Tf
0.01 Tw 0 -1.453 Td
(Metabolism)Tj
/T1_0 1 Tf
-0.047 Tw 0 -1.296 Td
[(Dasa)-9.9 (tinib is metabolized in humans,)37 ( primarily by CYP3A4.)37 ( CYP3A4 is the primar)-17.9 (y enzyme)-10 ( )]TJ
-0.027 Tw 0 -1.003 Td
[(responsible for the forma)-10 (tion of the active metabolite.)37 ( Fla)-10 (vin-containing monooxygenase)-10 ( )]TJ
0.16 Tw 0 -1.003 Td
[(3 \(FMO-3\) and uridine diphospha)-9.9 (te-glucuronosyltransferase \(UGT\) enzymes are also)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
[(involved in the forma)-10 (tion of dasa)-10 (tinib metabolites.)]TJ
0.172 Tw 0 -1.296 Td
[(The exposure of the active metabolite,)37 ( which is equipotent to dasa)-10 (tinib,)37 ( represents)-10 ( )]TJ
0.019 Tw 0 -1.003 Td
[(a)-10 (pproxima)-9.9 (tely 5% of the )37.1 (AUC of dasa)-9.9 (tinib.)37 ( )37.1 (The active metabolite of dasa)-9.9 (tinib is unlikely)-9.9 ( )]TJ
-0.033 Tw 0 -1.003 Td
[(to play a major role in the obser)-18 (ved pharmacolog)-9.9 (y of the drug.)37 ( Dasa)-10 (tinib also has several)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(other inactive oxida)-10 (tive metabolites.)]TJ
/T1_6 1 Tf
0.01 Tw 0 -1.453 Td
(Excretion)Tj
/T1_0 1 Tf
0.218 Tw 0 -1.296 Td
[(Elimina)-10 (tion )0.5 (is )0.5 (primarily )0.5 (via )0.5 (the )0.5 (feces.)37.1 ( F)20 (ollo)-10 (wing )0.5 (a )0.5 (single )0.5 (radiolabeled dose of oral)-10 ( )]TJ
0.05 Tw 0 -1.003 Td
[(dasa)-9.9 (tinib,)37 ( 4% of the administered radioactivity was recovered in the urine and 85%\ in)-10 ( )]TJ
0.017 Tw 0 -1.003 Td
[(the feces within 10 days.)37 ( Unchanged dasa)-9.9 (tinib accounted for 0.1% of the administered)-10 ( )]TJ
0.03 Tw 0 -1.003 Td
[(dose in the urine and 19% of the administered dose in the feces with the\ remainder of)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
(the dose being metabolites.)Tj
/T1_1 1 Tf
0 -1.588 Td
[(Speci\037c P)24 (opulations)]TJ
/T1_0 1 Tf
-0.028 Tw 0 -1.296 Td
[(Age )0.6 (\(15 )0.5 (to )0.5 (86 )0.6 (years )0.6 (old\),)37 ( )0.6 (sex,)37 ( )0.5 (and )0.5 (renal )0.5 (impairment )0.5 (\(crea)-9.9 (tinine )0.5 (c)20 (learance )0.5 (21.6 )0.5 (mL/min )0.5 (to)-10 ( )]TJ
0.019 Tw 0 -1.003 Td
[(342.3 mL/min as estima)-9.9 (ted by Cockcroft Gault\) ha)-10 (ve no c)20 (linically relevant effect on the)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(pharmacokinetics of dasa)-9.9 (tinib.)]TJ
/T1_6 1 Tf
0 -1.588 Td
[(P)24 (ediatric P)24 (atients)]TJ
/T1_0 1 Tf
-0.038 Tw 0 -1.296 Td
[(The pharmacokinetics of dasa)-9.9 (tinib were evalua)-10 (ted in 43 pedia)-10 (tric pa)-9.9 (tients with leukemia)-10 ( )]TJ
0.065 Tw 0 -1.003 Td
[(or solid tumors a)-10 (t oral doses ranging from 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 477.8126 506.8668 Tm
(2)Tj
-0.01 Tc 0.065 Tw 8 0 0 8 480.6326 504.0668 Tm
( to 120 mg/m)Tj
0 Tc 0 Tw 6 0 0 6 521.6185 506.8668 Tm
(2)Tj
-0.01 Tc 0.065 Tw 8 0 0 8 524.4385 504.0668 Tm
[( once daily)55 (,)37 ( taken)-10 ( )]TJ
0.079 Tw -25.055 -1.003 Td
[(with or without food.)37 ( )36.9 (The pharmacokinetics sho)-10 (wed dose proportionality with a dose-)]TJ
0.146 Tw 0 -1.003 Td
[(rela)-10 (ted increase in exposure.)37 ( )37.1 (The mean )37 (T)]TJ
0.01 Tw 6 0 0 6 449.41 487.5183 Tm
(max)Tj
0.146 Tw 8 0 0 8 458.6617 488.0183 Tm
[( was obser)-18 (ved between 0.5 hours and)-10 ( )]TJ
0.123 Tw -16.833 -1.003 Td
[(6 hours and the mean half-life was 2 hours to 5 hours.)37 ( )37 (The geometric mean \(CV%\))-9.9 ( )]TJ
0.15 Tw 0 -1.003 Td
[(of )0.5 (bod)-10 (y )0.5 (weight normalized c)20 (learance in )0.5 (these 43 )0.5 (pedia)-9.9 (tric )0.5 (pa)-10 (tients is 5.98 \(41.5%\))-10 ( )]TJ
0.064 Tw 0 -1.003 Td
[(L/h/kg.)37 ( In pedia)-9.9 (tric pa)-10 (tients with a dosing regimen of 60 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 509.3609 466.7456 Tm
(2)Tj
-0.01 Tc 0.064 Tw 8 0 0 8 512.1809 463.9456 Tm
[(,)37 ( the model simula)-9.9 (ted)-10 ( )]TJ
0.06 Tw -23.523 -1.003 Td
[(geometric mean \(CV%\) stead)-9.9 (y-sta)-10 (te plasma a)-10 (vera)-9.9 (ge concentra)-10 (tions of dasa)-10 (tinib were)-10 ( )]TJ
-0.014 Tw 0 -1.003 Td
[(14.7 \(64.6%\) ng/mL \(for 2 to <6 years old\),)37 ( 16.3 \(97.5%\) ng/mL \(for 6 to <12 years old\),)26.9 ( )]TJ
0.007 Tw 0 -1.003 Td
(and 18.2 \(67.7%\) ng/mL \(for 12 years and older\) )Tj
/T1_5 1 Tf
0 Tc 0 Tw ([)Tj
17.991 0 Td
(s)Tj
-0.01 Tc 0.007 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.03 Tw 2.482 0 Td
[(a)-10 (ge )-36.9 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.007 Tw 6.001 0 Td
[(tra)-9.9 (tion \(2.2\)])]TJ
/T1_0 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
-0.01 Tc 0.122 Tw -26.87 -1.003 Td
[(Dasa)-9.9 (tinib c)20 (learance and volume of distribution change with bod)-10 (y weight in pedia)-10 (tric)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(pa)-10 (tients.)37 ( Dasa)-10 (tinib has not been studied in pa)-10 (tients < 1 year old.)]TJ
0.084 Tw 0 -1.431 Td
[(The )0.5 (bioa)-9.9 (vailability )0.5 (of dispersed )0.5 (tablets in pedia)-10 (tric pa)-10 (tients )0.5 (was )0.5 (estima)-9.9 (ted )0.5 (to )0.5 (be 36%)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
[(lo)-10 (wer than tha)-10 (t of intact tablets.)]TJ
/T1_6 1 Tf
0 -1.588 Td
[(P)24 (atients with Hepatic Impairment)]TJ
/T1_0 1 Tf
0.266 Tw 0 -1.296 Td
[(Compared to subjects with normal liver function,)37 ( pa)-9.9 (tients with modera)-10 (te hepa)-9.9 (tic)-10 ( )]TJ
0.02 Tw 0 -1.003 Td
(impairment \(Child Pugh B\) had decreases in mean C)Tj
0.01 Tw 6 0 0 6 475.5179 372.7635 Tm
(max)Tj
0.02 Tw 8 0 0 8 484.7697 373.2635 Tm
[( by 47% and mean )36.8 (AUC by 8%.)27 ( )]TJ
0.101 Tw -20.096 -1.003 Td
[(P)18 (a)-10 (tients )0.5 (with )0.5 (severe hepa)-10 (tic )0.5 (impairment )0.5 (\(Child Pugh C\) )0.5 (had )0.5 (decreases )0.5 (in mean )0.5 (C)]TJ
0.01 Tw 6 0 0 6 566.6883 364.7392 Tm
(max)Tj
0 Tc 0 Tw 8 0 0 8 576.0001 365.2392 Tm
( )Tj
-0.01 Tc -31.5 -1.003 Td
[(by 43% and in mean )37 (AUC by 28% compared to the subjects with normal liver function.)]TJ
/T1_1 1 Tf
0 -1.588 Td
(Drug Interaction Studies)Tj
/T1_5 1 Tf
0 -1.363 Td
(Cytochrome P450 Enzymes)Tj
/T1_0 1 Tf
-0.03 Tw 0 -1.476 Td
[(The coadministra)-9.9 (tion of ketoconazole \(strong CYP3A4 inhibitor\) twice daily increased t\he)-10 ( )]TJ
0.052 Tw 0 -1.003 Td
(mean C)Tj
0.01 Tw 6 0 0 6 346.5944 313.2781 Tm
(max)Tj
0.052 Tw 8 0 0 8 355.8461 313.7781 Tm
[( of dasa)-10 (tinib by 4-fold and the mean )36.7 (AUC of dasa)-10 (tinib by 5-fold follo)-10 (wing a)-10 ( )]TJ
0 Tw -3.981 -1.003 Td
(single oral dose of 20 mg.)Tj
0.163 Tw 0 -1.431 Td
[(The coadministra)-9.9 (tion of rifampin \(strong CYP3A4 inducer\) once daily decreased the)-10 ( )]TJ
0 Tw 0 -1.003 Td
(mean C)Tj
0.01 Tw 6 0 0 6 346.1756 285.7855 Tm
(max)Tj
0 Tw 8 0 0 8 355.4273 286.2855 Tm
[( of dasa)-10 (tinib by 81% and the mean )37 (AUC of dasa)-10 (tinib by 82%.)]TJ
0.065 Tw -3.928 -1.431 Td
[(Dasa)-9.9 (tinib is a time-dependent inhibitor of CYP3A4.)37 ( Dasa)-10 (tinib does not inhibit CYP1A2,)27 ( )]TJ
0 Tw 0 -1.003 Td
[(2A6,)37 ( 2B6,)37 ( 2C8,)37 ( 2C9,)37 ( 2C19,)37 ( 2D6,)37 ( or 2E1.)37 ( Dasa)-10 (tinib does not induce CYP enzymes.)]TJ
/T1_5 1 Tf
-0.037 Tw 0 -1.498 Td
[(Gastric Acid )-36.9 (Reducing Agents)]TJ
/T1_0 1 Tf
-0.022 Tw 0 -1.476 Td
[(The administra)-10 (tion )0.5 (of 30 mL )0.5 (of aluminum hydroxide/ma)-9.9 (gnesium hydroxide 2 hours prior)-10 ( )]TJ
-0.023 Tw 0 -1.003 Td
[(to a single dose of SPR)18 (YCEL was associa)-9.9 (ted with no relevant change in the mean )36.9 (AUC of)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
[(dasa)-9.9 (tinib; ho)-10 (wever)74.1 (,)37 ( the mean C)]TJ
0.01 Tw 6 0 0 6 414.422 226.4801 Tm
(max)Tj
0 Tw 8 0 0 8 423.6737 226.9801 Tm
[( of dasa)-10 (tinib was increased by 26%.)]TJ
-0.049 Tw -12.459 -1.431 Td
[(The simultaneous administra)-10 (tion of 30 mL of aluminum hydroxide/ma)-10 (gnesium hydroxide)-10 ( )]TJ
-0.019 Tw 0 -1.003 Td
[(with a single dose of SPR)18 (YCEL was associa)-9.9 (ted with a 55% reduction in the mean )37 (AUC of)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(dasa)-9.9 (tinib and a 58% reduction in the mean C)]TJ
0.01 Tw 6 0 0 6 454.1652 198.9875 Tm
(max)Tj
0 Tw 8 0 0 8 463.4169 199.4875 Tm
[( of dasa)-10 (tinib.)]TJ
0.319 Tw -17.427 -1.431 Td
[(The administra)-10 (tion of a single dose of SPR)18 (YCEL 10 hours follo)-9.9 (wing famotidine)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.01 Tw -31.5 -1.003 Td
(\(H)Tj
0 Tc 0 Tw 6 0 0 6 330.0639 179.519 Tm
(2)Tj
-0.01 Tc 0.161 Tw 8 0 0 8 332.8839 180.019 Tm
[( anta)-10 (gonist\) reduced the mean )37.2 (AUC of dasa)-10 (tinib by 61% and the mean C)]TJ
0.01 Tw 6 0 0 6 558.0785 179.519 Tm
(max)Tj
0.161 Tw 8 0 0 8 567.3303 180.019 Tm
[( of)-10 ( )]TJ
0 Tw -30.416 -1.003 Td
[(dasa)-9.9 (tinib by 63%.)]TJ
-0.042 Tw 0 -1.431 Td
[(The administra)-10 (tion of a single 100 mg dose of SPR)18 (YCEL 22 hours follo)-9.9 (wing a 40 mg dose)-9.9 ( )]TJ
-0.038 Tw 0 -1.003 Td
[(of omeprazole \(proton pump inhibitor\) a)-10 (t stead)-9.9 (y sta)-9.9 (te reduced the mean )36.7 (AUC of dasa)-10 (tinib)-9.9 ( )]TJ
0 Tw 0 -1.003 Td
(by 43% and the mean C)Tj
0.01 Tw 6 0 0 6 393.6466 144.0021 Tm
(max)Tj
0 Tw 8 0 0 8 402.8984 144.5021 Tm
[( of dasa)-10 (tinib by 42%.)]TJ
/T1_5 1 Tf
0.01 Tw -9.862 -1.498 Td
[(T)74 (ransporters)]TJ
/T1_0 1 Tf
0 Tw 0 -1.476 Td
[(Dasa)-9.9 (tinib is not an inhibitor of P-gp )]TJ
/T1_5 1 Tf
(in vitro)Tj
/T1_0 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 0 -2.263 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(NONCLINIC)18 (AL TOXICOLOGY)]TJ
0.01 Tw -3.375 -1.791 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Carcinogenesis,)37 ( Mutagenesis,)37 ( Impairment of F)20 (ertility)]TJ
/T1_0 1 Tf
0.15 Tw -3.375 -1.521 Td
[(In a 2-year carcinogenicity stud)-10 (y)55 (,)37 ( ra)-10 (ts were administered oral doses of dasa)-9.9 (tinib a)-9.9 (t)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -0.044 Tw -31.5 -1.003 Td
[(0.3,)37 ( 1,)37 ( and 3)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.624 0 Td
[(mg/kg/day)55 (.)37 ( )37.1 (The highest dose resulted in a plasma drug exposure \(AUC\) level)-9.9 ( )]TJ
0.054 Tw -4.624 -1.003 Td
[(a)-10 (pproxima)-9.9 (tely 60% of the human exposure a)-10 (t 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
18.707 0 Td
[(mg once daily)55 (.)37 ( Dasa)-10 (tinib induced a)-10 ( )]TJ
-0.017 Tw -18.707 -1.003 Td
[(sta)-10 (tistically signi\037cant increase in the combined incidence of squamous \cell carcinomas)-10 ( )]TJ
0.022 Tw 0 -1.003 Td
[(and )0.5 (pa)-9.9 (pillomas )0.5 (in )0.5 (the )0.5 (uterus )0.5 (and )0.5 (cer)-18 (vix )0.5 (of )0.5 (high-dose )0.5 (females )0.5 (and )0.5 (prosta)-10 (te )0.5 (adenoma )0.5 (in)-10 ( )]TJ
0 Tw 0 -1.003 Td
[(lo)-10 (w-dose males.)]TJ
ET
endstreamendobj38 0 obj<</Metadata 93 0 R>>endobj93 0 obj<</Length 1623/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.0-c000 79.cca54b0, 2022/11/26-09:29:55        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#">
         <dc:format>application/postscript</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">chemstruct</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>Bristol Myers</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <xmp:CreatorTool>Adobe Illustrator CS2</xmp:CreatorTool>
         <xmp:CreateDate>2007-10-09T10:48:45-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2007-11-14T13:12:37-05:00</xmp:ModifyDate>
         <xmp:MetadataDate>2007-11-14T13:12:37-05:00</xmp:MetadataDate>
         <xmpMM:DocumentID>uuid:89F5A43B77E711DCBAA69278F1D14B3D</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:AC14BEB3944411DC9D20ACAF37F3B60D</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:8222C0B274C411DC8FAD99C84716D7A7</stRef:instanceID>
            <stRef:documentID>uuid:8222C0B174C411DC8FAD99C84716D7A7</stRef:documentID>
         </xmpMM:DerivedFrom>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj35 0 obj<</BaseFont/IEWGNW+Geneva/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 94 0 R/LastChar 183/Subtype/Type1/Type/Font/Widths[333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667]>>endobj36 0 obj<</BaseFont/IEWGNW+HelveticaNeue-Medium/Encoding/WinAnsiEncoding/FirstChar 50/FontDescriptor 95 0 R/LastChar 108/Subtype/Type1/Type/Font/Widths[556 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 722 0 0 0 0 0 722 760 0 0 0 648 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 241]>>endobj37 0 obj<</BaseFont/IEWGNW+SymbolStd/Encoding 96 0 R/FirstChar 31/FontDescriptor 97 0 R/LastChar 31/Subtype/Type1/ToUnicode 98 0 R/Type/Font/Widths[549]>>endobj31 0 obj<</BaseFont/IEWGNW+HelveticaNeueLTStd-BdCnO/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 99 0 R/LastChar 121/Subtype/Type1/ToUnicode 100 0 R/Type/Font/Widths[240 0 0 0 0 0 0 0 0 0 0 0 240 370 0 0 0 0 0 0 0 0 0 0 0 0 240 0 0 0 0 0 0 556 556 537 574 481 463 556 556 258 0 0 463 740 574 0 519 0 556 519 480 538 519 0 0 0 0 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 0 333 444 296 500 444 704 462 444]>>endobj99 0 obj<</Ascent 961/CapHeight 714/CharSet(/space/comma/hyphen/colon/A/B/C/D/E/F/G/H/I/L/M/N/P/R/S/T/U/V/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/r/s/t/u/v/w/x/y)/Descent -271/Flags 96/FontBBox[-171 -271 1116 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 101 0 R/FontName/IEWGNW+HelveticaNeueLTStd-BdCnO/FontStretch/Condensed/FontWeight 700/ItalicAngle -12/StemV 140/Type/FontDescriptor/XHeight 538>>endobj100 0 obj<</Filter/FlateDecode/Length 439>>stream
Hâ\ìÕn£@ÑÔÛsL6f∫	YJÏDÚa¥ﬁ} c)–¸ˆ€EEYië|¶ÙnäÕnªK˝‰ãüyh˜qÚ«>u9^Ükn£?ƒSü‹≤Ù]ﬂNüWÛo{nFWÿÊ˝Ì2≈Û.W◊æ¯e7/Sæ˘ªÁn8ƒ{W¸»]Ã}:˘ª?õ˝Ω/ˆ◊q¸àÁò&øÎµÔ‚—Çæ5„˜Ê}1o{ÿuvøün∂ÁﬂøocÙÂ|Ω§L;tÒ26mÃM:EW/ÏX˚˙Õéµã©˚Ô~%‹v8∂ÔMvuâá[å7‰xKﬁØûg∂≈’’rf[åKr	^ëW‡ä\Å9ÄÖ,`%+¯ë¸~"?ÅÈS¡ß¢OüÍï¸jË‡Ë‡Ë‡Ë‡Ë‡Ë‡#Ï%Ë%Ã‰s9¬Aé0Gê#Ãë9áΩΩÑΩΩÑΩΩÑÔS>ÂÖ¸f_A_a_A_a_A_y#€ü[+ª+∫+ùŒJgÖ≥“Y·¨tV8+ùŒJgÖ≥“Y·¨t∂ÉÙ91)õ|ˇ5ØÌ5g’˘Ûòg”Ÿß¯ıç√ËmN˜WÄ »]Ÿ1endstreamendobj101 0 obj<</Filter/FlateDecode/Length 3351/Subtype/Type1C>>stream
HâlUPSWæ!úC@àîk*˜ZT©÷.lmµ ∏"¥AË–@ÖìDà’
>ê‚ë«.´uu@‘_XZ´ˆa«ÈÓN¡2+≥5˛óv∫ÁÜZ›ôNÊÃπˇπÁˇÚùˇˇæseåª#ì…ÑÑÿ¥•+“¬„uy6ù’ê≠Y°+‘-OQ[µskóì§=/äúLú‰˛Å∑õ8≈[Eë£?è¸ºâ'ä·/‹û2±⁄èqì¿¸e¡KL≈fCŒ´Rtt‰la^d‰<·u≠)K'®ã-V]æEH0fõÃ&≥∆™”FØÁÂ	Æã`÷Ytfõ¥¯¡`4Ç’¨—ÍÚ5Ê˜ì^Xn0ö¨≈:a	Eâ†I9äk÷iÉQ∞Æ—	+#‘B2E7ZçQ+§¸ñù§◊≤uÆ≈|M±@9˝v∂Œl’–ŸDaÃBn°Ÿ`—≤≠ì—Ú‹®…◊˝ìY0–‰Qx£Eß{ˆzi~V|ƒ‹8uäº,huzÜë—„#c8ÜyQ¡Ãqc^bò˘ÓÃ‚âå⁄ÉôK…$0À+S≈¥3?…ﬁï˝Mˆo∑9n´‹n…ÚÈÚ˘n˘uwo˜M°˘»äé‚∏?ˆH˜¯T·≠hV¸Ë…z¶z÷x˜‚º≤ΩŒNûê3Åx/ıÆÚæ‡3Ÿ'’ß9∫ƒ·.Ã+Fì«*0Ï WTd!ÏF0àâ@.™@
∆vyå·L◊3,$4∆‚ïÙD§H©t@§Ï§ÀøáHU.âDpE…GzsNNy`i,»jNﬂip6É?R
∞ºdÉ–+/QôâÇOp#x!	t®∂»ª˝! ÉHDY–©ûE ØÎmNìø_GëüCº»ﬁs∏√,|¬ºÖ+	ùfa˝h&"qòÏ#æ™ÌtıKDöÏp¬˚è …È'ŒáY”a;“Â[0ƒ‹˜æ˛°∂w—^≈vè;áª˛æˇûÇÑ©~ÌÒ‚H9üi™¯ÛÛ“R>ﬁÆ)à·≤∞-L≈é\≈◊⁄,Q≈|‘˙4sß∆ ^ªSlv @0|arqXÃW˝t‰ Ñì,é‰%ëíü¡”QN" èÉ7oB D„I&π´“∏ƒ¬SêwéáÃˆøﬁæÕ›®Õ.‰ï√ß∏Õ)◊A®¸≤?aPvvÛ†?[SI:G6∫Xˆap€E^Y√ì‘¨‹Âa‹ü∞≤ AãñBGm@óÿ!áÃ—Lô˝ﬂL$ŒquÄƒß!AŸxTÜO@Ç›„›±”≤_{.õñ-ﬂÑkøø},ò÷⁄Óú˚-5lr˙˝ 3a≥ù¢(nS¡Ù÷Ùo…<é,è&IŸ€<q§Ó"ÀıwΩtéﬂéŸR{r‚˚¢
;∂NCqÈbƒv.\ü®7pQªÄÅ◊Nw≤˝ãÓJM|ÍFﬁ%åÖ¶"JÒ8¡~@É„	ùB0ÃñTÇﬂ$Màƒ‡+–$EJb™∑çf….Cß2¸üÓrïFiße%»π∏“ﬂu‘›XqŸÿ_o˚!D◊a˘EIæ‡#ˆ£ÌxÁX?wïÆà¯Ha¿ØTòË«*—V\-V"íãï√„L∫FÒsÌ°€ùbM´@ıkn ≥”‘X—éîmÙÏ'ùêO’°•ÇsùΩN¢{¶<Óá≠¸ìÜÇ'$î#’.ÅÙ‚/g«ñÚãK2oIÍêä◊Û≤®1< ,f≥#pW|¨bo·-π	v~aIF~óÑIÒX®ä¬_áƒé‹√W‘õx3ô∫ŸTQPSë∏rß•Æ˙T›ù¿Vﬂ“=˚cÍß>Ω^ˇPÚì≤)˘™‰ßCXŸÊ≤âﬂ%ò±¬G`~8U»??ã™‹HœgÍX‡ÿ{Èº·«¯ÉﬂóÙÃ<⁄†n*kÆ9£`o∑Ìn:}ÉÎŸßç∑ÛÑ´#Í÷?ˆêIôˆ·Û)≠	©‡µä˛Ò?r[,ˆeä§ﬁ3≠‚mjÔØ„´Íërm› ’4b°¢hÕ]wR$&Ïÿ†K4R´iÏrAü›9ÍV$˚ä:V“Ω”∆6#¢Œ˙è<9üXväwäõ%mHÔﬁ(5•∆sÒÂ?ﬂÁZñ%5¸¬Ï†BÅπ§VÍq"Üœ§∂Œƒƒ8÷à*^±)´ÏCØ~˝∂C~a*LÄ¿DbœS1y™vÏCm{ZZ⁄∏sõ≥>‰ÀräKVoå≤Ñ≠}'À™XRr ˙GéÌºŸVwÈåÀR≈[ı˙ ™¶≤÷ ÜΩ]Ωp"Ä=?\ø˛â‚ÇÁhàÔZæb-—´í7§ZÙú˛£„ß˜5-ÕWjV5Ó9RßP6∏\˝ƒ	Ø˘A 1àÅÌÑr8¢œ∆∆ﬁ>Æw[Ò4ÛtXíí∏é^∫Œ≥•$çëÆq∂≥ˆ2ïÚ;áé€∫9@ﬂAzÈÌkæ#àK”⁄VÎ¯≠∏làa•›>$*…˙a
$@†\‹√*`õﬂ˝ñ∞aÉ…⁄tû‰et«C°wøÜi·©1^^g‘fpâél·¡∑ÈhÔ-Ó¬VuΩ$ûßxv¨{JΩóÎ{é˙
.iú˙–8Ôq”·˜àçöÆΩ(Ø>ç#(.ä§ØÊŸ≥$]s<
◊›Vﬂuö[b1˜a“êÏ%øTrqT™v∂"à˛d0dGV®…dí«ì…&3˝§s‡g ^hÂâ/N(\ª&É{{À’ku¸ûvt‡æ™∫u’¥\Ó·.WfDóÚJí@ïõ<ÙØGE~wE*ª˛‘Cb2˙BØ‚öÛ®u◊˛⁄S‹ˇØ˙†®™(æÀŒ}ÆÜ;¥è5Î6ºI—6&I≠â&-∑atP‚√Zëõ°E	w	¡]MÿZX>Ç»W|ä(TöÊ„§EM„GNê%35x›ù°{´ˇ4’_Ô›˚Ó=˜úﬂ9øﬂ=œÂ*≤ª˛ªSø#~™$3≥8oK0á∂£◊9À4¡iHÿÌÁ¡`n˝8´mÖ'◊Å Ø~ƒõ¯Li≥‘•„;¨·4±º›µocKÙDõ.êÿƒûM‡Ö˚áö{œ–∏sàÔå∂•%F·ú\ßÀ&Y6◊Q—Q´¶i	Ãça<Yˇ˝8¨h@!ï!>ï¸LzËç–V?tè:„»cÈBêe_Xép\˛ˆÕ3íÂK)≠ÑU™ÂuòCÁ´:Zq_ïyáMxŸΩ—È“J4[ü4∏GƒdÌJ°Ö4ÂB¢6∫,7)Õá°_5ÃL 'u±O‚e…≤N◊√åÙóºpõ§WçîÎﬁ∞⁄“„pAaQI°`~ŸÎÍÏ'0¯Ù›9)ÄF∫˙OÚY∞”¢ñŒ™`˜C˜£-Ã⁄ãóÆê˝ûÂà&¡)à–˜-d≈ˆi)“,Ë√0úÛ∏È);úf8∞‹Ã≠~\∆·‹G_Wuµı„WF¸a!ƒÌç˛}˙'	#æ˚œ˙Ω_·≠Qië&
–Ë±‰ˆ0a¥ƒ≈”?^1*7Ycò{˚–˘nÏ—ôo&Àv™. vî¿öiÂ£S›†\K&·Mzq®!¯⁄=Îz!<„	9¶&¡õÙ$lïÚe‡’X?yèïFì'“AˆEG·–äIj†AÕ∞aÓÀÆ¶4ıøDr›,KLYJ∏ÑìÌÊœ™Ωb<˙≥#—õƒ¸ü¢"≈¸'˛àaâh—H˛|∑?>◊—’ÍØö>¡bµ›.
|w,G≈áãp‰Æwbˆ»T_ïmò®|
õ◊LkáÊGlä˘˘^õÇ¢_æÛ<tÔg#æœˇ@k(bPﬂ‘(‘¸x†ˇ•V5ﬂ˘JKBu~Ω≥˘ÒèÀN◊u·±êS‡ø)Õ+≤IWÉ˜a=•‹ou∆1Ú(&+Øg7∂'“Ô§,oÃØ;Xò¢Ê˚ÚSÕâÿ¯^˚`π‡®ET<éÃ¿” _AØÇHJoèl%QfUô@Å;Zév°Ó.≤∂Ÿm8˘hÕYóp˙ËK'<∑PLR•HãvÇñJ:\ì{ª6í9nMM3‚§ºSüWì“"6˝Çõ’ÃSY}∆õ¯À—∆ë^&ô&ô8 yE≈HëœnG÷Ëés∞.–ükrw!X«A…ÇiXË¡fIAÙO`^ë√ˆY)∂°˜y#¯,£ã˘Ω†ó¥4„˘n-Çµ‰∞ÕÙ™!´ÈÃqÆú~%—À£Z6¢¶si74l—¢,ïFTpIÚ÷%√Êƒ"íD“&7ã¡péÿÎ:hÉÂn“¥†!Jó‘ßrÉnåﬂ3Õ∞˝∂ 6…ŒÃìg‹jzò]R≥›4¨∑Ú2ﬁ›â≠÷‚´†…Á‚E)¬
ëÉÊ“[•Ó—≤E95sÒ5ƒT©¶33•ÓÈ ≈≥K¿Ôëâ Jß”YŸ·Ì=CüŒ2ß”{i±∑
}•˝∫ø õ”ZÍendstreamendobj96 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/beta]/Type/Encoding>>endobj97 0 obj<</Ascent 1010/CapHeight 688/CharSet(/beta)/Descent -293/Flags 32/FontBBox[-180 -293 1090 1010]/FontFamily(Symbol Std)/FontFile3 102 0 R/FontName/IEWGNW+SymbolStd/FontStretch/Normal/FontWeight 500/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 502>>endobj98 0 obj<</Filter/FlateDecode/Length 235>>stream
Hâ\êœjƒ ∆Ô>≈wãâΩJ†›≤êCˇ–¥`tí
ç ƒÚˆ›ePæÔ7|é<˜œ}‰;E;`Ü…G∏∆ç,¬à≥¢U‡ºÕ∑Æﬁv1IHÜá}Õ∏ÙaäBkê,Æôv8<∫8‚Q»7rH>Ãp¯:Gê√ñ“.24–u‡p‚A/&ΩöAVÏ‘;÷}ﬁOÃ¸9>˜Ñ†jﬂ^√ÿËpM∆"ô0£–W˙¬’	ÓüÆÆ‘8ŸoCB∑ˆ6O™+§*d}
yÛî¸U∏¥g´˚®°Jæ≤0Ué¯` cƒq˝endstreamendobj102 0 obj<</Filter/FlateDecode/Length 455/Subtype/Type1C>>stream
Hâbd`ab`ddÙtw˜◊ÆÃM œ	.I	 ˝êa¸!ŒÚCñGÙ∑«ÔùøÆ˝jc˝Ó∆ˇ›Sp∆è!fFF÷§¸§‘íDÁ¸Ç ¢ÃÙåCKSi&-A§•òä)8¶ ı(Wó§Ê+xÊ%Á‰%ñ§¶Ë)8Ê‰(Ä*V(J-N-*
ÍªáT§*X(§§¶1000∂30›Ã‡«»¸££{Ôè7{Å§ ^Ênñ?˛t∞}Ô˚}TÙ∑›˜…¨ﬂ_∞˝V¯}@Ù;àÛg˚∂80˚ª›o üÌ«~QÎ7à«˜cg’Æ¯Ì?XN~Ô^+t„Ê˜©üÑ˜◊|7⁄ ∫5oeÕ÷ñ--[˚÷N_:Â¸ö%¶Ôn?‹∞±¯n üïV≠]6Ì“‘”âª Ê∏Uõ‚û¬ë]êm)ıWô=¢!≤-BÓ[ﬂí	KñHu˝¨›ænÁ∫ôrã¶¨ÎYü!§Í7GQvscceuoy_“¥äÍ¶ÊÚ‚’U≥õñLò◊ª¢ojÀ¨*·=Gºgˇf©qnÕ©IO.M/èù?'gzÕ‹äπ|Û~öŒ˙;ÉÌ9◊nÄ  {˝…†endstreamendobj95 0 obj<</Ascent 952/CapHeight 714/CharSet(/two/three/C/H/N/O/S/l)/Descent -221/Flags 32/FontBBox[-165 -221 1066 952]/FontFamily(Helvetica 65 Medium)/FontFile3 103 0 R/FontName/IEWGNW+HelveticaNeue-Medium/FontStretch/Normal/FontWeight 500/ItalicAngle 0/StemV 116/Type/FontDescriptor/XHeight 500>>endobj103 0 obj<</Filter/FlateDecode/Length 872/Subtype/Type1C>>stream
HâlílSU«ﬂmªª≤‚ì∑∑Œ¶›˙.õ†ÕÏ6qõM5c¸êec≥n}ìW∑µæ∂É!(í`√	Bó8ëÑiâ†$ãl3«òv`âMÿ‚Bˇ8Ø;˝√;4£˜èÛΩ9˜‹Ô˝úìKãI Ñî4nl›‘‹Z±YÌÍU„ZG∞YM®ﬁ≠jHKt/ùª1≥%Àã±__¸f±)ÖAÈ˙¢R(ò9uÒÖH¥O◊^›gOvxÿ”ııOÒÿP˝0>√¸°Hª ^Íã≈’ÓkÏÈàË—àå´°J∆¸]]lÁ“›€©∆TΩógˇfaZåY\Ü‘Ó†˛ãt≤&≠'Ôã™^^‘≈¸õX∞'T—ô∆bâˆò“Ç∫¶∆*ˇ∑!æd°Hx\UBµP#lñÒ1aèpãTêVrîLõZM›9ª»å‘˘(j6Rvú•èŒ\Ω3bΩ=Ú”0;3- °´Î0´‹@È|Ú≥ü3Æ˘!ˇûcJ?,ÿU›Ëm⁄^sÛ≠ÜNEvhﬁùy´ﬁô+ºt57O ≠*è¬~H€3Ôﬂ?Ñƒ˘‹éÄoÕ+„3I7Rä´ìw<PÁ'–_¿°»+3/ﬂX˜ë˚Ω|πÓáOæ˘—	+–2∆_[Y∑
Ké.q‹Ïˇjb⁄5ˆu«vE~æv]‘ótãå+‰KêårÕYüÒÜ˝ T¢¸+÷∑bãp∂apÖ0¯·( ﬂá
ä¥¸ÌÊz4ª–ª\P
•„\ºø_ﬂ÷0§àCΩ0Ô#ì A$Ûd1ﬂLAß@ P¬aL√0Jî◊f˚»ÿ`lÊâb∞gí“π3y‡‡•∂‹Ÿ~ä”∆Ÿ<tPÒ∑Ä_‰∂∆älƒ˛Ã0¡hÉ6‰äaeïº„Ë¬R,›¬≈˚ofE<¯–¥HN…ΩÀ@íœ]Ç#v‹ò«zx÷eP65∑∑ΩÁywÁ)\sÂp“∫;•ùøÊº99Ù›ΩQ≠Í7H<(M£ÌËÿåÂ˛À~√n˘‹|Ù˚7ØÌ∑^8¸ybó≥•ΩMO¨Ω
&∑ò[˚Á∆¯+ [¶T<0òb8Î(û|p2w7ïˇWÚ¥>=Ò‡DnˆÙ≤LP€ÒÂb∂≥([aˇCÄ ´&∏¶endstreamendobj94 0 obj<</Ascent 997/CapHeight 700/CharSet(/space/periodcentered)/Descent -430/Flags 32/FontBBox[-280 -430 1280 997]/FontFile3 104 0 R/FontName/IEWGNW+Geneva/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 500>>endobj104 0 obj<</Filter/FlateDecode/Length 140/Subtype/Type1C>>stream
Hâbd`ad`dd‰Ûtw˜◊vOÕK-KâHˇêÊ˝!√#ˆ{Õ'VÜ_ï¨∑˘ˆ}ób`j—w©,HU0PHIMÉÍFÜ"fFF)Yù?¸vâ˛aˇ€ıÉùÕÈäËÔ“?æó≤Ò}»˜Sˇá“˜T—Ô¢øÅêùØªõ ¿ äp.Lendstreamendobj34 0 obj[/Separation/Black/DeviceCMYK<</C0[0.0 0.0 0.0 0.0]/C1[0.0 0.0 0.0 1.0]/Domain[0 1]/FunctionType 2/N 1.0/Range[0.0 1.0 0.0 1.0 0.0 1.0 0.0 1.0]>>]endobj32 0 obj<</Length 22379>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 273.9181 cm
0 0 m
42.279 0 l
S
Q
q 1 0 0 1 36 166.9381 cm
0 0 m
65.351 0 l
S
Q
q 1 0 0 1 36 92.138 cm
0 0 m
13.544 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.005 Tc -0.08 Tw 8 0 0 8 36 727.248 Tm
(Ear and Labyrinth Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc -0.08 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
( tinnitus; )Tj
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( vertigo,)37 ( hearing loss.)]TJ
/T1_0 1 Tf
0 Tw 0 -1.427 Td
[(Hepatobiliar)-18 (y Disorders:)]TJ
/T1_1 1 Tf
0 Tc /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( cholestasis,)37 ( cholec)20 (ystitis,)37 ( hepa)-9.9 (titis.)]TJ
/T1_0 1 Tf
0.436 Tw 0 -1.427 Td
[(Renal and Urinar)-18 (y Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.436 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( urinar)-18 (y frequenc)20 (y)55 (,)37 ( renal failure,)32 ( )]TJ
0.005 Tw 0 -1 Td
(proteinuria; )Tj
/T1_2 1 Tf
4.395 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0 Tw 2.769 0 Td
(\226 renal impairment.)Tj
/T1_0 1 Tf
0.393 Tw -7.164 -1.427 Td
[(Immune System )0.5 (Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.393 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( )0.5 (hypersensitivity \(inc)20 (luding er)-18 (ythema)-5 ( )]TJ
0.005 Tw 0 -1 Td
(nodosum\).)Tj
/T1_0 1 Tf
0.379 Tw 0 -1.427 Td
(Endocrine Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.379 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
( hypothyroidism; )Tj
/T1_2 1 Tf
0.005 Tw (<0.1% )Tj
/T1_1 1 Tf
0.379 Tw 24.323 0 Td
[(\226 hyperthyroidism,)32 ( )]TJ
0.005 Tw -24.323 -1 Td
(thyroiditis.)Tj
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.697 Td
(6.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)24 (ostmarketing Experience)]TJ
/T1_1 1 Tf
-0.005 Tc 0.083 Tw -3.375 -1.383 Td
[(The follo)-9.9 (wing additional adverse reactions ha)-10 (ve been identi\037ed during post a)-10 (pproval)-5 ( )]TJ
0.007 Tw 0 -1 Td
[(use of SPR)18 (YCEL.)37 ( Because these reactions are reported voluntarily from a popula)-9.9 (tion of)-5 ( )]TJ
-0.002 Tw 0 -1 Td
[(uncertain size,)37 ( it is not al)-10 (ways possible to reliably estima)-10 (te their frequenc)20 (y or establish)-5 ( )]TJ
0 Tw 0 -1 Td
[(a causal rela)-9.9 (tionship to drug exposure.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.383 Td
(Infections:)Tj
/T1_1 1 Tf
0 Tw /Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
4.393 0 Td
[(hepa)-9.9 (titis B virus reactiva)-10 (tion)]TJ
/T1_3 1 Tf
-4.393 -1.427 Td
(Cardiac disorders:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
7.395 0 Td
[(a)-10 (trial \037brilla)-10 (tion/a)-10 (trial \035utter)]TJ
/T1_3 1 Tf
-7.395 -1.427 Td
[(Respirator)-18 (y)55 (,)37 ( thoracic,)37 ( and mediastinal disorders:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
19.089 0 Td
(interstitial lung disease)Tj
/T1_3 1 Tf
-19.089 -1.427 Td
(Skin and subcutaneous tissue disorders:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
16.068 0 Td
(Stevens-Johnson syndrome)Tj
/T1_3 1 Tf
-16.068 -1.427 Td
[(Renal and urinar)-18 (y disorders:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
11.31 0 Td
(nephrotic syndrome)Tj
/T1_3 1 Tf
-11.31 -1.427 Td
(Blood and lymphatic system disorders:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
15.398 0 Td
[(thrombotic microangiopa)-9.9 (thy)]TJ
/T1_3 1 Tf
-15.398 -1.427 Td
[(Hepatobiliar)-17.9 (y disorders:)]TJ
/T1_1 1 Tf
0.093 Tw /Span<</ActualText<FEFF2004>>> BDC 
( )Tj
EMC 
[(hepa)-9.9 (totoxicity)]TJ
/T1_3 1 Tf
0.01 Tw 0 -2.035 Td
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(DR)-10 (UG INTERACTIONS)]TJ
0.01 Tw -3.375 -1.923 Td
(7.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Effect of Other Drugs on Dasatinib)Tj
-3.375 -1.653 Td
(Strong CYP3A4 Inhibitors)Tj
/T1_1 1 Tf
-0.005 Tc 0.574 Tw 0 -1.337 Td
[(The coadministra)-9.9 (tion with strong CYP3A inhibitors may increase dasa)-10 (tinib)-5 ( )]TJ
0.005 Tw 0 -1 Td
[(concentra)-10 (tions )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 5.659 0 Td
([)Tj
0.254 0 Td
(s)Tj
-0.005 Tc 0.042 Tw 0.402 0 Td
[(ee Clinical Pharmacolog)-10 (y \(12.3\))]TJ
0 Tc 0 Tw (])Tj
/T1_1 1 Tf
-0.005 Tc 0.042 Tw 11.909 0 Td
[(.)37 ( Increased dasa)-10 (tinib concentra)-10 (tions)-5 ( )]TJ
0.079 Tw -18.223 -1 Td
[(may increase the risk of toxicity)55 (.)37 ( )36.9 (Avoid concomitant use of strong CYP3A4 inhibitors.)32 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc -0.005 Tw -31.5 -1 Td
[(If concomitant administra)-10 (tion of a strong CYP3A4 inhibitor cannot be a)-10 (voided,)37 ( consider)-5 ( )]TJ
0 Tw 0 -1 Td
[(a SPR)18 (YCEL dose reduction )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
10.123 0 Td
(s)Tj
-0.005 Tc 0.402 0 Td
(ee Do)Tj
0 Tc (s)Tj
-0.005 Tc -0.037 Tw 2.505 0 Td
[(a)-10 (ge )-37 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 6.062 0 Td
[(tra)-10 (tion \(2.5\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_3 1 Tf
-0.01 Tc -19.092 -1.653 Td
(Strong CYP3A4 Inducers)Tj
/T1_1 1 Tf
-0.005 Tc 0.009 Tw 0 -1.337 Td
[(The coadministra)-10 (tion of SPR)18 (YCEL with strong CYP3A inducers may decrease dasa)-10 (tinib)-5 ( )]TJ
0.005 Tw 0 -1 Td
[(concentra)-10 (tions )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 5.611 0 Td
([)Tj
0.254 0 Td
(s)Tj
-0.005 Tc -0.006 Tw 0.402 0 Td
[(ee Clinical Pharmacolog)-10 (y \(12.3\))]TJ
0 Tc 0 Tw (])Tj
/T1_1 1 Tf
-0.005 Tc -0.006 Tw 11.766 0 Td
[(.)37 ( Decreased dasa)-9.9 (tinib concentra)-10 (tions)-5 ( )]TJ
0.052 Tw -18.033 -1 Td
[(may reduce ef\037cac)20 (y)55 (.)37 ( Consider alterna)-9.9 (tive drugs with less enzyme induction potential.)32 ( )]TJ
0.016 Tw 0 -1 Td
[(If concomitant administra)-10 (tion of a strong CYP3A4 inducer cannot be a)-9.9 (voided,)37 ( consider)-5 ( )]TJ
0 Tw 0 -1 Td
[(a SPR)18 (YCEL dose increase.)]TJ
/T1_3 1 Tf
-0.01 Tc 0 -1.653 Td
(Gastric Acid Reducing Agents)Tj
/T1_1 1 Tf
-0.004 Tc -0.01 Tw 0 -1.427 Td
[(The coadministra)-10 (tion of SPR)18 (YCEL with a gastric acid reducing a)-9.9 (gent may decrease the)-3.9 ( )]TJ
0 Tw 0 -1 Td
[(concentra)-10 (tions of dasa)-9.9 (tinib.)37 ( Decreased dasa)-9.9 (tinib concentra)-10 (tions may reduce ef\037cac)20 (y)55 (.)]TJ
0.437 Tw 0 -1.383 Td
(Do not administer H)Tj
0 Tc 0 Tw 6 0 0 6 104.5191 341.648 Tm
(2)Tj
-0.004 Tc 0.437 Tw 8 0 0 8 107.3751 342.148 Tm
[( anta)-10 (gonists or proton pump inhibitors with SPR)17.9 (YCEL.)33 ( )]TJ
0.14 Tw -8.922 -1 Td
(Consider the use of antacids in place of H)Tj
0 Tc 0 Tw 6 0 0 6 166.369 333.648 Tm
(2)Tj
-0.004 Tc 0.14 Tw 8 0 0 8 169.2249 334.148 Tm
[( anta)-10 (gonists or proton pump inhibitors.)33 ( )]TJ
0.034 Tw -16.653 -1 Td
[(Administer the antacid a)-10 (t least 2 hours prior to or 2 hours after the dose of SPR)18 (YCEL.)33 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.004 Tc -31.5 -1 Td
[(Avoid simultaneous administra)-10 (tion of SPR)18 (YCEL with antacids.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.99 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(USE IN SPECIFIC POPULA)55 (TIONS)]TJ
0.01 Tw -3.375 -1.923 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(Pregnanc)10 (y)]TJ
/T1_1 1 Tf
0 Tw -3.375 -1.45 Td
[(Risk Summar)-17.9 (y)]TJ
0.114 Tw 0 -1.292 Td
[(Based on limited human da)-10 (ta,)37 ( SPR)18 (YCEL can cause fetal harm when administered to)-10 ( )]TJ
0.255 Tw 0 -1 Td
[(a pregnant woman.)37 ( )37.1 (Adverse pharmacologic effects inc)20 (luding hydrops fetalis,)37 ( fetal)-10 ( )]TJ
0.048 Tw 0 -1 Td
[(leukopenia,)37 ( and fetal thromboc)20 (ytopenia ha)-10 (ve been reported with ma)-9.9 (ternal exposure to)-10 ( )]TJ
0.12 Tw 0 -1 Td
[(SPR)18 (YCEL.)37 ( )36.7 (Animal reproduction studies in ra)-10 (ts ha)-9.9 (ve demonstra)-9.9 (ted extensive mortality)-10 ( )]TJ
0.098 Tw 0 -1 Td
[(during organogenesis,)37 ( the fetal period,)37 ( and in neona)-10 (tes.)37 ( Skeletal malforma)-9.9 (tions were)-10 ( )]TJ
0.091 Tw 0 -1 Td
[(obser)-18 (ved in a limited number of sur)-18 (viving ra)-10 (t and rabbit conceptuses.)37 ( )36.9 (These \037ndings)-10 ( )]TJ
0.378 Tw 0 -1 Td
[(occurred a)-10 (t dasa)-10 (tinib plasma concentra)-10 (tions belo)-10 (w those in humans receiving)-10 ( )]TJ
0.117 Tw 0 -1 Td
[(thera)-10 (peutic doses of dasa)-9.9 (tinib )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
11.772 0 Td
(s)Tj
-0.01 Tc 0.117 Tw 0.397 0 Td
[(ee Da)-10 (ta])]TJ
/T1_1 1 Tf
[(.)37 ( )36.7 (Advise a pregnant woman of the potential)-9.9 ( )]TJ
0 Tw -12.169 -1 Td
(risk to a fetus.)Tj
-0.005 Tc 0.098 Tw 0 -1.427 Td
[(The )0.5 (estima)-10 (ted )0.5 (background risk )0.5 (in the U.S.)37 ( )0.5 (general popula)-9.9 (tion of major )0.5 (birth )0.5 (defects)-5 ( )]TJ
0 Tw 0 -1 Td
[(is 2% to 4% and of miscarria)-10 (ge is 15% to 20% of c)20 (linically recognized pregnancies.)]TJ
-0.01 Tc 0 -1.653 Td
[(Clinical Considera)-10 (tions)]TJ
/T1_2 1 Tf
-0.037 Tw 0 -1.36 Td
[(F)24 (etal/Neona)-9.9 (tal Adverse )-37 (Reactions)]TJ
/T1_1 1 Tf
-0.005 Tc 0.052 Tw 0 -1.292 Td
[(T)74 (ransplacental transfer of dasa)-10 (tinib has been reported.)37 ( Dasa)-10 (tinib has been measured)-5 ( )]TJ
0.063 Tw 0 -1 Td
[(in fetal plasma and amniotic \035uid a)-9.9 (t concentra)-10 (tions comparable to those in ma)-10 (ternal)-5 ( )]TJ
0.265 Tw 0 -1 Td
[(plasma.)37 ( Hydrops fetalis,)36.9 ( fetal leukopenia,)37 ( and fetal thromboc)20 (ytopenia ha)-10 (ve been)-5 ( )]TJ
-0.002 Tw 0 -1 Td
[(reported with ma)-10 (ternal exposure to dasa)-10 (tinib.)37 ( )37.3 (These adverse pharmacologic effects on)-5 ( )]TJ
0.028 Tw 0 -1 Td
[(the fetus are similar to adverse reactions obser)-18 (ved in adult pa)-10 (tients and may result in)-5 ( )]TJ
0 Tw 0 -1 Td
[(fetal harm or neona)-10 (tal dea)-9.9 (th )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
10.842 0 Td
(s)Tj
-0.005 Tc -0.037 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 4.48 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.005 Tc 6.101 0 Td
[( \(5.1,)37 ( 5.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -21.824 -1.697 Td
[(Da)-10 (ta)]TJ
/T1_2 1 Tf
0 Tw 0 -1.36 Td
[(Human Da)-10 (ta)]TJ
/T1_1 1 Tf
-0.005 Tc -0.043 Tw 0 -1.292 Td
[(Based on human experience,)37 ( dasa)-10 (tinib )0.5 (is suspected )0.5 (to cause )0.5 (congenital malforma)-10 (tions,)32 ( )]TJ
0.033 Tw 0 -1 Td
[(inc)20 (luding neural tube defects,)37 ( and harmful pharmacological effects on the fetus when)-5 ( )]TJ
0 Tw 0 -1 Td
[(administered during pregnanc)20 (y)54.9 (.)]TJ
ET
q 1 0 0 1 324 578.9042 cm
0 0 m
42.279 0 l
S
Q
q 1 0 0 1 324 486.6914 cm
0 0 m
40.143 0 l
S
Q
q 1 0 0 1 324 446.428 cm
0 0 m
24.895 0 l
S
Q
q 1 0 0 1 324 398.0645 cm
0 0 m
77.375 0 l
S
Q
q 1 0 0 1 324 343.2494 cm
0 0 m
24.68 0 l
S
Q
q 1 0 0 1 324 249.2507 cm
0 0 m
147.877 0 l
S
Q
BT
/T1_2 1 Tf
-0.01 Tc 8 0 0 8 324 727.248 Tm
[(Animal Da)-10 (ta)]TJ
/T1_1 1 Tf
-0.005 Tc 0.215 Tw 0 -1.303 Td
[(In nonc)20 (linical studies a)-10 (t plasma concentra)-10 (tions belo)-10 (w those obser)-18 (ved in humans)-5 ( )]TJ
0.026 Tw 0 -1.011 Td
[(receiving thera)-10 (peutic doses of dasa)-10 (tinib,)37 ( embr)-18 (yo-fetal toxicities were obser)-18 (ved in ra)-10 (ts)-5 ( )]TJ
-0.024 Tw 0 -1.011 Td
[(and rabbits.)37 ( F)24 (etal dea)-10 (th was obser)-18 (ved in ra)-10 (ts.)37 ( In both ra)-10 (ts and rabbits,)37 ( the lo)-10 (west doses)-5 ( )]TJ
0.166 Tw 0 -1.011 Td
[(of dasa)-10 (tinib tested \(ra)-10 (t:)37 ( 2.5 mg/kg/day [15 mg/m)]TJ
0 Tc 0 Tw 6 0 0 6 475.6635 695.3646 Tm
(2)Tj
-0.005 Tc 0.166 Tw 8 0 0 8 478.5134 692.5646 Tm
[(/day] and rabbit:)37 ( 0.5 mg/kg/day)-5 ( )]TJ
0.156 Tw -19.314 -1.011 Td
([6 mg/m)Tj
0 Tc 0 Tw 6 0 0 6 350.2808 687.2787 Tm
(2)Tj
-0.005 Tc 0.156 Tw 8 0 0 8 353.1308 684.4787 Tm
[(/day]\) resulted in embr)-18 (yo-fetal toxicities.)36.9 ( )36.9 (These doses produced ma)-10 (ternal)-5 ( )]TJ
0.045 Tw -3.641 -1.011 Td
[(AUCs of 105 ng\225h/mL and 44 ng\225h/mL \(0.1-fold the human )36.8 (AUC\) in ra)-10 (ts and rabbits,)32 ( )]TJ
0.094 Tw 0 -1.011 Td
[(respectively)55 (.)37 ( Embr)-18 (yo-fetal toxicities inc)20 (luded skeletal malforma)-10 (tions a)-10 (t multiple sites)-5 ( )]TJ
0.153 Tw 0 -1.011 Td
[(\(sca)-10 (pula,)37 ( )0.5 (humerus,)37 ( )0.5 (femur)74 (,)37 ( )0.5 (radius,)37 ( )0.5 (ribs,)37 ( )0.5 (and )0.5 (c)20 (la)-10 (vic)20 (le\),)37 ( )0.5 (reduced )0.5 (ossi\037ca)-9.9 (tion )0.5 (\(sternum;)-5 ( )]TJ
0.131 Tw 0 -1.011 Td
[(thoracic,)37 ( lumbar)74 (,)37 ( and sacral vertebrae; forepa)-10 (w phalanges; pelvis; and hyoid bod)-10 (y\),)32 ( )]TJ
0.33 Tw 0 -1.011 Td
[(edema,)37 ( and microhepa)-10 (tia.)37 ( In a pre- and postna)-10 (tal development stud)-10 (y in ra)-9.9 (ts,)31.9 ( )]TJ
0.063 Tw 0 -1.011 Td
[(administra)-10 (tion of dasa)-9.9 (tinib from gesta)-10 (tion day \(GD\) 16 through lacta)-9.9 (tion day \(LD\) 20,)32 ( )]TJ
0.094 Tw 0 -1.011 Td
[(GD 21 through LD 20,)36.9 ( or LD 4 through LD 20 resulted in extensive pup mortality a)-10 (t)-5 ( )]TJ
-0.027 Tw 0 -1.011 Td
[(ma)-10 (ternal exposures tha)-9.9 (t were belo)-9.9 (w the exposures in pa)-10 (tients trea)-9.9 (ted with dasa)-9.9 (tinib a)-9.9 (t)-5 ( )]TJ
0 Tw 0 -1.011 Td
(the recommended labeling dose.)Tj
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -2.271 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Lactation)Tj
/T1_1 1 Tf
0 Tw -3.375 -1.663 Td
[(Risk Summar)-17.9 (y)]TJ
-0.005 Tc -0.001 Tw 0 -1.303 Td
[(No da)-10 (ta are a)-10 (vailable regarding the presence of dasa)-9.9 (tinib in human milk,)37 ( the effects of)-5 ( )]TJ
0.003 Tw 0 -1.011 Td
[(the drug on the breastfed child,)37 ( or the effects of the drug on milk production.)37 ( Ho)-9.9 (wever)74 (,)32 ( )]TJ
0.076 Tw 0 -1.011 Td
[(dasa)-10 (tinib is present in the milk of lacta)-10 (ting ra)-10 (ts.)37 ( Because of the potential for serious)-5 ( )]TJ
-0.062 Tw 0 -1.011 Td
[(adverse reactions in nursing children from SPR)17.9 (YCEL,)37 ( breastfeeding is not recommended)-5 ( )]TJ
0 Tw 0 -1.011 Td
[(during trea)-10 (tment with SPR)18 (YCEL and for 2 weeks after the last dose.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -2.271 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(F)20 (emales and Males of Reproductive P)24 (otential)]TJ
/T1_1 1 Tf
0.088 Tw -3.375 -1.393 Td
[(SPR)18 (YCEL can cause fetal harm when administered to a pregnant woman )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
27.602 0 Td
(s)Tj
-0.01 Tc 0.088 Tw 0.397 0 Td
(ee U)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.088 Tw 2.092 0 Td
[(e in)-10 ( )]TJ
0 Tw -30.091 -1.011 Td
[(Speci\037c P)18 (opula)-9.9 (tion)]TJ
0 Tc (s)Tj
-0.01 Tc 7.244 0 Td
( \(8.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -7.244 -1.506 Td
(Contraception)Tj
-0.017 Tw 0 -1.303 Td
[(Advise females of reproductive potential and males with female partners \of reproductive)-10 ( )]TJ
0.012 Tw 0 -1.011 Td
[(potential to use effective contraception during trea)-9.9 (tment with SPR)18 (YCEL and for 30 days)-10 ( )]TJ
0 Tw 0 -1.011 Td
(after the last dose.)Tj
0.01 Tw 0 -1.708 Td
(Infertility)Tj
-0.005 Tc -0.028 Tw 0 -1.303 Td
[(Based on animal da)-10 (ta,)37 ( dasa)-10 (tinib may result in dama)-10 (ge to female and male reproductive)-5 ( )]TJ
0.005 Tw 0 -1.011 Td
(tissues )Tj
/T1_2 1 Tf
0 Tc 0 Tw 2.791 0 Td
([)Tj
0.254 0 Td
(s)Tj
-0.005 Tc 0.402 0 Td
[(ee Nonc)20 (linical )37 (T)74 (oxicolog)-10 (y \(13.1\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_3 1 Tf
-0.01 Tc 0.01 Tw -3.447 -2.271 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(P)24 (ediatric Use)]TJ
/T1_1 1 Tf
0.01 Tw -3.375 -1.461 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( CML in Chronic Phase)Tj
-0.005 Tc 0.136 Tw -1.514 -1.303 Td
[(The safety and effectiveness of SPR)18 (YCEL monothera)-10 (py ha)-9.9 (ve been demonstra)-10 (ted in)-5 ( )]TJ
0.221 Tw 0 -1.011 Td
[(pedia)-10 (tric pa)-10 (tients with newly dia)-9.9 (gnosed chronic phase CML )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
23.97 0 Td
(s)Tj
-0.005 Tc 0.221 Tw 0.402 0 Td
(ee Clinical Studie)Tj
0 Tc 0 Tw (s)Tj
( )Tj
-0.005 Tc 0.005 Tw -24.372 -1.011 Td
(\(14.3\)])Tj
/T1_1 1 Tf
-0.014 Tw [(.)37 ( )36.6 (There are no da)-10 (ta in children under 1 year of a)-10 (ge.)37 ( )36.6 (Adverse reactions associa)-9.9 (ted)-5 ( )]TJ
-0.034 Tw 0 -1.011 Td
[(with bone gro)-9.9 (wth and development were reported in 5 \(5.2%\) of )0.5 (pa)-9.9 (tients )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
26.647 0 Td
(s)Tj
-0.005 Tc -0.071 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
( )Tj
-0.005 Tc -27.049 -1.011 Td
(and Precaution)Tj
0 Tc (s)Tj
-0.005 Tc 5.866 0 Td
( \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -5.866 -1.506 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc -0.037 Tw 0.59 -0.125 Td
( ALL)Tj
-0.005 Tc -0.026 Tw -1.514 -1.303 Td
[(The safety and effectiveness of SPR)17.9 (YCEL in combina)-9.9 (tion with chemothera)-9.9 (py ha)-10 (ve been)-5 ( )]TJ
0.044 Tw 0 -1.011 Td
[(demonstra)-9.9 (ted in pedia)-10 (tric pa)-10 (tients one year and over with newly dia)-9.9 (gnosed Ph)]TJ
0 Tc 0 Tw 29.087 0.125 Td
(+)Tj
-0.005 Tc 0.007 Tw 0.595 -0.125 Td
[( ALL.)32 ( )]TJ
-0.029 Tw -29.682 -1.011 Td
[(Use of SPR)18 (YCEL in pedia)-9.9 (tric pa)-10 (tients is supported )0.5 (by evidence from one )0.5 (pedia)-10 (tric stud)-10 (y)55 (.)32 ( )]TJ
-0.004 Tw 0 -1.011 Td
[(There are no da)-10 (ta in children under 1 year of a)-10 (ge.)37 ( One case of grade 1 osteopenia was)-5 ( )]TJ
0.005 Tw 0 -1.011 Td
(reported.)Tj
0.008 Tw 0 -1.438 Td
[(The safety pro\037le of SPR)18 (YCEL in pedia)-10 (tric subjects was comparable to tha)-10 (t reported in)-5 ( )]TJ
-0.017 Tw 0 -1.011 Td
(studies in adult subjects )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
9.234 0 Td
(s)Tj
-0.005 Tc -0.054 Tw 0.402 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc -0.017 Tw 3.545 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc -0.017 Tw 4.222 0 Td
( \(6.1\) and Clinical Studie)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc -0.017 Tw 9.215 0 Td
[( \(14.3,)37 ( 14.4\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.005 Tc 0.297 Tw -26.618 -1.438 Td
[(Monitor bone gro)-9.9 (wth and development in pedia)-10 (tric pa)-10 (tients )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
24.429 0 Td
(s)Tj
-0.005 Tc 0.26 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.297 Tw 4.777 0 Td
[( and)-5 ( )]TJ
0.005 Tw -29.608 -1.011 Td
(Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc 4.276 0 Td
( \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc -4.276 -1.506 Td
[(P)18 (edia)-9.9 (tric P)18.1 (a)-10 (tients with Dif\037culty Swallo)-10 (wing )37 (T)74 (ablets)]TJ
-0.005 Tc 0.22 Tw 0 -1.303 Td
[(F)18 (ive pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 8.227 0.125 Td
(+)Tj
-0.005 Tc 0.22 Tw 0.595 -0.125 Td
[( )36.7 (ALL 2 to 10 years of a)-9.9 (ge received a)-10 (t least one dose of)-5 ( )]TJ
0.128 Tw -8.822 -1.011 Td
[(SPR)18 (YCEL tablet dispersed in juice on Stud)-10 (y CA180372.)37 ( )36.9 (The exposure for dispersed)-5 ( )]TJ
0.017 Tw 0 -1.011 Td
[(tablets was 36% lo)-10 (wer as compared to intact tablets in pedia)-10 (tric pa)-9.9 (tients )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
27.335 0 Td
(s)Tj
-0.005 Tc 0.017 Tw 0.402 0 Td
[(ee Clinical)-5 ( )]TJ
0.074 Tw -27.737 -1.011 Td
[(Pharmacolog)-10 (y \(12.3\))]TJ
0 Tc 0 Tw (])Tj
/T1_1 1 Tf
-0.005 Tc 0.074 Tw 7.882 0 Td
[(.)37 ( Due to the limited a)-9.9 (vailable c)20 (linical da)-10 (ta,)37 ( it is unc)20 (lear whether)-4.9 ( )]TJ
0 Tw -7.882 -1.011 Td
[(dispersing SPR)18 (YCEL tablets signi\037cantly alters the safety and/or ef\037cac)20 (y of SPR)18 (YCEL.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.708 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Geriatric Use)Tj
/T1_1 1 Tf
-0.005 Tc 0.055 Tw -3.375 -1.393 Td
[(Of )0.5 (the )0.5 (2712 )0.5 (pa)-10 (tients )0.5 (in )0.5 (c)20 (linical )0.5 (studies )0.5 (of )0.5 (SPR)18 (YCEL,)37 ( )0.5 (617 )0.5 (\(23%\) )0.5 (were )0.5 (65 )0.5 (years )0.5 (of )0.5 (a)-10 (ge)-5 ( )]TJ
0.048 Tw 0 -1.011 Td
[(and older)74 (,)37 ( and 123 \(5%\) were 75 years of a)-10 (ge and older)74 (.)37 ( No differences in con\037rmed)-5 ( )]TJ
0.209 Tw 0 -1.011 Td
[(Complete Cytogenetic Response \(cCCyR\) and MMR were obser)-18 (ved between older)-5 ( )]TJ
0.085 Tw 0 -1.011 Td
[(and younger pa)-10 (tients.)37 ( )37.1 (While the safety pro\037le of SPR)18 (YCEL in the geria)-10 (tric popula)-9.9 (tion)-5 ( )]TJ
0.101 Tw 0 -1.011 Td
[(was similar to tha)-10 (t in the younger popula)-10 (tion,)37 ( pa)-10 (tients a)-10 (ged 65 years and older are)-5 ( )]TJ
0.308 Tw 0 -1.011 Td
[(more likely to experience the commonly reported adverse reactions of fa)-10 (tigue,)32 ( )]TJ
0.191 Tw 0 -1.011 Td
[(pleural effusion,)37 ( diarrhea,)37 ( d)-10 (yspnea,)37 ( cough,)37 ( lo)-10 (wer gastrointestinal hemorrha)-10 (ge,)37 ( and)-5.1 ( )]TJ
0.261 Tw 0 -1.011 Td
[(a)-10 (ppetite disturbance,)37 ( and more likely to experience the less frequently reported)-5 ( )]TJ
0.098 Tw 0 -1.011 Td
[(adverse )0.5 (reactions of )0.5 (abdominal distention,)36.9 ( )0.5 (dizziness,)37 ( pericardial )0.5 (effusion,)37 ( congestive)-5 ( )]TJ
0.133 Tw 0 -1.011 Td
[(heart failure,)37 ( hypertension,)37 ( pulmonar)-18 (y edema,)37 ( and weight decrease,)37 ( and should be)-5 ( )]TJ
0 Tw 0 -1.011 Td
[(monitored c)19.9 (losely)55 (.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.01 Tw 0 -1.911 Td
(10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(OVERDOSAGE)Tj
/T1_1 1 Tf
-0.005 Tc 0.092 Tw -3.375 -1.303 Td
[(Experience with overdose of SPR)17.9 (YCEL in c)20 (linical studies is limited to isola)-10 (ted cases.)32 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc -0.032 Tw -31.5 -1.011 Td
[(The highest overdosa)-9.9 (ge of 280 mg per day for 1 week was reported in two pa)-9.9 (tients and)-5 ( )]TJ
0.058 Tw 0 -1.011 Td
[(both developed severe myelosuppression and bleeding.)37 ( Since SPR)18 (YCEL is associa)-10 (ted)-5 ( )]TJ
0.265 Tw 0 -1.011 Td
(with severe myelosuppression )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
12.319 0 Td
(s)Tj
-0.005 Tc 0.228 Tw 0.402 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.265 Tw 4.745 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.265 Tw 6.63 0 Td
( \(5.1\))Tj
0 Tc 0 Tw ( )Tj
-0.005 Tc 0.005 Tw 2.656 0 Td
(and)Tj
0 Tc 0 Tw ( )Tj
-0.005 Tc 0.005 Tw 1.818 0 Td
(Adver)Tj
0 Tc 0 Tw (s)Tj
2.486 0 Td
(e )Tj
-0.005 Tc 0.005 Tw -31.056 -1.011 Td
(Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.005 Tc 0.145 Tw 3.565 0 Td
[( )0.5 (\(6.1\)])]TJ
/T1_1 1 Tf
[(,)37 ( )0.6 (monitor )0.6 (pa)-10 (tients )0.5 (who )0.6 (ingest )0.5 (more )0.5 (than )0.6 (the )0.5 (recommended )0.5 (dosa)-10 (ge)-5 ( )]TJ
0 Tw -3.565 -1.011 Td
[(c)20 (losely for myelosuppression and give a)-10 (ppropria)-10 (te supportive trea)-9.9 (tment.)]TJ
ET
endstreamendobj30 0 obj<</Length 28781>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 252 -25.312 re
36 707.648 97.92 -12.912 re
133.92 707.648 154.08 -12.912 re
36 694.736 97.92 -12.912 re
133.92 694.736 77.04 -12.912 re
210.96 694.736 77.04 -12.912 re
36 681.824 97.92 -11.981 re
133.92 681.824 77.04 -11.981 re
210.96 681.824 77.04 -11.981 re
36 669.843 97.92 -11.731 re
133.92 669.843 77.04 -11.731 re
210.96 669.843 77.04 -11.731 re
36 658.112 97.92 -11.731 re
133.92 658.112 77.04 -11.731 re
210.96 658.112 77.04 -11.731 re
36 646.381 97.92 -11.731 re
133.92 646.381 77.04 -11.731 re
210.96 646.381 77.04 -11.731 re
36 634.65 97.92 -11.731 re
133.92 634.65 77.04 -11.731 re
210.96 634.65 77.04 -11.731 re
36 622.919 97.92 -11.731 re
133.92 622.919 77.04 -11.731 re
210.96 622.919 77.04 -11.731 re
36 611.188 97.92 -11.731 re
133.92 611.188 77.04 -11.731 re
210.96 611.188 77.04 -11.731 re
36 599.456 97.92 -11.731 re
133.92 599.456 77.04 -11.731 re
210.96 599.456 77.04 -11.731 re
36 587.725 97.92 -11.731 re
133.92 587.725 77.04 -11.731 re
210.96 587.725 77.04 -11.731 re
36 575.994 97.92 -11.731 re
133.92 575.994 77.04 -11.731 re
210.96 575.994 77.04 -11.731 re
36 564.263 97.92 -11.731 re
133.92 564.263 77.04 -11.731 re
210.96 564.263 77.04 -11.731 re
36 552.532 97.92 -11.731 re
133.92 552.532 77.04 -11.731 re
210.96 552.532 77.04 -11.731 re
36 540.801 97.92 -11.731 re
133.92 540.801 77.04 -11.731 re
210.96 540.801 77.04 -11.731 re
36 529.07 97.92 -11.731 re
133.92 529.07 77.04 -11.731 re
210.96 529.07 77.04 -11.731 re
36 517.339 97.92 -11.731 re
133.92 517.339 77.04 -11.731 re
210.96 517.339 77.04 -11.731 re
36 505.608 97.92 -11.731 re
133.92 505.608 77.04 -11.731 re
210.96 505.608 77.04 -11.731 re
36 493.876 97.92 -11.731 re
133.92 493.876 77.04 -11.731 re
210.96 493.876 77.04 -11.731 re
36 482.145 97.92 -11.731 re
133.92 482.145 77.04 -11.731 re
210.96 482.145 77.04 -11.731 re
36 470.414 97.92 -11.731 re
133.92 470.414 77.04 -11.731 re
210.96 470.414 77.04 -11.731 re
36 458.683 97.92 -11.731 re
133.92 458.683 77.04 -11.731 re
210.96 458.683 77.04 -11.731 re
36 446.952 97.92 -11.731 re
133.92 446.952 77.04 -11.731 re
210.96 446.952 77.04 -11.731 re
36 435.221 97.92 -11.731 re
133.92 435.221 77.04 -11.731 re
210.96 435.221 77.04 -11.731 re
36 423.49 97.92 -11.731 re
133.92 423.49 77.04 -11.731 re
210.96 423.49 77.04 -11.731 re
36 411.759 97.92 -11.731 re
133.92 411.759 77.04 -11.731 re
210.96 411.759 77.04 -11.731 re
36 400.027 97.92 -11.731 re
133.92 400.027 77.04 -11.731 re
210.96 400.027 77.04 -11.731 re
36 388.296 97.92 -11.731 re
133.92 388.296 77.04 -11.731 re
210.96 388.296 77.04 -11.731 re
36 376.565 97.92 -11.731 re
133.92 376.565 77.04 -11.731 re
210.96 376.565 77.04 -11.731 re
36 364.834 97.92 -11.731 re
133.92 364.834 77.04 -11.731 re
210.96 364.834 77.04 -11.731 re
36 353.103 97.92 -11.731 re
133.92 353.103 77.04 -11.731 re
210.96 353.103 77.04 -11.731 re
36 341.372 97.92 -11.731 re
133.92 341.372 77.04 -11.731 re
210.96 341.372 77.04 -11.731 re
36 329.641 97.92 -11.731 re
133.92 329.641 77.04 -11.731 re
210.96 329.641 77.04 -11.731 re
36 317.91 97.92 -11.731 re
133.92 317.91 77.04 -11.731 re
210.96 317.91 77.04 -11.731 re
36 306.179 97.92 -11.731 re
133.92 306.179 77.04 -11.731 re
210.96 306.179 77.04 -11.731 re
36 294.447 97.92 -11.731 re
133.92 294.447 77.04 -11.731 re
210.96 294.447 77.04 -11.731 re
36 282.716 97.92 -11.731 re
133.92 282.716 77.04 -11.731 re
210.96 282.716 77.04 -11.731 re
36 270.985 97.92 -11.731 re
133.92 270.985 77.04 -11.731 re
210.96 270.985 77.04 -11.731 re
36 259.254 97.92 -11.731 re
133.92 259.254 77.04 -11.731 re
210.96 259.254 77.04 -11.731 re
36 247.523 97.92 -11.731 re
133.92 247.523 77.04 -11.731 re
210.96 247.523 77.04 -11.731 re
36 235.792 97.92 -11.731 re
133.92 235.792 77.04 -11.731 re
210.96 235.792 77.04 -11.731 re
f
0 0 0 1 K
1.01 w 
/GS1 gs
q 1 0 0 1 36 224.0608 cm
0 0 m
97.92 0 l
S
Q
q 1 0 0 1 133.92 224.0608 cm
0 0 m
77.04 0 l
S
Q
0.5 w 
q 1 0 0 1 210.96 669.8431 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 658.112 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 646.3809 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 634.6498 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 622.9186 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 611.1876 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 587.7253 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 575.9942 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 564.2631 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 552.532 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 540.8008 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 529.0697 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 517.3386 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 505.6075 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 493.8764 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 482.1453 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 470.4142 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 458.683 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 446.9519 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 435.2208 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 423.4897 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 411.7586 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 400.0275 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 388.2964 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 376.5652 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 364.8341 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 353.103 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 341.3719 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 329.6408 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 317.9097 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 306.1786 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 294.4474 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 282.7163 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 270.9852 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 259.2541 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 247.523 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 235.7919 cm
0 0 m
0 11.731 l
S
Q
q 1 0 0 1 210.96 224.5658 cm
0 0 m
0 11.226 l
S
Q
1.01 w 
q 1 0 0 1 210.96 224.0608 cm
0 0 m
77.04 0 l
S
Q
0.5 w 
q 1 0 0 1 36 681.8242 cm
0 0 m
97.92 0 l
S
Q
q 1 0 0 1 210.96 681.8242 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 694.7361 cm
0 0 m
77.04 0 l
S
Q
1 w 
q 1 0 0 1 36 707.6481 cm
0 0 m
97.92 0 l
S
Q
q 1 0 0 1 133.92 707.6481 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 707.6481 cm
0 0 m
77.04 0 l
S
Q
0.5 w 
q 1 0 0 1 133.92 694.7361 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 682.0742 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 133.92 681.8242 cm
0 0 m
77.04 0 l
S
Q
q 1 0 0 1 210.96 599.4564 cm
0 0 m
0 11.731 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.01 Tc 0.35 Tw 8 0 0 8 36 727.248 Tm
[(Table )326 (14:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(Adverse Reactions )0.5 (Reported )0.5 (in \03620% )0.5 (of Pediatric )0.5 (Patients)-10 ( )]TJ
0.341 Tw 0 -1 Td
(with Ph)Tj
0 Tc 0 Tw 3.27 0.125 Td
(+)Tj
-0.01 Tc 0.341 Tw 0.59 -0.125 Td
[( ALL Treated with SPRYCEL in Combination with)-10 ( )]TJ
0.024 Tw -3.86 -1 Td
(Chemotherapy CA180372 \(N=81\))Tj
-0.02 Tc 7.2 0 0 8 179.3743 698.3361 Tm
(Percent \(%\) of Patients)Tj
-0.01 Tc -19.913 -1.614 Td
(Adverse Reaction)Tj
-0.02 Tc 16.984 0 Td
(All Grades)Tj
10.819 0 Td
(Grade 3/4)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -27.803 -1.571 Td
(Mucositis)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(93)Tj
10.97 0 Td
(60)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(F)24 (ebrile neutropenia)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(86)Tj
10.97 0 Td
(86)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Pyrexia)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(85)Tj
10.97 0 Td
(17)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(84)Tj
10.97 0 Td
(31)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(84)Tj
10.97 0 Td
(11)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
[(V)18 (omiting)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(83)Tj
10.97 0 Td
(17)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(83)Tj
10.97 0 Td
(25)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(78)Tj
10.97 0 Td
(17)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Cough)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(78)Tj
0 Tc 0 Tw 11.207 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(77)Tj
10.97 0 Td
(15)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Rash)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(68)Tj
0 Tc 0 Tw 11.207 0 Td
(7)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(59)Tj
0 Tc 0 Tw 11.207 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
[(Constipa)-10 (tion)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(57)Tj
0 Tc 0 Tw 11.207 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Arrhythmia)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(47)Tj
10.97 0 Td
(12)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Hypertension)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(47)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Edema)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(47)Tj
0 Tc 0 Tw 11.207 0 Td
(6)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
(Viral infection)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(40)Tj
10.97 0 Td
(12)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Hypotension)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(40)Tj
10.97 0 Td
(26)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Decreased a)-10 (ppetite)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(38)Tj
10.97 0 Td
(22)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Hypersensitivity)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(36)Tj
10.97 0 Td
(20)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Upper respira)-10 (tor)-17.9 (y tract infection)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(36)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Dyspnea)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(35)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Epistaxis)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(31)Tj
0 Tc 0 Tw 11.207 0 Td
(6)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
[(P)18 (eripheral neuropa)-10 (thy)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(31)Tj
0 Tc 0 Tw 11.207 0 Td
(7)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
[(Sepsis \(exc)20 (luding fungal\))]TJ
-0.005 Tc 0.005 Tw 18.345 0 Td
(n/a)Tj
11.08 0 Td
(31)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Altered sta)-10 (te of consciousness)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(30)Tj
0 Tc 0 Tw 11.207 0 Td
(4)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
(Fungal infection)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(30)Tj
10.97 0 Td
(11)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Pneumonia \(exc)20 (luding fungal\))]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(28)Tj
10.97 0 Td
(25)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
(Pruritus)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(28)Tj
0 Tc 0 Tw 11.271 0 Td
(-)Tj
-0.01 Tc 0.024 Tw -29.727 -1.466 Td
[(Clostridial infection \(exc)20 (luding sepsis\))]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(25)Tj
10.97 0 Td
(14)Tj
-0.01 Tc -0.013 Tw -29.425 -1.466 Td
[(Urinar)-18 (y T)74 (ract )-37 (Infection)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(24)Tj
10.97 0 Td
(14)Tj
-0.01 Tc 0.024 Tw -29.425 -1.466 Td
[(Bacteremia \(exc)20 (luding fungal\))]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(22)Tj
10.97 0 Td
(20)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
[(Er)-18 (ythema)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(22)Tj
0 Tc 0 Tw 11.207 0 Td
(6)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Chills)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(21)Tj
0 Tc 0 Tw 11.271 0 Td
(-)Tj
-0.01 Tc 0.024 Tw -29.727 -1.466 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(21)Tj
0 Tc 0 Tw 11.207 0 Td
(9)Tj
-0.01 Tc 0.01 Tw -29.663 -1.466 Td
(Sinusitis)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(21)Tj
10.97 0 Td
(10)Tj
-0.01 Tc 0.01 Tw -29.425 -1.466 Td
[(Dehydra)-10 (tion)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(20)Tj
0 Tc 0 Tw 11.207 0 Td
(9)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
[(Renal insufficienc)20 (y)]TJ
-0.005 Tc 0.005 Tw 18.455 0 Td
(20)Tj
0 Tc 0 Tw 11.207 0 Td
(9)Tj
-0.01 Tc 0.024 Tw -29.663 -1.466 Td
(Visual impairment)Tj
-0.005 Tc 0.005 Tw 18.455 0 Td
(20)Tj
0 Tc 0 Tw 11.271 0 Td
(-)Tj
-0.01 Tc 0.053 Tw 8 0 0 8 36 203.6964 Tm
[(The incidence of common adverse reactions a)-10 (ttributed by the investiga)-10 (tor to SPR)18 (YCEL)-10 ( )]TJ
0.159 Tw 0 -1.065 Td
[(\(reported a)-9.9 (t a frequenc)20 (y of \03610%,)37 ( all grades and grade 3/4,)37 ( respectively\) on stud)-10 (y)-10 ( )]TJ
0.112 Tw 0 -1.065 Td
[(\(N=81\),)37.1 ( inc)20 (luded febrile neutropenia \(23%,)37 ( 23%\),)37 ( nausea \(21%,)37 ( 4%\),)37.1 ( vomiting \(19%,)27 ( )]TJ
-0.005 Tw 0 -1.065 Td
[(4%\),)37 ( mucositis \(17%,)37 ( 6%\),)37 ( musculoskeletal pain \(17%,)37 ( 2%\),)37 ( abdominal pain \(16%,)37 ( 5%\),)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.23 Tw -31.5 -1.065 Td
[(diarrhea )0.6 (\(16%,)37 ( )0.6 (7%\),)37 ( )0.6 (rash )0.6 (\(15%,)37 ( )0.6 (0%\),)37 ( )0.5 (fa)-10 (tigue )0.6 (\(12%,)37 ( )0.6 (0%\),)37 ( )0.6 (pyrexia )0.5 (\(12%,)37 ( )0.5 (6%\),)37 ( )0.5 (and)-10 ( )]TJ
0 Tw 0 -1.065 Td
[(headache \(12%,)37 ( 5%\).)]TJ
-0.045 Tw 0 -1.492 Td
[(CTCAE grade 3/4 labora)-9.9 (tor)-18 (y abnormalities in pedia)-10 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 24.942 0.125 Td
(+)Tj
-0.01 Tc -0.045 Tw 0.59 -0.125 Td
[( )37.2 (ALL trea)-10 (ted with)-10 ( )]TJ
0 Tw -25.532 -1.065 Td
[(SPR)18 (YCEL in combina)-10 (tion with chemothera)-10 (py are sho)-10 (wn in )37 (T)74 (able 15.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 130.041 252 -25.312 re
36 104.729 105.84 -13.635 re
141.84 104.729 146.16 -13.635 re
36 91.094 105.84 -11.731 re
141.84 91.094 146.16 -11.731 re
36 79.363 105.84 -11.731 re
141.84 79.363 146.16 -11.731 re
36 67.632 105.84 -11.731 re
141.84 67.632 146.16 -11.731 re
36 55.901 105.84 -11.731 re
141.84 55.901 146.16 -11.731 re
f
1 w 
/GS1 gs
q 1 0 0 1 36 104.7294 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 141.84 104.7294 cm
0 0 m
146.16 0 l
S
Q
0.505 w 
q 1 0 0 1 36 91.0944 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 141.84 91.0944 cm
0 0 m
146.16 0 l
S
Q
0.5 w 
q 1 0 0 1 36 44.17 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 141.84 44.17 cm
0 0 m
146.16 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.022 Tw 8 0 0 8 36 124.3294 Tm
[(Table )-2 (15:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTCAE Grade 3/4 Laboratory Abnormalities in \03610% of Pediatric)-10 ( )]TJ
0.158 Tw 0 -1 Td
(Patients with Ph)Tj
0 Tc 0 Tw 6.634 0.125 Td
(+)Tj
-0.01 Tc 0.158 Tw 0.59 -0.125 Td
[( ALL Treated with SPRYCEL in Combination)-10 ( )]TJ
0.024 Tw -7.224 -1 Td
(with Chemotherapy CA180372 \(N=81\))Tj
7.2 0 0 8 182.715 95.056 Tm
[(P)24 (ercent \(%\) of P)24 (atients)]TJ
-20.377 -1.585 Td
[(Hematolog)-10 (y P)24 (arameters)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.466 Td
( )Tj
EMC 
1.262 0 Td
(Neutropenia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(96)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.373 -1.466 Td
( )Tj
EMC 
1.262 0 Td
[(Thromboc)20 (ytopenia)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(88)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.373 -1.466 Td
( )Tj
EMC 
1.262 0 Td
(Anemia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(82)Tj
/T1_2 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 253.872 35.8177 Tm
(\(Continued\))Tj
ET
q 1 0 0 1 324 561.7136 cm
0 0 m
119.269 0 l
S
Q
0 0 0 0 k
/GS0 gs
324 732.96 252 -25.312 re
324 707.648 105.84 -13.635 re
429.84 707.648 146.16 -13.635 re
324 694.013 252 -5.964 re
324 688.049 105.84 -11.472 re
429.84 688.049 146.16 -11.472 re
324 676.577 105.84 -11.472 re
429.84 676.577 146.16 -11.472 re
324 665.105 105.84 -11.472 re
429.84 665.105 146.16 -11.472 re
324 653.633 105.84 -11.472 re
429.84 653.633 146.16 -11.472 re
324 642.161 105.84 -11.472 re
429.84 642.161 146.16 -11.472 re
324 630.689 105.84 -11.472 re
429.84 630.689 146.16 -11.472 re
324 619.217 105.84 -11.472 re
429.84 619.217 146.16 -11.472 re
324 607.745 105.84 -11.472 re
429.84 607.745 146.16 -11.472 re
324 596.273 252 -12.912 re
f
1 w 
/GS1 gs
q 1 0 0 1 324 707.6481 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 707.6481 cm
0 0 m
146.16 0 l
S
Q
0.505 w 
q 1 0 0 1 324 694.0131 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 694.0131 cm
0 0 m
146.16 0 l
S
Q
1.01 w 
q 1 0 0 1 324 596.2733 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 596.2733 cm
0 0 m
146.16 0 l
S
Q
0.505 w 
q 1 0 0 1 324 583.3614 cm
0 0 m
105.84 0 l
S
Q
q 1 0 0 1 429.84 583.3614 cm
0 0 m
146.16 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.022 Tw 8 0 0 8 324 727.248 Tm
[(Table )-2 (15:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTCAE Grade 3/4 Laboratory Abnormalities in \03610% of Pediatric)-10 ( )]TJ
0.158 Tw 0 -1 Td
(Patients with Ph)Tj
0 Tc 0 Tw 6.634 0.125 Td
(+)Tj
-0.01 Tc 0.158 Tw 0.59 -0.125 Td
[( ALL Treated with SPRYCEL in Combination)-10 ( )]TJ
0.024 Tw -7.224 -1 Td
(with Chemotherapy CA180372 \(N=81\))Tj
7.2 0 0 8 470.715 697.9745 Tm
[(P)24 (ercent \(%\) of P)24 (atients)]TJ
-0.02 Tc -20.377 -2.315 Td
[(Biochemistr)-18 (y P)24 (arameters)]TJ
/T1_1 1 Tf
-0.01 Tc /Span<</ActualText<FEFF0009>>> BDC 
0 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGPT \(AL)94.1 (T\))]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(47)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
(Hypokalemia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(40)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGOT \(AST\))]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(26)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
(Hypocalcemia)Tj
-0.005 Tc 0.005 Tw 23.11 0 Td
(19)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Hypona)-10 (tremia)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(19)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Bilirubin)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(11)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-24.372 -1.434 Td
( )Tj
EMC 
1.262 0 Td
[(Hypophospha)-9.9 (temia)]TJ
-0.005 Tc 0.005 Tw 23.11 0 Td
(11)Tj
0 Tw -24.372 -1.524 Td
[(T)74 (oxicity grading is per CTCAE version 4.)]TJ
-0.01 Tc 8 0 0 8 324 563.0436 Tm
[(Additional P)18 (ooled Da)-9.9 (ta from Clinical )37 (T)74 (rials)]TJ
-0.005 Tc -0.025 Tw 0 -1.316 Td
[(The follo)-9.9 (wing additional adverse reactions were reported in adult and pedia)-10 (tric pa)-10 (tients)-5 ( )]TJ
0.197 Tw 0 -1.023 Td
[(\(n=2809\) in SPR)18 (YCEL CML c)20 (linical studies and adult pa)-9.9 (tients in Ph)]TJ
0 Tc 0 Tw 26.185 0.125 Td
(+)Tj
-0.005 Tc 0.16 Tw 0.595 -0.125 Td
[( ALL )-37.2 (c)20 (linical)-5 ( )]TJ
0 Tc 0 Tw 4.72 0 Td
( )Tj
-0.005 Tc 0.119 Tw -31.5 -1.023 Td
[(studies )0.5 (a)-10 (t )0.5 (a )0.5 (frequenc)20 (y )0.5 (of )0.5 (\03610%,)37 ( )0.5 (1%\226<10%,)37 ( )0.5 (0.1%\226<1%,)37 ( )0.5 (or )0.5 (<0.1%.)37 ( )37.5 (These )0.5 (adverse)-5 ( )]TJ
0 Tw 0 -1.023 Td
[(reactions are inc)20 (luded based on c)20 (linical relevance.)]TJ
/T1_3 1 Tf
-0.01 Tc 0.059 Tw 0 -1.451 Td
(Gastrointestinal Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.059 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( mucosal in\035amma)-9.9 (tion \(inc)20 (luding mucositis/)]TJ
0.193 Tw 0 -1.023 Td
[(stoma)-10 (titis\),)37 ( d)-10 (yspepsia,)37.1 ( abdominal distension,)37 ( constipa)-10 (tion,)37.1 ( gastritis,)37 ( colitis \(inc)20 (luding)-10 ( )]TJ
0.165 Tw 0 -1.023 Td
[(neutropenic )0.6 (colitis\),)37 ( )0.5 (oral )0.5 (soft )0.6 (tissue )0.6 (disorder; )]TJ
/T1_2 1 Tf
17.095 0 Td
[(0.1%\226<1% )0.5 (\226)]TJ
/T1_1 1 Tf
[( )0.5 (ascites,)37 ( )0.5 (d)-10 (yspha)-10 (gia,)37 ( )0.5 (anal)-9.9 ( )]TJ
0.098 Tw -17.095 -1.023 Td
[(\037ssure,)37 ( upper gastrointestinal ulcer)74 (,)37 ( esopha)-10 (gitis,)37 ( pancrea)-10 (titis,)37 ( gastroesopha)-9.9 (geal re\035ux)-10 ( )]TJ
0.01 Tw 0 -1.023 Td
(disease; )Tj
/T1_2 1 Tf
3.181 0 Td
(<0.1% )Tj
/T1_1 1 Tf
-0.022 Tw 2.717 0 Td
[(\226 protein losing gastroenteropa)-10 (thy)55.1 (,)36.9 ( ileus,)37.1 ( acute pancrea)-10 (titis,)37 ( anal \037stula.)]TJ
/T1_3 1 Tf
0.075 Tw -5.898 -1.451 Td
(General Disorders and Administration-Site Conditions:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.01 Tw (\03610%)Tj
/T1_1 1 Tf
0.075 Tw [( \226 peripheral edema,)27 ( )]TJ
0.155 Tw 0 -1.023 Td
(face edema; )Tj
/T1_2 1 Tf
(1%\226<10% \226)Tj
/T1_1 1 Tf
[( asthenia,)37 ( chest pain,)37 ( chills; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( malaise,)37 ( other)-10 ( )]TJ
0 Tw 0 -1.023 Td
[(super\037cial edema,)37 ( peripheral s)-10 (welling; )]TJ
/T1_2 1 Tf
0.01 Tw (<0.1% )Tj
/T1_1 1 Tf
0 Tw 16.851 0 Td
(\226 gait disturbance.)Tj
/T1_3 1 Tf
0.18 Tw -16.851 -1.451 Td
[(Skin and Subcutaneous T)18 (issue Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.18 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( alopecia,)37 ( acne,)37 ( dr)-18 (y skin,)27 ( )]TJ
0.276 Tw 0 -1.023 Td
[(hyperhidrosis,)37.1 ( urticaria,)37 ( derma)-10 (titis \(inc)20 (luding eczema\); )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( pigmenta)-10 (tion)-9.9 ( )]TJ
0.314 Tw 0 -1.023 Td
[(disorder)74 (,)37 ( skin ulcer)74 (,)37 ( bullous conditions,)37 ( photosensitivity)55 (,)37 ( )0.5 (nail disorder)74 (,)37 ( )0.5 (neutrophilic)-10 ( )]TJ
0.204 Tw 0 -1.023 Td
[(derma)-10 (tosis,)37 ( panniculitis,)37.1 ( palmar)37 (-plantar er)-18 (ythrod)-10 (ysesthesia syndrome,)37 ( hair disorder;)-10 ( )]TJ
/T1_2 1 Tf
0.01 Tw 0 -1.023 Td
(<0.1%)Tj
/T1_1 1 Tf
0 Tw [( \226 leukoc)20 (ytoc)20 (lastic vasculitis,)37 ( skin \037brosis.)]TJ
/T1_3 1 Tf
0.247 Tw 0 -1.451 Td
[(Respirator)-18 (y)55.1 (,)37 ( Thoracic,)37 ( and Mediastinal Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.01 Tc 0.247 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( lung in\037ltra)-10 (tion,)27 ( )]TJ
0.289 Tw 0 -1.023 Td
[(pneumonitis,)37 ( cough; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( asthma,)37 ( bronchospasm,)37 ( d)-10 (ysphonia,)37 ( pulmonar)-18 (y)-10 ( )]TJ
0.377 Tw 0 -1.023 Td
(arterial hypertension; )Tj
/T1_2 1 Tf
0.01 Tw (<0.1% )Tj
/T1_1 1 Tf
0.377 Tw 11.706 0 Td
[(\226 acute respira)-9.9 (tor)-17.9 (y distress syndrome,)37 ( pulmonar)-18 (y)-10 ( )]TJ
0.01 Tw -11.706 -1.023 Td
(embolism.)Tj
/T1_3 1 Tf
-0.005 Tc 0.652 Tw 0 -1.451 Td
[(Ner)-18 (vous System Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.652 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( neuropa)-9.9 (thy \(inc)20 (luding peripheral)-5 ( )]TJ
0.383 Tw 0 -1.023 Td
[(neuropa)-10 (thy\),)37 ( dizziness,)37 ( d)-9.9 (ysgeusia,)37 ( somnolence; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( amnesia,)37 ( tremor)74 (,)32 ( )]TJ
0.116 Tw 0 -1.023 Td
[(syncope,)37 ( balance disorder; )]TJ
/T1_2 1 Tf
0.005 Tw (<0.1% )Tj
/T1_1 1 Tf
0.116 Tw 13.217 0 Td
[(\226 convulsion,)37 ( cerebrovascular accident,)37 ( transient)-5 ( )]TJ
0 Tw -13.217 -1.023 Td
[(ischemic a)-10 (ttack,)37 ( optic neuritis,)37 ( )37 (VIIth ner)-18 (ve paralysis,)37 ( dementia,)37 ( a)-10 (taxia.)]TJ
/T1_3 1 Tf
0.635 Tw 0 -1.451 Td
[(Blood and L)37 (ymphatic System Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.635 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( lymphadenopa)-9.9 (thy)55 (,)31.9 ( )]TJ
0.005 Tw 0 -1.023 Td
(lymphopenia; )Tj
/T1_2 1 Tf
5.135 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0 Tw 2.769 0 Td
[(\226 a)-10 (plasia pure red cell.)]TJ
/T1_3 1 Tf
0.532 Tw -7.904 -1.451 Td
[(Musculoskeletal and Connective T)18 (issue Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.532 Tw 22.058 0 Td
(1%\226<10% \226)Tj
/T1_1 1 Tf
[( muscular)-5 ( )]TJ
-0.034 Tw -22.058 -1.023 Td
[(weakness,)37 ( musculoskeletal stiffness; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( rhabdomyolysis,)37 ( tendonitis,)37 ( musc)20 (le)-5 ( )]TJ
0.046 Tw 0 -1.023 Td
[(in\035amma)-10 (tion,)37 ( osteonecrosis,)37 ( arthritis; )]TJ
/T1_2 1 Tf
0.005 Tw (<0.1%)Tj
/T1_1 1 Tf
0.046 Tw [( \226 epiphyses delayed fusion \(reported a)-10 (t)-5 ( )]TJ
/T1_2 1 Tf
0.005 Tw 0 -1.023 Td
(1%\226<10%)Tj
/T1_1 1 Tf
0.046 Tw [( in the pedia)-10 (tric studies\),)37 ( gro)-10 (wth retarda)-10 (tion \(reported a)-10 (t )]TJ
/T1_2 1 Tf
0.005 Tw (1%\226<10%)Tj
/T1_1 1 Tf
0.046 Tw [( in the)-4.9 ( )]TJ
0 Tw 0 -1.023 Td
[(pedia)-10 (tric studies\).)]TJ
/T1_3 1 Tf
0.005 Tw 0 -1.451 Td
(Investigations:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc -0.038 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( weight increased,)37 ( weight decreased; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( blood)-5 ( )]TJ
0 Tw 0 -1.023 Td
[(crea)-10 (tine phosphokinase increased,)37 ( gamma-glutamyltransferase increased.)]TJ
/T1_3 1 Tf
0.316 Tw 0 -1.451 Td
(Infections and Infestations:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.316 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( pneumonia \(inc)20 (luding bacterial,)37 ( viral,)32 ( )]TJ
0.241 Tw 0 -1.023 Td
[(and fungal\),)37 ( upper respira)-10 (tor)-17.9 (y tract infection/in\035amma)-10 (tion,)37 ( herpes virus infection,)32 ( )]TJ
0 Tw 0 -1.023 Td
[(enterocolitis infection,)37 ( sepsis \(inc)20 (luding fa)-10 (tal outcomes [0.2%]\).)]TJ
/T1_3 1 Tf
0.671 Tw 0 -1.451 Td
(Metabolism and Nutrition Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.671 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( a)-10 (ppetite disturbances,)32 ( )]TJ
0.005 Tw 0 -1.023 Td
(hyperuricemia; )Tj
/T1_2 1 Tf
0.13 Tw 5.81 0 Td
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( hypoalbuminemia,)37 ( tumor lysis syndrome,)37 ( dehydra)-10 (tion,)31.9 ( )]TJ
0.005 Tw -5.81 -1.023 Td
(hypercholesterolemia; )Tj
/T1_2 1 Tf
8.291 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0 Tw 2.769 0 Td
(\226 diabetes mellitus.)Tj
/T1_3 1 Tf
0.293 Tw -11.06 -1.451 Td
(Cardiac Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.293 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( arrhythmia \(inc)20 (luding tachycardia\),)37 ( palpita)-10 (tions;)-5 ( )]TJ
/T1_2 1 Tf
0.351 Tw 0 -1.023 Td
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( angina pectoris,)37 ( cardiomegaly)55 (,)36.9 ( pericarditis,)37 ( ventricular arrhythmia)-5 ( )]TJ
0.357 Tw 0 -1.023 Td
[(\(inc)20 (luding ventricular tachycardia\),)37 ( electrocardiogram )36.6 (T)55 (-wa)-10 (ve abnormal,)37 ( troponin)-5 ( )]TJ
0.005 Tw 0 -1.023 Td
(increased; )Tj
/T1_2 1 Tf
4.162 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0.147 Tw 2.915 0 Td
[(\226 )0.5 (cor )0.5 (pulmonale,)37 ( )0.5 (myocarditis,)37 ( )0.5 (acute )0.5 (coronar)-18 (y )0.5 (syndrome,)37 ( )0.5 (cardiac)-5 ( )]TJ
0 Tw -7.078 -1.023 Td
[(arrest,)37 ( electrocardiogram PR prolonga)-10 (tion,)37 ( coronar)-18 (y arter)-18 (y disease,)37 ( pleuropericarditis.)]TJ
/T1_3 1 Tf
0.277 Tw 0 -1.451 Td
(Eye Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.277 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( visual disorder \(inc)20 (luding visual disturbance,)37.1 ( vision)-5 ( )]TJ
0.284 Tw 0 -1.023 Td
[(blurred,)37 ( and visual acuity reduced\),)37 ( dr)-18 (y eye; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( conjunctivitis,)37 ( visual)-5 ( )]TJ
0 Tw 0 -1.023 Td
[(impairment,)36.9 ( lacrima)-10 (tion increased,)37 ( )]TJ
/T1_2 1 Tf
0.005 Tw (<0.1%)Tj
/T1_1 1 Tf
0 Tw ( \226 photophobia.)Tj
/T1_3 1 Tf
0.045 Tw 0 -1.451 Td
[(V)18 (ascular Disorders:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.045 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( \035ushing,)37 ( hypertension; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( hypotension,)32 ( )]TJ
0.313 Tw 0 -1.023 Td
[(thrombophlebitis,)37 ( )0.6 (thrombosis; )]TJ
/T1_2 1 Tf
0.005 Tw 11.709 0 Td
(<0.1% )Tj
/T1_1 1 Tf
0.313 Tw 3.081 0 Td
[(\226 )0.6 (livedo )0.5 (reticularis,)37 ( )0.5 (deep )0.6 (vein )0.6 (thrombosis,)32 ( )]TJ
0.005 Tw -14.79 -1.023 Td
(embolism.)Tj
/T1_3 1 Tf
0.215 Tw 0 -1.451 Td
(Psychiatric Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.215 Tw (1%\226<10% \226)Tj
/T1_1 1 Tf
[( insomnia,)37 ( depression; )]TJ
/T1_2 1 Tf
(0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( anxiety)55 (,)32 ( )]TJ
0 Tw 0 -1.023 Td
[(affect lability)55 (,)37 ( confusional sta)-10 (te,)37 ( libido decreased.)]TJ
/T1_3 1 Tf
0 -1.451 Td
[(Pregnanc)10 (y)55 (,)37 ( Puerperium,)37 ( and P)24 (erinatal Conditions:)]TJ
/T1_1 1 Tf
0 Tc /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc 0.005 Tw (<0.1% )Tj
/T1_1 1 Tf
0 Tw 22.349 0 Td
(\226 abortion.)Tj
/T1_3 1 Tf
-0.022 Tw -22.349 -1.451 Td
(Reproductive System and Breast Disorders:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc -0.022 Tw (0.1%\226<1% \226)Tj
/T1_1 1 Tf
[( g)-10 (ynecomastia,)37 ( menstrual)-5 ( )]TJ
0.005 Tw 0 -1.023 Td
[(disorder)74 (.)]TJ
/T1_3 1 Tf
0 Tw 0 -1.451 Td
[(Injur)-18 (y)55 (,)37 ( P)24 (oisoning,)37 ( and Procedural Complications:)]TJ
/T1_1 1 Tf
0 Tc /Span<</ActualText<FEFF2005>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
-0.005 Tc (1%\226<10% \226)Tj
/T1_1 1 Tf
( contusion.)Tj
/T1_2 1 Tf
-0.01 Tc 0.01 Tw 0 85.428 Td
(\(Continued\))Tj
ET
endstreamendobj22 0 obj<</Length 32770>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 251.937 -17.312 re
36 715.648 88.497 -12.912 re
124.497 715.648 81.72 -12.912 re
206.217 715.648 81.72 -12.912 re
36 702.736 88.497 -12.912 re
124.497 702.736 163.44 -12.912 re
36 689.824 88.497 -10.282 re
124.497 689.824 81.72 -10.282 re
206.217 689.824 81.72 -10.282 re
36 679.542 88.497 -10.032 re
124.497 679.542 81.72 -10.032 re
206.217 679.542 81.72 -10.032 re
36 669.51 88.497 -10.032 re
124.497 669.51 81.72 -10.032 re
206.217 669.51 81.72 -10.032 re
36 659.478 88.497 -10.032 re
124.497 659.478 81.72 -10.032 re
206.217 659.478 81.72 -10.032 re
36 649.447 88.497 -10.032 re
124.497 649.447 81.72 -10.032 re
206.217 649.447 81.72 -10.032 re
36 639.415 88.497 -10.032 re
124.497 639.415 81.72 -10.032 re
206.217 639.415 81.72 -10.032 re
36 629.383 88.497 -10.032 re
124.497 629.383 81.72 -10.032 re
206.217 629.383 81.72 -10.032 re
36 619.351 88.497 -10.032 re
124.497 619.351 81.72 -10.032 re
206.217 619.351 81.72 -10.032 re
36 609.319 88.497 -10.752 re
124.497 609.319 81.72 -10.752 re
206.217 609.319 81.72 -10.752 re
f
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 689.8242 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 124.4975 689.8242 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 206.2175 689.8242 cm
0 0 m
81.72 0 l
S
Q
1 w 
q 1 0 0 1 36 598.567 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 206.2175 598.567 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 206.2175 679.5423 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 669.5104 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 659.4785 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 649.4465 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 639.4147 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 629.3828 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 619.3508 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 609.3189 cm
0 0 m
0 10.032 l
S
Q
q 1 0 0 1 206.2175 599.067 cm
0 0 m
0 10.252 l
S
Q
1 w 
q 1 0 0 1 124.4975 598.567 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 206.2175 702.7361 cm
0 0 m
81.72 0 l
S
Q
1 w 
q 1 0 0 1 36 715.6481 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 206.2175 715.6481 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 124.4975 715.6481 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 206.2175 702.9861 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 124.4975 702.7361 cm
0 0 m
81.72 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.015 Tc 0.44 Tw 8 0 0 8 36 727.248 Tm
[(T)-5 (a)-5 (b)-5 (l)-5 (e)-5 ( )411 (1)-5 (1)-4.9 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.538 0 Td
( )Tj
EMC 
3.087 0 Td
[(Adverse )0.5 (Reactions )0.5 (Reported in )0.5 (\03610% of Dasatinib-Treated)-15 ( )]TJ
0.024 Tw 0 -1 Td
(Pediatric Patients with Chronic Phase CML \(n=97\))Tj
-0.02 Tc 7.2 0 0 8 151.2036 706.3361 Tm
(All Grades)Tj
11.469 0 Td
(Grade 3/4)Tj
-0.01 Tc -27.469 -1.614 Td
(Adverse Reaction)Tj
-0.02 Tc 19.254 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -19.254 -1.465 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(28)Tj
0 Tc 0 Tw 11.622 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(20)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(21)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -29.094 -1.254 Td
(Skin rash)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(19)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
[(V)18 (omiting)]TJ
-0.005 Tc 0.005 Tw 17.471 0 Td
(13)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -29.094 -1.254 Td
[(P)18 (ain in extremity)]TJ
-0.005 Tc 0.005 Tw 17.471 0 Td
(19)Tj
0 Tc 0 Tw 11.622 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.094 -1.254 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(16)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 17.471 0 Td
(10)Tj
0 Tc 0 Tw 11.622 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.094 -1.254 Td
(Arthralgia)Tj
-0.005 Tc 0.005 Tw 17.471 0 Td
(10)Tj
0 Tc 0 Tw 11.622 0 Td
(1)Tj
-0.01 Tc 0.187 Tw 8 0 0 8 36 577.4811 Tm
[(Adverse reactions associa)-10 (ted with bone gro)-10 (wth and development were reported in)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.067 Tw -31.5 -1.156 Td
[(5 \(5.2%\) of pedia)-9.9 (tric pa)-10 (tients with chronic phase CML )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
20.446 0 Td
(s)Tj
-0.01 Tc 0.03 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.067 Tw 4.492 0 Td
( and Precaution)Tj
0 Tc 0 Tw (s)Tj
( )Tj
-0.01 Tc 0.01 Tw -25.335 -1.156 Td
(\(5.10\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.01 Tc -0.037 Tw 0 -2.078 Td
[(Labora)-10 (tor)-18 (y Abnormalities)]TJ
/T1_1 1 Tf
0.029 Tw 8.08 0 0 8.08 36 530.6743 Tm
[(Myelosuppression was commonly reported in all pa)-10 (tient popula)-10 (tions.)37 ( )36.9 (The frequenc)20 (y of)-10 ( )]TJ
0.058 Tw 0 -1.154 Td
[(Grade 3 or 4 neutropenia,)37.1 ( thromboc)20 (ytopenia,)37 ( and anemia was higher in pa)-9.9 (tients with)-10 ( )]TJ
-0.019 Tw 0 -1.154 Td
[(advanced phase CML than in chronic phase CML \(T)74 (ables 12 and 13\).)37 ( Myelosuppression)-9.9 ( )]TJ
0.043 Tw 0 -1.154 Td
[(was )0.5 (reported in )0.5 (pa)-9.9 (tients with )0.5 (normal baseline labora)-10 (tor)-18 (y )0.5 (values )0.5 (as )0.5 (well )0.5 (as )0.5 (in )0.5 (pa)-9.9 (tients)-10 ( )]TJ
0 Tw 0 -1.154 Td
[(with pre-existing labora)-9.9 (tor)-18 (y abnormalities.)]TJ
0.157 Tw 0 -1.447 Td
[(In pa)-10 (tients who experienced severe myelosuppression,)37 ( recover)-17.9 (y generally occurred)-10 ( )]TJ
0.292 Tw 0 -1.154 Td
[(follo)-10 (wing dose interruption or reduction; permanent discontinua)-10 (tion of trea)-10 (tment)-9.9 ( )]TJ
0.036 Tw 0 -1.154 Td
[(occurred in 2% of adult pa)-9.9 (tients with newly dia)-10 (gnosed chronic phase CML and 5% of)-9.9 ( )]TJ
-0.024 Tw 0 -1.154 Td
[(adult pa)-9.9 (tients with resistance or intolerance to prior ima)-10 (tinib thera)-10 (py )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
24.835 0 Td
(s)Tj
-0.01 Tc -0.061 Tw 0.397 0 Td
[(ee W)18 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.024 Tw 4.401 0 Td
[( and)-10 ( )]TJ
0.01 Tw -29.632 -1.154 Td
(Precaution)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.221 0 Td
( \(5.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.049 Tw -4.221 -1.447 Td
[(Grade 3 or 4 eleva)-10 (tions of transaminases or bilirubin and Grade 3 or 4 hypocalcemia,)27 ( )]TJ
0.01 Tw 0 -1.154 Td
[(hypokalemia,)37 ( and hypophospha)-9.9 (temia were reported in pa)-10 (tients with all phases of CML)-9.9 ( )]TJ
0.091 Tw 0 -1.154 Td
[(but )0.5 (were )0.5 (reported )0.5 (with )0.5 (an increased frequenc)20 (y in )0.5 (pa)-10 (tients with myeloid )0.5 (or )0.5 (lymphoid)-10 ( )]TJ
0.048 Tw 0 -1.154 Td
[(blast phase CML.)37 ( Eleva)-9.9 (tions in transaminases or bilirubin were usually mana)-9.9 (ged with)-10 ( )]TJ
0.062 Tw 0 -1.154 Td
[(dose reduction or interruption.)37 ( P)18.1 (a)-10 (tients developing Grade 3 or 4 hypocalcemia during)-10 ( )]TJ
0 Tw 0 -1.154 Td
[(SPR)18 (YCEL thera)-10 (py often had recover)-18 (y with oral calcium supplementa)-10 (tion.)]TJ
-0.006 Tw 8 0 0 8 36 374.4735 Tm
[(Labora)-10 (tor)-18 (y abnormalities )0.5 (reported in adult pa)-10 (tients )0.5 (with )0.5 (newly )0.5 (dia)-10 (gnosed chronic phase)-10 ( )]TJ
0.018 Tw 0 -1.156 Td
[(CML are sho)-9.9 (wn in )37.1 (T)74 (able 12.)37 ( )37.1 (There were no discontinua)-10 (tions of SPR)18 (YCEL thera)-10 (py in this)-10 ( )]TJ
0 Tw 0 -1.156 Td
[(pa)-10 (tient popula)-10 (tion due to biochemical labora)-9.9 (tor)-18 (y parameters.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 344.656 252 -25.312 re
36 319.344 81.72 -21.226 re
117.72 319.344 85.14 -21.226 re
202.86 319.344 85.14 -21.226 re
36 298.118 81.72 -13.635 re
117.72 298.118 170.28 -13.635 re
36 284.483 81.72 -12.192 re
117.72 284.483 85.14 -12.192 re
202.86 284.483 85.14 -12.192 re
36 272.291 81.72 -12.192 re
117.72 272.291 85.14 -12.192 re
202.86 272.291 85.14 -12.192 re
36 260.099 81.72 -12.192 re
117.72 260.099 85.14 -12.192 re
202.86 260.099 85.14 -12.192 re
36 247.907 81.72 -12.192 re
117.72 247.907 85.14 -12.192 re
202.86 247.907 85.14 -12.192 re
36 235.715 81.72 -12.192 re
117.72 235.715 85.14 -12.192 re
202.86 235.715 85.14 -12.192 re
36 223.523 81.72 -12.192 re
117.72 223.523 85.14 -12.192 re
202.86 223.523 85.14 -12.192 re
36 211.332 81.72 -12.192 re
117.72 211.332 85.14 -12.192 re
202.86 211.332 85.14 -12.192 re
36 199.14 81.72 -12.192 re
117.72 199.14 85.14 -12.192 re
202.86 199.14 85.14 -12.192 re
36 186.948 81.72 -12.192 re
117.72 186.948 85.14 -12.192 re
202.86 186.948 85.14 -12.192 re
36 174.756 81.72 -12.192 re
117.72 174.756 85.14 -12.192 re
202.86 174.756 85.14 -12.192 re
36 162.564 81.72 -12.192 re
117.72 162.564 85.14 -12.192 re
202.86 162.564 85.14 -12.192 re
36 150.372 81.72 -12.192 re
117.72 150.372 85.14 -12.192 re
202.86 150.372 85.14 -12.192 re
36 138.18 252 -62.85 re
f
1.01 w 
/GS1 gs
q 1 0 0 1 36 138.1801 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 138.1801 cm
0 0 m
85.14 0 l
S
Q
0.505 w 
q 1 0 0 1 36 75.33 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 75.33 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 202.86 75.33 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 117.72 298.118 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 36 284.483 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 284.483 cm
0 0 m
85.14 0 l
S
Q
1 w 
q 1 0 0 1 36 319.344 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 319.344 cm
0 0 m
85.14 0 l
S
Q
0.505 w 
q 1 0 0 1 202.86 284.483 cm
0 0 m
85.14 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 272.2911 cm
0 0 m
0 11.939 l
S
Q
q 1 0 0 1 202.86 260.0992 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 247.9073 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 223.5235 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 202.86 211.3315 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 199.1396 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 186.9477 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 174.7558 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 162.5639 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 150.372 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 202.86 138.6851 cm
0 0 m
0 11.687 l
S
Q
1.01 w 
q 1 0 0 1 202.86 138.1801 cm
0 0 m
85.14 0 l
S
Q
1 w 
q 1 0 0 1 202.86 319.344 cm
0 0 m
85.14 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 298.3705 cm
0 0 m
0 20.473 l
S
Q
0.505 w 
q 1 0 0 1 202.86 298.118 cm
0 0 m
85.14 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 235.9654 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 36 235.7154 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 235.7154 cm
0 0 m
85.14 0 l
S
Q
q 1 0 0 1 202.86 235.7154 cm
0 0 m
85.14 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.085 Tw 8 0 0 8 36 338.944 Tm
[(Table )61 (12:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTC Grade 3/4 Laboratory Abnormalities in Adult Patients with)-10 ( )]TJ
0.107 Tw 0 -1 Td
[(Newly Diagnosed Chronic Phase CML \(minimum of 60 months)-10 ( )]TJ
0.01 Tw 0 -1 Td
(follow-up\))Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 147.6552 309.8751 Tm
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 172.6748 309.8751 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 149.322 301.8751 Tm
(\(n=258\))Tj
11.799 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 256.8336 309.8751 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 234.712 301.8751 Tm
(\(n=258\))Tj
0.024 Tw -8.811 -1.634 Td
(Percent \(%\) of Patients)Tj
-0.01 Tc -18.788 -1.659 Td
[(Hematolog)-10 (y P)24 (arameters)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Neutropenia)Tj
-0.005 Tc 0.005 Tw 15.505 0 Td
(29)Tj
12.095 0 Td
(24)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.862 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Thromboc)20 (ytopenia)]TJ
-0.005 Tc 0.005 Tw 15.505 0 Td
(22)Tj
12.095 0 Td
(14)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.862 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Anemia)Tj
-0.005 Tc 0.005 Tw 15.505 0 Td
(13)Tj
0 Tc 0 Tw 12.332 0 Td
(9)Tj
/T1_0 1 Tf
-0.01 Tc 0.024 Tw -29.1 -1.524 Td
[(Biochemistr)-17.9 (y P)24 (arameters)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Hypophospha)-9.9 (temia)]TJ
0 Tc 0 Tw 15.743 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 11.857 0 Td
(31)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-28.862 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypokalemia)Tj
0 Tc 0 Tw 15.743 0 Td
(0)Tj
12.095 0 Td
(3)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypocalcemia)Tj
0 Tc 0 Tw 15.743 0 Td
(4)Tj
12.095 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGPT \(AL)94.1 (T\))]TJ
-0.005 Tc 0.005 Tw 15.445 0 Td
(<1)Tj
0 Tc 0 Tw 12.392 0 Td
(2)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGOT \(AST\))]TJ
-0.005 Tc 0.005 Tw 15.445 0 Td
(<1)Tj
0 Tc 0 Tw 12.392 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Bilirubin)]TJ
0 Tc 0 Tw 15.743 0 Td
(1)Tj
12.095 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.1 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Crea)-10 (tinine)]TJ
0 Tc 0 Tw 15.743 0 Td
(1)Tj
12.095 0 Td
(1)Tj
-0.005 Tc -0.022 Tw -29.1 -1.811 Td
[(CTC grades:)37 ( neutropenia \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.773 0 Td
(3 \0360.5\226<1.0 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 168.3716 129.7301 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 170.9366 126.9301 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.517 0 Td
(4 <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 228.2297 129.7301 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 230.7947 126.9301 Tm
[(/L\); thromboc)20 (ytopenia)-5 ( )]TJ
0.034 Tw -27.055 -1 Td
(\(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.63 0 Td
[(3 \03625\226<50 )0.5 (\327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 100.3503 121.7301 Tm
(9)Tj
-0.005 Tc 0.034 Tw 7.2 0 0 8 102.9152 118.9301 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.572 0 Td
[(4 <25 )0.5 (\327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 160.1055 121.7301 Tm
(9)Tj
-0.005 Tc 0.034 Tw 7.2 0 0 8 162.6705 118.9301 Tm
(/L\); anemia \(hemoglobin Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.573 0 Td
(3 \03665\226<80)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.461 0 Td
[(g/L,)32 ( )]TJ
-0.062 Tw -33.627 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
(4 <65)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.428 0 Td
[(g/L\); eleva)-10 (ted crea)-9.9 (tinine \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.474 0 Td
[(3 >3\2266 \327 upper limit of normal range \(ULN\),)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
18.225 0 Td
[(4)-5 ( )]TJ
0.073 Tw -34.52 -1 Td
[(>6 \327 ULN\); eleva)-10 (ted bilirubin \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
13.805 0 Td
[(3 >3\22610 \327 )0.5 (ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
8.911 0 Td
[(4 >10 \327 )0.5 (ULN\); eleva)-10 (ted )0.5 (SGOT or)-5 ( )]TJ
0.107 Tw -22.716 -1 Td
(SGPT \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.933 0 Td
[(3 >5\22620 \327 ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
9.048 0 Td
(4 >20 \327 ULN\); hypocalcemia \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
13.959 0 Td
(3 <7.0\2266.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.512 0 Td
[(mg/dL,)32 ( )]TJ
0.274 Tw -32.452 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
[(4 <6.0 mg/dL\); hypophospha)-10 (temia \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
16.662 0 Td
(3 <2.0\2261.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
4.679 0 Td
[(mg/dL,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.446 0 Td
(4 <1.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.999 0 Td
[(mg/dL\);)-5 ( )]TJ
0 Tw -32.179 -1 Td
(hypokalemia \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(3 <3.0\2262.5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mmol/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(4 <2.5 mmol/L\).)Tj
-0.01 Tc -0.024 Tw 8 0 0 8 36.0001 54.4917 Tm
[(Labora)-10 (tor)-18 (y abnormalities reported in pa)-9.9 (tients with CML resistant or intolerant to ima)-10 (tinib)-10 ( )]TJ
-0.026 Tw 0 -1.156 Td
[(who received the recommended starting doses of SPR)18 (YCEL are sho)-9.9 (wn by disease phase)-10 ( )]TJ
-0.037 Tw 0 -1.156 Td
[(in T)74 (able)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.964 0 Td
(13.)Tj
ET
0 0 0 0 k
/GS0 gs
324 732.96 252 -28.726 re
324 704.234 69.75 -20.912 re
393.75 704.234 63.45 -20.912 re
457.2 704.234 118.8 -20.912 re
324 683.322 69.75 -28.912 re
393.75 683.322 63.45 -28.912 re
457.2 683.322 39.84 -28.912 re
497.04 683.322 39.48 -28.912 re
536.52 683.322 39.48 -28.912 re
324 654.41 252 -13.635 re
324 640.775 69.75 -12.192 re
393.75 640.775 63.45 -12.192 re
457.2 640.775 39.84 -12.192 re
497.04 640.775 39.48 -12.192 re
536.52 640.775 39.48 -12.192 re
324 628.583 69.75 -12.192 re
393.75 628.583 63.45 -12.192 re
457.2 628.583 39.84 -12.192 re
497.04 628.583 39.48 -12.192 re
536.52 628.583 39.48 -12.192 re
324 616.391 69.75 -12.192 re
393.75 616.391 63.45 -12.192 re
457.2 616.391 39.84 -12.192 re
497.04 616.391 39.48 -12.192 re
536.52 616.391 39.48 -12.192 re
324 604.199 69.75 -12.192 re
393.75 604.199 63.45 -12.192 re
457.2 604.199 39.84 -12.192 re
497.04 604.199 39.48 -12.192 re
536.52 604.199 39.48 -12.192 re
324 592.007 69.75 -12.192 re
393.75 592.007 63.45 -12.192 re
457.2 592.007 39.84 -12.192 re
497.04 592.007 39.48 -12.192 re
536.52 592.007 39.48 -12.192 re
324 579.816 69.75 -12.192 re
393.75 579.816 63.45 -12.192 re
457.2 579.816 39.84 -12.192 re
497.04 579.816 39.48 -12.192 re
536.52 579.816 39.48 -12.192 re
324 567.624 69.75 -12.192 re
393.75 567.624 63.45 -12.192 re
457.2 567.624 39.84 -12.192 re
497.04 567.624 39.48 -12.192 re
536.52 567.624 39.48 -12.192 re
324 555.432 69.75 -12.192 re
393.75 555.432 63.45 -12.192 re
457.2 555.432 39.84 -12.192 re
497.04 555.432 39.48 -12.192 re
536.52 555.432 39.48 -12.192 re
324 543.24 69.75 -12.192 re
393.75 543.24 63.45 -12.192 re
457.2 543.24 39.84 -12.192 re
497.04 543.24 39.48 -12.192 re
536.52 543.24 39.48 -12.192 re
324 531.048 69.75 -12.192 re
393.75 531.048 63.45 -12.192 re
457.2 531.048 39.84 -12.192 re
497.04 531.048 39.48 -12.192 re
536.52 531.048 39.48 -12.192 re
324 518.856 69.75 -12.192 re
393.75 518.856 63.45 -12.192 re
457.2 518.856 39.84 -12.192 re
497.04 518.856 39.48 -12.192 re
536.52 518.856 39.48 -12.192 re
324 506.664 69.75 -12.192 re
393.75 506.664 63.45 -12.192 re
457.2 506.664 39.84 -12.192 re
497.04 506.664 39.48 -12.192 re
536.52 506.664 39.48 -12.192 re
324 494.472 252 -78.73 re
f
1 w 
/GS1 gs
q 1 0 0 1 324 704.2339 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 457.2 704.2339 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 704.2339 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 704.2339 cm
0 0 m
39.48 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 683.322 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 683.322 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 683.322 cm
0 0 m
39.48 0 l
S
Q
0.505 w 
q 1 0 0 1 457.2 654.4102 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 654.4102 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 654.4102 cm
0 0 m
39.48 0 l
S
Q
1 w 
q 1 0 0 1 393.75 704.2339 cm
0 0 m
63.45 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 683.572 cm
0 0 m
0 20.162 l
S
Q
q 1 0 0 1 393.75 683.322 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 654.6627 cm
0 0 m
0 28.409 l
S
Q
0.505 w 
q 1 0 0 1 393.75 654.4102 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 640.7751 cm
0 0 m
39.84 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 628.5833 cm
0 0 m
0 11.939 l
S
Q
q 1 0 0 1 457.2 616.3913 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 604.1994 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 579.8156 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 457.2 567.6237 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 555.4318 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 543.2398 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 531.0479 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 518.856 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 506.6641 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 457.2 494.9772 cm
0 0 m
0 11.687 l
S
Q
1.01 w 
q 1 0 0 1 457.2 494.4722 cm
0 0 m
39.84 0 l
S
Q
0.5 w 
q 1 0 0 1 457.2 592.2574 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 324 592.0074 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 592.0074 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 592.0074 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 592.0074 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 592.0074 cm
0 0 m
39.48 0 l
S
Q
1.01 w 
q 1 0 0 1 324 494.4722 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 494.4722 cm
0 0 m
63.45 0 l
S
Q
0.505 w 
q 1 0 0 1 324 415.7422 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 415.7422 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 457.2 415.7422 cm
0 0 m
39.84 0 l
S
Q
q 1 0 0 1 497.04 415.7422 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 415.7422 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 324 640.7751 cm
0 0 m
69.75 0 l
S
Q
q 1 0 0 1 393.75 640.7751 cm
0 0 m
63.45 0 l
S
Q
q 1 0 0 1 497.04 640.7751 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 640.7751 cm
0 0 m
39.48 0 l
S
Q
1.01 w 
q 1 0 0 1 497.04 494.4722 cm
0 0 m
39.48 0 l
S
Q
q 1 0 0 1 536.52 494.4722 cm
0 0 m
39.48 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.294 Tw 8 0 0 8 324 723.8699 Tm
[(Table )270 (13:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.691 0 Td
[(CTC )0.5 (Grade 3/4 Laboratory )0.5 (Abnormalities )0.5 (in Clinical Studies)-10 ( )]TJ
0.18 Tw 0 -1 Td
[(of CML in Adults: Resistance or Intolerance to Prior Imatinib)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Therapy)Tj
-0.015 Tc 0.024 Tw 7.2 0 0 8 398.3937 694.9221 Tm
(Chronic Phase CML)Tj
0 Tc 0 Tw 7.2 0 0 8 452.3063 694.9221 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 399.6789 686.9221 Tm
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
12.135 1 Td
(Advanced Phase CML)Tj
0 Tc 0 Tw 7.2 0 0 8 546.3958 694.9221 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 491.0539 686.9221 Tm
(140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw -10.632 -3.489 Td
(\(n=165\))Tj
6.486 2 Td
(Accelerated)Tj
0 Tc 0 Tw 7.2 0 0 8 493.7553 675.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 469.1029 667.0101 Tm
(Phase)Tj
0 Tc 0 Tw 7.2 0 0 8 485.857 667.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 466.637 659.0101 Tm
(\(n=157\))Tj
5.471 2 Td
(Myeloid)Tj
0 Tc 0 Tw 7.2 0 0 8 527.533 675.0101 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 500.6236 667.0101 Tm
(Blast Phase)Tj
0 Tc 0 Tw 7.2 0 0 8 532.9364 667.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 507.5929 659.0101 Tm
(\(n=74\))Tj
4.887 2 Td
[(Lymphoid)-20 ( )]TJ
0.024 Tw -0.371 -1 Td
(Blast Phase)Tj
0 Tc 0 Tw 7.2 0 0 8 572.4164 667.0101 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 547.073 659.0101 Tm
(\(n=33\))Tj
-0.01 Tc 0.024 Tw -17.955 -1.739 Td
[(P)24 (ercent \(%\) of P)24 (atients)]TJ
0.013 Tw -13.027 -1.659 Td
[(Hematolog)-10 (y P)24 (arameters*)]TJ
/T1_1 1 Tf
1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Neutropenia)Tj
-0.005 Tc 0.005 Tw 12.336 0 Td
(36)Tj
7.24 0 Td
(58)Tj
5.458 0 Td
(77)Tj
5.483 0 Td
(79)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Thromboc)20 (ytopenia)]TJ
-0.005 Tc 0.005 Tw 12.336 0 Td
(24)Tj
7.24 0 Td
(63)Tj
5.458 0 Td
(78)Tj
5.483 0 Td
(85)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Anemia)Tj
-0.005 Tc 0.005 Tw 12.336 0 Td
(13)Tj
7.24 0 Td
(47)Tj
5.458 0 Td
(74)Tj
5.483 0 Td
(52)Tj
/T1_0 1 Tf
-0.02 Tc 0.024 Tw -31.781 -1.524 Td
[(Biochemistr)-18 (y P)24 (arameters)]TJ
/T1_1 1 Tf
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Hypophospha)-9.9 (temia)]TJ
-0.005 Tc 0.005 Tw 12.336 0 Td
(10)Tj
7.24 0 Td
(13)Tj
5.458 0 Td
(12)Tj
5.483 0 Td
(18)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypokalemia)Tj
0 Tc 0 Tw 12.574 0 Td
(2)Tj
7.24 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 5.221 0 Td
(11)Tj
5.483 0 Td
(15)Tj
-0.01 Tc 1.033 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
(Hypocalcemia)Tj
-0.005 Tc 0.005 Tw 12.276 0 Td
(<1)Tj
0 Tc 0 Tw 7.538 0 Td
(4)Tj
5.458 0 Td
(9)Tj
-0.005 Tc 0.005 Tw 5.246 0 Td
(12)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.781 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGPT \(AL)94.1 (T\))]TJ
0 Tc 0 Tw 12.574 0 Td
(0)Tj
7.24 0 Td
(2)Tj
5.458 0 Td
(5)Tj
5.483 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.018 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted SGOT \(AST\))]TJ
-0.005 Tc 0.005 Tw 12.276 0 Td
(<1)Tj
0 Tc 0 Tw 7.538 0 Td
(0)Tj
5.458 0 Td
(4)Tj
5.483 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.018 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Bilirubin)]TJ
-0.005 Tc 0.005 Tw 12.276 0 Td
(<1)Tj
0 Tc 0 Tw 7.538 0 Td
(1)Tj
5.458 0 Td
(3)Tj
5.483 0 Td
(6)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.018 -1.524 Td
( )Tj
EMC 
1.262 0 Td
[(Eleva)-10 (ted Crea)-10 (tinine)]TJ
0 Tc 0 Tw 12.574 0 Td
(0)Tj
7.24 0 Td
(2)Tj
5.458 0 Td
(8)Tj
5.483 0 Td
(0)Tj
-0.005 Tc -0.022 Tw -32.018 -1.569 Td
[(CTC grades:)37 ( neutropenia \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.773 0 Td
(3 \0360.5\226<1.0 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 456.3716 487.9602 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 458.9366 485.1602 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.517 0 Td
(4 <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 516.2297 487.9602 Tm
(9)Tj
-0.005 Tc -0.022 Tw 7.2 0 0 8 518.7947 485.1602 Tm
[(/L\); thromboc)20 (ytopenia)-5 ( )]TJ
0.031 Tw -27.055 -1 Td
(\(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.63 0 Td
(3 \03625\226<50 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 388.2899 479.9602 Tm
(9)Tj
-0.005 Tc 0.031 Tw 7.2 0 0 8 390.8548 477.1602 Tm
[(/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
3.57 0 Td
(4 <25 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 447.9646 479.9602 Tm
(9)Tj
-0.005 Tc 0.031 Tw 7.2 0 0 8 450.5295 477.1602 Tm
(/L\); anemia \(hemoglobin Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.565 0 Td
[(3 \03665\226<80 g/L,)32 ( )]TJ
0.177 Tw -29.139 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
[(4 )0.6 (<65 )0.5 (g/L\); )0.6 (eleva)-10 (ted )0.5 (crea)-9.9 (tinine )0.5 (\(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
15.033 0 Td
[(3 )0.6 (>3\2266 )0.5 (\327 )0.6 (upper )0.5 (limit )0.5 (of )0.6 (normal )0.5 (range )0.6 (\(ULN\),)32 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576.0001 469.1602 Tm
( )Tj
-0.005 Tc 0.349 Tw 7.2 0 0 8 324.0001 461.1602 Tm
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
2.394 0 Td
[(4 >6 \327 ULN\); eleva)-10 (ted bilirubin \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
16.244 0 Td
[(3 >3\22610 \327 ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
10.016 0 Td
[(4 >10 \327 ULN\);)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576.0001 461.1602 Tm
( )Tj
-0.005 Tc 0.37 Tw 7.2 0 0 8 324.0001 453.1602 Tm
[(eleva)-10 (ted SGOT or SGPT \(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
12.855 0 Td
[(3 >5\22620 \327 ULN,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
10.101 0 Td
[(4 >20 \327 ULN\); hypocalcemia)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576.0001 453.1602 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 324.0001 445.1602 Tm
(\(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(3 )-45.6 (<7.0\2266.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg/dL,)36.9 ( )-45.6 (Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(4 )-45.7 (<6.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg/dL\); )-45.6 (hypophospha)-10 (temia )-45.7 (\(Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(3 )-45.7 (<2.0\2261.0)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg/dL,)32 ( )]TJ
0 -1 Td
(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(4 <1.0)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg/dL\); hypokalemia \(Grade)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(3 <3.0\2262.5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mmol/L,)37 ( Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(4 <2.5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mmol/L\).)Tj
-0.02 Tw 0 -1.227 Td
(* )Tj
/Span<</ActualText<FEFF0007>>> BDC 
0.582 0 Td
( )Tj
EMC 
T*
[(Hema)-9.9 (tolog)-10 (y parameters for 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
11.794 0 Td
[(mg once-daily dosing in chronic phase CML reflects 60-month)-5 ( )]TJ
0 Tw -11.794 -1 Td
[(minimum follo)-10 (w-up.)]TJ
0.072 Tw 8 0 0 8 324.0001 398.4897 Tm
[(Among adult pa)-10 (tients with chronic phase CML with resistance or intolerance to prior)-5 ( )]TJ
0.101 Tw 0 -1 Td
[(ima)-10 (tinib thera)-10 (py)55 (,)37 ( cumula)-9.9 (tive Grade 3 or 4 c)20 (ytopenias were similar a)-10 (t 2 and 5 years)-5 ( )]TJ
0.098 Tw 0 -1 Td
[(inc)20 (luding:)37 ( neutropenia \(36% )0.5 (vs 36%\),)36.9 ( )0.5 (thromboc)20 (ytopenia \(23% )0.5 (vs 24%\),)36.9 ( )0.5 (and )0.5 (anemia)-5 ( )]TJ
0 Tw 0 -1 Td
(\(13% vs 13%\).)Tj
0.063 Tw 0 -1.427 Td
[(In the pedia)-10 (tric studies in CML,)37 ( the ra)-10 (tes of labora)-9.9 (tor)-18 (y abnormalities were consistent)-5 ( )]TJ
0 Tw 0 -1 Td
[(with the kno)-9.9 (wn pro\037le for labora)-9.9 (tor)-18 (y parameters in adults.)]TJ
/T1_0 1 Tf
-0.01 Tc 0.257 Tw 0 -1.495 Td
[(Philadelphia Chromosome-P)24 (ositive Acute L)37 (ymphoblastic Leukemia \(Ph)]TJ
0 Tc 0 Tw 28.675 0.125 Td
(+)Tj
-0.01 Tc 0.257 Tw 0.59 -0.125 Td
[( ALL\))-10 ( )]TJ
0 Tc 0 Tw 2.235 0 Td
( )Tj
-0.01 Tc -31.5 -1 Td
(in Adults)Tj
/T1_1 1 Tf
-0.005 Tc -0.042 Tw 0 -1.292 Td
[(A total of 135 adult pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 12.756 0.125 Td
(+)Tj
-0.005 Tc -0.042 Tw 0.595 -0.125 Td
[( )37.3 (ALL were trea)-10 (ted with SPR)18 (YCEL in c)20 (linical studies.)32 ( )]TJ
0.048 Tw -13.351 -1 Td
[(The median dura)-10 (tion of trea)-10 (tment was 3 months \(range 0.03\22631 months\).)37 ( )37.1 (The safety)-4.9 ( )]TJ
0.043 Tw 0 -1 Td
[(pro\037le of pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 9.489 0.125 Td
(+)Tj
-0.005 Tc 0.043 Tw 0.595 -0.125 Td
[( )37.1 (ALL was similar to those with lymphoid blast phase CML.)32 ( )]TJ
0.084 Tw -10.084 -1 Td
[(The most frequently reported adverse reactions inc)20 (luded \035uid retention events,)37 ( such)-5 ( )]TJ
0.024 Tw 0 -1 Td
[(as pleural effusion \(24%\) and super\037cial edema \(19%\),)37 ( and gastrointestinal disorders,)32 ( )]TJ
0.243 Tw 0 -1 Td
[(such as diarrhea \(31%\),)37 ( nausea \(24%\),)37 ( and vomiting \(16%\).)37 ( Hemorrha)-10 (ge \(19%\),)32 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc 0.038 Tw -31.5 -1 Td
[(pyrexia \(17%\),)37 ( rash \(16%\),)37 ( and d)-10 (yspnea \(16%\) were also frequently reported.)37 ( Serious)-5 ( )]TJ
0.305 Tw 0 -1 Td
[(adverse reactions reported in \0365% of pa)-9.9 (tients inc)20 (luded pleural effusion \(11%\),)32.1 ( )]TJ
0 Tw 0 -1 Td
[(gastrointestinal bleeding \(7%\),)37 ( febrile neutropenia \(6%\),)37 ( and infection \(5%\).)]TJ
/T1_0 1 Tf
-0.01 Tc 0.084 Tw 0 -1.495 Td
[(Philadelphia Chromosome-P)24 (ositive Acute L)37 (ymphoblastic Leukemia \(Ph)]TJ
0 Tc 0 Tw 27.813 0.125 Td
(+)Tj
-0.01 Tc 0.084 Tw 0.59 -0.125 Td
[( ALL\) in)-10 ( )]TJ
0 Tw -28.403 -1 Td
[(P)24 (ediatric P)24 (atients)]TJ
/T1_1 1 Tf
0.252 Tw 0 -1.292 Td
[(The safety of SPR)18.1 (YCEL administered continuously in combina)-9.9 (tion with multia)-9.9 (gent)-10 ( )]TJ
-0.032 Tw 0 -1 Td
[(chemothera)-9.9 (py was determined in a multicohort stud)-9.9 (y of 81 pedia)-9.9 (tric pa)-9.9 (tients with newly)-10 ( )]TJ
0.071 Tw 0 -1 Td
[(dia)-9.9 (gnosed Ph)]TJ
0 Tc 0 Tw 4.94 0.125 Td
(+)Tj
-0.01 Tc 0.034 Tw 0.59 -0.125 Td
[( ALL.)37 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 2.117 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.071 Tw 0.397 0 Td
(ee Clinical Studie)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.071 Tw 6.728 0 Td
( \(14.4\)])Tj
/T1_1 1 Tf
[(.)37 ( )36.7 (The median dura)-10 (tion of thera)-10 (py was)-10 ( )]TJ
0 Tc 0 Tw 16.479 0 Td
( )Tj
-0.01 Tc -31.5 -1 Td
[(24 months \(range 2 to 27 months\).)27 ( )]TJ
0.016 Tw 0 -1.427 Td
[(F)20 (a)-10 (tal adverse reactions occurred in 3 pa)-9.9 (tients \(4%\),)37 ( all of which were due to infections.)27 ( )]TJ
-0.044 Tw 0 -1 Td
[(Eight \(10%\) pa)-9.9 (tients experienced adverse reactions leading to trea)-10 (tment discontinua)-9.9 (tion,)27 ( )]TJ
0.239 Tw 0 -1 Td
[(inc)20 (luding )0.5 (fungal )0.5 (sepsis,)37 ( )0.5 (hepa)-10 (totoxicity )0.5 (in )0.5 (the )0.5 (setting )0.5 (of )0.5 (graft )0.5 (versus )0.5 (host )0.6 (disease,)27 ( )]TJ
-0.066 Tw 0 -1 Td
[(thromboc)20 (ytopenia,)37 ( CMV infection,)37 ( pneumonia,)37 ( nausea,)37 ( enteritis and drug hypersensitivity)55 (.)27 ( )]TJ
0.127 Tw 0 -1.427 Td
[(The )0.6 (most )0.6 (common )0.5 (serious )0.6 (adverse )0.5 (reactions )0.5 (\(incidence )0.6 (\03610%\) )0.6 (were )0.6 (pyrexia,)37 ( )0.5 (febrile)-10 ( )]TJ
0.443 Tw 0 -1 Td
[(neutropenia,)37 ( mucositis,)37 ( diarrhea,)37 ( sepsis,)37 ( hypotension,)37 ( infections \(bacterial,)37 ( viral)-10 ( )]TJ
0.426 Tw 0 -1 Td
[(and )0.5 (fungal\),)37 ( hypersensitivity)55 (,)37 ( vomiting,)37 ( renal insuf\037cienc)20 (y)55.1 (,)36.9 ( )0.5 (abdominal )0.5 (pain,)37 ( )0.5 (and)-10 ( )]TJ
0 Tw 0 -1 Td
[(musculoskeletal pain.)27 ( )]TJ
0.071 Tw 0 -1.427 Td
[(The incidence of common adverse reactions \(incidence \03620%\) on stud)-10 (y are sho)-10 (wn in)-10 ( )]TJ
0 Tw 0 -1 Td
[(T)74 (able 14:)]TJ
ET
endstreamendobj5 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 105 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 25 0 R/GS1 23 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 5192>>/PageWidthList<</0 612.0>>>>>>>>endobj6 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 106 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 25 0 R/GS1 23 0 R/GS2 24 0 R>>/Font<</T1_0 107 0 R/T1_1 26 0 R/T1_2 27 0 R/T1_3 28 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 19653>>/PageWidthList<</0 612.0>>>>>>>>endobj7 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 108 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3912>>/PageWidthList<</0 612.0>>>>>>>>endobj8 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 109 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 25 0 R/GS2 24 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3929>>/PageWidthList<</0 612.0>>>>>>>>endobj9 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 110 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R/GS3 40 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00340062006300640036003200640039002D0033006500350033002D0034003900330061002D0061003300330064002D006400320034003500370031006400660062003700610039>/LastModified<FEFF0044003A00320030003200330030003200300037003100390032003400340030005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[17276.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[17299.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 3946>>/PageWidthList<</0 612.0>>>>>>>>endobj110 0 obj<</Length 47116>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 252 -25.312 re
36 707.648 81.72 -20.192 re
117.72 707.648 85.14 -20.192 re
202.86 707.648 85.14 -20.192 re
36 687.456 81.72 -12.192 re
117.72 687.456 42.57 -12.192 re
160.29 687.456 42.57 -12.192 re
202.86 687.456 42.57 -12.192 re
245.43 687.456 42.57 -12.192 re
36 675.264 81.72 -12.192 re
117.72 675.264 170.28 -12.192 re
36 663.072 81.72 -11.112 re
117.72 663.072 42.57 -11.112 re
160.29 663.072 42.57 -11.112 re
202.86 663.072 42.57 -11.112 re
245.43 663.072 42.57 -11.112 re
36 651.96 81.72 -11.112 re
117.72 651.96 42.57 -11.112 re
160.29 651.96 42.57 -11.112 re
202.86 651.96 42.57 -11.112 re
245.43 651.96 42.57 -11.112 re
36 640.849 81.72 -11.112 re
117.72 640.849 42.57 -11.112 re
160.29 640.849 42.57 -11.112 re
202.86 640.849 42.57 -11.112 re
245.43 640.849 42.57 -11.112 re
36 629.737 81.72 -11.112 re
117.72 629.737 42.57 -11.112 re
160.29 629.737 42.57 -11.112 re
202.86 629.737 42.57 -11.112 re
245.43 629.737 42.57 -11.112 re
36 618.625 81.72 -11.112 re
117.72 618.625 42.57 -11.112 re
160.29 618.625 42.57 -11.112 re
202.86 618.625 42.57 -11.112 re
245.43 618.625 42.57 -11.112 re
36 607.513 81.72 -11.112 re
117.72 607.513 42.57 -11.112 re
160.29 607.513 42.57 -11.112 re
202.86 607.513 42.57 -11.112 re
245.43 607.513 42.57 -11.112 re
36 596.401 81.72 -19.112 re
117.72 596.401 42.57 -19.112 re
160.29 596.401 42.57 -19.112 re
202.86 596.401 42.57 -19.112 re
245.43 596.401 42.57 -19.112 re
36 577.289 81.72 -11.112 re
117.72 577.289 42.57 -11.112 re
160.29 577.289 42.57 -11.112 re
202.86 577.289 42.57 -11.112 re
245.43 577.289 42.57 -11.112 re
36 566.177 81.72 -11.112 re
117.72 566.177 42.57 -11.112 re
160.29 566.177 42.57 -11.112 re
202.86 566.177 42.57 -11.112 re
245.43 566.177 42.57 -11.112 re
36 555.065 81.72 -11.112 re
117.72 555.065 42.57 -11.112 re
160.29 555.065 42.57 -11.112 re
202.86 555.065 42.57 -11.112 re
245.43 555.065 42.57 -11.112 re
36 543.953 81.72 -11.112 re
117.72 543.953 42.57 -11.112 re
160.29 543.953 42.57 -11.112 re
202.86 543.953 42.57 -11.112 re
245.43 543.953 42.57 -11.112 re
36 532.841 81.72 -11.112 re
117.72 532.841 42.57 -11.112 re
160.29 532.841 42.57 -11.112 re
202.86 532.841 42.57 -11.112 re
245.43 532.841 42.57 -11.112 re
36 521.729 81.72 -11.112 re
117.72 521.729 42.57 -11.112 re
160.29 521.729 42.57 -11.112 re
202.86 521.729 42.57 -11.112 re
245.43 521.729 42.57 -11.112 re
36 510.617 81.72 -11.112 re
117.72 510.617 42.57 -11.112 re
160.29 510.617 42.57 -11.112 re
202.86 510.617 42.57 -11.112 re
245.43 510.617 42.57 -11.112 re
36 499.505 81.72 -11.112 re
117.72 499.505 42.57 -11.112 re
160.29 499.505 42.57 -11.112 re
202.86 499.505 42.57 -11.112 re
245.43 499.505 42.57 -11.112 re
36 488.394 252 -38.712 re
f
0 0 0 1 K
/GS1 gs
q 1 0 0 1 202.86 707.6481 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 707.6481 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 675.2642 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 675.2642 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 36 488.3936 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 488.3936 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 488.3936 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 36 449.6817 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 449.6817 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 449.6817 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 449.6817 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 449.6817 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 117.72 707.6481 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 707.6481 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 202.86 687.7061 cm
0 0 m
0 19.442 l
S
Q
1 w 
q 1 0 0 1 36 707.6481 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 117.72 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 117.72 675.2642 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 36 663.0723 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 117.72 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 160.29 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 651.9604 cm
0 0 m
0 10.862 l
S
Q
q 1 0 0 1 245.43 663.0723 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 640.8485 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 629.7366 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 618.6246 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 596.4008 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 577.2889 cm
0 0 m
0 19.112 l
S
Q
q 1 0 0 1 202.86 566.177 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 555.0651 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 543.9532 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 532.8412 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 521.7294 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 510.6174 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 499.5055 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 202.86 488.8936 cm
0 0 m
0 10.612 l
S
Q
1 w 
q 1 0 0 1 202.86 488.3936 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 245.43 488.3936 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 160.29 687.4561 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 675.5142 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 160.29 675.2642 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 202.86 607.5128 cm
0 0 m
0 11.112 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.01 Tc 0.248 Tw 8 0 0 8 36 727.248 Tm
[(Table )224 (7:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-10 ( )]TJ
0.154 Tw 0 -1 Td
[(Newly Diagnosed Chronic Phase CML in the SPR)40 (Y)40 (CEL-T)40 (reated)-10 ( )]TJ
0.024 Tw 0 -1 Td
[(Arm \(n=25)20 (8\))]TJ
-0.02 Tc 7.2 0 0 8 134.0259 698.6961 Tm
(Minimum of 1)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(Year)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 187.9168 698.6961 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 146.424 690.6961 Tm
(Follow-up)Tj
0.024 Tw 9.926 1 Td
(Minimum of 5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(Years)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 274.8331 698.6961 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 231.814 690.6961 Tm
(Follow-up)Tj
0.024 Tw -14.839 -1.524 Td
(All Grades)Tj
5.979 0 Td
(Grade 3/4)Tj
5.863 0 Td
(All Grades)Tj
5.979 0 Td
(Grade 3/4)Tj
-0.01 Tc -30.179 -1.524 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 18.788 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -18.788 -1.456 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(19)Tj
0 Tc 0 Tw 6.133 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(38)Tj
0 Tc 0 Tw 6.15 0 Td
(5)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 12.579 0 Td
(10)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(28)Tj
0 Tc 0 Tw 6.15 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Superficial localized edema)Tj
0 Tc 0 Tw 12.816 0 Td
(9)Tj
5.895 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y hypertension)]TJ
0 Tc 0 Tw 12.816 0 Td
(1)Tj
5.895 0 Td
(0)Tj
6.18 0 Td
(5)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 12.816 0 Td
(2)Tj
5.895 0 Td
(0)Tj
6.18 0 Td
(4)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 12.816 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(4)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Congestive heart failure/)Tj
0 Tc 0 Tw 7.2 0 0 8 108.6389 587.9889 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF00090009>>> BDC 
7.2 0 0 8 36 579.9889 Tm
[( )-996 ( )]TJ
EMC 
2.083 0 Td
[(cardiac d)-10 (ysfunction)]TJ
0 Tc 0 Tw 5.4 0 0 6 101.7155 582.7889 Tm
(a)Tj
7.2 0 0 8 137.277 583.9889 Tm
(2)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -1.889 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y edema)]TJ
-0.005 Tc 0.005 Tw 12.519 0 Td
(<1)Tj
0 Tc 0 Tw 6.193 0 Td
(0)Tj
6.18 0 Td
(1)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(17)Tj
5.835 0 Td
(<1)Tj
6.24 0 Td
(22)Tj
0 Tc 0 Tw 6.15 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -32.054 -1.389 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(11)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
(Rash)Tj
0 Tc 0 Tw 5.4 0 0 6 48.9094 538.3412 Tm
(b)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 135.5671 535.5413 Tm
(11)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(12)Tj
0 Tc 0 Tw 6.133 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(14)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.054 -1.389 Td
(Abdominal pain)Tj
0 Tc 0 Tw 14.066 0 Td
(7)Tj
5.895 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(11)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.389 Td
[(F)20 (a)-10 (tigue)]TJ
0 Tc 0 Tw 14.066 0 Td
(8)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
6.24 0 Td
(11)Tj
5.853 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.389 Td
(Nausea)Tj
0 Tc 0 Tw 14.066 0 Td
(8)Tj
5.895 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.942 0 Td
(10)Tj
0 Tc 0 Tw 6.15 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 36.0001 481.8817 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.047 Tw 7.2 0 0 8 41.0001 479.0817 Tm
[(Inc)20 (ludes cardiac failure acute,)37 ( cardiac failure congestive,)37 ( cardiomyopa)-10 (thy)55 (,)37 ( diastolic d)-10 (ysfunction,)32 ( )]TJ
0 Tw 0 -1 Td
[(ejection fraction decreased,)36.9 ( and left ventricular d)-10 (ysfunction.)]TJ
0.005 Tw 5.4 0 0 6 36.0001 464.0817 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.074 Tw 7.2 0 0 8 41.0001 461.2817 Tm
[(Inc)20 (ludes er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( rash,)37 ( rash generalized,)37 ( rash macular)74 (,)37 ( rash pa)-9.9 (pular)74 (,)32 ( )]TJ
0 Tw 0 -1 Td
[(rash pustular)74 (,)37 ( skin exfolia)-10 (tion,)37 ( and rash vesicular)74 (.)]TJ
-0.01 Tc 0.194 Tw 8 0 0 8 36.0001 434.3896 Tm
[(At 60 months,)37 ( there were 26 dea)-10 (ths in dasa)-10 (tinib-trea)-10 (ted pa)-10 (tients \(10.1%\) and 26)-10 ( )]TJ
0.107 Tw 0 -1.025 Td
[(dea)-9.9 (ths in ima)-10 (tinib-trea)-9.9 (ted pa)-9.9 (tients \(10.1%\); 1 dea)-9.9 (th in each group was assessed by)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.025 Td
[(the investiga)-10 (tor as rela)-9.9 (ted to stud)-10 (y thera)-9.9 (py)55 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 407.704 252 -25.312 re
36 382.392 95.4 -12.192 re
131.4 382.392 156.6 -12.192 re
36 370.2 95.4 -20.192 re
131.4 370.2 156.6 -20.192 re
36 350.008 95.4 -12.192 re
131.4 350.008 78.3 -12.192 re
209.7 350.008 78.3 -12.192 re
36 337.816 95.4 -12.192 re
131.4 337.816 156.6 -12.192 re
36 325.624 95.4 -11.112 re
131.4 325.624 78.3 -11.112 re
209.7 325.624 78.3 -11.112 re
36 314.512 95.4 -11.112 re
131.4 314.512 78.3 -11.112 re
209.7 314.512 78.3 -11.112 re
36 303.4 95.4 -11.112 re
131.4 303.4 78.3 -11.112 re
209.7 303.4 78.3 -11.112 re
36 292.288 95.4 -11.112 re
131.4 292.288 78.3 -11.112 re
209.7 292.288 78.3 -11.112 re
36 281.176 95.4 -11.112 re
131.4 281.176 78.3 -11.112 re
209.7 281.176 78.3 -11.112 re
36 270.064 95.4 -11.112 re
131.4 270.064 78.3 -11.112 re
209.7 270.064 78.3 -11.112 re
36 258.953 95.4 -11.112 re
131.4 258.953 78.3 -11.112 re
209.7 258.953 78.3 -11.112 re
36 247.841 95.4 -11.112 re
131.4 247.841 78.3 -11.112 re
209.7 247.841 78.3 -11.112 re
36 236.729 95.4 -11.112 re
131.4 236.729 78.3 -11.112 re
209.7 236.729 78.3 -11.112 re
36 225.617 95.4 -11.112 re
131.4 225.617 78.3 -11.112 re
209.7 225.617 78.3 -11.112 re
36 214.505 95.4 -11.112 re
131.4 214.505 78.3 -11.112 re
209.7 214.505 78.3 -11.112 re
36 203.393 95.4 -11.112 re
131.4 203.393 78.3 -11.112 re
209.7 203.393 78.3 -11.112 re
36 192.281 95.4 -11.112 re
131.4 192.281 78.3 -11.112 re
209.7 192.281 78.3 -11.112 re
36 181.169 95.4 -11.112 re
131.4 181.169 78.3 -11.112 re
209.7 181.169 78.3 -11.112 re
36 170.057 95.4 -11.112 re
131.4 170.057 78.3 -11.112 re
209.7 170.057 78.3 -11.112 re
36 158.945 95.4 -19.112 re
131.4 158.945 78.3 -19.112 re
209.7 158.945 78.3 -19.112 re
36 139.833 95.4 -11.112 re
131.4 139.833 78.3 -11.112 re
209.7 139.833 78.3 -11.112 re
36 128.721 95.4 -11.112 re
131.4 128.721 78.3 -11.112 re
209.7 128.721 78.3 -11.112 re
36 117.61 95.4 -11.112 re
131.4 117.61 78.3 -11.112 re
209.7 117.61 78.3 -11.112 re
36 106.498 95.4 -11.112 re
131.4 106.498 78.3 -11.112 re
209.7 106.498 78.3 -11.112 re
36 95.386 95.4 -11.112 re
131.4 95.386 78.3 -11.112 re
209.7 95.386 78.3 -11.112 re
36 84.274 95.4 -11.112 re
131.4 84.274 78.3 -11.112 re
209.7 84.274 78.3 -11.112 re
36 73.162 252 -36.912 re
f
/GS1 gs
q 1 0 0 1 209.7001 325.624 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 314.5121 cm
0 0 m
0 10.862 l
S
Q
q 1 0 0 1 209.7001 303.4001 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 292.2882 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 281.1763 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 270.0644 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 258.9525 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 247.8406 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 236.7287 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 225.6168 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 214.5048 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 203.3929 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 192.281 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 181.1691 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 170.0572 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 139.8333 cm
0 0 m
0 19.112 l
S
Q
q 1 0 0 1 209.7001 128.7214 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 117.6095 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 106.4976 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 95.3857 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 84.2738 cm
0 0 m
0 11.112 l
S
Q
q 1 0 0 1 209.7001 73.6619 cm
0 0 m
0 10.612 l
S
Q
1 w 
q 1 0 0 1 209.7001 73.1619 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 209.7001 350.0078 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 338.0659 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 209.7001 337.8159 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 158.9453 cm
0 0 m
0 11.112 l
S
Q
1 w 
q 1 0 0 1 36.0001 73.1619 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4001 73.1619 cm
0 0 m
78.3 0 l
S
Q
0.5 w 
q 1 0 0 1 36.0001 36.25 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4001 36.25 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 36.25 cm
0 0 m
78.3 0 l
S
Q
1 w 
q 1 0 0 1 131.4001 382.3916 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 382.3916 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 36.0001 382.3916 cm
0 0 m
95.4 0 l
S
Q
0.5 w 
q 1 0 0 1 131.4001 370.1997 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 209.7001 370.1997 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 131.4001 350.0078 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 131.4001 337.8159 cm
0 0 m
78.3 0 l
S
Q
q 1 0 0 1 36.0001 325.624 cm
0 0 m
95.4 0 l
S
Q
q 1 0 0 1 131.4001 325.624 cm
0 0 m
78.3 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
0.248 Tw 8 0 0 8 36.0001 401.9916 Tm
[(Table )224 (8:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-10 ( )]TJ
0.25 Tw 0 -1 Td
[(Chronic Phase CML Resistant or Intolerant to Prior Imatinib)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Therapy \(minimum of 84 months follow-up\))Tj
-0.02 Tc 7.2 0 0 8 184.029 373.4397 Tm
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw 2.099 -1.524 Td
(Chronic)Tj
0 Tc 0 Tw 7.2 0 0 8 220.2588 361.2478 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 198.8571 353.2478 Tm
(\(n=165\))Tj
0.024 Tw -5.897 -1.524 Td
(All Grades)Tj
10.994 0 Td
(Grade 3/4)Tj
-0.01 Tc -27.715 -1.524 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 19.738 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -19.738 -1.456 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(48)Tj
0 Tc 0 Tw 11.38 0 Td
(7)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Superficial localized edema)Tj
-0.005 Tc 0.005 Tw 16.943 0 Td
(22)Tj
0 Tc 0 Tw 11.38 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 16.943 0 Td
(28)Tj
0 Tc 0 Tw 11.38 0 Td
(5)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 17.18 0 Td
(4)Tj
11.142 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 17.18 0 Td
(3)Tj
11.142 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y hypertension)]TJ
0 Tc 0 Tw 17.18 0 Td
(2)Tj
11.142 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(33)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(28)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(26)Tj
0 Tc 0 Tw 11.38 0 Td
(4)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Dyspnea)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(24)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.024 Tw -29.573 -1.389 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(22)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(18)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.573 -1.389 Td
(Skin rash)Tj
0 Tc 0 Tw 5.4 0 0 6 60.4436 186.6691 Tm
(a)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 166.9872 183.8691 Tm
(18)Tj
0 Tc 0 Tw 11.38 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(My)-10 (algia)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(13)Tj
0 Tc 0 Tw 11.38 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Arthralgia)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(13)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.573 -1.389 Td
[(Infection \(inc)20 (luding bacterial,)37 ( viral,)27 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 126.3578 150.5334 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 36.0001 142.5334 Tm
( )Tj
EMC 
1.25 0 Td
[(fungal,)37 ( and non-specified\))]TJ
-0.005 Tc 0.005 Tw 16.943 0.5 Td
(13)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -29.573 -1.889 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(12)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(Hemorrha)-9.9 (ge)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(12)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.573 -1.389 Td
( )Tj
EMC 
1.25 0 Td
(Gastrointestinal bleeding)Tj
0 Tc 0 Tw 17.18 0 Td
(2)Tj
11.142 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
(Pruritus)Tj
-0.005 Tc 0.005 Tw 18.193 0 Td
(12)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(P)18 (ain)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(11)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -29.573 -1.389 Td
[(Constipa)-10 (tion)]TJ
-0.005 Tc 0.005 Tw 18.193 0 Td
(10)Tj
0 Tc 0 Tw 11.38 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 36.0001 66.6499 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.046 Tw 7.2 0 0 8 41.0001 63.8499 Tm
[(Inc)20 (ludes drug eruption,)37 ( er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( er)-18 (ythrosis,)37 ( exfolia)-9.9 (tive rash,)37 ( generalized)-5 ( )]TJ
0.318 Tw 0 -1 Td
[(er)-18 (ythema,)37 ( )0.5 (genital )0.5 (rash,)37 ( )0.5 (hea)-9.9 (t )0.5 (rash,)37 ( )0.5 (milia,)37 ( )0.5 (rash,)37 ( )0.5 (rash )0.5 (er)-18 (ythema)-9.9 (tous,)37 ( )0.5 (rash )0.5 (follicular)74 (,)37 ( )0.5 (rash)-5 ( )]TJ
0.046 Tw 0 -1 Td
[(generalized,)36.9 ( rash macular)74 (,)37 ( rash maculopa)-10 (pular)74 (,)37 ( rash pa)-9.9 (pular)73.9 (,)37.1 ( rash pruritic,)37 ( rash pustular)74 (,)37 ( skin)-5 ( )]TJ
0 Tw 0 -1 Td
[(exfolia)-9.9 (tion,)37 ( skin irrita)-10 (tion,)37 ( urticaria vesiculosa,)36.9 ( and rash vesicular)74 (.)]TJ
-0.01 Tc 0.015 Tw 8 0 0 8 324 727.248 Tm
[(Cumula)-10 (tive ra)-9.9 (tes of selected adverse reactions tha)-10 (t were reported over time in pa)-10 (tients)-10 ( )]TJ
0.021 Tw 0 -1.024 Td
[(trea)-10 (ted with the 100 mg once daily recommended starting dose in a randomized\ dose-)]TJ
-0.024 Tw 0 -1.024 Td
[(optimiza)-10 (tion trial of ima)-10 (tinib-resistant or -intolerant pa)-10 (tients with chronic phase CML are)-9.9 ( )]TJ
0 Tw 0 -1.024 Td
[(sho)-10 (wn in )37 (T)74 (able 9.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 692.407 252 -17.312 re
324 675.095 65.88 -20.912 re
389.88 675.095 62.04 -20.912 re
451.92 675.095 62.04 -20.912 re
513.96 675.095 62.04 -20.912 re
324 654.183 65.88 -21.57 re
389.88 654.183 31.02 -21.57 re
420.9 654.183 31.02 -21.57 re
451.92 654.183 31.02 -21.57 re
482.94 654.183 31.02 -21.57 re
513.96 654.183 31.02 -21.57 re
544.98 654.183 31.02 -21.57 re
324 632.613 65.88 -13.5 re
389.88 632.613 186.12 -13.5 re
324 619.113 65.88 -11.472 re
389.88 619.113 31.02 -11.472 re
420.9 619.113 31.02 -11.472 re
451.92 619.113 31.02 -11.472 re
482.94 619.113 31.02 -11.472 re
513.96 619.113 31.02 -11.472 re
544.98 619.113 31.02 -11.472 re
324 607.641 65.88 -11.472 re
389.88 607.641 31.02 -11.472 re
420.9 607.641 31.02 -11.472 re
451.92 607.641 31.02 -11.472 re
482.94 607.641 31.02 -11.472 re
513.96 607.641 31.02 -11.472 re
544.98 607.641 31.02 -11.472 re
324 596.169 65.88 -11.472 re
389.88 596.169 31.02 -11.472 re
420.9 596.169 31.02 -11.472 re
451.92 596.169 31.02 -11.472 re
482.94 596.169 31.02 -11.472 re
513.96 596.169 31.02 -11.472 re
544.98 596.169 31.02 -11.472 re
324 584.697 65.88 -11.472 re
389.88 584.697 31.02 -11.472 re
420.9 584.697 31.02 -11.472 re
451.92 584.697 31.02 -11.472 re
482.94 584.697 31.02 -11.472 re
513.96 584.697 31.02 -11.472 re
544.98 584.697 31.02 -11.472 re
324 573.225 65.88 -11.472 re
389.88 573.225 31.02 -11.472 re
420.9 573.225 31.02 -11.472 re
451.92 573.225 31.02 -11.472 re
482.94 573.225 31.02 -11.472 re
513.96 573.225 31.02 -11.472 re
544.98 573.225 31.02 -11.472 re
324 561.753 65.88 -11.472 re
389.88 561.753 31.02 -11.472 re
420.9 561.753 31.02 -11.472 re
451.92 561.753 31.02 -11.472 re
482.94 561.753 31.02 -11.472 re
513.96 561.753 31.02 -11.472 re
544.98 561.753 31.02 -11.472 re
324 550.282 65.88 -19.472 re
389.88 550.282 31.02 -19.472 re
420.9 550.282 31.02 -19.472 re
451.92 550.282 31.02 -19.472 re
482.94 550.282 31.02 -19.472 re
513.96 550.282 31.02 -19.472 re
544.98 550.282 31.02 -19.472 re
324 530.81 65.88 -11.472 re
389.88 530.81 31.02 -11.472 re
420.9 530.81 31.02 -11.472 re
451.92 530.81 31.02 -11.472 re
482.94 530.81 31.02 -11.472 re
513.96 530.81 31.02 -11.472 re
544.98 530.81 31.02 -11.472 re
324 519.338 65.88 -19.472 re
389.88 519.338 31.02 -19.472 re
420.9 519.338 31.02 -19.472 re
451.92 519.338 31.02 -19.472 re
482.94 519.338 31.02 -19.472 re
513.96 519.338 31.02 -19.472 re
544.98 519.338 31.02 -19.472 re
324 499.866 252 -20.912 re
f
1 w 
/GS1 gs
q 1 0 0 1 389.88 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 675.095 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 451.92 654.433 cm
0 0 m
0 20.162 l
S
Q
q 1 0 0 1 389.88 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 632.863 cm
0 0 m
0 21.07 l
S
Q
q 1 0 0 1 482.94 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 632.863 cm
0 0 m
0 21.07 l
S
Q
q 1 0 0 1 389.88 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 632.613 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 324 619.113 cm
0 0 m
65.88 0 l
S
Q
q 1 0 0 1 389.88 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 607.6411 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 451.92 596.1692 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 584.6973 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 573.2253 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 561.7535 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 550.2816 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 530.8096 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 451.92 519.3377 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 451.92 500.3658 cm
0 0 m
0 18.972 l
S
Q
1 w 
q 1 0 0 1 420.9 499.8658 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 513.96 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 654.183 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 607.6411 cm
0 0 m
0 11.222 l
S
Q
q 1 0 0 1 544.98 619.113 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 596.1692 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 584.6973 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 573.2253 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 561.7535 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 550.2816 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 530.8096 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 513.96 519.3377 cm
0 0 m
0 11.472 l
S
Q
q 1 0 0 1 513.96 500.3658 cm
0 0 m
0 18.972 l
S
Q
1 w 
q 1 0 0 1 513.96 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 324 499.8658 cm
0 0 m
65.88 0 l
S
Q
q 1 0 0 1 389.88 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 499.8658 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 499.8658 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 324 478.9539 cm
0 0 m
65.88 0 l
S
Q
q 1 0 0 1 389.88 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 420.9 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 451.92 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 513.96 478.9539 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 544.98 478.9539 cm
0 0 m
31.02 0 l
S
Q
1 w 
q 1 0 0 1 451.92 675.095 cm
0 0 m
31.02 0 l
S
Q
q 1 0 0 1 482.94 675.095 cm
0 0 m
31.02 0 l
S
Q
0.5 w 
q 1 0 0 1 513.96 654.433 cm
0 0 m
0 20.162 l
S
Q
1 w 
q 1 0 0 1 324 675.095 cm
0 0 m
65.88 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.018 Tw 8 0 0 8 324 686.6949 Tm
[(Table )-42 (9:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Selected Adverse Reactions Reported in Adult Dose Optimization)-10 ( )]TJ
0.024 Tw 0 -1 Td
(Trial \(Imatinib-Intolerant or -Resistant Chronic Phase CML\))Tj
0 Tc 0 Tw 6 0 0 6 560.6205 681.4949 Tm
(a)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 404.2297 665.783 Tm
[(Minimum of)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 438.9331 665.783 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 395.9139 657.783 Tm
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years Follow-up)Tj
9.789 1 Td
[(Minimum of)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 501.0981 665.783 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 458.0789 657.783 Tm
(5)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years Follow-up)Tj
9.789 1 Td
[(Minimum of)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 563.2631 665.783 Tm
( )Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 520.2439 657.783 Tm
(7)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(Years Follow-up)Tj
0.02 Tw -16.45 -1.655 Td
(All)Tj
0 Tc 0 Tw 7.2 0 0 8 408.9755 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 395.753 636.5421 Tm
(Grades)Tj
4.503 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 446.0084 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 431.7779 636.5421 Tm
(3/4)Tj
4.471 1 Td
(All)Tj
0 Tc 0 Tw 7.2 0 0 8 471.1405 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 457.9179 636.5421 Tm
(Grades)Tj
4.486 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 508.0484 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 493.8179 636.5421 Tm
(3/4)Tj
4.471 1 Td
(All)Tj
0 Tc 0 Tw 7.2 0 0 8 533.1805 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 519.958 636.5421 Tm
(Grades)Tj
4.503 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 570.2134 644.5421 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 555.9828 636.5421 Tm
(3/4)Tj
-0.01 Tc 0.024 Tw -32.22 -1.692 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 17.688 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -17.688 -1.561 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 10.827 0 Td
(27)Tj
0 Tc 0 Tw 4.528 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(28)Tj
0 Tc 0 Tw 4.511 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(28)Tj
0 Tc 0 Tw 4.546 0 Td
(2)Tj
-0.01 Tc 0.024 Tw -32.856 -1.434 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 10.827 0 Td
(34)Tj
0 Tc 0 Tw 4.528 0 Td
(4)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(42)Tj
0 Tc 0 Tw 4.511 0 Td
(6)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(48)Tj
0 Tc 0 Tw 4.546 0 Td
(7)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(Superficial edema)Tj
-0.005 Tc 0.005 Tw 9.577 0 Td
(18)Tj
0 Tc 0 Tw 4.528 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(21)Tj
0 Tc 0 Tw 4.511 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(22)Tj
0 Tc 0 Tw 4.546 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 9.577 0 Td
(18)Tj
0 Tc 0 Tw 4.528 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(24)Tj
0 Tc 0 Tw 4.511 0 Td
(4)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(28)Tj
0 Tc 0 Tw 4.546 0 Td
(5)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 9.814 0 Td
(3)Tj
4.291 0 Td
(0)Tj
4.343 0 Td
(4)Tj
4.274 0 Td
(0)Tj
4.576 0 Td
(4)Tj
4.308 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 9.814 0 Td
(2)Tj
4.291 0 Td
(1)Tj
4.343 0 Td
(2)Tj
4.274 0 Td
(1)Tj
4.576 0 Td
(3)Tj
4.308 0 Td
(1)Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
[(Pulmonar)-17.9 (y)]TJ
0 Tc 0 Tw 7.2 0 0 8 360.7984 541.6896 Tm
( )Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 324 533.6896 Tm
( )Tj
EMC 
(hypertension)Tj
0 Tc 0 Tw 11.064 0.5 Td
(0)Tj
4.291 0 Td
(0)Tj
4.343 0 Td
(0)Tj
4.274 0 Td
(0)Tj
4.576 0 Td
(2)Tj
4.308 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -32.856 -1.934 Td
[(Hemorrha)-9.9 (ge)]TJ
-0.005 Tc 0.005 Tw 10.827 0 Td
(11)Tj
0 Tc 0 Tw 4.528 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 4.106 0 Td
(11)Tj
0 Tc 0 Tw 4.511 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 4.338 0 Td
(12)Tj
0 Tc 0 Tw 4.546 0 Td
(1)Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.856 -1.434 Td
( )Tj
EMC 
[(Gastrointestinal)-9.9 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 374.9891 510.7458 Tm
( )Tj
-0.01 Tc 1.02 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 324 502.7458 Tm
( )Tj
EMC 
(bleeding)Tj
0 Tc 0 Tw 11.064 0.5 Td
(2)Tj
4.291 0 Td
(1)Tj
4.343 0 Td
(2)Tj
4.274 0 Td
(1)Tj
4.576 0 Td
(2)Tj
4.308 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.4 0 0 6 324 493.3539 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.175 Tw 7.2 0 0 8 329 490.5539 Tm
[(Randomized dose-optimiza)-10 (tion trial results reported in the recommended starting dose of)-5 ( )]TJ
0 Tw 0 -1 Td
(100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily \(n=165\) popula)-10 (tion.)]TJ
ET
0 0 0 0 k
/GS0 gs
324.062 465.014 251.937 -25.312 re
324.062 439.702 88.497 -12.912 re
412.56 439.702 163.44 -12.912 re
324.062 426.79 88.497 -20.912 re
412.56 426.79 54.48 -20.912 re
467.04 426.79 54.48 -20.912 re
521.52 426.79 54.48 -20.912 re
324.062 405.878 88.497 -20.912 re
412.56 405.878 27.24 -20.912 re
439.8 405.878 27.24 -20.912 re
467.04 405.878 27.24 -20.912 re
494.28 405.878 27.24 -20.912 re
521.52 405.878 27.24 -20.912 re
548.76 405.878 27.24 -20.912 re
324.062 384.966 88.497 -12.912 re
412.56 384.966 163.44 -12.912 re
324.062 372.054 88.497 -11.902 re
412.56 372.054 27.24 -11.902 re
439.8 372.054 27.24 -11.902 re
467.04 372.054 27.24 -11.902 re
494.28 372.054 27.24 -11.902 re
521.52 372.054 27.24 -11.902 re
548.76 372.054 27.24 -11.902 re
324.062 360.152 88.497 -11.652 re
412.56 360.152 27.24 -11.652 re
439.8 360.152 27.24 -11.652 re
467.04 360.152 27.24 -11.652 re
494.28 360.152 27.24 -11.652 re
521.52 360.152 27.24 -11.652 re
548.76 360.152 27.24 -11.652 re
324.062 348.5 88.497 -11.652 re
412.56 348.5 27.24 -11.652 re
439.8 348.5 27.24 -11.652 re
467.04 348.5 27.24 -11.652 re
494.28 348.5 27.24 -11.652 re
521.52 348.5 27.24 -11.652 re
548.76 348.5 27.24 -11.652 re
324.062 336.848 88.497 -11.652 re
412.56 336.848 27.24 -11.652 re
439.8 336.848 27.24 -11.652 re
467.04 336.848 27.24 -11.652 re
494.28 336.848 27.24 -11.652 re
521.52 336.848 27.24 -11.652 re
548.76 336.848 27.24 -11.652 re
324.062 325.196 88.497 -11.652 re
412.56 325.196 27.24 -11.652 re
439.8 325.196 27.24 -11.652 re
467.04 325.196 27.24 -11.652 re
494.28 325.196 27.24 -11.652 re
521.52 325.196 27.24 -11.652 re
548.76 325.196 27.24 -11.652 re
324.062 313.544 88.497 -19.652 re
412.56 313.544 27.24 -19.652 re
439.8 313.544 27.24 -19.652 re
467.04 313.544 27.24 -19.652 re
494.28 313.544 27.24 -19.652 re
521.52 313.544 27.24 -19.652 re
548.76 313.544 27.24 -19.652 re
324.062 293.893 88.497 -11.652 re
412.56 293.893 27.24 -11.652 re
439.8 293.893 27.24 -11.652 re
467.04 293.893 27.24 -11.652 re
494.28 293.893 27.24 -11.652 re
521.52 293.893 27.24 -11.652 re
548.76 293.893 27.24 -11.652 re
324.062 282.241 88.497 -11.652 re
412.56 282.241 27.24 -11.652 re
439.8 282.241 27.24 -11.652 re
467.04 282.241 27.24 -11.652 re
494.28 282.241 27.24 -11.652 re
521.52 282.241 27.24 -11.652 re
548.76 282.241 27.24 -11.652 re
324.062 270.589 88.497 -11.652 re
412.56 270.589 27.24 -11.652 re
439.8 270.589 27.24 -11.652 re
467.04 270.589 27.24 -11.652 re
494.28 270.589 27.24 -11.652 re
521.52 270.589 27.24 -11.652 re
548.76 270.589 27.24 -11.652 re
324.062 258.937 88.497 -11.652 re
412.56 258.937 27.24 -11.652 re
439.8 258.937 27.24 -11.652 re
467.04 258.937 27.24 -11.652 re
494.28 258.937 27.24 -11.652 re
521.52 258.937 27.24 -11.652 re
548.76 258.937 27.24 -11.652 re
324.062 247.285 88.497 -11.652 re
412.56 247.285 27.24 -11.652 re
439.8 247.285 27.24 -11.652 re
467.04 247.285 27.24 -11.652 re
494.28 247.285 27.24 -11.652 re
521.52 247.285 27.24 -11.652 re
548.76 247.285 27.24 -11.652 re
324.062 235.633 88.497 -11.652 re
412.56 235.633 27.24 -11.652 re
439.8 235.633 27.24 -11.652 re
467.04 235.633 27.24 -11.652 re
494.28 235.633 27.24 -11.652 re
521.52 235.633 27.24 -11.652 re
548.76 235.633 27.24 -11.652 re
324.062 223.981 88.497 -11.652 re
412.56 223.981 27.24 -11.652 re
439.8 223.981 27.24 -11.652 re
467.04 223.981 27.24 -11.652 re
494.28 223.981 27.24 -11.652 re
521.52 223.981 27.24 -11.652 re
548.76 223.981 27.24 -11.652 re
324.062 212.329 88.497 -11.652 re
412.56 212.329 27.24 -11.652 re
439.8 212.329 27.24 -11.652 re
467.04 212.329 27.24 -11.652 re
494.28 212.329 27.24 -11.652 re
521.52 212.329 27.24 -11.652 re
548.76 212.329 27.24 -11.652 re
324.062 200.677 88.497 -11.652 re
412.56 200.677 27.24 -11.652 re
439.8 200.677 27.24 -11.652 re
467.04 200.677 27.24 -11.652 re
494.28 200.677 27.24 -11.652 re
521.52 200.677 27.24 -11.652 re
548.76 200.677 27.24 -11.652 re
324.062 189.025 88.497 -19.652 re
412.56 189.025 27.24 -19.652 re
439.8 189.025 27.24 -19.652 re
467.04 189.025 27.24 -19.652 re
494.28 189.025 27.24 -19.652 re
521.52 189.025 27.24 -19.652 re
548.76 189.025 27.24 -19.652 re
324.062 169.373 88.497 -11.652 re
412.56 169.373 27.24 -11.652 re
439.8 169.373 27.24 -11.652 re
467.04 169.373 27.24 -11.652 re
494.28 169.373 27.24 -11.652 re
521.52 169.373 27.24 -11.652 re
548.76 169.373 27.24 -11.652 re
324.062 157.721 88.497 -11.652 re
412.56 157.721 27.24 -11.652 re
439.8 157.721 27.24 -11.652 re
467.04 157.721 27.24 -11.652 re
494.28 157.721 27.24 -11.652 re
521.52 157.721 27.24 -11.652 re
548.76 157.721 27.24 -11.652 re
324.062 146.07 88.497 -11.652 re
412.56 146.07 27.24 -11.652 re
439.8 146.07 27.24 -11.652 re
467.04 146.07 27.24 -11.652 re
494.28 146.07 27.24 -11.652 re
521.52 146.07 27.24 -11.652 re
548.76 146.07 27.24 -11.652 re
324.062 134.418 88.497 -11.652 re
412.56 134.418 27.24 -11.652 re
439.8 134.418 27.24 -11.652 re
467.04 134.418 27.24 -11.652 re
494.28 134.418 27.24 -11.652 re
521.52 134.418 27.24 -11.652 re
548.76 134.418 27.24 -11.652 re
324.062 122.766 88.497 -11.652 re
412.56 122.766 27.24 -11.652 re
439.8 122.766 27.24 -11.652 re
467.04 122.766 27.24 -11.652 re
494.28 122.766 27.24 -11.652 re
521.52 122.766 27.24 -11.652 re
548.76 122.766 27.24 -11.652 re
324.062 111.114 88.497 -12.152 re
412.56 111.114 27.24 -12.152 re
439.8 111.114 27.24 -12.152 re
467.04 111.114 27.24 -12.152 re
494.28 111.114 27.24 -12.152 re
521.52 111.114 27.24 -12.152 re
548.76 111.114 27.24 -12.152 re
324.062 98.962 251.937 -62.712 re
f
/GS1 gs
q 1 0 0 1 324.0625 439.7016 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 412.56 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 439.7016 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 324 98.9619 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 412.56 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 98.9619 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 98.9619 cm
0 0 m
27.24 0 l
S
Q
0 0 0 0 K
0.125 w 
/GS3 gs
q 1 0 0 1 324.0625 36.5 cm
0 0 m
0 61.962 l
S
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 324 36.25 cm
0 0 m
88.56 0 l
S
Q
q 1 0 0 1 412.56 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 36.25 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 412.56 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 426.7897 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 324.0625 372.054 cm
0 0 m
88.497 0 l
S
Q
q 1 0 0 1 412.56 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 372.054 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 412.56 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 405.8778 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 412.56 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 439.8 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 467.04 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 494.28 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 521.52 384.9659 cm
0 0 m
27.24 0 l
S
Q
q 1 0 0 1 548.76 384.9659 cm
0 0 m
27.24 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.015 Tc 0.282 Tw 8 0 0 8 324.0625 459.3016 Tm
[(T)-5 (a)-5 (b)-5 (l)-5 (e)-5 ( )253 (1)-5 (0)-5 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.538 0 Td
( )Tj
EMC 
3.087 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-15 ( )]TJ
0.181 Tw 0 -1 Td
[(Advanced )0.5 (Phase CML Resistant or )0.5 (Intolerant )0.5 (to Prior Imatinib)-15 ( )]TJ
0.015 Tw 0 -1 Td
(Therapy)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 468.7529 430.3897 Tm
[(1)40 (40)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
(mg Once Daily)Tj
0.02 Tw -6.282 -1.614 Td
(Accelerated)Tj
0 Tc 0 Tw 7.2 0 0 8 456.0753 417.4778 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 428.957 409.4778 Tm
(\(n=157\))Tj
0.024 Tw 6.499 1 Td
(Myeloid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 512.8123 417.4778 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 485.0929 409.4778 Tm
(\(n=74\))Tj
0.024 Tw 5.89 1 Td
(Lymphoid Blast)Tj
0 Tc 0 Tw 7.2 0 0 8 570.0212 417.4778 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 539.573 409.4778 Tm
(\(n=33\))Tj
-16.247 -1.614 Td
[(All)-20 ( )]TJ
-0.84 -1 Td
(Grades)Tj
3.995 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 463.1434 396.5659 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 448.9129 388.5659 Tm
(3/4)Tj
3.911 1 Td
[(All)-20 ( )]TJ
-0.84 -1 Td
(Grades)Tj
3.995 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 517.6234 396.5659 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 503.3929 388.5659 Tm
(3/4)Tj
3.911 1 Td
[(All)-20 ( )]TJ
-0.84 -1 Td
(Grades)Tj
3.995 1 Td
[(Grade)-20 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 572.1034 396.5659 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 557.8729 388.5659 Tm
(3/4)Tj
-0.01 Tc 0.024 Tw -32.474 -1.614 Td
(Adverse Reaction)Tj
-0.02 Tc 19.254 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -19.254 -1.578 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(35)Tj
0 Tc 0 Tw 4.021 0 Td
(8)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(34)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(6)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
8 0 0 8 324.0625 351.3802 Tm
( )Tj
EMC 
1.125 0 Td
(Super\037cial localized edema)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 422.742 351.3802 Tm
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(14)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 12.455 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(6)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 12.693 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 12.693 0 Td
(3)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Congestive heart failure/)Tj
0 Tc 0 Tw 7.2 0 0 8 396.7015 304.7725 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF00090009>>> BDC 
7.2 0 0 8 324.0625 296.7725 Tm
[( )-996 ( )]TJ
EMC 
2.222 0 Td
[(cardiac d)-10 (ysfunction)]TJ
0 Tc 0 Tw 5.4 0 0 6 390.7781 299.5725 Tm
(a)Tj
7.2 0 0 8 424.452 304.7725 Tm
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(4)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -2.456 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y edema)]TJ
0 Tc 0 Tw 12.693 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(4)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(27)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(31)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 13.705 0 Td
(19)Tj
0 Tc 0 Tw 4.021 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Dyspnea)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(20)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.024 Tw -32.86 -1.456 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(11)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
3.783 0 Td
(8)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(19)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(23)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
-0.01 Tc 0.024 Tw -32.86 -1.456 Td
(Skin rash)Tj
0 Tc 0 Tw 5.4 0 0 6 348.506 206.3572 Tm
(b)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 422.742 203.5572 Tm
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(16)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(21)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Arthralgia)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(10)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
3.783 0 Td
(5)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.019 Tw -32.86 -1.456 Td
[(Infection \(inc)20 (luding bacterial,)37 ( viral,)]TJ
0 Tc 0 Tw 7.2 0 0 8 412.56 180.2534 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
7.2 0 0 8 324.0625 172.2534 Tm
( )Tj
EMC 
1.25 0 Td
[(fungal,)37 ( and non-specified\))]TJ
-0.005 Tc 0.005 Tw 12.455 1 Td
(10)Tj
0 Tc 0 Tw 4.021 0 Td
(6)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(14)Tj
0 Tc 0 Tw 4.021 0 Td
(7)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -2.456 Td
[(Hemorrha)-9.9 (ge)]TJ
-0.005 Tc 0.005 Tw 13.705 0 Td
(26)Tj
0 Tc 0 Tw 4.021 0 Td
(8)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(19)Tj
0 Tc 0 Tw 4.021 0 Td
(9)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(24)Tj
0 Tc 0 Tw 4.021 0 Td
(9)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(Gastrointestinal bleeding)Tj
0 Tc 0 Tw 12.693 0 Td
(8)Tj
3.783 0 Td
(6)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(7)Tj
3.783 0 Td
(9)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.86 -1.456 Td
( )Tj
EMC 
1.25 0 Td
(CNS bleeding)Tj
0 Tc 0 Tw 12.693 0 Td
(1)Tj
3.783 0 Td
(1)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(0)Tj
3.783 0 Td
(3)Tj
3.783 0 Td
(3)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
[(V)18 (omiting)]TJ
-0.005 Tc 0.005 Tw 13.705 0 Td
(11)Tj
0 Tc 0 Tw 4.021 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(12)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(15)Tj
0 Tc 0 Tw 4.021 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.86 -1.456 Td
(Pyrexia)Tj
-0.005 Tc 0.005 Tw 13.705 0 Td
(11)Tj
0 Tc 0 Tw 4.021 0 Td
(2)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(18)Tj
0 Tc 0 Tw 4.021 0 Td
(3)Tj
3.783 0 Td
(6)Tj
3.783 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.86 -1.456 Td
[(F)24 (ebrile neutropenia)]TJ
0 Tc 0 Tw 13.943 0 Td
(4)Tj
3.783 0 Td
(4)Tj
-0.005 Tc 0.005 Tw 3.546 0 Td
(12)Tj
3.783 0 Td
(12)Tj
3.783 0 Td
(12)Tj
3.783 0 Td
(12)Tj
5.4 0 0 6 324.125 92.45 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.145 Tw 7.2 0 0 8 327.725 89.65 Tm
[(Inc)20 (ludes ventricular d)-10 (ysfunction,)37 ( cardiac failure,)37 ( cardiac failure congestive,)37 ( cardiomyopa)-10 (thy)55 (,)32 ( )]TJ
0.656 Tw 0 -1 Td
[(congestive cardiomyopa)-10 (thy)55 (,)37 ( diastolic d)-10 (ysfunction,)37 ( ejection fraction decreased,)37 ( and)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 576 81.65 Tm
( )Tj
-0.005 Tc 7.2 0 0 8 327.725 73.65 Tm
(ventricular failure.)Tj
0.005 Tw 5.4 0 0 6 324.125 66.65 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.027 Tw 7.2 0 0 8 327.725 63.85 Tm
[(Inc)20 (ludes drug eruption,)37 ( er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( er)-18 (ythrosis,)37 ( exfolia)-10 (tive rash,)37 ( generalized)-5 ( )]TJ
0.334 Tw 0 -1 Td
[(er)-18 (ythema,)37 ( genital rash,)37 ( )0.5 (hea)-10 (t rash,)37 ( milia,)37 ( rash,)37 ( rash er)-17.9 (ythema)-10 (tous,)37 ( rash )0.5 (follicular)74 (,)37 ( rash)-5 ( )]TJ
0.062 Tw 0 -1 Td
[(generalized,)36.9 ( rash macular)74 (,)37 ( rash maculopa)-10 (pular)74 (,)37 ( rash pa)-10 (pular)74 (,)37 ( rash pruritic,)37 ( rash pustular)74 (,)37 ( skin)-5 ( )]TJ
0 Tw 0 -1 Td
[(exfolia)-9.9 (tion,)37 ( skin irrita)-10 (tion,)37 ( urticaria vesiculosa,)36.9 ( and rash vesicular)74 (.)]TJ
ET
endstreamendobj109 0 obj<</Length 30463>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 36 727.248 Tm
(5.8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(T)74 (umor L)37.1 (ysis Syndrome)]TJ
/T1_1 1 Tf
0.105 Tw -3.375 -1.36 Td
[(T)74 (umor lysis syndrome has been reported in pa)-10 (tients with resistance to prior ima)-9.9 (tinib)-10 ( )]TJ
-0.012 Tw 0 -1 Td
[(thera)-10 (py)55 (,)37 ( primarily in advanced phase disease.)37 ( Due to potential for tumor lysis syndrome,)27 ( )]TJ
0.168 Tw 0 -1 Td
[(maintain adequa)-9.9 (te hydra)-10 (tion,)37 ( correct uric acid levels prior to initia)-10 (ting thera)-10 (py with)-10 ( )]TJ
0.071 Tw 0 -1 Td
[(SPR)18 (YCEL,)37 ( and monitor electrolyte )0.5 (levels.)37 ( P)18 (a)-10 (tients )0.5 (with )0.5 (advanced sta)-9.9 (ge disease )0.5 (and/or)-9.9 ( )]TJ
0.048 Tw 0 -1 Td
[(high tumor burden may be a)-9.9 (t increased risk and should be monitored more frequently)-10 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 0 -1 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.517 0 Td
(e Reaction)Tj
0 Tc (s)Tj
-0.01 Tc 4.184 0 Td
( \(6.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -8.347 -1.697 Td
(5.9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Embr)-17.9 (yo-F)20 (etal T)74 (oxicity)]TJ
/T1_1 1 Tf
0.055 Tw -3.375 -1.36 Td
[(Based )0.5 (on )0.5 (limited )0.5 (human )0.5 (da)-9.9 (ta,)37 ( )0.5 (SPR)18 (YCEL )0.5 (can )0.5 (cause )0.5 (fetal )0.5 (harm )0.5 (when )0.5 (administered )0.5 (to )0.5 (a)-10 ( )]TJ
0.034 Tw 0 -1 Td
[(pregnant woman.)37 ( )37.1 (Adverse pharmacologic effects of SPR)18 (YCEL inc)20 (luding hydrops fetalis,)27 ( )]TJ
-0.04 Tw 0 -1 Td
[(fetal leukopenia,)37 ( and fetal thromboc)20 (ytopenia ha)-10 (ve been reported with ma)-10 (ternal exposure)-10 ( )]TJ
-0.006 Tw 0 -1 Td
[(to SPR)18 (YCEL.)37 ( )36.7 (Advise females of reproductive potential and males with female partners \of)-10 ( )]TJ
-0.029 Tw 0 -1 Td
[(reproductive potential )0.5 (to use effective contraception during trea)-10 (tment with )0.5 (SPR)18 (YCEL )0.5 (and)-10 ( )]TJ
0 Tw 0 -1 Td
(for 30 days after the last dose )Tj
/T1_2 1 Tf
0 Tc ([)Tj
11.228 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee U)Tj
0 Tc (s)Tj
-0.01 Tc 2.004 0 Td
[(e in Speci\037c P)18 (opula)-10 (tion)]TJ
0 Tc (s)Tj
-0.01 Tc 8.785 0 Td
[( \(8.1,)37 ( 8.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -22.413 -1.697 Td
(5.10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Effects on Growth and Development in P)24 (ediatric P)23.9 (atients)]TJ
/T1_1 1 Tf
0.038 Tw -3.375 -1.383 Td
[(In pedia)-10 (tric trials of SPR)18 (YCEL in chronic phase CML after a)-10 (t least 2 years of trea)-10 (tment,)27 ( )]TJ
0.192 Tw 0 -1 Td
[(adverse reactions associa)-10 (ted with bone gro)-9.9 (wth and development were reported in)-10 ( )]TJ
0.07 Tw 0 -1 Td
[(5\032)-70.3 (\(5.2%\) pa)-10 (tients,)37 ( one of which was severe in intensity \(Gro)-9.9 (wth Retarda)-10 (tion Grade\032)-70.4 (3\).)27 ( )]TJ
0.327 Tw 0 -1 Td
[(These 5 cases inc)20 (luded cases of epiphyses delayed fusion,)37 ( osteopenia,)37 ( gro)-10 (wth)-10 ( )]TJ
0.302 Tw 0 -1 Td
[(retarda)-10 (tion,)37 ( and g)-10 (ynecomastia )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
12.311 0 Td
(s)Tj
-0.01 Tc 0.265 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.302 Tw 3.819 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.302 Tw 4.486 0 Td
( \(6.1\) and U)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.302 Tw 5.475 0 Td
[(e in Speci\037c)-10 ( )]TJ
0.01 Tw -26.488 -1 Td
[(P)18 (opula)-10 (tion)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.043 Tw 4.158 0 Td
[( )0.5 (\(8.4\)])]TJ
/T1_1 1 Tf
[(.)37 ( )0.5 (Of )0.5 (these 5 )0.5 (cases,)37 ( 1 )0.5 (case of osteopenia and 1 )0.5 (case of g)-10 (ynecomastia)-10 ( )]TJ
0 Tw -4.158 -1 Td
[(resolved during trea)-10 (tment.)]TJ
0 -1.427 Td
[(Monitor bone gro)-10 (wth and development in pedia)-10 (tric pa)-10 (tients.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.697 Td
(5.11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Hepatotoxicity)Tj
/T1_1 1 Tf
0.121 Tw -3.375 -1.383 Td
[(SPR)18 (YCEL may cause hepa)-10 (totoxicity as measured by eleva)-10 (tions in bilirubin,)37 ( asparta)-10 (te)-9.9 ( )]TJ
0.03 Tw 0 -1 Td
[(aminotransferase \(AST\),)37 ( alanine aminotransferase \(AL)94 (T\),)37 ( and alkaline phospha)-9.9 (tase )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
30.225 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
[(ee)-10 ( )]TJ
-30.622 -1 Td
(Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.007 Tw 2.456 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.007 Tw 4.177 0 Td
( \(6.1\)])Tj
/T1_1 1 Tf
[(.)37 ( Monitor transaminases a)-9.9 (t baseline and monthly or as c)20 (linically)-10 ( )]TJ
-0.043 Tw -6.633 -1 Td
[(indica)-9.9 (ted during trea)-9.9 (tment.)37 ( Reduce dose,)37 ( withhold,)37 ( or permanently discontinue SPR)18 (YCEL)-9.9 ( )]TJ
-0.026 Tw 0 -1 Td
(based on severity )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
6.706 0 Td
(s)Tj
-0.01 Tc -0.026 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.063 Tw 2.449 0 Td
[(a)-10 (ge )-37.3 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.026 Tw 5.935 0 Td
[(tra)-9.9 (tion \(2.5\)])]TJ
/T1_1 1 Tf
[(.)37 ( )36.7 (When SPR)18 (YCEL is administered)-9.9 ( )]TJ
0.069 Tw -15.487 -1 Td
[(in )0.5 (combina)-10 (tion )0.5 (with )0.5 (chemothera)-9.9 (py)55 (,)37 ( )0.5 (liver )0.5 (toxicity )0.5 (in the )0.5 (form )0.5 (of )0.5 (transaminase )0.5 (eleva)-10 (tion)-10 ( )]TJ
0.047 Tw 0 -1 Td
[(and hyperbilirubinemia has been obser)-18 (ved.)37 ( Monitor hepa)-9.9 (tic function when SPR)18 (YCEL is)-10 ( )]TJ
0 Tw 0 -1 Td
[(used in combina)-10 (tion with chemothera)-10 (py)55 (.)]TJ
/T1_0 1 Tf
0.01 Tw 0 -2.17 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.081 Tw -3.375 -1.653 Td
[(The follo)-9.9 (wing c)20 (linically signi\037cant adverse reactions are discussed in grea)-10 (ter detail in)-10 ( )]TJ
0 Tw 0 -1 Td
(other sections of the labeling:)Tj
-0.018 Tc 0.018 Tw 0 -1.171 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.625 0 Td
(Myelosuppression )Tj
/T1_2 1 Tf
0.464 Tw 7.06 0 Td
[([see )0.5 (Dosa)-10 (ge and )37.5 (Administra)-10 (tion )0.5 (\(2.5\) and )37.4 (W)18 (arnings )0.5 (and)-18 ( )]TJ
0 Tw -7.06 -1 Td
(Precautions \(5.1\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Bleeding-rela)-10 (ted events )]TJ
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.2\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
(Fluid retention )Tj
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.3\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
(Cardiovascular toxicity )Tj
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.4\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Pulmonar)-18 (y arterial hypertension )]TJ
/T1_2 1 Tf
[([see )36.9 (W)18.1 (arnings and Precautions \(5.5\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(QT prolonga)-9.9 (tion )]TJ
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.6\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(Severe derma)-10 (tologic reactions )]TJ
/T1_2 1 Tf
[([see )37 (W)18.1 (arnings and Precautions \(5.7\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(T)74 (umor lysis syndrome )]TJ
/T1_2 1 Tf
[([see )37 (W)18.1 (arnings and Precautions \(5.8\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.29 Tw 1.625 0 Td
[(Effects on gro)-9.9 (wth and development in pedia)-10 (tric pa)-10 (tients )]TJ
/T1_2 1 Tf
0.253 Tw [([see W)18 (arnings )-36.9 (and)-10 ( )]TJ
0 Tw 0 -1 Td
(Precautions \(5.10\)])Tj
/T1_1 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.01 Tw -1.625 -1.162 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.625 0 Td
[(Hepa)-10 (totoxicity )]TJ
/T1_2 1 Tf
0 Tw 5.299 0 Td
[([see )37 (W)18 (arnings and Precautions \(5.11\)])]TJ
/T1_1 1 Tf
0 Tc (.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -6.924 -1.643 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Clinical T)74 (rials Experience)]TJ
/T1_1 1 Tf
0.004 Tw 8.08 0 0 8.08 36 275.308 Tm
[(Because c)20 (linical trials )0.5 (are conducted )0.5 (under )0.5 (widely )0.5 (var)-18 (ying conditions,)37 ( )0.5 (adverse reaction)-10 ( )]TJ
-0.015 Tw 0 -1 Td
[(ra)-10 (tes obser)-17.9 (ved in the c)20.1 (linical trials of a drug cannot be directly compared to ra)-10 (tes in the)-10 ( )]TJ
0 Tw 0 -1 Td
[(c)20 (linical trials of another drug and may not re\035ect the ra)-10 (tes obser)-18 (ved in practice.)]TJ
0.071 Tw 0 -1.512 Td
[(The da)-10 (ta described belo)-10 (w re\035ect exposure to SPR)18 (YCEL administered as single-a)-9.9 (gent)-10 ( )]TJ
0.106 Tw 0 -1 Td
[(thera)-10 (py a)-10 (t all doses tested in c)20 (linical studies \(n=2809\),)37 ( inc)20 (luding 324 adult pa)-10 (tients)-10 ( )]TJ
-0.044 Tw 0 -1 Td
[(with newly dia)-9.9 (gnosed chronic phase CML,)37 ( 2388 adult pa)-10 (tients with ima)-10 (tinib-resistant or)-10 ( )]TJ
0.02 Tw 0 -1 Td
(-intolerant chronic or advanced phase CML or Ph)Tj
0 Tc 0 Tw 17.766 0.124 Td
(+)Tj
-0.01 Tc 0.02 Tw 0.59 -0.124 Td
[( )37.3 (ALL,)37 ( and 97 pedia)-10 (tric pa)-9.9 (tients with)-10 ( )]TJ
0.079 Tw -18.356 -1 Td
[(chronic )0.5 (phase )0.5 (CML.)37 ( )37.5 (The )0.5 (median )0.5 (dura)-9.9 (tion )0.6 (of )0.5 (thera)-10 (py )0.5 (in )0.5 (a )0.5 (total )0.5 (of )0.5 (2712 )0.6 (adult )0.5 (pa)-9.9 (tients)-10 ( )]TJ
-0.008 Tw 0 -1 Td
[(was 19.2 months \(range 0 to 93.2 months\).)37.1 ( In a randomized trial in pa)-9.9 (tients with newly)-10 ( )]TJ
0.055 Tw 0 -1 Td
[(dia)-9.9 (gnosed chronic phase CML,)37 ( the median dura)-10 (tion of thera)-10 (py was a)-10 (pproxima)-9.9 (tely 60)-10 ( )]TJ
-0.017 Tw 0 -1 Td
[(months.)37 ( )37.4 (The median dura)-10 (tion of thera)-10 (py in 1618 adult pa)-9.9 (tients with chronic phase CML)-9.9 ( )]TJ
0 Tw 0 -1 Td
(was 29 months \(range 0 to 92.9 months\).)Tj
0.084 Tw 0 -1.512 Td
[(The )0.5 (median )0.5 (dura)-10 (tion of thera)-10 (py )0.5 (in 1094 adult pa)-9.9 (tients )0.5 (with advanced )0.5 (phase CML or)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.124 Td
(+)Tj
-0.01 Tc 0.59 -0.124 Td
[( )37 (ALL was 6.2 months \(range 0 to 93.2 months\).)]TJ
0.312 Tw -1.514 -1.512 Td
[(In two non-randomized trials in 97 pedia)-10 (tric pa)-9.9 (tients with chronic phase CML)-9.9 ( )]TJ
0 Tc 0 Tw 8.08 0 0 8.08 288 149.7681 Tm
( )Tj
-0.01 Tc 0.245 Tw 8.08 0 0 8.08 36 141.688 Tm
[(\(51 pa)-10 (tients newly dia)-9.9 (gnosed and 46 pa)-10 (tients resistant or intolerant to previous)-10 ( )]TJ
0.183 Tw 0 -1 Td
[(trea)-10 (tment with ima)-9.9 (tinib\),)37 ( the median dura)-10 (tion of thera)-10 (py was 51.1 months \(range)-10 ( )]TJ
0 Tc 0 Tw 8.08 0 0 8.08 288 133.608 Tm
( )Tj
-0.01 Tc 8.08 0 0 8.08 36 125.5281 Tm
(1.9 to 99.6 months\).)Tj
0.052 Tw 0 -1.512 Td
[(In the overall popula)-10 (tion of 2712 adult pa)-10 (tients,)37 ( 88% of pa)-10 (tients experienced adverse)-10 ( )]TJ
0.067 Tw 0 -1 Td
[(reactions a)-10 (t some time and 19% experienced adverse reactions leading to trea)-9.9 (tment)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(discontinua)-10 (tion.)]TJ
-0.011 Tw 0 -1.512 Td
[(In the randomized )0.5 (trial in adult )0.5 (pa)-10 (tients with )0.5 (newly dia)-9.9 (gnosed chronic phase CML,)37 ( drug)-10 ( )]TJ
-0.057 Tw 0 -1 Td
[(was )0.5 (discontinued )0.5 (for )0.5 (adverse reactions in )0.5 (16% )0.5 (of pa)-10 (tients with a )0.5 (minimum of 60 )0.5 (months)-9.9 ( )]TJ
-0.045 Tw 0 -1 Td
[(of follo)-10 (w-up.)37 ( )37.1 (After a minimum of 60 months of follo)-9.9 (w-up,)37 ( the cumula)-10 (tive discontinua)-10 (tion)-10 ( )]TJ
-0.02 Tw 0 -1 Td
[(ra)-10 (te was 39%.)37 ( )37.1 (Among the 1618 pa)-10 (tients with chronic phase CML,)37 ( drug-rela)-10 (ted adverse)-10 ( )]TJ
0.012 Tw 0 -1 Td
[(reactions leading to discontinua)-10 (tion were reported in 329 \(20.3%\) pa)-10 (tients; among the)-10 ( )]TJ
0.066 Tw 0 -1 Td
[(1094 )0.5 (pa)-9.9 (tients )0.5 (with advanced phase )0.5 (CML )0.5 (or Ph)]TJ
0 Tc 0 Tw 17.28 0.124 Td
(+)Tj
-0.01 Tc 0.066 Tw 0.59 -0.124 Td
[( )37.5 (ALL,)37 ( )0.5 (drug-rela)-10 (ted )0.5 (adverse )0.5 (reactions)-10 ( )]TJ
0 Tw -17.87 -1 Td
[(leading to discontinua)-10 (tion were reported in 191 \(17.5%\) pa)-9.9 (tients.)]TJ
ET
0 0 0 1 K
4 M 
q 1 0 0 1 31.5 509.2048 cm
0 0 m
0 -65.952 l
S
Q
BT
0.475 Tw 8.08 0 0 8.08 324 727.1909 Tm
[(Among the 97 pedia)-9.9 (tric subjects,)37 ( drug-rela)-10 (ted adverse reactions leading to)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(discontinua)-10 (tion were reported in 1 pa)-9.9 (tient \(1%\).)]TJ
0.07 Tw 0 -1.518 Td
[(Adverse reactions reported in \03610% of adult pa)-10 (tients,)37 ( and other adverse reactions of)-10 ( )]TJ
-0.005 Tw 0 -1.006 Td
[(interest,)37 ( in a randomized trial in pa)-10 (tients with newly dia)-10 (gnosed chronic phase CML a)-9.9 (t a)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(median follo)-10 (w-up of a)-9.9 (pproxima)-9.9 (tely 60 months are presented in )37 (T)74 (able 6.)]TJ
-0.023 Tw 0 -1.518 Td
[(Adverse reactions reported in \03610% of adult pa)-10 (tients trea)-10 (ted a)-10 (t the recommended dose)-10 ( )]TJ
-0.002 Tw 0 -1.006 Td
[(of 100 mg once daily \(n=165\),)36.9 ( and other adverse reactions of interest,)37 ( in a randomized)-10 ( )]TJ
0.129 Tw 0 -1.006 Td
[(dose-optimiza)-10 (tion trial of pa)-10 (tients with chronic phase CML resistant or intolerant to)-10 ( )]TJ
-0.017 Tw 0 -1.006 Td
[(prior ima)-10 (tinib thera)-10 (py a)-10 (t a median follo)-9.9 (w-up of a)-10 (pproxima)-10 (tely 84 months are presented)-10 ( )]TJ
-0.037 Tw 0 -1.006 Td
[(in T)74 (able )-37 (8.)]TJ
0.151 Tw 0 -1.518 Td
[(Adverse reactions reported in \03610% of pedia)-10 (tric pa)-10 (tients a)-10 (t a median follo)-9.9 (w-up of)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(a)-10 (pproxima)-9.9 (tely 51.1 months are presented in )37 (T)74 (able 11.)]TJ
-0.047 Tw 0 -1.518 Td
[(Drug-rela)-10 (ted serious adverse reactions \(SARs\) were reported for 16.7% of adult \pa)-10 (tients)-10 ( )]TJ
0.066 Tw 0 -1.006 Td
[(in )0.5 (the )0.5 (randomized )0.5 (trial )0.5 (of )0.5 (pa)-10 (tients )0.5 (with )0.6 (newly )0.6 (dia)-10 (gnosed )0.5 (chronic )0.5 (phase )0.5 (CML.)36.9 ( )0.6 (Serious)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(adverse reactions reported in \0365% of pa)-10 (tients inc)20 (luded pleural effusion \(5%\).)]TJ
0.078 Tw 0 -1.518 Td
[(Drug-rela)-10 (ted SARs were reported for 26.1% of pa)-9.9 (tients trea)-10 (ted a)-10 (t the recommended)-9.9 ( )]TJ
0.05 Tw 0 -1.006 Td
[(dose of 100 mg once )0.5 (daily in the randomized dose-optimiza)-10 (tion )0.5 (trial of adult )0.5 (pa)-10 (tients)-10 ( )]TJ
-0.031 Tw 0 -1.006 Td
[(with chronic phase CML resistant or intolerant to prior ima)-10 (tinib thera)-9.9 (py)55.1 (.)37 ( Serious adverse)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(reactions reported in \0365% of pa)-10 (tients inc)20 (luded pleural effusion \(10%\).)]TJ
0 -1.518 Td
[(Drug-rela)-10 (ted SARs were reported for 14.4% of pedia)-10 (tric pa)-10 (tients.)]TJ
/T1_0 1 Tf
8 0 0 8 324 535.2371 Tm
(Chronic Myeloid Leukemia \(CML\))Tj
/T1_1 1 Tf
0.366 Tw 0 -1.298 Td
[(Adverse reactions \(exc)20.1 (luding labora)-9.9 (tor)-18 (y abnormalities\) tha)-9.9 (t were reported in a)-10 (t)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.13 Tw -31.5 -1.006 Td
[(least 10% of adult pa)-9.9 (tients are sho)-10 (wn in )37.3 (T)74 (able 6 for newly dia)-10 (gnosed pa)-9.9 (tients with)-10 ( )]TJ
0.004 Tw 0 -1.006 Td
[(chronic phase CML and )36.8 (T)74 (ables 8 and 10 for CML pa)-10 (tients with resistance or intolerance)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(to prior ima)-10 (tinib thera)-9.9 (py)55 (.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 491.669 252 -25.312 re
324 466.357 81.72 -12.912 re
405.72 466.357 85.14 -12.912 re
490.86 466.357 85.14 -12.912 re
324 453.445 81.72 -20.912 re
405.72 453.445 42.57 -20.912 re
448.29 453.445 42.57 -20.912 re
490.86 453.445 42.57 -20.912 re
533.43 453.445 42.57 -20.912 re
324 432.533 81.72 -12.912 re
405.72 432.533 170.28 -12.912 re
324 419.621 81.72 -11.688 re
405.72 419.621 42.57 -11.688 re
448.29 419.621 42.57 -11.688 re
490.86 419.621 42.57 -11.688 re
533.43 419.621 42.57 -11.688 re
324 407.933 81.72 -11.688 re
405.72 407.933 42.57 -11.688 re
448.29 407.933 42.57 -11.688 re
490.86 407.933 42.57 -11.688 re
533.43 407.933 42.57 -11.688 re
324 396.245 81.72 -11.688 re
405.72 396.245 42.57 -11.688 re
448.29 396.245 42.57 -11.688 re
490.86 396.245 42.57 -11.688 re
533.43 396.245 42.57 -11.688 re
324 384.557 81.72 -11.688 re
405.72 384.557 42.57 -11.688 re
448.29 384.557 42.57 -11.688 re
490.86 384.557 42.57 -11.688 re
533.43 384.557 42.57 -11.688 re
324 372.869 81.72 -11.688 re
405.72 372.869 42.57 -11.688 re
448.29 372.869 42.57 -11.688 re
490.86 372.869 42.57 -11.688 re
533.43 372.869 42.57 -11.688 re
324 361.181 81.72 -11.688 re
405.72 361.181 42.57 -11.688 re
448.29 361.181 42.57 -11.688 re
490.86 361.181 42.57 -11.688 re
533.43 361.181 42.57 -11.688 re
324 349.493 81.72 -19.688 re
405.72 349.493 42.57 -19.688 re
448.29 349.493 42.57 -19.688 re
490.86 349.493 42.57 -19.688 re
533.43 349.493 42.57 -19.688 re
324 329.806 81.72 -11.688 re
405.72 329.806 42.57 -11.688 re
448.29 329.806 42.57 -11.688 re
490.86 329.806 42.57 -11.688 re
533.43 329.806 42.57 -11.688 re
324 318.118 81.72 -11.688 re
405.72 318.118 42.57 -11.688 re
448.29 318.118 42.57 -11.688 re
490.86 318.118 42.57 -11.688 re
533.43 318.118 42.57 -11.688 re
324 306.43 81.72 -11.688 re
405.72 306.43 42.57 -11.688 re
448.29 306.43 42.57 -11.688 re
490.86 306.43 42.57 -11.688 re
533.43 306.43 42.57 -11.688 re
324 294.742 81.72 -11.688 re
405.72 294.742 42.57 -11.688 re
448.29 294.742 42.57 -11.688 re
490.86 294.742 42.57 -11.688 re
533.43 294.742 42.57 -11.688 re
324 283.054 81.72 -11.688 re
405.72 283.054 42.57 -11.688 re
448.29 283.054 42.57 -11.688 re
490.86 283.054 42.57 -11.688 re
533.43 283.054 42.57 -11.688 re
324 271.366 81.72 -11.688 re
405.72 271.366 42.57 -11.688 re
448.29 271.366 42.57 -11.688 re
490.86 271.366 42.57 -11.688 re
533.43 271.366 42.57 -11.688 re
324 259.678 81.72 -11.688 re
405.72 259.678 42.57 -11.688 re
448.29 259.678 42.57 -11.688 re
490.86 259.678 42.57 -11.688 re
533.43 259.678 42.57 -11.688 re
324 247.99 81.72 -11.688 re
405.72 247.99 42.57 -11.688 re
448.29 247.99 42.57 -11.688 re
490.86 247.99 42.57 -11.688 re
533.43 247.99 42.57 -11.688 re
324 236.302 81.72 -11.688 re
405.72 236.302 42.57 -11.688 re
448.29 236.302 42.57 -11.688 re
490.86 236.302 42.57 -11.688 re
533.43 236.302 42.57 -11.688 re
324 224.614 81.72 -11.688 re
405.72 224.614 42.57 -11.688 re
448.29 224.614 42.57 -11.688 re
490.86 224.614 42.57 -11.688 re
533.43 224.614 42.57 -11.688 re
324 212.926 81.72 -11.688 re
405.72 212.926 42.57 -11.688 re
448.29 212.926 42.57 -11.688 re
490.86 212.926 42.57 -11.688 re
533.43 212.926 42.57 -11.688 re
324 201.239 81.72 -11.688 re
405.72 201.239 42.57 -11.688 re
448.29 201.239 42.57 -11.688 re
490.86 201.239 42.57 -11.688 re
533.43 201.239 42.57 -11.688 re
324 189.551 81.72 -11.688 re
405.72 189.551 42.57 -11.688 re
448.29 189.551 42.57 -11.688 re
490.86 189.551 42.57 -11.688 re
533.43 189.551 42.57 -11.688 re
324 177.863 81.72 -11.688 re
405.72 177.863 42.57 -11.688 re
448.29 177.863 42.57 -11.688 re
490.86 177.863 42.57 -11.688 re
533.43 177.863 42.57 -11.688 re
324 166.175 81.72 -11.688 re
405.72 166.175 42.57 -11.688 re
448.29 166.175 42.57 -11.688 re
490.86 166.175 42.57 -11.688 re
533.43 166.175 42.57 -11.688 re
324 154.487 81.72 -11.688 re
405.72 154.487 42.57 -11.688 re
448.29 154.487 42.57 -11.688 re
490.86 154.487 42.57 -11.688 re
533.43 154.487 42.57 -11.688 re
324 142.799 252 -71.072 re
f
0.5 w 10 M 
/GS2 gs
q 1 0 0 1 490.86 419.621 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 407.9331 cm
0 0 m
0 11.438 l
S
Q
q 1 0 0 1 533.43 419.621 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 396.2451 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 384.5573 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 372.8693 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 349.4935 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 329.8056 cm
0 0 m
0 19.688 l
S
Q
q 1 0 0 1 490.86 318.1177 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 306.4297 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 271.366 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 259.6781 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 247.9902 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 236.3023 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 224.6143 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 212.9265 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 201.2385 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 189.5506 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 177.8627 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 166.1748 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 154.4869 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 143.299 cm
0 0 m
0 11.188 l
S
Q
1 w 
q 1 0 0 1 490.86 142.799 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 142.799 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 466.3567 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 466.3567 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 490.86 361.1814 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 432.5329 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 432.5329 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 283.0539 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 490.86 294.7418 cm
0 0 m
0 11.688 l
S
Q
q 1 0 0 1 448.29 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 432.7829 cm
0 0 m
0 20.412 l
S
Q
q 1 0 0 1 448.29 432.5329 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 324 142.799 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 405.72 142.799 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 142.799 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 324 71.7271 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 405.72 71.7271 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 71.7271 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 490.86 71.7271 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 533.43 71.7271 cm
0 0 m
42.57 0 l
S
Q
1 w 
q 1 0 0 1 405.72 466.3567 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 466.3567 cm
0 0 m
42.57 0 l
S
Q
0.5 w 
q 1 0 0 1 490.86 453.6948 cm
0 0 m
0 12.162 l
S
Q
1 w 
q 1 0 0 1 324 466.3567 cm
0 0 m
81.72 0 l
S
Q
0.5 w 
q 1 0 0 1 405.72 453.4448 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 405.72 432.5329 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 324 419.621 cm
0 0 m
81.72 0 l
S
Q
q 1 0 0 1 405.72 419.621 cm
0 0 m
42.57 0 l
S
Q
q 1 0 0 1 448.29 419.621 cm
0 0 m
42.57 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.248 Tw 8 0 0 8 324 485.9567 Tm
[(Table )224 (6:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Adverse Reactions Reported in \03610% of Adult Patients with)-10 ( )]TJ
-0.025 Tc 0.206 Tw 0 -1 Td
[(N)-15 (e)-15 (w)-15 (l)-15 (y)-14.9 ( )-14.6 (Diagnosed )0.5 (Chronic Phase )0.5 (CML )0.5 (\(minimum of 60 )0.5 (months)-25 ( )]TJ
0.025 Tw 0 -1 Td
(follow-up\))Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 434.1361 457.0448 Tm
(All Grades)Tj
11.944 0 Td
(Grade 3/4)Tj
0.02 Tw -14.672 -1.614 Td
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 439.5148 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 416.162 436.1329 Tm
(\(n=258\))Tj
5.835 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 480.7286 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 458.607 436.1329 Tm
(\(n=258\))Tj
5.716 1 Td
(SPRYCEL)Tj
0 Tc 0 Tw 7.2 0 0 8 524.7798 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 501.427 436.1329 Tm
(\(n=258\))Tj
5.835 1 Td
(Imatinib)Tj
0 Tc 0 Tw 7.2 0 0 8 565.9936 444.1329 Tm
( )Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 543.8719 436.1329 Tm
(\(n=258\))Tj
-0.01 Tc 0.024 Tw -30.538 -1.614 Td
[(Adverse Reaction)-10 ( )]TJ
-0.02 Tc 18.788 0 Td
(Percent \(%\) of Patients)Tj
/T1_1 1 Tf
-0.01 Tc -18.788 -1.537 Td
(Fluid retention)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(38)Tj
5.895 0 Td
(45)Tj
0 Tc 0 Tw 6.417 0 Td
(5)Tj
5.913 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Pleural effusion)Tj
-0.005 Tc 0.005 Tw 12.579 0 Td
(28)Tj
0 Tc 0 Tw 6.133 0 Td
(1)Tj
6.18 0 Td
(3)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Superficial localized edema)Tj
-0.005 Tc 0.005 Tw 12.579 0 Td
(14)Tj
5.895 0 Td
(38)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -1.461 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y hypertension)]TJ
0 Tc 0 Tw 12.816 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 5.598 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(1)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Generalized edema)Tj
0 Tc 0 Tw 12.816 0 Td
(4)Tj
5.895 0 Td
(7)Tj
6.18 0 Td
(0)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
[(P)18 (ericardial effusion)]TJ
0 Tc 0 Tw 12.816 0 Td
(4)Tj
5.895 0 Td
(1)Tj
6.18 0 Td
(1)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Congestive heart failure/)Tj
0 Tc 0 Tw 7.2 0 0 8 396.639 340.7936 Tm
( )Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF00090009>>> BDC 
7.2 0 0 8 324 332.7936 Tm
[( )-996 ( )]TJ
EMC 
2.083 0 Td
[(cardiac d)-10 (ysfunction)]TJ
0 Tc 0 Tw 5.4 0 0 6 389.7156 335.5936 Tm
(a)Tj
7.2 0 0 8 425.277 340.7936 Tm
(2)Tj
5.895 0 Td
(1)Tj
-0.005 Tc 0.005 Tw 5.882 0 Td
(<1)Tj
5.912 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -2.461 Td
( )Tj
EMC 
1.25 0 Td
[(Pulmonar)-18 (y edema)]TJ
0 Tc 0 Tw 12.816 0 Td
(1)Tj
5.895 0 Td
(0)Tj
6.18 0 Td
(0)Tj
5.913 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Diarrhea)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(22)Tj
5.895 0 Td
(23)Tj
0 Tc 0 Tw 6.417 0 Td
(1)Tj
5.913 0 Td
(1)Tj
-0.01 Tc 0.024 Tw -32.054 -1.461 Td
(Musculoskeletal pain)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(14)Tj
5.895 0 Td
(17)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.461 Td
(Rash)Tj
0 Tc 0 Tw 5.4 0 0 6 336.9094 288.8419 Tm
(b)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 423.5671 286.0419 Tm
(14)Tj
5.895 0 Td
(18)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(2)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Headache)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(14)Tj
5.895 0 Td
(11)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.054 -1.461 Td
(Abdominal pain)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(11)Tj
0 Tc 0 Tw 6.133 0 Td
(8)Tj
6.18 0 Td
(0)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
[(F)20 (a)-10 (tigue)]TJ
-0.005 Tc 0.005 Tw 13.829 0 Td
(11)Tj
5.895 0 Td
(12)Tj
6.12 0 Td
(<1)Tj
0 Tc 0 Tw 6.21 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Nausea)Tj
-0.005 Tc 0.005 Tw 13.829 0 Td
(10)Tj
5.895 0 Td
(25)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
[(My)-10 (algia)]TJ
0 Tc 0 Tw 14.066 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(12)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.01 Tw -32.054 -1.461 Td
(Arthralgia)Tj
0 Tc 0 Tw 14.066 0 Td
(7)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(10)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.461 Td
[(Hemorrha)-9.9 (ge)]TJ
0 Tc 0 Tw 5.4 0 0 6 356.1327 207.0265 Tm
(c)Tj
7.2 0 0 8 425.277 204.2265 Tm
(8)Tj
5.895 0 Td
(8)Tj
6.18 0 Td
(1)Tj
5.912 0 Td
(1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Gastrointestinal bleeding)Tj
0 Tc 0 Tw 12.816 0 Td
(2)Tj
5.895 0 Td
(2)Tj
6.18 0 Td
(1)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-32.054 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(Other bleeding)Tj
0 Tc 0 Tw 5.4 0 0 6 371.0872 183.6507 Tm
(d)Tj
7.2 0 0 8 425.277 180.8507 Tm
(6)Tj
5.895 0 Td
(6)Tj
6.18 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-31.756 -1.461 Td
( )Tj
EMC 
1.25 0 Td
(CNS bleeding)Tj
-0.005 Tc 0.005 Tw 12.519 0 Td
(<1)Tj
5.895 0 Td
(<1)Tj
0 Tc 0 Tw 6.477 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
-0.01 Tc 0.01 Tw -31.756 -1.461 Td
[(V)18 (omiting)]TJ
0 Tc 0 Tw 14.066 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(12)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
5.912 0 Td
(0)Tj
-0.01 Tc 0.024 Tw -32.054 -1.461 Td
[(Musc)20 (le spasms)]TJ
0 Tc 0 Tw 14.066 0 Td
(5)Tj
-0.005 Tc 0.005 Tw 5.658 0 Td
(21)Tj
0 Tc 0 Tw 6.417 0 Td
(0)Tj
-0.005 Tc 0.005 Tw 5.615 0 Td
(<1)Tj
5.4 0 0 6 324 136.2871 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.047 Tw 7.2 0 0 8 329 133.4871 Tm
[(Inc)20 (ludes cardiac failure acute,)37 ( cardiac failure congestive,)37 ( cardiomyopa)-10 (thy)55 (,)37 ( diastolic d)-10 (ysfunction,)32 ( )]TJ
0 Tw 0 -1 Td
[(ejection fraction decreased,)36.9 ( and left ventricular d)-10 (ysfunction.)]TJ
0.005 Tw 5.4 0 0 6 324 119.5671 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.074 Tw 7.2 0 0 8 329 116.7671 Tm
[(Inc)20 (ludes er)-18 (ythema,)37 ( er)-18 (ythema multiforme,)37 ( rash,)37 ( rash generalized,)37 ( rash macular)74 (,)37 ( rash pa)-9.9 (pular)74 (,)32 ( )]TJ
0 Tw 0 -1 Td
[(rash pustular)74 (,)37 ( skin exfolia)-10 (tion,)37 ( and rash vesicular)74 (.)]TJ
0.005 Tw 5.4 0 0 6 324 102.8471 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 329 100.0471 Tm
[(Adverse reaction of special interest with <10% frequenc)20 (y)55 (.)]TJ
0.005 Tw 5.4 0 0 6 324 94.1271 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.102 Tw 7.2 0 0 8 329 91.3271 Tm
[(Inc)20 (ludes conjunctival hemorrha)-10 (ge,)37 ( ear hemorrha)-9.9 (ge,)36.9 ( ecchymosis,)37 ( epistaxis,)37 ( eye hemorrha)-10 (ge,)32 ( )]TJ
0.073 Tw 0 -1 Td
[(gingival bleeding,)37 ( hema)-9.9 (toma,)37 ( hema)-10 (turia,)37 ( hemoptysis,)37 ( intra-abdominal hema)-10 (toma,)36.9 ( petechiae,)32 ( )]TJ
0 Tw 0 -1 Td
[(sc)20 (leral hemorrha)-10 (ge,)37 ( uterine hemorrha)-10 (ge,)37 ( and va)-9.9 (ginal hemorrha)-10 (ge.)]TJ
-0.01 Tc -0.03 Tw 8 0 0 8 324 52.0914 Tm
[(A )0.5 (comparison )0.5 (of )0.5 (cumula)-10 (tive )0.5 (ra)-10 (tes )0.5 (of )0.5 (adverse )0.5 (reactions )0.5 (reported )0.5 (in )0.5 (\03610% )0.5 (of )0.5 (pa)-9.9 (tients )0.5 (with)-10 ( )]TJ
0.034 Tw 0 -1.006 Td
[(minimum follo)-9.9 (w-up of 1 and 5 years in a randomized trial of newly dia)-9.9 (gnosed pa)-10 (tients)-10 ( )]TJ
0 Tw 0 -1.006 Td
[(with chronic phase CML trea)-9.9 (ted with SPR)18 (YCEL are sho)-10 (wn in )37 (T)74 (able 7.)]TJ
ET
endstreamendobj108 0 obj<</Length 24855>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.01 Tc 0.465 Tw 8 0 0 8 36 727.2481 Tm
[(F)20 (or pedia)-10 (tric pa)-9.9 (tients with chronic phase CML,)37 ( if Grade \0363 neutropenia or)-9.9 ( )]TJ
0.366 Tw 0 -1.006 Td
[(thromboc)20 (ytopenia recurs during complete hema)-10 (tologic response \(CHR\),)36.9 ( interrupt)-10 ( )]TJ
0.15 Tw 0 -1.006 Td
[(SPR)18 (YCEL )0.5 (and )0.5 (resume )0.5 (a)-10 (t )0.5 (a )0.5 (reduced )0.5 (dose.)37 ( )0.5 (Implement )0.5 (temporar)-18 (y )0.5 (dose )0.5 (reductions )0.5 (for)-9.9 ( )]TJ
0 Tw 0 -1.006 Td
[(intermedia)-9.9 (te degrees of c)20 (ytopenia and disease response as needed.)]TJ
0.036 Tw 0 -1.434 Td
[(F)20 (or pedia)-9.9 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 10.652 0.125 Td
(+)Tj
-0.01 Tc 0.036 Tw 0.59 -0.125 Td
[( )36.9 (ALL,)37 ( if neutropenia and/or thromboc)20 (ytopenia result in a)-9.9 ( )]TJ
0 Tc 0 Tw 20.258 0 Td
( )Tj
-0.01 Tc 0.148 Tw -31.5 -1.006 Td
[(delay of the next block of trea)-10 (tment by more than 14 days,)37 ( interrupt SPR)18 (YCEL and)-10 ( )]TJ
-0.026 Tw 0 -1.006 Td
[(resume a)-10 (t the same dose level once the next block of trea)-9.9 (tment is started.)37 ( If neutropenia)-9.9 ( )]TJ
0.136 Tw 0 -1.006 Td
[(and/or thromboc)20 (ytopenia persist and the next block of trea)-9.9 (tment is delayed another)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.13 Tw -31.5 -1.006 Td
[(7 days,)37 ( perform a bone marro)-9.9 (w assessment to assess cellularity and percenta)-10 (ge of)-10 ( )]TJ
0.222 Tw 0 -1.006 Td
[(blasts.)37 ( If marro)-10 (w cellularity is <10%,)37 ( interrupt trea)-10 (tment with SPR)18 (YCEL until )37 (ANC)-9.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.013 Tw -31.5 -1.006 Td
(>500/\033L \(0.5 x 10)Tj
0 Tc 0 Tw 6 0 0 6 88.958 646.1302 Tm
(9)Tj
-0.01 Tc 0.013 Tw 8 0 0 8 91.7779 643.3302 Tm
[(/L\),)37 ( a)-9.9 (t which time trea)-9.9 (tment may be resumed a)-9.9 (t full dose.)37 ( If marro)-10 (w)-10 ( )]TJ
0 Tw -6.972 -1.006 Td
[(cellularity is >10%,)37.1 ( resumption of trea)-9.9 (tment with SPR)18 (YCEL may be considered.)]TJ
/T1_1 1 Tf
0 -1.501 Td
(Non-Hematologic Adverse Reactions)Tj
/T1_0 1 Tf
0.114 Tw 0 -1.299 Td
[(F)20 (or adults with Ph)]TJ
0 Tc 0 Tw 6.805 0.125 Td
(+)Tj
-0.01 Tc 0.114 Tw 0.59 -0.125 Td
[( CML and )36.7 (ALL,)37 ( and pedia)-10 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 17.04 0.125 Td
(+)Tj
-0.01 Tc 0.114 Tw 0.59 -0.125 Td
[( CML,)37 ( if a severe)-10 ( )]TJ
0 Tc 0 Tw 6.475 0 Td
( )Tj
-0.01 Tc 0.208 Tw -31.5 -1.006 Td
[(non-hema)-10 (tologic adverse reaction develops with SPR)18 (YCEL use,)37.1 ( trea)-9.9 (tment must be)-9.9 ( )]TJ
0.182 Tw 0 -1.006 Td
[(withheld until the adverse reaction has resolved or improved.)37 ( )37.2 (Thereafter)74 (,)37 ( trea)-10 (tment)-10 ( )]TJ
0.191 Tw 0 -1.006 Td
[(can )0.5 (be resumed as )0.5 (a)-10 (ppropria)-10 (te )0.5 (a)-10 (t a )0.5 (reduced dose depending on the severity and)-9.9 ( )]TJ
0.01 Tw 0 -1.006 Td
(recurrence)Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
4.147 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
[(ee W)18.1 (arning)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.425 0 Td
( and Precaution)Tj
0 Tc (s)Tj
-0.01 Tc 6.021 0 Td
( \(5\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.139 Tw -14.99 -1.299 Td
[(F)20 (or pedia)-10 (tric pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 11.066 0.125 Td
(+)Tj
-0.01 Tc 0.139 Tw 0.59 -0.125 Td
[( )36.6 (ALL,)37 ( interrupt trea)-10 (tment for cases of grade \0363 non-)]TJ
0.103 Tw -11.656 -1.006 Td
[(hema)-10 (tologic adverse reactions with the exception of liver function test abno\rmalities,)27 ( )]TJ
0.033 Tw 0 -1.006 Td
[(and resume a)-9.9 (t a reduced dose when resolved to grade \0341.)37 ( F)20 (or eleva)-10 (ted direct bilirubin)-10 ( )]TJ
0.198 Tw 0 -1.006 Td
[(over )0.5 (5 )0.6 (times )0.6 (the )0.5 (institutional )0.6 (upper )0.5 (limit )0.6 (of )0.5 (normal )0.6 (\(ULN\),)37 ( )0.5 (interrupt )0.5 (trea)-10 (tment )0.5 (until)-10 ( )]TJ
-0.057 Tw 0 -1.006 Td
[(improvement to baseline or grade \0341.)37 ( F)20 (or eleva)-10 (ted )36.9 (AST/AL)94 (T over 15 times the institutional)-10 ( )]TJ
0.045 Tw 0 -1.006 Td
[(ULN,)37 ( interrupt trea)-10 (tment until improvement to baseline or grade <1.)37 ( F)20 (or recurrent liver)-9.9 ( )]TJ
0.116 Tw 0 -1.006 Td
[(function )0.5 (test )0.5 (abnormalities )0.6 (as )0.5 (above,)37 ( )0.6 (reduce )0.6 (the )0.5 (dose )0.5 (if )0.5 (this )0.6 (adverse )0.5 (reaction )0.6 (recurs)-10 ( )]TJ
-0.016 Tw 0 -1.006 Td
[(after reinitia)-9.9 (tion of SPR)18 (YCEL.)37 ( Dose reduction recommenda)-9.9 (tions are described in )36.9 (T)74 (able 5.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 495.894 252 -17.312 re
36 478.582 67.68 -16.965 re
103.68 478.582 30.72 -16.965 re
134.4 478.582 153.6 -16.965 re
36 461.617 67.68 -92.912 re
103.68 461.617 30.72 -26.456 re
134.4 461.617 51.2 -26.456 re
185.6 461.617 51.2 -26.456 re
236.8 461.617 51.2 -26.456 re
103.68 435.161 30.72 -66.456 re
134.4 435.161 51.2 -12.912 re
185.6 435.161 51.2 -12.912 re
236.8 435.161 51.2 -12.912 re
134.4 422.249 51.2 -13.386 re
185.6 422.249 51.2 -13.386 re
236.8 422.249 51.2 -13.386 re
134.4 408.863 51.2 -13.386 re
185.6 408.863 51.2 -13.386 re
236.8 408.863 51.2 -13.386 re
134.4 395.477 51.2 -13.386 re
185.6 395.477 51.2 -13.386 re
236.8 395.477 51.2 -13.386 re
134.4 382.091 51.2 -13.386 re
185.6 382.091 51.2 -13.386 re
236.8 382.091 51.2 -13.386 re
36 368.705 67.68 -52.912 re
103.68 368.705 30.72 -52.912 re
134.4 368.705 51.2 -12.912 re
185.6 368.705 51.2 -12.912 re
236.8 368.705 51.2 -12.912 re
134.4 355.793 51.2 -12.912 re
185.6 355.793 51.2 -12.912 re
236.8 355.793 51.2 -12.912 re
134.4 342.881 51.2 -12.912 re
185.6 342.881 51.2 -12.912 re
236.8 342.881 51.2 -12.912 re
134.4 329.969 51.2 -14.176 re
185.6 329.969 51.2 -14.176 re
236.8 329.969 51.2 -14.176 re
36 315.793 67.68 -84.912 re
103.68 315.793 81.92 -84.912 re
185.6 315.793 51.2 -84.912 re
236.8 315.793 51.2 -84.912 re
36 230.881 252 -12.912 re
f
0 0 0 1 K
1.01 w 
/GS2 gs
q 1 0 0 1 36 230.881 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 103.68 230.881 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 134.4 230.881 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 185.6 230.881 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 236.8 230.881 cm
0 0 m
51.2 0 l
S
Q
0.505 w 
q 1 0 0 1 36 217.9691 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 103.68 217.9691 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 134.4 217.9691 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 185.6 217.9691 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 236.8 217.9691 cm
0 0 m
51.2 0 l
S
Q
1 w 
q 1 0 0 1 36 478.5817 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 103.68 478.5817 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 134.4 478.5817 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 185.6 478.5817 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 236.8 478.5817 cm
0 0 m
51.2 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0.145 Tw 8 0 0 8 36 490.1817 Tm
[(Table )121 (5:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.75 0 Td
[(Dose Adjustments for Non-Hematologic Toxicities in Pediatric)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Patients)Tj
-0.02 Tc 0.024 Tw 7.2 0 0 8 167.4464 467.2432 Tm
(Dose \(maximum dose per day\))Tj
/T1_0 1 Tf
-0.01 Tc -18.256 -1.867 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If a non-hema)-10 (tologic)-10 ( )]TJ
-1.25 -1 Td
[(toxicity grade 2 occurs,)27 ( )]TJ
0 -1 Td
[(consider interrupting)-10 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL if no recover)-18 (y)-9.9 ( )]TJ
0 -1 Td
[(despite symptoma)-9.9 (tic)-10 ( )]TJ
0 -1 Td
[(thera)-10 (py; once recovered)-10 ( )]TJ
0 -1 Td
[(to grade \0341,)37 ( resume)-10 ( )]TJ
0 -1 Td
[(a)-10 (t the original starting)-10 ( )]TJ
0 -1 Td
[(dose.)37 ( Resume SPR)18 (YCEL)-9.9 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose for)-9.9 ( )]TJ
0 -1 Td
(recurrent events.)Tj
/T1_1 1 Tf
0.01 Tw 13.667 10 Td
[(Original)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 157.9003 452.3048 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 134.4 444.3048 Tm
(Starting Dose)Tj
7.111 1 Td
[(One-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
0.024 Tw 7.111 1 Td
[(T)74 (wo-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
-18.489 -2.307 Td
[(T)74 (ablets)]TJ
/T1_0 1 Tf
0.024 Tw 4.267 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
0.01 Tw 7.111 0 Td
(**)Tj
0.024 Tw -14.222 -1.614 Td
(60 mg)Tj
7.111 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
-14.222 -1.673 Td
(70 mg)Tj
7.111 0 Td
(60 mg)Tj
7.111 0 Td
(50 mg)Tj
-14.222 -1.673 Td
(100 mg)Tj
7.111 0 Td
(80 mg)Tj
7.111 0 Td
(70 mg)Tj
-27.889 -3.346 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If a non-hema)-10 (tologic)-10 ( )]TJ
-1.25 -1 Td
[(toxicity grade 3 occurs,)27 ( )]TJ
0 -1 Td
[(stop SPR)18 (YCEL until)-10 ( )]TJ
0 -1 Td
[(recover)-18 (y to grade \0341 and)-10 ( )]TJ
0 -1 Td
[(then resume a)-10 (t a reduced)-10 ( )]TJ
0.01 Tw 0 -1 Td
(dose.)Tj
0.024 Tw 0 -1.614 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If direct bilirubin is)-10 ( )]TJ
-1.25 -1 Td
[(>5 ULN or )37 (AST/AL)94 (T)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 88.0695 298.481 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 36 290.481 Tm
[(>15 ULN,)37 ( interrupt)-9.9 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL until recover)-18 (y)-10 ( )]TJ
0 -1 Td
[(to grade \0341 and then)-10 ( )]TJ
0 -1 Td
[(resume SPR)18.1 (YCEL a)-10 (t)-9.9 ( )]TJ
0 -1 Td
[(the original starting)-10 ( )]TJ
0 -1 Td
[(dose.)37 ( Resume SPR)18 (YCEL)-9.9 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose for)-9.9 ( )]TJ
0 -1 Td
[(recurrent hepa)-10 (totoxicity)55 (.)]TJ
-0.005 Tc 0 Tw 8 0 0 8 36 221.569 Tm
(**)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.75 0 Td
[(lo)-10 (wer tablet dose not a)-10 (vailable)]TJ
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -0.75 -3.175 Td
(2.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Duration of T)73.9 (reatment)]TJ
/T1_0 1 Tf
0.179 Tw -3.375 -1.389 Td
[(In c)20 (linical studies,)37 ( trea)-9.9 (tment with SPR)18 (YCEL in adults and in pedia)-9.9 (tric pa)-10 (tients with)-10 ( )]TJ
0.015 Tw 0 -1.006 Td
[(chronic phase )0.5 (CML )0.5 (was )0.5 (continued until disease )0.5 (progression )0.5 (or )0.5 (until )0.5 (no )0.5 (longer )0.5 (tolera)-10 (ted)-10 ( )]TJ
0.124 Tw 0 -1.006 Td
[(by the pa)-10 (tient.)37 ( )36.6 (The effect of stopping trea)-10 (tment on long-term disease outcome after)-10 ( )]TJ
0.107 Tw 0 -1.006 Td
[(the achievement of a c)20 (ytogenetic response \(inc)20 (luding complete c)20 (ytogenetic response)-10 ( )]TJ
0 Tw 0 -1.006 Td
([CCyR]\) or major molecular response \(MMR and MR4.5\) has not been esta\blished.)Tj
0.168 Tw 0 -1.434 Td
[(In c)20 (linical studies,)37 ( trea)-10 (tment with SPR)18 (YCEL in pedia)-9.9 (tric pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 27.314 0.125 Td
(+)Tj
-0.01 Tc 0.131 Tw 0.59 -0.125 Td
[( ALL )-36.8 (was)-10 ( )]TJ
0.05 Tw -27.904 -1.006 Td
[(administered for a maximum dura)-9.9 (tion of 2 years )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
18.261 0 Td
(s)Tj
-0.01 Tc 0.05 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.013 Tw 2.525 0 Td
[(a)-10 (ge )-36.8 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.05 Tw 6.086 0 Td
[(tra)-9.9 (tion \(2.2\))-9.9 ( )]TJ
0 Tw -27.269 -1.006 Td
(and Clinical Studie)Tj
0 Tc (s)Tj
-0.01 Tc 7.058 0 Td
( \(14.4\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.231 Tw -7.058 -1.434 Td
[(SPR)18 (YCEL is a hazardous product.)37 ( F)20 (ollo)-10 (w a)-10 (pplicable special handling and disposal)-10 ( )]TJ
0.01 Tw 0 -1.006 Td
(procedures.)Tj
0 Tc 0 Tw 6 0 0 6 70.2073 108.5689 Tm
(1)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 36 87.6391 Tm
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
/T1_0 1 Tf
0.082 Tw -3.375 -1.659 Td
[(SPR)18 (YCEL \(dasa)-10 (tinib\) )36.7 (T)74 (ablets are a)-10 (vailable as 20-mg,)37 ( 50-mg,)37 ( 70-mg,)37 ( 80-mg,)37 ( 100-mg,)27 ( )]TJ
0 Tw 0 -1.006 Td
[(and 140-mg white to off-white,)37 ( biconvex,)37.1 ( \037lm-coa)-9.9 (ted tablets.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -2.131 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(CONTRAINDIC)18 (A)55 (TIONS)]TJ
/T1_0 1 Tf
-3.375 -1.659 Td
(None.)Tj
/T1_1 1 Tf
36 86.406 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(W)18 (ARNINGS AND PREC)18 (AUTIONS)]TJ
0.01 Tw -3.375 -1.968 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Myelosuppression)Tj
/T1_0 1 Tf
0.362 Tw -3.375 -1.428 Td
[(T)74 (rea)-9.9 (tment with SPR)18 (YCEL is associa)-10 (ted with severe \(NCI CTCAE Grade)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
28.416 0 Td
[(3 or 4\))-10 ( )]TJ
0 Tw -28.416 -1.045 Td
[(thromboc)20 (ytopenia,)37 ( )0.6 (neutropenia,)37 ( )0.6 (and )0.6 (anemia,)37 ( )0.5 (which )0.6 (occur )0.5 (earlier )0.6 (and )0.6 (more )0.6 (frequently )0.6 (in)-10 ( )]TJ
-0.005 Tw 0 -1.045 Td
[(pa)-10 (tients with advanced phase CML or Ph)]TJ
0 Tc 0 Tw 14.679 0.125 Td
(+)Tj
-0.01 Tc -0.005 Tw 0.59 -0.125 Td
[( )37.4 (ALL than in pa)-10 (tients with chronic phase CML)-10 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw -15.269 -1.045 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc -0.037 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 3.517 0 Td
(e Reaction)Tj
0 Tc (s)Tj
-0.01 Tc 4.184 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.214 Tw -8.347 -1.338 Td
[(In pa)-10 (tients with chronic phase CML,)37 ( perform complete blood counts \(CBCs\) ever)-17.9 (y)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.281 Tw -31.5 -1.045 Td
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
0.7 0 Td
(weeks for 12)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
5.497 0 Td
[(weeks,)37 ( then ever)-18 (y 3)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
8.315 0 Td
[(months thereafter)74 (,)37 ( or as c)20 (linically indica)-9.9 (ted.)27 ( )]TJ
0.099 Tw -14.513 -1.045 Td
[(In pa)-10 (tients with advanced phase CML or Ph)]TJ
0 Tc 0 Tw 16.283 0.125 Td
(+)Tj
-0.01 Tc 0.099 Tw 0.59 -0.125 Td
[( )36.7 (ALL,)37 ( perform CBCs weekly for the \037rst)-10 ( )]TJ
0 Tw -16.873 -1.045 Td
(2)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(months and then monthly thereafter)74 (,)37 ( or as c)20 (linically indica)-10 (ted.)]TJ
0.359 Tw 0 -1.338 Td
[(In pedia)-10 (tric pa)-9.9 (tients with Ph)]TJ
0 Tc 0 Tw 11.457 0.125 Td
(+)Tj
-0.01 Tc 0.359 Tw 0.59 -0.125 Td
[( )37 (ALL trea)-10 (ted with SPR)18 (YCEL in combina)-9.9 (tion with)-10 ( )]TJ
0.074 Tw -12.047 -1.045 Td
[(chemothera)-9.9 (py)55 (,)37 ( perform CBCs prior to the start of each block of chemothera)-10 (py and as)-10 ( )]TJ
0.168 Tw 0 -1.045 Td
[(c)20 (linically indica)-10 (ted.)37 ( During the consolida)-9.9 (tion blocks of chemothera)-10 (py)55 (,)37 ( perform CBCs)-9.9 ( )]TJ
0 Tw 0 -1.045 Td
[(ever)-18 (y 2 days until recover)-18 (y)55 (.)]TJ
0.439 Tw 0 -1.473 Td
[(Myelosuppression is generally reversible and usually mana)-9.9 (ged by withholding)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc -31.5 -1.045 Td
[(SPR)18 (YCEL temporarily and/or dose reduction )]TJ
/T1_2 1 Tf
0 Tc ([)Tj
16.189 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee Do)Tj
0 Tc (s)Tj
-0.01 Tc -0.037 Tw 2.475 0 Td
[(a)-10 (ge )-37 (and Admini)]TJ
0 Tc 0 Tw (s)Tj
-0.01 Tc 5.987 0 Td
[(tra)-9.9 (tion \(2.5\)])]TJ
/T1_0 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -25.047 -1.743 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Bleeding-Related Events)Tj
/T1_0 1 Tf
0.062 Tw -3.375 -1.428 Td
[(SPR)18 (YCEL can )0.5 (cause )0.5 (serious )0.5 (and fa)-10 (tal )0.5 (bleeding.)37 ( )0.5 (In )0.5 (all )0.5 (CML )0.5 (or )0.5 (Ph)]TJ
0 Tc 0 Tw 23.459 0.125 Td
(+)Tj
-0.01 Tc 0.062 Tw 0.59 -0.125 Td
[( )37.4 (ALL )0.5 (c)20 (linical )0.5 (studies,)27 ( )]TJ
0.197 Tw -24.049 -1.045 Td
[(Grade \0363 central ner)-18 (vous system \(CNS\) hemorrha)-10 (ges,)37 ( inc)20 (luding fa)-10 (talities,)37 ( occurred)-10 ( )]TJ
0.276 Tw 0 -1.045 Td
[(in <1% of pa)-9.9 (tients receiving SPR)18 (YCEL.)37 ( )37.4 (The )0.5 (incidence of Grade 3/4 )0.5 (hemorrha)-10 (ge)-10 ( )]TJ
0.08 Tw 0 -1.045 Td
[(occurred in 5.8% of adult pa)-10 (tients and generally required trea)-9.9 (tment interruptions and)-10 ( )]TJ
0.037 Tw 0 -1.045 Td
[(transfusions.)37 ( )37.4 (The incidence of Grade 5 hemorrha)-10 (ge occurred in 0.4% of adult pa)-10 (tients.)27 ( )]TJ
-0.042 Tw 0 -1.045 Td
[(The most frequent site of hemorrha)-10 (ge was gastrointestinal )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
21.214 0 Td
(s)Tj
-0.01 Tc -0.079 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.042 Tw 3.475 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc -0.042 Tw 4.142 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
0 Tc 0 Tw 2.272 0 Td
( )Tj
-0.01 Tc 0.007 Tw -31.5 -1.045 Td
[(Most bleeding events in c)19.9 (linical studies were associa)-10 (ted with severe thromboc)20 (ytopenia.)27 ( )]TJ
0.089 Tw 0 -1.045 Td
[(In )0.5 (addition to causing thromboc)20 (ytopenia in )0.5 (human subjects,)37 ( )0.5 (dasa)-10 (tinib caused )0.5 (pla)-10 (telet)-10 ( )]TJ
0.01 Tw 0 -1.045 Td
[(d)-10 (ysfunction )]TJ
/T1_2 1 Tf
0 Tw 4.387 0 Td
(in vitro)Tj
/T1_0 1 Tf
0 Tc (.)Tj
-0.01 Tc 0.089 Tw -4.387 -1.338 Td
[(Concomitant medica)-10 (tions tha)-10 (t inhibit pla)-10 (telet function or anticoa)-9.9 (gulants may increase)-10 ( )]TJ
0 Tw 0 -1.045 Td
[(the risk of hemorrha)-10 (ge.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.608 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Fluid Retention)Tj
/T1_0 1 Tf
0.19 Tw -3.375 -1.428 Td
[(SPR)18 (YCEL may cause \035uid retention )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
14.065 0 Td
(s)Tj
-0.01 Tc 0.153 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.19 Tw 3.707 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.19 Tw 4.374 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( )36.7 (After 5 years of)-10 ( )]TJ
0.037 Tw -22.544 -1.045 Td
[(follo)-10 (w-up in the adult randomized newly dia)-9.9 (gnosed chronic phase CML stud)-9.9 (y \(n=258\),)27 ( )]TJ
0.092 Tw 0 -1.045 Td
[(Grade 3 or 4 \035uid retention was reported in 5% of pa)-10 (tients,)37 ( inc)20 (luding 3% of pa)-10 (tients)-10 ( )]TJ
0.058 Tw 0 -1.045 Td
[(with Grade 3 or 4 pleural effusion.)37 ( In adult pa)-10 (tients with newly dia)-9.9 (gnosed or ima)-10 (tinib-)]TJ
0.036 Tw 0 -1.045 Td
[(resistant or -intolerant chronic phase CML,)37.1 ( Grade 3 or 4 \035uid retention occurred in 6%)-10 ( )]TJ
0.051 Tw 0 -1.045 Td
[(of pa)-10 (tients trea)-10 (ted with SPR)17.9 (YCEL a)-10 (t the recommended dose \(n=548\).)37.1 ( In adult pa)-10 (tients)-10 ( )]TJ
-0.002 Tw 0 -1.045 Td
(with advanced phase CML or Ph)Tj
0 Tc 0 Tw 11.601 0.125 Td
(+)Tj
-0.01 Tc -0.002 Tw 0.59 -0.125 Td
[( )36.6 (ALL trea)-9.9 (ted with SPR)18 (YCEL a)-10 (t the recommended dose)-10 ( )]TJ
0.029 Tw -12.191 -1.045 Td
[(\(n=304\),)37 ( Grade 3 or 4 \035uid retention was reported in 8% of pa)-10 (tients,)37 ( inc)20 (luding Grade 3)-10 ( )]TJ
0.009 Tw 0 -1.045 Td
[(or 4 pleural effusion reported in 7% of pa)-9.9 (tients.)37 ( In pedia)-10 (tric pa)-9.9 (tients with chronic phase)-10 ( )]TJ
0 Tw 0 -1.045 Td
[(CML,)37 ( cases of Grade 1 or 2 \035uid retention were reported in 10.3% of pa)-10 (tients.)]TJ
0.132 Tw 0 -1.338 Td
[(Evalua)-10 (te pa)-10 (tients who develop symptoms of pleural effusion or other \035uid retenti\on,)27 ( )]TJ
0.102 Tw 0 -1.045 Td
[(such as new or worsened d)-10 (yspnea on exertion or a)-10 (t rest,)37 ( pleuritic chest pain,)37.1 ( or dr)-18 (y)-10 ( )]TJ
-0.025 Tw 0 -1.045 Td
[(cough,)37 ( promptly with a chest x-ray or additional dia)-10 (gnostic ima)-10 (ging as a)-9.9 (ppropria)-9.9 (te.)37 ( Fluid)-10 ( )]TJ
0.007 Tw 0 -1.045 Td
[(retention events were typically mana)-10 (ged by supportive care measures tha)-10 (t may inc)20 (lude)-10 ( )]TJ
0.01 Tw 0 -1.045 Td
[(diuretics or short courses of steroids.)37 ( Severe pleural effusion may require thoracentesis)-10 ( )]TJ
0.002 Tw 0 -1.045 Td
[(and oxygen thera)-10 (py)55 (.)37 ( Consider dose reduction or trea)-10 (tment interruption )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
25.713 0 Td
(s)Tj
-0.01 Tc 0.002 Tw 0.397 0 Td
(ee Do)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.002 Tw 2.477 0 Td
[(a)-10 (ge and)-10 ( )]TJ
0.01 Tw -28.587 -1.045 Td
(Admini)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 2.893 0 Td
[(tra)-9.9 (tion \(2.5\)])]TJ
/T1_0 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -2.893 -1.608 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Cardio)-10 (v)16 (ascular T)74 (oxicity)]TJ
/T1_0 1 Tf
0.126 Tw -3.375 -1.428 Td
[(SPR)18 (YCEL can cause cardiac d)-10 (ysfunction )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
15.555 0 Td
(s)Tj
-0.01 Tc 0.089 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.126 Tw 3.643 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.126 Tw 4.31 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( )37.2 (After 5 years)-10 ( )]TJ
0.18 Tw -23.905 -1.045 Td
[(of follo)-10 (w-up in the randomized newly dia)-10 (gnosed chronic phase CML trial in adults)-10 ( )]TJ
0.175 Tw 0 -1.045 Td
[(\(n=258\),)37 ( the follo)-9.9 (wing cardiac adverse reactions occurred:)37 ( cardiac ischemic events)-10 ( )]TJ
0.132 Tw 0 -1.045 Td
[(\(3.9% dasa)-10 (tinib vs 1.6% ima)-10 (tinib\),)37 ( cardiac-rela)-10 (ted \035uid retention \(8.5% dasa)-10 (tinib vs)-10 ( )]TJ
0.052 Tw 0 -1.045 Td
[(3.9% )0.5 (ima)-10 (tinib\),)37 ( )0.5 (and )0.5 (conduction )0.5 (system )0.5 (abnormalities,)37 ( )0.5 (most )0.5 (commonly )0.5 (arrhythmia )0.5 (and)-10 ( )]TJ
0.061 Tw 0 -1.045 Td
[(palpita)-10 (tions \(7.0% dasa)-9.9 (tinib vs 5.0% ima)-10 (tinib\).)37 ( )36.6 (T)74 (wo cases \(0.8%\) of peripheral arterial)-10 ( )]TJ
0.235 Tw 0 -1.045 Td
[(occ)20 (lusive disease occurred with ima)-10 (tinib and 2 \(0.8%\) transient ischemic a)-9.9 (ttacks)-9.9 ( )]TJ
-0.001 Tw 0 -1.045 Td
[(occurred with dasa)-10 (tinib.)37 ( Monitor pa)-9.9 (tients for signs or symptoms consistent with cardiac)-10 ( )]TJ
0 Tw 0 -1.045 Td
[(d)-10 (ysfunction and trea)-10 (t a)-9.9 (ppropria)-9.9 (tely)55 (.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.743 Td
(5.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Pulmonar)-18 (y Arterial Hypertension)]TJ
/T1_0 1 Tf
0.046 Tw -3.375 -1.405 Td
[(SPR)18 (YCEL may increase the risk of developing pulmonar)-17.9 (y arterial hypertension \(P)37 (AH\) in)-10 ( )]TJ
0.103 Tw 0 -1.045 Td
[(adult and pedia)-9.9 (tric )0.5 (pa)-10 (tients )0.5 (which )0.5 (may )0.5 (occur )0.5 (an)-10 (y )0.5 (time )0.5 (after initia)-10 (tion,)37 ( inc)20 (luding after)-10 ( )]TJ
0.097 Tw 0 -1.045 Td
[(more than 1 year of trea)-10 (tment.)37 ( Manifesta)-9.9 (tions inc)20 (lude d)-10 (yspnea,)37 ( fa)-9.9 (tigue,)37 ( hypoxia,)37 ( and)-10 ( )]TJ
0.047 Tw 0 -1.045 Td
(\035uid retention )Tj
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
5.542 0 Td
(s)Tj
-0.01 Tc 0.01 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.047 Tw 3.564 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.047 Tw 4.231 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( P)37 (AH may be reversible on discontinua)-10 (tion)-10 ( )]TJ
0.063 Tw -13.733 -1.045 Td
[(of SPR)18 (YCEL.)37 ( Evalua)-10 (te pa)-10 (tients for signs and symptoms of underlying cardiopulmonar)-18 (y)-10 ( )]TJ
0.027 Tw 0 -1.045 Td
[(disease prior to initia)-9.9 (ting SPR)18 (YCEL and during trea)-10 (tment.)37 ( If P)37 (AH is con\037rmed,)37 ( SPR)18 (YCEL)-10 ( )]TJ
0 Tw 0 -1.045 Td
(should be permanently discontinued.)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.743 Td
(5.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(QT Prolongation)Tj
/T1_0 1 Tf
0.049 Tw -3.375 -1.405 Td
[(SPR)18 (YCEL may increase the risk of prolonga)-9.9 (tion of QTc in pa)-9.9 (tients inc)20 (luding those with)-10 ( )]TJ
0.028 Tw 0 -1.045 Td
[(hypokalemia )0.5 (or )0.5 (hypoma)-10 (gnesemia,)37 ( )0.5 (pa)-10 (tients )0.5 (with )0.5 (congenital )0.5 (long )0.5 (QT )0.5 (syndrome,)37 ( )0.5 (pa)-9.9 (tients)-9.9 ( )]TJ
-0.056 Tw 0 -1.045 Td
[(taking antiarrhythmic medicines or other medicinal products tha)-9.9 (t lead to QT prolonga)-10 (tion,)27 ( )]TJ
0.051 Tw 0 -1.045 Td
[(and cumula)-10 (tive high-dose anthrac)20.1 (yc)20 (line thera)-10 (py )]TJ
/T1_2 1 Tf
0 Tc 0 Tw ([)Tj
18.04 0 Td
(s)Tj
-0.01 Tc 0.014 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.051 Tw 3.568 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.051 Tw 4.235 0 Td
( \(6.1\)])Tj
/T1_0 1 Tf
[(.)37 ( Correct)-10 ( )]TJ
0 Tw -26.24 -1.045 Td
[(hypokalemia or hypoma)-10 (gnesemia prior to and during SPR)18 (YCEL administra)-9.9 (tion.)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.743 Td
(5.7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Severe Dermatologic Reactions)Tj
/T1_0 1 Tf
0.177 Tw -3.375 -1.405 Td
[(Cases of severe mucocutaneous derma)-10 (tologic reactions,)37 ( inc)19.9 (luding Stevens-Johnson)-9.9 ( )]TJ
0.01 Tw 0 -1.045 Td
(syndrome )Tj
/T1_2 1 Tf
0 Tc 0 Tw 3.841 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.009 Tw 0.397 0 Td
(ee Adver)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.046 Tw 3.563 0 Td
(e Reaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 0.046 Tw 4.23 0 Td
( \(6.2\)])Tj
/T1_0 1 Tf
[( and er)-18 (ythema multiforme,)37 ( ha)-9.9 (ve been reported)-10 ( )]TJ
0.04 Tw -12.28 -1.045 Td
[(in )0.6 (pa)-10 (tients )0.5 (trea)-10 (ted )0.6 (with )0.6 (SPR)18 (YCEL.)37 ( )0.6 (Discontinue )0.6 (permanently )0.6 (in )0.5 (pa)-9.9 (tients )0.6 (who )0.5 (experience)-10 ( )]TJ
-0.017 Tw 0 -1.045 Td
[(a severe mucocutaneous reaction during trea)-10 (tment if no other etiolog)-10 (y can be identi\037ed.)]TJ
ET
endstreamendobj106 0 obj<</Length 26195>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 324 747.0331 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 493.5973 750.2881 Tm
[(SPR)37 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 530.2369 752.0881 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 534.9768 750.2881 Tm
( \(dasatinib\))Tj
/T1_1 1 Tf
-0.005 Tc -62.372 0 Td
[(FULL PRESCRIBING INFORMA)55 (TION)]TJ
-0.01 Tc 0.01 Tw 0 -2.125 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(INDIC)18 (A)55 (TIONS AND USAGE)]TJ
/T1_2 1 Tf
0.01 Tw -3.375 -1.653 Td
[(SPR)18 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 62.3997 721.8663 Tm
(\256)Tj
-0.01 Tc 8 0 0 8 67.1396 720.0663 Tm
[( \(dasa)-10 (tinib\) is indica)-9.9 (ted for the trea)-9.9 (tment of adult pa)-10 (tients with)]TJ
0.01 Tw -3.892 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.507 Tw 1.625 0 Td
[(newly dia)-10 (gnosed Philadelphia chromosome-positive \(Ph)]TJ
0 Tc 0 Tw 22.1 0.125 Td
(+)Tj
-0.01 Tc 0.507 Tw 0.59 -0.125 Td
[(\) chronic myeloid)-10 ( )]TJ
0 Tw -22.69 -1 Td
(leukemia \(CML\) in chronic phase.)Tj
0.01 Tw -1.625 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.026 Tw 1.625 0 Td
[(chronic,)37 ( )0.5 (accelera)-10 (ted,)37 ( )0.5 (or )0.5 (myeloid )0.5 (or )0.5 (lymphoid blast )0.5 (phase )0.5 (Ph)]TJ
0 Tc 0 Tw 21.644 0.125 Td
(+)Tj
-0.01 Tc 0.026 Tw 0.59 -0.125 Td
[( )0.5 (CML )0.5 (with )0.5 (resistance)-10 ( )]TJ
0 Tw -22.234 -1 Td
[(or intolerance to prior thera)-9.9 (py inc)20 (luding ima)-10 (tinib.)]TJ
0.01 Tw -1.625 -1.225 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.144 Tw 1.625 0 Td
[(Philadelphia )0.5 (chromosome-positive )0.5 (acute )0.5 (lymphoblastic )0.5 (leukemia )0.5 (\(Ph)]TJ
0 Tc 0 Tw 25.442 0.125 Td
(+)Tj
-0.01 Tc 0.107 Tw 0.59 -0.125 Td
[( )0.5 (ALL\) )-36.5 (with)-10 ( )]TJ
0 Tw -26.032 -1 Td
[(resistance or intolerance to prior thera)-10 (py)55 (.)]TJ
0.097 Tw -1.625 -1.428 Td
[(SPR)18 (YCEL \(dasa)-10 (tinib\) is indica)-9.9 (ted for the trea)-10 (tment of pedia)-10 (tric pa)-10 (tients 1 year of a)-10 (ge)-9.9 ( )]TJ
0 Tw 0 -1 Td
(and older with)Tj
0.01 Tw 1.125 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.625 0 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( CML in chronic phase.)Tj
0.01 Tw -3.139 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(newly dia)-10 (gnosed Ph)]TJ
0 Tc 7.214 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL in combina)-10 (tion with chemothera)-10 (py)55 (.)]TJ
/T1_1 1 Tf
0.01 Tw -10.554 -2.035 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(DOSAGE AND ADMINISTRA)55 (TION)]TJ
0.01 Tw -3.375 -1.653 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Dosage of SPR)18 (YCEL in Adult P)24 (atients)]TJ
/T1_2 1 Tf
0.168 Tw -3.375 -1.563 Td
[(The )0.6 (recommended )0.6 (starting )0.6 (dosa)-10 (ge )0.6 (of )0.6 (SPR)18 (YCEL )0.6 (for )0.6 (chronic )0.5 (phase )0.5 (CML )0.5 (in )0.6 (adults )0.6 (is)-10 ( )]TJ
0.034 Tw 0 -1 Td
[(100 mg administered orally once daily)55.1 (.)37 ( )37.2 (The recommended starting dosa)-10 (ge of SPR)18 (YCEL)-10 ( )]TJ
0.012 Tw 0 -1 Td
[(for accelera)-10 (ted phase CML,)37 ( myeloid or lymphoid blast phase CML,)37 ( or Ph)]TJ
0 Tc 0 Tw 26.026 0.125 Td
(+)Tj
-0.01 Tc 0.012 Tw 0.59 -0.125 Td
[( )36.8 (ALL in adults)-9.9 ( )]TJ
-0.011 Tw -26.616 -1 Td
[(is 140 mg administered orally once daily)55 (.)37 ( )37.2 (T)74 (ablets should not be crushed,)37.1 ( cut,)37 ( or chewed;)-9.9 ( )]TJ
0.03 Tw 0 -1 Td
[(they should be s)-10 (wallo)-10 (wed whole.)37 ( SPR)18 (YCEL can be taken with or without a meal,)37 ( either)-10 ( )]TJ
0 Tw 0 -1 Td
(in the morning or in the evening.)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.585 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
[(Dosage of SPR)18 (YCEL in P)24 (ediatric P)24 (atients with CML or Ph)]TJ
0 Tc 21.693 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
( ALL)Tj
/T1_2 1 Tf
0.034 Tw -25.658 -1.563 Td
[(The recommended starting dosa)-9.9 (ge for pedia)-10 (trics is based on bod)-9.9 (y weight as sho)-10 (wn in)-10 ( )]TJ
-0.041 Tw 0 -1 Td
[(T)74 (able 1.)37 ( )37 (The recommended dose should be administered orally once daily with or wi\thout)-9.9 ( )]TJ
0.047 Tw 0 -1 Td
[(food.)37 ( Recalcula)-10 (te the dose ever)-18 (y 3 months based on changes in bod)-10 (y weight,)37 ( or more)-10 ( )]TJ
0 Tw 0 -1 Td
[(often if necessar)-17.9 (y)55 (.)]TJ
/T1_1 1 Tf
0.158 Tw 0 -1.428 Td
[(Do not crush,)37 ( cut or chew tablets.)37 ( Swallow tablets whole.)]TJ
/T1_2 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
23.657 0 Td
[( )36.9 (There are additional)-10 ( )]TJ
0.243 Tw -23.657 -1 Td
[(administra)-10 (tion considera)-9.9 (tions for pedia)-9.9 (tric pa)-10 (tients who ha)-10 (ve dif\037culty s)-10 (wallo)-10 (wing)-10 ( )]TJ
0 Tw 0 -1 Td
(tablets whole )Tj
/T1_3 1 Tf
0 Tc ([)Tj
5.272 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee U)Tj
0 Tc (s)Tj
-0.01 Tc 2.004 0 Td
[(e in Speci\037c P)18 (opula)-10 (tion)]TJ
0 Tc (s)Tj
-0.01 Tc 8.785 0 Td
[( \(8.4\) and Clinical Pharmacolog)-10 (y \(12.3\)])]TJ
/T1_2 1 Tf
0 Tc (.)Tj
ET
0 0 0 0 k
/GS1 gs
36 457.503 252 -9.312 re
36 448.191 138.96 -12.912 re
174.96 448.191 113.04 -12.912 re
36 435.279 138.96 -10.752 re
174.96 435.279 113.04 -10.752 re
36 424.527 138.96 -10.752 re
174.96 424.527 113.04 -10.752 re
36 413.775 138.96 -10.752 re
174.96 413.775 113.04 -10.752 re
36 403.023 138.96 -10.752 re
174.96 403.023 113.04 -10.752 re
36 392.271 252 -30.712 re
f
1 w 
/GS2 gs
q 1 0 0 1 36 392.2714 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 392.2714 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 36 361.5595 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 361.5595 cm
0 0 m
113.04 0 l
S
Q
1 w 
q 1 0 0 1 36 448.191 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 448.191 cm
0 0 m
113.04 0 l
S
Q
0.5 w 
q 1 0 0 1 36 435.2791 cm
0 0 m
138.96 0 l
S
Q
q 1 0 0 1 174.96 435.2791 cm
0 0 m
113.04 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
-0.02 Tc 0.024 Tw 8 0 0 8 36 451.791 Tm
[(T)-10 (a)-10 (b)-10 (l)-10 (e)-10 ( )-10 (1)-10 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.068 0 Td
( )Tj
EMC 
3.557 0 Td
(Dosage of SPRYCEL for Pediatric Patients)Tj
0 Tc 0 Tw 6 0 0 6 214.7256 454.5909 Tm
(a)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 36 438.879 Tm
[(Body W)18 (eight \(kg\))]TJ
0 Tc 0 Tw 5.4 0 0 6 84.1025 441.679 Tm
(b)Tj
7.2 0 0 8 86.8025 438.879 Tm
( )Tj
-0.02 Tc 0.024 Tw 17.075 0 Td
(Daily Dose \(mg\))Tj
/T1_2 1 Tf
-0.01 Tc -24.131 -1.479 Td
(10 to less than 20)Tj
-0.005 Tc 25.956 0 Td
(40 mg)Tj
-0.01 Tc -25.956 -1.344 Td
(20 to less than 30)Tj
-0.005 Tc 25.956 0 Td
(60 mg)Tj
-0.01 Tc -25.956 -1.344 Td
(30 to less than 45)Tj
-0.005 Tc 25.956 0 Td
(70 mg)Tj
-0.01 Tc -25.956 -1.344 Td
[(a)-10 (t least 45)]TJ
-0.005 Tc 25.718 0 Td
(100 mg)Tj
0.005 Tw 5.4 0 0 6 36 385.7595 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.053 Tw 7.2 0 0 8 39.6 382.9595 Tm
[(F)20 (or pedia)-10 (tric pa)-10 (tients with Ph)]TJ
0 Tc 0 Tw 10.87 0.125 Td
(+)Tj
-0.005 Tc 0.053 Tw 0.595 -0.125 Td
[( )37 (ALL,)37 ( begin SPR)18 (YCEL thera)-10 (py on or before day 15 of induction)-5 ( )]TJ
0 Tw -11.465 -1 Td
[(chemothera)-10 (py)55 (,)37 ( when dia)-10 (gnosis is confirmed and continue for 2 years.)]TJ
0.005 Tw 5.4 0 0 6 36 367.9595 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 39.6 365.1595 Tm
[(T)74 (ablet dosing is not recommended for pa)-10 (tients weighing less than 10 kg.)]TJ
-0.01 Tc 0.077 Tw 8 0 0 8 36 346.4687 Tm
[(Refer to Section 2.4 for recommenda)-10 (tions on dose escala)-10 (tion in adults with CML and)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Ph)Tj
0 Tc 0 Tw 0.924 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL,)37 ( and pedia)-10 (tric pa)-10 (tients with CML.)]TJ
/T1_1 1 Tf
0.01 Tw -1.514 -1.585 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Dose Modi\037cation)Tj
-3.375 -1.63 Td
(Strong CYP3A4 Inducers)Tj
/T1_2 1 Tf
0.081 Tw 0 -1.293 Td
[(Avoid the use of concomitant strong CYP3A4 inducers and St.)37.1 ( John\222)55 (s wort.)37.1 ( If pa)-10 (tients)-10 ( )]TJ
0.053 Tw 0 -1 Td
[(must be coadministered a strong CYP3A4 inducer)74 (,)37 ( consider a SPR)17.9 (YCEL dose increase.)27 ( )]TJ
0.038 Tw 0 -1 Td
[(If the dose of SPR)18 (YCEL is increased,)37 ( monitor the pa)-10 (tient carefully for toxicity )]TJ
/T1_3 1 Tf
0 Tc 0 Tw ([)Tj
28.219 0 Td
(s)Tj
-0.01 Tc 0.038 Tw 0.397 0 Td
[(ee Drug)-9.9 ( )]TJ
0.01 Tw -28.616 -1 Td
(Interaction)Tj
0 Tc 0 Tw (s)Tj
-0.01 Tc 4.193 0 Td
( \(7.1\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc -4.193 -1.495 Td
(Strong CYP3A4 Inhibitors)Tj
/T1_2 1 Tf
-0.025 Tw 0 -1.293 Td
[(Avoid the use of concomitant strong CYP3A4 inhibitors and gra)-9.9 (pefruit juice.)37 ( Recommend)-10 ( )]TJ
0.136 Tw 0 -1 Td
[(selecting an alterna)-9.9 (te concomitant medica)-10 (tion with no or minimal enzyme inhibition)-10 ( )]TJ
0.049 Tw 0 -1 Td
[(potential,)37 ( if possible.)37 ( If SPR)18 (YCEL must be administered with a strong CYP3A4 inhibitor)74 (,)27 ( )]TJ
0 Tw 0 -1 Td
(consider a dose decrease to:)Tj
0.01 Tw 1.125 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(40 mg daily for pa)-9.9 (tients taking SPR)18 (YCEL 140 mg daily)55 (.)]TJ
0.01 Tw -1.625 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(20 mg daily for pa)-9.9 (tients taking SPR)18 (YCEL 100 mg daily)55 (.)]TJ
0.01 Tw -1.625 -1.36 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 1.625 0 Td
[(20 mg daily for pa)-9.9 (tients taking SPR)18 (YCEL 70 mg daily)55 (.)]TJ
0.013 Tw -2.75 -1.428 Td
[(F)20 (or pa)-10 (tients taking SPR)18.1 (YCEL 60 mg or 40 mg daily)55 (,)37 ( consider interrupting SPR)18 (YCEL until)-10 ( )]TJ
0.035 Tw 0 -1 Td
[(the )0.5 (inhibitor is )0.5 (discontinued.)37 ( )37.5 (Allo)-9.9 (w )0.5 (a )0.5 (washout )0.5 (period )0.5 (of )0.5 (a)-10 (pproxima)-9.9 (tely )0.5 (1 )0.5 (week )0.5 (after )0.5 (the)-10 ( )]TJ
0 Tw 0 -1 Td
[(inhibitor is stopped before reinitia)-10 (ting SPR)18 (YCEL.)]TJ
0.152 Tw 0 -1.428 Td
[(These reduced doses of SPR)18 (YCEL are predicted to adjust the area under the cur)-18 (ve)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.08 Tw -31.5 -1 Td
[(\(AUC\) to the range obser)-17.9 (ved without CYP3A4 inhibitors; ho)-9.9 (wever)74 (,)37 ( c)20 (linical da)-10 (ta are not)-10 ( )]TJ
0.096 Tw 0 -1 Td
[(a)-10 (vailable with )0.5 (these )0.5 (dose )0.5 (adjustments )0.5 (in pa)-9.9 (tients receiving strong )0.5 (CYP3A4 )0.5 (inhibitors.)27 ( )]TJ
0.058 Tw 0 -1 Td
[(If SPR)18 (YCEL is not tolera)-10 (ted after dose reduction,)37 ( either discontinue the strong CYP3A4)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(inhibitor or interrupt SPR)18 (YCEL until the inhibitor is discontinued.)37 ( )37.1 (Allo)-9.9 (w a washout period)-10 ( )]TJ
0.163 Tw 0 -1 Td
[(of a)-9.9 (pproxima)-10 (tely 1 week after the inhibitor is stopped before the SPR)18 (YCEL dose is)-10 ( )]TJ
0.01 Tw 0 -1 Td
(increased )Tj
/T1_3 1 Tf
0 Tc 0 Tw 3.731 0 Td
([)Tj
0.249 0 Td
(s)Tj
-0.01 Tc 0.397 0 Td
(ee Drug Interaction)Tj
0 Tc (s)Tj
-0.01 Tc 7.259 0 Td
( \(7.1\)])Tj
/T1_2 1 Tf
0 Tc (.)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -11.636 -2.013 Td
(2.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.033 Tw 3.375 0 Td
(Dose Escalation in Adults with CML and Ph)Tj
0 Tc 0 Tw 16.822 0.125 Td
(+)Tj
-0.01 Tc 0.033 Tw 0.59 -0.125 Td
[( ALL,)37 ( and P)24 (ediatric P)24 (atients)-10 ( )]TJ
0 Tw -17.412 -1 Td
(with CML)Tj
/T1_2 1 Tf
0.108 Tw -3.375 -1.563 Td
[(F)20 (or adult pa)-10 (tients with CML and Ph)]TJ
0 Tc 0 Tw 13.253 0.125 Td
(+)Tj
-0.01 Tc 0.108 Tw 0.59 -0.125 Td
[( )37 (ALL,)37 ( consider dose escala)-9.9 (tion to 140 mg once)-9.9 ( )]TJ
0.012 Tw -13.843 -1 Td
(daily \(chronic phase CML\) or 180 mg once daily \(advanced phase CML an\d Ph)Tj
0 Tc 0 Tw 28.217 0.125 Td
(+)Tj
-0.01 Tc -0.025 Tw 0.59 -0.125 Td
[( ALL\) )-37 (in)-9.9 ( )]TJ
-0.039 Tw -28.807 -1 Td
[(pa)-10 (tients who do not achieve a hema)-10 (tologic or c)20 (ytogenetic response a)-10 (t the recommended)-10 ( )]TJ
0.085 Tw 0 -1 Td
[(starting dosa)-9.9 (ge.)37 ( F)20 (or pedia)-9.9 (tric pa)-10 (tients with CML,)37 ( consider dose escala)-10 (tion to 120 mg)-10 ( )]TJ
-0.053 Tw 0 -1 Td
[(once daily \(see )37.1 (T)74 (able 2 belo)-9.9 (w\).)37 ( Dose escala)-9.9 (tion is not recommended for pedia)-10 (tric pa)-10 (tients)-10 ( )]TJ
0 Tw 0 -1 Td
(with Ph)Tj
0 Tc 2.688 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL,)37 ( where SPR)18 (YCEL is administered in combina)-10 (tion with chemothera)-10 (py)55 (.)]TJ
-0.007 Tw 32.722 86.406 Td
[(Escala)-10 (te the SPR)18 (YCEL dose as sho)-10 (wn in )36.7 (T)74 (able 2 in pedia)-9.9 (tric pa)-10 (tients with chronic phase)-10 ( )]TJ
0.064 Tw 0 -1.02 Td
[(CML who do not achieve a hema)-10 (tologic or c)20 (ytogenetic response a)-10 (t the recommended)-10 ( )]TJ
0 Tw 0 -1.02 Td
[(starting dosa)-10 (ge.)]TJ
ET
0 0 0 0 k
/GS1 gs
324 701.762 252 -9.312 re
324 692.45 69.48 -12.912 re
393.48 692.45 182.52 -12.912 re
324 679.539 69.48 -12.912 re
393.48 679.539 91.26 -12.912 re
484.74 679.539 91.26 -12.912 re
324 666.627 69.48 -10.752 re
393.48 666.627 91.26 -10.752 re
484.74 666.627 91.26 -10.752 re
324 655.875 69.48 -10.752 re
393.48 655.875 91.26 -10.752 re
484.74 655.875 91.26 -10.752 re
324 645.123 69.48 -10.752 re
393.48 645.123 91.26 -10.752 re
484.74 645.123 91.26 -10.752 re
324 634.371 69.48 -10.752 re
393.48 634.371 91.26 -10.752 re
484.74 634.371 91.26 -10.752 re
f
1 w 
/GS2 gs
q 1 0 0 1 324 623.6189 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 623.6189 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 623.6189 cm
0 0 m
91.26 0 l
S
Q
0.5 w 
q 1 0 0 1 324 666.6266 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 666.6266 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 666.6266 cm
0 0 m
91.26 0 l
S
Q
1 w 
q 1 0 0 1 324 692.4504 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 692.4504 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 692.4504 cm
0 0 m
91.26 0 l
S
Q
0.5 w 
q 1 0 0 1 324 679.5385 cm
0 0 m
69.48 0 l
S
Q
q 1 0 0 1 393.48 679.5385 cm
0 0 m
91.26 0 l
S
Q
q 1 0 0 1 484.74 679.5385 cm
0 0 m
91.26 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
-0.02 Tc 0.024 Tw 8 0 0 8 324 696.0504 Tm
[(T)-10 (a)-10 (b)-10 (l)-10 (e)-10 ( )-10 (2)-10 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.068 0 Td
( )Tj
EMC 
3.557 0 Td
(Dose Escalation for Pediatric CML)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 324 683.1385 Tm
(Formulation)Tj
0.024 Tw 9.65 0 Td
(Dose \(maximum dose per day\))Tj
0 -1.614 Td
(Starting Dose)Tj
0.01 Tw 12.675 0 Td
(Escalation)Tj
-22.325 -1.479 Td
[(T)74 (ablets)]TJ
/T1_2 1 Tf
0.024 Tw 9.65 0 Td
(40 mg)Tj
12.675 0 Td
(50 mg)Tj
-12.675 -1.344 Td
(60 mg)Tj
12.675 0 Td
(70 mg)Tj
-12.675 -1.344 Td
(70 mg)Tj
12.675 0 Td
(90 mg)Tj
-12.675 -1.344 Td
(100 mg)Tj
12.675 0 Td
(120 mg)Tj
/T1_1 1 Tf
0.01 Tw 8 0 0 8 324 608.1169 Tm
(2.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 3.375 0 Td
(Dose Adjustment for Adverse Reactions)Tj
0.01 Tw -3.375 -1.47 Td
(Myelosuppression)Tj
/T1_2 1 Tf
-0.025 Tw 0 -1.313 Td
[(In )0.6 (c)20 (linical )0.5 (studies,)37 ( )0.5 (myelosuppression )0.5 (was )0.5 (mana)-10 (ged )0.6 (by )0.6 (dose )0.6 (interruption,)37 ( )0.6 (dose )0.5 (reduction,)27 ( )]TJ
0.188 Tw 0 -1.02 Td
[(or discontinua)-10 (tion of stud)-10 (y thera)-9.9 (py)55 (.)37 ( Hema)-10 (topoietic gro)-9.9 (wth factor has been used in)-10 ( )]TJ
0.134 Tw 0 -1.02 Td
[(pa)-10 (tients )0.5 (with resistant )0.5 (myelosuppression.)37 ( )0.5 (Guidelines )0.5 (for )0.5 (dose )0.5 (modi\037ca)-10 (tions )0.5 (for )0.5 (adult)-10 ( )]TJ
0 Tw 0 -1.02 Td
[(and pedia)-10 (tric pa)-10 (tients are summarized in )37 (T)74 (ables 3 and 4,)37 ( respectively)55 (.)]TJ
ET
0 0 0 0 k
/GS1 gs
324 552.205 252 -17.312 re
324 534.893 67.68 -135.72 re
391.68 534.893 75.6 -135.72 re
467.28 534.893 108.72 -135.72 re
324 399.173 67.68 -118.85 re
391.68 399.173 75.6 -118.85 re
467.28 399.173 108.72 -118.85 re
324 280.323 252 -12.912 re
f
1.01 w 
/GS2 gs
q 1 0 0 1 324 280.3234 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 280.3234 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 280.3234 cm
0 0 m
108.72 0 l
S
Q
0.505 w 
q 1 0 0 1 324 267.4115 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 267.4115 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 267.4115 cm
0 0 m
108.72 0 l
S
Q
1 w 
q 1 0 0 1 324 534.8934 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 534.8934 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 534.8934 cm
0 0 m
108.72 0 l
S
Q
0.5 w 
q 1 0 0 1 324 399.1734 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.68 399.1734 cm
0 0 m
75.6 0 l
S
Q
q 1 0 0 1 467.28 399.1734 cm
0 0 m
108.72 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
0.224 Tw 8 0 0 8 324 546.4934 Tm
[(Table )200 (3:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.75 0 Td
[(Dose Adjustments for Neutropenia and Thrombocytopenia in)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Adults)Tj
/T1_2 1 Tf
-0.005 Tc 0.024 Tw 7.2 0 0 8 332.0322 470.4884 Tm
(Chronic Phase CML)Tj
-0.468 -1 Td
(\(starting dose 100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.926 0 Td
[(mg)-5 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 388.8496 462.4884 Tm
( )Tj
-0.005 Tc 0.024 Tw 7.2 0 0 8 343.6096 454.4884 Tm
(once daily\))Tj
8.385 2 Td
(ANC* <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 447.2484 473.2884 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 449.8134 470.4884 Tm
(/L)Tj
-3.192 -1 Td
(or)Tj
0.024 Tw -3.658 -1 Td
[(Pla)-10 (telets <50 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 450.7365 457.2884 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 453.3015 454.4884 Tm
(/L)Tj
-0.01 Tc 0.024 Tw 1.941 8.554 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(Stop SPR)18 (YCEL until )37 (ANC \0361.0 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 567.632 525.7234 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 570.1699 522.9234 Tm
[(/L)-10 ( )]TJ
0.024 Tw -13.04 -1 Td
[(and pla)-10 (telets \03650 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 536.4777 517.7234 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 539.0156 514.9234 Tm
(/L.)Tj
0.024 Tw -9.963 -1 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(Resume trea)-10 (tment with SPR)18 (YCEL a)-10 (t)-10 ( )]TJ
0 -1 Td
[(the original starting dose if recover)-18 (y)-10 ( )]TJ
0 -1 Td
(occurs in \0347 days.)Tj
-1.25 -1 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If pla)-10 (telets <25 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 530.7609 485.7234 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 533.2988 482.9234 Tm
[(/L or recurrence)-9.9 ( )]TJ
-7.919 -1 Td
[(of )37 (ANC <0.5 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 523.0575 477.7234 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 525.5955 474.9234 Tm
[(/L for >7 days,)27 ( )]TJ
-6.849 -1 Td
[(repea)-10 (t Step 1 and resume SPR)18.1 (YCEL)-10 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose of 80)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once)-10 ( )]TJ
0 -1 Td
[(daily for second episode.)37 ( F)20 (or)-9.9 ( )]TJ
0 -1 Td
[(third episode,)37 ( further reduce dose)-10 ( )]TJ
0 -1 Td
(to 50)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily \(for newly)-10 ( )]TJ
0 -1 Td
[(dia)-9.9 (gnosed pa)-10 (tients\) or discontinue)-10 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL \(for pa)-10 (tients resistant or)-10 ( )]TJ
0 -1 Td
[(intolerant to prior thera)-10 (py inc)20 (luding)-10 ( )]TJ
0.01 Tw 0 -1 Td
[(ima)-9.9 (tinib\).)]TJ
-0.005 Tc 0.024 Tw -20.896 -6.465 Td
[(Accelera)-10 (ted Phase CML,)32 ( )]TJ
0.54 -1 Td
[(Blast Phase CML and)-5 ( )]TJ
0.005 Tw 2.341 -1 Td
(Ph)Tj
0 Tc 0 Tw 0.934 0.125 Td
(+)Tj
-0.005 Tc -0.013 Tw 0.595 -0.125 Td
( ALL)Tj
0.024 Tw -4.017 -1 Td
(\(starting dose 140)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
6.926 0 Td
[(mg)-5 ( )]TJ
-4.849 -1 Td
(once daily\))Tj
8.385 3 Td
(ANC* <0.5 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 447.2484 346.0034 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 449.8133 343.2034 Tm
(/L)Tj
-3.192 -1 Td
(or)Tj
0.024 Tw -3.658 -1 Td
[(Pla)-10 (telets <10 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 450.7364 330.0034 Tm
(9)Tj
-0.005 Tc 0.005 Tw 7.2 0 0 8 453.3014 327.2034 Tm
(/L)Tj
-0.01 Tc 0.024 Tw 1.941 7.5 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(Check if c)20 (ytopenia is rela)-10 (ted to)-10 ( )]TJ
0 -1 Td
[(leukemia \(marro)-9.9 (w aspira)-10 (te or biopsy\).)]TJ
-1.25 -1 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia is unrela)-10 (ted to leukemia,)27 ( )]TJ
0 -1 Td
[(stop SPR)18 (YCEL until )37 (ANC \0361)60 (.0 )40 (\327 )80 (10)]TJ
0 Tc 0 Tw 5.4 0 0 6 565.6663 366.0034 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 568.2043 363.2034 Tm
(/L)Tj
0.024 Tw /Span<</ActualText<FEFF0009>>> BDC 
-14.017 -1 Td
( )Tj
EMC 
1.25 0 Td
[(and pla)-10 (telets \03620 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 536.4776 358.0034 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 539.0156 355.2034 Tm
[(/L and)-10 ( )]TJ
-8.713 -1 Td
[(resume a)-9.9 (t the original starting dose.)]TJ
-1.25 -1 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If recurrence of c)20 (ytopenia,)37 ( repea)-10 (t)-9.9 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 564.3333 339.2034 Tm
( )Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 476.2799 331.2034 Tm
[(Step 1 and resume SPR)18 (YCEL a)-10 (t a)-9.9 ( )]TJ
0 -1 Td
(reduced dose of 100)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)-10 ( )]TJ
0 -1 Td
(\(second episode\) or 80)Tj
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)-9.9 ( )]TJ
0 -1 Td
(\(third episode\).)Tj
-1.25 -1 Td
(4.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia is rela)-10 (ted to leukemia,)27 ( )]TJ
0 -1 Td
[(consider dose escala)-10 (tion to 1)20.1 (80)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg)-10 ( )]TJ
0 -1 Td
[(once daily)55.1 (.)]TJ
-0.005 Tc 0.005 Tw 8 0 0 8 323.9999 271.0115 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 7.2 0 0 8 326.9999 271.0115 Tm
[(ANC:)37 ( absolute neutrophil count)]TJ
ET
0 0 0 0 k
/GS1 gs
324 257.457 252 -17.312 re
324 240.145 67.68 -16.965 re
391.68 240.145 30.72 -16.965 re
422.4 240.145 153.6 -16.965 re
324 223.18 67.68 -52.912 re
391.68 223.18 30.72 -26.456 re
422.4 223.18 51.2 -26.456 re
473.6 223.18 51.2 -26.456 re
524.8 223.18 51.2 -26.456 re
391.68 196.724 30.72 -26.456 re
422.4 196.724 51.2 -12.912 re
473.6 196.724 51.2 -12.912 re
524.8 196.724 51.2 -12.912 re
422.4 183.812 51.2 -13.544 re
473.6 183.812 51.2 -13.544 re
524.8 183.812 51.2 -13.544 re
324 170.268 67.68 -68.912 re
391.68 170.268 30.72 -68.912 re
422.4 170.268 51.2 -12.912 re
473.6 170.268 51.2 -12.912 re
524.8 170.268 51.2 -12.912 re
422.4 157.356 51.2 -12.912 re
473.6 157.356 51.2 -12.912 re
524.8 157.356 51.2 -12.912 re
422.4 144.444 51.2 -12.912 re
473.6 144.444 51.2 -12.912 re
524.8 144.444 51.2 -12.912 re
422.4 131.532 51.2 -30.176 re
473.6 131.532 51.2 -30.176 re
524.8 131.532 51.2 -30.176 re
324 101.356 67.68 -44.192 re
391.68 101.356 81.92 -44.192 re
473.6 101.356 51.2 -44.192 re
524.8 101.356 51.2 -44.192 re
324 57.164 252 -20.912 re
f
1.01 w 
/GS2 gs
q 1 0 0 1 323.9999 57.1644 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.6799 57.1644 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 422.3999 57.1644 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 473.5999 57.1644 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 524.7999 57.1644 cm
0 0 m
51.2 0 l
S
Q
0.505 w 
q 1 0 0 1 323.9999 36.2525 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.6799 36.2525 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 422.3999 36.2525 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 473.5999 36.2525 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 524.7999 36.2525 cm
0 0 m
51.2 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 240.1451 cm
0 0 m
67.68 0 l
S
Q
q 1 0 0 1 391.6799 240.1451 cm
0 0 m
30.72 0 l
S
Q
q 1 0 0 1 422.3999 240.1451 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 473.5999 240.1451 cm
0 0 m
51.2 0 l
S
Q
q 1 0 0 1 524.7999 240.1451 cm
0 0 m
51.2 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_1 1 Tf
-0.01 Tc 0.024 Tw 8 0 0 8 323.9999 251.7451 Tm
(Table 4:)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
6.625 0 Td
[(Dose Adjustments for Neutropenia and Thrombocytopenia in)-10 ( )]TJ
0 -1 Td
(Pediatric Patients with Ph)Tj
0 Tc 0 Tw 10.065 0.125 Td
(+)Tj
-0.01 Tc 0.024 Tw 0.59 -0.125 Td
( CML)Tj
-0.02 Tc 7.2 0 0 8 457.2463 228.8067 Tm
(Dose \(maximum dose per day\))Tj
/T1_2 1 Tf
-0.01 Tc -18.506 -1.777 Td
(1.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia persists)-10 ( )]TJ
-1.25 -1 Td
[(for more than 3 weeks,)27 ( )]TJ
0 -1 Td
[(check if c)20.1 (ytopenia is)-10 ( )]TJ
0 -1 Td
[(rela)-10 (ted to leukemia)-9.9 ( )]TJ
0 -1 Td
[(\(marro)-10 (w aspira)-9.9 (te or)-10 ( )]TJ
0.01 Tw 0 -1 Td
(biopsy\).)Tj
/T1_1 1 Tf
0.024 Tw 13.667 5 Td
[(Original Starting)-10 ( )]TJ
0 Tc 0 Tw 7.2 0 0 8 469.9405 214.5882 Tm
( )Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 422.3999 206.5882 Tm
(Dose)Tj
0.024 Tw 7.111 1 Td
[(One-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
0.024 Tw 7.111 1 Td
[(T)74 (wo-Level Dose)-10 ( )]TJ
0.01 Tw 0 -1 Td
(Reduction)Tj
-18.489 -2.307 Td
[(T)74 (ablets)]TJ
/T1_2 1 Tf
0.024 Tw 4.267 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
0.01 Tw 7.111 0 Td
(**)Tj
0.024 Tw -14.222 -1.614 Td
(60 mg)Tj
7.111 0 Td
(40 mg)Tj
7.111 0 Td
(20 mg)Tj
-27.889 -1.783 Td
(2.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)19.9 (ytopenia is)-10 ( )]TJ
-1.25 -1 Td
[(unrela)-10 (ted to leukemia,)27 ( )]TJ
0 -1 Td
[(stop SPR)18 (YCEL until)-10 ( )]TJ
0 -1 Td
(ANC* \0361.0 \327 10)Tj
0 Tc 0 Tw 5.4 0 0 6 366.0184 139.7563 Tm
(9)Tj
-0.01 Tc 0.024 Tw 7.2 0 0 8 368.5564 136.9563 Tm
[(/L and)-10 ( )]TJ
-6.188 -1 Td
[(pla)-9.9 (telets \03675 \327 10)]TJ
0 Tc 0 Tw 5.4 0 0 6 372.7211 131.7563 Tm
(9)Tj
-0.01 Tc 0.01 Tw 7.2 0 0 8 375.259 128.9563 Tm
[(/L)-10 ( )]TJ
0.024 Tw -7.119 -1 Td
[(and resume a)-10 (t the)-10 ( )]TJ
0 -1 Td
[(original starting dose or)-10 ( )]TJ
0 -1 Td
[(a)-10 (t a reduced dose.)]TJ
13.667 7 Td
(70 mg)Tj
7.111 0 Td
(60 mg)Tj
7.111 0 Td
(50 mg)Tj
-14.222 -1.614 Td
(100 mg)Tj
7.111 0 Td
(80 mg)Tj
7.111 0 Td
(70 mg)Tj
-27.889 -6.955 Td
(3.)Tj
/Span<</ActualText<FEFF0009>>> BDC 
0.663 0 Td
( )Tj
EMC 
0.587 0 Td
[(If c)20 (ytopenia recurs,)27 ( )]TJ
-1.25 -1 Td
[(repea)-10 (t marro)-10 (w aspira)-9.9 (te/)]TJ
0 -1 Td
[(biopsy and resume)-9.9 ( )]TJ
0 -1 Td
[(SPR)18 (YCEL a)-10 (t a reduced)-10 ( )]TJ
0.01 Tw 0 -1 Td
(dose.)Tj
-0.005 Tc 0 Tw 8 0 0 8 323.9999 47.8525 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.375 0 Td
[(ANC:)37 ( absolute neutrophil count)]TJ
-0.375 -1 Td
(**)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.75 0 Td
[(lo)-10 (wer tablet dose not a)-10 (vailable)]TJ
ET
endstreamendobj107 0 obj<</BaseFont/IEWGNW+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 111 0 R/LastChar 174/Subtype/Type1/ToUnicode 112 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 741 0 648 0 0 0 0 0 0 593 0 0 0 667 0 722 649 0 0 0 0 0 667 0 0 0 0 0 0 0 574 611 0 611 0 0 0 0 258 0 0 0 0 593 0 0 0 0 537 352 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj111 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/C/E/L/P/R/S/Y/a/b/d/i/n/s/t/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 113 0 R/FontName/IEWGNW+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj112 0 obj<</Filter/FlateDecode/Length 312>>stream
Hâ\ëÀj√0E˜˙äY6ã‡G#;cn
^ÙA›~Ä#çSA-ŸY¯Ô;“Ñ*∞Á›{ëfí¶}j≠Y y˜ìÍpÅ¡XÌqûÆ^!úÒb¨»r–F-∑]¸´±w"!s∑Œé≠&QUê|–·º¯éz:„F$o^£7ˆ_M∑Å§ª:˜É#⁄R®k–8P–KÔ^˚!â∂m´È‹,Îñ<äœ’!‰qüÒe‘§qvΩBﬂ€ä*•UCıL´hıøÛlœ∂Û†æ{/™<à”î
Òûy¯¿| ﬁ=F¶B,ôe‡Üπ!ñú#CéÃôÛ¿Ïï¡+9SÜÃ"ãLÖòıE–;Ê]`÷Qb>óúYÜÃíıe–YC%<¸ˆ¬–ö‹˚´ÆﬁSk„8cOC7ç≈˚ƒ›‰Ä\·ø ][ó>endstreamendobj113 0 obj<</Filter/FlateDecode/Length 1660/Subtype/Type1C>>stream
HâÑTPT◊~è›ΩHû ÚÓÍ€ÁJ4éÏ.(ÇEàPA	âbˆ!K`üŸ]˛Qõ611$„OIàm‚h#QÒ'ñ4qtbíF#€©î∆§§ñÛÏtzój:È¥”wgÓ=ÁæsæsæsÔ=,£`Xñùñëöóûï7g©TV)yùEˆ,©BZûõ„uD-q¯åäÅU¬‘ ‘—uÔ¬Ω"çÚ‘DeÀ‰èßj]°LÄfÎMë7÷∏ùJº¢5a˛|3ù,„s¨Y¥Y,61Ÿ!JbNç«+ï{ƒWëÏﬁ(ªÌ^…-&óïâ„Œ—-y$w•Ûˇ".w∫doÕFIL//\˙?@~‰%:=¢]Ù∫Ì©‹Ó~VîãˇÌüBSâ¶Nú49∑‰ù.—["â´£s¢≈4EóW¥ªbÓèﬁŸ≈≈Œ"i|≥‹^#Rb?ı.í‹^;]e
„K+‹Nè√Y‰u .œpóΩ\˙/Y»n—IîQxóGí˛ÉdLZNÆ_âR1C?ñ	bÇôHf&≈XôX&éIdñ0)L*≥å…frô’ÃFGèà…bV2çÃ96å]ƒÊ≥˚ÿ»˚Ta™R’y’êzñ∫Q˝[M>FnÎQæÌaÈŸ£⁄¶V∆V¯ºÇΩ<&¡NÒ,~≈◊¢ıëÇqíêÍD9√˚%Ùkú/Ä√πï˜©bœÄIÀ«d>uÎ1gÎ—“É∂8UÄ`íëN∞ÅM1á¡˙L¯ç¯˝‘∏åˇÑálò≠K>ÿ`öÄ¡‰+|‰¥°Mè1%hMFQ‡æ≠Ö•"ÿ£`Uç=°∏xH®∆à€h5‡sé	XÇÖ@WxR`"H€cD3â⁄≤:céßØÅò ìœ“e˙µœV?˛öë€±"®-Qˆ2ÖΩÆº>ûn~~Q CT?D∏'©©“_ı¿j;D‡_ï~¥ÓÕˆJh••¿˘ˇBò©Z!ÅÊp4Åi†¡4#^!`Eéé¸˛bù≈≤¨nâ9¬]£ù†Üu˜1∫∆£P°¨§ˇÌ“≈ø4Ó\’ò∂ø êÍÚ{MÉ›[ø¨∏íÙ´¿Ì⁄˛Œw.ÍÅI¸#Ü	>˛~Ä≈‰Û£Âi)Ry™Æπ8•	∏–0cò· òu}∫°xû««·—«¿fÄ5?‹Åáa∆uÂµu}ò˛°≥Â#˝Ôz€{Æ|R1∑Y 3Åúvg#èB*ŒD˝h·ﬂe·Æ<∫9Iø$æ.W–≈'6˙´2VP≈Be-~*ø&∞OYÆ¡B{Õa\ á5òJ`èo©ÜK›4ú¯5¿ph'ò† L∫n%÷Úe/≈¢j]a€Ÿ3ÔΩ~ºU8æ≥ß©£=≥ÓÚÁõøqŒ–sÏÁY+_â€lå›+cê~˙µßÓ\∏¥˜D∑†´n™›Q€\ëds˚÷'ÙÜ&·§7#1'·î_\È¶—Ë!ÖÃ™–s4ÚÛ4Ú)]˝πp0›©K€µ´]^5¸ ™X+Q5ôôÈYSblÑ64e¢o-?∑xa||qˇ7∑éÙY˜ST?ü≠ˇBUPÿ±4a[#9˝lˆÅ,öìh!çF›)úqÈ∏‘€qæKÿNa?ONàä-æ˘ıÕŒÎC∑.à8_x{•≤ªÍ{b{ÈÎÈì≤õÊAc‰Û7LÙ¢Rõ¯;≥A=Œhùøñîè	:»›Æ˙.Ωeü'`7’ø–BòtÁd?!Ø‹ 4]ﬂóh–r‚¶azÏ˚‘"ì∆xÚ8ÌU*ÄCqò˙óƒÉÛ˜˜/h9≠?v‚’Œ”«Ísw¥d†˚Ÿå£®1†
â#,7\7jå#◊?£œœ´+Ã…{Î”óÈ˚Ô~ëﬁÙÀ√Ïmÿ<ÁO=fÆ˘Ï%ëW´n˝ÊP”éT⁄Ü˙M/◊ûﬁ≤Î§Zˇ6<CÀÅ•ˆ:ÏªÆ≥{F`  XÄQÌÅ{<VCŒÇıtd¿,®Ü*ÃÄô∏ûézS´Ñëp⁄Õ&”Œ`Ö–·D⁄…°'aZq2LÇELAâÄÙ3d”5∑™!SÛiÛ…É}˙?≠Ë2	h#À¯œ…—ì/<YÚ¬Zc2·j˜éÏ≈“›ÿ6{[GZ}}ªµ˜7w¬ÅñÔ[|ﬁ4¶	£ØÖÑÄÈıêá‡TÿXˇO Ãâendstreamendobj105 0 obj<</Length 21735>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8 0 0 8 36 750.2881 Tm
[(HIGHLIGHTS OF PRESCRIBING INFORMA)55 (TION)]TJ
0.19 Tw 0 -1.366 Td
[(These )0.5 (highlights do )0.5 (not inc)20 (lude all the )0.5 (information )0.5 (needed to use )0.5 (SPR)18 (YCEL)]TJ
0 Tc 0 Tw 6 0 0 6 283.2001 742.1587 Tm
(\256)Tj
8 0 0 8 288 739.3587 Tm
( )Tj
T*
( )Tj
-0.01 Tc -31.5 -1.051 Td
[(safely and effectively)55 (.)37 ( See full prescribing information for SPR)18 (YCEL.)]TJ
0 -1.749 Td
[(SPR)18 (YCEL \(dasatinib\) tablets,)37 ( for oral use)]TJ
0 -1.366 Td
[(Initial U.S.)37.1 ( Appro)-10 (v)16 (al: 2006)]TJ
0.01 Tw 0 -1.802 Td
(-----------------------------)Tj
0 Tw 10.731 0 Td
(RECENT MAJOR CHANGES)Tj
-0.12 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-----------------------------)Tj
/T1_1 1 Tf
0 Tw -10.731 -1.384 Td
[(W)18 (arnings and Precautions \(5.11\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.872 0 Td
(2/2023)Tj
/T1_0 1 Tf
0.01 Tw -28.872 -1.712 Td
(------------------------------)Tj
0 Tw 10.903 0 Td
[(INDIC)18.1 (A)54.9 (TIONS AND USAGE)]TJ
0.052 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-----------------------------)Tj
0 Tw -10.903 -1.366 Td
[(SPR)18 (YCEL is a kinase inhibitor indicated for the treatment of)]TJ
/T1_1 1 Tf
0.01 Tw 0 -1.519 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.185 Tw 2.25 0 Td
[(newly dia)-9.9 (gnosed adults with Philadelphia chromosome-positive \(Ph)]TJ
0 Tc 0 Tw 25.352 0.125 Td
(+)Tj
-0.01 Tc 0.185 Tw 0.59 -0.125 Td
[(\) chronic)-9.9 ( )]TJ
0 Tw -25.942 -1.114 Td
[(myeloid leukemia \(CML\) in chronic phase.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -2.25 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.106 Tw 2.25 0 Td
[(adults with chronic,)37 ( accelera)-10 (ted,)37.1 ( or myeloid or lymphoid blast phase Ph)]TJ
0 Tc 0 Tw 26.677 0.125 Td
(+)Tj
-0.01 Tc 0.106 Tw 0.59 -0.125 Td
[( CML)-10 ( )]TJ
0 Tw -27.267 -1.114 Td
[(with resistance or intolerance to prior thera)-9.9 (py inc)20 (luding ima)-9.9 (tinib.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -2.25 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.288 Tw 2.25 0 Td
[(adults with Philadelphia chromosome-positive acute lymphoblastic leukemi\a)-9.9 ( )]TJ
0 Tc 0 Tw 29.25 0 Td
( )Tj
-0.01 Tc 0.01 Tw -29.25 -1.114 Td
(\(Ph)Tj
0 Tc 0 Tw 1.155 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( )37 (ALL\) with resistance or intolerance to prior thera)-9.9 (py)55 (.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -3.995 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 2.25 0 Td
[(pedia)-9.9 (tric pa)-9.9 (tients 1 year of a)-9.9 (ge and older with Ph)]TJ
0 Tc 17.699 0.125 Td
(+)Tj
-0.01 Tc 0.59 -0.125 Td
[( CML in chronic phase.)37 ( \(1,)37 ( 14\))]TJ
0.01 Tw -20.539 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.172 Tw 2.25 0 Td
[(pedia)-9.9 (tric pa)-9.9 (tients 1 year of a)-9.9 (ge and older with newly dia)-10 (gnosed Ph)]TJ
0 Tc 0 Tw 25.878 0.125 Td
(+)Tj
-0.01 Tc 0.135 Tw 0.59 -0.125 Td
[( ALL )-36.8 (in)-10 ( )]TJ
0 Tw -26.468 -1.114 Td
[(combina)-10 (tion with chemothera)-10 (py)55 (.)37 ( \(1,)37 ( 14\))]TJ
/T1_0 1 Tf
0.01 Tw -2.25 -1.847 Td
(---------------------------)Tj
0 Tw [(DOSAGE AND ADMINISTRA)55 (TION)]TJ
-0.05 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
0.01 Tw 0 -1.519 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 2.25 0 Td
[(Chronic phase CML in adults:)37 ( 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)55 (.)37 ( \(2\))]TJ
0.01 Tw -2.25 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.123 Tw 2.25 0 Td
[(Accelera)-10 (ted phase CML,)37 ( myeloid or lymphoid blast phase CML,)37 ( or Ph)]TJ
0 Tc 0 Tw 25.976 0.125 Td
(+)Tj
-0.01 Tc 0.086 Tw 0.59 -0.125 Td
[( ALL )-36.8 (in)-10 ( )]TJ
0 Tw -26.566 -1.114 Td
[(adults:)37 ( 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg once daily)55 (.)37 ( \(2\))]TJ
0.01 Tw -2.25 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.008 Tw 2.25 0 Td
[(Chronic phase CML and )37.2 (ALL in pedia)-10 (trics:)37 ( starting dose based on bod)-10 (y weight.)37 ( \(2\))]TJ
0.01 Tw -2.25 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tw 2.25 0 Td
[(Administer orally)55 (,)37 ( with or without a meal.)37 ( Do not crush,)37.1 ( cut,)37 ( or chew tablets.)37 ( \(2\))]TJ
/T1_0 1 Tf
0.01 Tw -2.25 -1.847 Td
(-------------------------)Tj
0 Tw 9.27 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
-0.141 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------)Tj
/T1_1 1 Tf
0 Tw -9.27 -1.384 Td
[(T)74 (ablets:)37 ( 20)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( 50)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37.1 ( 70)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( 80)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( 100)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg,)37 ( and 140)]TJ
/Span<</ActualText<FEFF202F>>> BDC 
( )Tj
EMC 
[(mg.)37.1 ( \(3\))]TJ
/T1_0 1 Tf
0 Tc 0 -1.681 Td
(-------------------------------)Tj
-0.01 Tc 0.01 Tw 11.67 0 Td
[(CONTRAINDIC)18 (A)55 (TIONS)]TJ
0 Tc -0.09 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------------)Tj
/T1_1 1 Tf
-0.01 Tc 0 Tw -11.67 -1.384 Td
[(None.)37.1 ( \(4\))]TJ
/T1_0 1 Tf
0.01 Tw 0 -1.712 Td
(---------------------------)Tj
0 Tw 9.833 0 Td
[(W)18 (ARNINGS AND PREC)18 (AUTIONS)]TJ
0.062 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
0.01 Tw -9.833 -1.519 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.108 Tw 2.25 0 Td
(Myelosuppression and Bleeding Events:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.625 0 Td
[( Severe thromboc)20 (ytopenia,)37 ( neutropenia,)27 ( )]TJ
0.05 Tw -14.625 -1.114 Td
[(and anemia may occur)74 (.)37 ( Use caution if used concomitantly with medica)-10 (tions tha)-10 (t)-9.9 ( )]TJ
-0.05 Tw 0 -1.114 Td
[(inhibit pla)-9.9 (telet function or anticoa)-10 (gulants.)37 ( Monitor complete blood counts regularly)55 (.)27 ( )]TJ
0 Tw 0 -1.114 Td
[(T)74 (ransfuse and interrupt SPR)18 (YCEL when indica)-10 (ted.)37 ( \(2.5,)37 ( 5.1,)37 ( 5.2\))]TJ
0.01 Tw -2.25 -1.564 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.152 Tw 2.25 0 Td
(Fluid Retention:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.78 0 Td
[( Fluid retention,)37 ( sometimes severe,)37 ( inc)20 (luding pleural effusions.)27 ( )]TJ
0 Tw -5.78 -1.114 Td
[(Mana)-9.9 (ge with supportive care measures and/or dose modi\037ca)-10 (tion.)37 ( \(2.5,)37 ( 5.3\))]TJ
0.01 Tw -2.25 -1.541 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.298 Tw 2.25 0 Td
[(Cardiovascular T)74 (oxicity:)]TJ
/T1_1 1 Tf
0.335 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.768 0 Td
[( Monitor pa)-9.9 (tients for signs or symptoms and trea)-10 (t)-10 ( )]TJ
0 Tw -8.768 -1.114 Td
[(a)-10 (ppropria)-10 (tely)55 (.)37 ( \(5.4\))]TJ
0.01 Tw 33.75 51.396 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.172 Tw 2.25 0 Td
[(Pulmonar)-18 (y )37 (Arterial Hypertension \(P)37 (AH\):)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.471 0 Td
[( SPR)18 (YCEL \(dasa)-10 (tinib\) may increase the)-10 ( )]TJ
0 Tc 0 Tw 14.779 0 Td
( )Tj
-0.01 Tc 0.18 Tw -29.25 -1.062 Td
[(risk of developing P)37 (AH which may be reversible on discontinua)-10 (tion.)37 ( Consider)-10 ( )]TJ
0.252 Tw 0 -1.062 Td
[(baseline risk and evalua)-10 (te pa)-9.9 (tients for signs and symptoms of P)37 (AH during)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(trea)-10 (tment.)37 ( Stop SPR)18 (YCEL if P)37 (AH is con\037rmed.)37 ( \(5.5\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.007 Tw 2.25 0 Td
[(QT Prolonga)-10 (tion:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.996 0 Td
[( Use SPR)18 (YCEL with caution in pa)-10 (tients who ha)-9.9 (ve or may develop)-10 ( )]TJ
0 Tw -5.996 -1.062 Td
[(prolonga)-10 (tion of the QT inter)-18 (val.)37 ( \(5.6\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.326 Tw 2.25 0 Td
[(Severe Derma)-9.9 (tologic Reactions:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
12.163 0 Td
[( Individual cases of severe mucocutaneous)-10 ( )]TJ
0 Tw -12.163 -1.062 Td
[(derma)-10 (tologic reactions ha)-10 (ve been reported.)37 ( \(5.7\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.272 Tw 2.25 0 Td
[(T)74 (umor L)37 (ysis Syndrome:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.969 0 Td
[( )36.7 (T)74 (umor lysis syndrome has been reported.)37 ( Maintain)-10 ( )]TJ
0.143 Tw -8.969 -1.062 Td
[(adequa)-10 (te hydra)-10 (tion and correct uric acid levels prior to initia)-10 (ting thera)-10 (py with)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(SPR)18 (YCEL.)37 ( \(5.8\))]TJ
0.01 Tw -2.25 -1.468 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.178 Tw 2.25 0 Td
[(Embr)-17.9 (yo-F)24 (etal T)74 (oxicity:)]TJ
/T1_1 1 Tf
0.215 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
8.142 0 Td
[( Can cause fetal harm.)37.1 ( )37.1 (Advise pa)-10 (tients of reproductive)-10 ( )]TJ
-0.016 Tw -8.142 -1.062 Td
[(potential )0.5 (of )0.5 (potential )0.5 (risk )0.5 (to fetus )0.5 (and )0.5 (to )0.5 (use )0.5 (effective )0.5 (contraception.)37 ( )0.5 (\(5.9,)37.1 ( 8.1,)37 ( )0.5 (8.3\))]TJ
0.01 Tw -2.25 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0.205 Tw 2.25 0 Td
[(Effects on Gro)-10 (wth and Development in P)18 (edia)-10 (tric P)18 (a)-10 (tients:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
21.961 0 Td
[( epiphyses delayed)-10 ( )]TJ
0.151 Tw -21.961 -1.062 Td
[(fusion,)37 ( osteopenia,)37 ( gro)-10 (wth retarda)-10 (tion,)37 ( and g)-10 (ynecomastia ha)-10 (ve been reported.)27 ( )]TJ
0 Tw 0 -1.062 Td
[(Monitor bone gro)-9.9 (wth and development in pedia)-10 (tric pa)-10 (tients.)37 ( \(5.10\))]TJ
0.01 Tw -2.25 -1.49 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
2.25 0 Td
[(Hepa)-10 (totoxicity:)]TJ
/T1_1 1 Tf
0.132 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.33 0 Td
[( )37 (Assess liver function before initia)-9.9 (tion of trea)-9.9 (tment and monthly)-10 ( )]TJ
0.112 Tw -5.33 -1.062 Td
[(thereafter or as c)20 (linically indica)-10 (ted.)37 ( Monitor liver function when combined with)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(chemothera)-10 (py kno)-9.9 (wn to be associa)-10 (ted with liver d)-10 (ysfunction.)37.1 ( \(5.11\))]TJ
/T1_0 1 Tf
0.01 Tw -2.25 -1.765 Td
(--------------------------------)Tj
0 Tw 11.614 0 Td
(ADVERSE REACTIONS)Tj
0 Tc -0.147 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------------)Tj
/T1_1 1 Tf
-0.01 Tc 0.008 Tw -11.614 -1.332 Td
[(Most )0.5 (common adverse )0.5 (reactions )0.5 (\(\03615%\) )0.5 (in pa)-9.9 (tients )0.5 (receiving )0.5 (SPR)18 (YCEL )0.5 (as single-a)-9.9 (gent)-10 ( )]TJ
0.194 Tw 0 -1.062 Td
[(thera)-10 (py )0.6 (inc)20 (luded )0.6 (myelosuppression,)37 ( )0.6 (\035uid )0.6 (retention )0.6 (events,)37 ( )0.5 (diarrhea,)37 ( )0.5 (headache,)37 ( )0.6 (skin)-10 ( )]TJ
0 Tw 0 -1.062 Td
[(rash,)37.1 ( hemorrha)-10 (ge,)37 ( d)-9.9 (yspnea,)37 ( fa)-10 (tigue,)37 ( nausea,)37 ( and musculoskeletal pain.)37 ( \(6\))]TJ
0.279 Tw 0 -1.242 Td
[(Most common adverse reactions \(\03630%\) in pedia)-10 (tric pa)-10 (tients receiving SPR)18 (YCEL)-9.9 ( )]TJ
0.213 Tw 0 -1.062 Td
[(in combina)-9.9 (tion with chemothera)-10 (py inc)20 (luded )0.5 (mucositis,)37 ( febrile neutropenia,)37 ( pyrexia,)27 ( )]TJ
0.157 Tw 0 -1.063 Td
[(diarrhea,)37 ( nausea,)37 ( vomiting,)37 ( musculoskeletal pain,)37 ( abdominal pain,)37 ( cough,)37 ( headache,)27 ( )]TJ
0.073 Tw 0 -1.062 Td
[(rash,)37.1 ( fa)-10 (tigue,)37 ( constipa)-9.9 (tion,)37 ( arrhythmia,)37 ( hypertension,)37 ( edema,)37 ( infections \(bacterial,)37 ( viral)-10 ( )]TJ
0.317 Tw 0 -1.062 Td
[(and fungal\),)37 ( hypotension,)37 ( decreased a)-9.9 (ppetite,)37 ( hypersensitivity)55 (,)37 ( d)-10 (yspnea,)37 ( epistaxis,)27 ( )]TJ
0 Tw 0 -1.062 Td
[(peripheral neuropa)-9.9 (thy)55 (,)37 ( and altered sta)-10 (te of consciousness.)37 ( \(6\))]TJ
/T1_0 1 Tf
0.253 Tw 0 -1.495 Td
[(T)74 (o report SUSPECTED ADVERSE REACTIONS,)37 ( contact Bristol-Myers Squibb at)-10 ( )]TJ
0 Tw 0 -1 Td
[(1-800-721-5072 or FD)34 (A at 1-800-FD)34.1 (A-1088 or www)37 (.fda.go)-10 (v/medwatch.)]TJ
0.01 Tw 0 -1.976 Td
(--------------------------------)Tj
0 Tw 11.684 0 Td
[(DR)-10 (UG INTERACTIONS)]TJ
0.113 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------------)Tj
/T1_1 1 Tf
0.01 Tw -11.684 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0 Tw 2.25 0 Td
(Strong CYP3A4 Inhibitors:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.256 0 Td
[( Dose reduction may be necessar)-17.9 (y)55 (.)37 ( \(2.3,)37 ( 7.1\))]TJ
0.01 Tw -11.506 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0 Tw 2.25 0 Td
(Strong CYP3A4 Inducers:)Tj
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.035 0 Td
[( Dose increase may be necessar)-18 (y)55 (.)37.1 ( \(2.3,)37 ( 7.1\))]TJ
0.01 Tw -11.285 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
2.25 0 Td
(Antacids:)Tj
/T1_1 1 Tf
0 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.348 0 Td
[( )37 (Avoid simultaneous administra)-10 (tion.)37 ( \(7.1\))]TJ
0.01 Tw -5.598 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
0 Tc 0 Tw 2.25 0 Td
(H)Tj
-0.01 Tc 0.01 Tw 6 0 0 6 346.2158 400.3981 Tm
(2 )Tj
0 Tw 8 0 0 8 350.4157 400.8981 Tm
[(Anta)-9.9 (gonists and Proton Pump Inhibitors:)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
14.457 0 Td
[( )37 (Avoid coadministra)-10 (tion.)37 ( \(7.1\))]TJ
/T1_0 1 Tf
0.01 Tw -17.759 -1.742 Td
(---------------------------)Tj
0 Tw 9.813 0 Td
[(USE IN SPECIFIC POPULA)54.9 (TIONS)]TJ
0 Tc -0.098 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------)Tj
/T1_1 1 Tf
-0.01 Tc 0.01 Tw -9.813 -1.445 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
/T1_2 1 Tf
2.25 0 Td
[(Lacta)-10 (tion:)]TJ
/T1_1 1 Tf
0 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.569 0 Td
[( )37 (Advise women not to breastfeed.)37.1 ( \(8.2\))]TJ
/T1_0 1 Tf
-0.051 Tw -5.819 -2.134 Td
[(See 1)40 (7 for P)54 (A)55 (TIENT COUNSELING INFORMA)55 (TION and FD)34 (A-appro)-10 (ved patient labeling.)]TJ
0.01 Tw 25.318 -1.526 Td
(Revised:)Tj
0 1 0 0 k
/GS1 gs
0 Tc 0 Tw ( )Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw 3.5 0 Td
(2/2023)Tj
0 Tw -64.818 -4.91 Td
[(FULL PRESCRIBING INFORMA)55 (TION: CONTENTS*)]TJ
-0.005 Tc 0 -1.346 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(INDIC)18 (A)55 (TIONS AND USAGE)]TJ
-3.125 -1.301 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(DOSAGE AND ADMINISTRA)55 (TION)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dosa)-10 (ge of SPR)17.9 (YCEL in )37 (Adult P)18 (a)-10 (tients)]TJ
-3.038 -1.225 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dosa)-10 (ge of SPR)17.9 (YCEL in P)18 (edia)-10 (tric P)18 (a)-10 (tients with CML or Ph)]TJ
0 Tc 20.489 0.125 Td
(+)Tj
-0.005 Tc -0.037 Tw 0.595 -0.125 Td
( ALL)Tj
0 Tw -24.121 -1.225 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dose Modi\037ca)-10 (tion)]TJ
-3.038 -1.225 Td
(2.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dose Escala)-10 (tion in )37 (Adults with CML and Ph)]TJ
0 Tc 15.575 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( )37 (ALL,)37 ( and P)18 (edia)-10 (tric)-5 ( )]TJ
-16.17 -1 Td
[(P)18 (a)-10 (tients with CML)]TJ
-0.037 Tw -3.038 -1.225 Td
(2.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dose Adjustment )-37 (for Adverse )-37 (Reactions)]TJ
-3.038 -1.225 Td
(2.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Dura)-10 (tion )-37 (of T)74 (rea)-9.9 (tment)]TJ
/T1_0 1 Tf
0 Tw -6.187 -1.279 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
2.415 Tw -3.125 -1.301 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
[(CONTRAINDIC)18 (A)55 (TIONS)]TJ
0 Tw 0 -1.301 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(W)18 (ARNINGS AND PREC)18 (AUTIONS)]TJ
/T1_1 1 Tf
1.618 Tw 0.025 -1.247 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Myelosuppression)Tj
0 Tw -3.038 -1.225 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Bleeding-Rela)-10 (ted Events)]TJ
-3.038 -1.225 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Fluid Retention)Tj
-0.037 Tw -3.038 -1.225 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Cardiovascular T)74 (oxicity)]TJ
-3.038 -1.225 Td
(5.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Pulmonar)-18 (y Arterial )-37 (Hypertension)]TJ
0 Tw -3.038 -1.225 Td
(5.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(QT Prolonga)-10 (tion)]TJ
-3.038 -1.225 Td
(5.7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Severe Derma)-10 (tologic Reactions)]TJ
-3.038 -1.225 Td
(5.8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(T)74 (umor L)37 (ysis Syndrome)]TJ
-0.037 Tw -3.038 -1.225 Td
(5.9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Embr)-18 (yo-F)24 (etal T)73.9 (oxicity)]TJ
0 Tw -3.038 -1.225 Td
(5.10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Effects on Gro)-10 (wth and Development in P)18.1 (edia)-10 (tric P)18 (a)-10 (tients)]TJ
1.143 Tw -3.038 -1.225 Td
(5.11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Hepa)-10 (totoxicity)]TJ
/T1_0 1 Tf
0 Tw -6.187 -1.279 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
-0.037 Tw 0.025 -1.247 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Clinical T)74 (rials )-37 (Experience)]TJ
0 Tw -3.038 -1.225 Td
(6.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(P)18 (ostmarketing Experience)]TJ
/T1_0 1 Tf
29.813 32.15 Td
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(DR)-10 (UG INTERACTIONS)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(7.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Effect of Other Drugs on Dasa)-10 (tinib)]TJ
/T1_0 1 Tf
-6.187 -1.279 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(USE IN SPECIFIC POPULA)55 (TIONS)]TJ
/T1_1 1 Tf
1.618 Tw 0.025 -1.247 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Pregnanc)20 (y)]TJ
-3.038 -1.225 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Lacta)-10 (tion)]TJ
0 Tw -3.038 -1.225 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(F)24 (emales and Males of Reproductive P)18 (otential)]TJ
-3.038 -1.225 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(P)18 (edia)-10 (tric Use)]TJ
-3.038 -1.225 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Geria)-10 (tric Use)]TJ
/T1_0 1 Tf
1.94 Tw -6.187 -1.279 Td
(10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
(OVERDOSAGE)Tj
0 -1.301 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
(DESCRIPTION)Tj
0 Tw 0 -1.301 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CLINIC)18 (AL PHARMACOLOGY)]TJ
/T1_1 1 Tf
-0.037 Tw 0.025 -1.247 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Mechanism )-37 (of Action)]TJ
1.143 Tw -3.038 -1.225 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Pharmacod)-9.9 (ynamics)]TJ
-3.038 -1.225 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
0 Tw -6.187 -1.279 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(NONCLINIC)18 (AL TOXICOLOGY)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Carcinogenesis,)37 ( Muta)-9.9 (genesis,)36.9 ( Impairment of F)24 (ertility)]TJ
/T1_0 1 Tf
-6.187 -1.279 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CLINIC)18 (AL STUDIES)]TJ
/T1_1 1 Tf
0.025 -1.247 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Newly Dia)-10 (gnosed Chronic Phase CML in )37 (Adults)]TJ
-3.038 -1.225 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(Ima)-10 (tinib-Resistant or -Intolerant CML or Ph)]TJ
0 Tc 15.639 0.125 Td
(+)Tj
-0.005 Tc -0.037 Tw 0.595 -0.125 Td
[( ALL )-37 (in Adults)]TJ
0 Tw -19.271 -1.225 Td
(14.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
[(CML in P)18 (edia)-10 (tric P)17.9 (a)-9.9 (tients)]TJ
1.143 Tw -3.038 -1.225 Td
(14.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.038 0 Td
(Ph)Tj
0 Tc 0 Tw 0.934 0.125 Td
(+)Tj
-0.005 Tc 0.595 -0.125 Td
[( )37 (ALL in P)18 (edia)-10 (tric P)17.9 (a)-9.9 (tients)]TJ
/T1_0 1 Tf
1.94 Tw -7.716 -1.279 Td
(15)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
(REFERENCES)Tj
0 Tw 0 -1.301 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
-3.125 -1.301 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(P)54 (A)55 (TIENT COUNSELING INFORMA)55 (TION)]TJ
/T1_1 1 Tf
-3.125 -2.385 Td
[(*Sections or subsections omitted from the full prescribing informa)-9.9 (tion are not listed.)]TJ
ET
0 0 0 1 K
4 M 
q 1 0 0 1 36 36.5 cm
0 0 m
540 0 l
S
Q
q 1 0 0 1 36 325.688 cm
0 0 m
540 0 l
S
Q
endstreamendobj114 0 obj<</CreationDate(D:20230207142440-05'00')/Creator(Adobe InDesign 18.1 \(Macintosh\))/ModDate(D:20230207142441-05'00')/Producer(Adobe PDF Library 17.0)/Trapped/False>>endobjxref
0 115
0000000000 65535 f
0000000016 00000 n
0000000124 00000 n
0000012592 00000 n
0000000000 00000 f
0000457843 00000 n
0000458797 00000 n
0000459776 00000 n
0000460967 00000 n
0000462158 00000 n
0000012871 00000 n
0000014062 00000 n
0000015265 00000 n
0000016458 00000 n
0000012652 00000 n
0000012741 00000 n
0000017739 00000 n
0000018942 00000 n
0000020134 00000 n
0000021326 00000 n
0000022449 00000 n
0000023572 00000 n
0000425021 00000 n
0000165124 00000 n
0000279665 00000 n
0000073090 00000 n
0000258732 00000 n
0000259346 00000 n
0000260136 00000 n
0000255067 00000 n
0000396188 00000 n
0000365841 00000 n
0000373757 00000 n
0000339982 00000 n
0000373594 00000 n
0000364924 00000 n
0000365381 00000 n
0000365678 00000 n
0000363187 00000 n
0000312175 00000 n
0000339868 00000 n
0000279777 00000 n
0000234246 00000 n
0000212518 00000 n
0000078487 00000 n
0000190392 00000 n
0000079104 00000 n
0000078616 00000 n
0000051897 00000 n
0000165237 00000 n
0000024709 00000 n
0000073201 00000 n
0000052377 00000 n
0000052874 00000 n
0000053127 00000 n
0000053508 00000 n
0000073238 00000 n
0000134543 00000 n
0000134568 00000 n
0000107636 00000 n
0000107883 00000 n
0000079667 00000 n
0000079920 00000 n
0000080447 00000 n
0000108377 00000 n
0000135176 00000 n
0000135644 00000 n
0000135713 00000 n
0000135973 00000 n
0000136082 00000 n
0000190526 00000 n
0000190551 00000 n
0000191047 00000 n
0000191425 00000 n
0000191494 00000 n
0000191760 00000 n
0000191861 00000 n
0000255753 00000 n
0000256256 00000 n
0000256606 00000 n
0000256987 00000 n
0000273554 00000 n
0000273651 00000 n
0000274210 00000 n
0000266745 00000 n
0000266878 00000 n
0000267606 00000 n
0000260689 00000 n
0000260786 00000 n
0000261339 00000 n
0000261951 00000 n
0000268325 00000 n
0000274842 00000 n
0000363224 00000 n
0000373111 00000 n
0000371848 00000 n
0000370649 00000 n
0000370734 00000 n
0000371004 00000 n
0000366298 00000 n
0000366703 00000 n
0000367212 00000 n
0000371308 00000 n
0000372154 00000 n
0000373369 00000 n
0000595175 00000 n
0000565941 00000 n
0000592189 00000 n
0000541033 00000 n
0000510517 00000 n
0000463348 00000 n
0000592695 00000 n
0000593047 00000 n
0000593429 00000 n
0000616963 00000 n
trailer<</Size 115/Root 1 0 R/Info 114 0 R/ID[<28C4C96D3C1C438AA861043F7B3AFD4F><6245D8B2F9A54FD1BDCA79A1BBB109F8>]>>startxref617146%%EOF2 0 obj<</Length 14758/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.0-c000 79.cca54b0, 2022/11/26-09:29:55        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2023-02-07T14:24:40-05:00</xmp:CreateDate>
         <xmp:MetadataDate>2023-02-13T08:21:58-05:00</xmp:MetadataDate>
         <xmp:ModifyDate>2023-02-13T08:21:58-05:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 18.1 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:e4b78575-3f0f-6844-a2fd-e64948f5112f</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:72764818-cad5-43f1-84b8-ee3fa1a8b760</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:416fb827-e348-4ddb-892d-dba471b43a8b</stRef:instanceID>
            <stRef:documentID>xmp.did:4bcd62d9-3e53-493a-a33d-d24571dfb7a9</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 18.1 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2023-02-07T14:24:40-05:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">SPRYCEL U.S. Prescribing Information</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Bag>
               <rdf:li>Bristol Myers Squibb</rdf:li>
            </rdf:Bag>
         </dc:creator>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1157997266</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Geneva</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1157997266</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Geneva</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>13.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2360395111</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>PostScript</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2360395111</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>29583</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeue-Medium</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>001.002</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2027153225</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2027153225</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4226815537</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4226815537</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1672649462</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>TrueType Collection</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1672649462</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Apple Computer</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Helvetica</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>13.0</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1593802331</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Verdana</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1593802331</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Microsoft</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Verdana-Bold</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.02</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2888882455</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2888882455</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.045</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>endstreamendobj115 0 obj<</Author(Bristol Myers Squibb)/CreationDate(D:20230207142440-05'00')/Creator(Adobe InDesign 18.1 \(Macintosh\))/ModDate(D:20230213082158-05'00')/Producer(Adobe PDF Library 17.0)/Title(SPRYCEL U.S. Prescribing Information)/Trapped/False>>endobjxref
0 1
0000000000 65535 f
2 1
0000619601 00000 n
115 1
0000634436 00000 n
trailer<</Size 116/Root 1 0 R/Info 115 0 R/ID[<28C4C96D3C1C438AA861043F7B3AFD4F><21746159409C400C889CF298E9B10CEB>]/Prev 617146>>startxref634692%%EOF